<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>Remsma, INN-infliximab</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="author" content="CHMP"/>
<meta name="keywords" content="Remsma, INN-infliximab"/>
<meta name="date" content="2023-03-14T16:04:59+00:00"/>
<meta name="subject" content="EPAR"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:12px;font-family:ArialMT;color:#000000;}
	.ft11{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft12{font-size:17px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft13{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft14{font-size:19px;font-family:TimesNewRomanPS;color:#000000;}
	.ft15{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
	.ft16{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
	.ft17{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page1-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft10">1&#160;</p>
<p style="position:absolute;top:89px;left:447px;white-space:nowrap" class="ft16"><b>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:525px;left:412px;white-space:nowrap" class="ft11"><b>ANNEX I&#160;</b></p>
<p style="position:absolute;top:544px;left:447px;white-space:nowrap" class="ft12">&#160;</p>
<p style="position:absolute;top:563px;left:264px;white-space:nowrap" class="ft11"><b>SUMMARY OF&#160;PRODUCT&#160;CHARACTERISTICS&#160;</b></p>
<p style="position:absolute;top:583px;left:106px;white-space:nowrap" class="ft17"><i>&#160;<br/></i>&#160;</p>
<p style="position:absolute;top:602px;left:149px;white-space:nowrap" class="ft12">&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft14"><b>&#160;</b></p>
<p style="position:absolute;top:622px;left:322px;white-space:nowrap" class="ft14"><b>&#160;</b></p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft28{font-size:17px;font-family:MVTXZP+SymbolMT;color:#000000;}
	.ft29{font-size:17px;font-family:ArialMT;color:#000000;}
	.ft210{font-size:17px;line-height:18px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft211{font-size:17px;line-height:19px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft20">2&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft21"><b>1.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft21"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft211">&#160;<br/>Remsima&#160;100&#160;mg powder&#160;for&#160;concentrate&#160;for&#160;solution&#160;for&#160;infusion&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:184px;left:149px;white-space:nowrap" class="ft21"><b>QUALITATIVE&#160;AND&#160;QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft211">&#160;<br/>One&#160;vial&#160;contains&#160;100&#160;mg&#160;of&#160;infliximab*.&#160;After&#160;reconstitution&#160;each&#160;mL&#160;contains&#160;10&#160;mg&#160;of&#160;infliximab.&#160;&#160;<br/>&#160;<br/>*&#160;Infliximab&#160;is&#160;a chimeric human-murine&#160;IgG1 monoclonal&#160;antibody&#160;produced&#160;in murine&#160;hybridoma&#160;<br/>cells&#160;by recombinant&#160;DNA&#160;technology.&#160;<br/>&#160;<br/>For&#160;the&#160;full&#160;list&#160;of&#160;excipients, see&#160;section 6.1.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:375px;left:149px;white-space:nowrap" class="ft21"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft211">&#160;<br/>Powder&#160;for&#160;concentrate&#160;for&#160;solution for&#160;infusion&#160;(powder&#160;for&#160;concentrate)&#160;<br/>&#160;<br/>The&#160;powder&#160;is&#160;white.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:509px;left:149px;white-space:nowrap" class="ft21"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft211">&#160;<br/><b>4.1&#160;</b></p>
<p style="position:absolute;top:548px;left:149px;white-space:nowrap" class="ft21"><b>Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:568px;left:106px;white-space:nowrap" class="ft211"><i>&#160;<br/></i>Rheumatoid&#160;arthritis&#160;<br/>&#160;<br/>Remsima, in combination&#160;with&#160;methotrexate, is&#160;indicated&#160;for&#160;the&#160;reduction of&#160;signs&#160;and symptoms&#160;as&#160;<br/>well&#160;as&#160;the&#160;improvement&#160;in physical&#160;function in:&#160;</p>
<p style="position:absolute;top:659px;left:106px;white-space:nowrap" class="ft28">•&#160;</p>
<p style="position:absolute;top:664px;left:149px;white-space:nowrap" class="ft210">adult&#160;patients with&#160;active disease when&#160;the&#160;response&#160;to&#160;disease-modifying&#160;antirheumatic&#160;drugs&#160;<br/>(DMARDs), including methotrexate,&#160;has&#160;been inadequate.&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft28">•&#160;</p>
<p style="position:absolute;top:703px;left:149px;white-space:nowrap" class="ft210">adult&#160;patients&#160;with severe, active&#160;and progressive&#160;disease&#160;not&#160;previously treated with&#160;<br/>methotrexate or&#160;other&#160;DMARDs.&#160;</p>
<p style="position:absolute;top:741px;left:106px;white-space:nowrap" class="ft211">In these&#160;patient&#160;populations, a&#160;reduction&#160;in&#160;the&#160;rate&#160;of&#160;the&#160;progression of&#160;joint&#160;damage,&#160;as measured&#160;by&#160;<br/>X-ray, has&#160;been demonstrated (see&#160;section&#160;5.1).&#160;<br/>&#160;<br/>Adult&#160;Crohn’s&#160;disease&#160;<br/>&#160;<br/>Remsima is indicated&#160;for:&#160;</p>
<p style="position:absolute;top:851px;left:106px;white-space:nowrap" class="ft28">•&#160;</p>
<p style="position:absolute;top:856px;left:149px;white-space:nowrap" class="ft210">treatment&#160;of&#160;moderately&#160;to severely&#160;active&#160;Crohn’s&#160;disease,&#160;in&#160;adult&#160;patients&#160;who&#160;have&#160;not&#160;<br/>responded&#160;despite a&#160;full&#160;and&#160;adequate course&#160;of&#160;therapy with&#160;a&#160;corticosteroid and/or&#160;an&#160;<br/>immunosuppressant;&#160;or&#160;who&#160;are&#160;intolerant&#160;to&#160;or&#160;have&#160;medical&#160;contraindications for&#160;such&#160;<br/>therapies.&#160;</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft28">•&#160;</p>
<p style="position:absolute;top:933px;left:149px;white-space:nowrap" class="ft211">treatment&#160;of&#160;fistulising,&#160;active Crohn’s disease,&#160;in&#160;adult&#160;patients who&#160;have not&#160;responded&#160;despite&#160;<br/>a full&#160;and&#160;adequate&#160;course&#160;of&#160;therapy with conventional&#160;treatment&#160;(including antibiotics,&#160;<br/>drainage&#160;and immunosuppressive&#160;therapy).&#160;</p>
<p style="position:absolute;top:990px;left:106px;white-space:nowrap" class="ft211">&#160;<br/>Paediatric&#160;Crohn’s disease&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;severe,&#160;active Crohn’s disease&#160;in&#160;children and adolescents&#160;aged&#160;<br/>6 to 17&#160;years,&#160;who have&#160;not&#160;responded to&#160;conventional&#160;therapy including&#160;a&#160;corticosteroid, an&#160;<br/>immunomodulator&#160;and&#160;primary nutrition&#160;therapy;&#160;or&#160;who are&#160;intolerant&#160;to or&#160;have&#160;contraindications&#160;for&#160;<br/>such therapies.&#160;Infliximab has&#160;been studied only&#160;in combination with conventional&#160;<br/>immunosuppressive therapy.&#160;<br/>&#160;</p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page3-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft30">3&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft311">Ulcerative colitis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;moderately&#160;to&#160;severely&#160;active ulcerative colitis&#160;in&#160;adult&#160;patients&#160;<br/>who have&#160;had an&#160;inadequate&#160;response&#160;to&#160;conventional&#160;therapy including&#160;corticosteroids&#160;and&#160;<br/>6-mercaptopurine&#160;(6-MP)&#160;or&#160;azathioprine (AZA),&#160;or&#160;who&#160;are intolerant&#160;to&#160;or&#160;have&#160;medical&#160;<br/>contraindications for&#160;such&#160;therapies.&#160;<br/>&#160;<br/>Paediatric&#160;ulcerative colitis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;severely&#160;active&#160;ulcerative colitis in&#160;children&#160;and&#160;adolescents&#160;<br/>aged 6&#160;to 17&#160;years,&#160;who&#160;have&#160;had&#160;an inadequate&#160;response&#160;to conventional&#160;therapy&#160;including&#160;<br/>corticosteroids and&#160;6-MP&#160;or&#160;AZA, or&#160;who&#160;are&#160;intolerant&#160;to&#160;or&#160;have&#160;medical&#160;contraindications&#160;for&#160;such&#160;<br/>therapies.&#160;<br/>&#160;<br/>Ankylosing spondylitis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;severe,&#160;active ankylosing&#160;spondylitis,&#160;in&#160;adult&#160;patients who&#160;have&#160;<br/>responded inadequately to conventional&#160;therapy.&#160;<br/>&#160;<br/>Psoriatic&#160;arthritis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;active and&#160;progressive&#160;psoriatic&#160;arthritis&#160;in adult&#160;patients&#160;when&#160;<br/>the&#160;response&#160;to&#160;previous&#160;DMARD&#160;therapy&#160;has been&#160;inadequate.&#160;<br/>Remsima should&#160;be administered:&#160;</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft38">•&#160;</p>
<p style="position:absolute;top:546px;left:149px;white-space:nowrap" class="ft32">in&#160;combination&#160;with&#160;methotrexate&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft38">•&#160;</p>
<p style="position:absolute;top:566px;left:149px;white-space:nowrap" class="ft310">or&#160;alone&#160;in patients&#160;who&#160;show&#160;intolerance&#160;to methotrexate&#160;or&#160;for&#160;whom&#160;methotrexate is&#160;<br/>contraindicated.&#160;</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft311">Infliximab&#160;has&#160;been shown&#160;to improve&#160;physical&#160;function in patients&#160;with psoriatic&#160;arthritis, and to&#160;<br/>reduce&#160;the&#160;rate&#160;of&#160;progression of&#160;peripheral&#160;joint&#160;damage&#160;as&#160;measured by&#160;X-ray&#160;in&#160;patients with&#160;<br/>polyarticular&#160;symmetrical&#160;subtypes&#160;of&#160;the&#160;disease (see&#160;section&#160;5.1).&#160;<br/>&#160;<br/>Psoriasis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;moderate to&#160;severe plaque psoriasis&#160;in&#160;adult&#160;patients who&#160;failed&#160;<br/>to respond to,&#160;or&#160;who&#160;have&#160;a&#160;contraindication to, or&#160;are&#160;intolerant&#160;to other&#160;systemic&#160;therapy&#160;including&#160;<br/>ciclosporin, methotrexate&#160;or&#160;psoralen&#160;ultra-violet&#160;A&#160;(PUVA)&#160;(see&#160;section 5.1).&#160;<br/>&#160;<br/><b>4.2&#160;</b></p>
<p style="position:absolute;top:794px;left:149px;white-space:nowrap" class="ft31"><b>Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:813px;left:106px;white-space:nowrap" class="ft310">&#160;<br/>Remsima&#160;treatment&#160;is&#160;to&#160;be&#160;initiated and&#160;supervised&#160;by&#160;qualified physicians&#160;experienced&#160;in&#160;the&#160;<br/>diagnosis&#160;and treatment&#160;of&#160;rheumatoid&#160;arthritis, inflammatory bowel&#160;diseases, ankylosing&#160;spondylitis,&#160;<br/>psoriatic&#160;arthritis&#160;or&#160;psoriasis.&#160;Remsima should&#160;be administered&#160;intravenously.&#160;Remsima&#160;infusions&#160;<br/>should be&#160;administered&#160;by qualified&#160;healthcare&#160;professionals&#160;trained&#160;to detect&#160;any infusion-related&#160;<br/>issues.&#160;Patients treated&#160;with&#160;Remsima should&#160;be given&#160;the package&#160;leaflet&#160;and&#160;the&#160;patient&#160;reminder&#160;<br/>card.&#160;<br/>&#160;<br/>During Remsima&#160;treatment,&#160;other&#160;concomitant&#160;therapies, e.g.&#160;corticosteroids&#160;and&#160;immunosuppressants&#160;<br/>should be&#160;optimised.&#160;<br/>&#160;<br/>It is&#160;important to&#160;check&#160;the&#160;product&#160;labels&#160;to&#160;ensure&#160;that the&#160;correct&#160;formulation&#160;(intravenous&#160;or&#160;<br/>subcutaneous)&#160;is&#160;being administered&#160;to&#160;the&#160;patient, as&#160;prescribed. Remsima&#160;subcutaneous&#160;formulation&#160;<br/>is&#160;not&#160;intended&#160;for&#160;intravenous&#160;administration&#160;and should be&#160;administered via&#160;a&#160;subcutaneous&#160;injection&#160;<br/>only.&#160;<br/>&#160;</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft412{font-size:17px;line-height:24px;font-family:TimesNewRomanPS;color:#000000;}
	.ft413{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
	.ft414{font-size:17px;line-height:15px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page4-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft40">4&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft411">Posology&#160;<br/><i>&#160;</i></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft414"><i>Adults&#160;(≥18&#160;years)&#160;&#160;<br/>&#160;<br/>Rheumatoid&#160;arthritis&#160;<br/></i>3&#160;mg/kg given&#160;as&#160;an&#160;intravenous&#160;infusion followed&#160;by additional&#160;3&#160;mg/kg&#160;infusion&#160;doses&#160;at&#160;2 and&#160;<br/>6&#160;weeks&#160;after&#160;the&#160;first&#160;infusion, then every&#160;8&#160;weeks&#160;thereafter.&#160;<br/>&#160;<br/>Remsima&#160;must be&#160;given&#160;concomitantly&#160;with&#160;methotrexate.&#160;&#160;<br/>&#160;<br/>Available&#160;data&#160;suggest&#160;that&#160;the&#160;clinical&#160;response&#160;is&#160;usually achieved&#160;within 12&#160;weeks&#160;of&#160;treatment.&#160;If&#160;a&#160;<br/>patient&#160;has&#160;an inadequate&#160;response&#160;or&#160;loses&#160;response&#160;after&#160;this&#160;period, consideration&#160;may&#160;be&#160;given to&#160;<br/>increase the dose step-wise&#160;by approximately 1.5&#160;mg/kg,&#160;up&#160;to&#160;a&#160;maximum of&#160;7.5&#160;mg/kg every&#160;<br/>8&#160;weeks.&#160;Alternatively,&#160;administration&#160;of&#160;3&#160;mg/kg as&#160;often as&#160;every 4&#160;weeks&#160;may&#160;be considered.&#160;If&#160;<br/>adequate&#160;response&#160;is&#160;achieved, patients&#160;should be&#160;continued on&#160;the&#160;selected dose&#160;or&#160;dose&#160;frequency.&#160;<br/>Continued&#160;therapy&#160;should be&#160;carefully reconsidered&#160;in&#160;patients&#160;who show&#160;no&#160;evidence of&#160;therapeutic&#160;<br/>benefit&#160;within the&#160;first&#160;12&#160;weeks of&#160;treatment&#160;or&#160;after&#160;dose adjustment.&#160;<br/>&#160;<br/><i>Moderately&#160;to&#160;severely&#160;active Crohn’s disease&#160;<br/></i>5&#160;mg/kg given&#160;as&#160;an intravenous&#160;infusion&#160;followed by&#160;an additional&#160;5&#160;mg/kg infusion&#160;2&#160;weeks&#160;after&#160;the&#160;<br/>first infusion. If&#160;a&#160;patient&#160;does&#160;not&#160;respond after&#160;2&#160;doses,&#160;no additional&#160;treatment&#160;with infliximab&#160;<br/>should be&#160;given. Available&#160;data&#160;do not&#160;support&#160;further&#160;infliximab&#160;treatment,&#160;in patients&#160;not&#160;responding&#160;<br/>within&#160;6&#160;weeks&#160;of&#160;the&#160;initial infusion.&#160;<br/>&#160;<br/>In&#160;responding patients,&#160;the&#160;alternative strategies for&#160;continued&#160;treatment&#160;are:&#160;<br/>•&#160;</p>
<p style="position:absolute;top:565px;left:149px;white-space:nowrap" class="ft410">Maintenance:&#160;Additional&#160;infusion&#160;of&#160;5&#160;mg/kg at&#160;6&#160;weeks&#160;after&#160;the&#160;initial&#160;dose,&#160;followed by&#160;<br/>infusions&#160;every&#160;8&#160;weeks or&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft48">•&#160;</p>
<p style="position:absolute;top:604px;left:149px;white-space:nowrap" class="ft410">Re-administration: Infusion&#160;of&#160;5&#160;mg/kg if&#160;signs&#160;and&#160;symptoms&#160;of&#160;the&#160;disease&#160;recur&#160;(see&#160;<br/>‘Re-administration’&#160;below&#160;and section 4.4).&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft410">&#160;<br/>Although comparative&#160;data&#160;are&#160;lacking,&#160;limited data&#160;in&#160;patients&#160;who&#160;initially&#160;responded to 5&#160;mg/kg but&#160;<br/>who lost&#160;response&#160;indicate&#160;that&#160;some&#160;patients&#160;may regain response&#160;with dose&#160;escalation&#160;(see&#160;<br/>section&#160;5.1). Continued&#160;therapy should be&#160;carefully&#160;reconsidered in&#160;patients&#160;who show&#160;no evidence&#160;of&#160;<br/>therapeutic benefit&#160;after&#160;dose adjustment.&#160;<br/>&#160;<br/><i>Fistulising, active&#160;Crohn’s&#160;disease&#160;<br/></i>5&#160;mg/kg given&#160;as&#160;an intravenous&#160;infusion&#160;followed by&#160;additional&#160;5&#160;mg/kg&#160;infusions at&#160;2&#160;and&#160;6&#160;weeks&#160;<br/>after&#160;the&#160;first&#160;infusion. If&#160;a&#160;patient&#160;does&#160;not&#160;respond&#160;after&#160;3&#160;doses,&#160;no&#160;additional&#160;treatment&#160;with&#160;<br/>infliximab should be&#160;given.&#160;<br/>&#160;<br/>In&#160;responding&#160;patients,&#160;the&#160;alternative strategies for&#160;continued&#160;treatment&#160;are:&#160;</p>
<p style="position:absolute;top:865px;left:106px;white-space:nowrap" class="ft48">•&#160;</p>
<p style="position:absolute;top:870px;left:149px;white-space:nowrap" class="ft42">Maintenance:&#160;Additional&#160;infusions&#160;of&#160;5&#160;mg/kg&#160;every 8&#160;weeks or&#160;</p>
<p style="position:absolute;top:885px;left:106px;white-space:nowrap" class="ft48">•&#160;</p>
<p style="position:absolute;top:890px;left:149px;white-space:nowrap" class="ft410">Re-administration: Infusion&#160;of&#160;5&#160;mg/kg if&#160;signs&#160;and&#160;symptoms&#160;of&#160;the&#160;disease&#160;recur&#160;followed by&#160;<br/>infusions&#160;of&#160;5&#160;mg/kg&#160;every 8&#160;weeks (see&#160;‘Re-administration’&#160;below&#160;and&#160;section 4.4).&#160;</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft411">&#160;<br/>Although comparative&#160;data&#160;are&#160;lacking,&#160;limited&#160;data&#160;in patients&#160;who initially responded&#160;to&#160;5&#160;mg/kg but&#160;<br/>who lost&#160;response&#160;indicate&#160;that&#160;some&#160;patients&#160;may regain response&#160;with dose&#160;escalation&#160;(see&#160;<br/>section&#160;5.1). Continued&#160;therapy should be&#160;carefully&#160;reconsidered in&#160;patients&#160;who show&#160;no&#160;evidence of&#160;<br/>therapeutic benefit&#160;after&#160;dose adjustment.&#160;<br/>&#160;<br/>In Crohn’s&#160;disease, experience&#160;with re-administration&#160;if&#160;signs and&#160;symptoms of&#160;disease recur&#160;is&#160;limited&#160;<br/>and comparative&#160;data&#160;on&#160;the&#160;benefit/risk of&#160;the&#160;alternative&#160;strategies&#160;for&#160;continued&#160;treatment&#160;are&#160;<br/>lacking.&#160;<br/>&#160;<br/><i>Ulcerative colitis&#160;<br/></i>5&#160;mg/kg given&#160;as&#160;an intravenous&#160;infusion&#160;followed by&#160;additional&#160;5&#160;mg/kg&#160;infusion&#160;doses&#160;at&#160;2 and&#160;<br/>6&#160;weeks&#160;after&#160;the&#160;first&#160;infusion, then every&#160;8&#160;weeks&#160;thereafter.&#160;</p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page5-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft50">5&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft510">&#160;<br/>Available&#160;data&#160;suggest&#160;that&#160;the&#160;clinical&#160;response&#160;is&#160;usually achieved&#160;within 14&#160;weeks&#160;of&#160;treatment, i.e.&#160;<br/>three&#160;doses. Continued&#160;therapy should be&#160;carefully&#160;reconsidered in&#160;patients&#160;who show&#160;no evidence&#160;of&#160;<br/>therapeutic&#160;benefit within&#160;this&#160;time&#160;period.&#160;<br/>&#160;<br/><i>Ankylosing spondylitis&#160;<br/></i>5&#160;mg/kg given&#160;as&#160;an intravenous&#160;infusion followed&#160;by additional&#160;5&#160;mg/kg&#160;infusion&#160;doses&#160;at&#160;2 and&#160;<br/>6&#160;weeks&#160;after&#160;the&#160;first&#160;infusion, then every&#160;6 to&#160;8&#160;weeks. If&#160;a&#160;patient&#160;does&#160;not&#160;respond by 6&#160;weeks (i.e.&#160;<br/>after&#160;2&#160;doses),&#160;no additional&#160;treatment&#160;with&#160;infliximab&#160;should be&#160;given.&#160;<br/>&#160;<br/><i>Psoriatic&#160;arthritis&#160;<br/></i>5&#160;mg/kg given&#160;as&#160;an intravenous&#160;infusion&#160;followed by&#160;additional&#160;5&#160;mg/kg&#160;infusion&#160;doses&#160;at&#160;2 and&#160;<br/>6&#160;weeks&#160;after&#160;the&#160;first&#160;infusion, then every&#160;8&#160;weeks&#160;thereafter.&#160;<br/>&#160;<br/><i>Psoriasis&#160;<br/></i>5&#160;mg/kg given&#160;as&#160;an intravenous&#160;infusion&#160;followed by&#160;additional&#160;5&#160;mg/kg&#160;infusion&#160;doses&#160;at&#160;2&#160;and&#160;<br/>6&#160;weeks&#160;after&#160;the&#160;first&#160;infusion, then every&#160;8&#160;weeks&#160;thereafter. If&#160;a&#160;patient&#160;shows&#160;no response&#160;after&#160;<br/>14&#160;weeks&#160;(i.e.&#160;after&#160;4&#160;doses), no additional&#160;treatment&#160;with&#160;infliximab&#160;should be&#160;given.&#160;<br/>&#160;<br/><i>Re-administration for&#160;Crohn’s&#160;disease&#160;and&#160;rheumatoid arthritis&#160;<br/></i>If&#160;the signs and&#160;symptoms&#160;of&#160;disease&#160;recur,&#160;infliximab&#160;can&#160;be&#160;re-administered within 16&#160;weeks&#160;<br/>following the&#160;last&#160;infusion.&#160;In clinical&#160;studies,&#160;delayed&#160;hypersensitivity&#160;reactions&#160;have&#160;been uncommon&#160;<br/>and&#160;have&#160;occurred&#160;after&#160;infliximab-free intervals&#160;of&#160;less&#160;than&#160;1&#160;year&#160;(see&#160;sections&#160;4.4 and 4.8). The&#160;<br/>safety&#160;and&#160;efficacy&#160;of&#160;re-administration&#160;after&#160;an&#160;infliximab-free interval&#160;of&#160;more&#160;than&#160;16&#160;weeks has not&#160;<br/>been&#160;established.&#160;This applies to&#160;both&#160;Crohn’s disease&#160;patients and&#160;rheumatoid&#160;arthritis&#160;patients.&#160;<br/>&#160;<br/><i>Re-administration for&#160;ulcerative&#160;colitis&#160;<br/></i>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;re-administration, other&#160;than&#160;every&#160;8&#160;weeks,&#160;has not&#160;been&#160;established&#160;(see&#160;<br/>sections&#160;4.4&#160;and 4.8).&#160;<br/>&#160;<br/><i>Re-administration for&#160;ankylosing&#160;spondylitis&#160;<br/></i>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;re-administration,&#160;other&#160;than&#160;every 6 to 8&#160;weeks,&#160;has not&#160;been&#160;established&#160;<br/>(see&#160;sections&#160;4.4&#160;and 4.8).&#160;<br/>&#160;<br/><i>Re-administration for&#160;psoriatic&#160;arthritis&#160;<br/></i>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;re-administration, other&#160;than&#160;every&#160;8&#160;weeks,&#160;has not&#160;been&#160;established&#160;(see&#160;<br/>sections 4.4 and&#160;4.8).&#160;<br/>&#160;<br/><i>Re-administration for&#160;psoriasis&#160;<br/></i>Limited&#160;experience from&#160;re-treatment&#160;with&#160;one&#160;single&#160;infliximab dose&#160;in&#160;psoriasis&#160;after&#160;an interval&#160;of&#160;<br/>20&#160;weeks&#160;suggests reduced&#160;efficacy&#160;and&#160;a higher&#160;incidence of&#160;mild&#160;to&#160;moderate&#160;infusion&#160;reactions&#160;<br/>when&#160;compared to&#160;the&#160;initial&#160;induction regimen (see&#160;section&#160;5.1).&#160;<br/>&#160;<br/>Limited&#160;experience from&#160;re-treatment&#160;following&#160;disease flare&#160;by&#160;a&#160;re-induction&#160;regimen suggests&#160;a&#160;<br/>higher&#160;incidence&#160;of&#160;infusion reactions,&#160;including&#160;serious&#160;ones, when&#160;compared to&#160;8-weekly&#160;<br/>maintenance treatment&#160;(see&#160;section&#160;4.8).&#160;<br/>&#160;<br/><i>Re-administration across&#160;indications&#160;<br/></i>In&#160;case&#160;maintenance therapy&#160;is&#160;interrupted,&#160;and&#160;there is&#160;a need&#160;to&#160;restart&#160;treatment,&#160;use of&#160;a&#160;<br/>re-induction regimen&#160;is&#160;not&#160;recommended&#160;(see&#160;section 4.8).&#160;In&#160;this&#160;situation,&#160;infliximab&#160;should be&#160;<br/>re-initiated as&#160;a&#160;single&#160;dose&#160;followed by the&#160;maintenance&#160;dose&#160;recommendations&#160;described&#160;above.&#160;<br/>&#160;</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page6-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft60">6&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft610">Special&#160;populations&#160;<br/>&#160;<br/><i>Elderly&#160;<br/>&#160;<br/></i>Specific&#160;studies&#160;of&#160;infliximab in&#160;elderly patients&#160;have&#160;not&#160;been conducted. No&#160;major&#160;age-related&#160;<br/>differences&#160;in clearance&#160;or&#160;volume&#160;of&#160;distribution were&#160;observed&#160;in clinical&#160;studies. No dose&#160;<br/>adjustment&#160;is&#160;required (see&#160;section 5.2).&#160;For&#160;more&#160;information about&#160;the&#160;safety of&#160;infliximab in&#160;elderly&#160;<br/>patients&#160;(see&#160;sections&#160;4.4 and 4.8).&#160;<br/>&#160;<br/><i>Renal&#160;and/or&#160;hepatic&#160;impairment&#160;<br/>&#160;<br/></i>Infliximab has&#160;not&#160;been&#160;studied&#160;in these&#160;patient&#160;populations.&#160;No&#160;dose recommendations can&#160;be&#160;made&#160;<br/>(see section&#160;5.2).&#160;<br/>&#160;<br/><i>Paediatric&#160;population&#160;<br/>&#160;<br/>Crohn’s&#160;disease&#160;(6&#160;to 17&#160;years)&#160;<br/></i>5&#160;mg/kg given&#160;as&#160;an intravenous&#160;infusion&#160;followed by&#160;additional&#160;5&#160;mg/kg&#160;infusion&#160;doses&#160;at&#160;2 and&#160;<br/>6&#160;weeks&#160;after&#160;the&#160;first&#160;infusion, then every&#160;8&#160;weeks&#160;thereafter. Available&#160;data&#160;do&#160;not&#160;support&#160;further&#160;<br/>infliximab&#160;treatment&#160;in children&#160;and adolescents&#160;not&#160;responding within the&#160;first&#160;10&#160;weeks of&#160;treatment&#160;<br/>(see section&#160;5.1).&#160;<br/>&#160;<br/>Some patients&#160;may&#160;require&#160;a shorter&#160;dosing&#160;interval&#160;to&#160;maintain&#160;clinical&#160;benefit,&#160;while for&#160;others a&#160;<br/>longer&#160;dosing&#160;interval&#160;may&#160;be&#160;sufficient.&#160;Patients&#160;who&#160;have&#160;had&#160;their&#160;dose&#160;interval&#160;shortened&#160;to&#160;less&#160;<br/>than 8&#160;weeks&#160;may be&#160;at&#160;greater&#160;risk&#160;for&#160;adverse&#160;reactions. Continued therapy with&#160;a&#160;shortened&#160;interval&#160;<br/>should&#160;be&#160;carefully&#160;considered&#160;in&#160;those&#160;patients&#160;who&#160;show&#160;no&#160;evidence&#160;of&#160;additional&#160;therapeutic&#160;<br/>benefit&#160;after&#160;a&#160;change&#160;in&#160;dosing&#160;interval.&#160;<br/>&#160;<br/>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;infliximab&#160;have not&#160;been&#160;studied&#160;in&#160;children&#160;with&#160;Crohn’s disease below&#160;the&#160;<br/>age of&#160;6&#160;years.&#160;Currently&#160;available&#160;pharmacokinetic&#160;data&#160;are&#160;described&#160;in section 5.2 but&#160;no&#160;<br/>recommendation on&#160;a&#160;posology can&#160;be&#160;made&#160;in&#160;children younger&#160;than 6&#160;years.&#160;<br/>&#160;<br/><i>Ulcerative colitis (6&#160;to&#160;17&#160;years)&#160;<br/></i>5&#160;mg/kg given&#160;as&#160;an intravenous&#160;infusion&#160;followed by&#160;additional&#160;5&#160;mg/kg&#160;infusion&#160;doses&#160;at&#160;2 and&#160;<br/>6&#160;weeks&#160;after&#160;the&#160;first&#160;infusion, then every&#160;8&#160;weeks&#160;thereafter. Available&#160;data&#160;do&#160;not&#160;support&#160;further&#160;<br/>infliximab&#160;treatment&#160;in&#160;paediatric&#160;patients&#160;not responding&#160;within&#160;the&#160;first 8&#160;weeks&#160;of&#160;treatment&#160;(see&#160;<br/>section 5.1).&#160;<br/>&#160;<br/>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;infliximab&#160;have&#160;not&#160;been studied&#160;in children with ulcerative&#160;colitis&#160;below&#160;<br/>the&#160;age&#160;of&#160;6&#160;years. Currently available&#160;pharmacokinetic&#160;data&#160;are&#160;described in&#160;section 5.2 but&#160;no&#160;<br/>recommendation on&#160;a&#160;posology can&#160;be&#160;made&#160;in&#160;children younger&#160;than 6&#160;years.&#160;<br/>&#160;<br/><i>Psoriasis&#160;<br/></i>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;infliximab&#160;in children&#160;and&#160;adolescents&#160;younger&#160;than 18&#160;years for&#160;the&#160;<br/>indication&#160;of&#160;psoriasis&#160;have&#160;not&#160;been established. Currently&#160;available&#160;data&#160;are&#160;described&#160;in section&#160;5.2&#160;<br/>but&#160;no recommendation on a&#160;posology can&#160;be&#160;made.&#160;<br/>&#160;<br/><i>Juvenile idiopathic arthritis,&#160;psoriatic arthritis and&#160;ankylosing&#160;spondylitis&#160;<br/></i>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;infliximab&#160;in&#160;children and adolescents&#160;younger&#160;than 18&#160;years for&#160;the&#160;<br/>indications&#160;of&#160;juvenile&#160;idiopathic&#160;arthritis, psoriatic&#160;arthritis&#160;and&#160;ankylosing spondylitis&#160;have&#160;not&#160;been&#160;<br/>established. Currently&#160;available&#160;data are&#160;described in&#160;section 5.2&#160;but&#160;no recommendation on&#160;a&#160;<br/>posology can be&#160;made.&#160;<br/>&#160;<br/><i>Juvenile rheumatoid&#160;arthritis&#160;<br/></i>The&#160;safety and&#160;efficacy&#160;of&#160;infliximab in&#160;children and adolescents&#160;younger&#160;than 18&#160;years&#160;for&#160;the&#160;<br/>indication&#160;of&#160;juvenile&#160;rheumatoid&#160;arthritis&#160;have&#160;not&#160;been established. Currently available&#160;data&#160;are&#160;<br/>described in sections&#160;4.8 and 5.2 but&#160;no&#160;recommendation on a&#160;posology can be&#160;made.&#160;</p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page7-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft70">7&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft711">&#160;<br/>Method&#160;of&#160;administration&#160;<br/>&#160;<br/>Infliximab&#160;should be&#160;administered intravenously&#160;over&#160;a 2&#160;hour&#160;period.&#160;All&#160;patients administered&#160;<br/>infliximab&#160;are&#160;to&#160;be observed&#160;for&#160;at&#160;least&#160;1-2&#160;hours&#160;post-infusion&#160;for&#160;acute&#160;infusion-related&#160;reactions.&#160;<br/>Emergency&#160;equipment,&#160;such&#160;as adrenaline,&#160;antihistamines,&#160;corticosteroids&#160;and&#160;an&#160;artificial&#160;airway&#160;must&#160;<br/>be&#160;available. Patients&#160;may&#160;be&#160;pre-treated with e.g., an&#160;antihistamine, hydrocortisone&#160;and/or&#160;<br/>paracetamol&#160;and infusion&#160;rate&#160;may be&#160;slowed&#160;in order&#160;to decrease&#160;the&#160;risk of&#160;infusion-related&#160;reactions&#160;<br/>especially&#160;if&#160;infusion-related reactions&#160;have&#160;occurred previously (see&#160;section 4.4).&#160;<br/><i>&#160;<br/>Shortened infusions&#160;across&#160;adult&#160;indications&#160;<br/></i>&#160;<br/>In&#160;carefully&#160;selected&#160;adult&#160;patients who&#160;have&#160;tolerated&#160;at&#160;least&#160;3&#160;initial&#160;2-hour&#160;infusions&#160;of&#160;infliximab&#160;<br/>(induction phase)&#160;and are&#160;receiving&#160;maintenance&#160;therapy, consideration&#160;may be&#160;given to&#160;administering&#160;<br/>subsequent&#160;infusions&#160;over&#160;a&#160;period of&#160;not&#160;less&#160;than&#160;1&#160;hour. If&#160;an&#160;infusion reaction occurs&#160;in&#160;association&#160;<br/>with&#160;a&#160;shortened infusion, a&#160;slower&#160;infusion&#160;rate&#160;may be&#160;considered&#160;for&#160;future&#160;infusions&#160;if&#160;treatment&#160;is&#160;<br/>to be&#160;continued. Shortened&#160;infusions&#160;at&#160;doses&#160;&gt;6&#160;mg/kg have&#160;not&#160;been&#160;studied&#160;(see&#160;section 4.8).&#160;<br/>&#160;<br/>For&#160;preparation and&#160;administration instructions, see&#160;section&#160;6.6.&#160;<br/>&#160;<br/><b>4.3&#160;</b></p>
<p style="position:absolute;top:469px;left:149px;white-space:nowrap" class="ft71"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:488px;left:106px;white-space:nowrap" class="ft711">&#160;<br/>Hypersensitivity&#160;to the&#160;active&#160;substance,&#160;to other&#160;murine&#160;proteins,&#160;or&#160;to any of&#160;the&#160;excipients&#160;listed&#160;in&#160;<br/>section 6.1.&#160;<br/>&#160;<br/>Patients with&#160;tuberculosis or&#160;other&#160;severe&#160;infections such&#160;as&#160;sepsis,&#160;abscesses,&#160;and&#160;opportunistic&#160;<br/>infections&#160;(see&#160;section&#160;4.4).&#160;<br/>&#160;<br/>Patients with&#160;moderate or&#160;severe heart&#160;failure&#160;(NYHA&#160;class&#160;III/IV)&#160;(see&#160;sections&#160;4.4 and 4.8).&#160;<br/>&#160;<br/><b>4.4&#160;</b></p>
<p style="position:absolute;top:659px;left:149px;white-space:nowrap" class="ft71"><b>Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:678px;left:106px;white-space:nowrap" class="ft711"><b>&#160;<br/></b>Traceability&#160;<br/><b>&#160;<br/></b>In&#160;order&#160;to&#160;improve&#160;the&#160;traceability&#160;of&#160;biological&#160;medicinal products,&#160;the&#160;tradename&#160;and&#160;the&#160;batch&#160;<br/>number&#160;of&#160;the&#160;administered&#160;product&#160;should be&#160;clearly recorded.&#160;<br/>&#160;<br/>Infusion&#160;reactions&#160;and&#160;hypersensitivity&#160;<br/><b>&#160;<br/></b>Infliximab&#160;has been&#160;associated&#160;with&#160;acute infusion-related&#160;reactions,&#160;including anaphylactic&#160;shock,&#160;<br/>and delayed hypersensitivity reactions&#160;(see&#160;section&#160;4.8).&#160;<br/>&#160;<br/>Acute&#160;infusion reactions&#160;including anaphylactic&#160;reactions&#160;may develop during (within seconds)&#160;or&#160;<br/>within a&#160;few&#160;hours&#160;following infusion. If&#160;acute&#160;infusion&#160;reactions&#160;occur, the&#160;infusion must&#160;be&#160;<br/>interrupted immediately. Emergency equipment, such&#160;as&#160;adrenaline, antihistamines, corticosteroids&#160;<br/>and&#160;an&#160;artificial&#160;airway&#160;must&#160;be available.&#160;Patients&#160;may&#160;be pre-treated with e.g., an&#160;antihistamine,&#160;<br/>hydrocortisone&#160;and/or&#160;paracetamol&#160;to prevent&#160;mild and transient&#160;effects.&#160;<br/>&#160;<br/>Antibodies&#160;to&#160;infliximab may develop&#160;and have&#160;been&#160;associated&#160;with&#160;an&#160;increased&#160;frequency&#160;of&#160;<br/>infusion reactions. A&#160;low&#160;proportion of&#160;the&#160;infusion&#160;reactions&#160;was&#160;serious&#160;allergic&#160;reactions. An&#160;<br/>association between&#160;development&#160;of&#160;antibodies&#160;to infliximab and reduced duration of&#160;response&#160;has&#160;<br/>also been observed. Concomitant&#160;administration of&#160;immunomodulators&#160;has&#160;been&#160;associated with&#160;lower&#160;<br/>incidence&#160;of&#160;antibodies&#160;to infliximab and&#160;a&#160;reduction in the&#160;frequency of&#160;infusion&#160;reactions. The&#160;effect&#160;<br/>of&#160;concomitant&#160;immunomodulator&#160;therapy was&#160;more&#160;profound in episodically-treated&#160;patients&#160;than&#160;in&#160;<br/>patients&#160;given&#160;maintenance&#160;therapy. Patients&#160;who discontinue&#160;immunosuppressants&#160;prior&#160;to or&#160;during&#160;<br/>infliximab&#160;treatment&#160;are&#160;at&#160;greater&#160;risk of&#160;developing these&#160;antibodies.&#160;Antibodies&#160;to infliximab cannot&#160;</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft815{font-size:10px;font-family:GHWNTB+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page8-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft80">8&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft810">always&#160;be detected&#160;in&#160;serum&#160;samples.&#160;If&#160;serious reactions occur,&#160;symptomatic treatment&#160;must&#160;be given&#160;<br/>and further&#160;infliximab&#160;infusions&#160;must&#160;not&#160;be&#160;administered (see&#160;section&#160;4.8).&#160;<br/>&#160;<br/>In&#160;clinical&#160;studies,&#160;delayed&#160;hypersensitivity&#160;reactions have been&#160;reported.&#160;Available data suggest&#160;an&#160;<br/>increased&#160;risk&#160;for&#160;delayed&#160;hypersensitivity&#160;with&#160;increasing&#160;infliximab-free interval.&#160;Patients&#160;should&#160;be&#160;<br/>advised&#160;to&#160;seek&#160;immediate&#160;medical&#160;advice if&#160;they&#160;experience any&#160;delayed&#160;adverse&#160;reaction&#160;(see section&#160;<br/>4.8). If&#160;patients&#160;are&#160;re-treated&#160;after&#160;a prolonged period,&#160;they must&#160;be&#160;closely&#160;monitored for&#160;signs&#160;and&#160;<br/>symptoms&#160;of&#160;delayed hypersensitivity.&#160;<br/>&#160;<br/>Infections&#160;<br/>&#160;<br/>Patients&#160;must&#160;be&#160;monitored&#160;closely&#160;for&#160;infections&#160;including&#160;tuberculosis&#160;before, during&#160;and after&#160;<br/>treatment with&#160;infliximab.&#160;Because the elimination&#160;of&#160;infliximab may take&#160;up to&#160;six&#160;months,&#160;<br/>monitoring should be&#160;continued throughout&#160;this&#160;period. Further&#160;treatment&#160;with&#160;infliximab&#160;must&#160;not&#160;be&#160;<br/>given&#160;if&#160;a&#160;patient&#160;develops&#160;a&#160;serious&#160;infection or&#160;sepsis.&#160;<br/>&#160;<br/>Caution should&#160;be&#160;exercised when considering&#160;the&#160;use&#160;of&#160;infliximab in patients&#160;with chronic&#160;infection&#160;<br/>or&#160;a&#160;history&#160;of&#160;recurrent&#160;infections,&#160;including&#160;concomitant&#160;immunosuppressive&#160;therapy. Patients&#160;<br/>should be&#160;advised of&#160;and avoid exposure&#160;to potential&#160;risk factors&#160;for&#160;infection&#160;as&#160;appropriate.&#160;<br/>&#160;<br/>Tumour&#160;necrosis&#160;factor&#160;alpha (TNFα)&#160;mediates&#160;inflammation&#160;and&#160;modulates&#160;cellular&#160;immune&#160;<br/>responses. Experimental&#160;data&#160;show&#160;that&#160;TNFα&#160;is&#160;essential&#160;for&#160;the&#160;clearing&#160;of&#160;intracellular&#160;infections.&#160;<br/>Clinical&#160;experience shows that&#160;host&#160;defence&#160;against&#160;infection&#160;is compromised&#160;in&#160;some patients&#160;treated&#160;<br/>with&#160;infliximab.&#160;<br/>&#160;<br/>It&#160;should be&#160;noted that&#160;suppression&#160;of&#160;TNFα&#160;may mask&#160;symptoms&#160;of&#160;infection such&#160;as&#160;fever. Early&#160;<br/>recognition&#160;of&#160;atypical&#160;clinical&#160;presentations of&#160;serious&#160;infections&#160;and&#160;of&#160;typical&#160;clinical&#160;presentation&#160;<br/>of&#160;rare&#160;and&#160;unusual&#160;infections&#160;is&#160;critical&#160;in order&#160;to&#160;minimise&#160;delays&#160;in diagnosis&#160;and treatment.&#160;&#160;<br/>&#160;<br/>Patients taking&#160;TNF-blockers&#160;are more&#160;susceptible&#160;to&#160;serious infections.&#160;<br/>&#160;<br/>Tuberculosis, bacterial&#160;infections,&#160;including sepsis&#160;and&#160;pneumonia, invasive&#160;fungal, viral, and&#160;other&#160;<br/>opportunistic&#160;infections&#160;have&#160;been&#160;observed&#160;in&#160;patients&#160;treated with infliximab.&#160;Some&#160;of&#160;these&#160;<br/>infections&#160;have&#160;been fatal;&#160;the&#160;most&#160;frequently reported&#160;opportunistic&#160;infections&#160;with&#160;a&#160;mortality&#160;rate&#160;<br/>of&#160;&gt;5%&#160;include&#160;pneumocystosis, candidiasis, listeriosis&#160;and aspergillosis.&#160;<br/>&#160;<br/>Patients&#160;who develop a&#160;new&#160;infection while&#160;undergoing&#160;treatment&#160;with&#160;infliximab,&#160;should be&#160;<br/>monitored closely&#160;and undergo&#160;a&#160;complete&#160;diagnostic&#160;evaluation. Administration of&#160;infliximab should&#160;<br/>be&#160;discontinued if&#160;a&#160;patient&#160;develops&#160;a&#160;new&#160;serious&#160;infection&#160;or&#160;sepsis,&#160;and appropriate&#160;antimicrobial&#160;<br/>or&#160;antifungal&#160;therapy should&#160;be&#160;initiated until&#160;the&#160;infection is&#160;controlled.&#160;<br/>&#160;<br/><i>Tuberculosis&#160;<br/>&#160;<br/></i>There&#160;have&#160;been reports&#160;of&#160;active&#160;tuberculosis&#160;in&#160;patients&#160;receiving infliximab.&#160;It&#160;should&#160;be&#160;noted&#160;that&#160;<br/>in the&#160;majority of&#160;these&#160;reports&#160;tuberculosis&#160;was&#160;extrapulmonary, presenting as&#160;either&#160;local&#160;or&#160;<br/>disseminated&#160;disease.&#160;<br/>&#160;<br/>Before&#160;starting&#160;treatment with&#160;infliximab,&#160;all&#160;patients&#160;must&#160;be&#160;evaluated for&#160;both&#160;active&#160;and&#160;inactive&#160;<br/>(‘latent’)&#160;tuberculosis. This&#160;evaluation&#160;should include&#160;a&#160;detailed&#160;medical&#160;history with personal&#160;history&#160;<br/>of&#160;tuberculosis&#160;or&#160;possible&#160;previous&#160;contact&#160;with tuberculosis&#160;and previous&#160;and/or&#160;current&#160;<br/>immunosuppressive&#160;therapy.&#160;Appropriate screening&#160;tests,&#160;(e.g.&#160;tuberculin skin&#160;test,&#160;chest&#160;X-ray,&#160;and/or&#160;<br/>Interferon&#160;Gamma Release&#160;Assay),&#160;should be&#160;performed in all&#160;patients&#160;(local&#160;recommendations&#160;may&#160;<br/>apply). It&#160;is&#160;recommended that&#160;the&#160;conduct&#160;of&#160;these&#160;tests should&#160;be&#160;recorded&#160;in&#160;the&#160;patient&#160;reminder&#160;<br/>card.&#160;Prescribers&#160;are&#160;reminded&#160;of&#160;the&#160;risk&#160;of&#160;false negative tuberculin&#160;skin&#160;test&#160;results,&#160;especially&#160;in&#160;<br/>patients&#160;who&#160;are&#160;severely ill&#160;or&#160;immunocompromised.&#160;<br/>&#160;<br/>If&#160;active&#160;tuberculosis&#160;is&#160;diagnosed, infliximab&#160;therapy&#160;must&#160;not&#160;be&#160;initiated (see&#160;section 4.3).&#160;&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft916{font-size:16px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft917{font-size:16px;line-height:18px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page9-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:440px;white-space:nowrap" class="ft90">9&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft910">&#160;<br/>If&#160;latent&#160;tuberculosis&#160;is&#160;suspected, a&#160;physician with expertise&#160;in&#160;the&#160;treatment&#160;of&#160;tuberculosis&#160;should be&#160;<br/>consulted. In all&#160;situations&#160;described below, the&#160;benefit/risk balance&#160;of&#160;infliximab&#160;therapy&#160;should be&#160;<br/>very&#160;carefully&#160;considered.&#160;<br/>&#160;<br/>If&#160;inactive (‘latent’)&#160;tuberculosis is diagnosed,&#160;treatment&#160;for&#160;latent&#160;tuberculosis&#160;must&#160;be started&#160;with&#160;<br/>antituberculosis&#160;therapy before&#160;the&#160;initiation of&#160;infliximab, and&#160;in accordance&#160;with&#160;local&#160;<br/>recommendations.&#160;<br/>&#160;<br/>In patients&#160;who have&#160;several&#160;or&#160;significant&#160;risk factors&#160;for&#160;tuberculosis&#160;and&#160;have&#160;a&#160;negative&#160;test&#160;for&#160;<br/>latent&#160;tuberculosis, antituberculosis&#160;therapy should be&#160;considered before&#160;the&#160;initiation of&#160;infliximab.&#160;&#160;<br/>&#160;<br/>Use&#160;of&#160;antituberculosis&#160;therapy should&#160;also be&#160;considered&#160;before&#160;the&#160;initiation&#160;of&#160;infliximab&#160;in&#160;patients&#160;<br/>with&#160;a&#160;past&#160;history&#160;of&#160;latent&#160;or&#160;active tuberculosis&#160;in&#160;whom&#160;an&#160;adequate course of&#160;treatment&#160;cannot&#160;be&#160;<br/>confirmed.&#160;<br/>&#160;<br/>Some&#160;cases of&#160;active tuberculosis have been&#160;reported&#160;in&#160;patients&#160;treated&#160;with&#160;infliximab&#160;during and&#160;<br/>after&#160;treatment for&#160;latent&#160;tuberculosis.&#160;<br/>&#160;<br/>All&#160;patients&#160;should&#160;be&#160;informed&#160;to seek&#160;medical&#160;advice&#160;if&#160;signs/symptoms&#160;suggestive&#160;of&#160;tuberculosis&#160;<br/>(e.g.&#160;persistent&#160;cough, wasting/weight&#160;loss, low-grade&#160;fever)&#160;appear&#160;during&#160;or&#160;after&#160;infliximab&#160;<br/>treatment.&#160;<br/>&#160;<br/><i>Invasive&#160;fungal&#160;infections&#160;<br/>&#160;<br/></i>In patients&#160;treated with&#160;infliximab, an&#160;invasive&#160;fungal&#160;infection such as&#160;aspergillosis, candidiasis,&#160;<br/>pneumocystosis, histoplasmosis, coccidioidomycosis&#160;or&#160;blastomycosis&#160;should&#160;be&#160;suspected&#160;if&#160;they&#160;<br/>develop&#160;a&#160;serious systemic&#160;illness,&#160;and&#160;a physician&#160;with&#160;expertise&#160;in&#160;the diagnosis&#160;and&#160;treatment&#160;of&#160;<br/>invasive&#160;fungal&#160;infections&#160;should be&#160;consulted&#160;at&#160;an early&#160;stage&#160;when&#160;investigating&#160;these patients.&#160;&#160;<br/>&#160;<br/>Invasive&#160;fungal&#160;infections&#160;may&#160;present&#160;as disseminated&#160;rather&#160;than&#160;localised&#160;disease,&#160;and&#160;antigen&#160;and&#160;<br/>antibody testing may&#160;be&#160;negative&#160;in&#160;some&#160;patients&#160;with&#160;active&#160;infection.&#160;Appropriate&#160;empiric&#160;<br/>antifungal&#160;therapy should be&#160;considered while&#160;a&#160;diagnostic&#160;workup is&#160;being performed&#160;taking&#160;into&#160;<br/>account&#160;both the&#160;risk&#160;for&#160;severe&#160;fungal&#160;infection and the&#160;risks&#160;of&#160;antifungal&#160;therapy.&#160;<br/>&#160;<br/>For&#160;patients&#160;who have&#160;resided in or&#160;travelled&#160;to&#160;regions&#160;where&#160;invasive&#160;fungal&#160;infections&#160;such as&#160;<br/>histoplasmosis,&#160;coccidioidomycosis, or&#160;blastomycosis&#160;are&#160;endemic, the&#160;benefits&#160;and risks&#160;of&#160;infliximab&#160;<br/>treatment&#160;should&#160;be&#160;carefully considered before&#160;initiation of&#160;infliximab&#160;therapy.&#160;<br/>&#160;<br/><i>Fistulising&#160;Crohn’s&#160;disease&#160;<br/></i>Patients&#160;with fistulising Crohn’s&#160;disease&#160;with acute&#160;suppurative&#160;fistulas&#160;must not&#160;initiate&#160;infliximab&#160;<br/>therapy&#160;until&#160;a source&#160;for&#160;possible&#160;infection,&#160;specifically&#160;abscess,&#160;has been&#160;excluded&#160;(see section&#160;4.3).&#160;<br/>&#160;<br/>Hepatitis B&#160;(HBV)&#160;reactivation&#160;<br/>&#160;<br/>Reactivation&#160;of&#160;hepatitis B&#160;has occurred&#160;in&#160;patients&#160;receiving&#160;a TNF-antagonist&#160;including&#160;infliximab,&#160;<br/>who&#160;are&#160;chronic&#160;carriers of&#160;this virus.&#160;Some cases&#160;have&#160;had&#160;fatal&#160;outcome.&#160;<br/>&#160;<br/>Patients should&#160;be tested&#160;for&#160;HBV&#160;infection&#160;before&#160;initiating&#160;treatment&#160;with&#160;infliximab.&#160;For&#160;patients&#160;<br/>who test&#160;positive&#160;for&#160;HBV&#160;infection, consultation with&#160;a&#160;physician with&#160;expertise&#160;in the&#160;treatment&#160;of&#160;<br/>hepatitis&#160;B&#160;is recommended.&#160;Carriers&#160;of&#160;HBV&#160;who&#160;require&#160;treatment with&#160;infliximab&#160;should&#160;be&#160;closely&#160;<br/>monitored&#160;for&#160;signs&#160;and symptoms&#160;of&#160;active&#160;HBV&#160;infection throughout&#160;therapy and for&#160;several&#160;months&#160;<br/>following termination of&#160;therapy. Adequate&#160;data&#160;of&#160;treating patients&#160;who are&#160;carriers&#160;of&#160;HBV&#160;with&#160;<br/>antiviral&#160;therapy in conjunction with&#160;TNF-antagonist&#160;therapy&#160;to prevent&#160;HBV&#160;reactivation are&#160;not&#160;<br/>available. In patients&#160;who develop HBV&#160;reactivation, infliximab should be&#160;stopped and effective&#160;<br/>antiviral&#160;therapy&#160;with&#160;appropriate&#160;supportive&#160;treatment&#160;should&#160;be&#160;initiated.&#160;<br/>&#160;</p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1018{font-size:17px;font-family:GHWNTB+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page10-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft100">10&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1011">Hepatobiliary events&#160;<br/>&#160;<br/>Cases of&#160;jaundice&#160;and&#160;non-infectious&#160;hepatitis, some&#160;with features&#160;of&#160;autoimmune&#160;hepatitis,&#160;have&#160;been&#160;<br/>observed&#160;in the&#160;post-marketing&#160;experience of&#160;infliximab.&#160;Isolated&#160;cases of&#160;liver&#160;failure&#160;resulting&#160;in&#160;<br/>liver&#160;transplantation&#160;or&#160;death have&#160;occurred. Patients&#160;with&#160;symptoms&#160;or&#160;signs&#160;of&#160;liver&#160;dysfunction&#160;<br/>should&#160;be&#160;evaluated&#160;for&#160;evidence&#160;of&#160;liver&#160;injury.&#160;If&#160;jaundice&#160;and/or&#160;ALT&#160;elevations&#160;</p>
<p style="position:absolute;top:178px;left:656px;white-space:nowrap" class="ft1018">≥5&#160;times&#160;the&#160;upper&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1011">limit&#160;of&#160;normal&#160;develop(s),&#160;infliximab&#160;should be&#160;discontinued, and a&#160;thorough&#160;investigation of&#160;the&#160;<br/>abnormality should be&#160;undertaken.&#160;<br/>&#160;<br/>Concurrent&#160;administration&#160;of&#160;TNF-alpha&#160;inhibitor&#160;and&#160;anakinra&#160;<br/>&#160;<br/>Serious infections&#160;and&#160;neutropenia&#160;were&#160;seen&#160;in clinical&#160;studies&#160;with concurrent&#160;use&#160;of&#160;anakinra&#160;and&#160;<br/>another&#160;TNFα-blocking agent, etanercept, with&#160;no added clinical&#160;benefit&#160;compared&#160;to etanercept&#160;alone.&#160;<br/>Because&#160;of&#160;the nature of&#160;the&#160;adverse&#160;reactions&#160;seen with combination of&#160;etanercept&#160;and&#160;anakinra&#160;<br/>therapy,&#160;similar&#160;toxicities&#160;may&#160;also result&#160;from&#160;the&#160;combination of&#160;anakinra&#160;and&#160;other&#160;TNFα-blocking&#160;<br/>agents. Therefore, the&#160;combination of&#160;infliximab&#160;and&#160;anakinra&#160;is&#160;not&#160;recommended.&#160;<br/>&#160;<br/>Concurrent&#160;administration&#160;of&#160;TNF-alpha&#160;inhibitor&#160;and&#160;abatacept&#160;<br/>&#160;<br/>In&#160;clinical studies&#160;concurrent administration&#160;of&#160;TNF-antagonists&#160;and&#160;abatacept&#160;has been&#160;associated&#160;<br/>with an increased risk of&#160;infections&#160;including serious&#160;infections&#160;compared to TNF-antagonists&#160;alone,&#160;<br/>without increased&#160;clinical benefit.&#160;The&#160;combination of&#160;infliximab and abatacept&#160;is&#160;not&#160;recommended.&#160;<br/>&#160;<br/>Concurrent administration&#160;with&#160;other&#160;biological&#160;therapeutics&#160;<br/>&#160;<br/>There&#160;is&#160;insufficient information&#160;regarding&#160;the&#160;concomitant use&#160;of&#160;infliximab&#160;with&#160;other&#160;biological&#160;<br/>therapeutics&#160;used&#160;to&#160;treat&#160;the&#160;same&#160;conditions&#160;as&#160;infliximab. The&#160;concomitant&#160;use&#160;of&#160;infliximab with&#160;<br/>these&#160;biologics&#160;is&#160;not&#160;recommended because&#160;of&#160;the&#160;possibility of&#160;an&#160;increased&#160;risk&#160;of&#160;infection, and&#160;<br/>other&#160;potential pharmacological interactions.&#160;<br/>&#160;<br/>Switching&#160;between&#160;biological DMARDs&#160;<br/>&#160;<br/>Care&#160;should be&#160;taken and&#160;patients&#160;should&#160;continue&#160;to&#160;be&#160;monitored&#160;when&#160;switching&#160;from&#160;one&#160;biologic&#160;<br/>to another,&#160;since&#160;overlapping biological&#160;activity&#160;may&#160;further&#160;increase&#160;the&#160;risk&#160;for&#160;adverse&#160;reactions,&#160;<br/>including&#160;infection.&#160;<br/>&#160;<br/>Vaccinations&#160;<br/>&#160;<br/>It&#160;is recommended&#160;that&#160;patients,&#160;if&#160;possible, be&#160;brought&#160;up to date&#160;with all&#160;vaccinations&#160;in agreement&#160;<br/>with&#160;current vaccination&#160;guidelines&#160;prior&#160;to&#160;initiating&#160;Remsima&#160;therapy. Patients&#160;on infliximab&#160;may&#160;<br/>receive concurrent&#160;vaccinations,&#160;except&#160;for&#160;live&#160;vaccines&#160;(see sections&#160;4.5 and&#160;4.6).&#160;<br/>&#160;<br/>In a&#160;subset&#160;of&#160;90 adult&#160;patients&#160;with&#160;rheumatoid arthritis&#160;from&#160;the&#160;ASPIRE&#160;study a&#160;similar&#160;proportion&#160;<br/>of&#160;patients&#160;in&#160;each&#160;treatment&#160;group (methotrexate&#160;plus:&#160;placebo [n&#160;=&#160;17], 3&#160;mg/kg [n&#160;=&#160;27]&#160;or&#160;6&#160;mg/kg&#160;<br/>infliximab&#160;[n&#160;=&#160;46])&#160;mounted an effective&#160;two-fold&#160;increase&#160;in titers&#160;to a&#160;polyvalent&#160;pneumococcal&#160;<br/>vaccine,&#160;indicating&#160;that infliximab&#160;did&#160;not interfere&#160;with&#160;T-cell&#160;independent&#160;humoral&#160;immune&#160;<br/>responses.&#160;However,&#160;studies&#160;from&#160;the&#160;published&#160;literature&#160;in&#160;various&#160;indications&#160;(e.g. rheumatoid&#160;<br/>arthritis,&#160;psoriasis,&#160;Crohn’s&#160;disease)&#160;suggest&#160;that&#160;non-live&#160;vaccinations&#160;received during&#160;treatment&#160;with&#160;<br/>anti-TNF&#160;therapies,&#160;including infliximab&#160;may&#160;elicit&#160;a&#160;lower&#160;immune&#160;response&#160;than in patients&#160;not&#160;<br/>receiving anti-TNF therapy.&#160;<br/>&#160;<br/>Live vaccines/therapeutic infectious agents&#160;<br/>&#160;<br/>In patients&#160;receiving anti-TNF&#160;therapy,&#160;limited&#160;data&#160;are&#160;available&#160;on&#160;the&#160;response&#160;to vaccination with&#160;<br/>live vaccines or&#160;on&#160;the&#160;secondary&#160;transmission&#160;of&#160;infection&#160;by&#160;live&#160;vaccines.&#160;Use of&#160;live vaccines&#160;can&#160;<br/>result&#160;in&#160;clinical&#160;infections, including&#160;disseminated infections.&#160;The&#160;concurrent&#160;administration&#160;of&#160;live&#160;<br/>vaccines&#160;with&#160;infliximab&#160;is not&#160;recommended.&#160;</p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page11-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft110">11&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1110">&#160;<br/>Infant&#160;exposure&#160;<i>in&#160;utero</i>&#160;<br/>In&#160;infants&#160;exposed&#160;<i>in utero</i>&#160;to&#160;infliximab,&#160;fatal&#160;outcome&#160;due to&#160;disseminated&#160;Bacillus Calmette-Guérin&#160;<br/>(BCG)&#160;infection has&#160;been reported&#160;following administration of&#160;BCG&#160;vaccine&#160;after&#160;birth.&#160;A&#160;twelve&#160;<br/>month waiting period following birth is&#160;recommended&#160;before&#160;the&#160;administration of&#160;live&#160;vaccines&#160;to&#160;<br/>infants&#160;exposed&#160;<i>in utero&#160;</i>to&#160;infliximab.&#160;If&#160;infant&#160;infliximab&#160;serum&#160;levels&#160;are&#160;undetectable&#160;or&#160;infliximab&#160;<br/>administration&#160;was&#160;limited&#160;to&#160;the&#160;first&#160;trimester&#160;of&#160;pregnancy,&#160;administration&#160;of&#160;a&#160;live&#160;vaccine&#160;might&#160;be&#160;<br/>considered&#160;at&#160;an&#160;earlier&#160;timepoint&#160;if&#160;there is a&#160;clear&#160;clinical&#160;benefit&#160;for&#160;the individual&#160;infant&#160;(see&#160;<br/>section&#160;4.6).&#160;<br/>&#160;<br/>Infant&#160;exposure&#160;via&#160;breast&#160;milk&#160;<br/>Administration&#160;of&#160;a&#160;live&#160;vaccine&#160;to&#160;a&#160;breastfed&#160;infant while&#160;the&#160;mother&#160;is&#160;receiving&#160;infliximab&#160;is&#160;not&#160;<br/>recommended&#160;unless infant&#160;infliximab&#160;serum&#160;levels&#160;are&#160;undetectable (see&#160;section&#160;4.6).&#160;<br/>&#160;<br/>Therapeutic infectious&#160;agents&#160;<br/>&#160;<br/>Other&#160;uses&#160;of&#160;therapeutic&#160;infectious agents such&#160;as&#160;live&#160;attenuated&#160;bacteria&#160;(e.g.,&#160;BCG&#160;bladder&#160;<br/>instillation&#160;for&#160;the&#160;treatment&#160;of&#160;cancer)&#160;could&#160;result&#160;in&#160;clinical infections,&#160;including&#160;disseminated&#160;<br/>infections. It&#160;is&#160;recommended that&#160;therapeutic&#160;infectious&#160;agents&#160;not&#160;be&#160;given concurrently&#160;with&#160;<br/>infliximab.&#160;<br/>&#160;<br/>Autoimmune&#160;processes&#160;<br/>&#160;<br/>The&#160;relative&#160;deficiency&#160;of&#160;TNFα&#160;caused&#160;by anti-TNF&#160;therapy&#160;may result&#160;in the&#160;initiation of&#160;an&#160;<br/>autoimmune process.&#160;If&#160;a&#160;patient&#160;develops symptoms suggestive of&#160;a&#160;lupus-like&#160;syndrome&#160;following&#160;<br/>treatment with&#160;infliximab&#160;and&#160;is&#160;positive&#160;for&#160;antibodies&#160;against&#160;double-stranded DNA, further&#160;<br/>treatment with&#160;infliximab&#160;must&#160;not&#160;be&#160;given (see&#160;section 4.8).&#160;<br/>&#160;<br/>Neurological&#160;events&#160;<br/>&#160;<br/>Use&#160;of&#160;TNF-blocking agents, including&#160;infliximab,&#160;has&#160;been&#160;associated&#160;with&#160;cases&#160;of&#160;new&#160;onset&#160;or&#160;<br/>exacerbation&#160;of&#160;clinical&#160;symptoms and/or&#160;radiographic evidence of&#160;central&#160;nervous system&#160;<br/>demyelinating disorders, including&#160;multiple&#160;sclerosis,&#160;and peripheral&#160;demyelinating disorders,&#160;<br/>including Guillain-Barré&#160;syndrome. In patients&#160;with pre-existing&#160;or&#160;recent&#160;onset&#160;of&#160;demyelinating&#160;<br/>disorders,&#160;the&#160;benefits&#160;and risks&#160;of&#160;anti-TNF&#160;treatment&#160;should be&#160;carefully&#160;considered before&#160;initiation&#160;<br/>of&#160;infliximab&#160;therapy.&#160;Discontinuation of&#160;infliximab&#160;should be&#160;considered if&#160;these&#160;disorders&#160;develop.&#160;<br/>&#160;<br/>Malignancies&#160;and lymphoproliferative&#160;disorders&#160;<br/>&#160;<br/>In&#160;the&#160;controlled&#160;portions&#160;of&#160;clinical studies&#160;of&#160;TNF-blocking&#160;agents,&#160;more&#160;cases&#160;of&#160;malignancies&#160;<br/>including lymphoma&#160;have&#160;been observed among patients&#160;receiving a&#160;TNF&#160;blocker&#160;compared with&#160;<br/>control&#160;patients. During clinical&#160;studies&#160;of&#160;infliximab&#160;across&#160;all&#160;approved&#160;indications&#160;the&#160;incidence&#160;of&#160;<br/>lymphoma&#160;in&#160;infliximab-treated&#160;patients&#160;was&#160;higher&#160;than expected in&#160;the&#160;general&#160;population, but&#160;the&#160;<br/>occurrence of&#160;lymphoma was rare. In&#160;the&#160;post-marketing setting, cases&#160;of&#160;leukaemia&#160;have&#160;been&#160;<br/>reported&#160;in&#160;patients&#160;treated&#160;with&#160;a&#160;TNF-antagonist. There&#160;is&#160;an&#160;increased background risk for&#160;<br/>lymphoma&#160;and leukaemia&#160;in rheumatoid arthritis&#160;patients&#160;with&#160;long-standing, highly active,&#160;<br/>inflammatory&#160;disease,&#160;which&#160;complicates&#160;risk&#160;estimation.&#160;<br/>&#160;<br/>In an exploratory clinical&#160;study evaluating the&#160;use&#160;of&#160;infliximab&#160;in patients&#160;with&#160;moderate&#160;to severe&#160;<br/>chronic obstructive pulmonary&#160;disease&#160;(COPD),&#160;more&#160;malignancies were&#160;reported&#160;in&#160;infliximab-<br/>treated&#160;patients&#160;compared&#160;with control&#160;patients.&#160;All&#160;patients&#160;had&#160;a&#160;history of&#160;heavy smoking. Caution&#160;<br/>should&#160;be&#160;exercised in&#160;considering treatment&#160;of&#160;patients&#160;with&#160;increased risk for&#160;malignancy due&#160;to&#160;<br/>heavy smoking.&#160;<br/>&#160;<br/>With the&#160;current&#160;knowledge, a&#160;risk&#160;for&#160;the&#160;development&#160;of&#160;lymphomas&#160;or&#160;other&#160;malignancies&#160;in&#160;<br/>patients treated&#160;with&#160;a TNF-blocking agent&#160;cannot&#160;be&#160;excluded (see&#160;section 4.8). Caution should&#160;be&#160;</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page12-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft120">12&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1210">exercised when&#160;considering&#160;TNF-blocking therapy for&#160;patients&#160;with a&#160;history of&#160;malignancy or&#160;when&#160;<br/>considering&#160;continuing&#160;treatment&#160;in patients&#160;who develop a&#160;malignancy.&#160;<br/>&#160;<br/>Caution should&#160;also be&#160;exercised in&#160;patients&#160;with&#160;psoriasis&#160;and a&#160;medical&#160;history of&#160;extensive&#160;<br/>immunosuppressant&#160;therapy or&#160;prolonged PUVA&#160;treatment.&#160;<br/>&#160;<br/>Malignancies,&#160;some fatal,&#160;have been&#160;reported&#160;among children,&#160;adolescents&#160;and young adults&#160;(up&#160;to&#160;<br/>22&#160;years of&#160;age)&#160;treated&#160;with&#160;TNF-</p>
<p style="position:absolute;top:216px;left:335px;white-space:nowrap" class="ft1218">blocking agents&#160;(initiation of&#160;therapy ≤18&#160;years&#160;of&#160;age),&#160;including&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft1210">infliximab&#160;in the&#160;post-marketing setting. Approximately half&#160;the&#160;cases&#160;were&#160;lymphomas. The&#160;other&#160;<br/>cases represented&#160;a variety&#160;of&#160;different&#160;malignancies and&#160;included&#160;rare&#160;malignancies usually&#160;associated&#160;<br/>with immunosuppression. A&#160;risk for&#160;the&#160;development&#160;of&#160;malignancies&#160;in&#160;patients&#160;treated&#160;with&#160;<br/>TNF-blockers&#160;cannot&#160;be&#160;excluded.&#160;<br/>&#160;<br/>Post-marketing cases&#160;of&#160;hepatosplenic T-cell&#160;lymphoma&#160;(HSTCL)&#160;have&#160;been reported in&#160;patients&#160;<br/>treated&#160;with&#160;TNF-blocking&#160;agents&#160;including infliximab. This&#160;rare&#160;type&#160;of&#160;T-cell&#160;lymphoma has a&#160;very&#160;<br/>aggressive disease&#160;course&#160;and&#160;is&#160;usually&#160;fatal.&#160;Almost&#160;all&#160;patients had&#160;received&#160;treatment&#160;with&#160;AZA or&#160;<br/>6-MP&#160;concomitantly with or&#160;immediately&#160;prior&#160;to a&#160;TNF-blocker. The&#160;vast&#160;majority of&#160;infliximab&#160;<br/>cases have occurred&#160;in&#160;patients with&#160;Crohn’s disease&#160;or&#160;ulcerative&#160;colitis&#160;and&#160;most&#160;were&#160;reported&#160;in&#160;<br/>adolescent&#160;or&#160;young adult&#160;males. The&#160;potential&#160;risk with the&#160;combination of&#160;AZA&#160;or&#160;6-MP&#160;and&#160;<br/>infliximab&#160;should be&#160;carefully&#160;considered. A&#160;risk for&#160;the&#160;development&#160;for&#160;hepatosplenic&#160;T-cell&#160;<br/>lymphoma&#160;in patients&#160;treated with&#160;infliximab&#160;cannot&#160;be&#160;excluded&#160;(see&#160;section 4.8).&#160;<br/>&#160;<br/>Melanoma&#160;and&#160;Merkel&#160;cell&#160;carcinoma&#160;have&#160;been&#160;reported&#160;in&#160;patients&#160;treated&#160;with&#160;TNF&#160;blocker&#160;<br/>therapy, including infliximab&#160;(see&#160;section&#160;4.8).&#160;Periodic&#160;skin examination is&#160;recommended,&#160;<br/>particularly&#160;for&#160;patients&#160;with&#160;risk&#160;factors&#160;for&#160;skin&#160;cancer.&#160;<br/>&#160;<br/>A&#160;population-based&#160;retrospective&#160;cohort&#160;study&#160;using&#160;data&#160;from&#160;Swedish national&#160;health registries&#160;<br/>found&#160;an&#160;increased&#160;incidence of&#160;cervical&#160;cancer&#160;in&#160;women&#160;with&#160;rheumatoid&#160;arthritis&#160;treated&#160;with&#160;<br/>infliximab compared to biologics-naïve&#160;patients&#160;or&#160;the&#160;general&#160;population,&#160;including those&#160;over&#160;<br/>60&#160;years&#160;of&#160;age.&#160;Periodic&#160;screening should&#160;continue&#160;in women treated&#160;with&#160;infliximab, including those&#160;<br/>over&#160;60&#160;years of&#160;age.&#160;<br/>&#160;<br/>All&#160;patients with&#160;ulcerative&#160;colitis who&#160;are&#160;at&#160;increased&#160;risk&#160;for&#160;dysplasia or&#160;colon&#160;carcinoma&#160;(for&#160;<br/>example, patients&#160;with long-standing ulcerative&#160;colitis&#160;or&#160;primary sclerosing cholangitis),&#160;or&#160;who had&#160;a&#160;<br/>prior&#160;history of&#160;dysplasia&#160;or&#160;colon&#160;carcinoma&#160;should&#160;be&#160;screened&#160;for&#160;dysplasia&#160;at&#160;regular&#160;intervals&#160;<br/>before&#160;therapy and throughout&#160;their&#160;disease&#160;course. This&#160;evaluation&#160;should include&#160;colonoscopy and&#160;<br/>biopsies&#160;per&#160;local&#160;recommendations.&#160;Current&#160;data&#160;do&#160;not indicate&#160;that&#160;infliximab&#160;treatment influences&#160;<br/>the&#160;risk for&#160;developing dysplasia&#160;or&#160;colon&#160;cancer.&#160;<br/>&#160;<br/>Since&#160;the&#160;possibility&#160;of&#160;increased&#160;risk of&#160;cancer&#160;development&#160;in patients&#160;with newly diagnosed&#160;<br/>dysplasia treated&#160;with&#160;infliximab&#160;is not&#160;established, the&#160;risk&#160;and&#160;benefits&#160;of&#160;continued&#160;therapy&#160;to the&#160;<br/>individual patients&#160;should&#160;be carefully&#160;considered&#160;by&#160;the clinician.&#160;<br/>&#160;<br/>Heart&#160;failure&#160;<br/>&#160;<br/>Infliximab should be&#160;used&#160;with caution&#160;in patients&#160;with mild heart&#160;failure&#160;(NYHA&#160;class&#160;I/II).&#160;Patients&#160;<br/>should be&#160;closely&#160;monitored and&#160;infliximab&#160;must&#160;not&#160;be&#160;continued&#160;in patients&#160;who&#160;develop new&#160;or&#160;<br/>worsening symptoms&#160;of&#160;heart&#160;failure&#160;(see&#160;sections&#160;4.3&#160;and&#160;4.8).&#160;<br/>&#160;<br/>Haematologic reactions&#160;<br/>&#160;<br/>There have been&#160;reports&#160;of&#160;pancytopenia,&#160;leukopenia, neutropenia, and thrombocytopenia&#160;in&#160;patients&#160;<br/>receiving TNF-blockers, including&#160;infliximab. All&#160;patients&#160;should be&#160;advised to&#160;seek immediate&#160;<br/>medical&#160;attention&#160;if&#160;they&#160;develop&#160;signs&#160;and symptoms&#160;suggestive&#160;of&#160;blood dyscrasias&#160;(e.g.&#160;persistent&#160;<br/>fever, bruising,&#160;bleeding, pallor). Discontinuation of&#160;infliximab&#160;therapy&#160;should&#160;be&#160;considered in&#160;<br/>patients&#160;with&#160;confirmed&#160;significant haematologic&#160;abnormalities.&#160;<br/>&#160;</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page13-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft130">13&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1311">Others&#160;<br/>&#160;<br/>There is limited safety experience&#160;of&#160;infliximab&#160;treatment&#160;in patients&#160;who have&#160;undergone&#160;surgical&#160;<br/>procedures,&#160;including arthroplasty. The&#160;long half-life&#160;of&#160;infliximab should&#160;be&#160;taken into consideration&#160;<br/>if&#160;a&#160;surgical&#160;procedure&#160;is planned.&#160;A&#160;patient&#160;who&#160;requires&#160;surgery&#160;while&#160;on&#160;infliximab&#160;should be&#160;<br/>closely&#160;monitored for&#160;infections,&#160;and appropriate&#160;actions&#160;should be&#160;taken.&#160;<br/>&#160;<br/>Failure&#160;to respond to&#160;treatment&#160;for&#160;Crohn’s&#160;disease&#160;may&#160;indicate&#160;the&#160;presence&#160;of&#160;a&#160;fixed&#160;fibrotic&#160;<br/>stricture&#160;that&#160;may require&#160;surgical&#160;treatment.&#160;There&#160;is&#160;no evidence&#160;to&#160;suggest that&#160;infliximab&#160;worsens&#160;<br/>or&#160;causes&#160;fibrotic strictures.&#160;<br/>&#160;<br/>Special&#160;populations&#160;&#160;<br/>&#160;<br/><i>Elderly&#160;<br/>&#160;<br/></i>The&#160;incidence&#160;of&#160;serious&#160;infections&#160;in infliximab-treated&#160;patients 65&#160;years&#160;and&#160;older&#160;was greater&#160;than&#160;<br/>in those&#160;under&#160;65&#160;years&#160;of&#160;age.&#160;Some of&#160;those had&#160;a&#160;fatal&#160;outcome.&#160;Particular&#160;attention&#160;regarding&#160;the&#160;<br/>risk&#160;for&#160;infection should be&#160;paid when treating the&#160;elderly (see&#160;section 4.8).&#160;<br/>&#160;<br/><i>Paediatric&#160;population&#160;<br/></i>&#160;<br/><i>Infections&#160;<br/></i>In clinical&#160;studies,&#160;infections&#160;have&#160;been&#160;reported&#160;in a&#160;higher&#160;proportion&#160;of&#160;paediatric patients&#160;compared&#160;<br/>to adult&#160;patients&#160;(see&#160;section 4.8).&#160;<br/>&#160;<br/><i>Vaccinations&#160;<br/></i>It&#160;is&#160;recommended that&#160;paediatric&#160;patients, if&#160;possible,&#160;be&#160;brought&#160;up to date&#160;with&#160;all&#160;vaccinations&#160;in&#160;<br/>agreement&#160;with&#160;current&#160;vaccination guidelines&#160;prior&#160;to&#160;initiating&#160;infliximab&#160;therapy.&#160;Paediatric patients&#160;<br/>on infliximab&#160;may receive&#160;concurrent&#160;vaccinations,&#160;except&#160;for&#160;live vaccines (see&#160;sections&#160;4.5 and&#160;4.6).&#160;<br/>&#160;<br/><i>Malignancies&#160;and lymphoproliferative&#160;disorders&#160;<br/></i>Malignancies,&#160;some&#160;fatal, have&#160;been reported&#160;among children,&#160;adolescents&#160;and young adults&#160;(up&#160;to&#160;<br/>22&#160;years of&#160;age)&#160;treated&#160;with&#160;TNF-</p>
<p style="position:absolute;top:690px;left:335px;white-space:nowrap" class="ft1318">blocking agents&#160;(initiation of&#160;therapy ≤18&#160;years&#160;of&#160;age),&#160;including&#160;</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft1311">infliximab&#160;in the&#160;post-marketing setting. Approximately half&#160;the&#160;cases&#160;were&#160;lymphomas. The&#160;other&#160;<br/>cases represented&#160;a variety&#160;of&#160;different&#160;malignancies and&#160;included&#160;rare&#160;malignancies usually&#160;associated&#160;<br/>with immunosuppression. A&#160;risk for&#160;the&#160;development&#160;of&#160;malignancies&#160;in&#160;children and&#160;adolescents&#160;<br/>treated&#160;with&#160;TNF-blockers&#160;cannot&#160;be&#160;excluded.&#160;<br/>&#160;<br/>Post-marketing cases&#160;of&#160;hepatosplenic&#160;T-cell&#160;lymphoma have been&#160;reported&#160;in&#160;patients treated&#160;with&#160;<br/>TNF-blocking&#160;agents&#160;including infliximab.&#160;This&#160;rare&#160;type&#160;of&#160;T-cell&#160;lymphoma&#160;has&#160;a&#160;very aggressive&#160;<br/>disease&#160;course and&#160;is usually&#160;fatal.&#160;Almost&#160;all patients&#160;had&#160;received&#160;treatment with&#160;AZA&#160;or&#160;6-MP&#160;<br/>concomitantly&#160;with&#160;or&#160;immediately&#160;prior&#160;to&#160;a&#160;TNF-blocker.&#160;The&#160;vast&#160;majority of&#160;infliximab&#160;cases have&#160;<br/>occurred&#160;in&#160;patients with&#160;Crohn’s&#160;disease or&#160;ulcerative&#160;colitis and&#160;most&#160;were reported&#160;in&#160;adolescent&#160;or&#160;<br/>young adult&#160;males. The&#160;potential&#160;risk with&#160;the&#160;combination&#160;of&#160;AZA&#160;or&#160;6-MP&#160;and&#160;infliximab should be&#160;<br/>carefully&#160;considered. A&#160;risk&#160;for&#160;the&#160;development&#160;for&#160;hepatosplenic&#160;T-cell&#160;lymphoma&#160;in&#160;patients treated&#160;<br/>with&#160;infliximab&#160;cannot&#160;be&#160;excluded (see&#160;section 4.8).&#160;<br/>&#160;<br/>Sodium&#160;content&#160;<br/>&#160;<br/>Remsima&#160;contains&#160;less&#160;than&#160;1 mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;dose,&#160;i.e. essentially&#160;‘sodium-free’.&#160;Remsima&#160;<br/>is&#160;however,&#160;diluted in sodium&#160;chloride&#160;9 mg/ml&#160;(0.9%)&#160;solution for&#160;infusion.&#160;This&#160;should be&#160;taken&#160;into&#160;<br/>consideration&#160;for&#160;patients&#160;on&#160;a controlled&#160;sodium&#160;diet&#160;(see section 6.6).&#160;<br/>&#160;<br/><b>4.5&#160;</b></p>
<p style="position:absolute;top:1097px;left:149px;white-space:nowrap" class="ft131"><b>Interaction&#160;with&#160;other&#160;medicinal&#160;products and&#160;other forms&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft1310">&#160;<br/>No interaction studies&#160;have&#160;been performed.&#160;<br/>&#160;</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page14-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft140">14&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1411">In&#160;rheumatoid&#160;arthritis,&#160;psoriatic&#160;arthritis&#160;and&#160;Crohn's disease patients,&#160;there are indications that&#160;<br/>concomitant&#160;use of&#160;methotrexate&#160;and&#160;other&#160;immunomodulators&#160;reduces&#160;the&#160;formation of&#160;antibodies&#160;<br/>against&#160;infliximab&#160;and&#160;increases the plasma concentrations of&#160;infliximab.&#160;However,&#160;the results&#160;are&#160;<br/>uncertain due&#160;to&#160;limitations&#160;in the&#160;methods&#160;used&#160;for&#160;serum&#160;analyses&#160;of&#160;infliximab and&#160;antibodies&#160;<br/>against infliximab.&#160;<br/>&#160;<br/>Corticosteroids&#160;do not&#160;appear&#160;to affect&#160;the&#160;pharmacokinetics&#160;of&#160;infliximab&#160;to a&#160;clinically relevant&#160;<br/>extent.&#160;<br/>&#160;<br/>The&#160;combination of&#160;infliximab&#160;with&#160;other&#160;biological&#160;therapeutics&#160;used&#160;to&#160;treat&#160;the&#160;same&#160;conditions&#160;as&#160;<br/>infliximab, including&#160;anakinra and&#160;abatacept,&#160;is not&#160;recommended&#160;(see&#160;section&#160;4.4).&#160;<br/>&#160;<br/>It&#160;is&#160;recommended that&#160;live&#160;vaccines&#160;not&#160;be&#160;given&#160;concurrently with&#160;infliximab.&#160;It&#160;is&#160;also&#160;<br/>recommended&#160;that&#160;live vaccines not&#160;be given&#160;to&#160;infants after&#160;<i>in utero</i>&#160;exposure to infliximab for&#160;<br/>12&#160;months&#160;following&#160;birth.&#160;If&#160;infant&#160;infliximab serum&#160;levels&#160;are&#160;undetectable&#160;or&#160;infliximab&#160;<br/>administration&#160;was&#160;limited&#160;to&#160;the&#160;first&#160;trimester&#160;of&#160;pregnancy,&#160;administration&#160;of&#160;a&#160;live&#160;vaccine&#160;might&#160;be&#160;<br/>considered&#160;at&#160;an earlier&#160;timepoint&#160;if&#160;there is a&#160;clear&#160;clinical&#160;benefit&#160;for&#160;the individual&#160;infant&#160;(see&#160;<br/>section 4.4).&#160;<br/>&#160;<br/>Administration&#160;of&#160;a&#160;live&#160;vaccine&#160;to&#160;a&#160;breastfed&#160;infant while&#160;the&#160;mother&#160;is&#160;receiving&#160;infliximab&#160;is&#160;not&#160;<br/>recommended&#160;unless infant&#160;infliximab&#160;serum&#160;levels&#160;are&#160;undetectable&#160;(see sections&#160;4.4 and 4.6).&#160;<br/>&#160;<br/>It&#160;is recommended&#160;that&#160;therapeutic&#160;infectious agents not&#160;be given&#160;concurrently&#160;with&#160;infliximab&#160;(see&#160;<br/>section 4.4).&#160;<br/>&#160;<br/><b>4.6&#160;</b></p>
<p style="position:absolute;top:566px;left:149px;white-space:nowrap" class="ft141"><b>Fertility, pregnancy and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft1410"><b>&#160;<br/></b>Women of&#160;childbearing&#160;potential&#160;<br/>&#160;<br/>Women of&#160;childbearing&#160;potential&#160;should consider&#160;the&#160;use&#160;of&#160;adequate&#160;contraception to prevent&#160;<br/>pregnancy and&#160;continue&#160;its&#160;use&#160;for&#160;at&#160;least&#160;6&#160;months&#160;after&#160;the&#160;last&#160;infliximab&#160;treatment.&#160;<br/>&#160;<br/>Pregnancy&#160;<br/>&#160;<br/>The moderate number&#160;of&#160;prospectively&#160;collected&#160;pregnancies exposed&#160;to infliximab&#160;resulting&#160;in live&#160;<br/>birth with&#160;known outcomes, including approximately&#160;1,100&#160;exposed during&#160;the&#160;first&#160;trimester, does&#160;not&#160;<br/>indicate&#160;an increase&#160;in the&#160;rate&#160;of&#160;malformation in&#160;the&#160;newborn.&#160;&#160;<br/>&#160;<br/>Based&#160;on an&#160;observational&#160;study from&#160;Northern Europe, an increased risk&#160;(OR, 95%&#160;CI;&#160;p-value)&#160;for&#160;<br/>C-section (1.50, 1.14-1.96;&#160;p&#160;=&#160;0.0032), preterm&#160;birth&#160;(1.48, 1.05-2.09;&#160;p&#160;=&#160;0.024),&#160;small&#160;for&#160;<br/>gestational&#160;age&#160;(2.79, 1.54-5.04;&#160;p&#160;=&#160;0.0007), and low&#160;birth&#160;weight&#160;(2.03,&#160;1.41-2.94;&#160;p&#160;=&#160;0.0002)&#160;was&#160;<br/>observed&#160;in women exposed during pregnancy&#160;to&#160;infliximab (with&#160;or&#160;without&#160;<br/>immunomodulators/corticosteroids, 270&#160;pregnancies)&#160;as&#160;compared&#160;to women exposed to&#160;<br/>immunomodulators&#160;and/or&#160;corticosteroids&#160;only (6,460&#160;pregnancies).&#160;The&#160;potential&#160;contribution&#160;of&#160;<br/>exposure&#160;to&#160;infliximab and/or&#160;the&#160;severity of&#160;the&#160;underlying disease&#160;in&#160;these&#160;outcomes&#160;remains&#160;<br/>unclear.&#160;<br/>&#160;<br/>Due&#160;to&#160;its&#160;inhibition&#160;of&#160;TNFα, infliximab administered&#160;during pregnancy could&#160;affect&#160;normal&#160;immune&#160;<br/>responses&#160;in&#160;the&#160;newborn. In a&#160;developmental&#160;toxicity study conducted&#160;in&#160;mice&#160;using&#160;an&#160;analogous&#160;<br/>antibody that&#160;selectively inhibits&#160;the&#160;functional&#160;activity&#160;of&#160;mouse&#160;TNFα, there&#160;was&#160;no indication of&#160;<br/>maternal toxicity,&#160;embryotoxicity&#160;or&#160;teratogenicity&#160;(see&#160;section&#160;5.3).&#160;<br/>&#160;<br/>The&#160;available&#160;clinical&#160;experience&#160;is&#160;limited.&#160;Infliximab&#160;should only be&#160;used during&#160;pregnancy&#160;if&#160;<br/>clearly needed.&#160;<br/>&#160;<br/>Infliximab&#160;crosses&#160;the&#160;placenta&#160;and&#160;has been&#160;detected&#160;in&#160;the serum&#160;of&#160;infants&#160;up to&#160;12&#160;months&#160;<br/>following birth.&#160;After&#160;<i>in&#160;utero</i>&#160;exposure&#160;to&#160;infliximab, infants&#160;may be&#160;at&#160;increased&#160;risk&#160;of&#160;infection,&#160;</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1519{font-size:17px;line-height:24px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page15-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft150">15&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1511">including serious&#160;disseminated&#160;infection&#160;that&#160;can become&#160;fatal.&#160;Administration&#160;of&#160;live&#160;vaccines&#160;<br/>(e.g.,&#160;BCG&#160;vaccine)&#160;to&#160;infants&#160;exposed to&#160;infliximab&#160;<i>in utero</i>&#160;is&#160;not&#160;recommended for&#160;12&#160;months&#160;after&#160;<br/>birth&#160;(see&#160;sections&#160;4.4&#160;and 4.5).&#160;If&#160;infant&#160;infliximab&#160;serum&#160;levels are undetectable or&#160;infliximab&#160;<br/>administration&#160;was&#160;limited&#160;to&#160;the&#160;first trimester&#160;of&#160;pregnancy, administration&#160;of&#160;a&#160;live&#160;vaccine&#160;might&#160;be&#160;<br/>considered&#160;at&#160;an&#160;earlier&#160;timepoint&#160;if&#160;there is&#160;a&#160;clear&#160;clinical&#160;benefit&#160;for&#160;the&#160;individual infant.&#160;Cases of&#160;<br/>agranulocytosis have also&#160;been&#160;reported&#160;(see section&#160;4.8).&#160;<br/>&#160;<br/>Breast-feeding&#160;<br/>&#160;<br/>Limited&#160;data&#160;from published&#160;literature&#160;indicate&#160;infliximab&#160;has been&#160;detected&#160;at low&#160;levels&#160;in human&#160;<br/>milk&#160;at&#160;concentrations&#160;up&#160;to&#160;5%&#160;of&#160;the maternal&#160;serum&#160;level.&#160;Infliximab has&#160;also been detected&#160;in&#160;<br/>infant&#160;serum&#160;after&#160;exposure&#160;to&#160;infliximab&#160;via breast&#160;milk.&#160;While&#160;systemic exposure&#160;in&#160;a breastfed&#160;<br/>infant&#160;is&#160;expected&#160;to be&#160;low&#160;because&#160;infliximab&#160;is&#160;largely&#160;degraded&#160;in&#160;the gastrointestinal&#160;tract,&#160;the&#160;<br/>administration&#160;of&#160;live&#160;vaccines&#160;to a&#160;breastfed&#160;infant&#160;when the&#160;mother&#160;is&#160;receiving&#160;infliximab is&#160;not&#160;<br/>recommended&#160;unless infant&#160;infliximab&#160;serum&#160;levels&#160;are&#160;undetectable.&#160;Infliximab&#160;could be&#160;considered&#160;<br/>for&#160;use&#160;during breast-feeding.&#160;<br/>&#160;<br/>Fertility&#160;<br/>&#160;<br/>There&#160;are&#160;insufficient&#160;preclinical&#160;data&#160;to&#160;draw&#160;conclusions on&#160;the&#160;effects of&#160;infliximab&#160;on&#160;fertility&#160;and&#160;<br/>general&#160;reproductive&#160;function (see&#160;section 5.3).&#160;<br/>&#160;<br/><b>4.7&#160;</b></p>
<p style="position:absolute;top:507px;left:149px;white-space:nowrap" class="ft151"><b>Effects&#160;on&#160;ability&#160;to drive&#160;and&#160;use machines&#160;</b></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft1511">&#160;<br/>Remsima&#160;may have&#160;a&#160;minor&#160;influence&#160;on&#160;the&#160;ability to&#160;drive&#160;and&#160;use&#160;machines. Dizziness&#160;may occur&#160;<br/>following&#160;administration&#160;of&#160;infliximab&#160;(see&#160;section&#160;4.8).&#160;<br/>&#160;<br/><b>4.8&#160;</b></p>
<p style="position:absolute;top:602px;left:149px;white-space:nowrap" class="ft151"><b>Undesirable effects&#160;</b></p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft1511">&#160;<br/>Summary&#160;of&#160;the&#160;safety&#160;profile&#160;<br/>&#160;<br/>Upper&#160;respiratory&#160;tract&#160;infection&#160;was the most&#160;common&#160;adverse drug&#160;reaction&#160;(ADR)&#160;reported&#160;in&#160;<br/>clinical trials,&#160;occurring in 25.3%&#160;of&#160;infliximab-treated patients&#160;compared&#160;with&#160;16.5%&#160;of&#160;control&#160;<br/>patients.&#160;The most&#160;serious&#160;ADRs associated&#160;with&#160;the&#160;use of&#160;TNF&#160;blockers&#160;that&#160;have&#160;been reported for&#160;<br/>infliximab&#160;include&#160;HBV&#160;reactivation,&#160;CHF&#160;(congestive&#160;heart&#160;failure),&#160;serious&#160;infections&#160;(including&#160;<br/>sepsis, opportunistic&#160;infections&#160;and TB), serum&#160;sickness&#160;(delayed hypersensitivity&#160;reactions),&#160;<br/>haematologic reactions,&#160;systemic&#160;lupus&#160;erythematosus/lupus-like&#160;syndrome, demyelinating disorders,&#160;<br/>hepatobiliary events, lymphoma,&#160;HSTCL,&#160;leukaemia,&#160;Merkel&#160;cell&#160;carcinoma,&#160;melanoma,&#160;paediatric&#160;<br/>malignancy,&#160;sarcoidosis/sarcoid-like&#160;reaction,&#160;intestinal&#160;or&#160;perianal&#160;abscess&#160;(in&#160;Crohn’s disease),&#160;and&#160;<br/>serious&#160;infusion&#160;reactions&#160;(see&#160;section 4.4).&#160;<br/>&#160;<br/>Tabulated&#160;list&#160;of&#160;adverse reactions&#160;<br/>&#160;<br/>Table&#160;1&#160;lists the ADRs based&#160;on&#160;experience from&#160;clinical&#160;studies&#160;as well&#160;as adverse reactions,&#160;some&#160;<br/>with&#160;fatal&#160;outcome, reported from&#160;post-marketing experience.&#160;Within&#160;the organ&#160;system&#160;classes,&#160;<br/>adverse&#160;reactions&#160;are&#160;listed under&#160;headings&#160;of&#160;frequency&#160;using&#160;the&#160;following categories:&#160;very&#160;common&#160;</p>
<p style="position:absolute;top:957px;left:106px;white-space:nowrap" class="ft1510">(≥&#160;1/10);&#160;common&#160;(≥&#160;1/100&#160;to &lt;&#160;1/10);&#160;uncommon (≥&#160;1/1,000 to&#160;&lt;&#160;1/100);&#160;rare&#160;(≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000);&#160;very&#160;rare&#160;(&lt;&#160;1/10,000), not&#160;known&#160;(cannot&#160;be&#160;estimated from&#160;the&#160;available&#160;data).&#160;Within&#160;<br/>each&#160;frequency&#160;grouping,&#160;undesirable effects&#160;are presented&#160;in&#160;order&#160;of&#160;decreasing&#160;seriousness.&#160;<br/>&#160;</p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page16-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft160">16&#160;</p>
<p style="position:absolute;top:89px;left:120px;white-space:nowrap" class="ft165"><b>Table&#160;1&#160;<br/>Adverse&#160;reactions&#160;in&#160;clinical&#160;studies and&#160;from&#160;post-marketing&#160;experience</b><i>&#160;</i></p>
<p style="position:absolute;top:128px;left:128px;white-space:nowrap" class="ft163"><i>Infections&#160;and infestations&#160;</i></p>
<p style="position:absolute;top:149px;left:157px;white-space:nowrap" class="ft162">Very&#160;common:&#160;</p>
<p style="position:absolute;top:149px;left:317px;white-space:nowrap" class="ft162">Viral&#160;infection (e.g.&#160;influenza, herpes&#160;virus&#160;infection).&#160;</p>
<p style="position:absolute;top:171px;left:157px;white-space:nowrap" class="ft162">Common:&#160;</p>
<p style="position:absolute;top:171px;left:317px;white-space:nowrap" class="ft162">Bacterial&#160;infections (e.g.&#160;sepsis,&#160;cellulitis,&#160;abscess).&#160;&#160;</p>
<p style="position:absolute;top:195px;left:157px;white-space:nowrap" class="ft162">Uncommon:&#160;</p>
<p style="position:absolute;top:195px;left:317px;white-space:nowrap" class="ft162">Tuberculosis, fungal&#160;infections&#160;(e.g. candidiasis,&#160;onychomycosis).&#160;</p>
<p style="position:absolute;top:217px;left:157px;white-space:nowrap" class="ft162">Rare:&#160;</p>
<p style="position:absolute;top:217px;left:317px;white-space:nowrap" class="ft1611">Meningitis,&#160;opportunistic&#160;infections&#160;(such as&#160;invasive&#160;fungal&#160;infections&#160;<br/>[pneumocystosis, histoplasmosis,&#160;aspergillosis, coccidioidomycosis,&#160;<br/>cryptococcosis,&#160;blastomycosis],&#160;bacterial&#160;infections&#160;[atypical&#160;<br/>mycobacterial,&#160;listeriosis,&#160;salmonellosis],&#160;and&#160;viral infections&#160;<br/>[cytomegalovirus]),&#160;parasitic&#160;infections, hepatitis&#160;B&#160;reactivation.&#160;</p>
<p style="position:absolute;top:325px;left:157px;white-space:nowrap" class="ft162">Not&#160;known:&#160;</p>
<p style="position:absolute;top:325px;left:317px;white-space:nowrap" class="ft1611">Vaccine&#160;breakthrough infection (after&#160;<i>in utero&#160;</i>exposure&#160;to&#160;<br/>infliximab)*.&#160;</p>
<p style="position:absolute;top:363px;left:128px;white-space:nowrap" class="ft163"><i>Neoplasms&#160;benign, malignant&#160;and&#160;unspecified (including cysts&#160;and polyps)&#160;</i></p>
<p style="position:absolute;top:384px;left:157px;white-space:nowrap" class="ft162">Rare:&#160;</p>
<p style="position:absolute;top:384px;left:317px;white-space:nowrap" class="ft1610">Lymphoma,&#160;non-Hodgkin’s&#160;lymphoma,&#160;Hodgkin’s&#160;disease, leukaemia,&#160;<br/>melanoma,&#160;cervical&#160;cancer.&#160;</p>
<p style="position:absolute;top:422px;left:157px;white-space:nowrap" class="ft162">Not&#160;known:&#160;</p>
<p style="position:absolute;top:422px;left:317px;white-space:nowrap" class="ft1610">Hepatosplenic T-cell&#160;lymphoma&#160;(primarily in&#160;adolescents&#160;and young&#160;<br/>adult&#160;males&#160;with&#160;Crohn’s disease and&#160;ulcerative colitis),&#160;Merkel&#160;cell&#160;<br/>carcinoma,&#160;Kaposi’s sarcoma.&#160;</p>
<p style="position:absolute;top:487px;left:128px;white-space:nowrap" class="ft163"><i>Blood and lymphatic&#160;system&#160;disorders&#160;</i></p>
<p style="position:absolute;top:508px;left:157px;white-space:nowrap" class="ft162">Common:&#160;</p>
<p style="position:absolute;top:508px;left:317px;white-space:nowrap" class="ft162">Neutropenia,&#160;leukopenia,&#160;anaemia, lymphadenopathy.&#160;</p>
<p style="position:absolute;top:527px;left:157px;white-space:nowrap" class="ft162">Uncommon:&#160;</p>
<p style="position:absolute;top:527px;left:317px;white-space:nowrap" class="ft162">Thrombocytopenia, lymphopenia, lymphocytosis.&#160;&#160;</p>
<p style="position:absolute;top:547px;left:157px;white-space:nowrap" class="ft162">Rare:&#160;</p>
<p style="position:absolute;top:547px;left:317px;white-space:nowrap" class="ft1610">Agranulocytosis&#160;(including&#160;infants&#160;exposed&#160;<i>in utero&#160;</i>to&#160;infliximab),&#160;<br/>thrombotic&#160;thrombocytopenic&#160;purpura, pancytopenia,&#160;haemolytic&#160;<br/>anaemia, idiopathic&#160;thrombocytopenic&#160;purpura.&#160;</p>
<p style="position:absolute;top:605px;left:128px;white-space:nowrap" class="ft163"><i>Immune system&#160;disorders&#160;</i></p>
<p style="position:absolute;top:626px;left:157px;white-space:nowrap" class="ft162">Common:&#160;</p>
<p style="position:absolute;top:626px;left:317px;white-space:nowrap" class="ft162">Allergic&#160;respiratory&#160;symptom.&#160;</p>
<p style="position:absolute;top:647px;left:157px;white-space:nowrap" class="ft162">Uncommon:&#160;</p>
<p style="position:absolute;top:647px;left:317px;white-space:nowrap" class="ft1611">Anaphylactic&#160;reaction, lupus-like&#160;syndrome,&#160;serum&#160;sickness&#160;or&#160;serum&#160;<br/>sickness-like reaction.&#160;</p>
<p style="position:absolute;top:685px;left:157px;white-space:nowrap" class="ft162">Rare&#160;&#160;</p>
<p style="position:absolute;top:685px;left:317px;white-space:nowrap" class="ft162">Anaphylactic&#160;shock, vasculitis, sarcoid-like reaction&#160;</p>
<p style="position:absolute;top:706px;left:128px;white-space:nowrap" class="ft163"><i>Metabolism&#160;and nutrition disorders&#160;</i></p>
<p style="position:absolute;top:728px;left:157px;white-space:nowrap" class="ft162">Uncommon:&#160;</p>
<p style="position:absolute;top:728px;left:317px;white-space:nowrap" class="ft162">Dyslipidaemia.&#160;</p>
<p style="position:absolute;top:748px;left:128px;white-space:nowrap" class="ft163"><i>Psychiatric&#160;disorders&#160;</i></p>
<p style="position:absolute;top:769px;left:157px;white-space:nowrap" class="ft162">Common:&#160;</p>
<p style="position:absolute;top:769px;left:317px;white-space:nowrap" class="ft162">Depression, insomnia.&#160;</p>
<p style="position:absolute;top:788px;left:157px;white-space:nowrap" class="ft162">Uncommon:&#160;</p>
<p style="position:absolute;top:788px;left:317px;white-space:nowrap" class="ft162">Amnesia,&#160;agitation, confusion, somnolence, nervousness.&#160;</p>
<p style="position:absolute;top:808px;left:157px;white-space:nowrap" class="ft162">Rare:&#160;</p>
<p style="position:absolute;top:808px;left:317px;white-space:nowrap" class="ft162">Apathy.&#160;</p>
<p style="position:absolute;top:836px;left:128px;white-space:nowrap" class="ft163"><i>Nervous&#160;system&#160;disorders&#160;</i></p>
<p style="position:absolute;top:857px;left:157px;white-space:nowrap" class="ft162">Very common:&#160;</p>
<p style="position:absolute;top:857px;left:317px;white-space:nowrap" class="ft162">Headache.&#160;</p>
<p style="position:absolute;top:881px;left:157px;white-space:nowrap" class="ft162">Common:&#160;</p>
<p style="position:absolute;top:881px;left:317px;white-space:nowrap" class="ft162">Vertigo, dizziness, hypoaesthesia, paraesthesia.&#160;</p>
<p style="position:absolute;top:903px;left:157px;white-space:nowrap" class="ft162">Uncommon:&#160;</p>
<p style="position:absolute;top:903px;left:317px;white-space:nowrap" class="ft162">Seizure,&#160;neuropathy.&#160;</p>
<p style="position:absolute;top:926px;left:157px;white-space:nowrap" class="ft162">Rare:&#160;</p>
<p style="position:absolute;top:926px;left:317px;white-space:nowrap" class="ft1610">Transverse&#160;myelitis,&#160;central&#160;nervous system&#160;demyelinating&#160;disorders&#160;<br/>(multiple&#160;sclerosis-like&#160;disease&#160;and optic&#160;neuritis), peripheral&#160;<br/>demyelinating&#160;disorders (such&#160;as Guillain-Barré&#160;syndrome, chronic&#160;<br/>inflammatory demyelinating polyneuropathy and multifocal&#160;motor&#160;<br/>neuropathy).&#160;</p>
<p style="position:absolute;top:1027px;left:157px;white-space:nowrap" class="ft162">Not&#160;known:&#160;</p>
<p style="position:absolute;top:1027px;left:317px;white-space:nowrap" class="ft162">Cerebrovascular&#160;accidents in&#160;close&#160;temporal&#160;association&#160;with&#160;infusion.&#160;</p>
<p style="position:absolute;top:1047px;left:128px;white-space:nowrap" class="ft163"><i>Eye disorders&#160;</i></p>
<p style="position:absolute;top:1069px;left:157px;white-space:nowrap" class="ft162">Common&#160;</p>
<p style="position:absolute;top:1069px;left:317px;white-space:nowrap" class="ft162">Conjunctivitis&#160;</p>
<p style="position:absolute;top:1091px;left:157px;white-space:nowrap" class="ft162">Uncommon&#160;</p>
<p style="position:absolute;top:1091px;left:317px;white-space:nowrap" class="ft162">Keratitis,&#160;periorbital&#160;oedema, hordeolum&#160;</p>
<p style="position:absolute;top:1114px;left:157px;white-space:nowrap" class="ft162">Rare&#160;</p>
<p style="position:absolute;top:1114px;left:317px;white-space:nowrap" class="ft162">Endophthalmitis&#160;</p>
<p style="position:absolute;top:1136px;left:157px;white-space:nowrap" class="ft162">Not&#160;known&#160;</p>
<p style="position:absolute;top:1136px;left:317px;white-space:nowrap" class="ft162">Transient&#160;visual&#160;loss&#160;occurring during or&#160;within&#160;2&#160;hours&#160;of&#160;infusion&#160;</p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page17-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft170">17&#160;</p>
<p style="position:absolute;top:90px;left:128px;white-space:nowrap" class="ft173"><i>Cardiac disorders&#160;</i></p>
<p style="position:absolute;top:111px;left:157px;white-space:nowrap" class="ft172">Common&#160;&#160;</p>
<p style="position:absolute;top:111px;left:317px;white-space:nowrap" class="ft172">Tachycardia,&#160;palpitation&#160;</p>
<p style="position:absolute;top:132px;left:157px;white-space:nowrap" class="ft172">Uncommon&#160;</p>
<p style="position:absolute;top:132px;left:317px;white-space:nowrap" class="ft1711">Cardiac failure&#160;(new&#160;onset&#160;or&#160;worsening), arrhythmia, syncope,&#160;<br/>bradycardia&#160;</p>
<p style="position:absolute;top:170px;left:157px;white-space:nowrap" class="ft172">Rare&#160;</p>
<p style="position:absolute;top:170px;left:317px;white-space:nowrap" class="ft172">Cyanosis, pericardial&#160;effusion&#160;</p>
<p style="position:absolute;top:191px;left:157px;white-space:nowrap" class="ft172">Not&#160;known&#160;</p>
<p style="position:absolute;top:191px;left:317px;white-space:nowrap" class="ft172">Myocardial&#160;ischaemia/myocardial infarction&#160;</p>
<p style="position:absolute;top:232px;left:128px;white-space:nowrap" class="ft173"><i>Vascular disorders&#160;</i></p>
<p style="position:absolute;top:254px;left:157px;white-space:nowrap" class="ft172">Common&#160;</p>
<p style="position:absolute;top:254px;left:317px;white-space:nowrap" class="ft172">Hypotension, hypertension,&#160;ecchymosis,&#160;hot&#160;flush,&#160;flushing&#160;</p>
<p style="position:absolute;top:275px;left:157px;white-space:nowrap" class="ft172">Uncommon&#160;</p>
<p style="position:absolute;top:275px;left:317px;white-space:nowrap" class="ft172">Peripheral ischaemia,&#160;thrombophlebitis,&#160;haematoma&#160;</p>
<p style="position:absolute;top:302px;left:157px;white-space:nowrap" class="ft172">Rare&#160;</p>
<p style="position:absolute;top:302px;left:317px;white-space:nowrap" class="ft172">Circulatory&#160;failure,&#160;petechia,&#160;vasospasm&#160;</p>
<p style="position:absolute;top:327px;left:128px;white-space:nowrap" class="ft173"><i>Respiratory, thoracic&#160;and mediastinal&#160;disorders&#160;</i></p>
<p style="position:absolute;top:351px;left:157px;white-space:nowrap" class="ft172">Very common&#160;</p>
<p style="position:absolute;top:351px;left:317px;white-space:nowrap" class="ft172">Upper&#160;respiratory tract&#160;infection,&#160;sinusitis&#160;</p>
<p style="position:absolute;top:374px;left:157px;white-space:nowrap" class="ft172">Common&#160;</p>
<p style="position:absolute;top:374px;left:317px;white-space:nowrap" class="ft1711">Lower&#160;respiratory tract&#160;infection (e.g. bronchitis,&#160;pneumonia),&#160;<br/>dyspnoea, epistaxis&#160;</p>
<p style="position:absolute;top:415px;left:157px;white-space:nowrap" class="ft172">Uncommon&#160;</p>
<p style="position:absolute;top:415px;left:317px;white-space:nowrap" class="ft172">Pulmonary oedema, bronchospasm,&#160;pleurisy,&#160;pleural&#160;effusion&#160;</p>
<p style="position:absolute;top:436px;left:157px;white-space:nowrap" class="ft172">Rare&#160;</p>
<p style="position:absolute;top:436px;left:317px;white-space:nowrap" class="ft1710">Interstitial&#160;lung disease&#160;(including&#160;rapidly&#160;progressive&#160;disease, lung&#160;<br/>fibrosis&#160;and pneumonitis)&#160;</p>
<p style="position:absolute;top:478px;left:128px;white-space:nowrap" class="ft173"><i>Gastrointestinal disorders&#160;</i></p>
<p style="position:absolute;top:499px;left:157px;white-space:nowrap" class="ft172">Very&#160;common:&#160;&#160;</p>
<p style="position:absolute;top:499px;left:317px;white-space:nowrap" class="ft172">Abdominal&#160;pain, nausea&#160;</p>
<p style="position:absolute;top:523px;left:157px;white-space:nowrap" class="ft172">Common:&#160;&#160;</p>
<p style="position:absolute;top:523px;left:317px;white-space:nowrap" class="ft1711">Gastrointestinal&#160;haemorrhage, diarrhoea,&#160;dyspepsia, gastroesophageal&#160;<br/>reflux, constipation&#160;</p>
<p style="position:absolute;top:561px;left:157px;white-space:nowrap" class="ft172">Uncommon&#160;</p>
<p style="position:absolute;top:561px;left:317px;white-space:nowrap" class="ft1711">Intestinal&#160;perforation, intestinal&#160;stenosis,&#160;diverticulitis,&#160;pancreatitis,&#160;<br/>cheilitis&#160;</p>
<p style="position:absolute;top:604px;left:128px;white-space:nowrap" class="ft173"><i>Hepatobiliary&#160;disorders&#160;</i></p>
<p style="position:absolute;top:626px;left:157px;white-space:nowrap" class="ft172">Common:&#160;</p>
<p style="position:absolute;top:626px;left:317px;white-space:nowrap" class="ft172">Hepatic&#160;function&#160;abnormal,&#160;transaminases increased.&#160;</p>
<p style="position:absolute;top:647px;left:157px;white-space:nowrap" class="ft172">Uncommon:&#160;</p>
<p style="position:absolute;top:647px;left:317px;white-space:nowrap" class="ft172">Hepatitis,&#160;hepatocellular&#160;damage,&#160;cholecystitis.&#160;</p>
<p style="position:absolute;top:669px;left:157px;white-space:nowrap" class="ft172">Rare:&#160;</p>
<p style="position:absolute;top:669px;left:317px;white-space:nowrap" class="ft172">Autoimmune&#160;hepatitis, jaundice.&#160;</p>
<p style="position:absolute;top:690px;left:157px;white-space:nowrap" class="ft172">Not&#160;known:&#160;</p>
<p style="position:absolute;top:690px;left:317px;white-space:nowrap" class="ft172">Liver&#160;failure.&#160;</p>
<p style="position:absolute;top:721px;left:128px;white-space:nowrap" class="ft173"><i>Skin and subcutaneous&#160;tissue&#160;disorders&#160;</i></p>
<p style="position:absolute;top:739px;left:157px;white-space:nowrap" class="ft172">Common:&#160;</p>
<p style="position:absolute;top:739px;left:317px;white-space:nowrap" class="ft1710">New&#160;onset&#160;or&#160;worsening&#160;psoriasis&#160;including&#160;pustular&#160;psoriasis&#160;<br/>(primarily&#160;palm &amp;&#160;soles), urticaria, rash, pruritus, hyperhidrosis, dry&#160;<br/>skin,&#160;fungal&#160;dermatitis,&#160;eczema,&#160;alopecia.&#160;</p>
<p style="position:absolute;top:796px;left:157px;white-space:nowrap" class="ft172">Uncommon:&#160;</p>
<p style="position:absolute;top:796px;left:317px;white-space:nowrap" class="ft1711">Bullous&#160;eruption,&#160;seborrhoea, rosacea, skin papilloma,&#160;hyperkeratosis,&#160;<br/>abnormal skin&#160;pigmentation.&#160;</p>
<p style="position:absolute;top:841px;left:157px;white-space:nowrap" class="ft172">Rare:&#160;</p>
<p style="position:absolute;top:841px;left:317px;white-space:nowrap" class="ft1711">Toxic&#160;epidermal&#160;necrolysis,&#160;Stevens-Johnson&#160;syndrome, erythema&#160;<br/>multiforme, furunculosis, linear&#160;IgA&#160;bullous&#160;dermatosis&#160;(LABD),&#160;<br/>acute generalised&#160;exanthematous&#160;pustulosis (AGEP),&#160;lichenoid&#160;<br/>reactions.&#160;</p>
<p style="position:absolute;top:917px;left:157px;white-space:nowrap" class="ft172">Not&#160;known:&#160;</p>
<p style="position:absolute;top:917px;left:317px;white-space:nowrap" class="ft172">Worsening of&#160;symptoms&#160;of&#160;dermatomyositis.&#160;</p>
<p style="position:absolute;top:945px;left:128px;white-space:nowrap" class="ft173"><i>Musculoskeletal&#160;and&#160;connective tissue disorders&#160;</i></p>
<p style="position:absolute;top:966px;left:157px;white-space:nowrap" class="ft172">Common:&#160;</p>
<p style="position:absolute;top:966px;left:311px;white-space:nowrap" class="ft172">Arthralgia,&#160;myalgia,&#160;back&#160;pain.&#160;</p>
<p style="position:absolute;top:998px;left:128px;white-space:nowrap" class="ft173"><i>Renal&#160;and urinary&#160;disorders&#160;</i></p>
<p style="position:absolute;top:1020px;left:157px;white-space:nowrap" class="ft172">Common:&#160;</p>
<p style="position:absolute;top:1020px;left:317px;white-space:nowrap" class="ft172">Urinary&#160;tract infection.&#160;</p>
<p style="position:absolute;top:1041px;left:157px;white-space:nowrap" class="ft172">Uncommon:&#160;</p>
<p style="position:absolute;top:1041px;left:317px;white-space:nowrap" class="ft172">Pyelonephritis.&#160;</p>
<p style="position:absolute;top:1074px;left:128px;white-space:nowrap" class="ft173"><i>Reproductive system&#160;and&#160;breast&#160;disorders&#160;</i></p>
<p style="position:absolute;top:1095px;left:157px;white-space:nowrap" class="ft172">Uncommon:&#160;</p>
<p style="position:absolute;top:1095px;left:311px;white-space:nowrap" class="ft172">Vaginitis.&#160;</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page18-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft180">18&#160;</p>
<p style="position:absolute;top:90px;left:128px;white-space:nowrap" class="ft183"><i>General&#160;disorders and&#160;administration site&#160;conditions&#160;</i></p>
<p style="position:absolute;top:111px;left:157px;white-space:nowrap" class="ft182">Very common:&#160;</p>
<p style="position:absolute;top:111px;left:317px;white-space:nowrap" class="ft182">Infusion-related&#160;reaction,&#160;pain.&#160;</p>
<p style="position:absolute;top:133px;left:157px;white-space:nowrap" class="ft182">Common:&#160;</p>
<p style="position:absolute;top:133px;left:317px;white-space:nowrap" class="ft182">Chest&#160;pain, fatigue,&#160;fever,&#160;injection site&#160;reaction,&#160;chills, oedema.&#160;</p>
<p style="position:absolute;top:155px;left:157px;white-space:nowrap" class="ft182">Uncommon:&#160;</p>
<p style="position:absolute;top:155px;left:317px;white-space:nowrap" class="ft182">Impaired healing.&#160;</p>
<p style="position:absolute;top:176px;left:157px;white-space:nowrap" class="ft182">Rare:&#160;</p>
<p style="position:absolute;top:176px;left:317px;white-space:nowrap" class="ft182">Granulomatous&#160;lesion.&#160;</p>
<p style="position:absolute;top:206px;left:128px;white-space:nowrap" class="ft183"><i>Investigations&#160;</i></p>
<p style="position:absolute;top:227px;left:157px;white-space:nowrap" class="ft182">Uncommon:&#160;</p>
<p style="position:absolute;top:227px;left:317px;white-space:nowrap" class="ft182">Autoantibody positive.&#160;</p>
<p style="position:absolute;top:249px;left:157px;white-space:nowrap" class="ft182">Rare:&#160;</p>
<p style="position:absolute;top:249px;left:317px;white-space:nowrap" class="ft182">Complement&#160;factor&#160;abnormal.&#160;</p>
<p style="position:absolute;top:281px;left:128px;white-space:nowrap" class="ft182">*&#160;&#160;including bovine&#160;tuberculosis&#160;(disseminated BCG&#160;infection), see&#160;section&#160;4.4&#160;</p>
<p style="position:absolute;top:300px;left:106px;white-space:nowrap" class="ft1811">&#160;<br/>Description&#160;of&#160;selected&#160;adverse&#160;drug&#160;reactions&#160;<br/>&#160;<br/>Infusion-related&#160;reactions&#160;<br/>&#160;<br/>An&#160;infusion-related&#160;reaction&#160;was&#160;defined in clinical&#160;studies&#160;as&#160;any adverse&#160;event&#160;occurring during&#160;an&#160;<br/>infusion&#160;or&#160;within&#160;1&#160;hour&#160;after&#160;an&#160;infusion.&#160;In&#160;phase&#160;III&#160;clinical&#160;studies,&#160;18%&#160;of&#160;infliximab-treated&#160;<br/>patients compared&#160;with&#160;5%&#160;of&#160;placebo-treated&#160;patients&#160;experienced an&#160;infusion-related&#160;reaction.&#160;<br/>Overall,&#160;a&#160;higher&#160;proportion of&#160;patients&#160;receiving infliximab&#160;monotherapy&#160;experienced&#160;an&#160;<br/>infusion-related&#160;reaction&#160;compared&#160;to&#160;patients&#160;receiving&#160;infliximab&#160;with&#160;concomitant&#160;<br/>immunomodulators.&#160;Approximately 3%&#160;of&#160;patients&#160;discontinued&#160;treatment&#160;due&#160;to&#160;infusion-related&#160;<br/>reactions&#160;and all&#160;patients&#160;recovered with or&#160;without&#160;medical&#160;therapy.&#160;Of&#160;infliximab-treated&#160;patients&#160;<br/>who had an&#160;infusion&#160;reaction during&#160;the&#160;induction period, through week 6, 27%&#160;experienced an&#160;<br/>infusion&#160;reaction during the&#160;maintenance&#160;period, week&#160;7 through week 54. Of&#160;patients&#160;who did&#160;not&#160;<br/>have&#160;an infusion&#160;reaction during&#160;the&#160;induction&#160;period,&#160;9%&#160;experienced an infusion&#160;reaction during the&#160;<br/>maintenance&#160;period.&#160;<br/>&#160;<br/>In&#160;a&#160;clinical&#160;study&#160;of&#160;patients&#160;with&#160;rheumatoid&#160;arthritis&#160;(ASPIRE),&#160;infusions&#160;were&#160;to be&#160;administered&#160;<br/>over&#160;2&#160;hours&#160;for&#160;the&#160;first&#160;3&#160;infusions.&#160;The&#160;duration&#160;of&#160;subsequent&#160;infusions&#160;could be&#160;shortened to&#160;not&#160;<br/>less&#160;than&#160;40&#160;minutes&#160;in patients&#160;who did&#160;not&#160;experience&#160;serious&#160;infusion&#160;reactions.&#160;In this&#160;trial,&#160;sixty&#160;<br/>six&#160;percent&#160;of&#160;the&#160;patients&#160;(686 out&#160;of&#160;1,040)&#160;received&#160;at&#160;least&#160;one&#160;shortened&#160;infusion of&#160;90&#160;minutes&#160;or&#160;<br/>less&#160;and 44%&#160;of&#160;the&#160;patients&#160;(454&#160;out&#160;of&#160;1,040)&#160;received at&#160;least&#160;one&#160;shortened infusion&#160;of&#160;60&#160;minutes&#160;<br/>or&#160;less.&#160;Of&#160;the infliximab-treated&#160;patients who&#160;received&#160;at&#160;least&#160;one&#160;shortened&#160;infusion,&#160;<br/>infusion-related reactions&#160;occurred&#160;in 15%&#160;of&#160;patients&#160;and serious&#160;infusion reactions&#160;occurred&#160;in 0.4%&#160;<br/>of&#160;patients.&#160;<br/>&#160;<br/>In a&#160;clinical&#160;study of&#160;patients&#160;with Crohn’s&#160;disease&#160;(SONIC), infusion-related&#160;reactions occurred&#160;in&#160;<br/>16.6%&#160;(27/163)&#160;of&#160;patients&#160;receiving infliximab monotherapy,&#160;5%&#160;(9/179)&#160;of&#160;patients&#160;receiving&#160;<br/>infliximab&#160;in combination&#160;with AZA, and&#160;5.6%&#160;(9/161)&#160;of&#160;patients&#160;receiving AZA&#160;monotherapy. One&#160;<br/>serious&#160;infusion reaction (&lt;1%)&#160;occurred in&#160;a&#160;patient&#160;on infliximab&#160;monotherapy.&#160;<br/>&#160;<br/>In post-marketing&#160;experience,&#160;cases&#160;of&#160;anaphylactic-like&#160;reactions, including laryngeal/pharyngeal&#160;<br/>oedema and&#160;severe bronchospasm,&#160;and&#160;seizure have been&#160;associated&#160;with&#160;infliximab&#160;administration&#160;<br/>(see&#160;section&#160;4.4).&#160;Cases of&#160;transient&#160;visual&#160;loss&#160;occurring during or&#160;within 2&#160;hours&#160;of&#160;infliximab&#160;<br/>infusion have&#160;been reported.&#160;Events&#160;(some&#160;fatal)&#160;of&#160;myocardial ischaemia/infarction&#160;and&#160;arrhythmia&#160;<br/>have been&#160;reported,&#160;some&#160;in&#160;close temporal&#160;association&#160;with&#160;infusion&#160;of&#160;infliximab;&#160;cerebrovascular&#160;<br/>accidents have&#160;also&#160;been&#160;reported in close&#160;temporal&#160;association with infusion&#160;of&#160;infliximab.&#160;<br/>&#160;<br/>Infusion&#160;reactions&#160;following re-administration&#160;of&#160;infliximab&#160;<br/>&#160;<br/>A&#160;clinical&#160;study&#160;in&#160;patients&#160;with&#160;moderate&#160;to&#160;severe psoriasis was designed&#160;to&#160;assess the efficacy&#160;and&#160;<br/>safety of&#160;long-term&#160;maintenance therapy&#160;versus re-treatment with&#160;an&#160;induction&#160;regimen&#160;of&#160;infliximab&#160;<br/>(maximum&#160;of&#160;four&#160;infusions&#160;at&#160;0, 2, 6&#160;and 14&#160;weeks)&#160;following&#160;disease flare.&#160;Patients did&#160;not&#160;receive&#160;<br/>any concomitant&#160;immunosuppressant&#160;therapy. In the&#160;re-treatment&#160;arm, 4%&#160;(8/219)&#160;of&#160;patients&#160;<br/>experienced a&#160;serious&#160;infusion&#160;reaction&#160;versus&#160;&lt;1%&#160;(1/222)&#160;on maintenance&#160;therapy.&#160;The&#160;majority of&#160;<br/>serious&#160;infusion reactions&#160;occurred during&#160;the&#160;second infusion at&#160;week&#160;2. The&#160;interval&#160;between&#160;the&#160;last&#160;</p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page19-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft190">19&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1910">maintenance&#160;dose&#160;and&#160;the first&#160;re-induction&#160;dose&#160;ranged from&#160;35-231&#160;days. Symptoms&#160;included, but&#160;<br/>were&#160;not&#160;limited&#160;to, dyspnoea, urticaria,&#160;facial&#160;oedema,&#160;and hypotension. In all&#160;cases, infliximab&#160;<br/>treatment was&#160;discontinued&#160;and/or&#160;other&#160;treatment instituted&#160;with&#160;complete&#160;resolution of&#160;signs&#160;and&#160;<br/>symptoms.&#160;<br/>&#160;<br/>Delayed hypersensitivity&#160;<br/>&#160;<br/>In clinical&#160;studies&#160;delayed&#160;hypersensitivity&#160;reactions&#160;have&#160;been uncommon and have&#160;occurred after&#160;<br/>infliximab-free&#160;intervals of&#160;less&#160;than&#160;1&#160;year. In&#160;the&#160;psoriasis&#160;studies, delayed&#160;hypersensitivity reactions&#160;<br/>occurred&#160;early&#160;in&#160;the&#160;treatment&#160;course. Signs&#160;and symptoms&#160;included&#160;myalgia&#160;and/or&#160;arthralgia&#160;with&#160;<br/>fever&#160;and/or&#160;rash, with&#160;some&#160;patients&#160;experiencing pruritus, facial,&#160;hand or&#160;lip oedema, dysphagia,&#160;<br/>urticaria,&#160;sore throat&#160;and&#160;headache.&#160;<br/>&#160;<br/>There are&#160;insufficient&#160;data on&#160;the incidence of&#160;delayed&#160;hypersensitivity&#160;reactions after&#160;infliximab-free&#160;<br/>intervals&#160;of&#160;more&#160;than&#160;1&#160;year&#160;but&#160;limited&#160;data&#160;from&#160;clinical&#160;studies&#160;suggest&#160;an&#160;increased&#160;risk&#160;for&#160;<br/>delayed hypersensitivity with increasing&#160;infliximab-free&#160;interval&#160;(see&#160;section 4.4).&#160;<br/>&#160;<br/>In&#160;a&#160;1-year&#160;clinical&#160;study&#160;with&#160;repeated&#160;infusions in&#160;patients with&#160;Crohn's disease&#160;(ACCENT&#160;I&#160;study),&#160;<br/>the&#160;incidence of&#160;serum&#160;sickness-like&#160;reactions was 2.4%.&#160;<br/>&#160;<br/>Immunogenicity&#160;<br/>&#160;<br/>Patients&#160;who developed&#160;antibodies&#160;to&#160;infliximab&#160;were&#160;more&#160;likely&#160;(approximately&#160;2-3&#160;fold)&#160;to develop&#160;<br/>infusion-related&#160;reactions.&#160;Use&#160;of&#160;concomitant&#160;immunosuppressant&#160;agents appeared&#160;to&#160;reduce the&#160;<br/>frequency&#160;of&#160;infusion-related&#160;reactions.&#160;<br/>In clinical&#160;studies&#160;using single&#160;and multiple&#160;infliximab&#160;doses&#160;ranging&#160;from&#160;1 to&#160;20&#160;mg/kg, antibodies&#160;<br/>to infliximab were&#160;detected&#160;in 14%&#160;of&#160;patients&#160;with any immunosuppressant&#160;therapy, and&#160;in 24%&#160;of&#160;<br/>patients&#160;without&#160;immunosuppressant&#160;therapy. In rheumatoid arthritis&#160;patients&#160;who&#160;received the&#160;<br/>recommended&#160;repeated&#160;treatment&#160;dose&#160;regimens with&#160;methotrexate,&#160;8%&#160;of&#160;patients developed&#160;<br/>antibodies&#160;to infliximab.&#160;In psoriatic&#160;arthritis&#160;patients&#160;who&#160;received&#160;5&#160;mg/kg with&#160;and without&#160;<br/>methotrexate, antibodies&#160;occurred overall&#160;in 15%&#160;of&#160;patients&#160;(antibodies&#160;occurred in 4%&#160;of&#160;patients&#160;<br/>receiving&#160;methotrexate&#160;and&#160;in 26%&#160;of&#160;patients&#160;not&#160;receiving&#160;methotrexate&#160;at&#160;baseline).&#160;In Crohn's&#160;<br/>disease&#160;patients who&#160;received&#160;maintenance&#160;treatment,&#160;antibodies&#160;to&#160;infliximab&#160;occurred&#160;overall&#160;in&#160;<br/>3.3%&#160;of&#160;patients&#160;receiving immunosuppressants&#160;and&#160;in&#160;13.3%&#160;of&#160;patients&#160;not&#160;receiving&#160;<br/>immunosuppressants.&#160;The&#160;antibody incidence&#160;was&#160;2-3&#160;fold higher&#160;for&#160;patients&#160;treated episodically.&#160;<br/>Due&#160;to&#160;methodological&#160;limitations, a&#160;negative&#160;assay did not&#160;exclude&#160;the&#160;presence&#160;of&#160;antibodies&#160;to&#160;<br/>infliximab.&#160;Some&#160;patients&#160;who developed&#160;high titres&#160;of&#160;antibodies&#160;to infliximab had evidence&#160;of&#160;<br/>reduced&#160;efficacy.&#160;In&#160;psoriasis patients treated&#160;with&#160;infliximab&#160;as a&#160;maintenance regimen&#160;in&#160;the absence&#160;<br/>of&#160;concomitant&#160;immunomodulators, approximately&#160;28%&#160;developed antibodies&#160;to infliximab&#160;(see&#160;<br/>section 4.4:&#160;&#34;Infusion&#160;reactions&#160;and hypersensitivity&#34;).&#160;<br/>&#160;<br/>Infections&#160;<br/>&#160;<br/>Tuberculosis, bacterial&#160;infections,&#160;including sepsis&#160;and&#160;pneumonia, invasive&#160;fungal, viral, and&#160;other&#160;<br/>opportunistic&#160;infections&#160;have&#160;been observed&#160;in patients&#160;receiving&#160;infliximab.&#160;Some&#160;of&#160;these&#160;infections&#160;<br/>have&#160;been&#160;fatal;&#160;the&#160;most&#160;frequently&#160;reported opportunistic&#160;infections&#160;with&#160;a&#160;mortality&#160;rate&#160;of&#160;&gt;5%&#160;<br/>include pneumocystosis,&#160;candidiasis,&#160;listeriosis and&#160;aspergillosis&#160;(see section&#160;4.4).&#160;<br/>&#160;<br/>In&#160;clinical&#160;studies&#160;36%&#160;of&#160;infliximab-treated patients&#160;were&#160;treated for&#160;infections&#160;compared with 25%&#160;of&#160;<br/>placebo-treated&#160;patients.&#160;<br/>&#160;<br/>In rheumatoid&#160;arthritis&#160;clinical&#160;studies, the&#160;incidence&#160;of&#160;serious&#160;infections&#160;including pneumonia&#160;was&#160;<br/>higher&#160;in infliximab plus&#160;methotrexate-treated&#160;patients&#160;compared&#160;with&#160;methotrexate alone especially&#160;at&#160;<br/>doses&#160;of&#160;6&#160;mg/kg or&#160;greater&#160;(see&#160;section 4.4).&#160;<br/>&#160;<br/>In post-marketing spontaneous&#160;reporting, infections&#160;are&#160;the&#160;most&#160;common&#160;serious&#160;adverse&#160;reaction.&#160;<br/>Some of&#160;the cases have resulted&#160;in&#160;a fatal&#160;outcome.&#160;Nearly&#160;50%&#160;of&#160;reported deaths&#160;have&#160;been&#160;</p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page20-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft200">20&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2011">associated&#160;with&#160;infection.&#160;Cases&#160;of&#160;tuberculosis,&#160;sometimes&#160;fatal,&#160;including&#160;miliary&#160;tuberculosis&#160;and&#160;<br/>tuberculosis&#160;with extra-pulmonary&#160;location have&#160;been&#160;reported (see&#160;section&#160;4.4).&#160;<br/>&#160;<br/>Malignancies and&#160;lymphoproliferative&#160;disorders&#160;<br/>&#160;<br/>In clinical&#160;studies&#160;with&#160;infliximab in which 5,780&#160;patients&#160;were&#160;treated, representing 5,494&#160;patient&#160;<br/>years,&#160;5&#160;cases&#160;of&#160;lymphomas&#160;and 26&#160;non-lymphoma&#160;malignancies&#160;were&#160;detected&#160;as&#160;compared with no&#160;<br/>lymphomas&#160;and&#160;1&#160;non-lymphoma&#160;malignancy&#160;in 1,600&#160;placebo-treated&#160;patients representing&#160;<br/>941&#160;patient&#160;years.&#160;<br/>&#160;<br/>In long-term safety&#160;follow-up of&#160;clinical&#160;studies&#160;with infliximab of&#160;up to&#160;5&#160;years,&#160;representing&#160;<br/>6,234&#160;patients-years&#160;(3,210&#160;patients),&#160;5&#160;cases&#160;of&#160;lymphoma&#160;and&#160;38&#160;cases&#160;of&#160;non-lymphoma&#160;<br/>malignancies&#160;were reported.&#160;<br/>&#160;<br/>Cases&#160;of&#160;malignancies,&#160;including&#160;lymphoma, have&#160;also&#160;been&#160;reported in&#160;the&#160;post-marketing setting&#160;<br/>(see section&#160;4.4).&#160;<br/>&#160;<br/>In an exploratory clinical&#160;study involving patients&#160;with&#160;moderate&#160;to severe&#160;COPD&#160;who were&#160;either&#160;<br/>current&#160;smokers&#160;or&#160;ex-smokers, 157&#160;adult&#160;patients were treated&#160;with&#160;infliximab&#160;at&#160;doses&#160;similar&#160;to&#160;<br/>those&#160;used in&#160;rheumatoid arthritis&#160;and Crohn’s&#160;disease.&#160;Nine&#160;of&#160;these&#160;patients&#160;developed&#160;malignancies,&#160;<br/>including 1&#160;lymphoma. The&#160;median duration of&#160;follow-up was&#160;0.8&#160;years&#160;(incidence&#160;5.7%&#160;[95%&#160;CI&#160;<br/>2.65%-10.6%].&#160;There&#160;was&#160;one&#160;reported&#160;malignancy amongst&#160;77&#160;control&#160;patients&#160;(median duration of&#160;<br/>follow-up 0.8&#160;years;&#160;incidence&#160;1.3%&#160;[95%&#160;CI&#160;0.03%-7.0%]). The&#160;majority of&#160;the&#160;malignancies&#160;<br/>developed in the&#160;lung&#160;or&#160;head and neck.&#160;<br/>&#160;<br/>A&#160;population-based retrospective&#160;cohort&#160;study&#160;found an increased&#160;incidence&#160;of&#160;cervical&#160;cancer&#160;in&#160;<br/>women with&#160;rheumatoid arthritis&#160;treated with&#160;infliximab compared to biologics-naïve patients or&#160;the&#160;<br/>general&#160;population,&#160;including those&#160;over&#160;60&#160;years of&#160;age (see section&#160;4.4).&#160;<br/>&#160;<br/>In addition,&#160;post-marketing&#160;cases&#160;of&#160;hepatosplenic&#160;T-cell&#160;lymphoma&#160;have&#160;been reported&#160;in patients&#160;<br/>treated&#160;with&#160;infliximab&#160;with&#160;the vast&#160;majority&#160;of&#160;cases&#160;occurring&#160;in&#160;Crohn’s disease&#160;and&#160;ulcerative&#160;<br/>colitis,&#160;and most&#160;of&#160;whom&#160;were&#160;adolescent&#160;or&#160;young adult&#160;males&#160;(see&#160;section 4.4).&#160;<br/>&#160;<br/>Heart&#160;failure&#160;<br/>&#160;<br/>In a&#160;Phase&#160;II&#160;study aimed at&#160;evaluating&#160;infliximab&#160;in CHF, higher&#160;incidence&#160;of&#160;mortality due&#160;to&#160;<br/>worsening&#160;of&#160;heart&#160;failure&#160;were seen&#160;in&#160;patients treated&#160;with&#160;infliximab,&#160;especially&#160;those treated&#160;with&#160;<br/>the&#160;higher&#160;dose&#160;of&#160;10&#160;mg/kg (i.e. twice&#160;the&#160;maximum&#160;approved dose). In this&#160;study 150&#160;patients&#160;with&#160;<br/>NYHA Class&#160;III-IV&#160;CHF&#160;(left ventricular&#160;ejection&#160;fraction&#160;</p>
<p style="position:absolute;top:806px;left:497px;white-space:nowrap" class="ft2018">≤35%) were&#160;treated&#160;with&#160;3&#160;infusions&#160;of&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft2010">infliximab&#160;5&#160;mg/kg, 10&#160;mg/kg, or&#160;placebo over&#160;6&#160;weeks.&#160;At&#160;38&#160;weeks,&#160;9 of&#160;101&#160;patients&#160;treated&#160;with&#160;<br/>infliximab&#160;(2&#160;at 5&#160;mg/kg and 7 at&#160;10&#160;mg/kg)&#160;died&#160;compared&#160;to one&#160;death&#160;among the&#160;49&#160;patients&#160;on&#160;<br/>placebo.&#160;<br/>&#160;<br/>There&#160;have&#160;been post-marketing reports&#160;of&#160;worsening&#160;heart&#160;failure, with and without&#160;identifiable&#160;<br/>precipitating factors,&#160;in patients&#160;taking&#160;infliximab. There&#160;have&#160;also been post-marketing reports&#160;of&#160;new&#160;<br/>onset&#160;heart&#160;failure, including&#160;heart&#160;failure&#160;in patients&#160;without&#160;known pre-existing cardiovascular&#160;<br/>disease.&#160;Some&#160;of&#160;these&#160;patients&#160;have&#160;been under&#160;50&#160;years of&#160;age.&#160;<br/>&#160;<br/>Hepatobiliary events&#160;<br/>&#160;<br/>In clinical&#160;studies,&#160;mild&#160;or&#160;moderate&#160;elevations&#160;of&#160;ALT&#160;and AST&#160;have&#160;been observed in&#160;patients&#160;<br/>receiving&#160;infliximab without&#160;progression to severe&#160;hepatic&#160;injury. Elevations&#160;of&#160;ALT&#160;</p>
<p style="position:absolute;top:1052px;left:671px;white-space:nowrap" class="ft2018">≥5&#160;x&#160;Upper&#160;</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft2010">Limit&#160;of&#160;Normal&#160;(ULN)&#160;have&#160;been observed (see&#160;Table&#160;2). Elevations&#160;of&#160;aminotransferases&#160;were&#160;<br/>observed&#160;(ALT&#160;more&#160;common&#160;than AST)&#160;in&#160;a&#160;greater&#160;proportion of&#160;patients&#160;receiving infliximab than&#160;<br/>in controls, both when&#160;infliximab was&#160;given as&#160;monotherapy and when it&#160;was&#160;used in combination&#160;<br/>with&#160;other&#160;immunosuppressive agents.&#160;Most&#160;aminotransferase abnormalities were&#160;transient;&#160;however,&#160;<br/>a small&#160;number&#160;of&#160;patients&#160;experienced&#160;more&#160;prolonged elevations. In general, patients&#160;who developed&#160;</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2120{font-size:15px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft2121{font-size:10px;font-family:TimesNewRomanPSMT;color:#000000;}
	.ft2122{font-size:15px;line-height:17px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page21-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft210">21&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2110">ALT&#160;and&#160;AST&#160;elevations were asymptomatic,&#160;and&#160;the&#160;abnormalities decreased&#160;or&#160;resolved&#160;with&#160;either&#160;<br/>continuation&#160;or&#160;discontinuation of&#160;infliximab, or&#160;modification&#160;of&#160;concomitant&#160;therapy.&#160;In&#160;<br/>post-marketing&#160;surveillance,&#160;cases of&#160;jaundice and&#160;hepatitis,&#160;some with&#160;features of&#160;autoimmune&#160;<br/>hepatitis,&#160;have&#160;been reported in patients&#160;receiving&#160;infliximab (see&#160;section 4.4).&#160;&#160;<br/>&#160;</p>
<p style="position:absolute;top:184px;left:420px;white-space:nowrap" class="ft211"><b>Table&#160;2&#160;</b></p>
<p style="position:absolute;top:203px;left:206px;white-space:nowrap" class="ft211"><b>Proportion&#160;of&#160;patients&#160;with&#160;increased&#160;ALT&#160;activity&#160;in&#160;clinical&#160;studies</b>&#160;</p>
<p style="position:absolute;top:242px;left:115px;white-space:nowrap" class="ft212">Indication&#160;</p>
<p style="position:absolute;top:233px;left:213px;white-space:nowrap" class="ft212">Number&#160;of&#160;patients3&#160;</p>
<p style="position:absolute;top:223px;left:373px;white-space:nowrap" class="ft212">Median follow-up&#160;</p>
<p style="position:absolute;top:242px;left:411px;white-space:nowrap" class="ft212">(wks)4&#160;</p>
<p style="position:absolute;top:227px;left:551px;white-space:nowrap" class="ft2118">≥3 x ULN&#160;</p>
<p style="position:absolute;top:227px;left:704px;white-space:nowrap" class="ft2118">≥5 x ULN&#160;</p>
<p style="position:absolute;top:262px;left:212px;white-space:nowrap" class="ft212">placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;</p>
<p style="position:absolute;top:282px;left:115px;white-space:nowrap" class="ft2110">Rheumatoid&#160;<br/>arthritis1&#160;</p>
<p style="position:absolute;top:291px;left:212px;white-space:nowrap" class="ft212">375&#160;</p>
<p style="position:absolute;top:291px;left:279px;white-space:nowrap" class="ft212">1,087&#160;</p>
<p style="position:absolute;top:291px;left:364px;white-space:nowrap" class="ft212">58.1&#160;</p>
<p style="position:absolute;top:291px;left:432px;white-space:nowrap" class="ft212">58.3&#160;</p>
<p style="position:absolute;top:291px;left:517px;white-space:nowrap" class="ft212">3.2%&#160;</p>
<p style="position:absolute;top:291px;left:584px;white-space:nowrap" class="ft212">3.9%&#160;</p>
<p style="position:absolute;top:291px;left:669px;white-space:nowrap" class="ft212">0.8%&#160;</p>
<p style="position:absolute;top:291px;left:737px;white-space:nowrap" class="ft212">0.9%&#160;</p>
<p style="position:absolute;top:320px;left:115px;white-space:nowrap" class="ft2110">Crohn’s&#160;<br/>disease2&#160;</p>
<p style="position:absolute;top:330px;left:212px;white-space:nowrap" class="ft212">324&#160;</p>
<p style="position:absolute;top:330px;left:279px;white-space:nowrap" class="ft212">1,034&#160;</p>
<p style="position:absolute;top:330px;left:364px;white-space:nowrap" class="ft212">53.7&#160;</p>
<p style="position:absolute;top:330px;left:432px;white-space:nowrap" class="ft212">54.0&#160;</p>
<p style="position:absolute;top:330px;left:517px;white-space:nowrap" class="ft212">2.2%&#160;</p>
<p style="position:absolute;top:330px;left:584px;white-space:nowrap" class="ft212">4.9%&#160;</p>
<p style="position:absolute;top:330px;left:669px;white-space:nowrap" class="ft212">0.0%&#160;</p>
<p style="position:absolute;top:330px;left:737px;white-space:nowrap" class="ft212">1.5%&#160;</p>
<p style="position:absolute;top:359px;left:115px;white-space:nowrap" class="ft2111">Paediatric&#160;<br/>Crohn’s&#160;<br/>disease&#160;</p>
<p style="position:absolute;top:378px;left:212px;white-space:nowrap" class="ft212">N/A&#160;</p>
<p style="position:absolute;top:378px;left:279px;white-space:nowrap" class="ft212">139&#160;</p>
<p style="position:absolute;top:378px;left:364px;white-space:nowrap" class="ft212">N/A&#160;</p>
<p style="position:absolute;top:378px;left:432px;white-space:nowrap" class="ft212">53.0&#160;</p>
<p style="position:absolute;top:378px;left:517px;white-space:nowrap" class="ft212">N/A&#160;</p>
<p style="position:absolute;top:378px;left:584px;white-space:nowrap" class="ft212">4.4%&#160;</p>
<p style="position:absolute;top:378px;left:669px;white-space:nowrap" class="ft212">N/A&#160;</p>
<p style="position:absolute;top:378px;left:737px;white-space:nowrap" class="ft212">1.5%&#160;</p>
<p style="position:absolute;top:417px;left:115px;white-space:nowrap" class="ft2111">Ulcerative&#160;<br/>colitis&#160;</p>
<p style="position:absolute;top:426px;left:212px;white-space:nowrap" class="ft212">242&#160;</p>
<p style="position:absolute;top:426px;left:279px;white-space:nowrap" class="ft212">482&#160;</p>
<p style="position:absolute;top:426px;left:364px;white-space:nowrap" class="ft212">30.1&#160;</p>
<p style="position:absolute;top:426px;left:432px;white-space:nowrap" class="ft212">30.8&#160;</p>
<p style="position:absolute;top:426px;left:517px;white-space:nowrap" class="ft212">1.2%&#160;</p>
<p style="position:absolute;top:426px;left:584px;white-space:nowrap" class="ft212">2.5%&#160;</p>
<p style="position:absolute;top:426px;left:669px;white-space:nowrap" class="ft212">0.4%&#160;</p>
<p style="position:absolute;top:426px;left:737px;white-space:nowrap" class="ft212">0.6%&#160;</p>
<p style="position:absolute;top:455px;left:115px;white-space:nowrap" class="ft2110">Paediatric&#160;<br/>Ulcerative&#160;<br/>colitis&#160;</p>
<p style="position:absolute;top:455px;left:212px;white-space:nowrap" class="ft212">N/A&#160;</p>
<p style="position:absolute;top:455px;left:279px;white-space:nowrap" class="ft212">60&#160;</p>
<p style="position:absolute;top:455px;left:364px;white-space:nowrap" class="ft212">N/A&#160;</p>
<p style="position:absolute;top:455px;left:432px;white-space:nowrap" class="ft212">49.4&#160;</p>
<p style="position:absolute;top:455px;left:517px;white-space:nowrap" class="ft212">N/A&#160;</p>
<p style="position:absolute;top:455px;left:584px;white-space:nowrap" class="ft212">6.7%&#160;</p>
<p style="position:absolute;top:455px;left:669px;white-space:nowrap" class="ft212">N/A&#160;</p>
<p style="position:absolute;top:455px;left:737px;white-space:nowrap" class="ft212">1.7%&#160;</p>
<p style="position:absolute;top:513px;left:115px;white-space:nowrap" class="ft2110">Ankylosing&#160;<br/>spondylitis&#160;</p>
<p style="position:absolute;top:522px;left:212px;white-space:nowrap" class="ft212">76&#160;</p>
<p style="position:absolute;top:522px;left:279px;white-space:nowrap" class="ft212">275&#160;</p>
<p style="position:absolute;top:522px;left:364px;white-space:nowrap" class="ft212">24.1&#160;</p>
<p style="position:absolute;top:522px;left:432px;white-space:nowrap" class="ft212">101.9&#160;</p>
<p style="position:absolute;top:522px;left:517px;white-space:nowrap" class="ft212">0.0%&#160;</p>
<p style="position:absolute;top:522px;left:584px;white-space:nowrap" class="ft212">9.5%&#160;</p>
<p style="position:absolute;top:522px;left:669px;white-space:nowrap" class="ft212">0.0%&#160;</p>
<p style="position:absolute;top:522px;left:737px;white-space:nowrap" class="ft212">3.6%&#160;</p>
<p style="position:absolute;top:552px;left:115px;white-space:nowrap" class="ft2110">Psoriatic&#160;<br/>arthritis&#160;</p>
<p style="position:absolute;top:561px;left:212px;white-space:nowrap" class="ft212">98&#160;</p>
<p style="position:absolute;top:561px;left:279px;white-space:nowrap" class="ft212">191&#160;</p>
<p style="position:absolute;top:561px;left:364px;white-space:nowrap" class="ft212">18.1&#160;</p>
<p style="position:absolute;top:561px;left:432px;white-space:nowrap" class="ft212">39.1&#160;</p>
<p style="position:absolute;top:561px;left:517px;white-space:nowrap" class="ft212">0.0%&#160;</p>
<p style="position:absolute;top:561px;left:584px;white-space:nowrap" class="ft212">6.8%&#160;</p>
<p style="position:absolute;top:561px;left:669px;white-space:nowrap" class="ft212">0.0%&#160;</p>
<p style="position:absolute;top:561px;left:737px;white-space:nowrap" class="ft212">2.1%&#160;</p>
<p style="position:absolute;top:590px;left:115px;white-space:nowrap" class="ft2110">Plaque&#160;<br/>psoriasis&#160;</p>
<p style="position:absolute;top:600px;left:212px;white-space:nowrap" class="ft212">281&#160;</p>
<p style="position:absolute;top:600px;left:279px;white-space:nowrap" class="ft212">1,175&#160;</p>
<p style="position:absolute;top:600px;left:364px;white-space:nowrap" class="ft212">16.1&#160;</p>
<p style="position:absolute;top:600px;left:432px;white-space:nowrap" class="ft212">50.1&#160;</p>
<p style="position:absolute;top:600px;left:517px;white-space:nowrap" class="ft212">0.4%&#160;</p>
<p style="position:absolute;top:600px;left:584px;white-space:nowrap" class="ft212">7.7%&#160;</p>
<p style="position:absolute;top:600px;left:669px;white-space:nowrap" class="ft212">0.0%&#160;</p>
<p style="position:absolute;top:600px;left:737px;white-space:nowrap" class="ft212">3.4%&#160;</p>
<p style="position:absolute;top:629px;left:106px;white-space:nowrap" class="ft212">1&#160;&#160;Placebo&#160;patients&#160;received methotrexate&#160;while&#160;infliximab&#160;patients&#160;received&#160;both infliximab and&#160;</p>
<p style="position:absolute;top:648px;left:128px;white-space:nowrap" class="ft212">methotrexate.&#160;</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft212">2&#160;&#160;Placebo patients&#160;in the&#160;2&#160;Phase III&#160;studies in&#160;Crohn’s&#160;disease,&#160;ACCENT&#160;I&#160;and&#160;ACCENT&#160;II,&#160;</p>
<p style="position:absolute;top:686px;left:128px;white-space:nowrap" class="ft2111">received&#160;an initial&#160;dose&#160;of&#160;5&#160;mg/kg infliximab at&#160;study&#160;start&#160;and were&#160;on&#160;placebo&#160;in the&#160;<br/>maintenance phase.&#160;Patients who&#160;were&#160;randomised&#160;to&#160;the placebo&#160;maintenance&#160;group and&#160;then&#160;later&#160;<br/>crossed&#160;over&#160;to infliximab are&#160;included in the&#160;infliximab&#160;group in the&#160;ALT&#160;analysis.&#160;In&#160;the Phase&#160;<br/>IIIb&#160;trial&#160;in&#160;Crohn’s disease,&#160;SONIC,&#160;placebo&#160;patients&#160;received&#160;AZA&#160;2.5&#160;mg/kg/day as&#160;active&#160;<br/>control&#160;in addition to placebo infliximab&#160;infusions.&#160;</p>
<p style="position:absolute;top:781px;left:106px;white-space:nowrap" class="ft2111">3&#160;&#160;Number&#160;of&#160;patients&#160;evaluated for&#160;ALT.&#160;<br/>4&#160;&#160;Median follow-up is&#160;based&#160;on patients&#160;treated.&#160;<br/>&#160;<br/>Antinuclear&#160;antibodies&#160;(ANA)/Anti-double-stranded&#160;DNA (dsDNA)&#160;antibodies&#160;<br/>&#160;<br/>Approximately half&#160;of&#160;infliximab-treated&#160;patients&#160;in&#160;clinical&#160;studies who&#160;were ANA&#160;negative at&#160;<br/>baseline&#160;developed a&#160;positive&#160;ANA&#160;during the&#160;study&#160;compared with&#160;approximately one&#160;fifth&#160;of&#160;<br/>placebo-treated&#160;patients.&#160;Anti-dsDNA&#160;antibodies&#160;were&#160;newly detected in approximately 17%&#160;of&#160;<br/>infliximab-treated&#160;patients&#160;compared&#160;with&#160;0%&#160;of&#160;placebo-treated&#160;patients.&#160;At&#160;the&#160;last&#160;evaluation,&#160;57%&#160;<br/>of&#160;infliximab-treated&#160;patients remained&#160;anti-dsDNA&#160;positive.&#160;Reports&#160;of&#160;lupus&#160;and&#160;lupus-like&#160;<br/>syndromes, however,&#160;remain uncommon (see&#160;section&#160;4.4).&#160;<br/>&#160;<br/>Paediatric&#160;population&#160;<br/>&#160;<br/><i>Juvenile rheumatoid&#160;arthritis patients&#160;<br/>&#160;<br/></i>Infliximab was&#160;studied in a&#160;clinical&#160;study in&#160;120&#160;patients (age range:&#160;4-17&#160;years&#160;old)&#160;with&#160;active&#160;<br/>juvenile rheumatoid&#160;arthritis despite&#160;methotrexate.&#160;Patients&#160;received&#160;3&#160;or&#160;6&#160;mg/kg infliximab&#160;as&#160;a&#160;<br/>3-dose&#160;induction&#160;regimen&#160;(weeks&#160;0, 2, 6 or&#160;weeks&#160;14,&#160;16, 20,&#160;respectively)&#160;followed&#160;by&#160;maintenance&#160;<br/>therapy every&#160;8&#160;weeks,&#160;in combination with methotrexate.&#160;<br/>&#160;</p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page22-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft220">22&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2213"><i>Infusion reactions&#160;<br/></i>Infusion&#160;reactions&#160;occurred&#160;in 35%&#160;of&#160;patients&#160;with juvenile&#160;rheumatoid&#160;arthritis&#160;receiving 3&#160;mg/kg&#160;<br/>compared with 17.5%&#160;of&#160;patients&#160;receiving&#160;6&#160;mg/kg. In the&#160;3&#160;mg/kg&#160;infliximab&#160;group, 4 out&#160;of&#160;<br/>60&#160;patients&#160;had a&#160;serious&#160;infusion reaction and&#160;3&#160;patients reported&#160;a possible anaphylactic reaction&#160;(2&#160;<br/>of&#160;which were&#160;among&#160;the&#160;serious&#160;infusion reactions). In the&#160;6&#160;mg/kg&#160;group, 2 out&#160;of&#160;57&#160;patients had&#160;a&#160;<br/>serious&#160;infusion reaction, one&#160;of&#160;whom&#160;had a&#160;possible&#160;anaphylactic&#160;reaction&#160;(see&#160;section&#160;4.4).&#160;<br/>&#160;<br/><i>Immunogenicity&#160;<br/></i>Antibodies&#160;to&#160;infliximab developed in 38%&#160;of&#160;patients&#160;receiving 3&#160;mg/kg&#160;compared&#160;with 12%&#160;of&#160;<br/>patients receiving&#160;6&#160;mg/kg. The&#160;antibody titres&#160;were&#160;notably higher&#160;for&#160;the&#160;3&#160;mg/kg compared to the&#160;<br/>6&#160;mg/kg group.&#160;<br/>&#160;<br/><i>Infections&#160;<br/></i>Infections&#160;occurred in 68%&#160;(41/60)&#160;of&#160;children receiving 3&#160;mg/kg&#160;over&#160;52&#160;weeks, 65%&#160;(37/57)&#160;of&#160;<br/>children receiving infliximab 6&#160;mg/kg&#160;over&#160;38&#160;weeks&#160;and 47%&#160;(28/60)&#160;of&#160;children receiving&#160;placebo&#160;<br/>over&#160;14&#160;weeks&#160;(see&#160;section 4.4).&#160;<br/>&#160;<br/><i>Paediatric&#160;Crohn’s&#160;disease&#160;patients&#160;<br/>&#160;<br/></i>The&#160;following adverse&#160;reactions&#160;were&#160;reported&#160;more&#160;commonly in&#160;paediatric&#160;Crohn’s&#160;disease&#160;patients&#160;<br/>in the&#160;REACH&#160;study (see&#160;section 5.1)&#160;than&#160;in adult&#160;Crohn’s&#160;disease&#160;patients:&#160;anaemia&#160;(10.7%), blood&#160;<br/>in stool&#160;(9.7%), leukopenia&#160;(8.7%), flushing&#160;(8.7%),&#160;viral&#160;infection (7.8%),&#160;neutropenia&#160;(6.8%),&#160;<br/>bacterial&#160;infection (5.8%),&#160;and respiratory tract&#160;allergic&#160;reaction&#160;(5.8%).&#160;In addition, bone&#160;fracture&#160;<br/>(6.8%) was&#160;reported, however, a&#160;causal&#160;association has&#160;not&#160;been&#160;established.&#160;Other&#160;special&#160;<br/>considerations&#160;are discussed&#160;below.&#160;<br/>&#160;<br/><i>Infusion</i>-<i>related&#160;reactions&#160;<br/></i>In REACH, 17.5%&#160;of&#160;randomised patients&#160;experienced 1 or&#160;more&#160;infusion&#160;reactions. There&#160;were&#160;no&#160;<br/>serious&#160;infusion reactions,&#160;and 2&#160;subjects&#160;in REACH&#160;had non-serious&#160;anaphylactic&#160;reactions.&#160;<br/>&#160;<br/><i>Immunogenicity&#160;<br/></i>Antibodies&#160;to&#160;infliximab were&#160;detected in 3 (2.9%)&#160;paediatric&#160;patients.&#160;<br/>&#160;<br/><i>Infections&#160;<br/></i>In the&#160;REACH&#160;study, infections&#160;were&#160;reported in 56.3%&#160;of&#160;randomised&#160;subjects treated&#160;with&#160;<br/>infliximab. Infections&#160;were&#160;reported more&#160;frequently for&#160;subjects&#160;who&#160;received q8&#160;week as&#160;opposed to&#160;<br/>q12&#160;week&#160;infusions&#160;(73.6%&#160;and 38.0%,&#160;respectively),&#160;while&#160;serious&#160;infections&#160;were&#160;reported&#160;for&#160;<br/>3&#160;subjects&#160;in the&#160;q8&#160;week and 4&#160;subjects in the&#160;q12&#160;week&#160;maintenance&#160;treatment&#160;group.&#160;The most&#160;<br/>commonly reported infections&#160;were&#160;upper&#160;respiratory tract&#160;infection&#160;and pharyngitis, and&#160;the&#160;most&#160;<br/>commonly&#160;reported&#160;serious&#160;infection&#160;was abscess.&#160;Three cases&#160;of&#160;pneumonia (1&#160;serious)&#160;and 2&#160;cases of&#160;<br/>herpes&#160;zoster&#160;(both non-serious)&#160;were reported.&#160;<br/>&#160;<br/><i>Paediatric&#160;ulcerative&#160;colitis&#160;patients&#160;<br/>&#160;<br/></i>Overall, the&#160;adverse&#160;reactions&#160;reported in the&#160;paediatric&#160;ulcerative&#160;colitis&#160;trial&#160;(C0168T72)&#160;and&#160;adult&#160;<br/>ulcerative colitis (ACT&#160;1&#160;and&#160;ACT&#160;2)&#160;studies were generally&#160;consistent. In C0168T72, the&#160;most&#160;<br/>common adverse&#160;reactions&#160;were&#160;upper&#160;respiratory tract&#160;infection, pharyngitis,&#160;abdominal&#160;pain,&#160;fever,&#160;<br/>and&#160;headache.&#160;The&#160;most&#160;common&#160;adverse event&#160;was worsening&#160;of&#160;ulcerative colitis,&#160;the&#160;incidence&#160;of&#160;<br/>which&#160;was&#160;higher&#160;in&#160;patients on the&#160;q12&#160;week&#160;vs.&#160;the q8&#160;week&#160;dosing regimen.&#160;<br/>&#160;<br/><i>Infusion</i>-<i>related&#160;reactions&#160;<br/></i>Overall, 8&#160;(13.3%)&#160;of&#160;60&#160;treated&#160;patients&#160;experienced one&#160;or&#160;more&#160;infusion reactions, with 4 of&#160;22&#160;<br/>(18.2%)&#160;in the&#160;q8&#160;week and&#160;3 of&#160;23&#160;(13.0%)&#160;in&#160;the&#160;q12&#160;week&#160;treatment&#160;maintenance&#160;group. No serious&#160;<br/>infusion&#160;reactions&#160;were&#160;reported.&#160;All&#160;infusion reactions&#160;were&#160;mild or&#160;moderate&#160;in intensity.&#160;<br/>&#160;<br/><i>Immunogenicity&#160;<br/></i>Antibodies&#160;to&#160;infliximab&#160;were&#160;detected&#160;in&#160;4&#160;(7.7%)&#160;patients&#160;through week&#160;54.&#160;</p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2323{font-size:17px;font-family:TimesNewRomanPSMT;color:#0000ff;}
-->
</style>
<div id="page23-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft230">23&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2311">&#160;<br/><i>Infections&#160;<br/></i>Infections&#160;were&#160;reported in&#160;31 (51.7%)&#160;of&#160;60&#160;treated patients&#160;in&#160;C0168T72&#160;and&#160;22 (36.7%)&#160;required&#160;<br/>oral&#160;or&#160;parenteral&#160;antimicrobial&#160;treatment. The&#160;proportion of&#160;patients&#160;with&#160;infections&#160;in C0168T72 was&#160;<br/>similar&#160;to&#160;that&#160;in the&#160;paediatric&#160;Crohn’s&#160;disease&#160;study&#160;(REACH)&#160;but&#160;higher&#160;than the&#160;proportion in the&#160;<br/>adults&#160;ulcerative&#160;colitis&#160;studies&#160;(ACT&#160;1 and&#160;ACT&#160;2). The&#160;overall&#160;incidence&#160;of&#160;infections&#160;in C0168T72&#160;<br/>was&#160;13/22 (59%)&#160;in&#160;the&#160;every 8&#160;week maintenance&#160;treatment&#160;group&#160;and 14/23&#160;(60.9%)&#160;in&#160;the&#160;every&#160;<br/>12&#160;week&#160;maintenance&#160;treatment&#160;group. Upper&#160;respiratory&#160;tract&#160;infection (7/60&#160;[12%])&#160;and pharyngitis&#160;<br/>(5/60&#160;[8%])&#160;were&#160;the&#160;most&#160;frequently reported&#160;respiratory system&#160;infections. Serious&#160;infections&#160;were&#160;<br/>reported&#160;in 12%&#160;(7/60)&#160;of&#160;all&#160;treated&#160;patients.&#160;<br/>&#160;<br/>In&#160;this&#160;study,&#160;there were more patients in&#160;the&#160;12 to&#160;17&#160;year&#160;age&#160;group than in the&#160;6 to&#160;11&#160;year&#160;age&#160;group&#160;<br/>(45/60 [75.0%])&#160;vs.15/60&#160;[25.0%]).&#160;While&#160;the&#160;numbers&#160;of&#160;patients&#160;in each subgroup are&#160;too&#160;small&#160;to&#160;<br/>make&#160;any definitive&#160;conclusions&#160;about&#160;the&#160;effect&#160;of&#160;age&#160;on safety events, there&#160;were&#160;higher&#160;proportions&#160;<br/>of&#160;patients&#160;with serious&#160;adverse&#160;events&#160;and discontinuation&#160;due&#160;to adverse&#160;events&#160;in the&#160;younger&#160;age&#160;<br/>group&#160;than&#160;in&#160;the&#160;older&#160;age&#160;group.&#160;While&#160;the&#160;proportion of&#160;patients&#160;with&#160;infections&#160;was&#160;also higher&#160;in&#160;<br/>the&#160;younger&#160;age&#160;group, for&#160;serious&#160;infections,&#160;the&#160;proportions&#160;were&#160;similar&#160;in the&#160;two age&#160;groups.&#160;<br/>Overall&#160;proportions&#160;of&#160;adverse&#160;events&#160;and infusion&#160;reactions&#160;were&#160;similar&#160;between&#160;the&#160;6&#160;to 11&#160;and 12&#160;<br/>to 17&#160;year&#160;age groups.&#160;<br/>&#160;<br/>Post-marketing&#160;experience&#160;<br/>&#160;<br/>Post-marketing&#160;spontaneous serious adverse&#160;reactions&#160;with&#160;infliximab&#160;in&#160;the&#160;paediatric&#160;population&#160;<br/>have&#160;included&#160;malignancies&#160;including hepatosplenic&#160;T-cell&#160;lymphomas,&#160;transient&#160;hepatic enzyme&#160;<br/>abnormalities, lupus-like syndromes,&#160;and&#160;positive auto-antibodies&#160;(see&#160;sections&#160;4.4&#160;and 4.8).&#160;<br/>&#160;<br/>Other&#160;special&#160;populations&#160;<br/>&#160;<br/><i>Elderly&#160;<br/>&#160;<br/></i>In&#160;rheumatoid&#160;arthritis&#160;clinical&#160;studies,&#160;the incidence of&#160;serious&#160;infections was&#160;greater&#160;in&#160;infliximab&#160;<br/>plus&#160;methotrexate-treated&#160;patients 65&#160;years&#160;and&#160;older&#160;(11.3%)&#160;than in&#160;those&#160;under&#160;65&#160;years of&#160;age&#160;<br/>(4.6%). In patients&#160;treated&#160;with&#160;methotrexate&#160;alone,&#160;the&#160;incidence&#160;of&#160;serious&#160;infections&#160;was&#160;5.2%&#160;in&#160;<br/>patients 65&#160;years&#160;and older&#160;compared to&#160;2.7%&#160;in&#160;patients&#160;under&#160;65 (see section&#160;4.4).&#160;<br/>&#160;<br/>Reporting of&#160;suspected&#160;adverse&#160;reactions&#160;<br/>&#160;<br/>Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important. It&#160;<br/>allows&#160;continued&#160;monitoring of&#160;the&#160;benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;<br/>professionals&#160;are&#160;asked&#160;to&#160;report&#160;any&#160;suspected&#160;adverse reactions via&#160;the&#160;national&#160;reporting system&#160;<br/>listed&#160;in&#160;Appendix V.&#160;<br/>&#160;<br/><b>4.9&#160;</b></p>
<p style="position:absolute;top:887px;left:149px;white-space:nowrap" class="ft231"><b>Overdose&#160;</b></p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft2311">&#160;<br/>No&#160;case&#160;of&#160;overdose has been&#160;reported.&#160;Single doses&#160;up&#160;to&#160;20&#160;mg/kg&#160;have&#160;been&#160;administered&#160;without&#160;<br/>toxic effects.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:1001px;left:149px;white-space:nowrap" class="ft231"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:1021px;left:106px;white-space:nowrap" class="ft2311">&#160;<br/><b>5.1&#160;</b></p>
<p style="position:absolute;top:1040px;left:149px;white-space:nowrap" class="ft231"><b>Pharmacodynamic&#160;properties</b>&#160;</p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft2311">&#160;<br/>Pharmacotherapeutic&#160;group:&#160;immunosuppressants, tumour&#160;necrosis&#160;factor&#160;alpha&#160;(TNFα)&#160;inhibitors,&#160;<br/>ATC&#160;code:&#160;L04AB02&#160;<br/>&#160;<br/>Remsima&#160;is&#160;a&#160;biosimilar&#160;medicinal product.&#160;Detailed&#160;information&#160;is&#160;available&#160;on&#160;the&#160;website&#160;of&#160;the&#160;<br/>European Medicines&#160;Agency&#160;http://www.ema.europa.eu.&#160;</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2424{font-size:17px;line-height:20px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page24-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft240">24&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2410">&#160;<br/>Mechanism&#160;of&#160;action&#160;<br/>&#160;<br/>Infliximab&#160;is&#160;a chimeric&#160;human-murine&#160;monoclonal&#160;antibody&#160;that&#160;binds&#160;with&#160;high affinity to&#160;both&#160;<br/>soluble&#160;and&#160;transmembrane&#160;forms&#160;of&#160;TNFα&#160;</p>
<p style="position:absolute;top:160px;left:393px;white-space:nowrap" class="ft2418">but&#160;not&#160;to&#160;lymphotoxin α&#160;(TNFβ).&#160;</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft2410">&#160;<br/>Pharmacodynamic effects&#160;<br/>&#160;<br/>Infliximab&#160;inhibits&#160;the&#160;functional activity&#160;of&#160;TNFα&#160;in a&#160;wide&#160;variety of&#160;<i>in vitro&#160;</i>bioassays.&#160;Infliximab&#160;<br/>prevented disease&#160;in transgenic&#160;mice&#160;that&#160;develop polyarthritis&#160;as&#160;a&#160;result&#160;of&#160;constitutive&#160;expression of&#160;<br/>human&#160;TNFα&#160;and when administered after&#160;disease&#160;onset,&#160;it&#160;allowed eroded joints&#160;to heal.&#160;<i>In&#160;vivo</i>,&#160;<br/>infliximab&#160;rapidly&#160;forms&#160;stable&#160;complexes&#160;with&#160;human&#160;TNFα,&#160;a process&#160;that&#160;parallels the loss of&#160;TNFα&#160;<br/>bioactivity.&#160;&#160;<br/>&#160;<br/>Elevated concentrations&#160;of&#160;TNFα&#160;have&#160;been&#160;found in&#160;the&#160;joints&#160;of&#160;rheumatoid arthritis&#160;patients&#160;and&#160;<br/>correlate with&#160;elevated&#160;disease activity.&#160;In&#160;rheumatoid&#160;arthritis,&#160;treatment&#160;with&#160;infliximab&#160;reduced&#160;<br/>infiltration&#160;of&#160;inflammatory&#160;cells&#160;into&#160;inflamed&#160;areas&#160;of&#160;the&#160;joint as&#160;well as&#160;expression of&#160;molecules&#160;<br/>mediating&#160;cellular&#160;adhesion, chemoattraction and&#160;tissue&#160;degradation.&#160;After&#160;infliximab treatment,&#160;<br/>patients&#160;exhibited&#160;decreased&#160;levels of&#160;serum&#160;interleukin&#160;6&#160;(IL-6)&#160;and C-reactive&#160;protein (CRP), and&#160;<br/>increased haemoglobin&#160;levels&#160;in rheumatoid&#160;arthritis&#160;patients&#160;with&#160;reduced&#160;haemoglobin levels,&#160;<br/>compared with baseline.&#160;Peripheral&#160;blood&#160;lymphocytes&#160;further&#160;showed no significant&#160;decrease&#160;in&#160;<br/>number&#160;or&#160;in&#160;proliferative&#160;responses&#160;to&#160;<i>in&#160;vitro</i>&#160;mitogenic&#160;stimulation when compared with&#160;untreated&#160;<br/>patients’&#160;cells.&#160;In&#160;psoriasis&#160;patients,&#160;treatment with&#160;infliximab&#160;resulted&#160;in&#160;decreases&#160;in&#160;epidermal&#160;<br/>inflammation and normalisation of&#160;keratinocyte&#160;differentiation&#160;in psoriatic&#160;plaques. In psoriatic&#160;<br/>arthritis, short&#160;term&#160;treatment&#160;with infliximab&#160;reduced&#160;the&#160;number&#160;of&#160;T-cells&#160;and blood vessels&#160;in the&#160;<br/>synovium&#160;and psoriatic&#160;skin.&#160;<br/>&#160;<br/>Histological&#160;evaluation of&#160;colonic&#160;biopsies, obtained before&#160;and 4&#160;weeks&#160;after&#160;administration of&#160;<br/>infliximab,&#160;revealed&#160;a substantial&#160;reduction&#160;in&#160;detectable&#160;TNFα. Infliximab treatment&#160;of&#160;Crohn’s&#160;<br/>disease patients&#160;was&#160;also&#160;associated&#160;with&#160;a substantial&#160;reduction&#160;of&#160;the commonly&#160;elevated&#160;serum&#160;<br/>inflammatory&#160;marker,&#160;CRP.&#160;Total peripheral white&#160;blood&#160;cell counts&#160;were&#160;minimally&#160;affected&#160;in&#160;<br/>infliximab-treated&#160;patients, although changes&#160;in&#160;lymphocytes, monocytes&#160;and&#160;neutrophils&#160;reflected&#160;<br/>shifts&#160;towards&#160;normal&#160;ranges.&#160;Peripheral&#160;blood mononuclear&#160;cells&#160;(PBMC)&#160;from&#160;infliximab-treated&#160;<br/>patients&#160;showed undiminished proliferative&#160;responsiveness&#160;to stimuli&#160;compared with untreated&#160;<br/>patients, and no substantial&#160;changes&#160;in cytokine&#160;production&#160;by stimulated PBMC&#160;were&#160;observed&#160;<br/>following treatment&#160;with infliximab.&#160;Analysis&#160;of&#160;lamina&#160;propria&#160;mononuclear&#160;cells&#160;obtained&#160;by biopsy&#160;<br/>of&#160;the&#160;intestinal&#160;mucosa&#160;showed that&#160;infliximab&#160;treatment&#160;caused&#160;a&#160;reduction in&#160;the&#160;number&#160;of&#160;cells&#160;<br/>capable of&#160;expressing&#160;TNFα&#160;and interferon&#160;γ. Additional&#160;histological&#160;studies&#160;provided evidence&#160;that&#160;<br/>treatment with&#160;infliximab&#160;reduces&#160;the&#160;infiltration&#160;of&#160;inflammatory&#160;cells&#160;into&#160;affected&#160;areas&#160;of&#160;the&#160;<br/>intestine&#160;and&#160;the presence of&#160;inflammation&#160;markers&#160;at&#160;these&#160;sites.&#160;Endoscopic studies of&#160;intestinal&#160;<br/>mucosa&#160;have&#160;shown evidence&#160;of&#160;mucosal&#160;healing&#160;in&#160;infliximab-treated&#160;patients.&#160;<br/>&#160;<br/>Clinical efficacy&#160;and&#160;safety&#160;<br/>&#160;<br/><i>Adult&#160;rheumatoid&#160;arthritis&#160;<br/>&#160;<br/></i>The efficacy&#160;of&#160;infliximab&#160;was assessed&#160;in&#160;two&#160;multicentre,&#160;randomised, double-blind, pivotal&#160;clinical&#160;<br/>studies:&#160;ATTRACT&#160;and ASPIRE. In both studies&#160;concurrent&#160;use&#160;of&#160;stable&#160;doses&#160;of&#160;folic&#160;acid, oral&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft2410">corticosteroids&#160;(≤10&#160;mg/day)&#160;and/or&#160;non-steroidal&#160;anti-inflammatory drugs&#160;(NSAIDs)&#160;was&#160;permitted.&#160;<br/>&#160;<br/>The primary&#160;endpoints were the&#160;reduction&#160;of&#160;signs and&#160;symptoms&#160;as assessed&#160;by&#160;the American&#160;<br/>College&#160;of&#160;Rheumatology criteria&#160;(ACR20 for&#160;ATTRACT, landmark ACR-N&#160;for&#160;ASPIRE),&#160;the&#160;<br/>prevention of&#160;structural&#160;joint&#160;damage, and the&#160;improvement&#160;in&#160;physical&#160;function.&#160;A&#160;reduction in&#160;signs&#160;<br/>and symptoms&#160;was&#160;defined&#160;to be&#160;at&#160;least&#160;a&#160;20%&#160;improvement&#160;(ACR20)&#160;in both tender&#160;and swollen&#160;<br/>joint&#160;counts, and&#160;in 3&#160;of&#160;the&#160;following 5&#160;criteria:&#160;(1)&#160;evaluator’s&#160;global&#160;assessment, (2)&#160;patient’s&#160;global&#160;<br/>assessment,&#160;(3)&#160;functional/disability&#160;measure,&#160;(4)&#160;visual&#160;analogue pain&#160;scale&#160;and&#160;(5)&#160;erythrocyte&#160;<br/>sedimentation rate&#160;or&#160;C-reactive&#160;protein. ACR-N&#160;uses&#160;the same&#160;criteria as&#160;the ACR20,&#160;calculated&#160;by&#160;</p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2525{font-size:15px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page25-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft250">25&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2511">taking&#160;the&#160;lowest&#160;percent improvement&#160;in&#160;swollen&#160;joint&#160;count,&#160;tender&#160;joint count,&#160;and&#160;the&#160;median&#160;of&#160;<br/>the&#160;remaining&#160;5&#160;components&#160;of&#160;the&#160;ACR&#160;response. Structural&#160;joint&#160;damage&#160;(erosions&#160;and&#160;joint&#160;space&#160;<br/>narrowing)&#160;in&#160;both hands&#160;and feet&#160;was&#160;measured&#160;by the&#160;change&#160;from&#160;baseline&#160;in&#160;the&#160;total&#160;van&#160;der&#160;<br/>Heijde-modified&#160;Sharp&#160;score (0-440). The&#160;Health Assessment&#160;Questionnaire&#160;(HAQ;&#160;scale&#160;0-3)&#160;was&#160;<br/>used&#160;to&#160;measure&#160;patients’&#160;average change&#160;from&#160;baseline scores&#160;over&#160;time,&#160;in&#160;physical&#160;function.&#160;<br/>&#160;<br/>The&#160;ATTRACT&#160;study&#160;evaluated&#160;responses&#160;at&#160;30, 54 and 102&#160;weeks in&#160;a placebo-controlled study&#160;of&#160;<br/>428&#160;patients&#160;with&#160;active&#160;rheumatoid arthritis&#160;despite&#160;treatment&#160;with methotrexate.&#160;Approximately 50%&#160;<br/>of&#160;patients were in&#160;functional&#160;Class III.&#160;Patients received&#160;placebo,&#160;3&#160;mg/kg&#160;or&#160;10&#160;mg/kg&#160;infliximab&#160;at&#160;<br/>weeks&#160;0, 2&#160;and 6, and&#160;then&#160;every&#160;4 or&#160;8&#160;weeks thereafter.&#160;All&#160;patients were on&#160;stable methotrexate&#160;<br/>doses (median&#160;15&#160;mg/wk)&#160;for&#160;6&#160;months&#160;prior&#160;to enrolment&#160;and were&#160;to&#160;remain on&#160;stable&#160;doses&#160;<br/>throughout&#160;the&#160;study.&#160;<br/>&#160;<br/>Results&#160;from&#160;week 54&#160;(ACR20, total&#160;van der&#160;Heijde-modified Sharp&#160;score&#160;and&#160;HAQ)&#160;are&#160;shown in&#160;<br/>Table 3.&#160;Higher&#160;degrees of&#160;clinical&#160;response&#160;(ACR50 and ACR70)&#160;were&#160;observed&#160;in all&#160;infliximab&#160;<br/>groups&#160;at&#160;30 and&#160;54&#160;weeks&#160;compared&#160;with&#160;methotrexate alone.&#160;<br/>&#160;<br/>A&#160;reduction in&#160;the&#160;rate&#160;of&#160;the&#160;progression of&#160;structural&#160;joint&#160;damage&#160;(erosions&#160;and&#160;joint&#160;space&#160;<br/>narrowing)&#160;was&#160;observed&#160;in&#160;all&#160;infliximab groups&#160;at&#160;54&#160;weeks (Table 3).&#160;<br/>&#160;<br/>The&#160;effects observed&#160;at&#160;54&#160;weeks&#160;were&#160;maintained through 102&#160;weeks. Due&#160;to&#160;a&#160;number&#160;of&#160;treatment&#160;<br/>withdrawals,&#160;the&#160;magnitude&#160;of&#160;the effect&#160;difference between&#160;infliximab&#160;and&#160;the methotrexate&#160;alone&#160;<br/>group cannot&#160;be&#160;defined.&#160;<br/>&#160;</p>
<p style="position:absolute;top:545px;left:420px;white-space:nowrap" class="ft251"><b>Table&#160;3&#160;</b></p>
<p style="position:absolute;top:564px;left:127px;white-space:nowrap" class="ft251"><b>Effects&#160;on&#160;ACR20, Structural&#160;Joint&#160;Damage&#160;and&#160;Physical&#160;Function&#160;at&#160;week&#160;54, ATTRACT&#160;</b></p>
<p style="position:absolute;top:584px;left:114px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:584px;left:293px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:584px;left:545px;white-space:nowrap" class="ft252">Infliximabb&#160;</p>
<p style="position:absolute;top:603px;left:114px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:603px;left:293px;white-space:nowrap" class="ft252">Controla&#160;</p>
<p style="position:absolute;top:603px;left:386px;white-space:nowrap" class="ft2510">3&#160;mg/kg&#160;<br/>q&#160;8&#160;wks&#160;</p>
<p style="position:absolute;top:604px;left:466px;white-space:nowrap" class="ft2511">3&#160;mg/kg&#160;<br/>q&#160;4&#160;wks&#160;</p>
<p style="position:absolute;top:604px;left:546px;white-space:nowrap" class="ft2511">10&#160;mg/kg&#160;<br/>q&#160;8&#160;wks&#160;</p>
<p style="position:absolute;top:604px;left:626px;white-space:nowrap" class="ft2511">10&#160;mg/kg&#160;<br/>q&#160;4&#160;wks&#160;</p>
<p style="position:absolute;top:603px;left:705px;white-space:nowrap" class="ft2510">All&#160;<br/>infliximabb&#160;</p>
<p style="position:absolute;top:643px;left:114px;white-space:nowrap" class="ft2511">Patients&#160;with ACR20&#160;<br/>response/Patients&#160;<br/>evaluated&#160;(%)&#160;</p>
<p style="position:absolute;top:643px;left:293px;white-space:nowrap" class="ft2510">15/88&#160;<br/>(17%)&#160;</p>
<p style="position:absolute;top:643px;left:386px;white-space:nowrap" class="ft2510">36/86&#160;<br/>(42%)&#160;</p>
<p style="position:absolute;top:643px;left:466px;white-space:nowrap" class="ft2510">41/86&#160;<br/>(48%)&#160;</p>
<p style="position:absolute;top:643px;left:546px;white-space:nowrap" class="ft2510">51/87&#160;<br/>(59%)&#160;</p>
<p style="position:absolute;top:643px;left:626px;white-space:nowrap" class="ft2510">48/81&#160;<br/>(59%)&#160;</p>
<p style="position:absolute;top:643px;left:705px;white-space:nowrap" class="ft2510">176/340&#160;<br/>(52%)&#160;</p>
<p style="position:absolute;top:701px;left:114px;white-space:nowrap" class="ft2510">Total&#160;scored&#160;(van&#160;der&#160;Heijde-modified Sharp score)&#160;<br/>Change&#160;from&#160;baseline&#160;<br/>(Mean&#160;±&#160;SDc)&#160;</p>
<p style="position:absolute;top:720px;left:293px;white-space:nowrap" class="ft2510">7.0&#160;±&#160;<br/>10.3&#160;</p>
<p style="position:absolute;top:720px;left:375px;white-space:nowrap" class="ft252">1.3 ±&#160;6.0&#160;</p>
<p style="position:absolute;top:720px;left:457px;white-space:nowrap" class="ft252">1.6 ±&#160;8.5&#160;</p>
<p style="position:absolute;top:720px;left:539px;white-space:nowrap" class="ft252">0.2 ±&#160;3.6&#160;</p>
<p style="position:absolute;top:720px;left:624px;white-space:nowrap" class="ft252">-0.7 ±&#160;3.8&#160;</p>
<p style="position:absolute;top:720px;left:710px;white-space:nowrap" class="ft252">0.6 ±&#160;5.9&#160;</p>
<p style="position:absolute;top:758px;left:114px;white-space:nowrap" class="ft2511">Median&#160;<br/>(Interquartile&#160;range)&#160;</p>
<p style="position:absolute;top:758px;left:293px;white-space:nowrap" class="ft2510">4.0&#160;<br/>(0.5,9.7)&#160;</p>
<p style="position:absolute;top:758px;left:386px;white-space:nowrap" class="ft2510">0.5&#160;<br/>(-1.5,3.0)&#160;</p>
<p style="position:absolute;top:758px;left:466px;white-space:nowrap" class="ft2510">0.1&#160;<br/>(-2.5,3.0)&#160;</p>
<p style="position:absolute;top:758px;left:546px;white-space:nowrap" class="ft2510">0.5&#160;<br/>(-1.5,2.0)&#160;</p>
<p style="position:absolute;top:758px;left:626px;white-space:nowrap" class="ft2510">-0.5&#160;<br/>(-3.0,1.5)&#160;</p>
<p style="position:absolute;top:758px;left:705px;white-space:nowrap" class="ft2510">0.0&#160;<br/>(-1.8,2.0)&#160;</p>
<p style="position:absolute;top:797px;left:114px;white-space:nowrap" class="ft2510">Patients&#160;with no&#160;<br/>deterioration/patients&#160;<br/>evaluated&#160;(%)c&#160;</p>
<p style="position:absolute;top:797px;left:293px;white-space:nowrap" class="ft2510">13/64&#160;<br/>(20%)&#160;</p>
<p style="position:absolute;top:797px;left:386px;white-space:nowrap" class="ft2510">34/71&#160;<br/>(48%)&#160;</p>
<p style="position:absolute;top:797px;left:466px;white-space:nowrap" class="ft2510">35/71&#160;<br/>(49%)&#160;</p>
<p style="position:absolute;top:797px;left:546px;white-space:nowrap" class="ft2510">37/77&#160;<br/>(48%)&#160;</p>
<p style="position:absolute;top:797px;left:626px;white-space:nowrap" class="ft2510">44/66&#160;<br/>(67%)&#160;</p>
<p style="position:absolute;top:797px;left:705px;white-space:nowrap" class="ft2510">150/285&#160;<br/>(53%)&#160;</p>
<p style="position:absolute;top:853px;left:114px;white-space:nowrap" class="ft2511">HAQ change&#160;from&#160;<br/>baseline&#160;over&#160;timee&#160;<br/>(patients evaluated)&#160;</p>
<p style="position:absolute;top:853px;left:293px;white-space:nowrap" class="ft252">87&#160;</p>
<p style="position:absolute;top:853px;left:386px;white-space:nowrap" class="ft252">86&#160;</p>
<p style="position:absolute;top:853px;left:466px;white-space:nowrap" class="ft252">85&#160;</p>
<p style="position:absolute;top:853px;left:546px;white-space:nowrap" class="ft252">87&#160;</p>
<p style="position:absolute;top:853px;left:626px;white-space:nowrap" class="ft252">81&#160;</p>
<p style="position:absolute;top:853px;left:705px;white-space:nowrap" class="ft252">339&#160;</p>
<p style="position:absolute;top:910px;left:114px;white-space:nowrap" class="ft252">Mean&#160;±&#160;SDc&#160;</p>
<p style="position:absolute;top:910px;left:293px;white-space:nowrap" class="ft252">0.2 ±&#160;0.3&#160;&#160;</p>
<p style="position:absolute;top:910px;left:386px;white-space:nowrap" class="ft252">0.4 ±&#160;0.3&#160;&#160;&#160;0.5 ±&#160;0.4&#160;&#160;&#160;0.5 ±&#160;0.5&#160;&#160;&#160;0.4 ±&#160;0.4&#160;&#160;&#160;0.4 ±&#160;0.4&#160;&#160;</p>
<p style="position:absolute;top:930px;left:114px;white-space:nowrap" class="ft252">a&#160;&#160;control&#160;=&#160;All&#160;patients had&#160;active RA&#160;despite&#160;treatment&#160;with&#160;stable&#160;methotrexate doses&#160;for&#160;6&#160;</p>
<p style="position:absolute;top:949px;left:136px;white-space:nowrap" class="ft252">months&#160;prior&#160;to&#160;enrolment&#160;and&#160;were&#160;to remain&#160;on&#160;stable&#160;doses&#160;throughout&#160;the&#160;study.&#160;Concurrent&#160;</p>
<p style="position:absolute;top:962px;left:136px;white-space:nowrap" class="ft2519">use&#160;of&#160;stable&#160;doses&#160;of&#160;oral&#160;corticosteroids&#160;(≤10&#160;mg/day)&#160;and/or&#160;NSAIDs&#160;was&#160;permitted, and&#160;<br/>folate&#160;supplementation&#160;was&#160;given.&#160;</p>
<p style="position:absolute;top:1006px;left:114px;white-space:nowrap" class="ft252">b&#160;&#160;all&#160;infliximab doses&#160;given&#160;in combination with&#160;methotrexate&#160;and&#160;folate&#160;with some&#160;on&#160;</p>
<p style="position:absolute;top:1025px;left:136px;white-space:nowrap" class="ft252">corticosteroids and/or&#160;NSAIDs&#160;</p>
<p style="position:absolute;top:1044px;left:114px;white-space:nowrap" class="ft2510">c&#160;&#160;p &lt;0.001,&#160;for&#160;each infliximab treatment&#160;group&#160;vs.&#160;control&#160;<br/>d&#160;&#160;greater&#160;values&#160;indicate&#160;more&#160;joint&#160;damage.&#160;<br/>e&#160;&#160;HAQ&#160;=&#160;Health&#160;Assessment&#160;Questionnaire;&#160;greater&#160;values indicate less&#160;disability.&#160;</p>
<p style="position:absolute;top:1101px;left:106px;white-space:nowrap" class="ft2511">&#160;<br/>The&#160;ASPIRE&#160;study&#160;evaluated responses&#160;at&#160;54&#160;weeks&#160;in&#160;1,004&#160;methotrexate&#160;naive patients with&#160;early&#160;</p>
<p style="position:absolute;top:1133px;left:106px;white-space:nowrap" class="ft2519">(≤3&#160;years&#160;disease duration,&#160;median&#160;0.6&#160;years)&#160;active&#160;rheumatoid arthritis&#160;(median&#160;swollen and tender&#160;<br/>joint&#160;count&#160;of&#160;19&#160;and 31,&#160;respectively).&#160;All&#160;patients received&#160;methotrexate&#160;(optimised&#160;to&#160;20&#160;mg/wk by&#160;</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page26-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft260">26&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2611">week&#160;8)&#160;and&#160;either&#160;placebo,&#160;3&#160;mg/kg&#160;or&#160;6&#160;mg/kg infliximab&#160;at&#160;weeks&#160;0,&#160;2, and&#160;6 and every 8&#160;weeks&#160;<br/>thereafter. Results&#160;from&#160;week 54 are&#160;shown in Table&#160;4.&#160;<br/>&#160;<br/>After 54&#160;weeks of&#160;treatment,&#160;both&#160;doses&#160;of&#160;infliximab&#160;+&#160;methotrexate&#160;resulted&#160;in&#160;statistically&#160;<br/>significantly&#160;greater&#160;improvement&#160;in&#160;signs&#160;and&#160;symptoms compared&#160;to&#160;methotrexate alone&#160;as&#160;<br/>measured by&#160;the&#160;proportion&#160;of&#160;patients&#160;achieving ACR20, 50 and 70&#160;responses.&#160;<br/>&#160;<br/>In&#160;ASPIRE,&#160;more&#160;than&#160;90%&#160;of&#160;patients had&#160;at&#160;least&#160;two&#160;evaluable X-rays. Reduction in&#160;the&#160;rate&#160;of&#160;<br/>progression of&#160;structural&#160;damage&#160;was&#160;observed&#160;at&#160;weeks&#160;30 and&#160;54 in the&#160;infliximab +&#160;methotrexate&#160;<br/>groups&#160;compared to methotrexate&#160;alone.&#160;<br/>&#160;</p>
<p style="position:absolute;top:298px;left:420px;white-space:nowrap" class="ft261"><b>Table&#160;4&#160;</b></p>
<p style="position:absolute;top:317px;left:141px;white-space:nowrap" class="ft261"><b>Effects&#160;on&#160;ACRn,&#160;Structural&#160;Joint&#160;Damage&#160;and Physical&#160;Function at&#160;week 54,&#160;ASPIRE&#160;</b></p>
<p style="position:absolute;top:337px;left:114px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:337px;left:379px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:337px;left:567px;white-space:nowrap" class="ft262">Infliximab&#160;+&#160;MTX&#160;</p>
<p style="position:absolute;top:357px;left:114px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:357px;left:379px;white-space:nowrap" class="ft2611">Placebo&#160;<br/>+&#160;MTX&#160;</p>
<p style="position:absolute;top:357px;left:483px;white-space:nowrap" class="ft262">3&#160;mg/kg&#160;</p>
<p style="position:absolute;top:357px;left:587px;white-space:nowrap" class="ft262">6&#160;mg/kg&#160;</p>
<p style="position:absolute;top:357px;left:690px;white-space:nowrap" class="ft262">Combined&#160;</p>
<p style="position:absolute;top:395px;left:114px;white-space:nowrap" class="ft262">Subjects&#160;randomised&#160;</p>
<p style="position:absolute;top:395px;left:379px;white-space:nowrap" class="ft262">282&#160;</p>
<p style="position:absolute;top:395px;left:483px;white-space:nowrap" class="ft262">359&#160;</p>
<p style="position:absolute;top:395px;left:587px;white-space:nowrap" class="ft262">363&#160;</p>
<p style="position:absolute;top:395px;left:690px;white-space:nowrap" class="ft262">722&#160;</p>
<p style="position:absolute;top:414px;left:114px;white-space:nowrap" class="ft2610">Percentage&#160;ACR&#160;improvement&#160;<br/>Mean&#160;±&#160;SDa&#160;</p>
<p style="position:absolute;top:433px;left:379px;white-space:nowrap" class="ft262">24.8&#160;±&#160;59.7&#160;</p>
<p style="position:absolute;top:433px;left:483px;white-space:nowrap" class="ft262">37.3&#160;±&#160;52.8&#160;</p>
<p style="position:absolute;top:433px;left:587px;white-space:nowrap" class="ft262">42.0&#160;±&#160;47.3&#160;</p>
<p style="position:absolute;top:433px;left:690px;white-space:nowrap" class="ft262">39.6&#160;±&#160;50.1&#160;</p>
<p style="position:absolute;top:452px;left:114px;white-space:nowrap" class="ft2610">Change&#160;from&#160;baseline&#160;in&#160;total&#160;van der&#160;Heijde-modified Sharp scoreb&#160;<br/>Mean&#160;±&#160;SDa&#160;</p>
<p style="position:absolute;top:471px;left:379px;white-space:nowrap" class="ft262">3.70&#160;±&#160;9.61&#160;</p>
<p style="position:absolute;top:471px;left:483px;white-space:nowrap" class="ft262">0.42&#160;±&#160;5.82&#160;</p>
<p style="position:absolute;top:471px;left:587px;white-space:nowrap" class="ft262">0.51&#160;±&#160;5.55&#160;</p>
<p style="position:absolute;top:471px;left:690px;white-space:nowrap" class="ft262">0.46&#160;±&#160;5.68&#160;</p>
<p style="position:absolute;top:490px;left:114px;white-space:nowrap" class="ft262">Median&#160;</p>
<p style="position:absolute;top:490px;left:379px;white-space:nowrap" class="ft262">0.43&#160;</p>
<p style="position:absolute;top:490px;left:483px;white-space:nowrap" class="ft262">0.00&#160;</p>
<p style="position:absolute;top:490px;left:587px;white-space:nowrap" class="ft262">0.00&#160;</p>
<p style="position:absolute;top:490px;left:690px;white-space:nowrap" class="ft262">0.00&#160;</p>
<p style="position:absolute;top:509px;left:114px;white-space:nowrap" class="ft2610">Improvement&#160;from&#160;baseline&#160;in HAQ&#160;averaged over&#160;time&#160;from&#160;week 30&#160;to week 54c&#160;<br/>Mean&#160;±&#160;SDd&#160;</p>
<p style="position:absolute;top:528px;left:379px;white-space:nowrap" class="ft262">0.68 ±&#160;0.63&#160;</p>
<p style="position:absolute;top:528px;left:483px;white-space:nowrap" class="ft262">0.80&#160;±&#160;0.65&#160;</p>
<p style="position:absolute;top:528px;left:587px;white-space:nowrap" class="ft262">0.88&#160;±&#160;0.65&#160;</p>
<p style="position:absolute;top:528px;left:690px;white-space:nowrap" class="ft262">0.84&#160;±&#160;0.65&#160;</p>
<p style="position:absolute;top:548px;left:114px;white-space:nowrap" class="ft262">a&#160;</p>
<p style="position:absolute;top:548px;left:147px;white-space:nowrap" class="ft262">&#160;p &lt;0.001,&#160;for&#160;each infliximab treatment&#160;group&#160;vs&#160;control.&#160;</p>
<p style="position:absolute;top:567px;left:114px;white-space:nowrap" class="ft262">b&#160;</p>
<p style="position:absolute;top:567px;left:147px;white-space:nowrap" class="ft262">greater&#160;values&#160;indicate&#160;more&#160;joint&#160;damage.&#160;</p>
<p style="position:absolute;top:586px;left:114px;white-space:nowrap" class="ft262">c&#160;</p>
<p style="position:absolute;top:586px;left:147px;white-space:nowrap" class="ft262">HAQ&#160;=&#160;Health&#160;Assessment&#160;Questionnaire;&#160;greater&#160;values indicate less disability.&#160;</p>
<p style="position:absolute;top:605px;left:114px;white-space:nowrap" class="ft262">d&#160;</p>
<p style="position:absolute;top:605px;left:147px;white-space:nowrap" class="ft2611">p&#160;=&#160;0.030 and&#160;&lt;0.001 for&#160;the&#160;3&#160;mg/kg and&#160;6&#160;mg/kg&#160;treatment&#160;groups&#160;respectively&#160;vs.&#160;placebo&#160;+&#160;<br/>MTX.&#160;</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft2611">&#160;<br/>Data&#160;to&#160;support dose&#160;titration&#160;in&#160;rheumatoid&#160;arthritis&#160;come&#160;from ATTRACT,&#160;ASPIRE&#160;and&#160;the&#160;START&#160;<br/>study.&#160;START&#160;was&#160;a&#160;randomised,&#160;multicentre, double-blind, 3-arm,&#160;parallel-group&#160;safety&#160;study. In one&#160;<br/>of&#160;the&#160;study&#160;arms&#160;(group 2,&#160;n=329), patients&#160;with an&#160;inadequate&#160;response&#160;were&#160;allowed to dose&#160;titrate&#160;<br/>with 1.5&#160;mg/kg&#160;increments&#160;from 3&#160;up&#160;to&#160;9&#160;mg/kg. The&#160;majority&#160;(67%)&#160;of&#160;these&#160;patients&#160;did not&#160;require&#160;<br/>any&#160;dose&#160;titration. Of&#160;the&#160;patients&#160;who required&#160;a&#160;dose&#160;titration,&#160;80%&#160;achieved clinical&#160;response&#160;and&#160;<br/>the&#160;majority&#160;(64%)&#160;of&#160;these&#160;required only one&#160;adjustment&#160;of&#160;1.5&#160;mg/kg.&#160;<br/>&#160;<br/><i>Adult&#160;Crohn’s&#160;disease&#160;<br/></i>&#160;<br/><i>Induction&#160;treatment&#160;in&#160;moderately&#160;to&#160;severely active Crohn’s disease&#160;<br/></i>The efficacy&#160;of&#160;a single dose treatment&#160;with&#160;infliximab&#160;was assessed&#160;in&#160;108&#160;patients with&#160;active&#160;<br/>Crohn’s&#160;disease&#160;(Crohn’s&#160;Disease&#160;Activity Index&#160;(CDAI)&#160;</p>
<p style="position:absolute;top:865px;left:489px;white-space:nowrap" class="ft2618">≥220&#160;≤400)&#160;in&#160;a&#160;randomised,&#160;</p>
<p style="position:absolute;top:889px;left:106px;white-space:nowrap" class="ft2611">double-blinded, placebo-controlled, dose-response&#160;study. Of&#160;these&#160;108&#160;patients,&#160;27&#160;were&#160;treated&#160;with&#160;<br/>the&#160;recommended&#160;dosage&#160;of&#160;infliximab&#160;5&#160;mg/kg. All&#160;patients&#160;had&#160;experienced an&#160;inadequate&#160;response&#160;<br/>to prior&#160;conventional&#160;therapies. Concurrent&#160;use&#160;of&#160;stable&#160;doses&#160;of&#160;conventional&#160;therapies&#160;was&#160;<br/>permitted, and 92%&#160;of&#160;patients continued&#160;to&#160;receive these therapies.&#160;<br/>&#160;<br/>The&#160;primary&#160;endpoint&#160;was&#160;the&#160;proportion of&#160;patients&#160;who experienced a&#160;clinical&#160;response, defined as&#160;a&#160;<br/>decrease in&#160;CDAI&#160;by&#160;</p>
<p style="position:absolute;top:997px;left:249px;white-space:nowrap" class="ft2618">≥70&#160;points&#160;from&#160;baseline at&#160;the 4-week evaluation&#160;and without&#160;an&#160;increase&#160;in the&#160;</p>
<p style="position:absolute;top:1022px;left:106px;white-space:nowrap" class="ft2610">use of&#160;medicinal&#160;products or&#160;surgery&#160;for&#160;Crohn’s disease.&#160;Patients who&#160;responded&#160;at&#160;week&#160;4&#160;were&#160;<br/>followed&#160;to week 12. Secondary&#160;endpoints&#160;included&#160;the&#160;proportion of&#160;patients&#160;in&#160;clinical&#160;remission at&#160;<br/>week&#160;4&#160;(CDAI&#160;&lt;150)&#160;and&#160;clinical&#160;response over&#160;time.&#160;<br/>&#160;<br/>At&#160;week 4,&#160;following administration of&#160;a&#160;single&#160;dose,&#160;22/27&#160;(81%) of infliximab-treated&#160;patients&#160;<br/>receiving&#160;a 5&#160;mg/kg dose&#160;achieved&#160;a&#160;clinical&#160;response&#160;vs.&#160;4/25&#160;(16%)&#160;of&#160;the&#160;placebo-treated&#160;patients&#160;<br/>(p&#160;&lt;0.001). Also&#160;at&#160;week 4,&#160;13/27&#160;(48%)&#160;of infliximab-treated&#160;patients&#160;achieved&#160;a clinical&#160;remission&#160;<br/>(CDAI&#160;&lt;150)&#160;vs.&#160;1/25&#160;(4%)&#160;of&#160;placebo-treated&#160;patients.&#160;A&#160;response was observed&#160;within&#160;2&#160;weeks, with&#160;</p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2726{font-size:14px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page27-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft270">27&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2711">a maximum&#160;response at&#160;4&#160;weeks. At&#160;the&#160;last&#160;observation at&#160;12&#160;weeks, 13/27&#160;(48%) of&#160;<br/>infliximab-treated&#160;patients were&#160;still&#160;responding.&#160;<br/><i>&#160;<br/>Maintenance&#160;treatment&#160;in&#160;moderately to&#160;severely active Crohn’s disease&#160;in&#160;adults&#160;<br/></i>The efficacy&#160;of&#160;repeated&#160;infusions with&#160;infliximab&#160;was&#160;studied&#160;in&#160;a&#160;1-year&#160;clinical&#160;study (ACCENT&#160;I).&#160;<br/>A&#160;total&#160;of&#160;573&#160;patients with&#160;moderately&#160;to&#160;severely&#160;active Crohn’s disease (CDAI&#160;</p>
<p style="position:absolute;top:178px;left:649px;white-space:nowrap" class="ft2718">≥220&#160;≤400)&#160;received&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft2710">a&#160;single&#160;infusion of&#160;5&#160;mg/kg at&#160;week 0. 178 of&#160;the&#160;580&#160;enrolled patients&#160;(30.7%)&#160;were&#160;defined&#160;as&#160;<br/>having&#160;severe&#160;disease (CDAI&#160;score &gt;&#160;300 and concomitant&#160;corticosteroid and/or&#160;immunosuppressants)&#160;<br/>corresponding to&#160;the&#160;population defined&#160;in the&#160;indication (see&#160;section 4.1). At&#160;week&#160;2,&#160;all&#160;patients were&#160;<br/>assessed&#160;for&#160;clinical&#160;response and&#160;randomised&#160;to&#160;one of&#160;3&#160;treatment&#160;groups;&#160;a placebo&#160;maintenance&#160;<br/>group, 5&#160;mg/kg&#160;maintenance&#160;group and 10&#160;mg/kg&#160;maintenance&#160;group. All&#160;3&#160;groups&#160;received repeated&#160;<br/>infusions&#160;at&#160;week&#160;2, 6 and every 8&#160;weeks thereafter.&#160;<br/>&#160;<br/>Of&#160;the&#160;573&#160;patients&#160;randomised, 335 (58%)&#160;achieved clinical&#160;response&#160;by&#160;week&#160;2.&#160;These patients were&#160;<br/>classified&#160;as week-2&#160;responders&#160;and&#160;were&#160;included in the&#160;primary analysis&#160;(see&#160;Table&#160;5).&#160;Among&#160;<br/>patients classified&#160;as&#160;non-responders&#160;at&#160;week&#160;2,&#160;32%&#160;(26/81)&#160;in the&#160;placebo maintenance&#160;group&#160;and&#160;<br/>42%&#160;(68/163)&#160;in the&#160;infliximab&#160;group achieved&#160;clinical&#160;response&#160;by&#160;week&#160;6. There was no&#160;difference&#160;<br/>between groups&#160;in&#160;the&#160;number&#160;of&#160;late&#160;responders&#160;thereafter.&#160;<br/>&#160;<br/>The co-primary&#160;endpoints&#160;were&#160;the&#160;proportion of&#160;patients&#160;in clinical&#160;remission (CDAI&#160;&lt;150)&#160;at&#160;<br/>week&#160;30 and time&#160;to loss&#160;of&#160;response&#160;through week&#160;54.&#160;Corticosteroid tapering was&#160;permitted&#160;after&#160;<br/>week&#160;6.&#160;<br/>&#160;</p>
<p style="position:absolute;top:526px;left:420px;white-space:nowrap" class="ft271"><b>Table&#160;5&#160;</b></p>
<p style="position:absolute;top:545px;left:154px;white-space:nowrap" class="ft271"><b>Effects on&#160;response&#160;and&#160;remission&#160;rate,&#160;data&#160;from&#160;ACCENT&#160;I (Week-2&#160;responders)&#160;</b></p>
<p style="position:absolute;top:565px;left:114px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:565px;left:456px;white-space:nowrap" class="ft272">ACCENT&#160;I&#160;(Week-2 responders)&#160;</p>
<p style="position:absolute;top:584px;left:521px;white-space:nowrap" class="ft272">%&#160;of&#160;Patients<b>&#160;</b></p>
<p style="position:absolute;top:604px;left:114px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:604px;left:353px;white-space:nowrap" class="ft2710">Placebo&#160;<br/>Maintenance&#160;</p>
<p style="position:absolute;top:642px;left:402px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:661px;left:353px;white-space:nowrap" class="ft272">(n=110)&#160;</p>
<p style="position:absolute;top:604px;left:503px;white-space:nowrap" class="ft272">Infliximab&#160;</p>
<p style="position:absolute;top:623px;left:496px;white-space:nowrap" class="ft272">Maintenance&#160;</p>
<p style="position:absolute;top:642px;left:511px;white-space:nowrap" class="ft272">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:661px;left:512px;white-space:nowrap" class="ft272">(n=113)&#160;</p>
<p style="position:absolute;top:680px;left:509px;white-space:nowrap" class="ft272">(p value)&#160;</p>
<p style="position:absolute;top:604px;left:667px;white-space:nowrap" class="ft272">Infliximab&#160;</p>
<p style="position:absolute;top:623px;left:659px;white-space:nowrap" class="ft272">Maintenance&#160;</p>
<p style="position:absolute;top:642px;left:670px;white-space:nowrap" class="ft272">10&#160;mg/kg&#160;</p>
<p style="position:absolute;top:661px;left:675px;white-space:nowrap" class="ft272">(n=112)&#160;</p>
<p style="position:absolute;top:680px;left:672px;white-space:nowrap" class="ft272">(p value)&#160;</p>
<p style="position:absolute;top:700px;left:114px;white-space:nowrap" class="ft2710">Median&#160;time to&#160;loss of&#160;response&#160;<br/>through week&#160;54&#160;</p>
<p style="position:absolute;top:700px;left:353px;white-space:nowrap" class="ft272">19 weeks&#160;</p>
<p style="position:absolute;top:700px;left:507px;white-space:nowrap" class="ft272">38 weeks&#160;</p>
<p style="position:absolute;top:718px;left:514px;white-space:nowrap" class="ft272">(0.002)&#160;</p>
<p style="position:absolute;top:700px;left:666px;white-space:nowrap" class="ft272">&gt;54 weeks&#160;</p>
<p style="position:absolute;top:718px;left:673px;white-space:nowrap" class="ft272">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:737px;left:114px;white-space:nowrap" class="ft271"><b>Week&#160;30&#160;</b></p>
<p style="position:absolute;top:737px;left:353px;white-space:nowrap" class="ft271"><b>&#160;</b></p>
<p style="position:absolute;top:737px;left:468px;white-space:nowrap" class="ft271"><b>&#160;</b></p>
<p style="position:absolute;top:737px;left:625px;white-space:nowrap" class="ft271"><b>&#160;</b></p>
<p style="position:absolute;top:756px;left:114px;white-space:nowrap" class="ft272">Clinical&#160;Responsea&#160;</p>
<p style="position:absolute;top:756px;left:353px;white-space:nowrap" class="ft272">27.3&#160;</p>
<p style="position:absolute;top:757px;left:524px;white-space:nowrap" class="ft272">51.3&#160;</p>
<p style="position:absolute;top:776px;left:509px;white-space:nowrap" class="ft272">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:757px;left:687px;white-space:nowrap" class="ft272">59.1&#160;</p>
<p style="position:absolute;top:776px;left:673px;white-space:nowrap" class="ft272">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:795px;left:114px;white-space:nowrap" class="ft272">Clinical Remission&#160;</p>
<p style="position:absolute;top:795px;left:353px;white-space:nowrap" class="ft272">20.9&#160;</p>
<p style="position:absolute;top:795px;left:524px;white-space:nowrap" class="ft272">38.9&#160;</p>
<p style="position:absolute;top:814px;left:514px;white-space:nowrap" class="ft272">(0.003)&#160;</p>
<p style="position:absolute;top:795px;left:687px;white-space:nowrap" class="ft272">45.5&#160;</p>
<p style="position:absolute;top:814px;left:673px;white-space:nowrap" class="ft272">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:833px;left:114px;white-space:nowrap" class="ft272">Steroid-Free Remission&#160;</p>
<p style="position:absolute;top:833px;left:353px;white-space:nowrap" class="ft272">10.7 (6/56)&#160;</p>
<p style="position:absolute;top:834px;left:497px;white-space:nowrap" class="ft272">31.0 (18/58)&#160;</p>
<p style="position:absolute;top:853px;left:514px;white-space:nowrap" class="ft272">(0.008)&#160;</p>
<p style="position:absolute;top:834px;left:661px;white-space:nowrap" class="ft272">36.8 (21/57)&#160;</p>
<p style="position:absolute;top:853px;left:678px;white-space:nowrap" class="ft272">(0.001)&#160;</p>
<p style="position:absolute;top:872px;left:114px;white-space:nowrap" class="ft271"><b>Week&#160;54&#160;</b></p>
<p style="position:absolute;top:872px;left:353px;white-space:nowrap" class="ft271"><b>&#160;</b></p>
<p style="position:absolute;top:872px;left:538px;white-space:nowrap" class="ft271"><b>&#160;</b></p>
<p style="position:absolute;top:872px;left:702px;white-space:nowrap" class="ft271"><b>&#160;</b></p>
<p style="position:absolute;top:891px;left:114px;white-space:nowrap" class="ft272">Clinical&#160;Responsea&#160;</p>
<p style="position:absolute;top:891px;left:353px;white-space:nowrap" class="ft272">15.5&#160;</p>
<p style="position:absolute;top:891px;left:524px;white-space:nowrap" class="ft272">38.1&#160;</p>
<p style="position:absolute;top:910px;left:509px;white-space:nowrap" class="ft272">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:891px;left:687px;white-space:nowrap" class="ft272">47.7&#160;</p>
<p style="position:absolute;top:910px;left:673px;white-space:nowrap" class="ft272">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:929px;left:114px;white-space:nowrap" class="ft272">Clinical Remission&#160;</p>
<p style="position:absolute;top:929px;left:353px;white-space:nowrap" class="ft272">13.6&#160;</p>
<p style="position:absolute;top:930px;left:524px;white-space:nowrap" class="ft272">28.3&#160;</p>
<p style="position:absolute;top:949px;left:514px;white-space:nowrap" class="ft272">(0.007)&#160;</p>
<p style="position:absolute;top:930px;left:687px;white-space:nowrap" class="ft272">38.4&#160;</p>
<p style="position:absolute;top:949px;left:673px;white-space:nowrap" class="ft272">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:968px;left:114px;white-space:nowrap" class="ft2711">Sustained&#160;Steroid-Free&#160;<br/>Remissionb&#160;</p>
<p style="position:absolute;top:968px;left:353px;white-space:nowrap" class="ft272">5.7 (3/53)&#160;</p>
<p style="position:absolute;top:968px;left:497px;white-space:nowrap" class="ft272">17.9 (10/56)&#160;</p>
<p style="position:absolute;top:987px;left:514px;white-space:nowrap" class="ft272">(0.075)&#160;</p>
<p style="position:absolute;top:968px;left:661px;white-space:nowrap" class="ft272">28.6 (16/56)&#160;</p>
<p style="position:absolute;top:987px;left:678px;white-space:nowrap" class="ft272">(0.002)&#160;</p>
<p style="position:absolute;top:1007px;left:114px;white-space:nowrap" class="ft272">a&#160;</p>
<p style="position:absolute;top:1007px;left:147px;white-space:nowrap" class="ft272">Reduction in&#160;CDAI&#160;</p>
<p style="position:absolute;top:1001px;left:280px;white-space:nowrap" class="ft2718">≥25%&#160;and&#160;≥70&#160;points.&#160;</p>
<p style="position:absolute;top:1026px;left:114px;white-space:nowrap" class="ft272">b&#160;&#160;</p>
<p style="position:absolute;top:1026px;left:147px;white-space:nowrap" class="ft2710">CDAI&#160;&lt;150 at&#160;both Week&#160;30 and 54&#160;and not&#160;receiving&#160;corticosteroids&#160;in&#160;the&#160;3&#160;months&#160;prior&#160;to&#160;<br/>Week&#160;54 among patients&#160;who were&#160;receiving&#160;corticosteroids&#160;at&#160;baseline.&#160;</p>
<p style="position:absolute;top:1064px;left:106px;white-space:nowrap" class="ft2710">&#160;<br/>Beginning at&#160;week&#160;14, patients&#160;who had&#160;responded to&#160;treatment, but&#160;subsequently&#160;lost&#160;their&#160;clinical&#160;<br/>benefit,&#160;were allowed&#160;to&#160;cross over&#160;to&#160;a dose of&#160;infliximab&#160;5&#160;mg/kg&#160;higher&#160;than the&#160;dose&#160;to&#160;which they&#160;<br/>were&#160;originally randomised. Eighty&#160;nine&#160;percent&#160;(50/56)&#160;of&#160;patients&#160;who&#160;lost&#160;clinical&#160;response&#160;on&#160;<br/>infliximab&#160;5&#160;mg/kg maintenance&#160;therapy&#160;after&#160;week&#160;14 responded&#160;to&#160;treatment&#160;with infliximab&#160;<br/>10&#160;mg/kg.&#160;</p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page28-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft280">28&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2810">&#160;<br/>Improvements&#160;in quality of&#160;life&#160;measures, a&#160;reduction&#160;in disease-related hospitalisations&#160;and&#160;<br/>corticosteroid&#160;use were seen&#160;in&#160;the&#160;infliximab&#160;maintenance groups compared&#160;with&#160;the placebo&#160;<br/>maintenance&#160;group at&#160;weeks&#160;30 and&#160;54.&#160;<br/><i>&#160;<br/></i>Infliximab with or&#160;without&#160;AZA&#160;was&#160;assessed in&#160;a&#160;randomised,&#160;double-blind, active&#160;comparator&#160;study&#160;<br/>(SONIC)&#160;of&#160;508&#160;adult&#160;patients&#160;with&#160;moderate&#160;to severe&#160;Crohn’s&#160;disease&#160;(CDAI&#160;</p>
<p style="position:absolute;top:197px;left:631px;white-space:nowrap" class="ft2818">≥220&#160;≤450)&#160;who were&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft2811">naive&#160;to biologics&#160;and&#160;immunosuppressants&#160;and had&#160;a&#160;median disease&#160;duration of&#160;2.3&#160;years. At&#160;<br/>baseline 27.4%&#160;of&#160;patients&#160;were receiving&#160;systemic&#160;corticosteroids,&#160;14.2%&#160;of&#160;patients were receiving&#160;<br/>budesonide, and 54.3%&#160;of&#160;patients&#160;were&#160;receiving 5-ASA&#160;compounds. Patients&#160;were&#160;randomised to&#160;<br/>receive&#160;AZA&#160;monotherapy,&#160;infliximab&#160;monotherapy, or&#160;infliximab plus&#160;AZA&#160;combination therapy.&#160;<br/>Infliximab&#160;was&#160;administered&#160;at a&#160;dose&#160;of&#160;5&#160;mg/kg at&#160;weeks&#160;0,&#160;2, 6, and then every&#160;8 weeks. AZA&#160;was&#160;<br/>given at&#160;a&#160;dose&#160;of&#160;2.5&#160;mg/kg daily.&#160;<br/>&#160;<br/>The&#160;primary&#160;endpoint&#160;of&#160;the&#160;study was&#160;corticosteroid-free clinical&#160;remission&#160;at&#160;week&#160;26,&#160;defined as&#160;<br/>patients&#160;in clinical&#160;remission (CDAI&#160;of&#160;&lt;150)&#160;who,&#160;for&#160;at&#160;least&#160;3 weeks, had&#160;not taken&#160;oral systemic&#160;<br/>corticosteroids&#160;(prednisone&#160;or&#160;equivalent)&#160;or&#160;budesonide at&#160;a dose &gt;6&#160;mg/day.&#160;For&#160;results see Table 6.&#160;<br/>The&#160;proportions&#160;of&#160;patients&#160;with&#160;mucosal&#160;healing at&#160;week&#160;26 were&#160;significantly greater&#160;in&#160;the&#160;<br/>infliximab plus&#160;AZA&#160;combination (43.9%, p&lt;0.001)&#160;and infliximab&#160;monotherapy&#160;groups&#160;(30.1%,&#160;<br/>p=0.023)&#160;compared to the&#160;AZA&#160;monotherapy&#160;group (16.5%).&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:497px;left:420px;white-space:nowrap" class="ft281"><b>Table&#160;6&#160;</b></p>
<p style="position:absolute;top:516px;left:143px;white-space:nowrap" class="ft281"><b>Percent&#160;of&#160;patients achieving&#160;corticosteroid-free clinical&#160;remission&#160;at&#160;Week&#160;26,&#160;SONIC&#160;</b></p>
<p style="position:absolute;top:536px;left:225px;white-space:nowrap" class="ft281"><b>&#160;</b></p>
<p style="position:absolute;top:536px;left:385px;white-space:nowrap" class="ft282">AZA&#160;</p>
<p style="position:absolute;top:555px;left:358px;white-space:nowrap" class="ft282">Monotherapy&#160;</p>
<p style="position:absolute;top:536px;left:503px;white-space:nowrap" class="ft282">Infliximab&#160;</p>
<p style="position:absolute;top:555px;left:494px;white-space:nowrap" class="ft282">Monotherapy&#160;</p>
<p style="position:absolute;top:536px;left:641px;white-space:nowrap" class="ft282">Infliximab&#160;+&#160;AZA&#160;</p>
<p style="position:absolute;top:555px;left:632px;white-space:nowrap" class="ft282">Combination therapy&#160;</p>
<p style="position:absolute;top:574px;left:114px;white-space:nowrap" class="ft281"><b>Week&#160;26&#160;</b></p>
<p style="position:absolute;top:574px;left:353px;white-space:nowrap" class="ft281"><b>&#160;</b></p>
<p style="position:absolute;top:574px;left:468px;white-space:nowrap" class="ft281"><b>&#160;</b></p>
<p style="position:absolute;top:574px;left:625px;white-space:nowrap" class="ft281"><b>&#160;</b></p>
<p style="position:absolute;top:593px;left:114px;white-space:nowrap" class="ft282">All&#160;randomised&#160;patients&#160;</p>
<p style="position:absolute;top:593px;left:381px;white-space:nowrap" class="ft282">30.0%&#160;</p>
<p style="position:absolute;top:612px;left:374px;white-space:nowrap" class="ft282">(51/170)&#160;</p>
<p style="position:absolute;top:594px;left:486px;white-space:nowrap" class="ft282">44.4%&#160;(75/169)&#160;</p>
<p style="position:absolute;top:613px;left:501px;white-space:nowrap" class="ft282">(p=0.006)*&#160;</p>
<p style="position:absolute;top:594px;left:650px;white-space:nowrap" class="ft282">56.8%&#160;(96/169)&#160;</p>
<p style="position:absolute;top:613px;left:665px;white-space:nowrap" class="ft282">(p&lt;0.001)*&#160;</p>
<p style="position:absolute;top:633px;left:114px;white-space:nowrap" class="ft282">*&#160;&#160;p-values&#160;represent&#160;each infliximab&#160;treatment&#160;group&#160;vs.&#160;AZA&#160;monotherapy.&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft2810"><i>&#160;<br/></i>Similar&#160;trends in&#160;the&#160;achievement&#160;of&#160;corticosteroid-free&#160;clinical&#160;remission&#160;were observed&#160;at&#160;week&#160;50.&#160;<br/>Furthermore, improved quality of&#160;life&#160;as&#160;measured by IBDQ&#160;was&#160;observed with&#160;infliximab.&#160;<br/><i>&#160;<br/>Induction&#160;treatment&#160;in&#160;fistulising&#160;active&#160;Crohn’s&#160;disease&#160;<br/></i>The efficacy&#160;was assessed&#160;in&#160;a randomised,&#160;double-blinded, placebo-controlled study in&#160;94&#160;patients&#160;<br/>with&#160;fistulising&#160;Crohn’s&#160;disease&#160;who&#160;had&#160;fistulae&#160;that&#160;were&#160;of&#160;at least 3&#160;months’&#160;duration. Thirty&#160;one&#160;of&#160;<br/>these patients were treated&#160;with&#160;infliximab&#160;5&#160;mg/kg. Approximately 93%&#160;of&#160;the&#160;patients&#160;had&#160;<br/>previously&#160;received antibiotic&#160;or&#160;immunosuppressive&#160;therapy.&#160;<br/>&#160;<br/>Concurrent&#160;use&#160;of&#160;stable&#160;doses of&#160;conventional&#160;therapies was permitted,&#160;and 83%&#160;of&#160;patients&#160;continued&#160;<br/>to&#160;receive&#160;at&#160;least&#160;one of&#160;these&#160;therapies.&#160;Patients&#160;received&#160;three doses of&#160;either&#160;placebo&#160;or&#160;infliximab&#160;<br/>at&#160;weeks&#160;0, 2&#160;and 6.&#160;Patients&#160;were&#160;followed up&#160;to 26&#160;weeks. The&#160;primary endpoint&#160;was&#160;the&#160;proportion&#160;<br/>of&#160;patients&#160;who experienced&#160;a clinical&#160;response,&#160;defined&#160;as&#160;</p>
<p style="position:absolute;top:892px;left:498px;white-space:nowrap" class="ft2818">≥50%&#160;reduction&#160;from&#160;baseline&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:917px;left:106px;white-space:nowrap" class="ft2810">number&#160;of&#160;fistulae&#160;draining&#160;upon gentle&#160;compression&#160;on at&#160;least&#160;two consecutive&#160;visits&#160;(4&#160;weeks apart),&#160;<br/>without&#160;an&#160;increase&#160;in the&#160;use&#160;of&#160;medicinal&#160;products&#160;or&#160;surgery for&#160;Crohn’s&#160;disease.&#160;<br/>&#160;<br/>Sixty&#160;eight&#160;percent&#160;(21/31)&#160;of&#160;infliximab-treated&#160;patients receiving&#160;a&#160;5&#160;mg/kg&#160;dose&#160;regimen achieved a&#160;<br/>clinical&#160;response&#160;vs. 26%&#160;(8/31)&#160;placebo-treated&#160;patients&#160;(p=0.002).&#160;The&#160;median time&#160;to&#160;onset&#160;of&#160;<br/>response&#160;in the&#160;infliximab-treated group was&#160;2&#160;weeks.&#160;The&#160;median duration&#160;of&#160;response&#160;was&#160;12&#160;weeks.&#160;<br/>Additionally, closure&#160;of&#160;all&#160;fistulae&#160;was&#160;achieved&#160;in 55%&#160;of&#160;infliximab-treated patients&#160;compared with&#160;<br/>13%&#160;of&#160;placebo-treated&#160;patients&#160;(p=0.001).&#160;<br/><i>&#160;<br/>Maintenance&#160;treatment in&#160;fistulising&#160;active&#160;Crohn’s disease&#160;<br/></i>The efficacy&#160;of&#160;repeated&#160;infusions with&#160;infliximab&#160;in&#160;patients with&#160;fistulising&#160;Crohn’s disease was&#160;<br/>studied in&#160;a&#160;1-year&#160;clinical&#160;study&#160;(ACCENT&#160;II). A&#160;total&#160;of&#160;306&#160;patients&#160;received 3 doses&#160;of&#160;infliximab&#160;<br/>5&#160;mg/kg&#160;at week&#160;0, 2&#160;and 6.&#160;At&#160;baseline, 87%&#160;of&#160;the&#160;patients&#160;had perianal&#160;fistulae,&#160;14%&#160;had abdominal&#160;</p>
</div>
<!-- Page 29 -->
<a name="29"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page29-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft290">29&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft2910">fistulae,&#160;9%&#160;had&#160;rectovaginal&#160;fistulae.&#160;The&#160;median&#160;CDAI&#160;score was&#160;180.&#160;At&#160;week&#160;14, 282&#160;patients&#160;<br/>were assessed&#160;for&#160;clinical&#160;response and&#160;randomised&#160;to&#160;receive&#160;either&#160;placebo&#160;or&#160;5&#160;mg/kg infliximab&#160;<br/>every&#160;8&#160;weeks through&#160;week&#160;46.&#160;<br/>&#160;<br/>Week-14 responders&#160;(195/282)&#160;were&#160;analysed for&#160;the&#160;primary&#160;endpoint,&#160;which&#160;was&#160;time&#160;from&#160;<br/>randomisation to&#160;loss&#160;of&#160;response&#160;(see&#160;Table&#160;7). Corticosteroid tapering was&#160;permitted after&#160;week&#160;6.&#160;<br/>&#160;</p>
<p style="position:absolute;top:222px;left:420px;white-space:nowrap" class="ft291"><b>Table&#160;7&#160;</b></p>
<p style="position:absolute;top:241px;left:198px;white-space:nowrap" class="ft291"><b>Effects on&#160;response&#160;rate,&#160;data from&#160;ACCENT&#160;II&#160;(Week-14&#160;responders)&#160;</b></p>
<p style="position:absolute;top:261px;left:230px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:261px;left:454px;white-space:nowrap" class="ft292">ACCENT&#160;II&#160;(Week-14 responders)&#160;</p>
<p style="position:absolute;top:281px;left:230px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:281px;left:399px;white-space:nowrap" class="ft292">Placebo&#160;</p>
<p style="position:absolute;top:301px;left:383px;white-space:nowrap" class="ft292">Maintenance&#160;</p>
<p style="position:absolute;top:320px;left:403px;white-space:nowrap" class="ft292">(n=99)&#160;</p>
<p style="position:absolute;top:281px;left:535px;white-space:nowrap" class="ft292">Infliximab&#160;</p>
<p style="position:absolute;top:301px;left:527px;white-space:nowrap" class="ft292">Maintenance&#160;</p>
<p style="position:absolute;top:320px;left:537px;white-space:nowrap" class="ft292">(5&#160;mg/kg)&#160;</p>
<p style="position:absolute;top:339px;left:547px;white-space:nowrap" class="ft292">(n=96)&#160;</p>
<p style="position:absolute;top:281px;left:690px;white-space:nowrap" class="ft292">p-value&#160;</p>
<p style="position:absolute;top:359px;left:114px;white-space:nowrap" class="ft2911">Median&#160;time to&#160;loss of&#160;response&#160;<br/>through week&#160;54&#160;</p>
<p style="position:absolute;top:359px;left:394px;white-space:nowrap" class="ft292">14&#160;weeks&#160;</p>
<p style="position:absolute;top:359px;left:534px;white-space:nowrap" class="ft292">&gt;40&#160;weeks&#160;</p>
<p style="position:absolute;top:359px;left:691px;white-space:nowrap" class="ft292">&lt;0.001&#160;</p>
<p style="position:absolute;top:397px;left:114px;white-space:nowrap" class="ft291"><b>Week&#160;54&#160;</b></p>
<p style="position:absolute;top:397px;left:425px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:397px;left:570px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:397px;left:714px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:416px;left:114px;white-space:nowrap" class="ft292">Fistula&#160;Response (%)a&#160;</p>
<p style="position:absolute;top:416px;left:411px;white-space:nowrap" class="ft292">23.5&#160;</p>
<p style="position:absolute;top:416px;left:555px;white-space:nowrap" class="ft292">46.2&#160;</p>
<p style="position:absolute;top:416px;left:696px;white-space:nowrap" class="ft292">0.001&#160;</p>
<p style="position:absolute;top:435px;left:114px;white-space:nowrap" class="ft292">Complete&#160;fistula&#160;response&#160;(%)b&#160;</p>
<p style="position:absolute;top:435px;left:411px;white-space:nowrap" class="ft292">19.4&#160;</p>
<p style="position:absolute;top:435px;left:555px;white-space:nowrap" class="ft292">36.3&#160;</p>
<p style="position:absolute;top:435px;left:696px;white-space:nowrap" class="ft292">0.009&#160;</p>
<p style="position:absolute;top:455px;left:114px;white-space:nowrap" class="ft292">a&#160;</p>
<p style="position:absolute;top:455px;left:147px;white-space:nowrap" class="ft292">A&#160;</p>
<p style="position:absolute;top:449px;left:163px;white-space:nowrap" class="ft2918">≥50%&#160;reduction&#160;from&#160;baseline&#160;in the&#160;number&#160;of&#160;draining fistulas&#160;over&#160;a&#160;period of&#160;≥4 weeks.&#160;</p>
<p style="position:absolute;top:474px;left:114px;white-space:nowrap" class="ft292">b&#160;</p>
<p style="position:absolute;top:474px;left:147px;white-space:nowrap" class="ft292">Absence&#160;of&#160;any&#160;draining fistulas.&#160;</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft2910">&#160;<br/>Beginning at&#160;week 22,&#160;patients&#160;who&#160;initially&#160;responded&#160;to&#160;treatment and&#160;subsequently&#160;lost&#160;their&#160;<br/>response&#160;were eligible to&#160;cross&#160;over&#160;to&#160;active re-treatment&#160;every 8&#160;weeks at&#160;a dose&#160;of&#160;infliximab&#160;<br/>5&#160;mg/kg higher&#160;than&#160;the&#160;dose&#160;to which&#160;they were&#160;originally randomised. Among&#160;patients in&#160;the&#160;<br/>infliximab&#160;5&#160;mg/kg group&#160;who crossed&#160;over&#160;because&#160;of&#160;loss&#160;of&#160;fistula&#160;response&#160;after&#160;week&#160;22, 57%&#160;<br/>(12/21)&#160;responded&#160;to re-treatment with&#160;infliximab&#160;10&#160;mg/kg every 8&#160;weeks.&#160;<br/>&#160;<br/>There was no&#160;significant&#160;difference between&#160;placebo&#160;and&#160;infliximab&#160;for&#160;the&#160;proportion of&#160;patients&#160;with&#160;<br/>sustained&#160;closure of&#160;all&#160;fistulas&#160;through&#160;week&#160;54,&#160;for&#160;symptoms such&#160;as&#160;proctalgia,&#160;abscesses and&#160;<br/>urinary&#160;tract&#160;infection or&#160;for&#160;number&#160;of&#160;newly&#160;developed fistulas&#160;during&#160;treatment.&#160;<br/>&#160;<br/>Maintenance&#160;therapy with infliximab every 8&#160;weeks&#160;significantly&#160;reduced&#160;disease-related&#160;<br/>hospitalisations&#160;and&#160;surgeries&#160;compared with&#160;placebo.&#160;Furthermore, a&#160;reduction&#160;in&#160;corticosteroid use&#160;<br/>and improvements&#160;in quality of&#160;life&#160;were&#160;observed.&#160;<br/>&#160;<br/><i>Adult ulcerative&#160;colitis&#160;<br/>&#160;<br/></i>The&#160;safety&#160;and efficacy of&#160;infliximab&#160;were assessed&#160;in&#160;two&#160;(ACT&#160;1 and ACT&#160;2)&#160;randomised,&#160;<br/>double-blind,&#160;placebo-controlled&#160;clinical studies&#160;in&#160;adult patients&#160;with&#160;moderately&#160;to&#160;severely&#160;active&#160;<br/>ulcerative colitis (Mayo&#160;score 6&#160;to&#160;12;&#160;Endoscopy&#160;subscore&#160;</p>
<p style="position:absolute;top:847px;left:501px;white-space:nowrap" class="ft2918">≥2)&#160;with an&#160;inadequate&#160;response&#160;to&#160;</p>
<p style="position:absolute;top:872px;left:106px;white-space:nowrap" class="ft2911">conventional therapies&#160;[oral&#160;corticosteroids,&#160;aminosalicylates&#160;and/or&#160;immunomodulators&#160;(6-MP,&#160;<br/>AZA)].&#160;Concomitant&#160;stable&#160;doses&#160;of&#160;oral&#160;aminosalicylates,&#160;corticosteroids, and/or&#160;immunomodulatory&#160;<br/>agents&#160;were&#160;permitted. In both studies,&#160;patients&#160;were&#160;randomised to&#160;receive either&#160;placebo,&#160;5&#160;mg/kg&#160;<br/>infliximab, or&#160;10&#160;mg/kg&#160;infliximab at&#160;weeks&#160;0, 2,&#160;6, 14&#160;and 22,&#160;and&#160;in ACT&#160;1 at&#160;weeks&#160;30, 38 and 46.&#160;<br/>Corticosteroid taper&#160;was&#160;permitted&#160;after&#160;week 8.&#160;<br/>&#160;</p>
</div>
<!-- Page 30 -->
<a name="30"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page30-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft300">30&#160;</p>
<p style="position:absolute;top:89px;left:420px;white-space:nowrap" class="ft301"><b>Table&#160;8&#160;</b></p>
<p style="position:absolute;top:108px;left:144px;white-space:nowrap" class="ft301"><b>Effects&#160;on&#160;clinical&#160;response, clinical&#160;remission&#160;and&#160;mucosal&#160;healing at&#160;Weeks&#160;8 and&#160;30.&#160;</b></p>
<p style="position:absolute;top:127px;left:332px;white-space:nowrap" class="ft301"><b>Combined&#160;data&#160;from ACT&#160;1&#160;&amp; 2&#160;</b></p>
<p style="position:absolute;top:147px;left:114px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:147px;left:402px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:147px;left:586px;white-space:nowrap" class="ft302">Infliximab&#160;</p>
<p style="position:absolute;top:166px;left:114px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:166px;left:376px;white-space:nowrap" class="ft302">Placebo&#160;</p>
<p style="position:absolute;top:166px;left:481px;white-space:nowrap" class="ft302">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:166px;left:585px;white-space:nowrap" class="ft302">10&#160;mg/kg&#160;</p>
<p style="position:absolute;top:166px;left:695px;white-space:nowrap" class="ft302">Combined&#160;</p>
<p style="position:absolute;top:186px;left:114px;white-space:nowrap" class="ft302">Subjects&#160;randomised&#160;</p>
<p style="position:absolute;top:186px;left:390px;white-space:nowrap" class="ft302">244&#160;</p>
<p style="position:absolute;top:186px;left:496px;white-space:nowrap" class="ft302">242&#160;</p>
<p style="position:absolute;top:186px;left:604px;white-space:nowrap" class="ft302">242&#160;</p>
<p style="position:absolute;top:186px;left:717px;white-space:nowrap" class="ft302">484&#160;</p>
<p style="position:absolute;top:205px;left:114px;white-space:nowrap" class="ft3011"><b>Percentage of&#160;subjects in&#160;clinical&#160;response&#160;and&#160;in&#160;sustained clinical&#160;response</b>&#160;<br/>Clinical&#160;response&#160;at&#160;Week&#160;8a&#160;</p>
<p style="position:absolute;top:224px;left:381px;white-space:nowrap" class="ft302">33.2%&#160;</p>
<p style="position:absolute;top:224px;left:487px;white-space:nowrap" class="ft302">66.9%&#160;</p>
<p style="position:absolute;top:224px;left:595px;white-space:nowrap" class="ft302">65.3%&#160;</p>
<p style="position:absolute;top:224px;left:708px;white-space:nowrap" class="ft302">66.1%&#160;</p>
<p style="position:absolute;top:243px;left:114px;white-space:nowrap" class="ft302">Clinical&#160;response&#160;at&#160;Week&#160;30a&#160;</p>
<p style="position:absolute;top:243px;left:381px;white-space:nowrap" class="ft302">27.9%&#160;</p>
<p style="position:absolute;top:243px;left:487px;white-space:nowrap" class="ft302">49.6%&#160;</p>
<p style="position:absolute;top:243px;left:595px;white-space:nowrap" class="ft302">55.4%&#160;</p>
<p style="position:absolute;top:243px;left:708px;white-space:nowrap" class="ft302">52.5%&#160;</p>
<p style="position:absolute;top:262px;left:114px;white-space:nowrap" class="ft3010">Sustained response&#160;(clinical&#160;<br/>response&#160;at&#160;both&#160;Week&#160;8&#160;and&#160;<br/>Week 30)a&#160;</p>
<p style="position:absolute;top:262px;left:402px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:281px;left:381px;white-space:nowrap" class="ft302">19.3%&#160;</p>
<p style="position:absolute;top:262px;left:509px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:281px;left:487px;white-space:nowrap" class="ft302">45.0%&#160;</p>
<p style="position:absolute;top:262px;left:616px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:281px;left:595px;white-space:nowrap" class="ft302">49.6%&#160;</p>
<p style="position:absolute;top:262px;left:729px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:281px;left:708px;white-space:nowrap" class="ft302">47.3%&#160;</p>
<p style="position:absolute;top:320px;left:114px;white-space:nowrap" class="ft3010"><b>Percentage&#160;of&#160;subjects&#160;in&#160;clinical&#160;remission&#160;and&#160;sustained&#160;remission</b>&#160;<br/>Clinical&#160;remission&#160;at Week&#160;8a&#160;</p>
<p style="position:absolute;top:339px;left:381px;white-space:nowrap" class="ft302">10.2%&#160;</p>
<p style="position:absolute;top:339px;left:487px;white-space:nowrap" class="ft302">36.4%&#160;</p>
<p style="position:absolute;top:339px;left:595px;white-space:nowrap" class="ft302">29.8%&#160;</p>
<p style="position:absolute;top:339px;left:708px;white-space:nowrap" class="ft302">33.1%&#160;</p>
<p style="position:absolute;top:358px;left:114px;white-space:nowrap" class="ft302">Clinical&#160;remission&#160;at Week&#160;30a&#160;</p>
<p style="position:absolute;top:358px;left:381px;white-space:nowrap" class="ft302">13.1%&#160;</p>
<p style="position:absolute;top:358px;left:487px;white-space:nowrap" class="ft302">29.8%&#160;</p>
<p style="position:absolute;top:358px;left:595px;white-space:nowrap" class="ft302">36.4%&#160;</p>
<p style="position:absolute;top:358px;left:708px;white-space:nowrap" class="ft302">33.1%&#160;</p>
<p style="position:absolute;top:377px;left:114px;white-space:nowrap" class="ft3011">Sustained&#160;remission(in remission&#160;<br/>at&#160;both Week&#160;8 and&#160;Week 30)a&#160;</p>
<p style="position:absolute;top:377px;left:402px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:396px;left:385px;white-space:nowrap" class="ft302">5.3%&#160;</p>
<p style="position:absolute;top:377px;left:509px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:396px;left:487px;white-space:nowrap" class="ft302">19.0%&#160;</p>
<p style="position:absolute;top:377px;left:616px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:396px;left:595px;white-space:nowrap" class="ft302">24.4%&#160;</p>
<p style="position:absolute;top:377px;left:729px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:396px;left:708px;white-space:nowrap" class="ft302">21.7%&#160;</p>
<p style="position:absolute;top:416px;left:114px;white-space:nowrap" class="ft3011"><b>Percentage&#160;of&#160;subjects&#160;with&#160;mucosal&#160;healing</b>&#160;<br/>Mucosal&#160;healing&#160;at&#160;Week&#160;8a&#160;</p>
<p style="position:absolute;top:435px;left:381px;white-space:nowrap" class="ft302">32.4%&#160;</p>
<p style="position:absolute;top:435px;left:487px;white-space:nowrap" class="ft302">61.2%&#160;</p>
<p style="position:absolute;top:435px;left:595px;white-space:nowrap" class="ft302">60.3%&#160;</p>
<p style="position:absolute;top:435px;left:708px;white-space:nowrap" class="ft302">60.7%&#160;</p>
<p style="position:absolute;top:454px;left:114px;white-space:nowrap" class="ft302">Mucosal&#160;healing&#160;at&#160;Week&#160;30a&#160;</p>
<p style="position:absolute;top:454px;left:381px;white-space:nowrap" class="ft302">27.5%&#160;</p>
<p style="position:absolute;top:454px;left:487px;white-space:nowrap" class="ft302">48.3%&#160;</p>
<p style="position:absolute;top:454px;left:595px;white-space:nowrap" class="ft302">52.9%&#160;</p>
<p style="position:absolute;top:454px;left:708px;white-space:nowrap" class="ft302">50.6%&#160;</p>
<p style="position:absolute;top:474px;left:114px;white-space:nowrap" class="ft302">a&#160;</p>
<p style="position:absolute;top:474px;left:147px;white-space:nowrap" class="ft302">p &lt;0.001,&#160;for&#160;each infliximab treatment&#160;group vs.&#160;placebo.&#160;</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft3010">&#160;<br/>The&#160;efficacy&#160;of&#160;infliximab&#160;through week 54 was&#160;assessed in&#160;the&#160;ACT&#160;1 study.&#160;<br/>At&#160;54&#160;weeks, 44.9%&#160;of&#160;patients&#160;in&#160;the&#160;combined infliximab&#160;treatment&#160;group were&#160;in clinical&#160;response&#160;<br/>compared to&#160;19.8%&#160;in&#160;the&#160;placebo treatment&#160;group (p&lt;0.001). Clinical&#160;remission and mucosal&#160;healing&#160;<br/>occurred in a&#160;greater&#160;proportion of&#160;patients&#160;in&#160;the&#160;combined infliximab treatment&#160;group&#160;compared&#160;to&#160;<br/>the&#160;placebo&#160;treatment&#160;group at&#160;week 54&#160;(34.6%&#160;vs. 16.5%, p&lt;0.001&#160;and 46.1%&#160;vs.&#160;18.2%,&#160;p&lt;0.001,&#160;<br/>respectively). The&#160;proportions&#160;of&#160;patients&#160;in sustained&#160;response&#160;and sustained remission at&#160;week 54&#160;<br/>were&#160;greater&#160;in the&#160;combined&#160;infliximab treatment&#160;group&#160;than in the&#160;placebo treatment&#160;group (37.9%&#160;<br/>vs. 14.0%,&#160;p&lt;0.001;&#160;and&#160;20.2%&#160;vs. 6.6%, p&lt;0.001,&#160;respectively).&#160;<br/>&#160;<br/>A&#160;greater&#160;proportion of&#160;patients&#160;in&#160;the&#160;combined infliximab&#160;treatment&#160;group were&#160;able&#160;to discontinue&#160;<br/>corticosteroids&#160;while&#160;remaining&#160;in clinical&#160;remission compared&#160;to&#160;the&#160;placebo&#160;treatment&#160;group&#160;at&#160;both&#160;<br/>week&#160;30 (22.3%&#160;vs. 7.2%, p&#160;&lt;0.001, pooled&#160;ACT&#160;1&#160;&amp;&#160;ACT&#160;2 data)&#160;and&#160;week 54 (21.0%&#160;vs. 8.9%,&#160;<br/>p=0.022, ACT&#160;1 data).&#160;<br/>&#160;<br/>The&#160;pooled data&#160;analysis&#160;from&#160;the&#160;ACT&#160;1 and ACT&#160;2&#160;studies and&#160;their&#160;extensions,&#160;analysed&#160;from&#160;<br/>baseline&#160;through 54&#160;weeks, demonstrated a&#160;reduction of&#160;ulcerative&#160;colitis-related hospitalisations&#160;and&#160;<br/>surgical&#160;procedures&#160;with infliximab&#160;treatment. The&#160;number&#160;of&#160;ulcerative&#160;colitis-related&#160;hospitalisations&#160;<br/>was&#160;significantly&#160;lower&#160;in&#160;the&#160;5 and&#160;10&#160;mg/kg infliximab treatment&#160;groups&#160;than&#160;in&#160;the&#160;placebo&#160;group&#160;<br/>(mean number&#160;of&#160;hospitalisations&#160;per&#160;100&#160;subject-years:&#160;21 and&#160;19 vs.&#160;40&#160;in the&#160;placebo group;&#160;<br/>p=0.019&#160;and p=0.007,&#160;respectively). The&#160;number&#160;of&#160;ulcerative&#160;colitis-related&#160;surgical&#160;procedures was&#160;<br/>also&#160;lower&#160;in&#160;the&#160;5 and 10&#160;mg/kg&#160;infliximab&#160;treatment&#160;groups&#160;than in the&#160;placebo&#160;group&#160;(mean number&#160;<br/>of&#160;surgical&#160;procedures&#160;per&#160;100&#160;subject-years:&#160;22 and&#160;19&#160;vs.&#160;34<i>;&#160;</i>p=0.145 and p=0.022, respectively).&#160;<br/>&#160;<br/>The&#160;proportion of&#160;subjects&#160;who underwent&#160;colectomy&#160;at&#160;any time&#160;within&#160;54&#160;weeks&#160;following&#160;the&#160;first&#160;<br/>infusion&#160;of&#160;study agent&#160;were&#160;collected and&#160;pooled from&#160;the&#160;ACT&#160;1 and ACT&#160;2 studies&#160;and their&#160;<br/>extensions. Fewer&#160;subjects&#160;underwent&#160;colectomy&#160;in&#160;the&#160;5&#160;mg/kg infliximab&#160;group (28/242 or&#160;11.6%&#160;<br/>[N.S.])&#160;and the&#160;10&#160;mg/kg infliximab group&#160;(18/242&#160;or&#160;7.4%&#160;[p=0.011])&#160;than in&#160;the&#160;placebo group&#160;<br/>(36/244;&#160;14.8%).&#160;<br/>&#160;<br/>The&#160;reduction&#160;in&#160;incidence&#160;of&#160;colectomy was&#160;also examined in another&#160;randomised, double-blind study&#160;<br/>(C0168Y06)&#160;in&#160;hospitalised&#160;patients&#160;(n=45)&#160;with&#160;moderately&#160;to severely active&#160;ulcerative&#160;colitis&#160;who&#160;<br/>failed to respond to&#160;intravenous&#160;corticosteroids&#160;and&#160;who&#160;were&#160;therefore at&#160;higher&#160;risk&#160;for&#160;colectomy.&#160;<br/>Significantly&#160;fewer&#160;colectomies occurred&#160;within&#160;3&#160;months&#160;of&#160;study&#160;infusion&#160;in patients&#160;who received&#160;a&#160;<br/>single dose of&#160;5&#160;mg/kg infliximab compared to&#160;patients&#160;who received placebo (29.2%&#160;vs.&#160;66.7%&#160;<br/>respectively, p=0.017).&#160;</p>
</div>
<!-- Page 31 -->
<a name="31"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page31-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft310">31&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft3110">&#160;<br/>In&#160;ACT&#160;1 and ACT&#160;2, infliximab improved quality of&#160;life, confirmed&#160;by statistically&#160;significant&#160;<br/>improvement&#160;in both a&#160;disease&#160;specific&#160;measure, IBDQ, and by&#160;improvement&#160;in&#160;the&#160;generic&#160;36-item&#160;<br/>short&#160;form&#160;survey&#160;SF-36.&#160;<br/>&#160;<br/><i>Adult&#160;ankylosing spondylitis&#160;<br/>&#160;<br/></i>Efficacy&#160;and&#160;safety&#160;of&#160;infliximab&#160;were assessed&#160;in&#160;two&#160;multicentre,&#160;double-blind, placebo-controlled&#160;<br/>studies&#160;in patients&#160;with&#160;active&#160;ankylosing&#160;spondylitis&#160;(Bath Ankylosing Spondylitis&#160;Disease&#160;Activity&#160;<br/>Index&#160;[BASDAI]&#160;score&#160;</p>
<p style="position:absolute;top:254px;left:264px;white-space:nowrap" class="ft3118">≥&#160;4&#160;and spinal&#160;pain&#160;≥&#160;4 on&#160;a&#160;scale&#160;of&#160;1-10).&#160;</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft3110">&#160;<br/>In the&#160;first&#160;study (P01522),&#160;which had a&#160;3&#160;month double-blind phase,&#160;70&#160;patients received&#160;either&#160;<br/>5&#160;mg/kg&#160;infliximab or&#160;placebo at&#160;weeks&#160;0, 2, 6&#160;(35&#160;patients&#160;in each&#160;group). At&#160;week 12, placebo&#160;<br/>patients were switched&#160;to&#160;infliximab&#160;5&#160;mg/kg&#160;every 6&#160;weeks&#160;up to week 54.&#160;After&#160;the&#160;first&#160;year&#160;of&#160;the&#160;<br/>study,&#160;53&#160;patients&#160;continued into an open-label&#160;extension to week 102.&#160;<br/>&#160;<br/>In the&#160;second&#160;clinical&#160;study&#160;(ASSERT), 279&#160;patients were&#160;randomised&#160;to&#160;receive&#160;either&#160;placebo&#160;<br/>(Group&#160;1,&#160;n=78)&#160;or&#160;5&#160;mg/kg&#160;infliximab (Group&#160;2, n=201)&#160;at&#160;0, 2&#160;and 6&#160;weeks&#160;and&#160;every&#160;6&#160;weeks to&#160;<br/>week 24. Thereafter, all&#160;subjects&#160;continued on&#160;infliximab every 6&#160;weeks&#160;to week 96. Group&#160;1 received&#160;<br/>5&#160;mg/kg&#160;infliximab. In Group&#160;2, starting with the week&#160;36 infusion, patients&#160;who had a&#160;BASDAI&#160;</p>
<p style="position:absolute;top:444px;left:749px;white-space:nowrap" class="ft3118">≥3&#160;at&#160;</p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft3111">2&#160;consecutive visits,&#160;received&#160;7.5&#160;mg/kg infliximab every 6&#160;weeks&#160;thereafter&#160;through&#160;week&#160;96.&#160;<br/>&#160;<br/>In ASSERT, improvement&#160;in signs&#160;and symptoms&#160;was&#160;observed&#160;as&#160;early as&#160;week&#160;2. At&#160;week&#160;24, the&#160;<br/>number&#160;of&#160;ASAS&#160;20 responders&#160;was&#160;15/78&#160;(19%)&#160;in the&#160;placebo&#160;group, and&#160;123/201 (61%)&#160;in&#160;the&#160;<br/>5&#160;mg/kg&#160;infliximab group&#160;(p&lt;0.001). There&#160;were&#160;95&#160;subjects&#160;from&#160;group&#160;2 who continued on&#160;5&#160;mg/kg&#160;<br/>every&#160;6&#160;weeks.&#160;At&#160;102&#160;weeks there were&#160;80&#160;subjects&#160;still&#160;on&#160;infliximab&#160;treatment&#160;and among&#160;those, 71&#160;<br/>(89%)&#160;were&#160;ASAS&#160;20 responders.&#160;<br/>&#160;<br/>In P01522, improvement&#160;in&#160;signs&#160;and&#160;symptoms&#160;was&#160;also observed as&#160;early&#160;as&#160;week 2. At&#160;week 12,&#160;<br/>the&#160;number&#160;of&#160;BASDAI&#160;50 responders&#160;were&#160;3/35 (9%)&#160;in the&#160;placebo group, and 20/35&#160;(57%)&#160;in the&#160;<br/>5&#160;mg/kg group&#160;(p&lt;0.01). There&#160;were&#160;53&#160;subjects&#160;who&#160;continued&#160;on 5&#160;mg/kg every 6&#160;weeks.&#160;At&#160;<br/>102&#160;weeks&#160;there were&#160;49&#160;subjects&#160;still&#160;on&#160;infliximab&#160;treatment&#160;and&#160;among those,&#160;30 (61%)&#160;were&#160;<br/>BASDAI&#160;50 responders.&#160;<br/>&#160;<br/>In both studies, physical&#160;function and quality of&#160;life&#160;as&#160;measured by&#160;the&#160;BASFI&#160;and the&#160;physical&#160;<br/>component&#160;score&#160;of&#160;the&#160;SF-36&#160;were&#160;also&#160;improved&#160;significantly.&#160;<br/>&#160;<br/><i>Adult psoriatic&#160;arthritis&#160;<br/>&#160;<br/></i>Efficacy&#160;and&#160;safety&#160;were&#160;assessed&#160;in&#160;two&#160;multicentre,&#160;double-blind,&#160;placebo-controlled&#160;studies&#160;in&#160;<br/>patients with&#160;active psoriatic arthritis.&#160;<br/>&#160;<br/>In the&#160;first&#160;clinical&#160;study (IMPACT), efficacy and&#160;safety of&#160;infliximab were&#160;studied in 104&#160;patients&#160;<br/>with active&#160;polyarticular&#160;psoriatic&#160;arthritis. During&#160;the&#160;16-week double-blind phase, patients&#160;received&#160;<br/>either&#160;5&#160;mg/kg&#160;infliximab or&#160;placebo&#160;at&#160;weeks&#160;0, 2, 6,&#160;and 14 (52&#160;patients&#160;in&#160;each group). Starting&#160;at&#160;<br/>week 16, placebo patients&#160;were&#160;switched&#160;to infliximab and all&#160;patients&#160;subsequently&#160;received 5&#160;mg/kg&#160;<br/>infliximab every 8&#160;weeks&#160;up to week 46. After&#160;the&#160;first&#160;year&#160;of&#160;the&#160;study, 78&#160;patients continued into&#160;an&#160;<br/>open-label&#160;extension to week 98.&#160;<br/>&#160;<br/>In the&#160;second&#160;clinical&#160;study&#160;(IMPACT&#160;2), efficacy and&#160;safety of&#160;infliximab were&#160;studied&#160;in&#160;<br/>200&#160;patients&#160;with&#160;active&#160;psoriatic&#160;arthritis&#160;(</p>
<p style="position:absolute;top:1032px;left:390px;white-space:nowrap" class="ft3118">≥5 swollen&#160;joints&#160;and&#160;≥5 tender&#160;joints).&#160;Forty&#160;six&#160;percent&#160;of&#160;</p>
<p style="position:absolute;top:1057px;left:106px;white-space:nowrap" class="ft312">patients&#160;continued&#160;on stable&#160;doses&#160;of&#160;methotrexate&#160;(</p>
<p style="position:absolute;top:1051px;left:449px;white-space:nowrap" class="ft3118">≤25&#160;mg/week). During&#160;the&#160;24-week double-blind&#160;</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft3110">phase,&#160;patients received&#160;either&#160;5&#160;mg/kg&#160;infliximab&#160;or&#160;placebo&#160;at weeks&#160;0,&#160;2, 6,&#160;14, and&#160;22 (100&#160;patients&#160;<br/>in each group). At&#160;week 16,&#160;47&#160;placebo&#160;patients&#160;with&#160;&lt;10%&#160;improvement&#160;from&#160;baseline&#160;in&#160;both&#160;<br/>swollen and tender&#160;joint&#160;counts&#160;were&#160;switched&#160;to&#160;infliximab induction&#160;(early escape). At&#160;week&#160;24,&#160;all&#160;<br/>placebo-treated patients&#160;crossed over&#160;to&#160;infliximab&#160;induction. Dosing&#160;continued for&#160;all&#160;patients&#160;<br/>through week&#160;46.&#160;</p>
</div>
<!-- Page 32 -->
<a name="32"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page32-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft320">32&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft3210">&#160;<br/>Key&#160;efficacy&#160;results&#160;for&#160;IMPACT&#160;and IMPACT&#160;2 are&#160;shown in Table&#160;9&#160;below:&#160;<br/>&#160;</p>
<p style="position:absolute;top:146px;left:420px;white-space:nowrap" class="ft321"><b>Table&#160;9&#160;</b></p>
<p style="position:absolute;top:165px;left:254px;white-space:nowrap" class="ft321"><b>Effects&#160;on&#160;ACR&#160;and PASI&#160;in IMPACT&#160;and IMPACT&#160;2&#160;</b></p>
<p style="position:absolute;top:185px;left:114px;white-space:nowrap" class="ft3225"><b>&#160;</b></p>
<p style="position:absolute;top:185px;left:329px;white-space:nowrap" class="ft322">IMPACT&#160;</p>
<p style="position:absolute;top:185px;left:602px;white-space:nowrap" class="ft322">IMPACT 2*&#160;</p>
<p style="position:absolute;top:205px;left:114px;white-space:nowrap" class="ft3225"><b>&#160;</b></p>
<p style="position:absolute;top:205px;left:240px;white-space:nowrap" class="ft322">Placebo&#160;</p>
<p style="position:absolute;top:224px;left:231px;white-space:nowrap" class="ft322">(Week 16)&#160;</p>
<p style="position:absolute;top:205px;left:325px;white-space:nowrap" class="ft3211">Infliximab&#160;<br/>(Week 16)&#160;</p>
<p style="position:absolute;top:205px;left:421px;white-space:nowrap" class="ft3211">Infliximab&#160;<br/>(Week 98)&#160;</p>
<p style="position:absolute;top:205px;left:524px;white-space:nowrap" class="ft322">Placebo&#160;</p>
<p style="position:absolute;top:224px;left:515px;white-space:nowrap" class="ft322">(Week 24)&#160;</p>
<p style="position:absolute;top:205px;left:609px;white-space:nowrap" class="ft3211">Infliximab&#160;<br/>(Week 24)&#160;</p>
<p style="position:absolute;top:205px;left:704px;white-space:nowrap" class="ft3211">Infliximab&#160;<br/>(Week 54)&#160;</p>
<p style="position:absolute;top:244px;left:114px;white-space:nowrap" class="ft3211">Patients&#160;<br/>randomised&#160;</p>
<p style="position:absolute;top:244px;left:258px;white-space:nowrap" class="ft322">52&#160;</p>
<p style="position:absolute;top:244px;left:352px;white-space:nowrap" class="ft322">52&#160;</p>
<p style="position:absolute;top:244px;left:439px;white-space:nowrap" class="ft322">N/Aa&#160;</p>
<p style="position:absolute;top:244px;left:537px;white-space:nowrap" class="ft322">100&#160;</p>
<p style="position:absolute;top:244px;left:631px;white-space:nowrap" class="ft322">100&#160;</p>
<p style="position:absolute;top:244px;left:726px;white-space:nowrap" class="ft322">100&#160;</p>
<p style="position:absolute;top:282px;left:114px;white-space:nowrap" class="ft3210">ACR&#160;response&#160;&#160;<br/>(% of&#160;<br/>patients)&#160;<br/>N&#160;</p>
<p style="position:absolute;top:282px;left:266px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:320px;left:258px;white-space:nowrap" class="ft322">52&#160;</p>
<p style="position:absolute;top:282px;left:360px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:320px;left:352px;white-space:nowrap" class="ft322">52&#160;</p>
<p style="position:absolute;top:282px;left:456px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:320px;left:447px;white-space:nowrap" class="ft322">78&#160;</p>
<p style="position:absolute;top:282px;left:550px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:320px;left:537px;white-space:nowrap" class="ft322">100&#160;</p>
<p style="position:absolute;top:282px;left:644px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:320px;left:631px;white-space:nowrap" class="ft322">100&#160;</p>
<p style="position:absolute;top:282px;left:739px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:320px;left:726px;white-space:nowrap" class="ft322">100&#160;</p>
<p style="position:absolute;top:358px;left:114px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:358px;left:135px;white-space:nowrap" class="ft322">ACR 20&#160;</p>
<p style="position:absolute;top:377px;left:114px;white-space:nowrap" class="ft322">response*&#160;</p>
<p style="position:absolute;top:358px;left:239px;white-space:nowrap" class="ft322">5&#160;(10%)&#160;</p>
<p style="position:absolute;top:358px;left:329px;white-space:nowrap" class="ft322">34 (65%)&#160;</p>
<p style="position:absolute;top:358px;left:425px;white-space:nowrap" class="ft322">48 (62%)&#160;</p>
<p style="position:absolute;top:358px;left:519px;white-space:nowrap" class="ft322">16 (16%)&#160;</p>
<p style="position:absolute;top:358px;left:613px;white-space:nowrap" class="ft322">54 (54%)&#160;</p>
<p style="position:absolute;top:358px;left:708px;white-space:nowrap" class="ft322">53 (53%)&#160;</p>
<p style="position:absolute;top:396px;left:114px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:396px;left:135px;white-space:nowrap" class="ft322">ACR 50&#160;</p>
<p style="position:absolute;top:415px;left:114px;white-space:nowrap" class="ft322">response*&#160;</p>
<p style="position:absolute;top:396px;left:244px;white-space:nowrap" class="ft322">0&#160;(0%)&#160;</p>
<p style="position:absolute;top:396px;left:329px;white-space:nowrap" class="ft322">24 (46%)&#160;</p>
<p style="position:absolute;top:396px;left:425px;white-space:nowrap" class="ft322">35 (45%)&#160;</p>
<p style="position:absolute;top:396px;left:527px;white-space:nowrap" class="ft322">4&#160;(4%)&#160;</p>
<p style="position:absolute;top:396px;left:613px;white-space:nowrap" class="ft322">41&#160;(41%)&#160;</p>
<p style="position:absolute;top:396px;left:708px;white-space:nowrap" class="ft322">33 (33%)&#160;</p>
<p style="position:absolute;top:434px;left:114px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:434px;left:135px;white-space:nowrap" class="ft322">ACR 70&#160;</p>
<p style="position:absolute;top:453px;left:114px;white-space:nowrap" class="ft322">response*&#160;</p>
<p style="position:absolute;top:434px;left:244px;white-space:nowrap" class="ft322">0&#160;(0%)&#160;</p>
<p style="position:absolute;top:434px;left:329px;white-space:nowrap" class="ft322">15 (29%)&#160;</p>
<p style="position:absolute;top:434px;left:425px;white-space:nowrap" class="ft322">27 (35%)&#160;</p>
<p style="position:absolute;top:434px;left:527px;white-space:nowrap" class="ft322">2&#160;(2%)&#160;</p>
<p style="position:absolute;top:434px;left:613px;white-space:nowrap" class="ft322">27 (27%)&#160;</p>
<p style="position:absolute;top:434px;left:708px;white-space:nowrap" class="ft322">20 (20%)&#160;</p>
<p style="position:absolute;top:472px;left:114px;white-space:nowrap" class="ft3211">PASI&#160;<br/>response&#160;<br/>(% of&#160;<br/>patients)b&#160;<br/>N&#160;</p>
<p style="position:absolute;top:472px;left:266px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:472px;left:360px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:472px;left:456px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:472px;left:550px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:510px;left:541px;white-space:nowrap" class="ft322">87&#160;</p>
<p style="position:absolute;top:472px;left:644px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:510px;left:635px;white-space:nowrap" class="ft322">83&#160;</p>
<p style="position:absolute;top:472px;left:739px;white-space:nowrap" class="ft3211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:510px;left:731px;white-space:nowrap" class="ft322">82&#160;</p>
<p style="position:absolute;top:567px;left:114px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:567px;left:135px;white-space:nowrap" class="ft322">PASI&#160;75&#160;</p>
<p style="position:absolute;top:586px;left:114px;white-space:nowrap" class="ft322">response**&#160;</p>
<p style="position:absolute;top:567px;left:266px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:567px;left:360px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:567px;left:456px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:567px;left:527px;white-space:nowrap" class="ft322">1&#160;(1%)&#160;</p>
<p style="position:absolute;top:567px;left:613px;white-space:nowrap" class="ft322">50 (60%)&#160;</p>
<p style="position:absolute;top:567px;left:702px;white-space:nowrap" class="ft322">40 (48.8%)&#160;</p>
<p style="position:absolute;top:606px;left:114px;white-space:nowrap" class="ft322">*&#160;</p>
<p style="position:absolute;top:606px;left:147px;white-space:nowrap" class="ft322">ITT-analysis where subjects with&#160;missing&#160;data were&#160;included&#160;as&#160;non-responders.&#160;</p>
<p style="position:absolute;top:625px;left:114px;white-space:nowrap" class="ft322">a&#160;</p>
<p style="position:absolute;top:625px;left:147px;white-space:nowrap" class="ft3210">Week&#160;98 data&#160;for&#160;IMPACT&#160;includes&#160;combined placebo&#160;crossover&#160;and infliximab patients&#160;who&#160;<br/>entered the&#160;open-label&#160;extension.&#160;</p>
<p style="position:absolute;top:662px;left:114px;white-space:nowrap" class="ft322">b&#160;</p>
<p style="position:absolute;top:662px;left:147px;white-space:nowrap" class="ft3211">Based on&#160;patients&#160;with&#160;PASI&#160;&gt;2.5 at&#160;baseline&#160;for&#160;IMPACT, and patients&#160;with&#160;&gt;3%&#160;BSA&#160;<br/>psoriasis&#160;skin involvement&#160;at&#160;baseline in&#160;IMPACT&#160;2.&#160;</p>
<p style="position:absolute;top:700px;left:114px;white-space:nowrap" class="ft322">**&#160;&#160;PASI&#160;75 response&#160;for&#160;IMPACT&#160;not&#160;included due&#160;to&#160;low&#160;N;&#160;p&lt;0.001&#160;for&#160;infliximab&#160;vs.&#160;placebo&#160;</p>
<p style="position:absolute;top:719px;left:147px;white-space:nowrap" class="ft322">at&#160;week 24 for&#160;IMPACT&#160;2.&#160;</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft3211">&#160;<br/>In&#160;IMPACT&#160;and&#160;IMPACT&#160;2,&#160;clinical&#160;responses were observed&#160;as early&#160;as week&#160;2&#160;and&#160;were&#160;maintained&#160;<br/>through week&#160;98 and week&#160;54,&#160;respectively. Efficacy&#160;has&#160;been demonstrated with&#160;or&#160;without&#160;<br/>concomitant&#160;use of&#160;methotrexate.&#160;Decreases&#160;in&#160;parameters of&#160;peripheral&#160;activity&#160;characteristic of&#160;<br/>psoriatic&#160;arthritis&#160;(such as&#160;number&#160;of&#160;swollen&#160;joints, number&#160;of&#160;painful/tender&#160;joints,&#160;dactylitis&#160;and&#160;<br/>presence of&#160;enthesopathy)&#160;were&#160;seen&#160;in&#160;the infliximab-treated&#160;patients.&#160;<br/>&#160;<br/>Radiographic&#160;changes were&#160;assessed&#160;in&#160;IMPACT&#160;2. Radiographs&#160;of&#160;hands&#160;and&#160;feet&#160;were&#160;collected&#160;at&#160;<br/>baseline,&#160;weeks&#160;24 and&#160;54. Infliximab treatment&#160;reduced the&#160;rate&#160;of&#160;progression of&#160;peripheral&#160;joint&#160;<br/>damage&#160;compared with placebo&#160;treatment&#160;at&#160;the&#160;week&#160;24 primary&#160;endpoint&#160;as&#160;measured&#160;by change&#160;<br/>from baseline&#160;in&#160;total&#160;modified&#160;vdH-S&#160;score&#160;(mean&#160;±&#160;SD&#160;score&#160;was&#160;0.82 ±&#160;2.62&#160;in&#160;the&#160;placebo group&#160;<br/>compared with&#160;-0.70&#160;±&#160;2.53&#160;in the&#160;infliximab group;&#160;p&lt;0.001). In&#160;the&#160;infliximab&#160;group, the&#160;mean&#160;<br/>change&#160;in&#160;total modified&#160;vdH-S&#160;score&#160;remained below&#160;0 at&#160;the&#160;week 54&#160;timepoint.&#160;<br/>&#160;<br/>Infliximab-treated&#160;patients&#160;demonstrated&#160;significant improvement in&#160;physical function&#160;as assessed&#160;by&#160;<br/>HAQ.&#160;Significant improvements&#160;in&#160;health-related&#160;quality&#160;of&#160;life were also&#160;demonstrated&#160;as&#160;measured&#160;<br/>by the&#160;physical&#160;and mental&#160;component&#160;summary scores&#160;of&#160;the&#160;SF-36 in&#160;IMPACT&#160;2.&#160;<br/>&#160;<br/><i>Adult&#160;psoriasis&#160;<br/>&#160;<br/></i>The&#160;efficacy&#160;of&#160;infliximab&#160;was&#160;assessed in&#160;two multicentre,&#160;randomised, double-blind studies:&#160;SPIRIT&#160;<br/>and EXPRESS. Patients&#160;in&#160;both studies&#160;had plaque&#160;psoriasis&#160;(Body Surface&#160;Area&#160;[BSA]&#160;</p>
<p style="position:absolute;top:1131px;left:691px;white-space:nowrap" class="ft3218">≥10%&#160;and&#160;</p>
</div>
<!-- Page 33 -->
<a name="33"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page33-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft330">33&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft332">Psoriasis Area and&#160;Severity&#160;Index&#160;[PASI]&#160;score&#160;</p>
<p style="position:absolute;top:83px;left:424px;white-space:nowrap" class="ft3318">≥12).&#160;The&#160;primary&#160;endpoint&#160;in&#160;both studies&#160;was&#160;the&#160;</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft332">percent&#160;of&#160;patients&#160;who&#160;achieved&#160;</p>
<p style="position:absolute;top:102px;left:328px;white-space:nowrap" class="ft3318">≥75%&#160;improvement&#160;in PASI&#160;from&#160;baseline&#160;at&#160;week 10.&#160;</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft3311">&#160;<br/>SPIRIT&#160;evaluated the&#160;efficacy of&#160;infliximab&#160;induction&#160;therapy in&#160;249&#160;patients with&#160;plaque psoriasis&#160;<br/>that&#160;had&#160;previously&#160;received&#160;PUVA&#160;or&#160;systemic therapy.&#160;Patients&#160;received&#160;either&#160;3 or&#160;5&#160;mg/kg&#160;<br/>infliximab or&#160;placebo infusions&#160;at&#160;weeks&#160;0, 2&#160;and 6. Patients&#160;with a&#160;PGA&#160;score&#160;</p>
<p style="position:absolute;top:178px;left:629px;white-space:nowrap" class="ft3318">≥3&#160;were&#160;eligible&#160;to&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft3311">receive&#160;an additional&#160;infusion of&#160;the&#160;same&#160;treatment&#160;at&#160;week 26.&#160;<br/>In SPIRIT, the&#160;proportion of&#160;patients&#160;achieving PASI&#160;75 at&#160;week 10 was&#160;71.7%&#160;in&#160;the&#160;3&#160;mg/kg&#160;<br/>infliximab group,&#160;87.9%&#160;in&#160;the&#160;5&#160;mg/kg&#160;infliximab group, and 5.9%&#160;in&#160;the&#160;placebo&#160;group&#160;(p&lt;0.001).&#160;<br/>By week 26,&#160;twenty weeks&#160;after&#160;the&#160;last&#160;induction dose, 30%&#160;of&#160;patients&#160;in the&#160;5&#160;mg/kg&#160;group and&#160;<br/>13.8%&#160;of&#160;patients&#160;in the&#160;3&#160;mg/kg group were&#160;PASI&#160;75&#160;responders. Between weeks&#160;6 and&#160;26, symptoms&#160;<br/>of&#160;psoriasis gradually&#160;returned&#160;with&#160;a&#160;median&#160;time to&#160;disease&#160;relapse of&#160;&gt;20&#160;weeks.&#160;No&#160;rebound&#160;was&#160;<br/>observed.&#160;<br/>&#160;<br/>EXPRESS&#160;evaluated the&#160;efficacy of&#160;infliximab&#160;induction and&#160;maintenance&#160;therapy in 378&#160;patients&#160;<br/>with&#160;plaque psoriasis.&#160;Patients&#160;received&#160;5&#160;mg/kg&#160;infliximab-&#160;or&#160;placebo-infusions&#160;at&#160;weeks&#160;0, 2&#160;and 6&#160;<br/>followed&#160;by&#160;maintenance&#160;therapy&#160;every&#160;8&#160;weeks&#160;through week 22&#160;in&#160;the&#160;placebo group and&#160;through&#160;<br/>week 46&#160;in the&#160;infliximab group. At&#160;week 24, the&#160;placebo group crossed over&#160;to infliximab&#160;induction&#160;<br/>therapy (5&#160;mg/kg)&#160;followed&#160;by infliximab maintenance&#160;therapy&#160;(5&#160;mg/kg).&#160;Nail&#160;psoriasis was&#160;assessed&#160;<br/>using&#160;the&#160;Nail&#160;Psoriasis&#160;Severity Index (NAPSI). Prior&#160;therapy with PUVA, methotrexate, ciclosporin,&#160;<br/>or&#160;acitretin&#160;had been&#160;received by 71.4%&#160;of&#160;patients, although they were&#160;not&#160;necessarily&#160;therapy&#160;<br/>resistant.&#160;Key&#160;results are presented&#160;in&#160;Table&#160;10.&#160;In&#160;infliximab&#160;treated&#160;subjects,&#160;significant&#160;PASI&#160;50&#160;<br/>responses were apparent&#160;at&#160;the&#160;first&#160;visit&#160;(week&#160;2)&#160;and&#160;PASI&#160;75 responses&#160;by the&#160;second visit&#160;(week&#160;6).&#160;<br/>Efficacy was&#160;similar&#160;in&#160;the&#160;subgroup of&#160;patients&#160;that&#160;were&#160;exposed to previous&#160;systemic&#160;therapies&#160;<br/>compared to&#160;the&#160;overall&#160;study population.&#160;<br/>&#160;</p>
<p style="position:absolute;top:583px;left:416px;white-space:nowrap" class="ft331"><b>Table&#160;10&#160;</b></p>
<p style="position:absolute;top:602px;left:128px;white-space:nowrap" class="ft331"><b>Summary&#160;of&#160;PASI response,&#160;PGA&#160;response and&#160;percent&#160;of&#160;patients&#160;with&#160;all&#160;nails cleared&#160;at&#160;</b></p>
<p style="position:absolute;top:621px;left:334px;white-space:nowrap" class="ft331"><b>Weeks&#160;10, 24 and&#160;50. EXPRESS&#160;</b></p>
<p style="position:absolute;top:640px;left:114px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:635px;left:414px;white-space:nowrap" class="ft3318">Placebo → Infliximab&#160;</p>
<p style="position:absolute;top:660px;left:460px;white-space:nowrap" class="ft332">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:678px;left:446px;white-space:nowrap" class="ft332">(at&#160;week&#160;24)&#160;</p>
<p style="position:absolute;top:640px;left:652px;white-space:nowrap" class="ft332">Infliximab&#160;</p>
<p style="position:absolute;top:660px;left:660px;white-space:nowrap" class="ft332">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:698px;left:114px;white-space:nowrap" class="ft331"><b>Week&#160;10&#160;</b></p>
<p style="position:absolute;top:698px;left:487px;white-space:nowrap" class="ft331"><b>&#160;</b></p>
<p style="position:absolute;top:698px;left:687px;white-space:nowrap" class="ft331"><b>&#160;</b></p>
<p style="position:absolute;top:717px;left:114px;white-space:nowrap" class="ft332">N&#160;</p>
<p style="position:absolute;top:717px;left:479px;white-space:nowrap" class="ft332">77&#160;</p>
<p style="position:absolute;top:717px;left:674px;white-space:nowrap" class="ft332">301&#160;</p>
<p style="position:absolute;top:730px;left:114px;white-space:nowrap" class="ft3318">≥90%&#160;improvement&#160;</p>
<p style="position:absolute;top:736px;left:458px;white-space:nowrap" class="ft332">1 (1.3%)&#160;</p>
<p style="position:absolute;top:736px;left:642px;white-space:nowrap" class="ft332">172 (57.1%)&#160;a&#160;</p>
<p style="position:absolute;top:749px;left:114px;white-space:nowrap" class="ft3318">≥75%&#160;improvement&#160;&#160;</p>
<p style="position:absolute;top:755px;left:458px;white-space:nowrap" class="ft332">2 (2.6%)&#160;</p>
<p style="position:absolute;top:755px;left:642px;white-space:nowrap" class="ft332">242 (80.4%)&#160;a&#160;</p>
<p style="position:absolute;top:768px;left:114px;white-space:nowrap" class="ft3318">≥50%&#160;improvement&#160;</p>
<p style="position:absolute;top:774px;left:458px;white-space:nowrap" class="ft332">6 (7.8%)&#160;</p>
<p style="position:absolute;top:774px;left:646px;white-space:nowrap" class="ft332">274&#160;(91.0%)&#160;</p>
<p style="position:absolute;top:793px;left:114px;white-space:nowrap" class="ft332">PGA&#160;of&#160;cleared&#160;(0)&#160;or&#160;minimal&#160;(1)&#160;</p>
<p style="position:absolute;top:793px;left:458px;white-space:nowrap" class="ft332">3 (3.9%)&#160;</p>
<p style="position:absolute;top:793px;left:639px;white-space:nowrap" class="ft332">242 (82.9%)&#160;ab&#160;</p>
<p style="position:absolute;top:812px;left:114px;white-space:nowrap" class="ft3311">PGA&#160;of&#160;cleared (0),&#160;minimal&#160;(1), or&#160;<br/>mild (2)&#160;</p>
<p style="position:absolute;top:812px;left:450px;white-space:nowrap" class="ft332">14 (18.2%)&#160;</p>
<p style="position:absolute;top:812px;left:639px;white-space:nowrap" class="ft332">275 (94.2%)&#160;ab&#160;</p>
<p style="position:absolute;top:850px;left:114px;white-space:nowrap" class="ft331"><b>Week&#160;24&#160;</b></p>
<p style="position:absolute;top:850px;left:487px;white-space:nowrap" class="ft331"><b>&#160;</b></p>
<p style="position:absolute;top:850px;left:687px;white-space:nowrap" class="ft331"><b>&#160;</b></p>
<p style="position:absolute;top:869px;left:114px;white-space:nowrap" class="ft332">N&#160;</p>
<p style="position:absolute;top:869px;left:479px;white-space:nowrap" class="ft332">77&#160;</p>
<p style="position:absolute;top:869px;left:674px;white-space:nowrap" class="ft332">276&#160;</p>
<p style="position:absolute;top:882px;left:114px;white-space:nowrap" class="ft3318">≥90%&#160;improvement&#160;</p>
<p style="position:absolute;top:888px;left:458px;white-space:nowrap" class="ft332">1 (1.3%)&#160;</p>
<p style="position:absolute;top:888px;left:642px;white-space:nowrap" class="ft332">161 (58.3%)&#160;a&#160;</p>
<p style="position:absolute;top:901px;left:114px;white-space:nowrap" class="ft3318">≥75%&#160;improvement&#160;&#160;</p>
<p style="position:absolute;top:907px;left:458px;white-space:nowrap" class="ft332">3 (3.9%)&#160;</p>
<p style="position:absolute;top:907px;left:642px;white-space:nowrap" class="ft332">227 (82.2%)&#160;a&#160;</p>
<p style="position:absolute;top:920px;left:114px;white-space:nowrap" class="ft3318">≥50%&#160;improvement&#160;</p>
<p style="position:absolute;top:926px;left:458px;white-space:nowrap" class="ft332">5 (6.5%)&#160;</p>
<p style="position:absolute;top:926px;left:646px;white-space:nowrap" class="ft332">248 (89.9%)&#160;</p>
<p style="position:absolute;top:945px;left:114px;white-space:nowrap" class="ft332">PGA&#160;of&#160;cleared&#160;(0)&#160;or&#160;minimal&#160;(1)&#160;</p>
<p style="position:absolute;top:945px;left:458px;white-space:nowrap" class="ft332">2 (2.6%)&#160;</p>
<p style="position:absolute;top:945px;left:642px;white-space:nowrap" class="ft332">203 (73.6%)&#160;a&#160;</p>
<p style="position:absolute;top:964px;left:114px;white-space:nowrap" class="ft3310">PGA&#160;of&#160;cleared (0),&#160;minimal&#160;(1), or&#160;<br/>mild (2)&#160;</p>
<p style="position:absolute;top:964px;left:450px;white-space:nowrap" class="ft332">15 (19.5%)&#160;</p>
<p style="position:absolute;top:964px;left:642px;white-space:nowrap" class="ft332">246 (89.1%)&#160;a&#160;</p>
<p style="position:absolute;top:1002px;left:114px;white-space:nowrap" class="ft331"><b>Week&#160;50&#160;</b></p>
<p style="position:absolute;top:1002px;left:487px;white-space:nowrap" class="ft331"><b>&#160;</b></p>
<p style="position:absolute;top:1002px;left:687px;white-space:nowrap" class="ft331"><b>&#160;</b></p>
<p style="position:absolute;top:1021px;left:114px;white-space:nowrap" class="ft332">N&#160;</p>
<p style="position:absolute;top:1021px;left:479px;white-space:nowrap" class="ft332">68&#160;</p>
<p style="position:absolute;top:1021px;left:674px;white-space:nowrap" class="ft332">281&#160;</p>
<p style="position:absolute;top:1034px;left:114px;white-space:nowrap" class="ft3318">≥90%&#160;improvement&#160;</p>
<p style="position:absolute;top:1040px;left:450px;white-space:nowrap" class="ft332">34 (50.0%)&#160;</p>
<p style="position:absolute;top:1040px;left:646px;white-space:nowrap" class="ft332">127 (45.2%)&#160;</p>
<p style="position:absolute;top:1053px;left:114px;white-space:nowrap" class="ft3318">≥75%&#160;improvement&#160;&#160;</p>
<p style="position:absolute;top:1059px;left:450px;white-space:nowrap" class="ft332">52 (76.5%)&#160;</p>
<p style="position:absolute;top:1059px;left:646px;white-space:nowrap" class="ft332">170 (60.5%)&#160;</p>
<p style="position:absolute;top:1072px;left:114px;white-space:nowrap" class="ft3318">≥50%&#160;improvement&#160;</p>
<p style="position:absolute;top:1078px;left:450px;white-space:nowrap" class="ft332">61 (89.7%)&#160;</p>
<p style="position:absolute;top:1078px;left:646px;white-space:nowrap" class="ft332">193 (68.7%)&#160;</p>
<p style="position:absolute;top:1097px;left:114px;white-space:nowrap" class="ft332">PGA&#160;of&#160;cleared&#160;(0)&#160;or&#160;minimal&#160;(1)&#160;</p>
<p style="position:absolute;top:1097px;left:450px;white-space:nowrap" class="ft332">46 (67.6%)&#160;</p>
<p style="position:absolute;top:1097px;left:646px;white-space:nowrap" class="ft332">149 (53.0%)&#160;</p>
<p style="position:absolute;top:1116px;left:114px;white-space:nowrap" class="ft3310">PGA&#160;of&#160;cleared (0),&#160;minimal&#160;(1), or&#160;<br/>mild (2)&#160;</p>
<p style="position:absolute;top:1116px;left:450px;white-space:nowrap" class="ft332">59 (86.8%)&#160;</p>
<p style="position:absolute;top:1116px;left:646px;white-space:nowrap" class="ft332">189 (67.3%)&#160;</p>
</div>
<!-- Page 34 -->
<a name="34"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3427{font-size:10px;font-family:TimesNewRomanPS;color:#000000;}
	.ft3428{font-size:18px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page34-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft340">34&#160;</p>
<p style="position:absolute;top:90px;left:114px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:84px;left:414px;white-space:nowrap" class="ft3418">Placebo → Infliximab&#160;</p>
<p style="position:absolute;top:109px;left:460px;white-space:nowrap" class="ft342">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:128px;left:446px;white-space:nowrap" class="ft342">(at&#160;week&#160;24)&#160;</p>
<p style="position:absolute;top:90px;left:652px;white-space:nowrap" class="ft342">Infliximab&#160;</p>
<p style="position:absolute;top:109px;left:660px;white-space:nowrap" class="ft342">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:147px;left:114px;white-space:nowrap" class="ft341"><b>All&#160;nails clearedc&#160;</b>&#160;</p>
<p style="position:absolute;top:147px;left:487px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:147px;left:687px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:166px;left:114px;white-space:nowrap" class="ft342">Week&#160;10&#160;</p>
<p style="position:absolute;top:166px;left:450px;white-space:nowrap" class="ft342">1/65(1.5%)&#160;</p>
<p style="position:absolute;top:166px;left:639px;white-space:nowrap" class="ft342">16/235 (6.8%)&#160;</p>
<p style="position:absolute;top:185px;left:114px;white-space:nowrap" class="ft342">Week&#160;24&#160;</p>
<p style="position:absolute;top:185px;left:448px;white-space:nowrap" class="ft342">3/65 (4.6%)&#160;</p>
<p style="position:absolute;top:185px;left:631px;white-space:nowrap" class="ft342">58/223 (26.0%)&#160;a&#160;</p>
<p style="position:absolute;top:204px;left:114px;white-space:nowrap" class="ft342">Week&#160;50&#160;</p>
<p style="position:absolute;top:204px;left:440px;white-space:nowrap" class="ft342">27/64 (42.2%)&#160;</p>
<p style="position:absolute;top:204px;left:635px;white-space:nowrap" class="ft342">92/226 (40.7%)&#160;</p>
<p style="position:absolute;top:223px;left:114px;white-space:nowrap" class="ft342">a&#160;</p>
<p style="position:absolute;top:223px;left:147px;white-space:nowrap" class="ft342">p &lt;0.001,&#160;for&#160;each infliximab treatment&#160;group&#160;vs.&#160;control.&#160;</p>
<p style="position:absolute;top:242px;left:114px;white-space:nowrap" class="ft342">b&#160;</p>
<p style="position:absolute;top:242px;left:147px;white-space:nowrap" class="ft342">n =&#160;292.&#160;</p>
<p style="position:absolute;top:261px;left:114px;white-space:nowrap" class="ft342">c&#160;</p>
<p style="position:absolute;top:261px;left:147px;white-space:nowrap" class="ft3410">Analysis was based&#160;on&#160;subjects&#160;with&#160;nail&#160;psoriasis&#160;at&#160;baseline&#160;(81.8%&#160;of&#160;subjects).&#160;Mean&#160;<br/>baseline&#160;NAPSI&#160;scores&#160;were&#160;4.6 and 4.3&#160;in infliximab&#160;and placebo group.&#160;</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft3424">&#160;<br/>Significant&#160;improvements&#160;from&#160;baseline&#160;were&#160;demonstrated in DLQI&#160;(p&lt;0.001)&#160;and the&#160;physical&#160;and&#160;<br/>mental&#160;component&#160;scores&#160;of&#160;the&#160;SF&#160;36&#160;(p&lt;0.001 for&#160;each&#160;component&#160;comparison).&#160;&#160;<br/>&#160;<br/>Paediatric&#160;population&#160;<br/>&#160;<br/><i>Paediatric&#160;Crohn’s&#160;disease&#160;(6 to&#160;17 years)&#160;<br/>&#160;<br/></i>In the&#160;REACH&#160;study, 112&#160;patients&#160;(6&#160;to 17&#160;years, median&#160;age&#160;13.0&#160;years)&#160;with&#160;moderate to&#160;severe,&#160;<br/>active Crohn’s disease&#160;(median&#160;paediatric CDAI&#160;of&#160;40)&#160;and&#160;an&#160;inadequate&#160;response&#160;to conventional&#160;<br/>therapies&#160;were to&#160;receive 5&#160;mg/kg&#160;infliximab&#160;at weeks&#160;0, 2, and&#160;6. All&#160;patients&#160;were&#160;required&#160;to be&#160;on a&#160;<br/>stable dose of&#160;6-MP,&#160;AZA&#160;or&#160;MTX&#160;(35%&#160;were&#160;also&#160;receiving&#160;corticosteroids at&#160;baseline).&#160;Patients&#160;<br/>assessed&#160;by&#160;the investigator&#160;to be&#160;in clinical&#160;response&#160;at&#160;week&#160;10&#160;were&#160;randomised and&#160;received&#160;<br/>5&#160;mg/kg&#160;infliximab&#160;at&#160;either&#160;q8&#160;weeks&#160;or&#160;q12&#160;weeks as&#160;a&#160;maintenance treatment&#160;regimen.&#160;If&#160;response&#160;<br/>was&#160;lost&#160;during&#160;maintenance&#160;treatment,&#160;crossing over&#160;to a&#160;higher&#160;dose&#160;(10&#160;mg/kg)&#160;and/or&#160;shorter&#160;<br/>dosing interval&#160;(q8&#160;weeks)&#160;was allowed.&#160;Thirty&#160;two&#160;(32)&#160;evaluable paediatric patients&#160;crossed&#160;over&#160;<br/>(9&#160;subjects in&#160;the&#160;q8&#160;weeks and&#160;23&#160;subjects&#160;in the&#160;q12&#160;weeks&#160;maintenance&#160;groups). Twenty&#160;four&#160;of&#160;<br/>these&#160;patients&#160;(75.0%)&#160;regained clinical&#160;response&#160;after&#160;crossing over.&#160;<br/>The&#160;proportion of&#160;subjects&#160;in clinical&#160;response&#160;at&#160;week&#160;10 was&#160;88.4%&#160;(99/112). The&#160;proportion&#160;of&#160;<br/>subjects&#160;achieving&#160;clinical&#160;remission at&#160;week 10 was&#160;58.9%&#160;(66/112).&#160;<br/>At&#160;week 30,&#160;the&#160;proportion&#160;of&#160;subjects&#160;in&#160;clinical&#160;remission was&#160;higher&#160;in&#160;the&#160;q8&#160;week (59.6%, 31/52)&#160;<br/>than the&#160;q12&#160;week&#160;maintenance&#160;treatment&#160;group&#160;(35.3%, 18/51;&#160;p=0.013). At&#160;week 54, the&#160;figures&#160;<br/>were&#160;55.8%&#160;(29/52)&#160;and 23.5%&#160;(12/51)&#160;in the&#160;q8&#160;weeks&#160;and q12&#160;weeks maintenance&#160;groups,&#160;<br/>respectively&#160;(p&#160;&lt;&#160;0.001).&#160;<br/>Data&#160;about&#160;fistulas&#160;were&#160;derived from&#160;PCDAI&#160;scores.&#160;Of&#160;the&#160;22&#160;subjects&#160;that&#160;had&#160;fistulas&#160;at&#160;baseline,&#160;<br/>63.6%&#160;(14/22),&#160;59.1%&#160;(13/22)&#160;and 68.2%&#160;(15/22)&#160;were&#160;in complete&#160;fistula&#160;response&#160;at&#160;week 10, 30&#160;and&#160;<br/>54, respectively, in&#160;the&#160;combined&#160;q8&#160;weeks and&#160;q12&#160;weeks&#160;maintenance&#160;groups.&#160;<br/>&#160;<br/>In addition,&#160;statistically and&#160;clinically significant&#160;improvements&#160;in&#160;quality of&#160;life&#160;and height,&#160;as&#160;well&#160;as&#160;<br/>a&#160;significant&#160;reduction&#160;in corticosteroid&#160;use,&#160;were&#160;observed versus&#160;baseline.&#160;<br/>&#160;<br/><i>Paediatric&#160;ulcerative&#160;colitis&#160;(6&#160;to&#160;17</i></p>
<p style="position:absolute;top:888px;left:346px;white-space:nowrap" class="ft3428">&#160;<i>years)&#160;</i></p>
<p style="position:absolute;top:908px;left:106px;white-space:nowrap" class="ft3410"><i>&#160;<br/></i>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;infliximab&#160;were&#160;assessed&#160;in&#160;a&#160;multicentre,&#160;randomised,&#160;open-label,&#160;<br/>parallel-group clinical&#160;study (C0168T72)&#160;in 60&#160;paediatric&#160;patients&#160;aged 6&#160;through&#160;17&#160;years (median&#160;<br/>age&#160;14.5&#160;years)&#160;with moderately to severely&#160;active&#160;ulcerative&#160;colitis&#160;(Mayo score&#160;of&#160;6 to&#160;12;&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft3424">endoscopic&#160;subscore&#160;≥&#160;2)&#160;with&#160;an inadequate&#160;response&#160;to conventional&#160;therapies. At&#160;baseline&#160;53%&#160;of&#160;<br/>patients&#160;were&#160;receiving immunomodulator&#160;therapy (6-MP, AZA&#160;and/or&#160;MTX)&#160;and 62%&#160;of&#160;patients&#160;<br/>were receiving&#160;corticosteroids.&#160;Discontinuation&#160;of&#160;immunomodulators and&#160;corticosteroid&#160;taper&#160;were&#160;<br/>permitted after&#160;week 0.&#160;<br/>&#160;<br/>All&#160;patients&#160;received&#160;an&#160;induction regimen of&#160;5&#160;mg/kg&#160;infliximab at&#160;weeks&#160;0,&#160;2, and 6. Patients&#160;who&#160;<br/>did not&#160;respond to&#160;infliximab at&#160;week 8&#160;(n=15)&#160;received no further&#160;medicinal&#160;product&#160;and returned&#160;for&#160;<br/>safety follow-up. At&#160;week&#160;8, 45&#160;patients were randomised&#160;and&#160;received&#160;5</p>
<p style="position:absolute;top:1117px;left:589px;white-space:nowrap" class="ft3428">&#160;mg/kg&#160;infliximab at&#160;either&#160;</p>
<p style="position:absolute;top:1139px;left:106px;white-space:nowrap" class="ft342">q8</p>
<p style="position:absolute;top:1138px;left:123px;white-space:nowrap" class="ft3428">&#160;weeks or&#160;q12&#160;weeks&#160;as&#160;a&#160;maintenance treatment&#160;regimen.&#160;</p>
<p style="position:absolute;top:1158px;left:106px;white-space:nowrap" class="ft342">&#160;</p>
</div>
<!-- Page 35 -->
<a name="35"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page35-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft350">35&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft352">The&#160;proportion of&#160;patients&#160;in clinical&#160;response&#160;at&#160;week&#160;8 was&#160;73.3%&#160;(44/60). Clinical&#160;response&#160;at&#160;week</p>
<p style="position:absolute;top:88px;left:785px;white-space:nowrap" class="ft3528">&#160;</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3524">8 was&#160;similar&#160;between those&#160;with&#160;or&#160;without&#160;concomitant&#160;immunomodulator&#160;use&#160;at&#160;baseline. Clinical&#160;<br/>remission at&#160;week 8 was&#160;33.3%&#160;(17/51)&#160;as&#160;measured by the&#160;Paediatric&#160;Ulcerative&#160;Colitis&#160;Activity&#160;<br/>Index&#160;(PUCAI)&#160;score.&#160;<br/>&#160;<br/>At&#160;week 54,&#160;the&#160;proportion&#160;of&#160;patients&#160;in&#160;clinical&#160;remission&#160;as&#160;measured by&#160;the&#160;PUCAI&#160;score&#160;was&#160;38%&#160;<br/>(8/21)&#160;in the&#160;q8</p>
<p style="position:absolute;top:203px;left:209px;white-space:nowrap" class="ft3528">&#160;week&#160;maintenance&#160;group and&#160;18%&#160;(4/22)&#160;in&#160;the&#160;q12&#160;week&#160;maintenance treatment&#160;</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft3524">group. For&#160;patients&#160;receiving corticosteroids&#160;at&#160;baseline, the&#160;proportion of&#160;patients&#160;in remission and&#160;not&#160;<br/>receiving corticosteroids&#160;at&#160;week 54 was&#160;38.5%&#160;(5/13)&#160;for&#160;the&#160;q8</p>
<p style="position:absolute;top:243px;left:534px;white-space:nowrap" class="ft3528">&#160;week&#160;and 0%&#160;(0/13)&#160;for&#160;the&#160;</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft352">q12</p>
<p style="position:absolute;top:264px;left:131px;white-space:nowrap" class="ft3528">&#160;week&#160;maintenance treatment&#160;group.&#160;</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft3524">&#160;<br/>In this&#160;study, there&#160;were&#160;more&#160;patients&#160;in the&#160;12&#160;to 17</p>
<p style="position:absolute;top:303px;left:458px;white-space:nowrap" class="ft3528">&#160;year&#160;age&#160;group than in the&#160;6 to&#160;11&#160;year&#160;age&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft3511">group (45/60&#160;vs.15/60). While&#160;the&#160;numbers&#160;of&#160;patients&#160;in&#160;each subgroup are&#160;too small&#160;to&#160;draw&#160;<br/>definitive conclusions about&#160;the effect&#160;of&#160;age,&#160;there was a higher&#160;number&#160;of&#160;patients&#160;in the&#160;younger&#160;age&#160;<br/>group&#160;who stepped up&#160;in&#160;dose&#160;or&#160;discontinued treatment&#160;due&#160;to inadequate&#160;efficacy.&#160;<br/>&#160;<br/><i>Other&#160;paediatric indications&#160;<br/>&#160;<br/></i>The&#160;European&#160;Medicines&#160;Agency has&#160;waived&#160;the&#160;obligation to&#160;submit&#160;the&#160;results&#160;of&#160;studies&#160;with&#160;the&#160;<br/>reference&#160;medicinal&#160;product&#160;containing&#160;infliximab&#160;in all&#160;subsets&#160;of&#160;the&#160;paediatric&#160;population in&#160;<br/>rheumatoid&#160;arthritis,&#160;juvenile&#160;idiopathic&#160;arthritis,&#160;psoriatic&#160;arthritis, ankylosing&#160;spondylitis, psoriasis&#160;<br/>and Crohn's&#160;disease&#160;(see&#160;section 4.2&#160;for&#160;information on&#160;paediatric&#160;use).&#160;<br/>&#160;<br/><b>5.2&#160;</b></p>
<p style="position:absolute;top:533px;left:149px;white-space:nowrap" class="ft351"><b>Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:553px;left:106px;white-space:nowrap" class="ft3510">&#160;<br/>Single&#160;intravenous&#160;infusions&#160;of&#160;1,&#160;3, 5, 10&#160;or&#160;20&#160;mg/kg&#160;of&#160;infliximab yielded dose&#160;proportional&#160;<br/>increases in&#160;the maximum&#160;serum&#160;concentration&#160;(Cmax)&#160;and&#160;area&#160;under&#160;the&#160;concentration-time&#160;curve&#160;<br/>(AUC).&#160;The volume of&#160;distribution&#160;at&#160;steady&#160;state (median&#160;Vd&#160;of&#160;3.0&#160;to 4.1&#160;litres)&#160;was&#160;not&#160;dependent&#160;<br/>on&#160;the&#160;administered&#160;dose&#160;and&#160;indicated&#160;that infliximab&#160;is&#160;predominantly distributed&#160;within the&#160;vascular&#160;<br/>compartment.&#160;No&#160;time-dependency of&#160;the&#160;Pharmacokinetics&#160;was&#160;observed. The&#160;elimination pathways&#160;<br/>for&#160;infliximab&#160;have&#160;not&#160;been characterised. Unchanged&#160;infliximab was&#160;not&#160;detected in urine. No&#160;major&#160;<br/>age-&#160;or&#160;weight-related differences&#160;in clearance&#160;or&#160;volume&#160;of&#160;distribution were&#160;observed&#160;in&#160;rheumatoid&#160;<br/>arthritis&#160;patients. The&#160;pharmacokinetics&#160;of&#160;infliximab&#160;in elderly patients&#160;has&#160;not&#160;been studied. Studies&#160;<br/>have&#160;not&#160;been performed&#160;in&#160;patients&#160;with&#160;liver&#160;or&#160;renal&#160;disease.&#160;<br/>&#160;<br/>At&#160;single&#160;doses&#160;of&#160;3, 5, or&#160;10&#160;mg/kg, the&#160;median&#160;Cmax&#160;values&#160;were&#160;77, 118 and&#160;277&#160;micrograms/mL,&#160;<br/>respectively.&#160;The&#160;median&#160;terminal&#160;half-life at&#160;these doses ranged&#160;from&#160;8&#160;to&#160;9.5&#160;days. In most&#160;patients,&#160;<br/>infliximab could&#160;be&#160;detected in&#160;the&#160;serum for&#160;at least 8&#160;weeks after&#160;the&#160;recommended&#160;single dose of&#160;<br/>5&#160;mg/kg&#160;for&#160;Crohn’s&#160;disease&#160;and&#160;the&#160;rheumatoid arthritis&#160;maintenance&#160;dose&#160;of&#160;3&#160;mg/kg every 8&#160;weeks.&#160;<br/>&#160;<br/>Repeated&#160;administration&#160;of&#160;infliximab (5&#160;mg/kg at&#160;0, 2&#160;and 6&#160;weeks&#160;in fistulising Crohn’s&#160;disease,&#160;3&#160;or&#160;<br/>10&#160;mg/kg&#160;every 4 or&#160;8&#160;weeks&#160;in&#160;rheumatoid&#160;arthritis)&#160;resulted&#160;in&#160;a&#160;slight&#160;accumulation&#160;of&#160;infliximab&#160;in&#160;<br/>serum&#160;after&#160;the&#160;second dose. No further&#160;clinically relevant&#160;accumulation was&#160;observed. In most&#160;<br/>fistulising&#160;Crohn’s&#160;disease&#160;patients,&#160;infliximab was&#160;detected in&#160;serum&#160;for&#160;12&#160;weeks&#160;(range 4-28&#160;weeks)&#160;<br/>after&#160;administration&#160;of&#160;the&#160;regimen.&#160;<br/>&#160;<br/>Paediatric&#160;population&#160;<br/><i>&#160;<br/></i>Population pharmacokinetic&#160;analysis&#160;based&#160;on data&#160;obtained&#160;from&#160;patients&#160;with&#160;ulcerative&#160;colitis&#160;<br/>(N=60),&#160;Crohn’s&#160;disease&#160;(N=112),&#160;juvenile&#160;rheumatoid&#160;arthritis (N=117)&#160;and&#160;Kawasaki&#160;disease&#160;<br/>(N=16)&#160;with&#160;an overall&#160;age&#160;range&#160;from&#160;2 months&#160;to&#160;17&#160;years&#160;indicated that&#160;exposure&#160;to infliximab was&#160;<br/>dependent&#160;on body&#160;weight&#160;in a&#160;non-linear&#160;way. Following administration of&#160;5&#160;mg/kg&#160;infliximab&#160;every&#160;<br/>8&#160;weeks, the&#160;predicted median&#160;steady-state&#160;infliximab exposure&#160;(area&#160;under&#160;concentration-time curve&#160;<br/>at&#160;steady state, AUCss)&#160;in&#160;paediatric&#160;patients&#160;aged&#160;6 years&#160;to 17&#160;years&#160;was&#160;approximately 20%&#160;lower&#160;<br/>than the&#160;predicted median&#160;steady-state&#160;medicinal product exposure in&#160;adults.&#160;The median&#160;AUCss in&#160;<br/>paediatric patients aged&#160;2&#160;years to&#160;less&#160;than&#160;6&#160;years&#160;was&#160;predicted&#160;to be&#160;approximately 40%&#160;lower&#160;than&#160;<br/>that&#160;in&#160;adults,&#160;although the&#160;number&#160;of&#160;patients&#160;supporting this&#160;estimate&#160;is&#160;limited.&#160;</p>
</div>
<!-- Page 36 -->
<a name="36"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page36-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft360">36&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft3611">&#160;<br/><b>5.3&#160;</b></p>
<p style="position:absolute;top:108px;left:149px;white-space:nowrap" class="ft361"><b>Preclinical&#160;safety&#160;data&#160;</b></p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft3610"><b>&#160;<br/></b>Infliximab&#160;does&#160;not cross&#160;react with&#160;TNFα&#160;from&#160;species&#160;other&#160;than human and&#160;chimpanzees. Therefore,&#160;<br/>conventional preclinical safety&#160;data&#160;with&#160;infliximab&#160;are&#160;limited.&#160;In&#160;a&#160;developmental toxicity&#160;study&#160;<br/>conducted&#160;in&#160;mice&#160;using&#160;an&#160;analogous&#160;antibody that&#160;selectively inhibits&#160;the&#160;functional&#160;activity of&#160;<br/>mouse&#160;TNFα,&#160;there&#160;was&#160;no indication of&#160;maternal&#160;toxicity, embryotoxicity or&#160;teratogenicity.&#160;In&#160;a&#160;<br/>fertility and general&#160;reproductive&#160;function study,&#160;the&#160;number&#160;of&#160;pregnant&#160;mice&#160;was&#160;reduced&#160;following&#160;<br/>administration of&#160;the&#160;same&#160;analogous&#160;antibody.&#160;It&#160;is&#160;not&#160;known whether&#160;this&#160;finding was&#160;due&#160;to&#160;effects&#160;<br/>on&#160;the&#160;males and/or&#160;the females.&#160;In&#160;a 6-month repeated dose&#160;toxicity&#160;study in mice,&#160;using&#160;the&#160;same&#160;<br/>analogous&#160;antibody&#160;against&#160;mouse&#160;TNFα, crystalline&#160;deposits&#160;were&#160;observed on the&#160;lens&#160;capsule&#160;of&#160;<br/>some&#160;of&#160;the&#160;treated&#160;male&#160;mice. No specific&#160;ophthalmologic&#160;examinations&#160;have&#160;been performed&#160;in&#160;<br/>patients to&#160;investigate the relevance&#160;of&#160;this finding&#160;for&#160;humans.&#160;<br/>&#160;<br/>Long-term&#160;studies&#160;have&#160;not&#160;been performed&#160;to evaluate&#160;the&#160;carcinogenic&#160;potential&#160;of&#160;infliximab.&#160;<br/>Studies&#160;in mice&#160;deficient&#160;in&#160;TNFα&#160;demonstrated&#160;no increase&#160;in tumours&#160;when challenged&#160;with&#160;known&#160;<br/>tumour&#160;initiators&#160;and/or&#160;promoters.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:450px;left:149px;white-space:nowrap" class="ft361"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:469px;left:106px;white-space:nowrap" class="ft3611">&#160;<br/><b>6.1&#160;</b></p>
<p style="position:absolute;top:489px;left:149px;white-space:nowrap" class="ft361"><b>List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft3611">&#160;<br/>Sucrose&#160;<br/>Polysorbate&#160;80&#160;<br/>Sodium&#160;dihydrogen&#160;phosphate&#160;monohydrate&#160;<br/>Disodium&#160;phosphate&#160;dihydrate&#160;&#160;<br/>&#160;<br/><b>6.2&#160;</b></p>
<p style="position:absolute;top:622px;left:149px;white-space:nowrap" class="ft361"><b>Incompatibilities&#160;</b></p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft3611">&#160;<br/>In&#160;the&#160;absence&#160;of&#160;compatibility&#160;studies,&#160;this&#160;medicinal product must&#160;not&#160;be&#160;mixed&#160;with&#160;other&#160;medicinal&#160;<br/>products.&#160;<br/>&#160;<br/><b>6.3&#160;</b></p>
<p style="position:absolute;top:718px;left:149px;white-space:nowrap" class="ft361"><b>Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:737px;left:106px;white-space:nowrap" class="ft3624">&#160;<br/>Before&#160;reconstitution:&#160;<br/>&#160;<br/>5&#160;years&#160;at&#160;2°C&#160;–&#160;8°C.&#160;<br/>&#160;<br/>Remsima may&#160;be&#160;stored at&#160;temperatures&#160;up&#160;to&#160;a&#160;maximum&#160;of&#160;25°C&#160;for&#160;a&#160;single&#160;period of&#160;up&#160;to 6&#160;<br/>months, but&#160;not&#160;exceeding the&#160;original&#160;expiry&#160;date. The&#160;new&#160;expiry date&#160;must&#160;be&#160;written on&#160;the&#160;carton.&#160;<br/>Upon removal&#160;from&#160;refrigerated storage, Remsima&#160;must&#160;not&#160;be&#160;returned&#160;to refrigerated&#160;storage.&#160;<br/>&#160;<br/>After&#160;reconstitution&#160;and dilution:&#160;<br/>&#160;<br/>Chemical and&#160;physical&#160;in&#160;use&#160;stability&#160;of&#160;the&#160;diluted&#160;solution&#160;has been&#160;demonstrated&#160;for&#160;up to&#160;60&#160;days&#160;<br/>at&#160;2 °C&#160;to 8 °C&#160;and&#160;for&#160;an&#160;additional&#160;24&#160;hours&#160;at&#160;25</p>
<p style="position:absolute;top:962px;left:443px;white-space:nowrap" class="ft368">°C&#160;after removal&#160;from&#160;refrigeration.&#160;From&#160;a&#160;</p>
<p style="position:absolute;top:986px;left:106px;white-space:nowrap" class="ft3611">microbiological&#160;point&#160;of&#160;view, the&#160;infusion&#160;solution&#160;should be&#160;administered&#160;immediately,&#160;in use&#160;<br/>storage&#160;times and&#160;conditions prior&#160;to&#160;use are&#160;the&#160;responsibility&#160;of&#160;the user&#160;and&#160;would&#160;normally&#160;not&#160;be&#160;<br/>longer&#160;than 24&#160;hours&#160;at&#160;2°C&#160;–&#160;8°C,&#160;unless&#160;reconstitution/dilution&#160;has&#160;been&#160;taken place&#160;in controlled&#160;<br/>and validated aseptic&#160;conditions.&#160;<br/>&#160;<br/><b>6.4&#160;</b></p>
<p style="position:absolute;top:1081px;left:149px;white-space:nowrap" class="ft361"><b>Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:1101px;left:106px;white-space:nowrap" class="ft3611">&#160;<br/>Store&#160;in a&#160;refrigerator&#160;(2°C&#160;–&#160;8°C).&#160;<br/>&#160;<br/>For&#160;storage&#160;conditions&#160;up to 25°C&#160;before&#160;reconstitution of&#160;the&#160;medicinal&#160;product, see&#160;section 6.3.&#160;</p>
</div>
<!-- Page 37 -->
<a name="37"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page37-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft370">37&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft3724">&#160;<br/>For&#160;storage&#160;conditions&#160;after&#160;reconstitution of&#160;the&#160;medicinal&#160;product, see&#160;section 6.3</p>
<p style="position:absolute;top:108px;left:654px;white-space:nowrap" class="ft3728">.&#160;</p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft3711">&#160;<br/><b>6.5&#160;</b></p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft371"><b>Nature&#160;and&#160;contents&#160;of&#160;container&#160;</b></p>
<p style="position:absolute;top:167px;left:106px;white-space:nowrap" class="ft3711">&#160;<br/>Type&#160;1&#160;glass vial&#160;with&#160;a&#160;(butyl)&#160;rubber&#160;stopper&#160;and&#160;an&#160;aluminium&#160;seal&#160;with&#160;a&#160;flip-off&#160;button.&#160;<br/>&#160;<br/>Pack&#160;sizes of&#160;1, 2, 3,&#160;4,&#160;5&#160;vials.&#160;<br/>&#160;<br/>Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;<br/>&#160;<br/><b>6.6&#160;</b></p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft371"><b>Special&#160;precautions&#160;for&#160;disposal&#160;and other&#160;handling&#160;</b></p>
<p style="position:absolute;top:322px;left:106px;white-space:nowrap" class="ft3711">&#160;<br/>1.&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft3711">The&#160;dose&#160;and the&#160;number&#160;of&#160;Remsima&#160;vials&#160;have&#160;to&#160;be&#160;calculated.&#160;Each&#160;Remsima&#160;vial&#160;contains&#160;<br/>100&#160;mg&#160;infliximab.&#160;The&#160;required&#160;total volume&#160;of&#160;reconstituted&#160;Remsima&#160;solution&#160;has&#160;to&#160;be&#160;<br/>calculated.&#160;</p>
<p style="position:absolute;top:398px;left:106px;white-space:nowrap" class="ft3710">&#160;<br/>2.&#160;</p>
<p style="position:absolute;top:417px;left:149px;white-space:nowrap" class="ft3711">Under&#160;aseptic&#160;conditions, each Remsima&#160;vial&#160;should be&#160;reconstituted with 10&#160;mL&#160;of&#160;water for&#160;<br/>injections, using a&#160;syringe&#160;equipped with a&#160;21-gauge&#160;(0.8&#160;mm)&#160;or&#160;smaller&#160;needle.&#160;The&#160;flip-top&#160;<br/>from&#160;the&#160;vial&#160;has&#160;to be&#160;removed and the&#160;top has&#160;to be&#160;wiped with a&#160;70%&#160;alcohol&#160;swab. The&#160;<br/>syringe&#160;needle&#160;should be&#160;inserted&#160;into the&#160;vial&#160;through&#160;the&#160;centre&#160;of&#160;the&#160;rubber&#160;stopper&#160;and the&#160;<br/>stream of&#160;water&#160;for&#160;injections&#160;directed&#160;to&#160;the&#160;glass&#160;wall&#160;of&#160;the&#160;vial.&#160;The&#160;solution&#160;has&#160;to&#160;be&#160;gently&#160;<br/>swirled by rotating&#160;the&#160;vial&#160;to dissolve&#160;the&#160;powder. Prolonged&#160;or&#160;vigorous&#160;agitation must&#160;be&#160;<br/>avoided.&#160;THE&#160;VIAL&#160;MUST&#160;NOT&#160;BE&#160;SHAKEN.&#160;Foaming&#160;of&#160;the&#160;solution&#160;on reconstitution may&#160;<br/>occur. The&#160;reconstituted solution should&#160;stand for&#160;5&#160;minutes. The&#160;solution should&#160;be&#160;colourless&#160;<br/>to light&#160;yellow&#160;and opalescent. The&#160;solution&#160;may develop a&#160;few&#160;fine&#160;translucent&#160;particles, as&#160;<br/>infliximab&#160;is&#160;a&#160;protein.&#160;The&#160;solution must&#160;not&#160;be&#160;used&#160;if&#160;opaque&#160;particles, discolouration, or&#160;<br/>other&#160;foreign&#160;particles are present.&#160;</p>
<p style="position:absolute;top:626px;left:106px;white-space:nowrap" class="ft3711">&#160;<br/>3.&#160;</p>
<p style="position:absolute;top:645px;left:149px;white-space:nowrap" class="ft3711">The&#160;required volume&#160;of&#160;the&#160;reconstituted Remsima&#160;solution should be&#160;diluted&#160;to 250&#160;mL&#160;with&#160;<br/>sodium chloride&#160;9&#160;mg/mL&#160;(0.9%)&#160;solution&#160;for&#160;infusion.&#160;Do not&#160;dilute&#160;the&#160;reconstituted&#160;Remsima&#160;<br/>solution with any&#160;other&#160;diluent. The&#160;dilution&#160;can&#160;be&#160;accomplished by&#160;withdrawing&#160;a&#160;volume&#160;of&#160;<br/>the&#160;sodium&#160;chloride&#160;9&#160;mg/mL&#160;(0.9%)&#160;solution&#160;for&#160;infusion&#160;from&#160;the&#160;250-mL&#160;glass&#160;bottle&#160;or&#160;<br/>infusion bag&#160;equal&#160;to the&#160;volume&#160;of&#160;reconstituted Remsima. The&#160;required volume&#160;of&#160;<br/>reconstituted Remsima&#160;solution&#160;should slowly be&#160;added to&#160;the&#160;250-mL&#160;infusion&#160;bottle&#160;or&#160;bag&#160;<br/>and gently be&#160;mixed.&#160;For&#160;volumes&#160;greater&#160;than&#160;250&#160;ml, either&#160;use&#160;a&#160;larger&#160;infusion&#160;bag (e.g.&#160;<br/>500&#160;ml, 1000&#160;ml)&#160;or&#160;use&#160;multiple&#160;250&#160;ml&#160;infusion&#160;bags&#160;to&#160;ensure&#160;that&#160;the&#160;concentration of&#160;the&#160;<br/>infusion solution does&#160;not&#160;exceed&#160;4&#160;mg/ml.&#160;If&#160;stored refrigerated after&#160;reconstitution&#160;and&#160;<br/>dilution, the&#160;infusion solution must&#160;be&#160;allowed to&#160;equilibrate&#160;at&#160;room&#160;temperature&#160;to 25 °C&#160;for&#160;3&#160;<br/>hours&#160;prior&#160;to Step 4&#160;(infusion). Storage&#160;beyond 24 hours&#160;at&#160;2 °C&#160;-&#160;8 °C&#160;applies&#160;to&#160;preparation of&#160;<br/>Remsima&#160;in&#160;the&#160;infusion&#160;bag&#160;only.&#160;</p>
<p style="position:absolute;top:873px;left:106px;white-space:nowrap" class="ft3711">&#160;<br/>4.&#160;</p>
<p style="position:absolute;top:892px;left:149px;white-space:nowrap" class="ft3711">The&#160;infusion solution has&#160;to be&#160;administered&#160;over&#160;a&#160;period&#160;of&#160;not&#160;less&#160;than the&#160;infusion&#160;time&#160;<br/>recommended&#160;(see&#160;section 4.2).&#160;Only an&#160;infusion set&#160;with&#160;an in-line, sterile, non-pyrogenic, low&#160;<br/>protein-binding filter&#160;(pore&#160;size&#160;1.2&#160;micrometre&#160;or&#160;less)&#160;should be&#160;used. Since&#160;no preservative&#160;is&#160;<br/>present,&#160;it&#160;is&#160;recommended&#160;that&#160;the&#160;administration of&#160;the&#160;solution&#160;for&#160;infusion is&#160;to&#160;be&#160;started&#160;as&#160;<br/>soon as&#160;possible&#160;and within&#160;3&#160;hours&#160;of&#160;reconstitution and&#160;dilution.&#160;If&#160;not&#160;used immediately,&#160;in&#160;<br/>use&#160;storage&#160;times&#160;and&#160;conditions&#160;prior&#160;to&#160;use&#160;are&#160;the&#160;responsibility of&#160;the&#160;user&#160;and&#160;would&#160;<br/>normally not&#160;be&#160;longer&#160;than&#160;24&#160;hours&#160;at&#160;2°C&#160;to 8°C, unless&#160;reconstitution/dilution&#160;has been&#160;<br/>taken&#160;place&#160;in controlled&#160;and validated&#160;aseptic conditions&#160;(see&#160;section&#160;6.3 above). Any&#160;unused&#160;<br/>portion of&#160;the&#160;infusion solution&#160;should not&#160;be&#160;stored for&#160;reuse.&#160;</p>
<p style="position:absolute;top:1063px;left:106px;white-space:nowrap" class="ft3711">&#160;<br/>5.&#160;</p>
<p style="position:absolute;top:1082px;left:149px;white-space:nowrap" class="ft3710">Remsima&#160;should&#160;be&#160;visually&#160;inspected&#160;for&#160;particulate&#160;matter&#160;or&#160;discolouration prior&#160;to&#160;<br/>administration.&#160;If&#160;visibly opaque&#160;particles, discolouration or&#160;foreign particles&#160;are&#160;observed&#160;it&#160;<br/>should not&#160;be&#160;used.&#160;</p>
<p style="position:absolute;top:1139px;left:106px;white-space:nowrap" class="ft372">&#160;</p>
</div>
<!-- Page 38 -->
<a name="38"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3829{font-size:18px;line-height:20px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page38-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft380">38&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft382">6.&#160;</p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft3811">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with local&#160;<br/>requirements.&#160;</p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft3811">&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:165px;left:149px;white-space:nowrap" class="ft381"><b>MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft3811">&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Hungary&#160;<br/>&#160;<br/>&#160;<br/><b>8.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;&#160;<br/></b>&#160;<br/>EU/1/13/853/001&#160;<br/>EU/1/13/853/002&#160;<br/>EU/1/13/853/003&#160;<br/>EU/1/13/853/004&#160;<br/>EU/1/13/853/005&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;&#160;DATE&#160;OF&#160;FIRST&#160;AUTHORISATION/RENEWAL&#160;OF&#160;THE&#160;AUTHORISATION&#160;<br/></b>&#160;<br/>Date&#160;of&#160;first authorisation:&#160;10&#160;September&#160;2013&#160;<br/>Date&#160;of&#160;latest&#160;renewal:&#160;21&#160;June&#160;2018&#160;<br/>&#160;<br/>&#160;<br/><b>10.&#160;&#160;DATE OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;<br/></b>&#160;<br/>Detailed&#160;information on&#160;this&#160;medicinal&#160;product&#160;is available&#160;on&#160;the website of&#160;the European&#160;Medicines&#160;<br/>Agency&#160;http://www.ema.europa.eu.&#160;</p>
<p style="position:absolute;top:663px;left:557px;white-space:nowrap" class="ft382">&#160;</p>
</div>
<!-- Page 39 -->
<a name="39"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page39-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft390">39&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft391"><b>1.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft391"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft3910">&#160;<br/>Remsima&#160;120&#160;mg solution&#160;for&#160;injection in&#160;pre-filled syringe&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled&#160;pen&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft391"><b>QUALITATIVE&#160;AND QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft3911">&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled syringe&#160;<br/>Each&#160;1&#160;mL&#160;single&#160;dose&#160;pre-filled syringe&#160;contains&#160;120&#160;mg&#160;of&#160;infliximab*.&#160;<br/>&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled&#160;pen&#160;<br/>Each&#160;1&#160;mL&#160;single&#160;dose&#160;pre-filled pen&#160;contains&#160;120&#160;mg&#160;of&#160;infliximab*.&#160;&#160;<br/>&#160;<br/>*&#160;Infliximab&#160;is&#160;a chimeric human-murine&#160;IgG1 monoclonal&#160;antibody&#160;produced&#160;in murine&#160;hybridoma&#160;<br/>cells&#160;by recombinant&#160;DNA&#160;technology.&#160;&#160;<br/>&#160;<br/>Excipient(s)&#160;with known effect&#160;<br/>Sorbitol&#160;45&#160;mg per&#160;1&#160;mL&#160;&#160;<br/>&#160;<br/>For&#160;the&#160;full&#160;list&#160;of&#160;excipients, see&#160;section 6.1.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:525px;left:149px;white-space:nowrap" class="ft391"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft3910">&#160;<br/>Solution&#160;for&#160;injection&#160;(injection).&#160;<br/>Clear&#160;to opalescent, colourless&#160;to pale&#160;brown solution.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:639px;left:149px;white-space:nowrap" class="ft391"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft3910">&#160;<br/><b>4.1&#160;</b></p>
<p style="position:absolute;top:677px;left:149px;white-space:nowrap" class="ft391"><b>THERAPEUTIC INDICATIONS&#160;</b></p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft3914">&#160;<br/>Rheumatoid&#160;arthritis&#160;<br/>&#160;<br/>Remsima,&#160;in&#160;combination&#160;with&#160;methotrexate,&#160;is&#160;indicated&#160;for&#160;the&#160;reduction of&#160;signs&#160;and symptoms&#160;as&#160;<br/>well&#160;as&#160;the improvement&#160;in physical&#160;function in:&#160;&#160;<br/>•&#160;</p>
<p style="position:absolute;top:792px;left:149px;white-space:nowrap" class="ft3910">adult&#160;patients with&#160;active disease when&#160;the&#160;response&#160;to&#160;disease-modifying&#160;antirheumatic&#160;drugs&#160;<br/>(DMARDs), including methotrexate,&#160;has&#160;been inadequate.&#160;&#160;</p>
<p style="position:absolute;top:826px;left:106px;white-space:nowrap" class="ft398">•&#160;</p>
<p style="position:absolute;top:831px;left:149px;white-space:nowrap" class="ft3910">adult&#160;patients&#160;with severe, active&#160;and progressive&#160;disease&#160;not&#160;previously treated with&#160;<br/>methotrexate&#160;or&#160;other&#160;DMARDs.&#160;&#160;</p>
<p style="position:absolute;top:869px;left:106px;white-space:nowrap" class="ft3914">In these&#160;patient&#160;populations, a&#160;reduction&#160;in&#160;the&#160;rate&#160;of&#160;the&#160;progression of&#160;joint&#160;damage, as&#160;measured&#160;by&#160;<br/>X-ray, has&#160;been demonstrated (see&#160;section&#160;5.1).&#160;&#160;<br/>&#160;<br/>Crohn’s&#160;disease&#160;<br/>&#160;<br/>Remsima is indicated&#160;for:&#160;<br/>•&#160;</p>
<p style="position:absolute;top:984px;left:149px;white-space:nowrap" class="ft3911">treatment of&#160;moderately&#160;to&#160;severely active&#160;Crohn’s&#160;disease,&#160;in&#160;adult&#160;patients&#160;who&#160;have&#160;not&#160;<br/>responded&#160;despite a&#160;full&#160;and&#160;adequate course&#160;of&#160;therapy&#160;with&#160;a corticosteroid&#160;and/or&#160;an&#160;<br/>immunosuppressant;&#160;or&#160;who&#160;are&#160;intolerant&#160;to&#160;or&#160;have&#160;medical&#160;contraindications for&#160;such&#160;<br/>therapies.&#160;</p>
<p style="position:absolute;top:1056px;left:106px;white-space:nowrap" class="ft398">•&#160;</p>
<p style="position:absolute;top:1061px;left:149px;white-space:nowrap" class="ft3910">treatment&#160;of&#160;fistulising,&#160;active Crohn’s disease,&#160;in&#160;adult&#160;patients who&#160;have not&#160;responded&#160;despite&#160;<br/>a&#160;full&#160;and adequate&#160;course&#160;of&#160;therapy with conventional&#160;treatment&#160;(including antibiotics,&#160;<br/>drainage&#160;and immunosuppressive&#160;therapy).&#160;</p>
<p style="position:absolute;top:1118px;left:106px;white-space:nowrap" class="ft392">&#160;</p>
</div>
<!-- Page 40 -->
<a name="40"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page40-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft400">40&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4010">Ulcerative colitis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;moderately&#160;to&#160;severely&#160;active ulcerative colitis&#160;in&#160;adult&#160;patients&#160;<br/>who have&#160;had an&#160;inadequate&#160;response&#160;to&#160;conventional&#160;therapy including&#160;corticosteroids&#160;and&#160;<br/>6-mercaptopurine&#160;(6-MP)&#160;or&#160;azathioprine (AZA),&#160;or&#160;who&#160;are&#160;intolerant to&#160;or&#160;have&#160;medical&#160;<br/>contraindications for&#160;such&#160;therapies.&#160;<br/>&#160;<br/>Ankylosing spondylitis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;severe,&#160;active ankylosing&#160;spondylitis,&#160;in&#160;adult&#160;patients who&#160;have&#160;<br/>responded inadequately to conventional&#160;therapy.&#160;<br/>&#160;<br/>Psoriatic&#160;arthritis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;active and&#160;progressive psoriatic&#160;arthritis&#160;in&#160;adult&#160;patients when&#160;<br/>the&#160;response&#160;to&#160;previous&#160;DMARD&#160;therapy&#160;has been&#160;inadequate.&#160;<br/>Remsima should&#160;be administered&#160;</p>
<p style="position:absolute;top:407px;left:106px;white-space:nowrap" class="ft408">•&#160;</p>
<p style="position:absolute;top:413px;left:149px;white-space:nowrap" class="ft402">in&#160;combination&#160;with&#160;methotrexate&#160;</p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft408">•&#160;</p>
<p style="position:absolute;top:433px;left:149px;white-space:nowrap" class="ft4010">or&#160;alone&#160;in patients&#160;who show&#160;intolerance&#160;to&#160;methotrexate&#160;or&#160;for&#160;whom&#160;methotrexate&#160;is&#160;<br/>contraindicated.&#160;</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft4011">Infliximab has&#160;been shown&#160;to improve&#160;physical&#160;function in patients&#160;with psoriatic&#160;arthritis, and to&#160;<br/>reduce the rate of&#160;progression&#160;of&#160;peripheral&#160;joint&#160;damage as&#160;measured&#160;by X-ray&#160;in&#160;patients with&#160;<br/>polyarticular&#160;symmetrical&#160;subtypes of&#160;the disease&#160;(see&#160;section&#160;5.1).&#160;<br/>&#160;<br/>Psoriasis&#160;<br/>&#160;<br/>Remsima is indicated&#160;for&#160;treatment&#160;of&#160;moderate to&#160;severe plaque psoriasis&#160;in&#160;adult&#160;patients who&#160;failed&#160;<br/>to respond to,&#160;or&#160;who&#160;have&#160;a&#160;contraindication&#160;to, or&#160;are&#160;intolerant&#160;to other&#160;systemic&#160;therapy&#160;including&#160;<br/>ciclosporin, methotrexate&#160;or&#160;psoralen&#160;ultra-violet&#160;A&#160;(PUVA)&#160;(see&#160;section 5.1).&#160;<br/>&#160;<br/><b>4.2&#160;</b></p>
<p style="position:absolute;top:661px;left:149px;white-space:nowrap" class="ft401"><b>Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft4011">&#160;<br/>Remsima&#160;treatment&#160;is&#160;to&#160;be&#160;initiated and&#160;supervised&#160;by&#160;qualified physicians&#160;experienced&#160;in&#160;the&#160;<br/>diagnosis&#160;and&#160;treatment&#160;of&#160;conditions for&#160;which&#160;Remsima is indicated.&#160;Patients treated&#160;with&#160;Remsima&#160;<br/>should be&#160;given&#160;the package leaflet&#160;and&#160;the patient&#160;reminder&#160;card. Instruction&#160;for&#160;use&#160;is&#160;provided in the&#160;<br/>package leaflet.&#160;&#160;<br/>&#160;<br/>For&#160;subsequent&#160;injections&#160;and after&#160;proper&#160;training&#160;in subcutaneous&#160;injection&#160;technique, patients&#160;may&#160;<br/>self-inject with&#160;Remsima&#160;if&#160;their&#160;physician determines&#160;that&#160;it&#160;is&#160;appropriate&#160;and&#160;with&#160;medical follow-<br/>up&#160;as necessary.&#160;Suitability&#160;of&#160;the patient&#160;for&#160;subcutaneous home use should&#160;be assessed&#160;and&#160;patients&#160;<br/>should be&#160;advised&#160;to inform&#160;their&#160;healthcare&#160;professional&#160;if&#160;they&#160;experience&#160;symptoms&#160;of&#160;an allergic&#160;<br/>reaction before&#160;administering the&#160;next&#160;dose.&#160;Patients should&#160;seek&#160;immediate medical&#160;attention&#160;if&#160;<br/>developing symptoms&#160;of&#160;serious&#160;allergic&#160;reactions&#160;(see&#160;section&#160;4.4).</p>
<p style="position:absolute;top:887px;left:554px;white-space:nowrap" class="ft4028">&#160;</p>
<p style="position:absolute;top:907px;left:106px;white-space:nowrap" class="ft4010">&#160;<br/>During Remsima&#160;treatment,&#160;other&#160;concomitant&#160;therapies, e.g.,&#160;corticosteroids&#160;and&#160;immunosuppressants&#160;<br/>should be&#160;optimised.&#160;&#160;<br/>&#160;<br/>It&#160;is&#160;important to&#160;check&#160;the&#160;product&#160;labels&#160;to&#160;ensure&#160;that the&#160;correct&#160;formulation&#160;(intravenous&#160;or&#160;<br/>subcutaneous)&#160;is&#160;being administered&#160;to&#160;the&#160;patient, as&#160;prescribed. Remsima&#160;subcutaneous&#160;formulation&#160;<br/>is&#160;not&#160;intended&#160;for&#160;intravenous&#160;administration&#160;and should be&#160;administered via&#160;a&#160;subcutaneous&#160;injection&#160;<br/>only.&#160;<br/>&#160;</p>
</div>
<!-- Page 41 -->
<a name="41"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4130{font-size:12px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page41-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft410">41&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4111">Posology&#160;<br/>&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft4110"><i>Adults&#160;(≥18&#160;years)&#160;<br/></i>&#160;<br/><i>Rheumatoid&#160;arthritis&#160;<br/></i>Treatment&#160;with&#160;Remsima&#160;subcutaneous&#160;formulation should be&#160;initiated with&#160;loading doses&#160;of&#160;<br/>infliximab&#160;which may be&#160;intravenous&#160;or&#160;subcutaneous. When subcutaneous&#160;loading&#160;is&#160;used,&#160;Remsima&#160;<br/>120 mg&#160;should be&#160;given as&#160;a&#160;subcutaneous&#160;injection followed&#160;by additional&#160;subcutaneous&#160;injections&#160;at&#160;<br/>1, 2, 3 and 4 weeks&#160;after&#160;the&#160;first&#160;injection,&#160;then&#160;every&#160;2 weeks&#160;thereafter.&#160;If&#160;intravenous&#160;loading&#160;doses&#160;<br/>of&#160;infliximab are&#160;given&#160;to&#160;initiate&#160;treatment, 2&#160;intravenous&#160;infusions&#160;of&#160;infliximab&#160;3 mg/kg should be&#160;<br/>given&#160;2&#160;weeks&#160;apart.&#160;The first&#160;treatment with&#160;Remsima&#160;administered&#160;subcutaneously&#160;should be&#160;<br/>initiated&#160;as&#160;maintenance&#160;therapy&#160;4&#160;weeks&#160;after&#160;the&#160;second intravenous&#160;administration. The&#160;<br/>recommended&#160;maintenance&#160;dose&#160;for&#160;Remsima&#160;subcutaneous&#160;formulation is&#160;120&#160;mg once&#160;every 2&#160;<br/>weeks.&#160;&#160;<br/>&#160;<br/>Remsima&#160;must&#160;be&#160;given&#160;concomitantly with&#160;methotrexate.&#160;&#160;<br/>&#160;<br/>Available&#160;data&#160;suggest&#160;that&#160;the&#160;clinical&#160;response&#160;is&#160;usually&#160;achieved within&#160;12&#160;weeks&#160;of&#160;treatment.&#160;<br/>Continued&#160;therapy&#160;should be&#160;carefully reconsidered&#160;in&#160;patients&#160;who show&#160;no evidence&#160;of&#160;therapeutic&#160;<br/>benefit&#160;within&#160;the&#160;first&#160;12&#160;weeks of&#160;treatment&#160;(see&#160;section&#160;5.1).&#160;&#160;<br/>&#160;<br/><i>Moderately&#160;to&#160;severely active Crohn’s disease&#160;<br/></i>Treatment&#160;with&#160;Remsima&#160;administered&#160;subcutaneously&#160;should be&#160;initiated&#160;as&#160;maintenance therapy&#160;4&#160;<br/>weeks&#160;after&#160;the&#160;last&#160;administration&#160;of&#160;two&#160;intravenous&#160;infusions&#160;of&#160;infliximab&#160;5&#160;mg/kg given&#160;2 weeks&#160;<br/>apart. The&#160;recommended&#160;dose&#160;for&#160;Remsima&#160;subcutaneous&#160;formulation&#160;is&#160;120&#160;mg&#160;once&#160;every&#160;2 weeks.&#160;<br/>If&#160;a patient&#160;does not&#160;respond&#160;after&#160;2&#160;doses&#160;of&#160;intravenous&#160;infusions,&#160;no additional&#160;treatment&#160;with&#160;<br/>infliximab should be&#160;given.&#160;Available&#160;data&#160;do not&#160;support&#160;further&#160;infliximab&#160;treatment, in patients&#160;not&#160;<br/>responding&#160;within 6&#160;weeks&#160;of&#160;the&#160;initial infusion.&#160;<br/>&#160;<br/><i>Fistulising, active&#160;Crohn’s&#160;disease&#160;<br/></i>Remsima&#160;120&#160;mg given as&#160;a&#160;subcutaneous&#160;injection 4&#160;weeks&#160;after&#160;the&#160;last&#160;administration&#160;of&#160;two&#160;<br/>intravenous&#160;infusions&#160;of&#160;infliximab&#160;5&#160;mg/kg given&#160;2 weeks&#160;apart. The&#160;recommended dose&#160;for&#160;<br/>Remsima&#160;subcutaneous&#160;formulation&#160;is&#160;120&#160;mg once&#160;every 2 weeks. If&#160;a&#160;patient&#160;does&#160;not&#160;respond&#160;after&#160;<br/>6&#160;doses&#160;(i.e. 2&#160;intravenous&#160;infusions&#160;and 4&#160;subcutaneous&#160;injections), no&#160;additional treatment&#160;with&#160;<br/>infliximab should be&#160;given.&#160;<br/>&#160;<br/>In Crohn’s&#160;disease, experience&#160;with re-administration&#160;if&#160;signs and&#160;symptoms of&#160;disease recur&#160;is&#160;limited&#160;<br/>and comparative&#160;data&#160;on&#160;the&#160;benefit/risk of&#160;the&#160;alternative&#160;strategies&#160;for&#160;continued&#160;treatment&#160;are&#160;<br/>lacking.&#160;<br/>&#160;<br/><i>Ulcerative colitis&#160;<br/></i>Treatment&#160;with&#160;Remsima&#160;administered&#160;subcutaneously&#160;should&#160;be&#160;initiated&#160;as maintenance&#160;therapy&#160;4&#160;<br/>weeks&#160;after&#160;the&#160;last&#160;administration&#160;of&#160;two intravenous&#160;infusions&#160;of&#160;infliximab&#160;5&#160;mg/kg given&#160;2&#160;weeks&#160;<br/>apart. The&#160;recommended&#160;dose&#160;for&#160;Remsima&#160;subcutaneous&#160;formulation&#160;is&#160;120&#160;mg&#160;once&#160;every&#160;2 weeks.&#160;&#160;<br/>&#160;<br/>Available&#160;data&#160;suggest&#160;that&#160;the&#160;clinical&#160;response&#160;is&#160;usually&#160;achieved within&#160;14&#160;weeks&#160;of&#160;treatment, i.e.&#160;<br/>2 intravenous&#160;infusions&#160;and&#160;4 subcutaneous&#160;injections&#160;(see&#160;section 5.1).&#160;Continued therapy should&#160;be&#160;<br/>carefully&#160;reconsidered&#160;in patients&#160;who show&#160;no evidence&#160;of&#160;therapeutic&#160;benefit&#160;within this&#160;time&#160;period.&#160;<br/>&#160;<br/><i>Ankylosing spondylitis&#160;<br/></i>Treatment&#160;with&#160;Remsima&#160;administered&#160;subcutaneously&#160;should be&#160;initiated as&#160;maintenance therapy&#160;4&#160;<br/>weeks after&#160;the&#160;last&#160;administration&#160;of&#160;two&#160;intravenous&#160;infusions&#160;of&#160;infliximab 5&#160;mg/kg given&#160;2 weeks&#160;<br/>apart.&#160;The&#160;recommended&#160;dose&#160;for&#160;Remsima&#160;subcutaneous&#160;formulation&#160;is&#160;120&#160;mg&#160;once every&#160;2&#160;weeks.&#160;<br/>If&#160;a&#160;patient&#160;does&#160;not&#160;respond by 6 weeks&#160;(i.e.&#160;after&#160;2 intravenous&#160;infusions), no&#160;additional&#160;treatment&#160;<br/>with infliximab should&#160;be&#160;given.&#160;<br/>&#160;<br/><i>Psoriatic&#160;arthritis&#160;</i></p>
</div>
<!-- Page 42 -->
<a name="42"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page42-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft420">42&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4210">Treatment&#160;with&#160;Remsima&#160;administered&#160;subcutaneously&#160;should&#160;be&#160;initiated&#160;as maintenance&#160;therapy&#160;4&#160;<br/>weeks after&#160;the&#160;last&#160;administration&#160;of&#160;two intravenous&#160;infusions&#160;of&#160;infliximab&#160;5&#160;mg/kg given&#160;2 weeks&#160;<br/>apart.&#160;The&#160;recommended&#160;dose&#160;for&#160;Remsima&#160;subcutaneous&#160;formulation&#160;is&#160;120&#160;mg&#160;once every&#160;2&#160;weeks.&#160;<br/><i>&#160;<br/>Psoriasis&#160;<br/></i>Treatment&#160;with&#160;Remsima&#160;administered&#160;subcutaneously&#160;should&#160;be&#160;initiated&#160;as maintenance&#160;therapy 4&#160;<br/>weeks after&#160;the&#160;last&#160;administration&#160;of&#160;two&#160;intravenous&#160;infusions&#160;of&#160;infliximab 5&#160;mg/kg given&#160;2 weeks&#160;<br/>apart.&#160;The&#160;recommended&#160;dose&#160;for&#160;Remsima&#160;subcutaneous&#160;formulation&#160;is&#160;120&#160;mg&#160;once every&#160;2&#160;weeks.&#160;<br/>If&#160;a&#160;patient&#160;shows&#160;no&#160;response&#160;after&#160;14&#160;weeks (i.e.&#160;2&#160;intravenous&#160;infusions&#160;and 5&#160;subcutaneous&#160;<br/>injections), no additional&#160;treatment&#160;with&#160;infliximab&#160;should be&#160;given.<i>&#160;<br/></i>&#160;<br/><i>Re-administration for&#160;Crohn’s disease&#160;and&#160;rheumatoid arthritis&#160;<br/></i>From&#160;experience&#160;with intravenous&#160;infliximab, if&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;disease recur,&#160;infliximab&#160;<br/>can&#160;be re-administered&#160;within&#160;16&#160;weeks&#160;following&#160;the&#160;last&#160;administration.&#160;In&#160;clinical studies&#160;with&#160;<br/>intravenous&#160;infliximab, delayed hypersensitivity&#160;reactions&#160;have&#160;been uncommon&#160;and have&#160;occurred&#160;<br/>after&#160;infliximab-free intervals&#160;of&#160;less than&#160;1&#160;year&#160;(see&#160;sections&#160;4.4 and 4.8). The&#160;safety and efficacy of&#160;<br/>re-administration&#160;after&#160;an&#160;infliximab-free&#160;interval&#160;of&#160;more&#160;than 16&#160;weeks&#160;has not&#160;been&#160;established.&#160;<br/>This&#160;applies&#160;to both Crohn’s&#160;disease&#160;patients&#160;and&#160;rheumatoid&#160;arthritis&#160;patients.&#160;<br/>&#160;<br/><i>Re-administration for&#160;ulcerative&#160;colitis&#160;<br/></i>From&#160;experience&#160;with intravenous&#160;infliximab, the&#160;safety and efficacy of&#160;re-administration, other&#160;than&#160;<br/>every&#160;8&#160;weeks,&#160;has not&#160;been&#160;established&#160;(see&#160;sections&#160;4.4&#160;and&#160;4.8).&#160;<br/>&#160;<br/><i>Re-administration for&#160;ankylosing&#160;spondylitis&#160;<br/></i>From&#160;experience&#160;with intravenous&#160;infliximab, the&#160;safety and efficacy of&#160;re-administration, other&#160;than&#160;<br/>every&#160;6 to&#160;8 weeks, has&#160;not&#160;been established (see&#160;sections&#160;4.4 and 4.8).&#160;<br/>&#160;<br/><i>Re-administration for&#160;psoriatic&#160;arthritis&#160;<br/></i>From&#160;experience&#160;with&#160;intravenous&#160;infliximab, the&#160;safety and efficacy of&#160;re-administration, other&#160;than&#160;<br/>every&#160;8&#160;weeks,&#160;has not&#160;been&#160;established&#160;(see&#160;sections&#160;4.4&#160;and&#160;4.8).&#160;<br/>&#160;<br/><i>Re-administration for&#160;psoriasis&#160;<br/></i>Limited&#160;experience from&#160;re-treatment&#160;with&#160;one&#160;single&#160;intravenous&#160;infliximab dose&#160;in psoriasis&#160;after&#160;an&#160;<br/>interval&#160;of&#160;20 weeks&#160;suggests&#160;reduced efficacy and a&#160;higher&#160;incidence&#160;of&#160;mild to&#160;moderate&#160;infusion&#160;<br/>reactions&#160;when compared&#160;to the&#160;initial&#160;induction&#160;regimen (see&#160;section&#160;5.1).&#160;<br/>&#160;<br/>Limited&#160;experience from&#160;re-treatment&#160;of&#160;intravenous&#160;infliximab following&#160;disease&#160;flare by&#160;a&#160;<br/>re-induction&#160;regimen suggests&#160;a&#160;higher&#160;incidence&#160;of&#160;infusion&#160;reactions, including&#160;serious&#160;ones, when&#160;<br/>compared&#160;to 8-weekly maintenance&#160;treatment&#160;of&#160;intravenous&#160;infliximab&#160;(see&#160;section&#160;4.8).&#160;<br/><i>&#160;<br/>Re-administration across&#160;indications&#160;<br/></i>In&#160;case&#160;maintenance therapy&#160;is&#160;interrupted,&#160;and&#160;there is&#160;a need&#160;to&#160;restart&#160;treatment,&#160;use of&#160;a&#160;<br/>re-induction&#160;regimen of&#160;intravenous&#160;infliximab is&#160;not&#160;recommended&#160;(see&#160;section 4.8). In this&#160;situation,&#160;<br/>infliximab should be&#160;re-initiated&#160;as&#160;a single dose of&#160;intravenous&#160;infliximab&#160;followed by the&#160;<br/>maintenance dose recommendations&#160;of&#160;subcutaneous&#160;infliximab&#160;described above&#160;given 4 weeks&#160;after&#160;<br/>the&#160;last&#160;administration&#160;of&#160;intravenous&#160;infliximab.&#160;<br/>&#160;<br/><i>Switching&#160;to and from&#160;Remsima subcutaneous&#160;formulation&#160;across&#160;indications&#160;<br/></i>When&#160;switching from&#160;the&#160;maintenance&#160;therapy of&#160;infliximab&#160;intravenous&#160;formulation to the&#160;<br/>subcutaneous&#160;formulation&#160;of&#160;Remsima,&#160;the&#160;subcutaneous&#160;formulation&#160;may be&#160;administered&#160;8&#160;weeks&#160;<br/>after&#160;the&#160;last&#160;administration&#160;of&#160;the&#160;intravenous&#160;infusions&#160;of&#160;infliximab.&#160;&#160;<br/>&#160;<br/>There&#160;is&#160;insufficient&#160;information&#160;regarding&#160;the switching&#160;of&#160;patients&#160;who received&#160;the&#160;intravenous&#160;<br/>infusions&#160;of&#160;infliximab&#160;higher&#160;than&#160;3 mg/kg&#160;for&#160;rheumatoid arthritis&#160;or&#160;5 mg/kg&#160;for&#160;Crohn’s&#160;disease&#160;<br/>every&#160;8&#160;weeks to&#160;the subcutaneous&#160;formulation&#160;of&#160;Remsima.&#160;<br/>&#160;</p>
</div>
<!-- Page 43 -->
<a name="43"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4331{font-size:17px;font-family:TimesNewRomanPSMT;color:#00b050;}
	.ft4332{font-size:17px;font-family:TimesNewRomanPSMT;color:#008000;}
-->
</style>
<div id="page43-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft430">43&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4311">Information&#160;regarding switching&#160;patients&#160;from&#160;the&#160;subcutaneous&#160;formulation to&#160;the&#160;intravenous&#160;<br/>formulation of&#160;Remsima&#160;is not&#160;available.&#160;&#160;<br/>&#160;<br/><i>Missed dose&#160;<br/>&#160;<br/></i>If&#160;patients&#160;miss&#160;an&#160;injection&#160;of&#160;Remsima&#160;subcutaneous&#160;formulation,&#160;they should be&#160;instructed to&#160;take&#160;<br/>the&#160;missed&#160;dose&#160;immediately&#160;in&#160;case&#160;this happens within&#160;7&#160;days&#160;from&#160;the&#160;missed&#160;dose,&#160;and&#160;then&#160;remain&#160;<br/>on&#160;their&#160;original&#160;dosing&#160;schedule.&#160;If&#160;the&#160;dose&#160;is&#160;delayed&#160;by 8 days&#160;or&#160;more,&#160;the&#160;patients&#160;should be&#160;<br/>instructed&#160;to&#160;skip the&#160;missed dose, wait&#160;until&#160;their&#160;next&#160;scheduled dose, and&#160;then remain on&#160;their&#160;<br/>original&#160;dosing&#160;schedule.&#160;<br/>&#160;<br/>Special&#160;populations&#160;<br/>&#160;<br/><i>Elderly&#160;&#160;<br/>&#160;<br/></i>Specific&#160;studies&#160;of&#160;infliximab in&#160;elderly patients&#160;have&#160;not&#160;been conducted. No&#160;major&#160;age-related&#160;<br/>differences&#160;in clearance&#160;or&#160;volume&#160;of&#160;distribution were&#160;observed&#160;in clinical&#160;studies&#160;with&#160;infliximab&#160;<br/>intravenous&#160;formulations&#160;and&#160;the&#160;same&#160;is&#160;expected for&#160;subcutaneous&#160;formulation.&#160;No&#160;dose&#160;adjustment&#160;<br/>is&#160;required (see&#160;section&#160;5.2). For&#160;more&#160;information about&#160;the&#160;safety of&#160;infliximab in elderly patients&#160;<br/>(see&#160;sections&#160;4.4&#160;and 4.8).&#160;&#160;<br/>&#160;<br/><i>Renal&#160;and/or&#160;hepatic&#160;impairment&#160;<br/>&#160;<br/></i>Infliximab has&#160;not&#160;been studied&#160;in&#160;these&#160;patient&#160;populations. No dose&#160;recommendations&#160;can be&#160;made&#160;<br/>(see&#160;section&#160;5.2).&#160;&#160;<br/>&#160;<br/><i>Paediatric&#160;population&#160;<br/>&#160;<br/></i>The&#160;safety and&#160;efficacy&#160;of&#160;Remsima subcutaneous&#160;therapy&#160;in children aged&#160;below&#160;18 years&#160;of&#160;age&#160;have&#160;<br/>not&#160;yet&#160;been&#160;established.&#160;No&#160;data are available.&#160;Therefore,&#160;subcutaneous use of&#160;Remsima is&#160;<br/>recommended&#160;for&#160;use only&#160;in&#160;adults.&#160;<br/>&#160;<br/>Method&#160;of&#160;administration&#160;&#160;<br/>&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled syringe&#160;or&#160;in pre-filled&#160;pen&#160;are&#160;administered by&#160;<br/>subcutaneous&#160;injection&#160;only. Full&#160;instructions&#160;for&#160;use&#160;are&#160;provided in&#160;the&#160;package&#160;leaflet.&#160;For&#160;the&#160;two&#160;<br/>initial&#160;intravenous&#160;infusions,&#160;patients&#160;may&#160;be pre-treated&#160;with,&#160;e.g.,&#160;an antihistamine, hydrocortisone&#160;<br/>and/or&#160;paracetamol&#160;and&#160;infusion rate&#160;may be&#160;slowed&#160;in order&#160;to decrease&#160;the&#160;risk&#160;of&#160;infusion-related&#160;<br/>reactions&#160;especially&#160;if&#160;infusion-related&#160;reactions have occurred&#160;previously&#160;(see section&#160;4.4).&#160;The&#160;<br/>physician should&#160;ensure&#160;appropriate&#160;follow-up&#160;of&#160;patients&#160;for&#160;any&#160;systemic injection&#160;reaction&#160;and&#160;<br/>localised&#160;injection&#160;site reaction&#160;after&#160;the&#160;initial&#160;subcutaneous&#160;injection&#160;is&#160;administered.&#160;&#160;<br/>&#160;<br/><b>4.3&#160;</b></p>
<p style="position:absolute;top:886px;left:149px;white-space:nowrap" class="ft431"><b>Contraindications&#160;</b></p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft4310">&#160;<br/>Hypersensitivity to&#160;the&#160;active&#160;substance,&#160;to other&#160;murine&#160;proteins&#160;or&#160;to&#160;any&#160;of&#160;the excipients listed&#160;in&#160;<br/>section 6.1.&#160;&#160;<br/>&#160;<br/>Patients&#160;with&#160;tuberculosis&#160;or&#160;other&#160;severe infections&#160;such&#160;as sepsis,&#160;abscesses and&#160;opportunistic&#160;<br/>infections&#160;(see&#160;section&#160;4.4).&#160;&#160;<br/>&#160;<br/>Patients with&#160;moderate or&#160;severe heart&#160;failure&#160;(NYHA&#160;class III/IV)&#160;(see&#160;sections&#160;4.4 and 4.8).&#160;<br/>&#160;</p>
</div>
<!-- Page 44 -->
<a name="44"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page44-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft440">44&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft441"><b>4.4&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft441"><b>Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft4410"><b>&#160;<br/></b>Traceability&#160;<br/>&#160;<br/>In&#160;order&#160;to&#160;improve&#160;the&#160;traceability of&#160;biological&#160;medicinal&#160;products,&#160;the&#160;tradename&#160;and&#160;the&#160;batch&#160;<br/>number&#160;of&#160;the&#160;administered&#160;product&#160;should be&#160;clearly recorded.&#160;<br/>&#160;<br/>Systemic&#160;injection&#160;reaction/&#160;localised&#160;injection&#160;site&#160;reaction/ hypersensitivity&#160;<br/>&#160;<br/>Infliximab has&#160;been associated with&#160;systemic&#160;injection&#160;reactions,&#160;anaphylactic shock&#160;and delayed&#160;<br/>hypersensitivity reactions&#160;(see&#160;section 4.8).&#160;<br/>&#160;<br/>Acute&#160;reactions&#160;including anaphylactic&#160;reactions&#160;may&#160;develop during (within seconds)&#160;or&#160;within&#160;a&#160;few&#160;<br/>hours&#160;following administration of&#160;infliximab. If&#160;acute&#160;reactions&#160;occur,&#160;medical&#160;treatment&#160;should be&#160;<br/>sought&#160;immediately.&#160;For&#160;this&#160;reason, the&#160;initial&#160;intravenous&#160;administrations&#160;should take&#160;place&#160;where&#160;<br/>emergency&#160;equipment,&#160;such&#160;as adrenaline,&#160;antihistamines,&#160;corticosteroids&#160;and&#160;an&#160;artificial&#160;airway&#160;is&#160;<br/>immediately&#160;available.&#160;Patients&#160;may&#160;be pre-treated with e.g., an antihistamine, hydrocortisone&#160;and/or&#160;<br/>paracetamol&#160;to&#160;prevent&#160;mild&#160;and&#160;transient&#160;effects.&#160;&#160;<br/>&#160;<br/>Localised&#160;injection&#160;site reactions&#160;predominantly&#160;of&#160;mild to&#160;moderate&#160;in nature&#160;included the&#160;following&#160;<br/>reactions&#160;limited&#160;to&#160;injection&#160;site:&#160;erythema, pain, pruritus,&#160;swelling,&#160;induration, bruising,&#160;haematoma,&#160;<br/>oedema, coldness,&#160;paraesthesia, haemorrhage,&#160;irritation, rash,&#160;ulcer,&#160;urticaria,&#160;application&#160;site&#160;vesicles&#160;<br/>and&#160;scab&#160;were reported&#160;to&#160;be associated&#160;with&#160;infliximab&#160;subcutaneous&#160;treatment.&#160;Most&#160;of&#160;these&#160;<br/>reactions&#160;may occur&#160;immediately or&#160;within&#160;24 hours&#160;after&#160;subcutaneous&#160;injection.&#160;Most&#160;of&#160;these&#160;<br/>reactions&#160;resolved&#160;spontaneously&#160;without&#160;any treatment.&#160;<br/>&#160;<br/>Antibodies&#160;to&#160;infliximab may develop&#160;and have&#160;been&#160;associated with an increased&#160;frequency of&#160;<br/>infusion&#160;reactions&#160;when&#160;administered&#160;by&#160;intravenous&#160;infusion.&#160;A&#160;low&#160;proportion&#160;of&#160;the&#160;infusion&#160;<br/>reactions&#160;was serious allergic reactions.&#160;An&#160;association&#160;between&#160;development&#160;of&#160;antibodies to&#160;<br/>infliximab and reduced duration of&#160;response&#160;has&#160;also&#160;been&#160;observed&#160;with&#160;intravenously&#160;administered&#160;<br/>infliximab. Concomitant&#160;administration of&#160;immunomodulators&#160;has&#160;been associated&#160;with&#160;lower&#160;<br/>incidence&#160;of&#160;antibodies&#160;to infliximab and&#160;in&#160;the&#160;case&#160;of&#160;intravenously&#160;administered&#160;infliximab,&#160;a&#160;<br/>reduction in the&#160;frequency&#160;of&#160;infusion&#160;reactions. The&#160;effect&#160;of&#160;concomitant&#160;immunomodulator&#160;therapy&#160;<br/>was&#160;more&#160;profound&#160;in episodically-treated&#160;patients than&#160;in&#160;patients&#160;given&#160;maintenance&#160;therapy.&#160;<br/>Patients&#160;who discontinue&#160;immunosuppressants&#160;prior&#160;to or&#160;during&#160;infliximab&#160;treatment are&#160;at greater&#160;<br/>risk&#160;of&#160;developing&#160;these&#160;antibodies. Antibodies&#160;to infliximab cannot&#160;always be detected&#160;in&#160;serum&#160;<br/>samples.&#160;If&#160;serious&#160;reactions occur,&#160;symptomatic&#160;treatment&#160;must&#160;be given&#160;and further&#160;infliximab&#160;must&#160;<br/>not&#160;be&#160;administered&#160;(see&#160;section 4.8).&#160;<br/>&#160;<br/>In&#160;clinical&#160;studies,&#160;delayed&#160;hypersensitivity&#160;reactions have been&#160;reported.&#160;Available data suggest&#160;an&#160;<br/>increased&#160;risk&#160;for&#160;delayed hypersensitivity with&#160;increasing infliximab&#160;free&#160;interval.&#160;Patients&#160;should&#160;be&#160;<br/>advised&#160;to&#160;seek&#160;immediate&#160;medical&#160;advice if&#160;they&#160;experience any&#160;delayed&#160;adverse&#160;reaction&#160;(see&#160;section&#160;<br/>4.8). If&#160;patients&#160;are&#160;re-treated after&#160;a&#160;prolonged period,&#160;they&#160;must&#160;be&#160;closely&#160;monitored for&#160;signs&#160;and&#160;<br/>symptoms&#160;of&#160;delayed hypersensitivity.&#160;<br/>&#160;<br/>Infections&#160;<br/>&#160;<br/>Patients&#160;must&#160;be&#160;monitored&#160;closely&#160;for&#160;infections&#160;including&#160;tuberculosis&#160;before, during&#160;and after&#160;<br/>treatment&#160;with&#160;infliximab.&#160;Because&#160;the&#160;elimination&#160;of&#160;infliximab&#160;may&#160;take&#160;up&#160;to six months,&#160;<br/>monitoring should be&#160;continued throughout&#160;this&#160;period. Further&#160;treatment&#160;with&#160;infliximab&#160;must&#160;not&#160;be&#160;<br/>given&#160;if&#160;a&#160;patient&#160;develops&#160;a&#160;serious&#160;infection or&#160;sepsis.&#160;<br/>&#160;<br/>Caution should&#160;be&#160;exercised when considering&#160;the&#160;use&#160;of&#160;infliximab in&#160;patients&#160;with chronic&#160;infection&#160;<br/>or&#160;a&#160;history&#160;of&#160;recurrent&#160;infections,&#160;including&#160;concomitant&#160;immunosuppressive&#160;therapy. Patients&#160;<br/>should be&#160;advised of&#160;and avoid exposure&#160;to potential&#160;risk factors&#160;for&#160;infection&#160;as&#160;appropriate.&#160;<br/>&#160;</p>
</div>
<!-- Page 45 -->
<a name="45"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4533{font-size:17px;line-height:24px;font-family:GHWNTB+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page45-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft450">45&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft452">Tumour&#160;necrosis&#160;factor&#160;alpha&#160;(T</p>
<p style="position:absolute;top:83px;left:320px;white-space:nowrap" class="ft4518">NFα)&#160;mediates&#160;inflammation&#160;and&#160;modulates&#160;cellular&#160;immune&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft4510">responses. Experimental&#160;data&#160;show&#160;that&#160;TNFα&#160;is&#160;essential&#160;for&#160;the&#160;clearing of&#160;intracellular&#160;infections.&#160;<br/>Clinical&#160;experience shows that&#160;host&#160;defence&#160;against&#160;infection&#160;is compromised&#160;in&#160;some patients&#160;treated&#160;<br/>with&#160;infliximab.&#160;<br/>&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft4510">It&#160;should be&#160;noted that&#160;suppression&#160;of&#160;TNFα&#160;may&#160;mask&#160;symptoms&#160;of&#160;infection such&#160;as&#160;fever. Early&#160;<br/>recognition&#160;of&#160;atypical&#160;clinical&#160;presentations of&#160;serious&#160;infections&#160;and&#160;of&#160;typical&#160;clinical&#160;presentation&#160;<br/>of&#160;rare&#160;and&#160;unusual&#160;infections&#160;is&#160;critical&#160;in&#160;order&#160;to&#160;minimise&#160;delays&#160;in&#160;diagnosis&#160;and&#160;treatment.&#160;&#160;<br/>&#160;<br/>Patients taking&#160;TNF-blockers&#160;are more&#160;susceptible&#160;to&#160;serious infections.&#160;<br/>&#160;<br/>Tuberculosis, bacterial&#160;infections,&#160;including sepsis&#160;and&#160;pneumonia, invasive&#160;fungal, viral, and&#160;other&#160;<br/>opportunistic&#160;infections&#160;have&#160;been&#160;observed&#160;in&#160;patients&#160;treated with infliximab. Some&#160;of&#160;these&#160;<br/>infections&#160;have&#160;been fatal;&#160;the&#160;most&#160;frequently reported&#160;opportunistic&#160;infections&#160;with&#160;a&#160;mortality&#160;rate&#160;<br/>of&#160;&gt;5%&#160;include&#160;pneumocystosis, candidiasis, listeriosis&#160;and aspergillosis.&#160;<br/>&#160;<br/>Patients&#160;who develop a&#160;new&#160;infection while&#160;undergoing&#160;treatment&#160;with&#160;infliximab,&#160;should be&#160;<br/>monitored closely&#160;and undergo&#160;a&#160;complete&#160;diagnostic&#160;evaluation. Administration of&#160;infliximab should&#160;<br/>be&#160;discontinued if&#160;a&#160;patient&#160;develops&#160;a&#160;new&#160;serious&#160;infection&#160;or&#160;sepsis,&#160;and appropriate&#160;antimicrobial&#160;<br/>or&#160;antifungal&#160;therapy should&#160;be&#160;initiated until&#160;the&#160;infection is&#160;controlled.&#160;<br/>&#160;<br/><i>Tuberculosis&#160;<br/>&#160;<br/></i>There&#160;have&#160;been reports&#160;of&#160;active&#160;tuberculosis&#160;in&#160;patients&#160;receiving infliximab.&#160;It&#160;should&#160;be&#160;noted&#160;that&#160;<br/>in the&#160;majority of&#160;these&#160;reports&#160;tuberculosis&#160;was&#160;extrapulmonary, presenting as&#160;either&#160;local&#160;or&#160;<br/>disseminated&#160;disease.&#160;&#160;<br/>&#160;<br/>Before&#160;starting&#160;treatment with&#160;infliximab,&#160;all&#160;patients&#160;must&#160;be&#160;evaluated for&#160;both&#160;active&#160;and&#160;inactive&#160;<br/>(‘latent’)&#160;tuberculosis. This&#160;evaluation&#160;should include&#160;a&#160;detailed&#160;medical&#160;history with personal&#160;history&#160;<br/>of&#160;tuberculosis&#160;or&#160;possible&#160;previous&#160;contact&#160;with tuberculosis&#160;and previous&#160;and/or&#160;current&#160;<br/>immunosuppressive&#160;therapy. Appropriate&#160;screening&#160;tests,&#160;(e.g.&#160;tuberculin skin&#160;test, chest&#160;X-ray, and/or&#160;<br/>Interferon&#160;Gamma Release&#160;Assay),&#160;should&#160;be performed&#160;in&#160;all&#160;patients&#160;(local&#160;recommendations&#160;may&#160;<br/>apply). It&#160;is&#160;recommended that&#160;the&#160;conduct&#160;of&#160;these&#160;tests should&#160;be&#160;recorded&#160;in&#160;the&#160;patient&#160;reminder&#160;<br/>card.&#160;Prescribers&#160;are&#160;reminded&#160;of&#160;the&#160;risk&#160;of&#160;false negative tuberculin&#160;skin&#160;test&#160;results,&#160;especially&#160;in&#160;<br/>patients&#160;who&#160;are&#160;severely ill&#160;or&#160;immunocompromised.&#160;<br/>&#160;<br/>If&#160;active&#160;tuberculosis&#160;is&#160;diagnosed,&#160;infliximab therapy&#160;must&#160;not&#160;be&#160;initiated (see&#160;section 4.3).&#160;<br/>&#160;<br/>If&#160;latent&#160;tuberculosis&#160;is&#160;suspected, a&#160;physician with expertise&#160;in&#160;the&#160;treatment&#160;of&#160;tuberculosis&#160;should be&#160;<br/>consulted. In all&#160;situations&#160;described below, the&#160;benefit/risk balance&#160;of&#160;infliximab&#160;therapy should&#160;be&#160;<br/>very&#160;carefully&#160;considered.&#160;<br/>&#160;<br/>If&#160;inactive&#160;(‘latent’)&#160;tuberculosis is diagnosed,&#160;treatment&#160;for&#160;latent&#160;tuberculosis&#160;must&#160;be started&#160;with&#160;<br/>antituberculosis&#160;therapy before&#160;the&#160;initiation of&#160;infliximab, and&#160;in accordance&#160;with&#160;local&#160;<br/>recommendations.&#160;<br/>&#160;<br/>In patients&#160;who have&#160;several&#160;or&#160;significant&#160;risk factors&#160;for&#160;tuberculosis&#160;and&#160;have&#160;a&#160;negative&#160;test&#160;for&#160;<br/>latent&#160;tuberculosis, antituberculosis&#160;therapy should be&#160;considered before&#160;the&#160;initiation of&#160;infliximab.&#160;<br/>&#160;<br/>Use&#160;of&#160;antituberculosis&#160;therapy should&#160;also be&#160;considered before&#160;the&#160;initiation of&#160;infliximab&#160;in&#160;patients&#160;<br/>with&#160;a&#160;past&#160;history&#160;of&#160;latent&#160;or&#160;active tuberculosis&#160;in&#160;whom&#160;an&#160;adequate course of&#160;treatment&#160;cannot&#160;be&#160;<br/>confirmed.&#160;<br/>&#160;<br/>Some&#160;cases of&#160;active tuberculosis have been&#160;reported&#160;in&#160;patients&#160;treated&#160;with&#160;infliximab during and&#160;<br/>after&#160;treatment&#160;for&#160;latent&#160;tuberculosis.&#160;<br/>&#160;</p>
</div>
<!-- Page 46 -->
<a name="46"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page46-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft460">46&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4610">All&#160;patients&#160;should&#160;be&#160;informed&#160;to seek&#160;medical&#160;advice&#160;if&#160;signs/symptoms&#160;suggestive&#160;of&#160;tuberculosis&#160;<br/>(e.g. persistent&#160;cough, wasting/weight&#160;loss, low-grade&#160;fever)&#160;appear&#160;during&#160;or&#160;after&#160;infliximab&#160;<br/>treatment.&#160;<br/>&#160;<br/><i>Invasive&#160;fungal&#160;infections&#160;<br/>&#160;<br/></i>In patients&#160;treated with&#160;infliximab, an&#160;invasive&#160;fungal&#160;infection such as&#160;aspergillosis, candidiasis,&#160;<br/>pneumocystosis, histoplasmosis, coccidioidomycosis&#160;or&#160;blastomycosis&#160;should&#160;be&#160;suspected&#160;if&#160;they&#160;<br/>develop&#160;a&#160;serious systemic&#160;illness,&#160;and&#160;a physician&#160;with&#160;expertise&#160;in&#160;the diagnosis&#160;and&#160;treatment&#160;of&#160;<br/>invasive&#160;fungal&#160;infections&#160;should be&#160;consulted&#160;at&#160;an early&#160;stage&#160;when&#160;investigating&#160;these patients.&#160;&#160;<br/>&#160;<br/>Invasive&#160;fungal&#160;infections&#160;may&#160;present&#160;as disseminated&#160;rather&#160;than&#160;localised&#160;disease,&#160;and&#160;antigen&#160;and&#160;<br/>antibody testing may&#160;be&#160;negative&#160;in&#160;some&#160;patients&#160;with&#160;active&#160;infection.&#160;Appropriate&#160;empiric&#160;<br/>antifungal&#160;therapy should be&#160;considered while&#160;a&#160;diagnostic&#160;workup is&#160;being performed&#160;taking&#160;into&#160;<br/>account&#160;both the&#160;risk&#160;for&#160;severe&#160;fungal&#160;infection and the&#160;risks&#160;of&#160;antifungal&#160;therapy.&#160;&#160;<br/>&#160;<br/>For&#160;patients&#160;who have&#160;resided in or&#160;travelled&#160;to&#160;regions&#160;where&#160;invasive&#160;fungal&#160;infections&#160;such as&#160;<br/>histoplasmosis,&#160;coccidioidomycosis, or&#160;blastomycosis&#160;are&#160;endemic, the&#160;benefits&#160;and risks&#160;of&#160;infliximab&#160;<br/>treatment&#160;should&#160;be&#160;carefully considered before&#160;initiation of&#160;infliximab&#160;therapy.&#160;<br/>&#160;<br/><i>Fistulising&#160;Crohn’s&#160;disease&#160;<br/></i>Patients&#160;with fistulising Crohn’s&#160;disease&#160;with&#160;acute&#160;suppurative&#160;fistulas&#160;must not&#160;initiate&#160;infliximab&#160;<br/>therapy&#160;until&#160;a source&#160;for&#160;possible&#160;infection,&#160;specifically&#160;abscess,&#160;has been&#160;excluded&#160;(see section&#160;4.3).&#160;<br/>&#160;<br/>Hepatitis B&#160;(HBV)&#160;reactivation&#160;<br/>&#160;<br/>Reactivation of&#160;hepatitis&#160;B&#160;has&#160;occurred&#160;in patients&#160;receiving&#160;a TNF-antagonist&#160;including&#160;infliximab,&#160;<br/>who&#160;are&#160;chronic&#160;carriers of&#160;this virus.&#160;Some cases&#160;have&#160;had&#160;fatal&#160;outcome.&#160;<br/>&#160;<br/>Patients should&#160;be tested&#160;for&#160;HBV&#160;infection&#160;before&#160;initiating&#160;treatment&#160;with&#160;infliximab.&#160;For&#160;patients&#160;<br/>who&#160;test positive&#160;for&#160;HBV&#160;infection, consultation with&#160;a&#160;physician with&#160;expertise&#160;in the&#160;treatment&#160;of&#160;<br/>hepatitis B&#160;is&#160;recommended.&#160;Carriers of&#160;HBV&#160;who&#160;require&#160;treatment&#160;with&#160;infliximab&#160;should&#160;be&#160;closely&#160;<br/>monitored&#160;for&#160;signs&#160;and symptoms&#160;of&#160;active&#160;HBV&#160;infection throughout&#160;therapy and&#160;for&#160;several&#160;months&#160;<br/>following termination of&#160;therapy. Adequate&#160;data&#160;of&#160;treating patients&#160;who are&#160;carriers&#160;of&#160;HBV&#160;with&#160;<br/>antiviral&#160;therapy in conjunction with&#160;TNF-antagonist&#160;therapy&#160;to prevent&#160;HBV&#160;reactivation are&#160;not&#160;<br/>available.&#160;In&#160;patients who&#160;develop&#160;HBV&#160;reactivation,&#160;infliximab&#160;should be&#160;stopped and effective&#160;<br/>antiviral&#160;therapy&#160;with&#160;appropriate&#160;supportive&#160;treatment&#160;should&#160;be&#160;initiated.&#160;<br/>&#160;<br/>Hepatobiliary events&#160;<br/>&#160;<br/>Cases of&#160;jaundice&#160;and&#160;non-infectious hepatitis,&#160;some with&#160;features of&#160;autoimmune&#160;hepatitis,&#160;have been&#160;<br/>observed&#160;in the&#160;post-marketing&#160;experience of&#160;infliximab.&#160;Isolated&#160;cases of&#160;liver&#160;failure&#160;resulting&#160;in&#160;<br/>liver&#160;transplantation&#160;or&#160;death have&#160;occurred. Patients&#160;with&#160;symptoms&#160;or&#160;signs&#160;of&#160;liver&#160;dysfunction&#160;<br/>should&#160;be&#160;evaluated&#160;for&#160;evidence&#160;of&#160;liver&#160;injury.&#160;If&#160;</p>
<p style="position:absolute;top:899px;left:443px;white-space:nowrap" class="ft4618">jaundice&#160;and/or&#160;ALT&#160;elevations&#160;≥5&#160;times&#160;the&#160;upper&#160;</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft4610">limit&#160;of&#160;normal&#160;develop(s),&#160;infliximab&#160;should be&#160;discontinued, and a&#160;thorough&#160;investigation of&#160;the&#160;<br/>abnormality should be&#160;undertaken.&#160;<br/>&#160;<br/>Concurrent&#160;administration&#160;of&#160;TNF-alpha&#160;inhibitor&#160;and&#160;anakinra&#160;<br/>&#160;<br/>Serious infections&#160;and&#160;neutropenia&#160;were&#160;seen&#160;in clinical&#160;studies&#160;with concurrent&#160;use&#160;of&#160;anakinra&#160;and&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft4619">another&#160;TNFα-blocking agent, etanercept, with&#160;no added clinical&#160;benefit&#160;compared&#160;to etanercept&#160;alone.&#160;<br/>Because of&#160;the&#160;nature&#160;of&#160;the adverse&#160;reactions seen&#160;with&#160;combination of&#160;etanercept&#160;and&#160;anakinra&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft4610">therapy,&#160;similar&#160;toxicities&#160;may&#160;also result&#160;from&#160;the&#160;combination of&#160;anakinra&#160;and&#160;other&#160;TNFα-blocking&#160;<br/>agents. Therefore, the&#160;combination of&#160;infliximab&#160;and anakinra&#160;is&#160;not&#160;recommended.&#160;<br/>&#160;<br/>Concurrent&#160;administration&#160;of&#160;TNF-alpha&#160;inhibitor&#160;and&#160;abatacept&#160;<br/>&#160;</p>
</div>
<!-- Page 47 -->
<a name="47"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page47-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft470">47&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4711">In&#160;clinical studies&#160;concurrent administration&#160;of&#160;TNF-antagonists&#160;and&#160;abatacept&#160;has been&#160;associated&#160;<br/>with an increased risk of&#160;infections&#160;including serious&#160;infections&#160;compared to TNF-antagonists&#160;alone,&#160;<br/>without&#160;increased clinical&#160;benefit. The&#160;combination of&#160;infliximab&#160;and&#160;abatacept&#160;is&#160;not&#160;recommended.&#160;<br/>&#160;<br/>Concurrent administration&#160;with&#160;other&#160;biological&#160;therapeutics&#160;<br/>&#160;<br/>There&#160;is&#160;insufficient information&#160;regarding&#160;the&#160;concomitant use&#160;of&#160;infliximab&#160;with&#160;other&#160;biological&#160;<br/>therapeutics&#160;used&#160;to&#160;treat&#160;the&#160;same&#160;conditions as&#160;infliximab.&#160;The&#160;concomitant use&#160;of&#160;infliximab&#160;with&#160;<br/>these&#160;biologics&#160;is&#160;not&#160;recommended because&#160;of&#160;the&#160;possibility of&#160;an&#160;increased&#160;risk&#160;of&#160;infection, and&#160;<br/>other&#160;potential pharmacological interactions.&#160;<br/>&#160;<br/>Switching&#160;between&#160;biological DMARDs&#160;<br/>&#160;<br/>Care&#160;should be&#160;taken and&#160;patients&#160;should&#160;continue&#160;to&#160;be&#160;monitored when&#160;switching from&#160;one&#160;biologic&#160;<br/>to another, since&#160;overlapping biological&#160;activity&#160;may&#160;further&#160;increase&#160;the&#160;risk&#160;for&#160;adverse&#160;reactions,&#160;<br/>including infection.&#160;<br/>&#160;<br/>Vaccinations&#160;<br/>&#160;<br/>It&#160;is recommended&#160;that&#160;patients,&#160;if&#160;possible, be&#160;brought&#160;up to date&#160;with all&#160;vaccinations&#160;in agreement&#160;<br/>with&#160;current vaccination&#160;guidelines&#160;prior&#160;to&#160;initiating&#160;Remsima&#160;therapy.&#160;Patients&#160;on&#160;infliximab&#160;may&#160;<br/>receive concurrent&#160;vaccinations,&#160;except&#160;for&#160;live&#160;vaccines&#160;(see sections&#160;4.5 and&#160;4.6).&#160;<br/>&#160;<br/>In a&#160;subset&#160;of&#160;90 adult&#160;patients&#160;with&#160;rheumatoid arthritis&#160;from&#160;the&#160;ASPIRE&#160;study a&#160;similar&#160;proportion&#160;<br/>of&#160;patients&#160;in&#160;each treatment&#160;group (methotrexate&#160;plus:&#160;placebo&#160;[n&#160;=&#160;17], 3&#160;mg/kg [n&#160;=&#160;27]&#160;or&#160;6&#160;mg/kg&#160;<br/>infliximab&#160;[n&#160;=&#160;46])&#160;mounted an effective&#160;two-fold&#160;increase&#160;in titers&#160;to a&#160;polyvalent&#160;pneumococcal&#160;<br/>vaccine,&#160;indicating&#160;that infliximab&#160;did&#160;not interfere&#160;with&#160;T-cell&#160;independent&#160;humoral&#160;immune&#160;<br/>responses. However, studies&#160;from&#160;the&#160;published literature&#160;in various&#160;indications&#160;(e.g. rheumatoid&#160;<br/>arthritis, psoriasis, Crohn’s&#160;disease)&#160;suggest&#160;that&#160;non-live&#160;vaccinations&#160;received during&#160;treatment&#160;with&#160;<br/>anti-TNF&#160;therapies,&#160;including infliximab&#160;may elicit&#160;a&#160;lower&#160;immune&#160;response&#160;than in patients&#160;not&#160;<br/>receiving anti-TNF therapy.&#160;<br/>&#160;<br/>Live vaccines/therapeutic infectious&#160;agents&#160;<br/>&#160;<br/>In patients&#160;receiving anti-TNF&#160;therapy,&#160;limited&#160;data&#160;are&#160;available&#160;on&#160;the&#160;response&#160;to vaccination with&#160;<br/>live vaccines or&#160;on&#160;the&#160;secondary&#160;transmission&#160;of&#160;infection&#160;by&#160;live&#160;vaccines.&#160;Use of&#160;live vaccines can&#160;<br/>result in&#160;clinical infections,&#160;including disseminated&#160;infections. The&#160;concurrent&#160;administration of&#160;live&#160;<br/>vaccines&#160;with&#160;infliximab&#160;is&#160;not&#160;recommended.&#160;<br/>&#160;<br/>Infant&#160;exposure<i>&#160;in&#160;utero</i>&#160;<br/>&#160;<br/>In&#160;infants&#160;exposed&#160;<i>in utero</i>&#160;to&#160;infliximab,&#160;fatal&#160;outcome&#160;due&#160;to&#160;disseminated&#160;Bacillus&#160;Calmette-Guérin&#160;<br/>(BCG)&#160;infection has&#160;been reported&#160;following administration of&#160;BCG&#160;vaccine&#160;after&#160;birth.&#160;A&#160;twelve&#160;<br/>month waiting period following birth is&#160;recommended&#160;before&#160;the&#160;administration of&#160;live&#160;vaccines to&#160;<br/>infants&#160;exposed&#160;<i>in utero&#160;</i>to&#160;infliximab.&#160;If&#160;infant&#160;infliximab serum&#160;levels&#160;are&#160;undetectable&#160;or&#160;infliximab&#160;<br/>administration&#160;was&#160;limited&#160;to&#160;the&#160;first&#160;trimester&#160;of&#160;pregnancy,&#160;administration&#160;of&#160;a&#160;live&#160;vaccine&#160;might&#160;be&#160;<br/>considered&#160;at&#160;an&#160;earlier&#160;timepoint if&#160;there&#160;is&#160;a&#160;clear&#160;clinical benefit&#160;for&#160;the&#160;individual infant&#160;(see&#160;<br/>section 4.6).&#160;<br/>&#160;<br/>Infant&#160;exposure&#160;via&#160;breast&#160;milk&#160;<br/>Administration&#160;of&#160;a&#160;live&#160;vaccine&#160;to&#160;a&#160;breastfed&#160;infant while&#160;the&#160;mother&#160;is&#160;receiving&#160;infliximab&#160;is&#160;not&#160;<br/>recommended&#160;unless infant&#160;infliximab&#160;serum&#160;levels&#160;are&#160;undetectable&#160;(see section&#160;4.6).&#160;<br/>&#160;<br/>Therapeutic infectious&#160;agents&#160;<br/>&#160;<br/>Other&#160;uses&#160;of&#160;therapeutic&#160;infectious agents such&#160;as&#160;live&#160;attenuated&#160;bacteria&#160;(e.g.,&#160;BCG&#160;bladder&#160;<br/>instillation&#160;for&#160;the&#160;treatment&#160;of&#160;cancer)&#160;could&#160;result&#160;in&#160;clinical infections, including disseminated&#160;</p>
</div>
<!-- Page 48 -->
<a name="48"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page48-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft480">48&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4810">infections. It&#160;is&#160;recommended that&#160;therapeutic&#160;infectious&#160;agents&#160;not&#160;be&#160;given&#160;concurrently with&#160;<br/>infliximab.&#160;<br/>&#160;<br/>Autoimmune&#160;processes&#160;<br/>&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft4810">The&#160;relative&#160;deficiency of&#160;TNFα&#160;caused&#160;by anti-TNF&#160;therapy&#160;may result&#160;in the&#160;initiation of&#160;an&#160;<br/>autoimmune&#160;process. If&#160;a&#160;patient&#160;develops&#160;symptoms&#160;suggestive&#160;of&#160;a&#160;lupus-like&#160;syndrome&#160;following&#160;<br/>treatment with&#160;infliximab&#160;and&#160;is&#160;positive&#160;for&#160;antibodies&#160;against&#160;double-stranded DNA, further&#160;<br/>treatment with&#160;infliximab&#160;must&#160;not&#160;be&#160;given (see&#160;section 4.8).&#160;<br/>&#160;<br/>Neurological&#160;events&#160;<br/>&#160;<br/>Use&#160;of&#160;TNF-blocking agents, including&#160;infliximab,&#160;has&#160;been associated with&#160;cases&#160;of&#160;new&#160;onset&#160;or&#160;<br/>exacerbation of&#160;clinical&#160;symptoms&#160;and/or&#160;radiographic evidence of&#160;central&#160;nervous system&#160;<br/>demyelinating disorders, including&#160;multiple&#160;sclerosis,&#160;and peripheral&#160;demyelinating disorders,&#160;<br/>including Guillain-Barré&#160;syndrome. In patients&#160;with pre-existing&#160;or&#160;recent&#160;onset&#160;of&#160;demyelinating&#160;<br/>disorders, the&#160;benefits&#160;and risks&#160;of&#160;anti-TNF&#160;treatment&#160;should be&#160;carefully&#160;considered before&#160;initiation&#160;<br/>of&#160;infliximab&#160;therapy.&#160;Discontinuation of&#160;infliximab&#160;should be&#160;considered if&#160;these&#160;disorders&#160;develop.&#160;&#160;<br/>&#160;<br/>Malignancies&#160;and lymphoproliferative&#160;disorders&#160;<br/>&#160;<br/>In the&#160;controlled&#160;portions&#160;of&#160;clinical studies&#160;of&#160;TNF-blocking&#160;agents,&#160;more&#160;cases&#160;of&#160;malignancies&#160;<br/>including lymphoma&#160;have&#160;been observed among patients&#160;receiving a&#160;TNF&#160;blocker&#160;compared with&#160;<br/>control&#160;patients.&#160;During&#160;clinical&#160;studies&#160;of&#160;infliximab across&#160;all&#160;approved indications the incidence&#160;of&#160;<br/>lymphoma&#160;in&#160;infliximab-treated&#160;patients&#160;was&#160;higher&#160;than expected in&#160;the&#160;general&#160;population, but&#160;the&#160;<br/>occurrence of&#160;lymphoma was rare.&#160;In&#160;the post-marketing setting, cases&#160;of&#160;leukaemia&#160;have&#160;been&#160;<br/>reported&#160;in&#160;patients&#160;treated&#160;with&#160;a&#160;TNF-antagonist. There&#160;is&#160;an&#160;increased background risk for&#160;<br/>lymphoma&#160;and leukaemia&#160;in rheumatoid arthritis&#160;patients&#160;with&#160;long-standing, highly active,&#160;<br/>inflammatory&#160;disease,&#160;which&#160;complicates&#160;risk&#160;estimation.&#160;&#160;<br/>&#160;<br/>In an exploratory clinical&#160;study evaluating the&#160;use&#160;of&#160;infliximab&#160;in&#160;patients&#160;with&#160;moderate&#160;to&#160;severe&#160;<br/>chronic obstructive pulmonary&#160;disease&#160;(COPD),&#160;more&#160;malignancies were&#160;reported&#160;in&#160;infliximab-<br/>treated patients&#160;compared&#160;with control&#160;patients.&#160;All&#160;patients&#160;had&#160;a&#160;history of&#160;heavy smoking. Caution&#160;<br/>should be&#160;exercised in&#160;considering treatment&#160;of&#160;patients&#160;with&#160;increased risk for&#160;malignancy due&#160;to&#160;<br/>heavy smoking.&#160;<br/>&#160;<br/>With the&#160;current&#160;knowledge, a&#160;risk&#160;for&#160;the&#160;development&#160;of&#160;lymphomas&#160;or&#160;other&#160;malignancies&#160;in&#160;<br/>patients treated&#160;with&#160;a TNF-blocking agent&#160;cannot&#160;be&#160;excluded (see&#160;section 4.8). Caution should&#160;be&#160;<br/>exercised when&#160;considering&#160;TNF-blocking therapy for&#160;patients&#160;with a&#160;history of&#160;malignancy or&#160;when&#160;<br/>considering&#160;continuing&#160;treatment&#160;in patients&#160;who develop a&#160;malignancy.&#160;<br/>&#160;<br/>Caution should&#160;also be&#160;exercised in&#160;patients&#160;with&#160;psoriasis&#160;and a&#160;medical&#160;history of&#160;extensive&#160;<br/>immunosuppressant&#160;therapy or&#160;prolonged PUVA&#160;treatment.&#160;<br/>&#160;<br/>Although subcutaneous&#160;administration&#160;is&#160;not&#160;indicated for&#160;children under&#160;age&#160;of&#160;18 years,&#160;it&#160;should be&#160;<br/>noted that&#160;malignancies,&#160;some fatal,&#160;have&#160;been&#160;reported among children, adolescents&#160;and young adults&#160;<br/>(up to 22 years&#160;of&#160;age)&#160;treated with TNF-</p>
<p style="position:absolute;top:956px;left:379px;white-space:nowrap" class="ft4818">blocking&#160;agents&#160;(initiation&#160;of&#160;therapy&#160;≤18&#160;years&#160;of&#160;age),&#160;</p>
<p style="position:absolute;top:981px;left:106px;white-space:nowrap" class="ft4810">including infliximab in the&#160;post-marketing setting. Approximately half&#160;the&#160;cases&#160;were&#160;lymphomas.&#160;<br/>The other&#160;cases represented&#160;a variety&#160;of&#160;different&#160;malignancies&#160;and&#160;included&#160;rare&#160;malignancies&#160;usually&#160;<br/>associated&#160;with&#160;immunosuppression.&#160;A&#160;risk&#160;for&#160;the development&#160;of&#160;malignancies&#160;in&#160;patients&#160;treated&#160;<br/>with&#160;TNF-blockers&#160;cannot&#160;be&#160;excluded.&#160;<br/>&#160;<br/>Post-marketing&#160;cases&#160;of&#160;hepatosplenic T-cell&#160;lymphoma&#160;(HSTCL)&#160;have&#160;been reported in&#160;patients&#160;<br/>treated&#160;with&#160;TNF-blocking&#160;agents&#160;including infliximab. This&#160;rare&#160;type&#160;of&#160;T-cell&#160;lymphoma has a&#160;very&#160;<br/>aggressive&#160;disease&#160;course and&#160;is usually&#160;fatal.&#160;Almost&#160;all&#160;patients had&#160;received&#160;treatment with&#160;AZA&#160;or&#160;<br/>6-MP&#160;concomitantly with or&#160;immediately&#160;prior&#160;to a&#160;TNF-blocker. The&#160;vast&#160;majority of&#160;infliximab&#160;<br/>cases have occurred&#160;in&#160;patients with&#160;Crohn’s disease&#160;or&#160;ulcerative&#160;colitis&#160;and&#160;most&#160;were&#160;reported&#160;in&#160;</p>
</div>
<!-- Page 49 -->
<a name="49"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page49-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft490">49&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft4910">adolescent&#160;or&#160;young adult&#160;males.&#160;The&#160;potential&#160;risk&#160;with&#160;the&#160;combination&#160;of&#160;AZA&#160;or&#160;6-MP&#160;and&#160;<br/>infliximab should be&#160;carefully&#160;considered. A&#160;risk for&#160;the&#160;development&#160;for&#160;hepatosplenic&#160;T-cell&#160;<br/>lymphoma&#160;in patients&#160;treated with&#160;infliximab&#160;cannot&#160;be&#160;excluded&#160;(see&#160;section 4.8).&#160;<br/>&#160;<br/>Melanoma and&#160;Merkel&#160;cell&#160;carcinoma have been&#160;reported&#160;in&#160;patients treated&#160;with&#160;TNF&#160;blocker&#160;<br/>therapy,&#160;including&#160;infliximab (see&#160;section&#160;4.8).&#160;Periodic&#160;skin examination is&#160;recommended,&#160;<br/>particularly&#160;for&#160;patients with&#160;risk&#160;factors&#160;for&#160;skin&#160;cancer.&#160;<br/>&#160;<br/>A&#160;population-based&#160;retrospective&#160;cohort&#160;study&#160;using&#160;data&#160;from&#160;Swedish national&#160;health registries&#160;<br/>found&#160;an&#160;increased&#160;incidence of&#160;cervical&#160;cancer&#160;in&#160;women&#160;with&#160;rheumatoid&#160;arthritis&#160;treated&#160;with&#160;<br/>infliximab compared to biologics-naïve&#160;patients&#160;or&#160;the&#160;general&#160;population,&#160;including those&#160;over&#160;60&#160;<br/>years&#160;of&#160;age. Periodic&#160;screening should continue&#160;in women&#160;treated with&#160;infliximab, including those&#160;<br/>over&#160;60&#160;years of&#160;age.&#160;<br/>&#160;<br/>All&#160;patients with&#160;ulcerative&#160;colitis who&#160;are&#160;at&#160;increased&#160;risk&#160;for&#160;dysplasia or&#160;colon&#160;carcinoma&#160;(for&#160;<br/>example, patients&#160;with&#160;long-standing ulcerative&#160;colitis&#160;or&#160;primary sclerosing cholangitis), or&#160;who had&#160;a&#160;<br/>prior&#160;history of&#160;dysplasia&#160;or&#160;colon&#160;carcinoma&#160;should&#160;be&#160;screened&#160;for&#160;dysplasia&#160;at&#160;regular&#160;intervals&#160;<br/>before&#160;therapy and throughout&#160;their&#160;disease&#160;course. This&#160;evaluation&#160;should&#160;include&#160;colonoscopy and&#160;<br/>biopsies&#160;per&#160;local&#160;recommendations.&#160;Current&#160;data&#160;do&#160;not&#160;indicate&#160;that&#160;infliximab&#160;treatment&#160;influences&#160;<br/>the&#160;risk for&#160;developing dysplasia&#160;or&#160;colon&#160;cancer.&#160;<br/>&#160;<br/>Since&#160;the&#160;possibility&#160;of&#160;increased&#160;risk&#160;of&#160;cancer&#160;development&#160;in&#160;patients with newly diagnosed&#160;<br/>dysplasia&#160;treated with infliximab is&#160;not&#160;established,&#160;the&#160;risk&#160;and benefits&#160;of&#160;continued therapy to&#160;the&#160;<br/>individual&#160;patients&#160;should&#160;be carefully&#160;considered&#160;by&#160;the clinician.&#160;<br/>&#160;<br/>Heart&#160;failure&#160;<br/>&#160;<br/>Infliximab&#160;should be&#160;used&#160;with caution&#160;in patients with&#160;mild&#160;heart&#160;failure (NYHA&#160;class I/II).&#160;Patients&#160;<br/>should be&#160;closely&#160;monitored and&#160;infliximab&#160;must&#160;not&#160;be&#160;continued&#160;in patients&#160;who&#160;develop new&#160;or&#160;<br/>worsening symptoms&#160;of&#160;heart&#160;failure&#160;(see&#160;sections&#160;4.3&#160;and 4.8).&#160;<br/>&#160;<br/>Haematologic reactions&#160;<br/>&#160;<br/>There have been&#160;reports&#160;of&#160;pancytopenia, leukopenia, neutropenia, and thrombocytopenia&#160;in&#160;patients&#160;<br/>receiving TNF-blockers, including&#160;infliximab. All&#160;patients&#160;should be&#160;advised to&#160;seek immediate&#160;<br/>medical&#160;attention&#160;if&#160;they&#160;develop&#160;signs&#160;and symptoms&#160;suggestive&#160;of&#160;blood dyscrasias (e.g.&#160;persistent&#160;<br/>fever, bruising,&#160;bleeding, pallor). Discontinuation of&#160;infliximab&#160;therapy&#160;should&#160;be&#160;considered in&#160;<br/>patients&#160;with&#160;confirmed&#160;significant haematologic&#160;abnormalities.&#160;<br/>&#160;<br/>Others&#160;<br/>&#160;<br/>There&#160;is&#160;limited&#160;safety&#160;experience&#160;of&#160;infliximab&#160;treatment&#160;in&#160;patients&#160;who have&#160;undergone&#160;surgical&#160;<br/>procedures,&#160;including arthroplasty. The&#160;long half-life&#160;of&#160;infliximab should&#160;be&#160;taken into consideration&#160;<br/>if&#160;a&#160;surgical&#160;procedure&#160;is&#160;planned. A&#160;patient&#160;who requires&#160;surgery while&#160;on&#160;infliximab&#160;should be&#160;<br/>closely monitored&#160;for&#160;infections,&#160;and appropriate&#160;actions&#160;should be&#160;taken.&#160;<br/>&#160;<br/>Failure&#160;to respond to&#160;treatment&#160;for&#160;Crohn’s&#160;disease&#160;may&#160;indicate&#160;the&#160;presence&#160;of&#160;a&#160;fixed&#160;fibrotic&#160;<br/>stricture that&#160;may&#160;require surgical&#160;treatment.&#160;There is&#160;no&#160;evidence to&#160;suggest&#160;that&#160;infliximab&#160;worsens&#160;<br/>or&#160;causes&#160;fibrotic strictures.&#160;<br/>&#160;<br/>Special&#160;populations&#160;<br/>&#160;<br/><i>Elderly&#160;<br/></i>&#160;<br/>The&#160;incidence&#160;of&#160;serious&#160;infections&#160;in infliximab-treated&#160;patients 65&#160;years&#160;and&#160;older&#160;was greater&#160;than&#160;<br/>in&#160;those&#160;under&#160;65&#160;years of&#160;age.&#160;Some of&#160;those had&#160;a&#160;fatal&#160;outcome.&#160;Particular&#160;attention regarding the&#160;<br/>risk&#160;for&#160;infection should be&#160;paid when treating the&#160;elderly (see&#160;section 4.8).&#160;</p>
</div>
<!-- Page 50 -->
<a name="50"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page50-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft500">50&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft5010">&#160;<br/>Sodium&#160;and&#160;sorbitol&#160;contents&#160;<br/>&#160;<br/>Remsima contains&#160;less&#160;than&#160;1 mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;dose,&#160;i.e.&#160;essentially ‘sodium-free’&#160;and&#160;45 mg&#160;<br/>sorbitol&#160;per&#160;1 mL&#160;(in each 120&#160;mg dose).&#160;&#160;<br/>&#160;<br/><b>4.5&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft501"><b>Interaction&#160;with&#160;other&#160;medicinal&#160;products and&#160;other forms&#160;of&#160;interaction</b>&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft5011">&#160;<br/>No interaction studies&#160;have&#160;been performed.&#160;&#160;<br/>&#160;<br/>In&#160;rheumatoid&#160;arthritis,&#160;psoriatic&#160;arthritis&#160;and Crohn's disease patients, there&#160;are&#160;indications&#160;that&#160;<br/>concomitant&#160;use&#160;of&#160;methotrexate&#160;and&#160;other&#160;immunomodulators&#160;reduces&#160;the&#160;formation of&#160;antibodies&#160;<br/>against&#160;infliximab&#160;and&#160;increases the plasma concentrations of&#160;infliximab.&#160;However,&#160;the results&#160;are&#160;<br/>uncertain due&#160;to&#160;limitations&#160;in the&#160;methods&#160;used&#160;for&#160;serum&#160;analyses&#160;of&#160;infliximab&#160;and antibodies&#160;<br/>against infliximab.&#160;<br/>&#160;<br/>Corticosteroids&#160;do not&#160;appear&#160;to affect&#160;the&#160;pharmacokinetics&#160;of&#160;infliximab&#160;to a&#160;clinically relevant&#160;<br/>extent.&#160;<br/>&#160;<br/>The&#160;combination of&#160;infliximab&#160;with&#160;other&#160;biological&#160;therapeutics used&#160;to&#160;treat&#160;the&#160;same conditions as&#160;<br/>infliximab,&#160;including anakinra&#160;and abatacept, is&#160;not&#160;recommended (see&#160;section 4.4).&#160;<br/>&#160;<br/>It&#160;is&#160;recommended that&#160;live&#160;vaccines&#160;not&#160;be&#160;given&#160;concurrently with&#160;Remsima.&#160;It&#160;is also&#160;recommended&#160;<br/>that&#160;live vaccines not&#160;be given&#160;to&#160;infants after&#160;<i>in&#160;utero</i>&#160;exposure&#160;to&#160;infliximab for&#160;12&#160;months&#160;following&#160;<br/>birth.&#160;If&#160;infant&#160;infliximab&#160;serum&#160;levels are undetectable&#160;or&#160;infliximab&#160;administration&#160;was limited&#160;to&#160;the&#160;<br/>first trimester&#160;of&#160;pregnancy,&#160;administration&#160;of&#160;a live vaccine&#160;might&#160;be&#160;considered&#160;at&#160;an&#160;earlier&#160;<br/>timepoint&#160;if&#160;there is&#160;a&#160;clear&#160;clinical&#160;benefit&#160;for&#160;the&#160;individual&#160;infant&#160;(see&#160;section&#160;4.4).&#160;<br/>&#160;<br/>Administration&#160;of&#160;a&#160;live&#160;vaccine&#160;to&#160;a&#160;breastfed&#160;infant&#160;while&#160;the&#160;mother&#160;is&#160;receiving&#160;infliximab is&#160;not&#160;<br/>recommended&#160;unless infant&#160;infliximab&#160;serum&#160;levels&#160;are&#160;undetectable (see&#160;sections&#160;4.4 and 4.6).&#160;<br/>&#160;<br/>It&#160;is recommended&#160;that&#160;therapeutic&#160;infectious agents not&#160;be given&#160;concurrently&#160;with&#160;infliximab&#160;(see&#160;<br/>section 4.4).&#160;<br/>&#160;<br/><b>4.6&#160;</b></p>
<p style="position:absolute;top:738px;left:149px;white-space:nowrap" class="ft501"><b>Fertility, pregnancy&#160;and&#160;lactation</b>&#160;</p>
<p style="position:absolute;top:757px;left:106px;white-space:nowrap" class="ft5010">&#160;<br/>Women of&#160;childbearing&#160;potential&#160;<br/>&#160;<br/>Women of&#160;childbearing&#160;potential&#160;should consider&#160;the&#160;use&#160;of&#160;adequate&#160;contraception to prevent&#160;<br/>pregnancy&#160;and&#160;continue&#160;its&#160;use for&#160;at&#160;least&#160;6&#160;months&#160;after&#160;the last&#160;infliximab&#160;treatment.&#160;&#160;<br/>&#160;<br/>Pregnancy&#160;<br/>&#160;<br/>The&#160;moderate&#160;number&#160;of&#160;prospectively&#160;collected pregnancies&#160;exposed to&#160;infliximab resulting&#160;in&#160;live&#160;<br/>birth with known outcomes, including approximately&#160;1,100 exposed during&#160;the&#160;first&#160;trimester,&#160;does&#160;not&#160;<br/>indicate&#160;an&#160;increase in&#160;the rate&#160;of&#160;malformation&#160;in&#160;the newborn.&#160;&#160;<br/>&#160;<br/>Based on&#160;an observational&#160;study&#160;from&#160;Northern Europe, an increased risk&#160;(OR, 95%&#160;CI;&#160;p-value)&#160;for&#160;<br/>C-section (1.50, 1.14-1.96;&#160;p =&#160;0.0032), preterm&#160;birth&#160;(1.48, 1.05-2.09;&#160;p&#160;=&#160;0.024),&#160;small&#160;for&#160;<br/>gestational&#160;age&#160;(2.79, 1.54-5.04;&#160;p&#160;=&#160;0.0007),&#160;and low&#160;birth weight&#160;(2.03, 1.41-2.94;&#160;p =&#160;0.0002)&#160;was&#160;<br/>observed&#160;in women exposed during pregnancy&#160;to&#160;infliximab (with&#160;or&#160;without&#160;<br/>immunomodulators/corticosteroids, 270&#160;pregnancies)&#160;as&#160;compared&#160;to women exposed to&#160;<br/>immunomodulators&#160;and/or&#160;corticosteroids&#160;only (6,460&#160;pregnancies).&#160;The&#160;potential&#160;contribution&#160;of&#160;<br/>exposure&#160;to infliximab and/or&#160;the&#160;severity of&#160;the&#160;underlying disease&#160;in&#160;these&#160;outcomes&#160;remains&#160;<br/>unclear.&#160;&#160;<br/>&#160;</p>
</div>
<!-- Page 51 -->
<a name="51"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page51-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft510">51&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft5133">Due&#160;to&#160;its&#160;inhibition of&#160;TNFα, infliximab&#160;administered&#160;during pregnancy could&#160;affect&#160;normal&#160;immune&#160;<br/>responses&#160;in&#160;the&#160;newborn. In a&#160;developmental&#160;toxicity&#160;study&#160;conducted in&#160;mice&#160;using an analogous&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft5110">antibody&#160;that&#160;selectively&#160;inhibits&#160;the&#160;functional&#160;activity of&#160;mouse&#160;TNFα, there&#160;was&#160;no indication of&#160;<br/>maternal toxicity,&#160;embryotoxicity&#160;or&#160;teratogenicity&#160;(see&#160;section&#160;5.3).&#160;&#160;<br/>&#160;<br/>The&#160;available&#160;clinical&#160;experience&#160;is&#160;limited. Infliximab&#160;should only be&#160;used during&#160;pregnancy&#160;if&#160;<br/>clearly needed.&#160;<br/>&#160;<br/>Infliximab&#160;crosses&#160;the&#160;placenta&#160;and&#160;has been&#160;detected&#160;in&#160;the serum&#160;of&#160;infants up&#160;to&#160;12&#160;months&#160;<br/>following birth. After&#160;<i>in&#160;utero</i>&#160;exposure&#160;to&#160;infliximab,&#160;infants&#160;may&#160;be&#160;at increased&#160;risk&#160;of&#160;infection,&#160;<br/>including&#160;serious&#160;disseminated infection that&#160;can&#160;become&#160;fatal.&#160;Administration of&#160;live&#160;vaccines&#160;(e.g.,&#160;<br/>BCG&#160;vaccine)&#160;to infants&#160;exposed to infliximab&#160;<i>in&#160;utero</i>&#160;is not&#160;recommended&#160;for&#160;12&#160;months&#160;after&#160;birth&#160;<br/>(see&#160;sections&#160;4.4&#160;and 4.5).&#160;If&#160;infant&#160;infliximab&#160;serum&#160;levels are&#160;undetectable or&#160;infliximab&#160;<br/>administration&#160;was&#160;limited&#160;to&#160;the&#160;first trimester&#160;of&#160;pregnancy, administration&#160;of&#160;a&#160;live&#160;vaccine&#160;might&#160;be&#160;<br/>considered&#160;at&#160;an&#160;earlier&#160;timepoint&#160;if&#160;there is&#160;a&#160;clear&#160;clinical&#160;benefit&#160;for&#160;the&#160;individual infant.&#160;Cases of&#160;<br/>agranulocytosis have also&#160;been&#160;reported&#160;(see section&#160;4.8).&#160;&#160;<br/>&#160;<br/>Breast-feeding&#160;<br/>&#160;<br/>Limited&#160;data&#160;from published&#160;literature&#160;indicate&#160;infliximab&#160;has been&#160;detected&#160;at&#160;low&#160;levels&#160;in human&#160;<br/>milk&#160;at&#160;concentrations&#160;up&#160;to&#160;5%&#160;of&#160;the maternal&#160;serum&#160;level.&#160;Infliximab has&#160;also been detected&#160;in&#160;<br/>infant&#160;serum&#160;after&#160;exposure&#160;to&#160;infliximab&#160;via breast&#160;milk.&#160;While&#160;systemic exposure&#160;in&#160;a breastfed&#160;<br/>infant&#160;is expected&#160;to&#160;be low&#160;because&#160;infliximab&#160;is&#160;largely degraded in the&#160;gastrointestinal&#160;tract,&#160;the&#160;<br/>administration&#160;of&#160;live&#160;vaccines&#160;to a&#160;breastfed&#160;infant&#160;when the&#160;mother&#160;is&#160;receiving&#160;infliximab is&#160;not&#160;<br/>recommended&#160;unless infant&#160;infliximab&#160;serum&#160;levels&#160;are&#160;undetectable.&#160;Infliximab could be&#160;considered&#160;<br/>for&#160;use&#160;during breast-feeding.&#160;<br/>&#160;<br/>Fertility&#160;<br/>There&#160;are&#160;insufficient&#160;preclinical&#160;data&#160;to&#160;draw&#160;conclusions on&#160;the&#160;effects of&#160;infliximab&#160;on&#160;fertility&#160;and&#160;<br/>general&#160;reproductive&#160;function (see&#160;section 5.3).&#160;<br/>&#160;<br/><b>4.7&#160;</b></p>
<p style="position:absolute;top:677px;left:149px;white-space:nowrap" class="ft511"><b>Effects&#160;on&#160;ability&#160;to drive&#160;and&#160;use&#160;machines</b>&#160;</p>
<p style="position:absolute;top:696px;left:106px;white-space:nowrap" class="ft5110">&#160;<br/>Remsima&#160;may have&#160;a&#160;minor&#160;influence&#160;on the&#160;ability&#160;to drive&#160;and use&#160;machines.&#160;Dizziness may&#160;occur&#160;<br/>following&#160;administration&#160;of&#160;infliximab&#160;(see&#160;section&#160;4.8).&#160;&#160;<br/>&#160;<br/><b>4.8&#160;</b></p>
<p style="position:absolute;top:772px;left:149px;white-space:nowrap" class="ft511"><b>Undesirable effects&#160;</b></p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft5110">&#160;<br/>Summary&#160;of&#160;the&#160;safety&#160;profile&#160;&#160;<br/>&#160;<br/>Upper&#160;respiratory&#160;tract&#160;infection&#160;was the&#160;most&#160;common&#160;adverse&#160;drug reaction (ADR)&#160;reported&#160;in&#160;<br/>clinical trials&#160;with&#160;infliximab, occurring&#160;in 25.3%&#160;of&#160;infliximab-treated&#160;patients&#160;compared&#160;with&#160;16.5%&#160;<br/>of&#160;control&#160;patients.&#160;The most&#160;serious ADRs associated&#160;with&#160;the use of&#160;TNF&#160;blockers that&#160;have&#160;been&#160;<br/>reported&#160;for&#160;infliximab&#160;include&#160;HBV&#160;reactivation,&#160;CHF&#160;(congestive&#160;heart&#160;failure),&#160;serious&#160;infections&#160;<br/>(including&#160;sepsis,&#160;opportunistic&#160;infections&#160;and TB),&#160;serum&#160;sickness&#160;(delayed hypersensitivity&#160;<br/>reactions), haematologic&#160;reactions,&#160;systemic&#160;lupus&#160;erythematosus/lupus-like&#160;syndrome, demyelinating&#160;<br/>disorders, hepatobiliary&#160;events,&#160;lymphoma, HSTCL,&#160;leukaemia,&#160;Merkel&#160;cell&#160;carcinoma,&#160;melanoma,&#160;<br/>sarcoidosis/sarcoid-like&#160;reaction,&#160;intestinal&#160;or&#160;perianal&#160;abscess&#160;(in&#160;Crohn’s disease)&#160;and&#160;serious&#160;<br/>infusion reactions&#160;(see&#160;section 4.4).&#160;<br/>&#160;<br/>The&#160;safety profile&#160;of&#160;Remsima&#160;subcutaneous&#160;formulation&#160;from&#160;active&#160;rheumatoid arthritis&#160;(evaluated&#160;<br/>in&#160;168&#160;and&#160;175&#160;patients&#160;for&#160;the&#160;subcutaneous&#160;infliximab&#160;group and the&#160;intravenous&#160;infliximab&#160;group,&#160;<br/>respectively),&#160;active Crohn’s disease&#160;(evaluated in&#160;59&#160;and&#160;38 patients&#160;for&#160;the&#160;subcutaneous&#160;infliximab&#160;<br/>group and&#160;the&#160;intravenous&#160;infliximab&#160;group,&#160;respectively)&#160;and&#160;active ulcerative colitis&#160;patients&#160;<br/>(evaluated&#160;in&#160;38&#160;and&#160;40&#160;patients&#160;for&#160;the&#160;subcutaneous&#160;infliximab&#160;group and&#160;the&#160;intravenous&#160;infliximab&#160;<br/>group, respectively)&#160;was&#160;overall&#160;similar&#160;to&#160;the&#160;safety profile&#160;of&#160;the&#160;intravenous&#160;formulation.&#160;&#160;<br/>&#160;</p>
</div>
<!-- Page 52 -->
<a name="52"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page52-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft520">52&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft5210">Tabulated&#160;list&#160;of&#160;adverse reactions&#160;&#160;<br/>&#160;<br/>Table&#160;1&#160;lists the ADRs&#160;based&#160;on&#160;experience from&#160;clinical&#160;studies&#160;as well&#160;as adverse reactions,&#160;some&#160;<br/>with&#160;fatal&#160;outcome, reported from&#160;post-marketing&#160;experience.&#160;Within&#160;the organ&#160;system&#160;classes,&#160;<br/>adverse&#160;reactions&#160;are&#160;listed under&#160;headings&#160;of&#160;frequency&#160;using&#160;the&#160;following categories:&#160;very&#160;common&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft5211">(≥&#160;1/10);&#160;common&#160;(≥&#160;1/100&#160;to &lt;&#160;1/10);&#160;uncommon (≥&#160;1/1,000 to&#160;&lt;&#160;1/100);&#160;rare&#160;(≥&#160;1/10,000 to&#160;<br/>&lt;&#160;1/1,000);&#160;very&#160;rare&#160;(&lt;&#160;1/10,000), not&#160;known&#160;(cannot&#160;be&#160;estimated from&#160;the&#160;available&#160;data).&#160;Within&#160;<br/>each&#160;frequency grouping, undesirable&#160;effects&#160;are&#160;presented&#160;in&#160;order&#160;of&#160;decreasing&#160;seriousness.&#160;<br/>&#160;</p>
<p style="position:absolute;top:260px;left:420px;white-space:nowrap" class="ft521"><b>Table&#160;1&#160;</b></p>
<p style="position:absolute;top:279px;left:138px;white-space:nowrap" class="ft521"><b>Adverse&#160;reactions&#160;in&#160;clinical&#160;studies and&#160;from&#160;post-marketing&#160;experience of&#160;intravenous&#160;</b></p>
<p style="position:absolute;top:298px;left:410px;white-space:nowrap" class="ft521"><b>infliximab&#160;</b><i>&#160;</i></p>
<p style="position:absolute;top:318px;left:128px;white-space:nowrap" class="ft523"><i>Infections&#160;and infestations&#160;</i></p>
<p style="position:absolute;top:339px;left:157px;white-space:nowrap" class="ft522">Very&#160;common:&#160;</p>
<p style="position:absolute;top:339px;left:317px;white-space:nowrap" class="ft522">Viral&#160;infection (e.g.&#160;influenza, herpes&#160;virus&#160;infection).&#160;</p>
<p style="position:absolute;top:361px;left:157px;white-space:nowrap" class="ft522">Common:&#160;</p>
<p style="position:absolute;top:361px;left:317px;white-space:nowrap" class="ft522">Bacterial&#160;infections (e.g.&#160;sepsis,&#160;cellulitis,&#160;abscess).&#160;&#160;</p>
<p style="position:absolute;top:385px;left:157px;white-space:nowrap" class="ft522">Uncommon:&#160;</p>
<p style="position:absolute;top:385px;left:317px;white-space:nowrap" class="ft522">Tuberculosis, fungal&#160;infections&#160;(e.g. candidiasis, onychomycosis).&#160;</p>
<p style="position:absolute;top:407px;left:157px;white-space:nowrap" class="ft522">Rare:&#160;</p>
<p style="position:absolute;top:407px;left:317px;white-space:nowrap" class="ft5211">Meningitis,&#160;opportunistic&#160;infections&#160;(such as&#160;invasive&#160;fungal&#160;infections&#160;<br/>[pneumocystosis, histoplasmosis,&#160;aspergillosis, coccidioidomycosis,&#160;<br/>cryptococcosis,&#160;blastomycosis],&#160;bacterial&#160;infections&#160;[atypical&#160;<br/>mycobacterial,&#160;listeriosis,&#160;salmonellosis],&#160;and&#160;viral&#160;infections&#160;<br/>[cytomegalovirus]),&#160;parasitic&#160;infections, hepatitis B&#160;reactivation.&#160;</p>
<p style="position:absolute;top:514px;left:157px;white-space:nowrap" class="ft522">Not&#160;known:&#160;</p>
<p style="position:absolute;top:514px;left:317px;white-space:nowrap" class="ft5211">Vaccine&#160;breakthrough infection (after&#160;<i>in utero&#160;</i>exposure&#160;to&#160;<br/>infliximab)*.&#160;</p>
<p style="position:absolute;top:553px;left:128px;white-space:nowrap" class="ft523"><i>Neoplasms&#160;benign, malignant&#160;and&#160;unspecified (including cysts&#160;and polyps)&#160;</i></p>
<p style="position:absolute;top:574px;left:157px;white-space:nowrap" class="ft522">Rare:&#160;</p>
<p style="position:absolute;top:574px;left:317px;white-space:nowrap" class="ft5210">Lymphoma,&#160;non-Hodgkin’s&#160;lymphoma,&#160;Hodgkin’s&#160;disease, leukaemia,&#160;<br/>melanoma,&#160;cervical&#160;cancer.&#160;</p>
<p style="position:absolute;top:612px;left:157px;white-space:nowrap" class="ft522">Not&#160;known:&#160;</p>
<p style="position:absolute;top:612px;left:317px;white-space:nowrap" class="ft5211">Hepatosplenic T-cell&#160;lymphoma&#160;(primarily in&#160;adolescents&#160;and young&#160;<br/>adult&#160;males with&#160;Crohn’s disease and&#160;ulcerative colitis),&#160;Merkel&#160;cell&#160;<br/>carcinoma, Kaposi’s&#160;sarcoma.&#160;</p>
<p style="position:absolute;top:677px;left:128px;white-space:nowrap" class="ft523"><i>Blood and lymphatic&#160;system&#160;disorders&#160;</i></p>
<p style="position:absolute;top:697px;left:157px;white-space:nowrap" class="ft522">Common:&#160;</p>
<p style="position:absolute;top:697px;left:317px;white-space:nowrap" class="ft522">Neutropenia, leukopenia,&#160;anaemia, lymphadenopathy.&#160;</p>
<p style="position:absolute;top:716px;left:157px;white-space:nowrap" class="ft522">Uncommon:&#160;</p>
<p style="position:absolute;top:716px;left:317px;white-space:nowrap" class="ft522">Thrombocytopenia, lymphopenia, lymphocytosis.&#160;&#160;</p>
<p style="position:absolute;top:737px;left:157px;white-space:nowrap" class="ft522">Rare:&#160;</p>
<p style="position:absolute;top:737px;left:317px;white-space:nowrap" class="ft5210">Agranulocytosis&#160;(including&#160;infants&#160;exposed&#160;<i>in utero&#160;</i>to&#160;infliximab),&#160;<br/>thrombotic&#160;thrombocytopenic&#160;purpura, pancytopenia,&#160;haemolytic&#160;<br/>anaemia, idiopathic&#160;thrombocytopenic&#160;purpura.&#160;</p>
<p style="position:absolute;top:794px;left:128px;white-space:nowrap" class="ft523"><i>Immune system&#160;disorders&#160;</i></p>
<p style="position:absolute;top:816px;left:157px;white-space:nowrap" class="ft522">Common:&#160;</p>
<p style="position:absolute;top:816px;left:317px;white-space:nowrap" class="ft522">Allergic&#160;respiratory&#160;symptom.&#160;</p>
<p style="position:absolute;top:836px;left:157px;white-space:nowrap" class="ft522">Uncommon:&#160;</p>
<p style="position:absolute;top:836px;left:317px;white-space:nowrap" class="ft5211">Anaphylactic&#160;reaction, lupus-like&#160;syndrome,&#160;serum&#160;sickness&#160;or&#160;serum&#160;<br/>sickness-like&#160;reaction.&#160;</p>
<p style="position:absolute;top:874px;left:157px;white-space:nowrap" class="ft522">Rare&#160;&#160;</p>
<p style="position:absolute;top:874px;left:317px;white-space:nowrap" class="ft522">Anaphylactic&#160;shock, vasculitis, sarcoid-like reaction&#160;</p>
<p style="position:absolute;top:896px;left:128px;white-space:nowrap" class="ft523"><i>Metabolism&#160;and nutrition disorders&#160;</i></p>
<p style="position:absolute;top:917px;left:157px;white-space:nowrap" class="ft522">Uncommon:&#160;</p>
<p style="position:absolute;top:917px;left:317px;white-space:nowrap" class="ft522">Dyslipidaemia.&#160;</p>
<p style="position:absolute;top:937px;left:128px;white-space:nowrap" class="ft523"><i>Psychiatric&#160;disorders&#160;</i></p>
<p style="position:absolute;top:959px;left:157px;white-space:nowrap" class="ft522">Common:&#160;</p>
<p style="position:absolute;top:959px;left:317px;white-space:nowrap" class="ft522">Depression,&#160;insomnia.&#160;</p>
<p style="position:absolute;top:978px;left:157px;white-space:nowrap" class="ft522">Uncommon:&#160;</p>
<p style="position:absolute;top:978px;left:317px;white-space:nowrap" class="ft522">Amnesia, agitation,&#160;confusion, somnolence, nervousness.&#160;</p>
<p style="position:absolute;top:997px;left:157px;white-space:nowrap" class="ft522">Rare:&#160;</p>
<p style="position:absolute;top:997px;left:317px;white-space:nowrap" class="ft522">Apathy.&#160;</p>
<p style="position:absolute;top:1025px;left:128px;white-space:nowrap" class="ft523"><i>Nervous&#160;system&#160;disorders&#160;</i></p>
<p style="position:absolute;top:1047px;left:157px;white-space:nowrap" class="ft522">Very&#160;common:&#160;</p>
<p style="position:absolute;top:1047px;left:317px;white-space:nowrap" class="ft522">Headache.&#160;</p>
<p style="position:absolute;top:1071px;left:157px;white-space:nowrap" class="ft522">Common:&#160;</p>
<p style="position:absolute;top:1071px;left:317px;white-space:nowrap" class="ft522">Vertigo,&#160;dizziness,&#160;hypoaesthesia,&#160;paraesthesia.&#160;</p>
<p style="position:absolute;top:1092px;left:157px;white-space:nowrap" class="ft522">Uncommon:&#160;</p>
<p style="position:absolute;top:1092px;left:317px;white-space:nowrap" class="ft522">Seizure, neuropathy.&#160;</p>
</div>
<!-- Page 53 -->
<a name="53"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page53-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft530">53&#160;</p>
<p style="position:absolute;top:89px;left:157px;white-space:nowrap" class="ft532">Rare:&#160;</p>
<p style="position:absolute;top:89px;left:317px;white-space:nowrap" class="ft5310">Transverse&#160;myelitis,&#160;central&#160;nervous system&#160;demyelinating disorders&#160;<br/>(multiple&#160;sclerosis-like&#160;disease&#160;and optic&#160;neuritis), peripheral&#160;<br/>demyelinating&#160;disorders (such&#160;as Guillain-Barré&#160;syndrome, chronic&#160;<br/>inflammatory demyelinating polyneuropathy and multifocal&#160;motor&#160;<br/>neuropathy).&#160;</p>
<p style="position:absolute;top:190px;left:157px;white-space:nowrap" class="ft532">Not&#160;known:&#160;</p>
<p style="position:absolute;top:190px;left:317px;white-space:nowrap" class="ft532">Cerebrovascular&#160;accidents in&#160;close&#160;temporal&#160;association&#160;with&#160;infusion.&#160;</p>
<p style="position:absolute;top:210px;left:128px;white-space:nowrap" class="ft533"><i>Eye disorders&#160;</i></p>
<p style="position:absolute;top:232px;left:157px;white-space:nowrap" class="ft532">Common&#160;</p>
<p style="position:absolute;top:232px;left:317px;white-space:nowrap" class="ft532">Conjunctivitis&#160;</p>
<p style="position:absolute;top:254px;left:157px;white-space:nowrap" class="ft532">Uncommon&#160;</p>
<p style="position:absolute;top:254px;left:317px;white-space:nowrap" class="ft532">Keratitis,&#160;periorbital&#160;oedema, hordeolum&#160;</p>
<p style="position:absolute;top:277px;left:157px;white-space:nowrap" class="ft532">Rare&#160;</p>
<p style="position:absolute;top:277px;left:317px;white-space:nowrap" class="ft532">Endophthalmitis&#160;</p>
<p style="position:absolute;top:299px;left:157px;white-space:nowrap" class="ft532">Not&#160;known&#160;</p>
<p style="position:absolute;top:299px;left:317px;white-space:nowrap" class="ft532">Transient&#160;visual&#160;loss&#160;occurring during or&#160;within&#160;2&#160;hours&#160;of&#160;infusion&#160;</p>
<p style="position:absolute;top:323px;left:128px;white-space:nowrap" class="ft533"><i>Cardiac disorders&#160;</i></p>
<p style="position:absolute;top:344px;left:157px;white-space:nowrap" class="ft532">Common&#160;&#160;</p>
<p style="position:absolute;top:344px;left:317px;white-space:nowrap" class="ft532">Tachycardia,&#160;palpitation&#160;</p>
<p style="position:absolute;top:365px;left:157px;white-space:nowrap" class="ft532">Uncommon&#160;</p>
<p style="position:absolute;top:365px;left:317px;white-space:nowrap" class="ft5311">Cardiac failure&#160;(new&#160;onset&#160;or&#160;worsening), arrhythmia, syncope,&#160;<br/>bradycardia&#160;</p>
<p style="position:absolute;top:403px;left:157px;white-space:nowrap" class="ft532">Rare&#160;</p>
<p style="position:absolute;top:403px;left:317px;white-space:nowrap" class="ft532">Cyanosis, pericardial&#160;effusion&#160;</p>
<p style="position:absolute;top:423px;left:157px;white-space:nowrap" class="ft532">Not&#160;known&#160;</p>
<p style="position:absolute;top:423px;left:317px;white-space:nowrap" class="ft532">Myocardial&#160;ischaemia/myocardial infarction&#160;</p>
<p style="position:absolute;top:465px;left:128px;white-space:nowrap" class="ft533"><i>Vascular disorders&#160;</i></p>
<p style="position:absolute;top:486px;left:157px;white-space:nowrap" class="ft532">Common&#160;</p>
<p style="position:absolute;top:486px;left:317px;white-space:nowrap" class="ft532">Hypotension, hypertension,&#160;ecchymosis,&#160;hot&#160;flush,&#160;flushing&#160;</p>
<p style="position:absolute;top:508px;left:157px;white-space:nowrap" class="ft532">Uncommon&#160;</p>
<p style="position:absolute;top:508px;left:317px;white-space:nowrap" class="ft532">Peripheral ischaemia,&#160;thrombophlebitis,&#160;haematoma&#160;</p>
<p style="position:absolute;top:535px;left:157px;white-space:nowrap" class="ft532">Rare&#160;</p>
<p style="position:absolute;top:535px;left:317px;white-space:nowrap" class="ft532">Circulatory&#160;failure,&#160;petechia,&#160;vasospasm&#160;</p>
<p style="position:absolute;top:560px;left:128px;white-space:nowrap" class="ft533"><i>Respiratory, thoracic&#160;and mediastinal&#160;disorders&#160;</i></p>
<p style="position:absolute;top:584px;left:157px;white-space:nowrap" class="ft532">Very common&#160;</p>
<p style="position:absolute;top:584px;left:317px;white-space:nowrap" class="ft532">Upper&#160;respiratory tract&#160;infection,&#160;sinusitis&#160;</p>
<p style="position:absolute;top:607px;left:157px;white-space:nowrap" class="ft532">Common&#160;</p>
<p style="position:absolute;top:607px;left:317px;white-space:nowrap" class="ft5311">Lower&#160;respiratory tract&#160;infection (e.g. bronchitis,&#160;pneumonia),&#160;<br/>dyspnoea, epistaxis&#160;</p>
<p style="position:absolute;top:647px;left:157px;white-space:nowrap" class="ft532">Uncommon&#160;</p>
<p style="position:absolute;top:647px;left:317px;white-space:nowrap" class="ft532">Pulmonary oedema, bronchospasm,&#160;pleurisy,&#160;pleural&#160;effusion&#160;</p>
<p style="position:absolute;top:669px;left:157px;white-space:nowrap" class="ft532">Rare&#160;</p>
<p style="position:absolute;top:669px;left:317px;white-space:nowrap" class="ft5310">Interstitial&#160;lung disease&#160;(including&#160;rapidly&#160;progressive&#160;disease, lung&#160;<br/>fibrosis&#160;and pneumonitis)&#160;</p>
<p style="position:absolute;top:710px;left:128px;white-space:nowrap" class="ft533"><i>Gastrointestinal disorders&#160;</i></p>
<p style="position:absolute;top:732px;left:157px;white-space:nowrap" class="ft532">Very&#160;common:&#160;&#160;</p>
<p style="position:absolute;top:732px;left:317px;white-space:nowrap" class="ft532">Abdominal&#160;pain, nausea&#160;</p>
<p style="position:absolute;top:755px;left:157px;white-space:nowrap" class="ft532">Common:&#160;&#160;</p>
<p style="position:absolute;top:755px;left:317px;white-space:nowrap" class="ft5311">Gastrointestinal&#160;haemorrhage, diarrhoea,&#160;dyspepsia, gastroesophageal&#160;<br/>reflux, constipation&#160;</p>
<p style="position:absolute;top:793px;left:157px;white-space:nowrap" class="ft532">Uncommon&#160;</p>
<p style="position:absolute;top:793px;left:317px;white-space:nowrap" class="ft5311">Intestinal&#160;perforation, intestinal&#160;stenosis,&#160;diverticulitis,&#160;pancreatitis,&#160;<br/>cheilitis&#160;</p>
<p style="position:absolute;top:837px;left:128px;white-space:nowrap" class="ft533"><i>Hepatobiliary&#160;disorders&#160;</i></p>
<p style="position:absolute;top:858px;left:157px;white-space:nowrap" class="ft532">Common:&#160;</p>
<p style="position:absolute;top:858px;left:317px;white-space:nowrap" class="ft532">Hepatic&#160;function&#160;abnormal,&#160;transaminases increased.&#160;</p>
<p style="position:absolute;top:880px;left:157px;white-space:nowrap" class="ft532">Uncommon:&#160;</p>
<p style="position:absolute;top:880px;left:317px;white-space:nowrap" class="ft532">Hepatitis,&#160;hepatocellular&#160;damage,&#160;cholecystitis.&#160;</p>
<p style="position:absolute;top:901px;left:157px;white-space:nowrap" class="ft532">Rare:&#160;</p>
<p style="position:absolute;top:901px;left:317px;white-space:nowrap" class="ft532">Autoimmune&#160;hepatitis, jaundice.&#160;</p>
<p style="position:absolute;top:923px;left:157px;white-space:nowrap" class="ft532">Not&#160;known:&#160;</p>
<p style="position:absolute;top:923px;left:317px;white-space:nowrap" class="ft532">Liver&#160;failure.&#160;</p>
<p style="position:absolute;top:953px;left:128px;white-space:nowrap" class="ft533"><i>Skin and subcutaneous&#160;tissue&#160;disorders&#160;</i></p>
<p style="position:absolute;top:972px;left:157px;white-space:nowrap" class="ft532">Common:&#160;</p>
<p style="position:absolute;top:972px;left:317px;white-space:nowrap" class="ft5310">New&#160;onset&#160;or&#160;worsening&#160;psoriasis&#160;including&#160;pustular&#160;psoriasis&#160;<br/>(primarily&#160;palm &amp;&#160;soles), urticaria, rash, pruritus, hyperhidrosis, dry&#160;<br/>skin,&#160;fungal&#160;dermatitis,&#160;eczema,&#160;alopecia.&#160;</p>
<p style="position:absolute;top:1029px;left:157px;white-space:nowrap" class="ft532">Uncommon:&#160;</p>
<p style="position:absolute;top:1029px;left:317px;white-space:nowrap" class="ft5311">Bullous&#160;eruption,&#160;seborrhoea, rosacea, skin papilloma,&#160;hyperkeratosis,&#160;<br/>abnormal skin&#160;pigmentation.&#160;</p>
<p style="position:absolute;top:1074px;left:157px;white-space:nowrap" class="ft532">Rare:&#160;</p>
<p style="position:absolute;top:1074px;left:317px;white-space:nowrap" class="ft5311">Toxic&#160;epidermal necrolysis,&#160;Stevens-Johnson syndrome, erythema&#160;<br/>multiforme, furunculosis, linear&#160;IgA&#160;bullous&#160;dermatosis&#160;(LABD),&#160;<br/>acute generalised&#160;exanthematous&#160;pustulosis (AGEP),&#160;lichenoid&#160;<br/>reactions.&#160;</p>
<p style="position:absolute;top:1150px;left:157px;white-space:nowrap" class="ft532">Not&#160;known:&#160;</p>
<p style="position:absolute;top:1150px;left:317px;white-space:nowrap" class="ft532">Worsening of&#160;symptoms&#160;of&#160;dermatomyositis.&#160;</p>
</div>
<!-- Page 54 -->
<a name="54"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page54-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft540">54&#160;</p>
<p style="position:absolute;top:90px;left:128px;white-space:nowrap" class="ft543"><i>Musculoskeletal&#160;and&#160;connective tissue disorders&#160;</i></p>
<p style="position:absolute;top:111px;left:157px;white-space:nowrap" class="ft542">Common:&#160;</p>
<p style="position:absolute;top:111px;left:311px;white-space:nowrap" class="ft542">Arthralgia,&#160;myalgia,&#160;back&#160;pain.&#160;</p>
<p style="position:absolute;top:143px;left:128px;white-space:nowrap" class="ft543"><i>Renal&#160;and urinary&#160;disorders&#160;</i></p>
<p style="position:absolute;top:164px;left:157px;white-space:nowrap" class="ft542">Common:&#160;</p>
<p style="position:absolute;top:164px;left:317px;white-space:nowrap" class="ft542">Urinary&#160;tract infection.&#160;</p>
<p style="position:absolute;top:186px;left:157px;white-space:nowrap" class="ft542">Uncommon:&#160;</p>
<p style="position:absolute;top:186px;left:317px;white-space:nowrap" class="ft542">Pyelonephritis.&#160;</p>
<p style="position:absolute;top:219px;left:128px;white-space:nowrap" class="ft543"><i>Reproductive system&#160;and&#160;breast&#160;disorders&#160;</i></p>
<p style="position:absolute;top:240px;left:157px;white-space:nowrap" class="ft542">Uncommon:&#160;</p>
<p style="position:absolute;top:240px;left:311px;white-space:nowrap" class="ft542">Vaginitis.&#160;</p>
<p style="position:absolute;top:271px;left:128px;white-space:nowrap" class="ft543"><i>General&#160;disorders and&#160;administration site&#160;conditions&#160;</i></p>
<p style="position:absolute;top:293px;left:157px;white-space:nowrap" class="ft542">Very&#160;common:&#160;</p>
<p style="position:absolute;top:293px;left:317px;white-space:nowrap" class="ft542">Infusion-related reaction, pain.&#160;</p>
<p style="position:absolute;top:314px;left:157px;white-space:nowrap" class="ft542">Common:&#160;</p>
<p style="position:absolute;top:314px;left:317px;white-space:nowrap" class="ft542">Chest&#160;pain, fatigue,&#160;fever,&#160;injection site&#160;reaction,&#160;chills, oedema.&#160;</p>
<p style="position:absolute;top:336px;left:157px;white-space:nowrap" class="ft542">Uncommon:&#160;</p>
<p style="position:absolute;top:336px;left:317px;white-space:nowrap" class="ft542">Impaired healing.&#160;</p>
<p style="position:absolute;top:358px;left:157px;white-space:nowrap" class="ft542">Rare:&#160;</p>
<p style="position:absolute;top:358px;left:317px;white-space:nowrap" class="ft542">Granulomatous&#160;lesion.&#160;</p>
<p style="position:absolute;top:387px;left:128px;white-space:nowrap" class="ft543"><i>Investigations&#160;</i></p>
<p style="position:absolute;top:409px;left:157px;white-space:nowrap" class="ft542">Uncommon:&#160;</p>
<p style="position:absolute;top:409px;left:317px;white-space:nowrap" class="ft542">Autoantibody positive.&#160;</p>
<p style="position:absolute;top:430px;left:157px;white-space:nowrap" class="ft542">Rare:&#160;</p>
<p style="position:absolute;top:430px;left:317px;white-space:nowrap" class="ft542">Complement&#160;factor&#160;abnormal.&#160;</p>
<p style="position:absolute;top:462px;left:128px;white-space:nowrap" class="ft542">*&#160;&#160;including bovine&#160;tuberculosis&#160;(disseminated BCG&#160;infection), see&#160;section&#160;4.4&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft5410">&#160;<br/>Description&#160;of&#160;selected&#160;adverse&#160;drug&#160;reactions&#160;<br/><i>&#160;<br/>Systemic&#160;injection&#160;reaction&#160;and&#160;localised&#160;injection&#160;site&#160;reaction&#160;in&#160;adult&#160;patients&#160;administered with&#160;<br/>Remsima&#160;subcutaneous&#160;formulation&#160;<br/></i>&#160;<br/>The&#160;safety profile&#160;of&#160;Remsima&#160;subcutaneous&#160;formulation in combination with&#160;methotrexate&#160;was&#160;<br/>evaluated&#160;in&#160;a Phase I/III&#160;parallel&#160;group study&#160;in patients&#160;with active&#160;rheumatoid arthritis.&#160;The&#160;safety&#160;<br/>population consisted of&#160;168&#160;patients&#160;in the&#160;Remsima&#160;subcutaneous&#160;group and 175&#160;patients&#160;in&#160;the&#160;<br/>Remsima&#160;intravenous&#160;group. For&#160;study&#160;details,&#160;see&#160;Section&#160;5.1.&#160;<br/>&#160;<br/>The incidence&#160;rate of&#160;systemic injection&#160;reactions&#160;(e.g.&#160;rash,&#160;pruritus,&#160;flushing and&#160;oedema)&#160;was&#160;1.2&#160;<br/>patients&#160;per&#160;100&#160;patient-years&#160;in the&#160;Remsima&#160;subcutaneous&#160;group&#160;(from&#160;Week 6)&#160;and 2.1 patients&#160;per&#160;<br/>100 patient-years&#160;in&#160;the&#160;Remsima&#160;intravenous&#160;group who switched to Remsima&#160;subcutaneous&#160;<br/>administration (from&#160;Week 30).&#160;All&#160;systemic&#160;injection&#160;reactions&#160;were&#160;mild&#160;to&#160;moderate.&#160;&#160;<br/>&#160;<br/>The incidence&#160;rate of&#160;localised&#160;injection&#160;site&#160;reactions&#160;(e.g.&#160;injection site&#160;erythema,&#160;pain,&#160;pruritus&#160;and&#160;<br/>swelling)&#160;was&#160;17.6 patients&#160;per&#160;100 patient-years&#160;in&#160;the&#160;Remsima subcutaneous group&#160;(from&#160;Week&#160;6)&#160;<br/>and 21.4&#160;patients&#160;per&#160;100 patient-years&#160;in&#160;those&#160;who switched to Remsima&#160;subcutaneous&#160;<br/>administration (from&#160;Week 30).&#160;Most&#160;of&#160;these&#160;reactions&#160;were&#160;mild to moderate&#160;and&#160;resolved&#160;<br/>spontaneously&#160;without&#160;any&#160;treatment&#160;within a&#160;day.&#160;<br/>&#160;<br/>In&#160;a Phase I&#160;study&#160;conducted&#160;in&#160;patients with&#160;active Crohn’s&#160;disease and&#160;active ulcerative colitis,&#160;the&#160;<br/>safety population consisted&#160;of&#160;97&#160;patients&#160;in&#160;the&#160;Remsima&#160;subcutaneous&#160;group&#160;(59&#160;patients with&#160;active&#160;<br/>Crohn’s&#160;disease&#160;and&#160;38&#160;patients with&#160;active ulcerative&#160;colitis)&#160;and&#160;78&#160;patients&#160;in&#160;the&#160;Remsima&#160;<br/>intravenous&#160;group&#160;(38&#160;patients with&#160;active Crohn’s disease&#160;and&#160;40&#160;patients&#160;with&#160;active&#160;ulcerative&#160;<br/>colitis)&#160;from&#160;Part&#160;1 and Part&#160;2 of&#160;the&#160;study. For&#160;study details, see&#160;Section 5.1.&#160;<br/>&#160;<br/>The incidence&#160;rate&#160;of&#160;systemic injection&#160;reactions&#160;(e.g.&#160;nausea and&#160;dizziness)&#160;was&#160;2.3&#160;patients&#160;per&#160;100&#160;<br/>patient-years&#160;in&#160;the&#160;Remsima&#160;subcutaneous&#160;group&#160;(from&#160;Week 6)&#160;and there were no&#160;systemic&#160;injection&#160;<br/>reactions&#160;reported in the&#160;Remsima&#160;intravenous&#160;group who switched to Remsima&#160;subcutaneous&#160;<br/>administration (from&#160;Week 30).&#160;<br/>&#160;<br/>The incidence&#160;rate&#160;of&#160;localised&#160;injection&#160;site&#160;reactions&#160;(e.g.&#160;injection&#160;site&#160;erythema,&#160;pain, pruritus,&#160;<br/>bruising)&#160;was&#160;23.3&#160;patients&#160;per&#160;100 patient-years&#160;in&#160;the&#160;Remsima subcutaneous group&#160;(from&#160;Week&#160;6)&#160;<br/>and 7.5 patients&#160;per&#160;100 patient-years&#160;in&#160;the&#160;Remsima&#160;intravenous&#160;group who&#160;switched&#160;to Remsima&#160;</p>
</div>
<!-- Page 55 -->
<a name="55"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page55-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft550">55&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft5510">subcutaneous&#160;administration (from&#160;Week 30).&#160;All&#160;of&#160;these reactions&#160;were&#160;mild to moderate&#160;and&#160;mostly&#160;<br/>resolved&#160;spontaneously without&#160;any treatment&#160;within&#160;a&#160;few&#160;days.&#160;<br/>&#160;<br/>In post-marketing&#160;experience,&#160;cases&#160;of&#160;anaphylactic-like&#160;reactions, including laryngeal/pharyngeal&#160;<br/>oedema and&#160;severe bronchospasm,&#160;and&#160;seizure have been&#160;associated&#160;with&#160;infliximab&#160;intravenous&#160;<br/>administration&#160;(see&#160;section 4.4).&#160;Cases of&#160;transient&#160;visual&#160;loss&#160;occurring&#160;during&#160;or&#160;within&#160;2&#160;hours&#160;of&#160;<br/>infliximab&#160;infusion have&#160;been reported.&#160;Events (some fatal)&#160;of&#160;myocardial&#160;ischaemia/infarction and&#160;<br/>arrhythmia&#160;have&#160;been reported, some&#160;in&#160;close&#160;temporal&#160;association with infusion&#160;of&#160;infliximab;&#160;<br/>cerebrovascular&#160;accidents have also&#160;been&#160;reported&#160;in&#160;close temporal&#160;association with infusion&#160;of&#160;<br/>infliximab.&#160;<br/>&#160;<br/><i>Delayed&#160;hypersensitivity&#160;<br/></i>&#160;<br/>In clinical&#160;studies&#160;delayed&#160;hypersensitivity&#160;reactions&#160;have&#160;been uncommon and have&#160;occurred after&#160;<br/>infliximab-free&#160;intervals of&#160;less&#160;than&#160;1&#160;year.&#160;In&#160;the psoriasis studies&#160;with intravenous&#160;infliximab,&#160;<br/>delayed hypersensitivity&#160;reactions&#160;occurred early in&#160;the&#160;treatment&#160;course. Signs&#160;and symptoms&#160;<br/>included&#160;myalgia&#160;and/or&#160;arthralgia&#160;with fever&#160;and/or&#160;rash, with some&#160;patients&#160;experiencing pruritus,&#160;<br/>facial,&#160;hand&#160;or&#160;lip&#160;oedema, dysphagia, urticaria, sore&#160;throat&#160;and&#160;headache.&#160;<br/>&#160;<br/>There are&#160;insufficient&#160;data on&#160;the incidence of&#160;delayed&#160;hypersensitivity&#160;reactions after&#160;infliximab-free&#160;<br/>intervals&#160;of&#160;more&#160;than&#160;1&#160;year&#160;but&#160;limited&#160;data&#160;from&#160;clinical&#160;studies&#160;suggest&#160;an&#160;increased&#160;risk&#160;for&#160;<br/>delayed&#160;hypersensitivity&#160;with&#160;increasing&#160;infliximab-free&#160;interval&#160;(see&#160;section 4.4).<i>&#160;<br/>&#160;<br/></i>In&#160;a&#160;1-year&#160;clinical&#160;study&#160;with&#160;repeated&#160;infusions of&#160;IV&#160;infliximab&#160;in&#160;patients with&#160;Crohn's disease&#160;<br/>(ACCENT&#160;I&#160;study), the&#160;incidence&#160;of&#160;serum&#160;sickness-like reactions was 2.4%.&#160;<br/><i>&#160;<br/>Immunogenicity&#160;&#160;<br/></i>&#160;<br/><i>Intravenous&#160;formulation&#160;<br/></i>&#160;<br/>Patients&#160;who&#160;developed antibodies&#160;to infliximab&#160;were&#160;more&#160;likely (approximately&#160;2-3&#160;fold)&#160;to develop&#160;<br/>infusion-related&#160;reactions.&#160;Use&#160;of&#160;concomitant&#160;immunosuppressant&#160;agents appeared&#160;to&#160;reduce the&#160;<br/>frequency&#160;of&#160;infusion-related&#160;reactions.&#160;<br/>In&#160;clinical studies&#160;using&#160;single&#160;and&#160;multiple&#160;infliximab&#160;doses&#160;ranging&#160;from&#160;1 to&#160;20&#160;mg/kg, antibodies&#160;<br/>to infliximab were&#160;detected&#160;in 14%&#160;of&#160;patients&#160;with any immunosuppressant&#160;therapy, and&#160;in 24%&#160;of&#160;<br/>patients&#160;without&#160;immunosuppressant&#160;therapy. In rheumatoid arthritis&#160;patients&#160;who&#160;received the&#160;<br/>recommended&#160;repeated&#160;treatment&#160;dose&#160;regimens with&#160;methotrexate,&#160;8%&#160;of&#160;patients developed&#160;<br/>antibodies&#160;to infliximab.&#160;In psoriatic&#160;arthritis&#160;patients&#160;who&#160;received&#160;5&#160;mg/kg with&#160;and without&#160;<br/>methotrexate, antibodies&#160;occurred overall&#160;in 15%&#160;of&#160;patients&#160;(antibodies&#160;occurred in 4%&#160;of&#160;patients&#160;<br/>receiving&#160;methotrexate&#160;and&#160;in 26%&#160;of&#160;patients&#160;not&#160;receiving&#160;methotrexate&#160;at&#160;baseline).&#160;In Crohn's&#160;<br/>disease&#160;patients who&#160;received&#160;maintenance&#160;treatment,&#160;antibodies&#160;to&#160;infliximab&#160;occurred&#160;overall&#160;in&#160;<br/>3.3%&#160;of&#160;patients&#160;receiving immunosuppressants&#160;and&#160;in&#160;13.3%&#160;of&#160;patients&#160;not&#160;receiving&#160;<br/>immunosuppressants.&#160;The&#160;antibody incidence&#160;was&#160;2-3&#160;fold higher&#160;for&#160;patients&#160;treated episodically.&#160;<br/>Due&#160;to&#160;methodological&#160;limitations, a&#160;negative&#160;assay did not&#160;exclude&#160;the&#160;presence&#160;of&#160;antibodies&#160;to&#160;<br/>infliximab. Some&#160;patients&#160;who developed&#160;high&#160;titres&#160;of&#160;antibodies&#160;to&#160;infliximab&#160;had&#160;evidence&#160;of&#160;<br/>reduced&#160;efficacy.&#160;In&#160;psoriasis patients treated&#160;with&#160;infliximab&#160;as a&#160;maintenance regimen&#160;in&#160;the absence&#160;<br/>of&#160;concomitant&#160;immunomodulators, approximately&#160;28%&#160;developed antibodies&#160;to&#160;infliximab (see&#160;<br/>section 4.4:&#160;&#34;Systemic&#160;injection&#160;reaction/ localised&#160;injection&#160;site&#160;reaction/ hypersensitivity&#34;).&#160;<br/>&#160;<br/>Because&#160;immunogenicity&#160;analyses are assay-specific, comparison of&#160;the&#160;incidence&#160;of&#160;antibodies&#160;to&#160;<br/>infliximab reported&#160;in&#160;this&#160;section&#160;with the&#160;incidence&#160;of&#160;antibodies&#160;in&#160;other&#160;studies&#160;may&#160;be&#160;misleading.&#160;<br/>&#160;<br/><i>Subcutaneous&#160;formulation&#160;<br/>&#160;<br/></i>In&#160;rheumatoid&#160;arthritis patients&#160;on&#160;maintenance treatment,&#160;the&#160;incidence of&#160;anti-infliximab antibodies&#160;<br/>following the&#160;subcutaneous&#160;infliximab was&#160;demonstrated to be&#160;not&#160;higher&#160;than that&#160;of&#160;the&#160;intravenous&#160;<br/>infliximab&#160;and&#160;anti-infliximab antibodies&#160;had&#160;no significant&#160;impact&#160;on&#160;efficacy&#160;(determined by disease&#160;</p>
</div>
<!-- Page 56 -->
<a name="56"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page56-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft560">56&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft5611">activity score&#160;in 28&#160;joints&#160;[DAS28]&#160;and American College&#160;of&#160;Rheumatology&#160;criteria&#160;20 [ACR20])&#160;and&#160;<br/>the safety&#160;profile.&#160;&#160;<br/>&#160;<br/>In Crohn's&#160;disease&#160;and&#160;ulcerative colitis patients on&#160;maintenance&#160;treatment,&#160;the incidence&#160;of&#160;<br/>anti-infliximab antibodies&#160;was&#160;not&#160;higher&#160;in patients&#160;who received subcutaneous&#160;infliximab&#160;in&#160;<br/>comparison to those&#160;who&#160;received&#160;intravenous&#160;infliximab&#160;and anti-infliximab antibodies&#160;had no&#160;<br/>significant&#160;impact on&#160;efficacy&#160;(determined&#160;by&#160;clinical&#160;response&#160;and&#160;clinical remission&#160;according&#160;to&#160;<br/>CDAI&#160;score for&#160;Crohn's disease&#160;patients or&#160;partial&#160;Mayo&#160;score for&#160;ulcerative colitis&#160;patients)&#160;and&#160;the&#160;<br/>safety&#160;profile.&#160;<br/>&#160;<br/><i>Infections&#160;<br/></i>&#160;<br/>Tuberculosis, bacterial&#160;infections,&#160;including sepsis&#160;and&#160;pneumonia, invasive&#160;fungal, viral, and&#160;other&#160;<br/>opportunistic&#160;infections&#160;have&#160;been observed&#160;in patients&#160;receiving infliximab.&#160;Some&#160;of&#160;these&#160;infections&#160;<br/>have&#160;been&#160;fatal;&#160;the&#160;most&#160;frequently&#160;reported opportunistic&#160;infections&#160;with&#160;a&#160;mortality&#160;rate&#160;of&#160;&gt;5%&#160;<br/>include pneumocystosis,&#160;candidiasis,&#160;listeriosis and&#160;aspergillosis&#160;(see section&#160;4.4).&#160;<br/>&#160;<br/>In&#160;clinical&#160;studies&#160;36%&#160;of&#160;infliximab-treated patients&#160;were&#160;treated for&#160;infections&#160;compared with 25%&#160;of&#160;<br/>placebo-treated&#160;patients.&#160;<br/>&#160;<br/>In rheumatoid&#160;arthritis&#160;clinical&#160;studies, the&#160;incidence&#160;of&#160;serious&#160;infections&#160;including pneumonia&#160;was&#160;<br/>higher&#160;in infliximab plus&#160;methotrexate-treated&#160;patients&#160;compared&#160;with&#160;methotrexate alone especially&#160;at&#160;<br/>doses&#160;of&#160;6&#160;mg/kg&#160;or&#160;greater&#160;(see&#160;section&#160;4.4).&#160;<br/>&#160;<br/>In post-marketing spontaneous&#160;reporting, infections&#160;are&#160;the&#160;most&#160;common&#160;serious&#160;adverse&#160;reaction.&#160;<br/>Some of&#160;the cases have resulted&#160;in&#160;a fatal&#160;outcome.&#160;Nearly&#160;50%&#160;of&#160;reported&#160;deaths&#160;have been&#160;<br/>associated&#160;with&#160;infection.&#160;Cases of&#160;tuberculosis,&#160;sometimes&#160;fatal,&#160;including&#160;miliary&#160;tuberculosis&#160;and&#160;<br/>tuberculosis&#160;with extra-pulmonary&#160;location have&#160;been&#160;reported (see&#160;section&#160;4.4).&#160;<br/>&#160;<br/><i>Malignancies&#160;and lymphoproliferative&#160;disorders&#160;<br/></i>&#160;<br/>In clinical&#160;studies&#160;with&#160;infliximab in which 5,780&#160;patients&#160;were&#160;treated,&#160;representing 5,494&#160;patient&#160;<br/>years,&#160;5&#160;cases&#160;of&#160;lymphomas&#160;and 26&#160;non-lymphoma&#160;malignancies&#160;were&#160;detected&#160;as&#160;compared with no&#160;<br/>lymphomas&#160;and&#160;1&#160;non-lymphoma&#160;malignancy&#160;in 1,600&#160;placebo-treated&#160;patients representing&#160;<br/>941&#160;patient&#160;years.&#160;<br/>&#160;<br/>In long-term safety&#160;follow-up of&#160;clinical&#160;studies&#160;with infliximab of&#160;up to&#160;5&#160;years,&#160;representing&#160;<br/>6,234&#160;patients-years&#160;(3,210&#160;patients),&#160;5&#160;cases&#160;of&#160;lymphoma&#160;and&#160;38&#160;cases of&#160;non-lymphoma&#160;<br/>malignancies&#160;were reported.&#160;<br/>&#160;<br/>Cases&#160;of&#160;malignancies,&#160;including&#160;lymphoma,&#160;have also&#160;been&#160;reported in&#160;the&#160;post-marketing setting&#160;<br/>(see section&#160;4.4).&#160;<br/>&#160;<br/>In an exploratory clinical&#160;study involving patients&#160;with&#160;moderate&#160;to severe&#160;COPD&#160;who were&#160;either&#160;<br/>current&#160;smokers&#160;or&#160;ex-smokers, 157&#160;adult&#160;patients were treated&#160;with&#160;infliximab&#160;at&#160;doses&#160;similar&#160;to&#160;<br/>those&#160;used in&#160;rheumatoid&#160;arthritis&#160;and&#160;Crohn’s&#160;disease.&#160;Nine of&#160;these patients developed&#160;malignancies,&#160;<br/>including 1&#160;lymphoma. The&#160;median duration of&#160;follow-up was&#160;0.8&#160;years&#160;(incidence&#160;5.7%&#160;[95%&#160;CI&#160;<br/>2.65%-10.6%].&#160;There&#160;was&#160;one&#160;reported&#160;malignancy amongst&#160;77&#160;control&#160;patients&#160;(median duration of&#160;<br/>follow-up 0.8&#160;years;&#160;incidence&#160;1.3%&#160;[95%&#160;CI&#160;0.03%-7.0%]). The&#160;majority of&#160;the&#160;malignancies&#160;<br/>developed&#160;in&#160;the&#160;lung or&#160;head and neck.&#160;<br/>&#160;<br/>A&#160;population-based retrospective&#160;cohort&#160;study&#160;found an increased&#160;incidence&#160;of&#160;cervical&#160;cancer&#160;in&#160;<br/>women with&#160;rheumatoid arthritis&#160;treated with&#160;infliximab compared to biologics-naïve patients or&#160;the&#160;<br/>general&#160;population,&#160;including those&#160;over&#160;60&#160;years of&#160;age (see section&#160;4.4).&#160;<br/>&#160;</p>
</div>
<!-- Page 57 -->
<a name="57"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page57-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft570">57&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft5710">In addition,&#160;post-marketing&#160;cases&#160;of&#160;hepatosplenic&#160;T-cell lymphoma&#160;have&#160;been reported&#160;in patients&#160;<br/>treated&#160;with&#160;infliximab&#160;with&#160;the vast&#160;majority&#160;of&#160;cases&#160;occurring&#160;in&#160;Crohn’s disease&#160;and&#160;ulcerative&#160;<br/>colitis,&#160;and most&#160;of&#160;whom&#160;were&#160;adolescent&#160;or&#160;young adult&#160;males&#160;(see&#160;section 4.4).&#160;<br/>&#160;<br/><i>Heart&#160;failure&#160;<br/></i>&#160;<br/>In&#160;a Phase II&#160;study&#160;aimed&#160;at&#160;evaluating&#160;infliximab&#160;in CHF, higher&#160;incidence&#160;of&#160;mortality due&#160;to&#160;<br/>worsening&#160;of&#160;heart&#160;failure&#160;were seen&#160;in&#160;patients treated&#160;with&#160;infliximab,&#160;especially&#160;those treated&#160;with&#160;<br/>the&#160;higher&#160;dose&#160;of&#160;10&#160;mg/kg (i.e. twice&#160;the&#160;maximum&#160;approved dose). In this&#160;study 150&#160;patients&#160;with&#160;<br/>NYHA Class&#160;III-IV&#160;CHF&#160;(left&#160;ventricular&#160;ejection&#160;fraction&#160;</p>
<p style="position:absolute;top:254px;left:497px;white-space:nowrap" class="ft5718">≤35%) were&#160;treated&#160;with&#160;3&#160;infusions&#160;of&#160;</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft5710">infliximab&#160;5&#160;mg/kg, 10&#160;mg/kg, or&#160;placebo over&#160;6&#160;weeks.&#160;At&#160;38&#160;weeks,&#160;9 of&#160;101&#160;patients&#160;treated&#160;with&#160;<br/>infliximab&#160;(2&#160;at 5&#160;mg/kg and 7 at&#160;10&#160;mg/kg)&#160;died&#160;compared&#160;to one&#160;death&#160;among the&#160;49&#160;patients&#160;on&#160;<br/>placebo.&#160;<br/>&#160;<br/>There&#160;have&#160;been post-marketing reports&#160;of&#160;worsening&#160;heart&#160;failure, with and without&#160;identifiable&#160;<br/>precipitating factors,&#160;in patients&#160;taking&#160;infliximab. There&#160;have&#160;also been post-marketing reports&#160;of&#160;new&#160;<br/>onset&#160;heart&#160;failure,&#160;including heart&#160;failure&#160;in patients&#160;without&#160;known pre-existing cardiovascular&#160;<br/>disease.&#160;Some&#160;of&#160;these&#160;patients&#160;have&#160;been under&#160;50&#160;years of&#160;age.&#160;<br/>&#160;<br/><i>Hepatobiliary&#160;events&#160;<br/></i>&#160;<br/>In&#160;clinical studies,&#160;mild&#160;or&#160;moderate&#160;elevations&#160;of&#160;ALT&#160;and&#160;AST&#160;have&#160;been observed in&#160;patients&#160;<br/>receiving&#160;infliximab without&#160;progression to severe&#160;hepatic&#160;injury. Elevations&#160;of&#160;ALT&#160;</p>
<p style="position:absolute;top:500px;left:671px;white-space:nowrap" class="ft5718">≥5&#160;x&#160;Upper&#160;</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft5711">Limit&#160;of&#160;Normal&#160;(ULN)&#160;have&#160;been observed (see&#160;Table&#160;2). Elevations&#160;of&#160;aminotransferases&#160;were&#160;<br/>observed (ALT&#160;more&#160;common than&#160;AST)&#160;in&#160;a&#160;greater&#160;proportion of&#160;patients&#160;receiving&#160;infliximab&#160;than&#160;<br/>in controls, both when&#160;infliximab was&#160;given as&#160;monotherapy and when it&#160;was&#160;used in combination&#160;<br/>with&#160;other&#160;immunosuppressive agents.&#160;Most&#160;aminotransferase abnormalities were&#160;transient;&#160;however,&#160;<br/>a&#160;small&#160;number&#160;of&#160;patients&#160;experienced&#160;more&#160;prolonged elevations. In general, patients&#160;who developed&#160;<br/>ALT&#160;and&#160;AST&#160;elevations were asymptomatic,&#160;and&#160;the&#160;abnormalities decreased&#160;or&#160;resolved&#160;with&#160;either&#160;<br/>continuation&#160;or&#160;discontinuation of&#160;infliximab, or&#160;modification&#160;of&#160;concomitant&#160;therapy.&#160;In&#160;<br/>post-marketing&#160;surveillance,&#160;cases of&#160;jaundice and&#160;hepatitis,&#160;some with&#160;features of&#160;autoimmune&#160;<br/>hepatitis,&#160;have&#160;been reported in patients&#160;receiving&#160;infliximab (see&#160;section 4.4).&#160;&#160;<br/>&#160;</p>
<p style="position:absolute;top:715px;left:420px;white-space:nowrap" class="ft571"><b>Table&#160;2&#160;</b></p>
<p style="position:absolute;top:735px;left:141px;white-space:nowrap" class="ft571"><b>Proportion of&#160;patients&#160;with increased&#160;ALT&#160;activity&#160;in&#160;clinical&#160;studies using&#160;intravenous&#160;</b></p>
<p style="position:absolute;top:754px;left:410px;white-space:nowrap" class="ft571"><b>infliximab</b>&#160;</p>
<p style="position:absolute;top:793px;left:115px;white-space:nowrap" class="ft572">Indication&#160;</p>
<p style="position:absolute;top:783px;left:214px;white-space:nowrap" class="ft572">Number&#160;of&#160;patients3&#160;</p>
<p style="position:absolute;top:773px;left:373px;white-space:nowrap" class="ft572">Median follow-up&#160;</p>
<p style="position:absolute;top:792px;left:411px;white-space:nowrap" class="ft572">(wks)4&#160;</p>
<p style="position:absolute;top:777px;left:549px;white-space:nowrap" class="ft5718">≥&#160;3 x ULN&#160;</p>
<p style="position:absolute;top:777px;left:702px;white-space:nowrap" class="ft5718">≥&#160;5 x ULN&#160;</p>
<p style="position:absolute;top:812px;left:212px;white-space:nowrap" class="ft572">placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;</p>
<p style="position:absolute;top:832px;left:115px;white-space:nowrap" class="ft5710">Rheumatoid&#160;<br/>arthritis1&#160;</p>
<p style="position:absolute;top:841px;left:225px;white-space:nowrap" class="ft572">375&#160;</p>
<p style="position:absolute;top:841px;left:295px;white-space:nowrap" class="ft572">1,087&#160;</p>
<p style="position:absolute;top:841px;left:375px;white-space:nowrap" class="ft572">58.1&#160;</p>
<p style="position:absolute;top:841px;left:452px;white-space:nowrap" class="ft572">58.3&#160;</p>
<p style="position:absolute;top:841px;left:525px;white-space:nowrap" class="ft572">3.2%&#160;</p>
<p style="position:absolute;top:841px;left:602px;white-space:nowrap" class="ft572">3.9%&#160;</p>
<p style="position:absolute;top:841px;left:678px;white-space:nowrap" class="ft572">0.8%&#160;</p>
<p style="position:absolute;top:841px;left:754px;white-space:nowrap" class="ft572">0.9%&#160;</p>
<p style="position:absolute;top:871px;left:115px;white-space:nowrap" class="ft5710">Crohn’s&#160;<br/>disease2&#160;</p>
<p style="position:absolute;top:880px;left:225px;white-space:nowrap" class="ft572">324&#160;</p>
<p style="position:absolute;top:880px;left:295px;white-space:nowrap" class="ft572">1,034&#160;</p>
<p style="position:absolute;top:880px;left:375px;white-space:nowrap" class="ft572">53.7&#160;</p>
<p style="position:absolute;top:880px;left:452px;white-space:nowrap" class="ft572">54.0&#160;</p>
<p style="position:absolute;top:880px;left:525px;white-space:nowrap" class="ft572">2.2%&#160;</p>
<p style="position:absolute;top:880px;left:602px;white-space:nowrap" class="ft572">4.9%&#160;</p>
<p style="position:absolute;top:880px;left:678px;white-space:nowrap" class="ft572">0.0%&#160;</p>
<p style="position:absolute;top:880px;left:754px;white-space:nowrap" class="ft572">1.5%&#160;</p>
<p style="position:absolute;top:909px;left:115px;white-space:nowrap" class="ft5710">Ulcerative&#160;<br/>colitis&#160;</p>
<p style="position:absolute;top:919px;left:225px;white-space:nowrap" class="ft572">242&#160;</p>
<p style="position:absolute;top:919px;left:301px;white-space:nowrap" class="ft572">482&#160;</p>
<p style="position:absolute;top:919px;left:375px;white-space:nowrap" class="ft572">30.1&#160;</p>
<p style="position:absolute;top:919px;left:452px;white-space:nowrap" class="ft572">30.8&#160;</p>
<p style="position:absolute;top:919px;left:525px;white-space:nowrap" class="ft572">1.2%&#160;</p>
<p style="position:absolute;top:919px;left:602px;white-space:nowrap" class="ft572">2.5%&#160;</p>
<p style="position:absolute;top:919px;left:678px;white-space:nowrap" class="ft572">0.4%&#160;</p>
<p style="position:absolute;top:919px;left:754px;white-space:nowrap" class="ft572">0.6%&#160;</p>
</div>
<!-- Page 58 -->
<a name="58"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page58-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft580">58&#160;</p>
<p style="position:absolute;top:109px;left:115px;white-space:nowrap" class="ft582">Indication&#160;</p>
<p style="position:absolute;top:99px;left:214px;white-space:nowrap" class="ft582">Number&#160;of&#160;patients3&#160;</p>
<p style="position:absolute;top:90px;left:373px;white-space:nowrap" class="ft582">Median follow-up&#160;</p>
<p style="position:absolute;top:109px;left:411px;white-space:nowrap" class="ft582">(wks)4&#160;</p>
<p style="position:absolute;top:93px;left:549px;white-space:nowrap" class="ft5818">≥&#160;3 x ULN&#160;</p>
<p style="position:absolute;top:93px;left:702px;white-space:nowrap" class="ft5818">≥&#160;5 x ULN&#160;</p>
<p style="position:absolute;top:129px;left:212px;white-space:nowrap" class="ft582">placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;&#160;placebo&#160;&#160;infliximab&#160;</p>
<p style="position:absolute;top:148px;left:115px;white-space:nowrap" class="ft5811">Ankylosing&#160;<br/>spondylitis&#160;</p>
<p style="position:absolute;top:158px;left:229px;white-space:nowrap" class="ft582">76&#160;</p>
<p style="position:absolute;top:158px;left:301px;white-space:nowrap" class="ft582">275&#160;</p>
<p style="position:absolute;top:158px;left:375px;white-space:nowrap" class="ft582">24.1&#160;</p>
<p style="position:absolute;top:158px;left:448px;white-space:nowrap" class="ft582">101.9&#160;</p>
<p style="position:absolute;top:158px;left:525px;white-space:nowrap" class="ft582">0.0%&#160;</p>
<p style="position:absolute;top:158px;left:602px;white-space:nowrap" class="ft582">9.5%&#160;</p>
<p style="position:absolute;top:158px;left:678px;white-space:nowrap" class="ft582">0.0%&#160;</p>
<p style="position:absolute;top:158px;left:754px;white-space:nowrap" class="ft582">3.6%&#160;</p>
<p style="position:absolute;top:187px;left:115px;white-space:nowrap" class="ft5811">Psoriatic&#160;<br/>arthritis&#160;</p>
<p style="position:absolute;top:196px;left:229px;white-space:nowrap" class="ft582">98&#160;</p>
<p style="position:absolute;top:196px;left:301px;white-space:nowrap" class="ft582">191&#160;</p>
<p style="position:absolute;top:196px;left:375px;white-space:nowrap" class="ft582">18.1&#160;</p>
<p style="position:absolute;top:196px;left:452px;white-space:nowrap" class="ft582">39.1&#160;</p>
<p style="position:absolute;top:196px;left:525px;white-space:nowrap" class="ft582">0.0%&#160;</p>
<p style="position:absolute;top:196px;left:602px;white-space:nowrap" class="ft582">6.8%&#160;</p>
<p style="position:absolute;top:196px;left:678px;white-space:nowrap" class="ft582">0.0%&#160;</p>
<p style="position:absolute;top:196px;left:754px;white-space:nowrap" class="ft582">2.1%&#160;</p>
<p style="position:absolute;top:226px;left:115px;white-space:nowrap" class="ft5811">Plaque&#160;<br/>psoriasis&#160;</p>
<p style="position:absolute;top:235px;left:225px;white-space:nowrap" class="ft582">281&#160;</p>
<p style="position:absolute;top:235px;left:295px;white-space:nowrap" class="ft582">1,175&#160;</p>
<p style="position:absolute;top:235px;left:375px;white-space:nowrap" class="ft582">16.1&#160;</p>
<p style="position:absolute;top:235px;left:452px;white-space:nowrap" class="ft582">50.1&#160;</p>
<p style="position:absolute;top:235px;left:525px;white-space:nowrap" class="ft582">0.4%&#160;</p>
<p style="position:absolute;top:235px;left:602px;white-space:nowrap" class="ft582">7.7%&#160;</p>
<p style="position:absolute;top:235px;left:678px;white-space:nowrap" class="ft582">0.0%&#160;</p>
<p style="position:absolute;top:235px;left:754px;white-space:nowrap" class="ft582">3.4%&#160;</p>
<p style="position:absolute;top:264px;left:106px;white-space:nowrap" class="ft582">1&#160;&#160;Placebo&#160;patients&#160;received methotrexate&#160;while&#160;infliximab&#160;patients&#160;received&#160;both infliximab and&#160;</p>
<p style="position:absolute;top:283px;left:128px;white-space:nowrap" class="ft582">methotrexate.&#160;</p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft582">2&#160;&#160;Placebo patients&#160;in the&#160;2&#160;Phase III&#160;studies in&#160;Crohn’s&#160;disease,&#160;ACCENT&#160;I&#160;and&#160;ACCENT&#160;II,&#160;</p>
<p style="position:absolute;top:321px;left:128px;white-space:nowrap" class="ft5810">received&#160;an initial&#160;dose&#160;of&#160;5&#160;mg/kg infliximab at&#160;study&#160;start&#160;and were&#160;on&#160;placebo&#160;in the&#160;<br/>maintenance phase.&#160;Patients who&#160;were&#160;randomised&#160;to&#160;the placebo&#160;maintenance&#160;group and&#160;then&#160;later&#160;<br/>crossed&#160;over&#160;to infliximab are&#160;included in the&#160;infliximab&#160;group in the&#160;ALT&#160;analysis.&#160;In&#160;the&#160;Phase&#160;<br/>IIIb&#160;trial&#160;in&#160;Crohn’s disease,&#160;SONIC,&#160;placebo&#160;patients&#160;received&#160;AZA&#160;2.5&#160;mg/kg/day as&#160;active&#160;<br/>control&#160;in addition to placebo infliximab&#160;infusions.&#160;</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft5810">3&#160;&#160;Number&#160;of&#160;patients&#160;evaluated for&#160;ALT.&#160;<br/>4&#160;&#160;Median follow-up is&#160;based&#160;on patients&#160;treated.&#160;<br/>&#160;<br/><i>Antinuclear&#160;antibodies&#160;(ANA)/Anti-double-stranded DNA&#160;(dsDNA)&#160;antibodies&#160;<br/></i>&#160;<br/>Approximately half&#160;of&#160;infliximab-treated&#160;patients&#160;in&#160;clinical&#160;studies who&#160;were ANA&#160;negative at&#160;<br/>baseline&#160;developed a&#160;positive&#160;ANA&#160;during the&#160;study&#160;compared with&#160;approximately one&#160;fifth&#160;of&#160;<br/>placebo-treated&#160;patients.&#160;Anti-dsDNA&#160;antibodies&#160;were&#160;newly detected in approximately 17%&#160;of&#160;<br/>infliximab-treated&#160;patients&#160;compared&#160;with&#160;0%&#160;of&#160;placebo-treated&#160;patients.&#160;At&#160;the&#160;last&#160;evaluation,&#160;57%&#160;<br/>of&#160;infliximab-treated&#160;patients remained&#160;anti-dsDNA&#160;positive.&#160;Reports&#160;of&#160;lupus&#160;and&#160;lupus-like&#160;<br/>syndromes, however,&#160;remain uncommon (see&#160;section&#160;4.4).&#160;<br/>&#160;<br/>Other&#160;special&#160;populations&#160;<br/>&#160;<br/><i>Elderly&#160;<br/></i>&#160;<br/>In&#160;rheumatoid arthritis&#160;clinical&#160;studies,&#160;the incidence of&#160;serious&#160;infections was&#160;greater&#160;in&#160;infliximab&#160;<br/>plus&#160;methotrexate-treated&#160;patients 65&#160;years&#160;and&#160;older&#160;(11.3%)&#160;than in&#160;those&#160;under&#160;65&#160;years of&#160;age&#160;<br/>(4.6%). In patients&#160;treated&#160;with&#160;methotrexate&#160;alone,&#160;the&#160;incidence&#160;of&#160;serious&#160;infections&#160;was&#160;5.2%&#160;in&#160;<br/>patients 65&#160;years&#160;and older&#160;compared to&#160;2.7%&#160;in&#160;patients&#160;under&#160;65 (see section&#160;4.4).&#160;<br/>&#160;<br/>Reporting of&#160;suspected&#160;adverse&#160;reactions&#160;<br/>Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important. It&#160;<br/>allows&#160;continued&#160;monitoring of&#160;the&#160;benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;<br/>professionals&#160;are&#160;asked&#160;to&#160;report&#160;any&#160;suspected&#160;adverse reactions via&#160;the&#160;national&#160;reporting system&#160;<br/>listed&#160;in&#160;Appendix V.&#160;<br/>&#160;<br/><b>4.9&#160;</b></p>
<p style="position:absolute;top:928px;left:149px;white-space:nowrap" class="ft581"><b>Overdose</b>&#160;</p>
<p style="position:absolute;top:947px;left:106px;white-space:nowrap" class="ft5811">&#160;<br/>Single&#160;intravenous&#160;doses&#160;up to 20&#160;mg/kg have&#160;been&#160;administered&#160;without&#160;toxic effects&#160;and&#160;repeated&#160;<br/>doses of&#160;Remsima&#160;subcutaneous formulation&#160;up&#160;to 240&#160;mg have&#160;been administered&#160;without&#160;toxic&#160;<br/>effects.&#160;There&#160;is no&#160;specific&#160;treatment&#160;for&#160;Remsima&#160;overdose. In the&#160;event&#160;of&#160;an overdose, the&#160;patient&#160;<br/>should&#160;be&#160;treated&#160;symptomatically&#160;and&#160;supportive&#160;measures instituted&#160;as&#160;required.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:1080px;left:149px;white-space:nowrap" class="ft581"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:1099px;left:106px;white-space:nowrap" class="ft5811">&#160;<br/><b>5.1&#160;</b></p>
<p style="position:absolute;top:1118px;left:149px;white-space:nowrap" class="ft581"><b>Pharmacodynamic&#160;properties</b>&#160;</p>
<p style="position:absolute;top:1137px;left:106px;white-space:nowrap" class="ft582">&#160;</p>
</div>
<!-- Page 59 -->
<a name="59"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page59-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft590">59&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft592">Pharmacotherapeutic group:&#160;</p>
<p style="position:absolute;top:83px;left:297px;white-space:nowrap" class="ft5918">immunosuppressants, tumour&#160;necrosis&#160;factor&#160;alpha&#160;(TNFα)&#160;inhibitors,&#160;</p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft5911">ATC&#160;code:&#160;L04AB02&#160;<br/>&#160;<br/>Remsima&#160;is&#160;a&#160;biosimilar&#160;medicinal&#160;product. Detailed information is&#160;available&#160;on&#160;the&#160;website&#160;of&#160;the&#160;<br/>European Medicines&#160;Agency&#160;http://www.ema.europa.eu.&#160;<br/>&#160;<br/>Mechanism&#160;of&#160;action&#160;<br/>&#160;<br/>Infliximab&#160;is&#160;a chimeric&#160;human-murine&#160;monoclonal&#160;antibody&#160;that&#160;binds&#160;with&#160;high affinity to&#160;both&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft5910">soluble&#160;and&#160;transmembrane&#160;forms&#160;of&#160;TNFα&#160;but&#160;not&#160;to&#160;lymphotoxin α&#160;(TNFβ).&#160;<br/>&#160;<br/>Pharmacodynamic effects&#160;<br/>&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft5919">Infliximab&#160;inhibits&#160;the&#160;functional&#160;activity&#160;of&#160;TNFα&#160;in a&#160;wide&#160;variety&#160;of&#160;<i>in vitro&#160;</i>bioassays.&#160;Infliximab&#160;<br/>prevented disease&#160;in transgenic&#160;mice&#160;that&#160;develop polyarthritis&#160;as&#160;a&#160;result&#160;of&#160;constitutive&#160;expression of&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft5919">human&#160;TNFα&#160;and when administered after&#160;disease&#160;onset,&#160;it&#160;allowed eroded joints&#160;to heal.&#160;<i>In&#160;vivo</i>,&#160;<br/>infliximab&#160;rapidly&#160;forms&#160;stable&#160;complexes&#160;with&#160;human&#160;</p>
<p style="position:absolute;top:387px;left:473px;white-space:nowrap" class="ft5918">TNFα, a&#160;process&#160;that&#160;parallels&#160;the&#160;loss&#160;of&#160;TNFα&#160;</p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft5911">bioactivity.&#160;<br/>&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft5910">Elevated&#160;concentrations&#160;of&#160;TNFα&#160;have&#160;been found&#160;in the&#160;joints&#160;of&#160;rheumatoid arthritis&#160;patients&#160;and&#160;<br/>correlate with&#160;elevated&#160;disease activity.&#160;In&#160;rheumatoid&#160;arthritis,&#160;treatment&#160;with&#160;infliximab&#160;reduced&#160;<br/>infiltration&#160;of&#160;inflammatory&#160;cells&#160;into&#160;inflamed&#160;areas&#160;of&#160;the&#160;joint&#160;as&#160;well&#160;as&#160;expression of&#160;molecules&#160;<br/>mediating&#160;cellular&#160;adhesion, chemoattraction and&#160;tissue&#160;degradation.&#160;After&#160;infliximab treatment,&#160;<br/>patients exhibited&#160;decreased&#160;levels&#160;of&#160;serum&#160;interleukin&#160;6&#160;(IL-6)&#160;and C-reactive&#160;protein (CRP), and&#160;<br/>increased&#160;haemoglobin&#160;levels&#160;in rheumatoid&#160;arthritis&#160;patients&#160;with&#160;reduced&#160;haemoglobin levels,&#160;<br/>compared with baseline.&#160;Peripheral&#160;blood&#160;lymphocytes&#160;further&#160;showed no significant&#160;decrease&#160;in&#160;<br/>number&#160;or&#160;in&#160;proliferative&#160;responses&#160;to&#160;<i>in&#160;vitro&#160;</i>mitogenic&#160;stimulation&#160;when&#160;compared&#160;with untreated&#160;<br/>patients’&#160;cells.&#160;In&#160;psoriasis&#160;patients,&#160;treatment&#160;with&#160;infliximab&#160;resulted&#160;in&#160;decreases&#160;in&#160;epidermal&#160;<br/>inflammation and normalisation of&#160;keratinocyte&#160;differentiation&#160;in psoriatic&#160;plaques. In psoriatic&#160;<br/>arthritis,&#160;short&#160;term&#160;treatment&#160;with infliximab&#160;reduced&#160;the&#160;number&#160;of&#160;T-cells&#160;and blood vessels&#160;in the&#160;<br/>synovium&#160;and psoriatic&#160;skin.&#160;<br/>&#160;<br/>Histological&#160;evaluation of&#160;colonic&#160;biopsies, obtained before&#160;and 4&#160;weeks&#160;after&#160;administration of&#160;<br/>infliximab,&#160;revealed&#160;a substantial&#160;reduction&#160;in&#160;detectable&#160;TNFα. Infliximab treatment&#160;of&#160;Crohn’s&#160;<br/>disease patients&#160;was&#160;also&#160;associated&#160;with&#160;a substantial&#160;reduction&#160;of&#160;the commonly&#160;elevated&#160;serum&#160;<br/>inflammatory&#160;marker,&#160;CRP.&#160;Total peripheral white&#160;blood&#160;cell counts&#160;were&#160;minimally&#160;affected&#160;in&#160;<br/>infliximab-treated&#160;patients,&#160;although changes&#160;in&#160;lymphocytes, monocytes&#160;and&#160;neutrophils&#160;reflected&#160;<br/>shifts&#160;towards&#160;normal&#160;ranges.&#160;Peripheral&#160;blood mononuclear&#160;cells&#160;(PBMC)&#160;from&#160;infliximab-treated&#160;<br/>patients&#160;showed&#160;undiminished&#160;proliferative&#160;responsiveness&#160;to&#160;stimuli&#160;compared&#160;with&#160;untreated&#160;<br/>patients, and no substantial&#160;changes&#160;in cytokine&#160;production&#160;by stimulated PBMC&#160;were&#160;observed&#160;<br/>following treatment&#160;with infliximab.&#160;Analysis&#160;of&#160;lamina&#160;propria&#160;mononuclear&#160;cells&#160;obtained&#160;by biopsy&#160;<br/>of&#160;the&#160;intestinal mucosa&#160;showed&#160;that infliximab&#160;treatment caused&#160;a&#160;reduction in&#160;the&#160;number&#160;of&#160;cells&#160;<br/>capable of&#160;expressing&#160;TNFα&#160;and interferon&#160;γ. Additional&#160;histological&#160;studies&#160;provided evidence&#160;that&#160;<br/>treatment with&#160;infliximab&#160;reduces&#160;the&#160;infiltration&#160;of&#160;inflammatory&#160;cells&#160;into&#160;affected&#160;areas&#160;of&#160;the&#160;<br/>intestine&#160;and the presence of&#160;inflammation&#160;markers&#160;at&#160;these&#160;sites.&#160;Endoscopic studies of&#160;intestinal&#160;<br/>mucosa&#160;have&#160;shown evidence&#160;of&#160;mucosal&#160;healing&#160;in&#160;infliximab-treated&#160;patients.&#160;<br/>&#160;<br/>Clinical&#160;efficacy&#160;and&#160;safety&#160;<br/><i>&#160;<br/>Adult&#160;rheumatoid&#160;arthritis&#160;<br/>&#160;<br/>Intravenous&#160;formulation&#160;<br/></i>&#160;<br/>The&#160;efficacy&#160;of&#160;infliximab&#160;intravenous&#160;formulation was&#160;assessed&#160;in&#160;two&#160;multicentre, randomised,&#160;<br/>double-blind, pivotal&#160;clinical&#160;studies:&#160;ATTRACT&#160;and&#160;ASPIRE. In both studies&#160;concurrent&#160;use&#160;of&#160;</p>
<p style="position:absolute;top:1128px;left:106px;white-space:nowrap" class="ft5919">stable&#160;doses&#160;of&#160;folic&#160;acid, oral&#160;corticosteroids&#160;(≤10&#160;mg/day)&#160;and/or&#160;non-steroidal&#160;anti-inflammatory&#160;<br/>drugs&#160;(NSAIDs)&#160;was permitted.&#160;</p>
</div>
<!-- Page 60 -->
<a name="60"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft6034{font-size:15px;font-family:GHWNTB+TimesNewRomanPSMT;color:#000000;}
	.ft6035{font-size:15px;line-height:22px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page60-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft600">60&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft6010">&#160;<br/>The primary&#160;endpoints were the&#160;reduction&#160;of&#160;signs and&#160;symptoms&#160;as assessed&#160;by&#160;the ACR&#160;criteria&#160;<br/>(ACR20 for&#160;ATTRACT, landmark ACR-N&#160;for&#160;ASPIRE), the&#160;prevention of&#160;structural&#160;joint&#160;damage,&#160;<br/>and the&#160;improvement&#160;in physical&#160;function. A&#160;reduction&#160;in signs&#160;and symptoms&#160;was&#160;defined to&#160;be&#160;at&#160;<br/>least&#160;a&#160;20%&#160;improvement&#160;(ACR20)&#160;in both&#160;tender&#160;and&#160;swollen joint&#160;counts, and&#160;in&#160;3 of&#160;the&#160;following&#160;<br/>5&#160;criteria:&#160;(1)&#160;evaluator’s&#160;global&#160;assessment,&#160;(2)&#160;patient’s global&#160;assessment, (3)&#160;functional/disability&#160;<br/>measure,&#160;(4)&#160;visual&#160;analogue pain&#160;scale&#160;and&#160;(5)&#160;erythrocyte&#160;sedimentation&#160;rate or&#160;C-reactive&#160;protein.&#160;<br/>ACR-N&#160;uses the same criteria&#160;as&#160;the ACR20,&#160;calculated&#160;by&#160;taking&#160;the lowest&#160;percent&#160;improvement&#160;in&#160;<br/>swollen joint&#160;count, tender&#160;joint&#160;count, and the&#160;median&#160;of&#160;the&#160;remaining&#160;5&#160;components&#160;of&#160;the&#160;ACR&#160;<br/>response.&#160;Structural&#160;joint&#160;damage (erosions and&#160;joint&#160;space narrowing)&#160;in&#160;both&#160;hands and&#160;feet&#160;was&#160;<br/>measured&#160;by the&#160;change&#160;from&#160;baseline&#160;in the&#160;total&#160;van der&#160;Heijde-modified&#160;Sharp&#160;score (0-440). The&#160;<br/>Health&#160;Assessment&#160;Questionnaire&#160;(HAQ;&#160;scale&#160;0-3)&#160;was used&#160;to&#160;measure patients’&#160;average change&#160;<br/>from&#160;baseline&#160;scores&#160;over&#160;time,&#160;in physical&#160;function.&#160;<br/>&#160;<br/>The&#160;ATTRACT&#160;study&#160;evaluated&#160;responses&#160;at&#160;30, 54 and 102&#160;weeks in&#160;a placebo-controlled study of&#160;<br/>428&#160;patients&#160;with&#160;active&#160;rheumatoid&#160;arthritis&#160;despite&#160;treatment with&#160;methotrexate.&#160;Approximately&#160;50%&#160;<br/>of&#160;patients were in&#160;functional&#160;Class III.&#160;Patients received&#160;placebo,&#160;3&#160;mg/kg&#160;or&#160;10&#160;mg/kg&#160;infliximab&#160;at&#160;<br/>weeks&#160;0, 2&#160;and 6, and&#160;then&#160;every&#160;4 or&#160;8&#160;weeks thereafter.&#160;All&#160;patients were on&#160;stable&#160;methotrexate&#160;<br/>doses (median&#160;15&#160;mg/wk)&#160;for&#160;6&#160;months&#160;prior&#160;to enrolment&#160;and were&#160;to&#160;remain on&#160;stable&#160;doses&#160;<br/>throughout&#160;the&#160;study.&#160;<br/>&#160;<br/>Results&#160;from&#160;week 54&#160;(ACR20, total&#160;van der&#160;Heijde-modified&#160;Sharp&#160;score and&#160;HAQ)&#160;are shown in&#160;<br/>Table&#160;3. Higher&#160;degrees&#160;of&#160;clinical&#160;response&#160;(ACR50 and ACR70)&#160;were&#160;observed&#160;in all&#160;infliximab&#160;<br/>groups&#160;at&#160;30 and&#160;54&#160;weeks&#160;compared&#160;with&#160;methotrexate alone.&#160;<br/>&#160;<br/>A&#160;reduction in&#160;the&#160;rate&#160;of&#160;the&#160;progression of&#160;structural&#160;joint&#160;damage&#160;(erosions&#160;and&#160;joint&#160;space&#160;<br/>narrowing)&#160;was&#160;observed&#160;in&#160;all&#160;infliximab groups&#160;at&#160;54&#160;weeks (Table 3).&#160;<br/>&#160;<br/>The&#160;effects observed&#160;at&#160;54&#160;weeks&#160;were&#160;maintained through 102&#160;weeks. Due&#160;to&#160;a&#160;number&#160;of&#160;treatment&#160;<br/>withdrawals,&#160;the&#160;magnitude&#160;of&#160;the effect&#160;difference between&#160;infliximab&#160;and&#160;the methotrexate&#160;alone&#160;<br/>group cannot&#160;be&#160;defined.&#160;<br/>&#160;</p>
<p style="position:absolute;top:696px;left:420px;white-space:nowrap" class="ft601"><b>Table&#160;3&#160;</b></p>
<p style="position:absolute;top:715px;left:127px;white-space:nowrap" class="ft601"><b>Effects&#160;on&#160;ACR20, Structural&#160;Joint&#160;Damage&#160;and&#160;Physical&#160;Function&#160;at&#160;week&#160;54, ATTRACT&#160;</b></p>
<p style="position:absolute;top:735px;left:114px;white-space:nowrap" class="ft602">&#160;</p>
<p style="position:absolute;top:735px;left:293px;white-space:nowrap" class="ft602">&#160;</p>
<p style="position:absolute;top:735px;left:545px;white-space:nowrap" class="ft602">Infliximabb&#160;</p>
<p style="position:absolute;top:755px;left:114px;white-space:nowrap" class="ft602">&#160;</p>
<p style="position:absolute;top:755px;left:293px;white-space:nowrap" class="ft602">Controla&#160;</p>
<p style="position:absolute;top:755px;left:386px;white-space:nowrap" class="ft6011">3&#160;mg/kg&#160;<br/>q&#160;8&#160;wks&#160;</p>
<p style="position:absolute;top:755px;left:466px;white-space:nowrap" class="ft6011">3&#160;mg/kg&#160;<br/>q&#160;4&#160;wks&#160;</p>
<p style="position:absolute;top:755px;left:546px;white-space:nowrap" class="ft6011">10&#160;mg/kg&#160;<br/>q&#160;8&#160;wks&#160;</p>
<p style="position:absolute;top:755px;left:626px;white-space:nowrap" class="ft6011">10&#160;mg/kg&#160;<br/>q&#160;4&#160;wks&#160;</p>
<p style="position:absolute;top:755px;left:705px;white-space:nowrap" class="ft6011">All&#160;<br/>infliximabb&#160;</p>
<p style="position:absolute;top:793px;left:114px;white-space:nowrap" class="ft6011">Patients&#160;with ACR20&#160;<br/>response/Patients&#160;<br/>evaluated&#160;(%)&#160;</p>
<p style="position:absolute;top:793px;left:293px;white-space:nowrap" class="ft6010">15/88&#160;<br/>(17%)&#160;</p>
<p style="position:absolute;top:793px;left:386px;white-space:nowrap" class="ft6010">36/86&#160;<br/>(42%)&#160;</p>
<p style="position:absolute;top:793px;left:466px;white-space:nowrap" class="ft6010">41/86&#160;<br/>(48%)&#160;</p>
<p style="position:absolute;top:793px;left:546px;white-space:nowrap" class="ft6010">51/87&#160;<br/>(59%)&#160;</p>
<p style="position:absolute;top:793px;left:626px;white-space:nowrap" class="ft6010">48/81&#160;<br/>(59%)&#160;</p>
<p style="position:absolute;top:793px;left:705px;white-space:nowrap" class="ft6010">176/340&#160;<br/>(52%)&#160;</p>
<p style="position:absolute;top:850px;left:114px;white-space:nowrap" class="ft6010">Total&#160;scored&#160;(van&#160;der&#160;Heijde-modified Sharp score)&#160;<br/>Change&#160;from&#160;baseline&#160;<br/>(Mean&#160;±&#160;SDc)&#160;</p>
<p style="position:absolute;top:869px;left:293px;white-space:nowrap" class="ft6010">7.0 ±&#160;<br/>10.3&#160;</p>
<p style="position:absolute;top:869px;left:375px;white-space:nowrap" class="ft602">1.3 ±&#160;6.0&#160;</p>
<p style="position:absolute;top:869px;left:457px;white-space:nowrap" class="ft602">1.6 ±&#160;8.5&#160;</p>
<p style="position:absolute;top:869px;left:539px;white-space:nowrap" class="ft602">0.2 ±&#160;3.6&#160;</p>
<p style="position:absolute;top:869px;left:624px;white-space:nowrap" class="ft602">-0.7 ±&#160;3.8&#160;</p>
<p style="position:absolute;top:869px;left:710px;white-space:nowrap" class="ft602">0.6 ±&#160;5.9&#160;</p>
<p style="position:absolute;top:907px;left:114px;white-space:nowrap" class="ft6010">Median&#160;<br/>(Interquartile&#160;range)&#160;</p>
<p style="position:absolute;top:907px;left:293px;white-space:nowrap" class="ft6010">4.0&#160;<br/>(0.5,9.7)&#160;</p>
<p style="position:absolute;top:907px;left:386px;white-space:nowrap" class="ft6010">0.5&#160;<br/>(-1.5,3.0)&#160;</p>
<p style="position:absolute;top:907px;left:466px;white-space:nowrap" class="ft6010">0.1&#160;<br/>(-2.5,3.0)&#160;</p>
<p style="position:absolute;top:907px;left:546px;white-space:nowrap" class="ft6010">0.5&#160;<br/>(-1.5,2.0)&#160;</p>
<p style="position:absolute;top:907px;left:626px;white-space:nowrap" class="ft6010">-0.5&#160;<br/>(-3.0,1.5)&#160;</p>
<p style="position:absolute;top:907px;left:705px;white-space:nowrap" class="ft6010">0.0&#160;<br/>(-1.8,2.0)&#160;</p>
<p style="position:absolute;top:945px;left:114px;white-space:nowrap" class="ft6010">Patients&#160;with no&#160;<br/>deterioration/patients&#160;<br/>evaluated&#160;(%)c&#160;</p>
<p style="position:absolute;top:945px;left:293px;white-space:nowrap" class="ft6011">13/64&#160;<br/>(20%)&#160;</p>
<p style="position:absolute;top:945px;left:386px;white-space:nowrap" class="ft6011">34/71&#160;<br/>(48%)&#160;</p>
<p style="position:absolute;top:945px;left:466px;white-space:nowrap" class="ft6011">35/71&#160;<br/>(49%)&#160;</p>
<p style="position:absolute;top:945px;left:546px;white-space:nowrap" class="ft6011">37/77&#160;<br/>(48%)&#160;</p>
<p style="position:absolute;top:945px;left:626px;white-space:nowrap" class="ft6011">44/66&#160;<br/>(67%)&#160;</p>
<p style="position:absolute;top:945px;left:705px;white-space:nowrap" class="ft6011">150/285&#160;<br/>(53%)&#160;</p>
<p style="position:absolute;top:1002px;left:114px;white-space:nowrap" class="ft6010">HAQ change&#160;from&#160;<br/>baseline&#160;over&#160;timee&#160;<br/>(patients evaluated)&#160;</p>
<p style="position:absolute;top:1002px;left:293px;white-space:nowrap" class="ft602">87&#160;</p>
<p style="position:absolute;top:1002px;left:386px;white-space:nowrap" class="ft602">86&#160;</p>
<p style="position:absolute;top:1002px;left:466px;white-space:nowrap" class="ft602">85&#160;</p>
<p style="position:absolute;top:1002px;left:546px;white-space:nowrap" class="ft602">87&#160;</p>
<p style="position:absolute;top:1002px;left:626px;white-space:nowrap" class="ft602">81&#160;</p>
<p style="position:absolute;top:1002px;left:705px;white-space:nowrap" class="ft602">339&#160;</p>
<p style="position:absolute;top:1059px;left:114px;white-space:nowrap" class="ft602">Mean&#160;±&#160;SDc&#160;</p>
<p style="position:absolute;top:1059px;left:293px;white-space:nowrap" class="ft602">0.2 ±&#160;0.3&#160;&#160;</p>
<p style="position:absolute;top:1059px;left:386px;white-space:nowrap" class="ft602">0.4 ±&#160;0.3&#160;&#160;&#160;0.5 ±&#160;0.4&#160;&#160;&#160;0.5 ±&#160;0.5&#160;&#160;&#160;0.4 ±&#160;0.4&#160;&#160;&#160;0.4 ±&#160;0.4&#160;&#160;</p>
<p style="position:absolute;top:1078px;left:114px;white-space:nowrap" class="ft6020">a&#160;</p>
<p style="position:absolute;top:1078px;left:157px;white-space:nowrap" class="ft6020">control&#160;=&#160;All patients&#160;had&#160;active&#160;RA&#160;despite&#160;treatment with&#160;stable&#160;methotrexate&#160;doses&#160;for&#160;6 months&#160;</p>
<p style="position:absolute;top:1096px;left:114px;white-space:nowrap" class="ft6020">prior&#160;to&#160;enrolment&#160;and&#160;were&#160;to&#160;remain on stable&#160;doses&#160;throughout&#160;the&#160;study.&#160;Concurrent&#160;use&#160;of&#160;stable&#160;doses&#160;of&#160;</p>
<p style="position:absolute;top:1108px;left:114px;white-space:nowrap" class="ft6035">oral&#160;corticosteroids&#160;(≤10&#160;mg/day)&#160;and/or&#160;NSAIDs&#160;was&#160;permitted,&#160;and folate&#160;supplementation was&#160;given.&#160;<br/>b&#160;</p>
<p style="position:absolute;top:1130px;left:157px;white-space:nowrap" class="ft6020">all infliximab doses&#160;given in combination&#160;with methotrexate&#160;and folate&#160;with some&#160;on&#160;corticosteroids&#160;</p>
<p style="position:absolute;top:1147px;left:114px;white-space:nowrap" class="ft6020">and/or&#160;NSAIDs&#160;</p>
</div>
<!-- Page 61 -->
<a name="61"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page61-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft610">61&#160;</p>
<p style="position:absolute;top:90px;left:114px;white-space:nowrap" class="ft612">&#160;</p>
<p style="position:absolute;top:90px;left:293px;white-space:nowrap" class="ft612">&#160;</p>
<p style="position:absolute;top:90px;left:545px;white-space:nowrap" class="ft612">Infliximabb&#160;</p>
<p style="position:absolute;top:109px;left:114px;white-space:nowrap" class="ft612">&#160;</p>
<p style="position:absolute;top:109px;left:293px;white-space:nowrap" class="ft612">Controla&#160;</p>
<p style="position:absolute;top:109px;left:386px;white-space:nowrap" class="ft6111">3&#160;mg/kg&#160;<br/>q&#160;8&#160;wks&#160;</p>
<p style="position:absolute;top:109px;left:466px;white-space:nowrap" class="ft6111">3&#160;mg/kg&#160;<br/>q&#160;4&#160;wks&#160;</p>
<p style="position:absolute;top:109px;left:546px;white-space:nowrap" class="ft6111">10&#160;mg/kg&#160;<br/>q&#160;8&#160;wks&#160;</p>
<p style="position:absolute;top:109px;left:626px;white-space:nowrap" class="ft6111">10&#160;mg/kg&#160;<br/>q&#160;4&#160;wks&#160;</p>
<p style="position:absolute;top:109px;left:705px;white-space:nowrap" class="ft6111">All&#160;<br/>infliximabb&#160;</p>
<p style="position:absolute;top:148px;left:114px;white-space:nowrap" class="ft6120">c&#160;</p>
<p style="position:absolute;top:148px;left:157px;white-space:nowrap" class="ft6120">p &lt;0.001,&#160;for&#160;each infliximab treatment&#160;group&#160;vs.&#160;control&#160;</p>
<p style="position:absolute;top:165px;left:114px;white-space:nowrap" class="ft6120">d&#160;</p>
<p style="position:absolute;top:165px;left:157px;white-space:nowrap" class="ft6120">greater&#160;values&#160;indicate more joint&#160;damage.&#160;</p>
<p style="position:absolute;top:183px;left:114px;white-space:nowrap" class="ft6120">e&#160;</p>
<p style="position:absolute;top:183px;left:157px;white-space:nowrap" class="ft6120">HAQ&#160;=&#160;Health&#160;Assessment&#160;Questionnaire;&#160;greater&#160;values&#160;indicate&#160;less&#160;disability.</p>
<p style="position:absolute;top:181px;left:640px;white-space:nowrap" class="ft612">&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft6110">&#160;<br/>The&#160;ASPIRE&#160;study&#160;evaluated responses&#160;at&#160;54&#160;weeks&#160;in&#160;1,004&#160;methotrexate&#160;naive patients with&#160;early&#160;</p>
<p style="position:absolute;top:232px;left:106px;white-space:nowrap" class="ft6110">(≤3&#160;years&#160;disease duration,&#160;median&#160;0.6&#160;years)&#160;active&#160;rheumatoid arthritis&#160;(median&#160;swollen and tender&#160;<br/>joint&#160;count&#160;of&#160;19&#160;and 31, respectively). All&#160;patients&#160;received&#160;methotrexate&#160;(optimised to 20&#160;mg/wk by&#160;<br/>week 8)&#160;and either&#160;placebo,&#160;3&#160;mg/kg&#160;or&#160;6&#160;mg/kg infliximab&#160;at&#160;weeks&#160;0,&#160;2, and&#160;6 and every 8&#160;weeks&#160;<br/>thereafter. Results&#160;from&#160;week 54 are&#160;shown in Table&#160;4.&#160;<br/>&#160;<br/>After 54&#160;weeks of&#160;treatment,&#160;both&#160;doses&#160;of&#160;infliximab&#160;+&#160;methotrexate&#160;resulted&#160;in&#160;statistically&#160;<br/>significantly&#160;greater&#160;improvement&#160;in&#160;signs&#160;and&#160;symptoms compared&#160;to&#160;methotrexate alone&#160;as&#160;<br/>measured by&#160;the&#160;proportion&#160;of&#160;patients&#160;achieving ACR20, 50 and 70&#160;responses.&#160;<br/>&#160;<br/>In&#160;ASPIRE,&#160;more than&#160;90%&#160;of&#160;patients had&#160;at&#160;least&#160;two&#160;evaluable X-rays. Reduction in&#160;the&#160;rate&#160;of&#160;<br/>progression of&#160;structural&#160;damage&#160;was&#160;observed&#160;at&#160;weeks&#160;30 and&#160;54 in the&#160;infliximab +&#160;methotrexate&#160;<br/>groups&#160;compared to methotrexate&#160;alone.&#160;<br/>&#160;</p>
<p style="position:absolute;top:485px;left:420px;white-space:nowrap" class="ft611"><b>Table&#160;4&#160;</b></p>
<p style="position:absolute;top:503px;left:141px;white-space:nowrap" class="ft611"><b>Effects&#160;on&#160;ACRn,&#160;Structural&#160;Joint&#160;Damage&#160;and Physical&#160;Function at&#160;week 54,&#160;ASPIRE&#160;</b></p>
<p style="position:absolute;top:523px;left:114px;white-space:nowrap" class="ft612">&#160;</p>
<p style="position:absolute;top:523px;left:379px;white-space:nowrap" class="ft612">&#160;</p>
<p style="position:absolute;top:523px;left:567px;white-space:nowrap" class="ft612">Infliximab&#160;+&#160;MTX&#160;</p>
<p style="position:absolute;top:543px;left:114px;white-space:nowrap" class="ft612">&#160;</p>
<p style="position:absolute;top:543px;left:379px;white-space:nowrap" class="ft6111">Placebo&#160;<br/>+&#160;MTX&#160;</p>
<p style="position:absolute;top:543px;left:483px;white-space:nowrap" class="ft612">3&#160;mg/kg&#160;</p>
<p style="position:absolute;top:543px;left:587px;white-space:nowrap" class="ft612">6&#160;mg/kg&#160;</p>
<p style="position:absolute;top:543px;left:690px;white-space:nowrap" class="ft612">Combined&#160;</p>
<p style="position:absolute;top:582px;left:114px;white-space:nowrap" class="ft612">Subjects&#160;randomised&#160;</p>
<p style="position:absolute;top:582px;left:379px;white-space:nowrap" class="ft612">282&#160;</p>
<p style="position:absolute;top:582px;left:483px;white-space:nowrap" class="ft612">359&#160;</p>
<p style="position:absolute;top:582px;left:587px;white-space:nowrap" class="ft612">363&#160;</p>
<p style="position:absolute;top:582px;left:690px;white-space:nowrap" class="ft612">722&#160;</p>
<p style="position:absolute;top:601px;left:114px;white-space:nowrap" class="ft6110">Percentage&#160;ACR&#160;improvement&#160;<br/>Mean&#160;±&#160;SDa&#160;</p>
<p style="position:absolute;top:620px;left:379px;white-space:nowrap" class="ft612">24.8&#160;±&#160;59.7&#160;</p>
<p style="position:absolute;top:620px;left:483px;white-space:nowrap" class="ft612">37.3&#160;±&#160;52.8&#160;</p>
<p style="position:absolute;top:620px;left:587px;white-space:nowrap" class="ft612">42.0&#160;±&#160;47.3&#160;</p>
<p style="position:absolute;top:620px;left:690px;white-space:nowrap" class="ft612">39.6&#160;±&#160;50.1&#160;</p>
<p style="position:absolute;top:639px;left:114px;white-space:nowrap" class="ft6110">Change&#160;from&#160;baseline&#160;in&#160;total&#160;van der&#160;Heijde-modified Sharp scoreb&#160;<br/>Mean&#160;±&#160;SDa&#160;</p>
<p style="position:absolute;top:658px;left:379px;white-space:nowrap" class="ft612">3.70&#160;±&#160;9.61&#160;</p>
<p style="position:absolute;top:658px;left:483px;white-space:nowrap" class="ft612">0.42&#160;±&#160;5.82&#160;</p>
<p style="position:absolute;top:658px;left:587px;white-space:nowrap" class="ft612">0.51&#160;±&#160;5.55&#160;</p>
<p style="position:absolute;top:658px;left:690px;white-space:nowrap" class="ft612">0.46&#160;±&#160;5.68&#160;</p>
<p style="position:absolute;top:676px;left:114px;white-space:nowrap" class="ft612">Median&#160;</p>
<p style="position:absolute;top:676px;left:379px;white-space:nowrap" class="ft612">0.43&#160;</p>
<p style="position:absolute;top:676px;left:483px;white-space:nowrap" class="ft612">0.00&#160;</p>
<p style="position:absolute;top:676px;left:587px;white-space:nowrap" class="ft612">0.00&#160;</p>
<p style="position:absolute;top:676px;left:690px;white-space:nowrap" class="ft612">0.00&#160;</p>
<p style="position:absolute;top:696px;left:114px;white-space:nowrap" class="ft6110">Improvement&#160;from&#160;baseline&#160;in HAQ&#160;averaged over&#160;time&#160;from&#160;week 30&#160;to week 54c&#160;<br/>Mean&#160;±&#160;SDd&#160;</p>
<p style="position:absolute;top:714px;left:379px;white-space:nowrap" class="ft612">0.68 ±&#160;0.63&#160;</p>
<p style="position:absolute;top:714px;left:483px;white-space:nowrap" class="ft612">0.80&#160;±&#160;0.65&#160;</p>
<p style="position:absolute;top:714px;left:587px;white-space:nowrap" class="ft612">0.88&#160;±&#160;0.65&#160;</p>
<p style="position:absolute;top:714px;left:690px;white-space:nowrap" class="ft612">0.84&#160;±&#160;0.65&#160;</p>
<p style="position:absolute;top:734px;left:114px;white-space:nowrap" class="ft6120">a&#160;</p>
<p style="position:absolute;top:734px;left:157px;white-space:nowrap" class="ft6120">&#160;p &lt;0.001,&#160;for&#160;each infliximab&#160;treatment&#160;group&#160;vs&#160;control.&#160;</p>
<p style="position:absolute;top:751px;left:114px;white-space:nowrap" class="ft6120">b&#160;</p>
<p style="position:absolute;top:751px;left:157px;white-space:nowrap" class="ft6120">greater&#160;values&#160;indicate more joint&#160;damage.&#160;</p>
<p style="position:absolute;top:768px;left:114px;white-space:nowrap" class="ft6120">c&#160;</p>
<p style="position:absolute;top:768px;left:157px;white-space:nowrap" class="ft6120">HAQ&#160;=&#160;Health&#160;Assessment Questionnaire; greater&#160;values&#160;indicate&#160;less&#160;disability.&#160;</p>
<p style="position:absolute;top:786px;left:114px;white-space:nowrap" class="ft6120">d&#160;</p>
<p style="position:absolute;top:786px;left:157px;white-space:nowrap" class="ft6120">p =&#160;0.030 and &lt;0.001 for&#160;the&#160;3&#160;mg/kg&#160;and 6&#160;mg/kg treatment&#160;groups&#160;respectively vs.&#160;placebo +&#160;MTX.</p>
<p style="position:absolute;top:785px;left:767px;white-space:nowrap" class="ft612">&#160;</p>
<p style="position:absolute;top:803px;left:106px;white-space:nowrap" class="ft6110">&#160;<br/>Data&#160;to&#160;support dose&#160;titration&#160;in&#160;rheumatoid&#160;arthritis&#160;come&#160;from ATTRACT,&#160;ASPIRE&#160;and&#160;the&#160;START&#160;<br/>study.&#160;START&#160;was&#160;a&#160;randomised,&#160;multicentre, double-blind, 3-arm,&#160;parallel-group&#160;safety&#160;study. In one&#160;<br/>of&#160;the&#160;study&#160;arms&#160;(group 2,&#160;n=329), patients&#160;with an&#160;inadequate&#160;response&#160;were&#160;allowed to dose&#160;titrate&#160;<br/>with 1.5&#160;mg/kg&#160;increments&#160;from 3&#160;up&#160;to&#160;9&#160;mg/kg. The&#160;majority&#160;(67%)&#160;of&#160;these&#160;patients&#160;did not&#160;require&#160;<br/>any dose&#160;titration. Of&#160;the&#160;patients&#160;who required&#160;a&#160;dose&#160;titration,&#160;80%&#160;achieved clinical&#160;response&#160;and&#160;<br/>the&#160;majority&#160;(64%)&#160;of&#160;these&#160;required only one&#160;adjustment&#160;of&#160;1.5&#160;mg/kg.&#160;<br/>&#160;<br/><i>Subcutaneous&#160;formulation&#160;<br/></i>&#160;<br/>The efficacy&#160;of&#160;subcutaneous infliximab&#160;in&#160;rheumatoid&#160;arthritis patients was&#160;assessed&#160;in&#160;a randomised,&#160;<br/>parallel-group pivotal&#160;Phase&#160;I/III&#160;study consisting of&#160;two parts:&#160;Part&#160;1&#160;to determine&#160;the&#160;optimal&#160;dose&#160;of&#160;<br/>subcutaneous&#160;infliximab&#160;and Part&#160;2 to demonstrate&#160;non-inferiority&#160;in&#160;terms of&#160;efficacy&#160;of&#160;subcutaneous&#160;<br/>infliximab compared to intravenous&#160;infliximab&#160;treatment&#160;in&#160;a&#160;double-blind&#160;setting.&#160;&#160;<br/>&#160;<br/>In Part&#160;2&#160;of&#160;this&#160;study,&#160;among&#160;357&#160;patients&#160;who&#160;were&#160;enrolled to&#160;receive 2&#160;doses of&#160;Remsima&#160;3&#160;mg/kg&#160;<br/>intravenously at&#160;Weeks&#160;0 and 2,&#160;167&#160;patients&#160;were randomised&#160;to&#160;receive&#160;Remsima&#160;120&#160;mg&#160;<br/>subcutaneously at&#160;Week 6&#160;and every 2 weeks&#160;up&#160;to&#160;Week 54, while&#160;176&#160;patients were&#160;randomised&#160;to&#160;</p>
</div>
<!-- Page 62 -->
<a name="62"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page62-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft620">62&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft6210">receive&#160;Remsima&#160;3&#160;mg/kg intravenously&#160;at&#160;Weeks&#160;6, 14&#160;and&#160;22 and then switched&#160;to&#160;Remsima&#160;120&#160;mg&#160;<br/>subcutaneous&#160;at&#160;Week 30&#160;once-every 2 weeks&#160;up&#160;to&#160;Week 54.&#160;Methotrexate was given&#160;concomitantly.&#160;&#160;<br/>&#160;<br/>The&#160;primary endpoint&#160;of&#160;the&#160;study&#160;was&#160;the&#160;treatment&#160;difference&#160;of&#160;the&#160;change&#160;from&#160;baseline&#160;of&#160;DAS28&#160;<br/>(CRP)&#160;at&#160;Week&#160;22.&#160;The estimate of&#160;treatment&#160;difference was 0.27&#160;with&#160;corresponding lower&#160;limit&#160;of&#160;<br/>the&#160;two-sided 95%&#160;confidence&#160;interval&#160;[CI]&#160;of&#160;0.02&#160;(95% CI:&#160;0.02,&#160;0.52),&#160;which was&#160;greater&#160;than the&#160;<br/>pre-specified non-inferiority&#160;margin&#160;of&#160;-0.6 indicating non-inferiority of&#160;Remsima&#160;subcutaneous&#160;<br/>formulation&#160;to&#160;Remsima&#160;intravenous&#160;formulation.&#160;<br/>&#160;<br/>The&#160;analysis&#160;of&#160;other&#160;efficacy&#160;endpoints&#160;showed that&#160;efficacy&#160;profile&#160;of&#160;Remsima subcutaneous&#160;<br/>formulation&#160;compared to&#160;Remsima&#160;intravenous&#160;formulation in&#160;RA&#160;patients&#160;was&#160;generally&#160;comparable&#160;<br/>in&#160;terms of&#160;disease activity&#160;measured&#160;by&#160;DAS28&#160;(CRP&#160;and&#160;ESR)&#160;and ACR&#160;response&#160;up&#160;to&#160;Week&#160;54.&#160;<br/>The mean&#160;scores&#160;for&#160;DAS28&#160;(CRP)&#160;and&#160;DAS28&#160;(ESR)&#160;gradually&#160;decreased&#160;from&#160;baseline&#160;at&#160;each&#160;time&#160;<br/>point&#160;until&#160;Week 54&#160;in&#160;each&#160;treatment&#160;arm&#160;(see&#160;Table&#160;5&#160;and&#160;Table 6,&#160;respectively).&#160;<br/>&#160;</p>
<p style="position:absolute;top:374px;left:420px;white-space:nowrap" class="ft621"><b>Table&#160;5&#160;</b></p>
<p style="position:absolute;top:393px;left:263px;white-space:nowrap" class="ft621"><b>Mean&#160;(SD)&#160;Actual&#160;Values of&#160;DAS28&#160;(CRP&#160;and&#160;ESR)</b>&#160;</p>
<p style="position:absolute;top:494px;left:111px;white-space:nowrap" class="ft621"><b>Visit&#160;</b></p>
<p style="position:absolute;top:417px;left:352px;white-space:nowrap" class="ft621"><b>DAS28&#160;(CRP)&#160;</b></p>
<p style="position:absolute;top:417px;left:609px;white-space:nowrap" class="ft621"><b>DAS28&#160;(ESR)&#160;</b></p>
<p style="position:absolute;top:446px;left:293px;white-space:nowrap" class="ft621"><b>Remsima&#160;IV&#160;</b></p>
<p style="position:absolute;top:470px;left:306px;white-space:nowrap" class="ft621"><b>3&#160;mg/kgb&#160;</b></p>
<p style="position:absolute;top:494px;left:309px;white-space:nowrap" class="ft621"><b>(N=174)&#160;</b></p>
<p style="position:absolute;top:446px;left:419px;white-space:nowrap" class="ft621"><b>Remsima&#160;SC&#160;</b></p>
<p style="position:absolute;top:470px;left:439px;white-space:nowrap" class="ft621"><b>120 mg&#160;</b></p>
<p style="position:absolute;top:495px;left:436px;white-space:nowrap" class="ft621"><b>(N=165)&#160;</b></p>
<p style="position:absolute;top:446px;left:550px;white-space:nowrap" class="ft621"><b>Remsima&#160;IV&#160;</b></p>
<p style="position:absolute;top:470px;left:563px;white-space:nowrap" class="ft621"><b>3&#160;mg/kgb&#160;</b></p>
<p style="position:absolute;top:494px;left:565px;white-space:nowrap" class="ft621"><b>(N=174)&#160;</b></p>
<p style="position:absolute;top:446px;left:677px;white-space:nowrap" class="ft621"><b>Remsima&#160;SC&#160;</b></p>
<p style="position:absolute;top:470px;left:697px;white-space:nowrap" class="ft621"><b>120 mg&#160;</b></p>
<p style="position:absolute;top:495px;left:694px;white-space:nowrap" class="ft621"><b>(N=165)&#160;</b></p>
<p style="position:absolute;top:522px;left:111px;white-space:nowrap" class="ft621"><b>Baseline&#160;</b></p>
<p style="position:absolute;top:524px;left:309px;white-space:nowrap" class="ft622">5.9&#160;(0.8)&#160;</p>
<p style="position:absolute;top:524px;left:437px;white-space:nowrap" class="ft622">6.0 (0.8)&#160;</p>
<p style="position:absolute;top:524px;left:566px;white-space:nowrap" class="ft622">6.6&#160;(0.8)&#160;</p>
<p style="position:absolute;top:524px;left:695px;white-space:nowrap" class="ft622">6.7 (0.8)&#160;</p>
<p style="position:absolute;top:553px;left:111px;white-space:nowrap" class="ft621"><b>Week&#160;6&#160;</b></p>
<p style="position:absolute;top:555px;left:309px;white-space:nowrap" class="ft622">4.1&#160;(1.2)&#160;</p>
<p style="position:absolute;top:555px;left:437px;white-space:nowrap" class="ft622">4.0 (1.2)&#160;</p>
<p style="position:absolute;top:555px;left:566px;white-space:nowrap" class="ft622">4.8 (1.3)&#160;</p>
<p style="position:absolute;top:555px;left:695px;white-space:nowrap" class="ft622">4.6 (1.2)&#160;</p>
<p style="position:absolute;top:583px;left:111px;white-space:nowrap" class="ft621"><b>Week&#160;22&#160;</b></p>
<p style="position:absolute;top:585px;left:307px;white-space:nowrap" class="ft622">3.5 (1.2)a&#160;</p>
<p style="position:absolute;top:585px;left:434px;white-space:nowrap" class="ft622">3.3 (1.1)a&#160;</p>
<p style="position:absolute;top:585px;left:566px;white-space:nowrap" class="ft622">4.1 (1.3)&#160;</p>
<p style="position:absolute;top:585px;left:695px;white-space:nowrap" class="ft622">4.0 (1.1)&#160;</p>
<p style="position:absolute;top:613px;left:111px;white-space:nowrap" class="ft621"><b>Week&#160;54&#160;</b></p>
<p style="position:absolute;top:616px;left:307px;white-space:nowrap" class="ft622">2.9 (1.2)b&#160;</p>
<p style="position:absolute;top:616px;left:437px;white-space:nowrap" class="ft622">2.8 (1.1)&#160;</p>
<p style="position:absolute;top:616px;left:563px;white-space:nowrap" class="ft622">3.4&#160;(1.3)b&#160;</p>
<p style="position:absolute;top:616px;left:695px;white-space:nowrap" class="ft622">3.4 (1.2)&#160;</p>
<p style="position:absolute;top:640px;left:106px;white-space:nowrap" class="ft6220">a&#160;</p>
<p style="position:absolute;top:640px;left:149px;white-space:nowrap" class="ft6220">Two-sided 95%&#160;CI&#160;for&#160;difference&#160;in the&#160;mean change&#160;from&#160;baseline&#160;for&#160;DAS28 (CRP)&#160;at&#160;Week 22 was&#160;</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft6222">well&#160;above the&#160;pre-defined non-inferiority&#160;margin&#160;of&#160;-0.6&#160;<br/>b&#160;&#160;</p>
<p style="position:absolute;top:675px;left:149px;white-space:nowrap" class="ft6220">Remsima&#160;IV&#160;was&#160;switched&#160;to&#160;Remsima&#160;SC&#160;at&#160;Week&#160;30</p>
<p style="position:absolute;top:674px;left:479px;white-space:nowrap" class="ft622">&#160;</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft622">&#160;</p>
<p style="position:absolute;top:711px;left:420px;white-space:nowrap" class="ft621"><b>Table&#160;6&#160;</b></p>
<p style="position:absolute;top:730px;left:152px;white-space:nowrap" class="ft621"><b>Proportions&#160;of&#160;Patients Achieving&#160;Clinical&#160;Response&#160;According&#160;to&#160;the ACR&#160;Criteria&#160;</b>&#160;</p>
<p style="position:absolute;top:755px;left:107px;white-space:nowrap" class="ft621"><b>&#160;</b></p>
<p style="position:absolute;top:755px;left:260px;white-space:nowrap" class="ft621"><b>ACR20&#160;</b></p>
<p style="position:absolute;top:755px;left:474px;white-space:nowrap" class="ft621"><b>ACR50&#160;</b></p>
<p style="position:absolute;top:755px;left:686px;white-space:nowrap" class="ft621"><b>ACR70&#160;</b></p>
<p style="position:absolute;top:832px;left:111px;white-space:nowrap" class="ft621"><b>Visit&#160;</b></p>
<p style="position:absolute;top:784px;left:189px;white-space:nowrap" class="ft621"><b>Remsima&#160;IV&#160;</b></p>
<p style="position:absolute;top:808px;left:202px;white-space:nowrap" class="ft621"><b>3&#160;mg/kga&#160;</b></p>
<p style="position:absolute;top:832px;left:205px;white-space:nowrap" class="ft621"><b>(N=174)&#160;</b></p>
<p style="position:absolute;top:784px;left:295px;white-space:nowrap" class="ft621"><b>Remsima&#160;SC&#160;</b></p>
<p style="position:absolute;top:808px;left:315px;white-space:nowrap" class="ft621"><b>120 mg&#160;</b></p>
<p style="position:absolute;top:832px;left:312px;white-space:nowrap" class="ft621"><b>(N=165)&#160;</b></p>
<p style="position:absolute;top:784px;left:403px;white-space:nowrap" class="ft621"><b>Remsima&#160;IV&#160;</b></p>
<p style="position:absolute;top:808px;left:416px;white-space:nowrap" class="ft621"><b>3&#160;mg/kga&#160;</b></p>
<p style="position:absolute;top:832px;left:418px;white-space:nowrap" class="ft621"><b>(N=174)&#160;</b></p>
<p style="position:absolute;top:784px;left:507px;white-space:nowrap" class="ft621"><b>Remsima&#160;SC&#160;</b></p>
<p style="position:absolute;top:808px;left:527px;white-space:nowrap" class="ft621"><b>120 mg&#160;</b></p>
<p style="position:absolute;top:832px;left:524px;white-space:nowrap" class="ft621"><b>(N=165)&#160;</b></p>
<p style="position:absolute;top:784px;left:615px;white-space:nowrap" class="ft621"><b>Remsima&#160;IV&#160;</b></p>
<p style="position:absolute;top:808px;left:629px;white-space:nowrap" class="ft621"><b>3&#160;mg/kga&#160;</b></p>
<p style="position:absolute;top:832px;left:631px;white-space:nowrap" class="ft621"><b>(N=174)&#160;</b></p>
<p style="position:absolute;top:784px;left:720px;white-space:nowrap" class="ft621"><b>Remsima&#160;SC&#160;</b></p>
<p style="position:absolute;top:808px;left:740px;white-space:nowrap" class="ft621"><b>120 mg&#160;</b></p>
<p style="position:absolute;top:832px;left:737px;white-space:nowrap" class="ft621"><b>(N=165)&#160;</b></p>
<p style="position:absolute;top:860px;left:111px;white-space:nowrap" class="ft621"><b>Week&#160;6&#160;</b></p>
<p style="position:absolute;top:862px;left:192px;white-space:nowrap" class="ft622">103&#160;(59.2%)&#160;</p>
<p style="position:absolute;top:862px;left:299px;white-space:nowrap" class="ft622">107&#160;(64.8%)&#160;</p>
<p style="position:absolute;top:862px;left:410px;white-space:nowrap" class="ft622">45 (25.9%)&#160;</p>
<p style="position:absolute;top:862px;left:516px;white-space:nowrap" class="ft622">47&#160;(28.5%)&#160;</p>
<p style="position:absolute;top:862px;left:622px;white-space:nowrap" class="ft622">18 (10.3%)&#160;</p>
<p style="position:absolute;top:862px;left:728px;white-space:nowrap" class="ft622">19 (11.5%)&#160;</p>
<p style="position:absolute;top:890px;left:111px;white-space:nowrap" class="ft621"><b>Week&#160;22&#160;</b></p>
<p style="position:absolute;top:893px;left:192px;white-space:nowrap" class="ft622">137&#160;(78.7%)&#160;</p>
<p style="position:absolute;top:893px;left:299px;white-space:nowrap" class="ft622">139&#160;(84.2%)&#160;</p>
<p style="position:absolute;top:893px;left:410px;white-space:nowrap" class="ft622">90&#160;(51.7%)&#160;</p>
<p style="position:absolute;top:893px;left:516px;white-space:nowrap" class="ft622">85&#160;(51.5%)&#160;</p>
<p style="position:absolute;top:893px;left:622px;white-space:nowrap" class="ft622">49 (28.2%)&#160;</p>
<p style="position:absolute;top:893px;left:728px;white-space:nowrap" class="ft622">46&#160;(27.9%)&#160;</p>
<p style="position:absolute;top:921px;left:111px;white-space:nowrap" class="ft621"><b>Week&#160;54&#160;&#160;</b>125 (71.8%)a&#160;</p>
<p style="position:absolute;top:923px;left:299px;white-space:nowrap" class="ft622">132&#160;(80.0%)&#160;</p>
<p style="position:absolute;top:923px;left:403px;white-space:nowrap" class="ft622">101 (58.0%)a&#160;</p>
<p style="position:absolute;top:923px;left:512px;white-space:nowrap" class="ft622">108&#160;(65.5%)&#160;</p>
<p style="position:absolute;top:923px;left:620px;white-space:nowrap" class="ft622">68 (39.1%)a&#160;</p>
<p style="position:absolute;top:923px;left:728px;white-space:nowrap" class="ft622">77&#160;(46.7%)&#160;</p>
<p style="position:absolute;top:948px;left:106px;white-space:nowrap" class="ft6220">a&#160;</p>
<p style="position:absolute;top:948px;left:149px;white-space:nowrap" class="ft6220">Remsima&#160;IV&#160;was&#160;switched&#160;to&#160;Remsima&#160;SC&#160;at&#160;Week&#160;30&#160;</p>
<p style="position:absolute;top:965px;left:106px;white-space:nowrap" class="ft6211">&#160;<br/>There&#160;are&#160;no clinical&#160;trials&#160;with Remsima&#160;120&#160;mg&#160;given subcutaneously without&#160;intravenous&#160;loading&#160;<br/>doses&#160;of&#160;infliximab&#160;in patients&#160;with&#160;rheumatoid arthritis. However, population pharmacokinetic&#160;and&#160;<br/>pharmacokinetic/pharmacodynamic&#160;modelling&#160;and simulation predicted&#160;comparable&#160;infliximab&#160;<br/>exposure&#160;(AUC&#160;over&#160;8 weeks)&#160;and efficacy (DAS28&#160;and ACR20 response)&#160;from&#160;Week 6&#160;onward&#160;in&#160;<br/>rheumatoid&#160;arthritis&#160;patients&#160;treated&#160;with&#160;Remsima&#160;120&#160;mg&#160;given&#160;without&#160;intravenous&#160;loading doses&#160;of&#160;<br/>infliximab&#160;when&#160;compared&#160;with&#160;Remsima&#160;3&#160;mg/kg&#160;given&#160;intravenously at&#160;Weeks&#160;0, 2 and 6, and&#160;then&#160;<br/>every&#160;8&#160;weeks.&#160;<br/>&#160;</p>
</div>
<!-- Page 63 -->
<a name="63"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft6336{font-size:17px;line-height:25px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page63-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft630">63&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft6310"><i>Adult&#160;Crohn’s&#160;disease&#160;<br/></i>&#160;<br/><i>Intravenous&#160;formulation&#160;<br/></i>&#160;<br/><i>Induction&#160;treatment&#160;in&#160;moderately&#160;to&#160;severely active Crohn’s disease&#160;<br/></i>The&#160;efficacy&#160;of&#160;a&#160;single&#160;dose&#160;treatment&#160;with&#160;infliximab&#160;intravenous&#160;formulation was&#160;assessed in&#160;<br/>108&#160;patients&#160;with active&#160;Crohn’s&#160;disease&#160;(CDAI&#160;</p>
<p style="position:absolute;top:197px;left:427px;white-space:nowrap" class="ft6318">≥220&#160;≤400)&#160;in&#160;a&#160;randomised,&#160;double-blinded,&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft6311">placebo-controlled, dose-response&#160;study. Of&#160;these&#160;108&#160;patients,&#160;27&#160;were&#160;treated&#160;with&#160;the recommended&#160;<br/>dosage&#160;of&#160;infliximab 5&#160;mg/kg. All&#160;patients&#160;had experienced an inadequate&#160;response&#160;to prior&#160;<br/>conventional&#160;therapies. Concurrent&#160;use&#160;of&#160;stable&#160;doses&#160;of&#160;conventional&#160;therapies&#160;was&#160;permitted,&#160;and&#160;<br/>92%&#160;of&#160;patients continued&#160;to&#160;receive these&#160;therapies.&#160;<br/>&#160;<br/>The&#160;primary&#160;endpoint&#160;was&#160;the&#160;proportion of&#160;patients&#160;who experienced a&#160;clinical&#160;response, defined as&#160;a&#160;<br/>decrease in&#160;CDAI&#160;by&#160;</p>
<p style="position:absolute;top:330px;left:249px;white-space:nowrap" class="ft6318">≥70&#160;points&#160;from&#160;baseline at&#160;the 4-week evaluation&#160;and without&#160;an&#160;increase&#160;in the&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft6311">use of&#160;medicinal&#160;products or&#160;surgery&#160;for&#160;Crohn’s disease.&#160;Patients who&#160;responded&#160;at&#160;week&#160;4&#160;were&#160;<br/>followed&#160;to week 12. Secondary&#160;endpoints&#160;included&#160;the&#160;proportion of&#160;patients&#160;in&#160;clinical&#160;remission at&#160;<br/>week&#160;4&#160;(CDAI&#160;&lt;150)&#160;and&#160;clinical&#160;response over&#160;time.&#160;<br/>&#160;<br/>At&#160;week 4,&#160;following administration of&#160;a&#160;single&#160;dose,&#160;22/27&#160;(81%) of infliximab-treated&#160;patients&#160;<br/>receiving&#160;a 5&#160;mg/kg dose&#160;achieved&#160;a&#160;clinical&#160;response&#160;vs.&#160;4/25&#160;(16%)&#160;of&#160;the&#160;placebo-treated&#160;patients&#160;<br/>(p&#160;&lt;0.001). Also&#160;at&#160;week 4,&#160;13/27&#160;(48%)&#160;of infliximab-treated&#160;patients achieved&#160;a&#160;clinical&#160;remission&#160;<br/>(CDAI&#160;&lt;150)&#160;vs.&#160;1/25&#160;(4%)&#160;of&#160;placebo-treated&#160;patients.&#160;A&#160;response was observed&#160;within&#160;2&#160;weeks, with&#160;<br/>a maximum&#160;response at&#160;4&#160;weeks. At&#160;the&#160;last&#160;observation at&#160;12&#160;weeks, 13/27&#160;(48%) of&#160;<br/>infliximab-treated&#160;patients were&#160;still&#160;responding.&#160;<br/><i>&#160;<br/>Maintenance&#160;treatment&#160;in moderately&#160;to&#160;severely active Crohn’s disease&#160;in&#160;adults&#160;<br/></i>The efficacy&#160;of&#160;repeated&#160;infusions with&#160;intravenous&#160;infliximab was&#160;studied&#160;in a&#160;1-year&#160;clinical&#160;study&#160;<br/>(ACCENT&#160;I).&#160;A&#160;total of&#160;573&#160;patients with&#160;moderately&#160;to&#160;severely&#160;active Crohn’s disease&#160;(CDAI&#160;</p>
<p style="position:absolute;top:596px;left:743px;white-space:nowrap" class="ft6318">≥220&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft6311">≤400)&#160;received&#160;a&#160;single&#160;infusion&#160;of&#160;5&#160;mg/kg at&#160;week 0.&#160;178 of&#160;the&#160;580&#160;enrolled patients&#160;(30.7%)&#160;were&#160;<br/>defined&#160;as having&#160;severe&#160;disease (CDAI&#160;score &gt;&#160;300 and concomitant&#160;corticosteroid and/or&#160;<br/>immunosuppressants)&#160;corresponding to the&#160;population&#160;defined&#160;in the&#160;indication&#160;(see&#160;section 4.1). At&#160;<br/>week&#160;2,&#160;all&#160;patients were&#160;assessed&#160;for&#160;clinical&#160;response&#160;and&#160;randomised&#160;to&#160;one of&#160;3&#160;treatment groups; a&#160;<br/>placebo&#160;maintenance&#160;group, 5&#160;mg/kg&#160;maintenance&#160;group and 10&#160;mg/kg&#160;maintenance&#160;group. All&#160;<br/>3&#160;groups&#160;received&#160;repeated&#160;infusions&#160;at&#160;week&#160;2, 6 and every 8&#160;weeks thereafter.&#160;<br/>&#160;<br/>Of&#160;the&#160;573&#160;patients&#160;randomised, 335 (58%)&#160;achieved clinical&#160;response&#160;by&#160;week&#160;2.&#160;These patients were&#160;<br/>classified&#160;as week-2&#160;responders&#160;and&#160;were&#160;included in the&#160;primary analysis&#160;(see&#160;Table&#160;7). Among&#160;<br/>patients classified&#160;as&#160;non-responders&#160;at&#160;week&#160;2,&#160;32%&#160;(26/81)&#160;in the&#160;placebo maintenance&#160;group&#160;and&#160;<br/>42%&#160;(68/163)&#160;in the&#160;infliximab&#160;group achieved&#160;clinical&#160;response&#160;by&#160;week&#160;6.&#160;There was no&#160;difference&#160;<br/>between groups&#160;in&#160;the&#160;number&#160;of&#160;late&#160;responders&#160;thereafter.&#160;<br/>&#160;<br/>The co-primary&#160;endpoints&#160;were&#160;the&#160;proportion of&#160;patients&#160;in clinical&#160;remission (CDAI&#160;&lt;150)&#160;at&#160;<br/>week&#160;30 and time&#160;to loss&#160;of&#160;response&#160;through week&#160;54.&#160;Corticosteroid tapering was&#160;permitted&#160;after&#160;<br/>week&#160;6.&#160;<br/>&#160;</p>
</div>
<!-- Page 64 -->
<a name="64"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page64-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft640">64&#160;</p>
<p style="position:absolute;top:89px;left:420px;white-space:nowrap" class="ft641"><b>Table&#160;7&#160;</b></p>
<p style="position:absolute;top:109px;left:154px;white-space:nowrap" class="ft641"><b>Effects on&#160;response&#160;and&#160;remission&#160;rate,&#160;data&#160;from&#160;ACCENT&#160;I&#160;(Week-2&#160;responders)&#160;</b></p>
<p style="position:absolute;top:128px;left:114px;white-space:nowrap" class="ft642">&#160;</p>
<p style="position:absolute;top:128px;left:456px;white-space:nowrap" class="ft642">ACCENT&#160;I&#160;(Week-2 responders)&#160;</p>
<p style="position:absolute;top:147px;left:521px;white-space:nowrap" class="ft642">%&#160;of&#160;Patients<b>&#160;</b></p>
<p style="position:absolute;top:167px;left:114px;white-space:nowrap" class="ft642">&#160;</p>
<p style="position:absolute;top:167px;left:353px;white-space:nowrap" class="ft6411">Placebo&#160;<br/>Maintenance&#160;</p>
<p style="position:absolute;top:205px;left:402px;white-space:nowrap" class="ft642">&#160;</p>
<p style="position:absolute;top:224px;left:353px;white-space:nowrap" class="ft642">(n=110)&#160;</p>
<p style="position:absolute;top:167px;left:503px;white-space:nowrap" class="ft642">Infliximab&#160;</p>
<p style="position:absolute;top:186px;left:496px;white-space:nowrap" class="ft642">Maintenance&#160;</p>
<p style="position:absolute;top:205px;left:511px;white-space:nowrap" class="ft642">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:224px;left:512px;white-space:nowrap" class="ft642">(n=113)&#160;</p>
<p style="position:absolute;top:243px;left:509px;white-space:nowrap" class="ft642">(p value)&#160;</p>
<p style="position:absolute;top:167px;left:667px;white-space:nowrap" class="ft642">Infliximab&#160;</p>
<p style="position:absolute;top:186px;left:659px;white-space:nowrap" class="ft642">Maintenance&#160;</p>
<p style="position:absolute;top:205px;left:670px;white-space:nowrap" class="ft642">10&#160;mg/kg&#160;</p>
<p style="position:absolute;top:224px;left:675px;white-space:nowrap" class="ft642">(n=112)&#160;</p>
<p style="position:absolute;top:243px;left:672px;white-space:nowrap" class="ft642">(p value)&#160;</p>
<p style="position:absolute;top:263px;left:114px;white-space:nowrap" class="ft6410">Median&#160;time to&#160;loss of&#160;response&#160;<br/>through week&#160;54&#160;</p>
<p style="position:absolute;top:263px;left:353px;white-space:nowrap" class="ft642">19&#160;weeks&#160;</p>
<p style="position:absolute;top:263px;left:507px;white-space:nowrap" class="ft642">38 weeks&#160;</p>
<p style="position:absolute;top:282px;left:514px;white-space:nowrap" class="ft642">(0.002)&#160;</p>
<p style="position:absolute;top:263px;left:666px;white-space:nowrap" class="ft642">&gt;54 weeks&#160;</p>
<p style="position:absolute;top:282px;left:673px;white-space:nowrap" class="ft642">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:300px;left:114px;white-space:nowrap" class="ft641"><b>Week&#160;30&#160;</b></p>
<p style="position:absolute;top:300px;left:353px;white-space:nowrap" class="ft641"><b>&#160;</b></p>
<p style="position:absolute;top:300px;left:468px;white-space:nowrap" class="ft641"><b>&#160;</b></p>
<p style="position:absolute;top:300px;left:625px;white-space:nowrap" class="ft641"><b>&#160;</b></p>
<p style="position:absolute;top:320px;left:114px;white-space:nowrap" class="ft642">Clinical&#160;Responsea&#160;</p>
<p style="position:absolute;top:320px;left:353px;white-space:nowrap" class="ft642">27.3&#160;</p>
<p style="position:absolute;top:320px;left:524px;white-space:nowrap" class="ft642">51.3&#160;</p>
<p style="position:absolute;top:339px;left:509px;white-space:nowrap" class="ft642">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:320px;left:687px;white-space:nowrap" class="ft642">59.1&#160;</p>
<p style="position:absolute;top:339px;left:673px;white-space:nowrap" class="ft642">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:358px;left:114px;white-space:nowrap" class="ft642">Clinical Remission&#160;</p>
<p style="position:absolute;top:358px;left:353px;white-space:nowrap" class="ft642">20.9&#160;</p>
<p style="position:absolute;top:358px;left:524px;white-space:nowrap" class="ft642">38.9&#160;</p>
<p style="position:absolute;top:377px;left:514px;white-space:nowrap" class="ft642">(0.003)&#160;</p>
<p style="position:absolute;top:358px;left:687px;white-space:nowrap" class="ft642">45.5&#160;</p>
<p style="position:absolute;top:377px;left:673px;white-space:nowrap" class="ft642">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:396px;left:114px;white-space:nowrap" class="ft642">Steroid-Free Remission&#160;</p>
<p style="position:absolute;top:396px;left:353px;white-space:nowrap" class="ft642">10.7 (6/56)&#160;</p>
<p style="position:absolute;top:397px;left:497px;white-space:nowrap" class="ft642">31.0 (18/58)&#160;</p>
<p style="position:absolute;top:416px;left:514px;white-space:nowrap" class="ft642">(0.008)&#160;</p>
<p style="position:absolute;top:397px;left:661px;white-space:nowrap" class="ft642">36.8 (21/57)&#160;</p>
<p style="position:absolute;top:416px;left:678px;white-space:nowrap" class="ft642">(0.001)&#160;</p>
<p style="position:absolute;top:435px;left:114px;white-space:nowrap" class="ft641"><b>Week&#160;54&#160;</b></p>
<p style="position:absolute;top:435px;left:353px;white-space:nowrap" class="ft641"><b>&#160;</b></p>
<p style="position:absolute;top:435px;left:538px;white-space:nowrap" class="ft641"><b>&#160;</b></p>
<p style="position:absolute;top:435px;left:702px;white-space:nowrap" class="ft641"><b>&#160;</b></p>
<p style="position:absolute;top:454px;left:114px;white-space:nowrap" class="ft642">Clinical&#160;Responsea&#160;</p>
<p style="position:absolute;top:454px;left:353px;white-space:nowrap" class="ft642">15.5&#160;</p>
<p style="position:absolute;top:454px;left:524px;white-space:nowrap" class="ft642">38.1&#160;</p>
<p style="position:absolute;top:473px;left:509px;white-space:nowrap" class="ft642">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:454px;left:687px;white-space:nowrap" class="ft642">47.7&#160;</p>
<p style="position:absolute;top:473px;left:673px;white-space:nowrap" class="ft642">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:492px;left:114px;white-space:nowrap" class="ft642">Clinical Remission&#160;</p>
<p style="position:absolute;top:492px;left:353px;white-space:nowrap" class="ft642">13.6&#160;</p>
<p style="position:absolute;top:493px;left:524px;white-space:nowrap" class="ft642">28.3&#160;</p>
<p style="position:absolute;top:512px;left:514px;white-space:nowrap" class="ft642">(0.007)&#160;</p>
<p style="position:absolute;top:493px;left:687px;white-space:nowrap" class="ft642">38.4&#160;</p>
<p style="position:absolute;top:512px;left:673px;white-space:nowrap" class="ft642">(&lt;0.001)&#160;</p>
<p style="position:absolute;top:531px;left:114px;white-space:nowrap" class="ft6410">Sustained&#160;Steroid-Free&#160;<br/>Remissionb&#160;</p>
<p style="position:absolute;top:531px;left:353px;white-space:nowrap" class="ft642">5.7 (3/53)&#160;</p>
<p style="position:absolute;top:531px;left:497px;white-space:nowrap" class="ft642">17.9 (10/56)&#160;</p>
<p style="position:absolute;top:550px;left:514px;white-space:nowrap" class="ft642">(0.075)&#160;</p>
<p style="position:absolute;top:531px;left:661px;white-space:nowrap" class="ft642">28.6 (16/56)&#160;</p>
<p style="position:absolute;top:550px;left:678px;white-space:nowrap" class="ft642">(0.002)&#160;</p>
<p style="position:absolute;top:570px;left:114px;white-space:nowrap" class="ft642">a&#160;&#160;Reduction in&#160;CDAI&#160;</p>
<p style="position:absolute;top:564px;left:269px;white-space:nowrap" class="ft6418">≥25%&#160;and ≥70&#160;points.&#160;</p>
<p style="position:absolute;top:589px;left:114px;white-space:nowrap" class="ft642">b&#160;&#160;&#160;CDAI&#160;&lt;150 at&#160;both Week&#160;30 and 54&#160;and not&#160;receiving&#160;corticosteroids&#160;in&#160;the&#160;3&#160;months&#160;prior&#160;to&#160;</p>
<p style="position:absolute;top:608px;left:136px;white-space:nowrap" class="ft642">Week&#160;54 among patients&#160;who were&#160;receiving&#160;corticosteroids&#160;at&#160;baseline.&#160;</p>
<p style="position:absolute;top:627px;left:106px;white-space:nowrap" class="ft6410">&#160;<br/>Beginning at&#160;week&#160;14, patients&#160;who had&#160;responded to&#160;treatment, but&#160;subsequently&#160;lost&#160;their&#160;clinical&#160;<br/>benefit,&#160;were allowed&#160;to&#160;cross over&#160;to&#160;a dose of&#160;infliximab&#160;5&#160;mg/kg&#160;higher&#160;than the&#160;dose&#160;to&#160;which they&#160;<br/>were&#160;originally randomised. Eighty nine&#160;percent&#160;(50/56)&#160;of&#160;patients&#160;who&#160;lost&#160;clinical&#160;response&#160;on&#160;<br/>infliximab&#160;5&#160;mg/kg maintenance&#160;therapy&#160;after&#160;week&#160;14 responded&#160;to&#160;treatment&#160;with infliximab&#160;<br/>10&#160;mg/kg.&#160;<br/>&#160;<br/>Improvements&#160;in quality of&#160;life&#160;measures, a&#160;reduction&#160;in disease-related hospitalisations&#160;and&#160;<br/>corticosteroid&#160;use were seen&#160;in&#160;the&#160;infliximab&#160;maintenance groups compared&#160;with&#160;the placebo&#160;<br/>maintenance&#160;group at&#160;weeks&#160;30 and&#160;54.&#160;<br/><i>&#160;<br/></i>Infliximab with or&#160;without&#160;AZA&#160;was&#160;assessed in&#160;a&#160;randomised,&#160;double-blind, active&#160;comparator&#160;study&#160;<br/>(SONIC)&#160;of&#160;508&#160;adult&#160;patients&#160;with&#160;moderate&#160;to severe&#160;Crohn’s&#160;disease&#160;(CDAI&#160;</p>
<p style="position:absolute;top:849px;left:631px;white-space:nowrap" class="ft6418">≥220&#160;≤450)&#160;who were&#160;</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft6410">naive&#160;to&#160;biologics&#160;and immunosuppressants and&#160;had&#160;a&#160;median&#160;disease duration&#160;of&#160;2.3&#160;years. At&#160;<br/>baseline 27.4%&#160;of&#160;patients&#160;were receiving&#160;systemic&#160;corticosteroids,&#160;14.2%&#160;of&#160;patients were&#160;receiving&#160;<br/>budesonide, and 54.3%&#160;of&#160;patients&#160;were&#160;receiving 5-ASA&#160;compounds. Patients&#160;were&#160;randomised to&#160;<br/>receive&#160;AZA&#160;monotherapy,&#160;infliximab&#160;monotherapy, or&#160;infliximab plus&#160;AZA&#160;combination therapy.&#160;<br/>Infliximab&#160;was&#160;administered&#160;at a&#160;dose&#160;of&#160;5&#160;mg/kg&#160;at&#160;weeks&#160;0,&#160;2, 6, and then every&#160;8 weeks. AZA&#160;was&#160;<br/>given at&#160;a&#160;dose&#160;of&#160;2.5&#160;mg/kg daily.&#160;<br/>&#160;<br/>The&#160;primary&#160;endpoint&#160;of&#160;the&#160;study&#160;was&#160;corticosteroid-free clinical&#160;remission&#160;at&#160;week&#160;26,&#160;defined as&#160;<br/>patients&#160;in clinical&#160;remission (CDAI&#160;of&#160;&lt;150)&#160;who,&#160;for&#160;at&#160;least&#160;3 weeks, had not&#160;taken oral&#160;systemic&#160;<br/>corticosteroids&#160;(prednisone&#160;or&#160;equivalent)&#160;or&#160;budesonide at&#160;a dose &gt;6&#160;mg/day.&#160;For&#160;results see Table&#160;8.&#160;<br/>The&#160;proportions&#160;of&#160;patients&#160;with&#160;mucosal&#160;healing at&#160;week&#160;26 were&#160;significantly greater&#160;in&#160;the&#160;<br/>infliximab plus&#160;AZA&#160;combination (43.9%, p&lt;0.001)&#160;and infliximab&#160;monotherapy&#160;groups&#160;(30.1%,&#160;<br/>p=0.023)&#160;compared to the&#160;AZA&#160;monotherapy&#160;group&#160;(16.5%).&#160;</p>
</div>
<!-- Page 65 -->
<a name="65"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page65-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft650">65&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft651"><b>&#160;</b></p>
<p style="position:absolute;top:117px;left:420px;white-space:nowrap" class="ft651"><b>Table&#160;8&#160;</b></p>
<p style="position:absolute;top:136px;left:143px;white-space:nowrap" class="ft651"><b>Percent&#160;of&#160;patients achieving&#160;corticosteroid-free clinical&#160;remission&#160;at&#160;Week&#160;26,&#160;SONIC&#160;</b></p>
<p style="position:absolute;top:156px;left:225px;white-space:nowrap" class="ft651"><b>&#160;</b></p>
<p style="position:absolute;top:156px;left:385px;white-space:nowrap" class="ft652">AZA&#160;</p>
<p style="position:absolute;top:175px;left:358px;white-space:nowrap" class="ft652">Monotherapy&#160;</p>
<p style="position:absolute;top:156px;left:503px;white-space:nowrap" class="ft652">Infliximab&#160;</p>
<p style="position:absolute;top:175px;left:494px;white-space:nowrap" class="ft652">Monotherapy&#160;</p>
<p style="position:absolute;top:156px;left:641px;white-space:nowrap" class="ft652">Infliximab&#160;+&#160;AZA&#160;</p>
<p style="position:absolute;top:175px;left:632px;white-space:nowrap" class="ft652">Combination therapy&#160;</p>
<p style="position:absolute;top:195px;left:114px;white-space:nowrap" class="ft651"><b>Week&#160;26&#160;</b></p>
<p style="position:absolute;top:195px;left:353px;white-space:nowrap" class="ft651"><b>&#160;</b></p>
<p style="position:absolute;top:195px;left:468px;white-space:nowrap" class="ft651"><b>&#160;</b></p>
<p style="position:absolute;top:195px;left:625px;white-space:nowrap" class="ft651"><b>&#160;</b></p>
<p style="position:absolute;top:214px;left:114px;white-space:nowrap" class="ft652">All&#160;randomised&#160;patients&#160;</p>
<p style="position:absolute;top:214px;left:381px;white-space:nowrap" class="ft652">30.0%&#160;</p>
<p style="position:absolute;top:233px;left:374px;white-space:nowrap" class="ft652">(51/170)&#160;</p>
<p style="position:absolute;top:214px;left:486px;white-space:nowrap" class="ft652">44.4%&#160;(75/169)&#160;</p>
<p style="position:absolute;top:233px;left:501px;white-space:nowrap" class="ft652">(p=0.006)*&#160;</p>
<p style="position:absolute;top:214px;left:650px;white-space:nowrap" class="ft652">56.8%&#160;(96/169)&#160;</p>
<p style="position:absolute;top:233px;left:665px;white-space:nowrap" class="ft652">(p&lt;0.001)*&#160;</p>
<p style="position:absolute;top:253px;left:114px;white-space:nowrap" class="ft652">*&#160;&#160;p-values&#160;represent&#160;each infliximab&#160;treatment&#160;group&#160;vs. AZA&#160;monotherapy.&#160;</p>
<p style="position:absolute;top:272px;left:106px;white-space:nowrap" class="ft6511"><i>&#160;<br/></i>Similar&#160;trends in&#160;the&#160;achievement&#160;of&#160;corticosteroid-free&#160;clinical&#160;remission&#160;were observed&#160;at&#160;week&#160;50.&#160;<br/>Furthermore, improved quality of&#160;life&#160;as&#160;measured by IBDQ&#160;was&#160;observed with&#160;infliximab.&#160;<br/><i>&#160;<br/>Induction&#160;treatment&#160;in&#160;fistulising&#160;active&#160;Crohn’s&#160;disease&#160;<br/></i>The efficacy&#160;was assessed&#160;in&#160;a randomised,&#160;double-blinded, placebo-controlled study in&#160;94&#160;patients&#160;<br/>with&#160;fistulising&#160;Crohn’s disease who&#160;had&#160;fistulae&#160;that&#160;were of&#160;at&#160;least&#160;3&#160;months’&#160;duration. Thirty&#160;one&#160;of&#160;<br/>these&#160;patients&#160;were&#160;treated with infliximab intravenous&#160;formulation 5&#160;mg/kg. Approximately&#160;93%&#160;of&#160;<br/>the&#160;patients&#160;had previously&#160;received antibiotic&#160;or&#160;immunosuppressive&#160;therapy.&#160;<br/>&#160;<br/>Concurrent&#160;use&#160;of&#160;stable&#160;doses&#160;of&#160;conventional&#160;therapies&#160;was&#160;permitted, and 83%&#160;of&#160;patients&#160;continued&#160;<br/>to&#160;receive&#160;at&#160;least&#160;one of&#160;these&#160;therapies.&#160;Patients&#160;received&#160;three doses of&#160;either&#160;placebo&#160;or&#160;infliximab&#160;<br/>at&#160;weeks&#160;0, 2&#160;and 6.&#160;Patients&#160;were&#160;followed up&#160;to 26&#160;weeks.&#160;The primary&#160;endpoint&#160;was&#160;the&#160;proportion&#160;<br/>of&#160;patients who&#160;experienced&#160;a clinical&#160;response,&#160;defined&#160;as&#160;</p>
<p style="position:absolute;top:513px;left:498px;white-space:nowrap" class="ft6518">≥50%&#160;reduction&#160;from&#160;baseline&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft6510">number&#160;of&#160;fistulae&#160;draining&#160;upon gentle&#160;compression&#160;on at&#160;least&#160;two consecutive&#160;visits&#160;(4&#160;weeks apart),&#160;<br/>without&#160;an&#160;increase&#160;in&#160;the use&#160;of&#160;medicinal&#160;products&#160;or&#160;surgery for&#160;Crohn’s&#160;disease.&#160;<br/>&#160;<br/>Sixty&#160;eight&#160;percent&#160;(21/31)&#160;of&#160;infliximab-treated&#160;patients receiving&#160;a&#160;5&#160;mg/kg&#160;dose&#160;regimen achieved a&#160;<br/>clinical&#160;response&#160;vs. 26%&#160;(8/31)&#160;placebo-treated&#160;patients&#160;(p=0.002).&#160;The&#160;median time&#160;to&#160;onset&#160;of&#160;<br/>response&#160;in the&#160;infliximab-treated group was&#160;2&#160;weeks.&#160;The&#160;median duration&#160;of&#160;response&#160;was&#160;12&#160;weeks.&#160;<br/>Additionally, closure&#160;of&#160;all&#160;fistulae&#160;was&#160;achieved&#160;in 55%&#160;of&#160;infliximab-treated patients&#160;compared with&#160;<br/>13%&#160;of&#160;placebo-treated&#160;patients&#160;(p=0.001).&#160;<br/><i>&#160;<br/>Maintenance&#160;treatment&#160;in fistulising active&#160;Crohn’s&#160;disease&#160;<br/></i>The efficacy&#160;of&#160;repeated&#160;infusions with&#160;infliximab&#160;in&#160;patients with&#160;fistulising&#160;Crohn’s disease was&#160;<br/>studied in&#160;a&#160;1-year&#160;clinical&#160;study&#160;(ACCENT&#160;II). A&#160;total&#160;of&#160;306&#160;patients&#160;received 3 doses&#160;of&#160;intravenous&#160;<br/>infliximab&#160;5&#160;mg/kg&#160;at&#160;week&#160;0, 2 and&#160;6. At&#160;baseline, 87%&#160;of&#160;the&#160;patients&#160;had perianal&#160;fistulae,&#160;14%&#160;had&#160;<br/>abdominal&#160;fistulae,&#160;9%&#160;had&#160;rectovaginal&#160;fistulae.&#160;The&#160;median&#160;CDAI&#160;score was&#160;180.&#160;At&#160;week&#160;14,&#160;<br/>282&#160;patients&#160;were&#160;assessed&#160;for&#160;clinical&#160;response&#160;and&#160;randomised&#160;to&#160;receive either&#160;placebo&#160;or&#160;5&#160;mg/kg&#160;<br/>infliximab every 8&#160;weeks&#160;through week&#160;46.&#160;<br/>&#160;<br/>Week-14 responders&#160;(195/282)&#160;were&#160;analysed for&#160;the&#160;primary&#160;endpoint,&#160;which&#160;was&#160;time&#160;from&#160;<br/>randomisation to&#160;loss&#160;of&#160;response&#160;(see&#160;Table&#160;9). Corticosteroid tapering was&#160;permitted after&#160;week&#160;6.&#160;<br/>&#160;</p>
<p style="position:absolute;top:917px;left:420px;white-space:nowrap" class="ft651"><b>Table&#160;9&#160;</b></p>
<p style="position:absolute;top:937px;left:198px;white-space:nowrap" class="ft651"><b>Effects on&#160;response&#160;rate,&#160;data&#160;from&#160;ACCENT&#160;II (Week-14&#160;responders)&#160;</b></p>
<p style="position:absolute;top:956px;left:230px;white-space:nowrap" class="ft652">&#160;</p>
<p style="position:absolute;top:956px;left:454px;white-space:nowrap" class="ft652">ACCENT&#160;II&#160;(Week-14 responders)&#160;</p>
<p style="position:absolute;top:976px;left:230px;white-space:nowrap" class="ft652">&#160;</p>
<p style="position:absolute;top:977px;left:399px;white-space:nowrap" class="ft652">Placebo&#160;</p>
<p style="position:absolute;top:996px;left:383px;white-space:nowrap" class="ft652">Maintenance&#160;</p>
<p style="position:absolute;top:1015px;left:403px;white-space:nowrap" class="ft652">(n=99)&#160;</p>
<p style="position:absolute;top:977px;left:535px;white-space:nowrap" class="ft652">Infliximab&#160;</p>
<p style="position:absolute;top:996px;left:527px;white-space:nowrap" class="ft652">Maintenance&#160;</p>
<p style="position:absolute;top:1016px;left:537px;white-space:nowrap" class="ft652">(5&#160;mg/kg)&#160;</p>
<p style="position:absolute;top:1035px;left:547px;white-space:nowrap" class="ft652">(n=96)&#160;</p>
<p style="position:absolute;top:976px;left:690px;white-space:nowrap" class="ft652">p-value&#160;</p>
<p style="position:absolute;top:1054px;left:114px;white-space:nowrap" class="ft6511">Median&#160;time to&#160;loss of&#160;response&#160;<br/>through week&#160;54&#160;</p>
<p style="position:absolute;top:1054px;left:394px;white-space:nowrap" class="ft652">14&#160;weeks&#160;</p>
<p style="position:absolute;top:1054px;left:534px;white-space:nowrap" class="ft652">&gt;40&#160;weeks&#160;</p>
<p style="position:absolute;top:1054px;left:691px;white-space:nowrap" class="ft652">&lt;0.001&#160;</p>
<p style="position:absolute;top:1092px;left:114px;white-space:nowrap" class="ft651"><b>Week&#160;54&#160;</b></p>
<p style="position:absolute;top:1092px;left:425px;white-space:nowrap" class="ft652">&#160;</p>
<p style="position:absolute;top:1092px;left:570px;white-space:nowrap" class="ft652">&#160;</p>
<p style="position:absolute;top:1092px;left:714px;white-space:nowrap" class="ft652">&#160;</p>
<p style="position:absolute;top:1111px;left:114px;white-space:nowrap" class="ft652">Fistula&#160;Response (%)a&#160;</p>
<p style="position:absolute;top:1111px;left:411px;white-space:nowrap" class="ft652">23.5&#160;</p>
<p style="position:absolute;top:1111px;left:555px;white-space:nowrap" class="ft652">46.2&#160;</p>
<p style="position:absolute;top:1111px;left:696px;white-space:nowrap" class="ft652">0.001&#160;</p>
<p style="position:absolute;top:1130px;left:114px;white-space:nowrap" class="ft652">Complete&#160;fistula&#160;response&#160;(%)b&#160;</p>
<p style="position:absolute;top:1130px;left:411px;white-space:nowrap" class="ft652">19.4&#160;</p>
<p style="position:absolute;top:1130px;left:555px;white-space:nowrap" class="ft652">36.3&#160;</p>
<p style="position:absolute;top:1130px;left:696px;white-space:nowrap" class="ft652">0.009&#160;</p>
</div>
<!-- Page 66 -->
<a name="66"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page66-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft660">66&#160;</p>
<p style="position:absolute;top:90px;left:114px;white-space:nowrap" class="ft662">a&#160;&#160;A&#160;</p>
<p style="position:absolute;top:84px;left:152px;white-space:nowrap" class="ft6618">≥50%&#160;reduction&#160;from&#160;baseline&#160;in the&#160;number&#160;of&#160;draining fistulas&#160;over&#160;a&#160;period of&#160;≥4 weeks.&#160;</p>
<p style="position:absolute;top:109px;left:114px;white-space:nowrap" class="ft662">b&#160;&#160;Absence&#160;of&#160;any draining&#160;fistulas.&#160;</p>
<p style="position:absolute;top:128px;left:106px;white-space:nowrap" class="ft6610">&#160;<br/>Beginning at&#160;week 22, patients&#160;who initially&#160;responded to&#160;treatment&#160;and subsequently&#160;lost&#160;their&#160;<br/>response&#160;were eligible to&#160;cross&#160;over&#160;to&#160;active re-treatment&#160;every 8&#160;weeks at&#160;a dose&#160;of&#160;infliximab&#160;<br/>5&#160;mg/kg higher&#160;than&#160;the&#160;dose&#160;to which&#160;they were&#160;originally randomised. Among&#160;patients&#160;in the&#160;<br/>infliximab&#160;5&#160;mg/kg group&#160;who crossed&#160;over&#160;because&#160;of&#160;loss&#160;of&#160;fistula&#160;response&#160;after&#160;week&#160;22, 57%&#160;<br/>(12/21)&#160;responded&#160;to re-treatment with&#160;infliximab&#160;10&#160;mg/kg every 8&#160;weeks.&#160;<br/>&#160;<br/>There was no&#160;significant&#160;difference between&#160;placebo and infliximab&#160;for&#160;the&#160;proportion of&#160;patients&#160;with&#160;<br/>sustained&#160;closure of&#160;all&#160;fistulas&#160;through&#160;week&#160;54,&#160;for&#160;symptoms such&#160;as&#160;proctalgia,&#160;abscesses and&#160;<br/>urinary&#160;tract&#160;infection or&#160;for&#160;number&#160;of&#160;newly&#160;developed fistulas&#160;during&#160;treatment.&#160;<br/>&#160;<br/>Maintenance&#160;therapy with infliximab every 8&#160;weeks&#160;significantly&#160;reduced&#160;disease-related&#160;<br/>hospitalisations&#160;and&#160;surgeries&#160;compared with&#160;placebo.&#160;Furthermore, a&#160;reduction&#160;in&#160;corticosteroid use&#160;<br/>and improvements&#160;in quality of&#160;life&#160;were&#160;observed.&#160;<br/><i>&#160;<br/>Subcutaneous&#160;formulation&#160;<br/>&#160;<br/></i>The efficacy&#160;of&#160;subcutaneous&#160;infliximab&#160;in&#160;active Crohn’s disease&#160;and&#160;active&#160;ulcerative&#160;colitis&#160;patients&#160;<br/>was assessed&#160;in&#160;an&#160;open-label,&#160;randomised, parallel-group, Phase&#160;I&#160;study&#160;consisting&#160;of&#160;two&#160;parts: Part&#160;<br/>1&#160;to&#160;determine&#160;the&#160;optimal&#160;dose&#160;of&#160;subcutaneous&#160;infliximab and&#160;Part&#160;2&#160;to demonstrate&#160;non-inferiority&#160;<br/>in&#160;terms of&#160;PK&#160;of&#160;subcutaneous&#160;infliximab&#160;compared to intravenous&#160;infliximab treatment.<i>&#160;<br/></i>&#160;<br/>In&#160;Part&#160;1 of&#160;this&#160;study,&#160;45&#160;patients&#160;with&#160;active&#160;Crohn’s&#160;disease&#160;were enrolled&#160;to&#160;receive 2&#160;doses&#160;of&#160;<br/>Remsima&#160;5&#160;mg/kg&#160;intravenously at&#160;Weeks&#160;0 and&#160;2 and&#160;subsequently&#160;44&#160;patients&#160;were randomised&#160;into&#160;<br/>four&#160;cohorts&#160;to&#160;receive Remsima 5&#160;mg/kg intravenously&#160;(n=13)&#160;at&#160;Week 6&#160;and every 8 weeks&#160;up to&#160;<br/>Week&#160;54, Remsima&#160;120&#160;mg&#160;subcutaneously (n=11), Remsima&#160;180&#160;mg subcutaneously&#160;(n=12)&#160;or&#160;<br/>Remsima&#160;240&#160;mg&#160;subcutaneously (n=8)&#160;at&#160;Week 6 and&#160;every 2 weeks&#160;up&#160;to Week&#160;54.&#160;&#160;<br/>&#160;<br/>In&#160;Part&#160;2&#160;of&#160;this&#160;study,&#160;among 136 patients&#160;(57 patients&#160;with&#160;active&#160;Crohn’s disease&#160;and 79&#160;patients&#160;<br/>with&#160;active&#160;ulcerative&#160;colitis)&#160;who were&#160;enrolled to&#160;receive&#160;2&#160;doses&#160;of&#160;Remsima 5&#160;mg/kg intravenously&#160;<br/>at&#160;Weeks&#160;0 and&#160;2, 66 patients&#160;(28 patients&#160;with&#160;active&#160;Crohn’s&#160;disease&#160;and 38 patients&#160;with&#160;active&#160;<br/>ulcerative&#160;colitis)&#160;were randomised&#160;to&#160;receive&#160;Remsima&#160;120/&#160;240&#160;mg subcutaneously at&#160;Week&#160;6 and&#160;<br/>every&#160;2&#160;weeks&#160;up&#160;to Week&#160;54, while&#160;65 patients&#160;(25 patients&#160;with&#160;active&#160;Crohn’s&#160;disease&#160;and 40&#160;<br/>patients with&#160;active&#160;ulcerative&#160;colitis)&#160;were randomised&#160;to&#160;receive Remsima 5&#160;mg/kg&#160;intravenously at&#160;<br/>Week&#160;6, 14 and 22&#160;and then switched&#160;to Remsima&#160;120/&#160;240&#160;mg&#160;subcutaneous&#160;formulation&#160;at&#160;Week 30&#160;<br/>once-every 2 weeks&#160;up&#160;to Week 54.&#160;The&#160;dosage&#160;of&#160;Remsima&#160;120/&#160;240&#160;mg subcutaneous&#160;formulation&#160;<br/>was&#160;determined based on&#160;the&#160;patient’s&#160;body&#160;weight&#160;at&#160;Week&#160;6&#160;for&#160;those who&#160;received&#160;Remsima&#160;<br/>subcutaneously and at&#160;Week 30 for&#160;those who&#160;switched&#160;to&#160;Remsima subcutaneous formulation&#160;<br/>(Remsima&#160;subcutaneous&#160;</p>
<p style="position:absolute;top:843px;left:271px;white-space:nowrap" class="ft6618">120 mg&#160;for&#160;patients&#160;&lt;80 kg;&#160;240 mg&#160;for&#160;patients&#160;≥80&#160;kg).&#160;</p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft6611">&#160;<br/>In&#160;active&#160;Crohn’s disease&#160;patients, the&#160;descriptive&#160;efficacy results&#160;following Remsima&#160;120&#160;mg&#160;<br/>subcutaneous&#160;formulation were&#160;generally comparable&#160;to Remsima&#160;5&#160;mg/kg intravenous&#160;formulation&#160;in&#160;<br/>terms of&#160;clinical&#160;response&#160;(CDAI-70 response&#160;</p>
<p style="position:absolute;top:919px;left:414px;white-space:nowrap" class="ft6618">defined&#160;as&#160;a&#160;decrease&#160;in CDAI&#160;by&#160;≥70 points&#160;and&#160;</p>
<p style="position:absolute;top:943px;left:106px;white-space:nowrap" class="ft662">CDAI-100 response&#160;defined as&#160;</p>
<p style="position:absolute;top:937px;left:314px;white-space:nowrap" class="ft6618">≥100 points&#160;from&#160;baseline), clinical&#160;remission&#160;(defined&#160;as&#160;an&#160;absolute&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft662">CDAI&#160;score&#160;of&#160;&lt;150 points)&#160;and&#160;endoscopy&#160;assessments&#160;(endoscopic response defined&#160;as&#160;a decrease&#160;in&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft6619">≥50%&#160;of&#160;overall&#160;Simplified&#160;Endoscopic&#160;Activity Score&#160;for&#160;Crohn’s&#160;Disease&#160;(SES-CD)&#160;score from&#160;the&#160;<br/>baseline&#160;value&#160;and endoscopic&#160;remission defined as&#160;an absolute&#160;SES-CD&#160;score of&#160;</p>
<p style="position:absolute;top:994px;left:647px;white-space:nowrap" class="ft6618">≤2 points).&#160;</p>
<p style="position:absolute;top:1019px;left:106px;white-space:nowrap" class="ft6610"><i>&#160;<br/>Adult ulcerative&#160;colitis&#160;<br/></i>&#160;<br/><i>Intravenous&#160;formulation&#160;<br/>&#160;<br/></i>The&#160;safety&#160;and&#160;efficacy&#160;of&#160;intravenous&#160;infliximab&#160;were&#160;assessed&#160;in&#160;two&#160;(ACT&#160;1 and&#160;ACT&#160;2)&#160;<br/>randomised, double-blind, placebo-controlled&#160;clinical studies&#160;in&#160;adult&#160;patients&#160;with&#160;moderately&#160;to&#160;<br/>severely&#160;active ulcerative colitis (Mayo&#160;score 6&#160;to&#160;12;&#160;Endoscopy&#160;subscore&#160;</p>
<p style="position:absolute;top:1146px;left:604px;white-space:nowrap" class="ft6618">≥&#160;2)&#160;with&#160;an inadequate&#160;</p>
</div>
<!-- Page 67 -->
<a name="67"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page67-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft670">67&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft6711">response&#160;to conventional&#160;therapies&#160;[oral&#160;corticosteroids, aminosalicylates&#160;and/or&#160;immunomodulators&#160;<br/>(6-MP,&#160;AZA)].&#160;Concomitant stable&#160;doses&#160;of&#160;oral aminosalicylates,&#160;corticosteroids,&#160;and/or&#160;<br/>immunomodulatory agents&#160;were&#160;permitted. In both studies,&#160;patients&#160;were&#160;randomised to receive&#160;either&#160;<br/>placebo, 5&#160;mg/kg&#160;infliximab, or&#160;10&#160;mg/kg&#160;infliximab&#160;at&#160;weeks&#160;0, 2, 6,&#160;14 and 22,&#160;and in ACT&#160;1&#160;at&#160;<br/>weeks&#160;30,&#160;38 and 46. Corticosteroid&#160;taper&#160;was&#160;permitted after&#160;week&#160;8.&#160;<br/>&#160;</p>
<p style="position:absolute;top:203px;left:416px;white-space:nowrap" class="ft671"><b>Table&#160;10&#160;</b></p>
<p style="position:absolute;top:222px;left:144px;white-space:nowrap" class="ft671"><b>Effects&#160;on&#160;clinical&#160;response, clinical&#160;remission&#160;and&#160;mucosal&#160;healing at&#160;Weeks&#160;8 and&#160;30.&#160;</b></p>
<p style="position:absolute;top:241px;left:332px;white-space:nowrap" class="ft671"><b>Combined&#160;data&#160;from ACT&#160;1&#160;&amp; 2&#160;</b></p>
<p style="position:absolute;top:260px;left:114px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:260px;left:402px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:260px;left:586px;white-space:nowrap" class="ft672">Infliximab&#160;</p>
<p style="position:absolute;top:280px;left:114px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:280px;left:376px;white-space:nowrap" class="ft672">Placebo&#160;</p>
<p style="position:absolute;top:280px;left:481px;white-space:nowrap" class="ft672">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:280px;left:585px;white-space:nowrap" class="ft672">10&#160;mg/kg&#160;</p>
<p style="position:absolute;top:280px;left:695px;white-space:nowrap" class="ft672">Combined&#160;</p>
<p style="position:absolute;top:300px;left:114px;white-space:nowrap" class="ft672">Subjects&#160;randomised&#160;</p>
<p style="position:absolute;top:300px;left:390px;white-space:nowrap" class="ft672">244&#160;</p>
<p style="position:absolute;top:300px;left:496px;white-space:nowrap" class="ft672">242&#160;</p>
<p style="position:absolute;top:300px;left:604px;white-space:nowrap" class="ft672">242&#160;</p>
<p style="position:absolute;top:300px;left:717px;white-space:nowrap" class="ft672">484&#160;</p>
<p style="position:absolute;top:319px;left:114px;white-space:nowrap" class="ft6710"><b>Percentage&#160;of&#160;subjects&#160;in&#160;clinical&#160;response and&#160;in&#160;sustained&#160;clinical&#160;response</b>&#160;<br/>Clinical&#160;response&#160;at&#160;Week&#160;8a&#160;</p>
<p style="position:absolute;top:338px;left:381px;white-space:nowrap" class="ft672">33.2%&#160;</p>
<p style="position:absolute;top:338px;left:487px;white-space:nowrap" class="ft672">66.9%&#160;</p>
<p style="position:absolute;top:338px;left:595px;white-space:nowrap" class="ft672">65.3%&#160;</p>
<p style="position:absolute;top:338px;left:708px;white-space:nowrap" class="ft672">66.1%&#160;</p>
<p style="position:absolute;top:357px;left:114px;white-space:nowrap" class="ft672">Clinical&#160;response&#160;at&#160;Week&#160;30a&#160;</p>
<p style="position:absolute;top:357px;left:381px;white-space:nowrap" class="ft672">27.9%&#160;</p>
<p style="position:absolute;top:357px;left:487px;white-space:nowrap" class="ft672">49.6%&#160;</p>
<p style="position:absolute;top:357px;left:595px;white-space:nowrap" class="ft672">55.4%&#160;</p>
<p style="position:absolute;top:357px;left:708px;white-space:nowrap" class="ft672">52.5%&#160;</p>
<p style="position:absolute;top:376px;left:114px;white-space:nowrap" class="ft6710">Sustained response&#160;(clinical&#160;<br/>response&#160;at&#160;both&#160;Week&#160;8&#160;and&#160;<br/>Week 30)a&#160;</p>
<p style="position:absolute;top:376px;left:402px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:395px;left:381px;white-space:nowrap" class="ft672">19.3%&#160;</p>
<p style="position:absolute;top:376px;left:509px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:395px;left:487px;white-space:nowrap" class="ft672">45.0%&#160;</p>
<p style="position:absolute;top:376px;left:616px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:395px;left:595px;white-space:nowrap" class="ft672">49.6%&#160;</p>
<p style="position:absolute;top:376px;left:729px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:395px;left:708px;white-space:nowrap" class="ft672">47.3%&#160;</p>
<p style="position:absolute;top:434px;left:114px;white-space:nowrap" class="ft6710"><b>Percentage&#160;of&#160;subjects&#160;in&#160;clinical&#160;remission&#160;and&#160;sustained&#160;remission</b>&#160;<br/>Clinical&#160;remission&#160;at Week&#160;8a&#160;</p>
<p style="position:absolute;top:453px;left:381px;white-space:nowrap" class="ft672">10.2%&#160;</p>
<p style="position:absolute;top:453px;left:487px;white-space:nowrap" class="ft672">36.4%&#160;</p>
<p style="position:absolute;top:453px;left:595px;white-space:nowrap" class="ft672">29.8%&#160;</p>
<p style="position:absolute;top:453px;left:708px;white-space:nowrap" class="ft672">33.1%&#160;</p>
<p style="position:absolute;top:471px;left:114px;white-space:nowrap" class="ft672">Clinical&#160;remission&#160;at&#160;Week&#160;30a&#160;</p>
<p style="position:absolute;top:471px;left:381px;white-space:nowrap" class="ft672">13.1%&#160;</p>
<p style="position:absolute;top:471px;left:487px;white-space:nowrap" class="ft672">29.8%&#160;</p>
<p style="position:absolute;top:471px;left:595px;white-space:nowrap" class="ft672">36.4%&#160;</p>
<p style="position:absolute;top:471px;left:708px;white-space:nowrap" class="ft672">33.1%&#160;</p>
<p style="position:absolute;top:491px;left:114px;white-space:nowrap" class="ft6711">Sustained&#160;remission(in remission&#160;<br/>at&#160;both Week&#160;8 and&#160;Week 30)a&#160;</p>
<p style="position:absolute;top:491px;left:402px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:509px;left:385px;white-space:nowrap" class="ft672">5.3%&#160;</p>
<p style="position:absolute;top:491px;left:509px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:509px;left:487px;white-space:nowrap" class="ft672">19.0%&#160;</p>
<p style="position:absolute;top:491px;left:616px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:509px;left:595px;white-space:nowrap" class="ft672">24.4%&#160;</p>
<p style="position:absolute;top:491px;left:729px;white-space:nowrap" class="ft672">&#160;</p>
<p style="position:absolute;top:509px;left:708px;white-space:nowrap" class="ft672">21.7%&#160;</p>
<p style="position:absolute;top:530px;left:114px;white-space:nowrap" class="ft6710"><b>Percentage&#160;of&#160;subjects&#160;with&#160;mucosal&#160;healing</b>&#160;<br/>Mucosal&#160;healing&#160;at&#160;Week&#160;8a&#160;</p>
<p style="position:absolute;top:549px;left:381px;white-space:nowrap" class="ft672">32.4%&#160;</p>
<p style="position:absolute;top:549px;left:487px;white-space:nowrap" class="ft672">61.2%&#160;</p>
<p style="position:absolute;top:549px;left:595px;white-space:nowrap" class="ft672">60.3%&#160;</p>
<p style="position:absolute;top:549px;left:708px;white-space:nowrap" class="ft672">60.7%&#160;</p>
<p style="position:absolute;top:568px;left:114px;white-space:nowrap" class="ft672">Mucosal&#160;healing&#160;at&#160;Week&#160;30a&#160;</p>
<p style="position:absolute;top:568px;left:381px;white-space:nowrap" class="ft672">27.5%&#160;</p>
<p style="position:absolute;top:568px;left:487px;white-space:nowrap" class="ft672">48.3%&#160;</p>
<p style="position:absolute;top:568px;left:595px;white-space:nowrap" class="ft672">52.9%&#160;</p>
<p style="position:absolute;top:568px;left:708px;white-space:nowrap" class="ft672">50.6%&#160;</p>
<p style="position:absolute;top:588px;left:114px;white-space:nowrap" class="ft672">a&#160;&#160;p &lt;0.001,&#160;for&#160;each infliximab treatment&#160;group vs.&#160;placebo.&#160;</p>
<p style="position:absolute;top:607px;left:106px;white-space:nowrap" class="ft6710">&#160;<br/>The&#160;efficacy&#160;of&#160;infliximab&#160;through week 54 was&#160;assessed in&#160;the&#160;ACT&#160;1 study.&#160;<br/>At&#160;54&#160;weeks, 44.9%&#160;of&#160;patients&#160;in&#160;the&#160;combined infliximab&#160;treatment&#160;group were&#160;in&#160;clinical&#160;response&#160;<br/>compared to&#160;19.8%&#160;in&#160;the&#160;placebo treatment&#160;group (p&lt;0.001). Clinical&#160;remission and mucosal&#160;healing&#160;<br/>occurred in a&#160;greater&#160;proportion of&#160;patients&#160;in&#160;the&#160;combined infliximab treatment&#160;group&#160;compared&#160;to&#160;<br/>the&#160;placebo&#160;treatment&#160;group at&#160;week 54&#160;(34.6%&#160;vs. 16.5%, p&lt;0.001&#160;and 46.1%&#160;vs.&#160;18.2%,&#160;p&lt;0.001,&#160;<br/>respectively). The&#160;proportions&#160;of&#160;patients&#160;in sustained&#160;response&#160;and sustained remission at&#160;week 54&#160;<br/>were&#160;greater&#160;in the&#160;combined&#160;infliximab treatment&#160;group&#160;than in the&#160;placebo treatment&#160;group (37.9%&#160;<br/>vs. 14.0%, p&lt;0.001;&#160;and&#160;20.2%&#160;vs. 6.6%, p&lt;0.001,&#160;respectively).&#160;<br/>&#160;<br/>A&#160;greater&#160;proportion of&#160;patients&#160;in&#160;the&#160;combined infliximab&#160;treatment&#160;group were&#160;able&#160;to discontinue&#160;<br/>corticosteroids&#160;while&#160;remaining&#160;in clinical&#160;remission compared&#160;to&#160;the&#160;placebo&#160;treatment&#160;group&#160;at&#160;both&#160;<br/>week&#160;30 (22.3%&#160;vs. 7.2%, p&#160;&lt;0.001, pooled&#160;ACT&#160;1&#160;&amp;&#160;ACT&#160;2 data)&#160;and&#160;week 54 (21.0%&#160;vs. 8.9%,&#160;<br/>p=0.022, ACT&#160;1 data).&#160;<br/>&#160;<br/>The&#160;pooled data&#160;analysis&#160;from&#160;the&#160;ACT&#160;1 and ACT&#160;2&#160;studies and&#160;their&#160;extensions,&#160;analysed&#160;from&#160;<br/>baseline&#160;through 54&#160;weeks, demonstrated a&#160;reduction of&#160;ulcerative&#160;colitis-related hospitalisations&#160;and&#160;<br/>surgical&#160;procedures&#160;with infliximab&#160;treatment. The&#160;number&#160;of&#160;ulcerative&#160;colitis-related&#160;hospitalisations&#160;<br/>was&#160;significantly&#160;lower&#160;in&#160;the&#160;5 and&#160;10&#160;mg/kg&#160;infliximab&#160;treatment&#160;groups&#160;than&#160;in&#160;the&#160;placebo group&#160;<br/>(mean number&#160;of&#160;hospitalisations&#160;per&#160;100&#160;subject-years:&#160;21 and&#160;19 vs.&#160;40&#160;in the&#160;placebo group;&#160;<br/>p=0.019&#160;and p=0.007,&#160;respectively). The&#160;number&#160;of&#160;ulcerative&#160;colitis-related&#160;surgical&#160;procedures was&#160;<br/>also&#160;lower&#160;in&#160;the&#160;5 and 10&#160;mg/kg&#160;infliximab treatment&#160;groups&#160;than in the&#160;placebo&#160;group&#160;(mean number&#160;<br/>of&#160;surgical&#160;procedures&#160;per&#160;100&#160;subject-years:&#160;22 and&#160;19&#160;vs.&#160;34<i>;&#160;</i>p=0.145 and p=0.022, respectively).&#160;<br/>&#160;<br/>The&#160;proportion of&#160;subjects&#160;who underwent&#160;colectomy&#160;at&#160;any time&#160;within&#160;54&#160;weeks&#160;following the&#160;first&#160;<br/>infusion of&#160;study agent&#160;were&#160;collected and&#160;pooled from&#160;the&#160;ACT&#160;1 and ACT&#160;2 studies&#160;and their&#160;<br/>extensions. Fewer&#160;subjects&#160;underwent&#160;colectomy&#160;in&#160;the&#160;5&#160;mg/kg infliximab&#160;group (28/242 or&#160;11.6%&#160;<br/>[N.S.])&#160;and the&#160;10&#160;mg/kg infliximab group&#160;(18/242&#160;or&#160;7.4%&#160;[p=0.011])&#160;than&#160;in the&#160;placebo group&#160;<br/>(36/244;&#160;14.8%).&#160;<br/>&#160;</p>
</div>
<!-- Page 68 -->
<a name="68"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page68-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft680">68&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft6810">The&#160;reduction&#160;in&#160;incidence&#160;of&#160;colectomy was&#160;also examined in another&#160;randomised, double-blind study&#160;<br/>(C0168Y06)&#160;in&#160;hospitalised&#160;patients&#160;(n=45)&#160;with&#160;moderately&#160;to severely active&#160;ulcerative&#160;colitis&#160;who&#160;<br/>failed to respond to&#160;intravenous&#160;corticosteroids&#160;and&#160;who&#160;were&#160;therefore at&#160;higher&#160;risk&#160;for&#160;colectomy.&#160;<br/>Significantly&#160;fewer&#160;colectomies occurred&#160;within&#160;3&#160;months&#160;of&#160;study&#160;infusion&#160;in patients&#160;who received&#160;a&#160;<br/>single dose of&#160;5&#160;mg/kg infliximab compared to&#160;patients&#160;who received placebo (29.2%&#160;vs.&#160;66.7%&#160;<br/>respectively, p=0.017).&#160;<br/>&#160;<br/>In&#160;ACT&#160;1 and ACT&#160;2, infliximab improved quality of&#160;life, confirmed&#160;by statistically&#160;significant&#160;<br/>improvement&#160;in both a&#160;disease&#160;specific&#160;measure, IBDQ, and by&#160;improvement&#160;in&#160;the&#160;generic&#160;36-item&#160;<br/>short&#160;form&#160;survey SF-36.&#160;<br/>&#160;<br/><i>Subcutaneous&#160;formulation&#160;<br/>&#160;<br/></i>The efficacy&#160;of&#160;subcutaneous&#160;infliximab&#160;in&#160;active&#160;ulcerative colitis patients&#160;was&#160;assessed&#160;in&#160;Part&#160;2&#160;of&#160;<br/>an open-label,&#160;randomised, parallel-group, Phase&#160;I&#160;study.&#160;For&#160;study&#160;details,&#160;see&#160;Section 5.1&#160;on&#160;Crohn’s&#160;<br/>disease, subcutaneous&#160;formulation.<i>&#160;<br/></i>&#160;<br/>In&#160;active ulcerative colitis patients, the&#160;descriptive&#160;efficacy results&#160;following Remsima&#160;120&#160;mg&#160;<br/>subcutaneous&#160;formulation&#160;were&#160;generally comparable&#160;to Remsima&#160;5&#160;mg/kg intravenous&#160;formulation&#160;in&#160;<br/>terms of&#160;clinical&#160;response&#160;(defined&#160;as a decrease from&#160;baseline in&#160;total&#160;Mayo&#160;score of&#160;at&#160;least&#160;3&#160;points&#160;<br/>and&#160;at&#160;least&#160;30%&#160;or&#160;a&#160;decrease from&#160;baseline in&#160;partial&#160;Mayo&#160;score at&#160;least&#160;2 points, with an&#160;<br/>accompanying&#160;decrease&#160;from&#160;baseline&#160;in&#160;the&#160;subscore for&#160;rectal&#160;bleeding&#160;of&#160;at&#160;least&#160;1&#160;point,&#160;or&#160;an&#160;<br/>absolute&#160;subscore&#160;for&#160;rectal&#160;bleeding&#160;of&#160;0&#160;or&#160;1),&#160;clinical&#160;remission&#160;(defined&#160;as a&#160;total&#160;Mayo&#160;score of&#160;</p>
<p style="position:absolute;top:500px;left:765px;white-space:nowrap" class="ft6818">≤2&#160;</p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft682">points&#160;with no&#160;individual&#160;subscore&#160;exceeding&#160;1 point,&#160;or&#160;partial&#160;Mayo score&#160;of&#160;</p>
<p style="position:absolute;top:519px;left:627px;white-space:nowrap" class="ft6818">≤1 point)&#160;and mucosal&#160;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft6810">healing (defined&#160;as&#160;absolute&#160;endoscopic&#160;subscore&#160;of&#160;0&#160;or&#160;1 from&#160;Mayo Scoring System).&#160;<br/>&#160;<br/><i>Adult&#160;ankylosing spondylitis&#160;<br/>&#160;<br/>Intravenous&#160;formulation&#160;<br/></i>&#160;<br/>Efficacy&#160;and safety&#160;of&#160;infliximab&#160;intravenous&#160;formulation&#160;were&#160;assessed in two&#160;multicentre,&#160;<br/>double-blind,&#160;placebo-controlled studies&#160;in patients&#160;with active&#160;ankylosing&#160;spondylitis&#160;(Bath&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft6810">Ankylosing Spondylitis&#160;Disease&#160;Activity Index&#160;[BASDAI]&#160;score&#160;≥&#160;4&#160;and&#160;spinal&#160;pain ≥&#160;4&#160;on&#160;a scale of&#160;<br/>1-10).&#160;<br/>&#160;<br/>In the&#160;first&#160;study (P01522),&#160;which had a&#160;3-month double-blind phase,&#160;70&#160;patients received&#160;either&#160;<br/>5&#160;mg/kg&#160;infliximab or&#160;placebo at&#160;weeks&#160;0, 2, 6&#160;(35&#160;patients&#160;in each&#160;group). At&#160;week 12, placebo&#160;<br/>patients were switched&#160;to&#160;infliximab&#160;5&#160;mg/kg&#160;every 6&#160;weeks up to week 54.&#160;After&#160;the&#160;first&#160;year&#160;of&#160;the&#160;<br/>study,&#160;53&#160;patients&#160;continued into an open-label&#160;extension to week 102.&#160;<br/>&#160;<br/>In the&#160;second&#160;clinical&#160;study&#160;(ASSERT), 279&#160;patients were&#160;randomised&#160;to&#160;receive either&#160;placebo&#160;<br/>(Group&#160;1,&#160;n=78)&#160;or&#160;5&#160;mg/kg&#160;infliximab (Group&#160;2,&#160;n=201)&#160;at&#160;0, 2&#160;and 6&#160;weeks&#160;and&#160;every&#160;6&#160;weeks to&#160;<br/>week 24. Thereafter, all&#160;subjects&#160;continued on&#160;infliximab every 6&#160;weeks&#160;to week 96. Group&#160;1 received&#160;<br/>5&#160;mg/kg&#160;infliximab. In Group&#160;2, starting with the&#160;week&#160;</p>
<p style="position:absolute;top:899px;left:473px;white-space:nowrap" class="ft6818">36 infusion, patients&#160;who had a&#160;BASDAI&#160;≥3 at&#160;</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft6810">2 consecutive visits,&#160;received&#160;7.5&#160;mg/kg infliximab every 6&#160;weeks&#160;thereafter&#160;through&#160;week&#160;96.&#160;<br/>&#160;<br/>In ASSERT, improvement&#160;in signs&#160;and symptoms&#160;was&#160;observed&#160;as&#160;early as&#160;week&#160;2. At&#160;week&#160;24, the&#160;<br/>number&#160;of&#160;ASAS&#160;20 responders&#160;was&#160;15/78&#160;(19%)&#160;in the&#160;placebo&#160;group, and&#160;123/201 (61%)&#160;in&#160;the&#160;<br/>5&#160;mg/kg&#160;infliximab group&#160;(p&lt;0.001). There&#160;were&#160;95&#160;subjects&#160;from&#160;group&#160;2 who continued on&#160;5&#160;mg/kg&#160;<br/>every&#160;6&#160;weeks.&#160;At&#160;102&#160;weeks there were&#160;80&#160;subjects&#160;still&#160;on infliximab treatment&#160;and&#160;among those,&#160;71&#160;<br/>(89%)&#160;were&#160;ASAS&#160;20 responders.&#160;<br/>&#160;<br/>In P01522, improvement&#160;in&#160;signs&#160;and&#160;symptoms&#160;was&#160;also observed as&#160;early&#160;as&#160;week 2. At&#160;week 12,&#160;<br/>the&#160;number&#160;of&#160;BASDAI&#160;50 responders&#160;were&#160;3/35 (9%)&#160;in the&#160;placebo group, and 20/35&#160;(57%)&#160;in the&#160;<br/>5&#160;mg/kg group&#160;(p&lt;0.01). There&#160;were&#160;53&#160;subjects&#160;who&#160;continued&#160;on 5&#160;mg/kg every 6&#160;weeks.&#160;At&#160;<br/>102&#160;weeks&#160;there were&#160;49&#160;subjects&#160;still&#160;on infliximab treatment&#160;and among&#160;those,&#160;30 (61%)&#160;were&#160;<br/>BASDAI&#160;50 responders.&#160;</p>
</div>
<!-- Page 69 -->
<a name="69"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page69-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft690">69&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft6910">&#160;<br/>In both studies, physical&#160;function and quality of&#160;life&#160;as&#160;measured by&#160;the&#160;BASFI&#160;and the&#160;physical&#160;<br/>component&#160;score&#160;of&#160;the&#160;SF-36&#160;were&#160;also&#160;improved&#160;significantly.&#160;<br/>&#160;<br/><i>Adult psoriatic&#160;arthritis&#160;<br/>&#160;<br/>Intravenous&#160;formulation&#160;<br/></i>&#160;<br/>Efficacy and&#160;safety&#160;of&#160;infliximab intravenous&#160;formulation were&#160;assessed&#160;in&#160;two multicentre,&#160;<br/>double-blind,&#160;placebo-controlled&#160;studies&#160;in&#160;patients with&#160;active&#160;psoriatic arthritis.&#160;<br/>&#160;<br/>In the&#160;first&#160;clinical&#160;study (IMPACT), efficacy and&#160;safety of&#160;infliximab were&#160;studied in 104&#160;patients&#160;<br/>with active&#160;polyarticular&#160;psoriatic&#160;arthritis. During&#160;the&#160;16-week double-blind phase, patients&#160;received&#160;<br/>either&#160;5&#160;mg/kg&#160;infliximab or&#160;placebo at&#160;weeks&#160;0, 2, 6,&#160;and 14 (52&#160;patients&#160;in&#160;each group). Starting&#160;at&#160;<br/>week 16, placebo patients&#160;were&#160;switched to&#160;infliximab&#160;and&#160;all&#160;patients&#160;subsequently received&#160;5&#160;mg/kg&#160;<br/>infliximab every 8&#160;weeks&#160;up to week 46. After&#160;the&#160;first&#160;year&#160;of&#160;the&#160;study, 78&#160;patients&#160;continued into&#160;an&#160;<br/>open-label&#160;extension to week 98.&#160;<br/>&#160;<br/>In the&#160;second&#160;clinical&#160;study&#160;(IMPACT&#160;2), efficacy and&#160;safety of&#160;infliximab were&#160;studied&#160;in&#160;<br/>200&#160;</p>
<p style="position:absolute;top:444px;left:135px;white-space:nowrap" class="ft6918">patients&#160;with active&#160;psoriatic&#160;arthritis&#160;(≥5 swollen&#160;joints&#160;and&#160;≥5&#160;tender&#160;joints).&#160;Forty&#160;six&#160;percent&#160;of&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft6910">patients&#160;continued&#160;on stable&#160;doses&#160;of&#160;methotrexate&#160;(≤25&#160;mg/week). During&#160;the&#160;24-week double-blind&#160;<br/>phase,&#160;patients received&#160;either&#160;5&#160;mg/kg&#160;infliximab&#160;or&#160;placebo&#160;at weeks&#160;0,&#160;2, 6,&#160;14, and&#160;22 (100&#160;patients&#160;<br/>in each group). At&#160;week 16,&#160;47&#160;placebo&#160;patients&#160;with&#160;&lt;10%&#160;improvement&#160;from baseline&#160;in&#160;both&#160;<br/>swollen and tender&#160;joint&#160;counts&#160;were&#160;switched&#160;to&#160;infliximab&#160;induction&#160;(early&#160;escape).&#160;At&#160;week&#160;24,&#160;all&#160;<br/>placebo-treated patients&#160;crossed over&#160;to&#160;infliximab&#160;induction. Dosing&#160;continued for&#160;all&#160;patients&#160;<br/>through week&#160;46.&#160;<br/>&#160;<br/>Key efficacy&#160;results&#160;for&#160;IMPACT&#160;and IMPACT&#160;2 are&#160;shown in&#160;Table&#160;11&#160;below:&#160;<br/>&#160;</p>
<p style="position:absolute;top:639px;left:416px;white-space:nowrap" class="ft691"><b>Table&#160;11&#160;</b></p>
<p style="position:absolute;top:658px;left:254px;white-space:nowrap" class="ft691"><b>Effects&#160;on&#160;ACR&#160;and PASI&#160;in IMPACT&#160;and IMPACT&#160;2&#160;</b></p>
<p style="position:absolute;top:678px;left:114px;white-space:nowrap" class="ft691"><b>&#160;</b></p>
<p style="position:absolute;top:678px;left:329px;white-space:nowrap" class="ft692">IMPACT&#160;</p>
<p style="position:absolute;top:678px;left:602px;white-space:nowrap" class="ft692">IMPACT 2*&#160;</p>
<p style="position:absolute;top:698px;left:114px;white-space:nowrap" class="ft691"><b>&#160;</b></p>
<p style="position:absolute;top:698px;left:228px;white-space:nowrap" class="ft6910">Placebo&#160;<br/>(Week 16)&#160;</p>
<p style="position:absolute;top:698px;left:321px;white-space:nowrap" class="ft6910">Infliximab&#160;<br/>(Week 16)&#160;</p>
<p style="position:absolute;top:698px;left:416px;white-space:nowrap" class="ft6910">Infliximab&#160;<br/>(Week 98)&#160;</p>
<p style="position:absolute;top:698px;left:511px;white-space:nowrap" class="ft6910">Placebo&#160;<br/>(Week 24)&#160;</p>
<p style="position:absolute;top:698px;left:604px;white-space:nowrap" class="ft6910">Infliximab&#160;<br/>(Week 24)&#160;</p>
<p style="position:absolute;top:698px;left:699px;white-space:nowrap" class="ft6910">Infliximab&#160;<br/>(Week 54)&#160;</p>
<p style="position:absolute;top:736px;left:114px;white-space:nowrap" class="ft6910">Patients&#160;<br/>randomised&#160;</p>
<p style="position:absolute;top:736px;left:258px;white-space:nowrap" class="ft692">52&#160;</p>
<p style="position:absolute;top:736px;left:352px;white-space:nowrap" class="ft692">52&#160;</p>
<p style="position:absolute;top:736px;left:439px;white-space:nowrap" class="ft692">N/Aa&#160;</p>
<p style="position:absolute;top:736px;left:537px;white-space:nowrap" class="ft692">100&#160;</p>
<p style="position:absolute;top:736px;left:631px;white-space:nowrap" class="ft692">100&#160;</p>
<p style="position:absolute;top:736px;left:726px;white-space:nowrap" class="ft692">100&#160;</p>
<p style="position:absolute;top:775px;left:114px;white-space:nowrap" class="ft6910">ACR&#160;response&#160;&#160;<br/>(% of&#160;<br/>patients)&#160;<br/>N&#160;</p>
<p style="position:absolute;top:785px;left:266px;white-space:nowrap" class="ft6910">&#160;<br/>&#160;</p>
<p style="position:absolute;top:822px;left:258px;white-space:nowrap" class="ft692">52&#160;</p>
<p style="position:absolute;top:785px;left:360px;white-space:nowrap" class="ft6910">&#160;<br/>&#160;</p>
<p style="position:absolute;top:822px;left:352px;white-space:nowrap" class="ft692">52&#160;</p>
<p style="position:absolute;top:785px;left:456px;white-space:nowrap" class="ft6910">&#160;<br/>&#160;</p>
<p style="position:absolute;top:822px;left:447px;white-space:nowrap" class="ft692">78&#160;</p>
<p style="position:absolute;top:785px;left:550px;white-space:nowrap" class="ft6910">&#160;<br/>&#160;</p>
<p style="position:absolute;top:822px;left:537px;white-space:nowrap" class="ft692">100&#160;</p>
<p style="position:absolute;top:785px;left:644px;white-space:nowrap" class="ft6910">&#160;<br/>&#160;</p>
<p style="position:absolute;top:822px;left:631px;white-space:nowrap" class="ft692">100&#160;</p>
<p style="position:absolute;top:785px;left:739px;white-space:nowrap" class="ft6910">&#160;<br/>&#160;</p>
<p style="position:absolute;top:822px;left:726px;white-space:nowrap" class="ft692">100&#160;</p>
<p style="position:absolute;top:851px;left:114px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:851px;left:157px;white-space:nowrap" class="ft692">ACR 20&#160;</p>
<p style="position:absolute;top:870px;left:114px;white-space:nowrap" class="ft692">response*&#160;</p>
<p style="position:absolute;top:860px;left:240px;white-space:nowrap" class="ft692">5&#160;(10%)&#160;</p>
<p style="position:absolute;top:860px;left:329px;white-space:nowrap" class="ft692">34 (65%)&#160;</p>
<p style="position:absolute;top:860px;left:425px;white-space:nowrap" class="ft692">48 (62%)&#160;</p>
<p style="position:absolute;top:860px;left:519px;white-space:nowrap" class="ft692">16 (16%)&#160;</p>
<p style="position:absolute;top:860px;left:613px;white-space:nowrap" class="ft692">54 (54%)&#160;</p>
<p style="position:absolute;top:860px;left:708px;white-space:nowrap" class="ft692">53 (53%)&#160;</p>
<p style="position:absolute;top:889px;left:114px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:889px;left:157px;white-space:nowrap" class="ft692">ACR 50&#160;</p>
<p style="position:absolute;top:908px;left:114px;white-space:nowrap" class="ft692">response*&#160;</p>
<p style="position:absolute;top:898px;left:244px;white-space:nowrap" class="ft692">0&#160;(0%)&#160;</p>
<p style="position:absolute;top:898px;left:329px;white-space:nowrap" class="ft692">24 (46%)&#160;</p>
<p style="position:absolute;top:898px;left:425px;white-space:nowrap" class="ft692">35 (45%)&#160;</p>
<p style="position:absolute;top:898px;left:527px;white-space:nowrap" class="ft692">4&#160;(4%)&#160;</p>
<p style="position:absolute;top:898px;left:613px;white-space:nowrap" class="ft692">41&#160;(41%)&#160;</p>
<p style="position:absolute;top:898px;left:708px;white-space:nowrap" class="ft692">33 (33%)&#160;</p>
<p style="position:absolute;top:927px;left:114px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:927px;left:157px;white-space:nowrap" class="ft692">ACR 70&#160;</p>
<p style="position:absolute;top:946px;left:114px;white-space:nowrap" class="ft692">response*&#160;</p>
<p style="position:absolute;top:936px;left:244px;white-space:nowrap" class="ft692">0&#160;(0%)&#160;</p>
<p style="position:absolute;top:936px;left:329px;white-space:nowrap" class="ft692">15 (29%)&#160;</p>
<p style="position:absolute;top:936px;left:425px;white-space:nowrap" class="ft692">27 (35%)&#160;</p>
<p style="position:absolute;top:936px;left:527px;white-space:nowrap" class="ft692">2&#160;(2%)&#160;</p>
<p style="position:absolute;top:936px;left:613px;white-space:nowrap" class="ft692">27 (27%)&#160;</p>
<p style="position:absolute;top:936px;left:708px;white-space:nowrap" class="ft692">20 (20%)&#160;</p>
<p style="position:absolute;top:965px;left:114px;white-space:nowrap" class="ft6911">PASI&#160;<br/>response&#160;<br/>(% of&#160;<br/>patients)b&#160;<br/>N&#160;</p>
<p style="position:absolute;top:1003px;left:266px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:1003px;left:360px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:1003px;left:456px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:984px;left:550px;white-space:nowrap" class="ft6911">&#160;<br/>&#160;</p>
<p style="position:absolute;top:1022px;left:541px;white-space:nowrap" class="ft692">87&#160;</p>
<p style="position:absolute;top:984px;left:644px;white-space:nowrap" class="ft6911">&#160;<br/>&#160;</p>
<p style="position:absolute;top:1022px;left:635px;white-space:nowrap" class="ft692">83&#160;</p>
<p style="position:absolute;top:984px;left:739px;white-space:nowrap" class="ft6911">&#160;<br/>&#160;</p>
<p style="position:absolute;top:1022px;left:731px;white-space:nowrap" class="ft692">82&#160;</p>
<p style="position:absolute;top:1060px;left:114px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:1060px;left:157px;white-space:nowrap" class="ft692">PASI&#160;</p>
<p style="position:absolute;top:1079px;left:114px;white-space:nowrap" class="ft692">75 response**&#160;</p>
<p style="position:absolute;top:1069px;left:266px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:1069px;left:360px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:1069px;left:456px;white-space:nowrap" class="ft692">&#160;</p>
<p style="position:absolute;top:1069px;left:527px;white-space:nowrap" class="ft692">1&#160;(1%)&#160;</p>
<p style="position:absolute;top:1069px;left:613px;white-space:nowrap" class="ft692">50 (60%)&#160;</p>
<p style="position:absolute;top:1069px;left:702px;white-space:nowrap" class="ft692">40 (48.8%)&#160;</p>
</div>
<!-- Page 70 -->
<a name="70"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page70-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft700">70&#160;</p>
<p style="position:absolute;top:90px;left:114px;white-space:nowrap" class="ft7010">*&#160;&#160;ITT-analysis where subjects with&#160;missing&#160;data were included&#160;as&#160;non-responders.&#160;<br/>a&#160;&#160;Week&#160;98 data&#160;for&#160;IMPACT&#160;includes&#160;combined placebo&#160;crossover&#160;and infliximab patients&#160;who&#160;</p>
<p style="position:absolute;top:128px;left:136px;white-space:nowrap" class="ft702">entered the&#160;open-label&#160;extension.&#160;</p>
<p style="position:absolute;top:147px;left:114px;white-space:nowrap" class="ft702">b&#160;&#160;Based on&#160;patients&#160;with&#160;PASI&#160;&gt;2.5 at&#160;baseline&#160;for&#160;IMPACT, and patients&#160;with&#160;&gt;3%&#160;BSA&#160;psoriasis&#160;</p>
<p style="position:absolute;top:166px;left:136px;white-space:nowrap" class="ft702">skin&#160;involvement at baseline&#160;in&#160;IMPACT&#160;2.&#160;</p>
<p style="position:absolute;top:185px;left:114px;white-space:nowrap" class="ft702">**&#160;PASI&#160;75 response&#160;for&#160;IMPACT&#160;not&#160;included due&#160;to&#160;low&#160;N;&#160;p&lt;0.001&#160;for&#160;infliximab vs. placebo at&#160;</p>
<p style="position:absolute;top:204px;left:136px;white-space:nowrap" class="ft702">week 24&#160;for&#160;IMPACT&#160;2.&#160;</p>
<p style="position:absolute;top:223px;left:106px;white-space:nowrap" class="ft7011">&#160;<br/>In&#160;IMPACT&#160;and&#160;IMPACT&#160;2,&#160;clinical&#160;responses were observed&#160;as early&#160;as week&#160;2&#160;and&#160;were maintained&#160;<br/>through week&#160;98 and week&#160;54,&#160;respectively. Efficacy&#160;has&#160;been demonstrated with&#160;or&#160;without&#160;<br/>concomitant&#160;use of&#160;methotrexate.&#160;Decreases&#160;in&#160;parameters of&#160;peripheral&#160;activity&#160;characteristic of&#160;<br/>psoriatic&#160;arthritis&#160;(such as&#160;number&#160;of&#160;swollen&#160;joints, number&#160;of&#160;painful/tender&#160;joints, dactylitis&#160;and&#160;<br/>presence of&#160;enthesopathy)&#160;were&#160;seen&#160;in&#160;the infliximab-treated&#160;patients.&#160;<br/>&#160;<br/>Radiographic&#160;changes were&#160;assessed&#160;in&#160;IMPACT&#160;2. Radiographs&#160;of&#160;hands&#160;and&#160;feet&#160;were&#160;collected&#160;at&#160;<br/>baseline, weeks&#160;24&#160;and 54.&#160;Infliximab&#160;treatment&#160;reduced the&#160;rate&#160;of&#160;progression&#160;of&#160;peripheral&#160;joint&#160;<br/>damage&#160;compared with placebo&#160;treatment&#160;at&#160;the&#160;week&#160;24 primary&#160;endpoint&#160;as&#160;measured&#160;by change&#160;<br/>from baseline&#160;in&#160;total&#160;modified&#160;vdH-S&#160;score&#160;(mean&#160;±&#160;SD&#160;score&#160;was&#160;0.82 ±&#160;2.62&#160;in&#160;the&#160;placebo group&#160;<br/>compared with&#160;-0.70&#160;±&#160;2.53&#160;in the&#160;infliximab&#160;group;&#160;p&lt;0.001). In&#160;the&#160;infliximab&#160;group, the&#160;mean&#160;<br/>change&#160;in&#160;total modified&#160;vdH-S&#160;score&#160;remained below&#160;0 at&#160;the&#160;week 54&#160;timepoint.&#160;<br/>&#160;<br/>Infliximab-treated&#160;patients demonstrated&#160;significant&#160;improvement&#160;in&#160;physical&#160;function&#160;as&#160;assessed&#160;by&#160;<br/>HAQ.&#160;Significant&#160;improvements&#160;in&#160;health-related&#160;quality&#160;of&#160;life were also&#160;demonstrated&#160;as&#160;measured&#160;<br/>by the&#160;physical&#160;and mental&#160;component&#160;summary scores&#160;of&#160;the&#160;SF-36 in&#160;IMPACT&#160;2.&#160;<br/>&#160;<br/><i>Adult&#160;psoriasis&#160;<br/>&#160;<br/>Intravenous&#160;formulation&#160;<br/></i>&#160;<br/>The&#160;efficacy&#160;of&#160;infliximab&#160;intravenous&#160;formulation was&#160;assessed&#160;in two multicentre,&#160;randomised,&#160;<br/>double-blind studies:&#160;SPIRIT&#160;and EXPRESS. Patients&#160;in both&#160;studies&#160;had&#160;plaque&#160;psoriasis&#160;(Body&#160;</p>
<p style="position:absolute;top:672px;left:106px;white-space:nowrap" class="ft7033">Surface&#160;Area&#160;[BSA]&#160;≥10%&#160;and Psoriasis&#160;Area&#160;and Severity Index&#160;[PASI]&#160;score&#160;≥12). The&#160;primary&#160;<br/>endpoint&#160;in both studies&#160;was&#160;the&#160;</p>
<p style="position:absolute;top:691px;left:323px;white-space:nowrap" class="ft7018">percent&#160;of&#160;patients&#160;who achieved ≥75%&#160;improvement&#160;in&#160;PASI&#160;from&#160;</p>
<p style="position:absolute;top:716px;left:106px;white-space:nowrap" class="ft7010">baseline at&#160;week&#160;10.&#160;<br/>&#160;<br/>SPIRIT&#160;evaluated the&#160;efficacy of&#160;infliximab&#160;induction&#160;therapy in&#160;249&#160;patients with&#160;plaque psoriasis&#160;<br/>that&#160;had&#160;previously&#160;received&#160;PUVA&#160;or&#160;systemic therapy.&#160;Patients&#160;received&#160;either&#160;3 or&#160;5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:786px;left:106px;white-space:nowrap" class="ft7010">infliximab or&#160;placebo infusions&#160;at&#160;weeks&#160;0, 2&#160;and 6. Patients&#160;with a&#160;PGA&#160;score&#160;≥3&#160;were&#160;eligible&#160;to&#160;<br/>receive&#160;an additional&#160;infusion of&#160;the&#160;same&#160;treatment&#160;at&#160;week 26.&#160;<br/>In SPIRIT, the&#160;proportion of&#160;patients&#160;achieving PASI&#160;75 at&#160;week 10 was&#160;71.7%&#160;in the&#160;3&#160;mg/kg&#160;<br/>infliximab group,&#160;87.9%&#160;in&#160;the&#160;5&#160;mg/kg&#160;infliximab group, and 5.9%&#160;in&#160;the&#160;placebo&#160;group&#160;(p&lt;0.001).&#160;<br/>By week 26,&#160;twenty weeks&#160;after&#160;the&#160;last&#160;induction dose, 30%&#160;of&#160;patients&#160;in the&#160;5&#160;mg/kg&#160;group and&#160;<br/>13.8%&#160;of&#160;patients&#160;in the&#160;3&#160;mg/kg group&#160;were&#160;PASI&#160;75&#160;responders. Between weeks&#160;6 and&#160;26, symptoms&#160;<br/>of&#160;psoriasis gradually&#160;returned&#160;with&#160;a&#160;median&#160;time to&#160;disease&#160;relapse of&#160;&gt;20&#160;weeks.&#160;No&#160;rebound&#160;was&#160;<br/>observed.&#160;<br/>&#160;<br/>EXPRESS&#160;evaluated the&#160;efficacy of&#160;infliximab&#160;induction and&#160;maintenance&#160;therapy in 378&#160;patients&#160;<br/>with&#160;plaque psoriasis.&#160;Patients&#160;received&#160;5&#160;mg/kg&#160;infliximab-&#160;or&#160;placebo-infusions&#160;at&#160;weeks&#160;0, 2&#160;and 6&#160;<br/>followed&#160;by&#160;maintenance&#160;therapy&#160;every&#160;8&#160;weeks&#160;through week 22&#160;in&#160;the&#160;placebo group and&#160;through&#160;<br/>week 46&#160;in the&#160;infliximab group. At&#160;week 24, the&#160;placebo group crossed over&#160;to infliximab&#160;induction&#160;<br/>therapy (5&#160;mg/kg)&#160;followed&#160;by infliximab maintenance&#160;therapy&#160;(5&#160;mg/kg).&#160;Nail&#160;psoriasis was&#160;assessed&#160;<br/>using&#160;the&#160;Nail&#160;Psoriasis&#160;Severity Index (NAPSI). Prior&#160;therapy with PUVA, methotrexate, ciclosporin,&#160;<br/>or&#160;acitretin&#160;had been&#160;received by 71.4%&#160;of&#160;patients, although they were&#160;not&#160;necessarily&#160;therapy&#160;<br/>resistant.&#160;Key&#160;results are presented&#160;in&#160;Table&#160;12. In&#160;infliximab&#160;treated&#160;subjects,&#160;significant PASI&#160;50&#160;<br/>responses were apparent&#160;at&#160;the&#160;first&#160;visit&#160;(week&#160;2)&#160;and&#160;PASI&#160;75&#160;responses&#160;by&#160;the&#160;second&#160;visit&#160;(week 6).&#160;<br/>Efficacy was&#160;similar&#160;in&#160;the&#160;subgroup of&#160;patients&#160;that&#160;were&#160;exposed to previous&#160;systemic&#160;therapies&#160;<br/>compared to&#160;the&#160;overall&#160;study population.&#160;</p>
</div>
<!-- Page 71 -->
<a name="71"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page71-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft710">71&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft712">&#160;</p>
<p style="position:absolute;top:108px;left:416px;white-space:nowrap" class="ft711"><b>Table&#160;12&#160;</b></p>
<p style="position:absolute;top:127px;left:128px;white-space:nowrap" class="ft711"><b>Summary&#160;of&#160;PASI response,&#160;PGA&#160;response and&#160;percent&#160;of&#160;patients&#160;with&#160;all&#160;nails cleared&#160;at&#160;</b></p>
<p style="position:absolute;top:146px;left:334px;white-space:nowrap" class="ft711"><b>Weeks&#160;10, 24 and&#160;50. EXPRESS&#160;</b></p>
<p style="position:absolute;top:166px;left:114px;white-space:nowrap" class="ft712">&#160;</p>
<p style="position:absolute;top:160px;left:414px;white-space:nowrap" class="ft7118">Placebo → Infliximab&#160;</p>
<p style="position:absolute;top:185px;left:460px;white-space:nowrap" class="ft712">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:204px;left:446px;white-space:nowrap" class="ft712">(at&#160;week&#160;24)&#160;</p>
<p style="position:absolute;top:166px;left:652px;white-space:nowrap" class="ft712">Infliximab&#160;</p>
<p style="position:absolute;top:185px;left:660px;white-space:nowrap" class="ft712">5&#160;mg/kg&#160;</p>
<p style="position:absolute;top:223px;left:114px;white-space:nowrap" class="ft711"><b>Week&#160;10&#160;</b></p>
<p style="position:absolute;top:223px;left:487px;white-space:nowrap" class="ft711"><b>&#160;</b></p>
<p style="position:absolute;top:223px;left:687px;white-space:nowrap" class="ft711"><b>&#160;</b></p>
<p style="position:absolute;top:242px;left:114px;white-space:nowrap" class="ft712">N&#160;</p>
<p style="position:absolute;top:242px;left:479px;white-space:nowrap" class="ft712">77&#160;</p>
<p style="position:absolute;top:242px;left:674px;white-space:nowrap" class="ft712">301&#160;</p>
<p style="position:absolute;top:255px;left:114px;white-space:nowrap" class="ft7118">≥90%&#160;improvement&#160;</p>
<p style="position:absolute;top:261px;left:458px;white-space:nowrap" class="ft712">1 (1.3%)&#160;</p>
<p style="position:absolute;top:261px;left:642px;white-space:nowrap" class="ft712">172 (57.1%)&#160;a&#160;</p>
<p style="position:absolute;top:274px;left:114px;white-space:nowrap" class="ft7118">≥75%&#160;improvement&#160;&#160;</p>
<p style="position:absolute;top:280px;left:458px;white-space:nowrap" class="ft712">2 (2.6%)&#160;</p>
<p style="position:absolute;top:280px;left:642px;white-space:nowrap" class="ft712">242 (80.4%)&#160;a&#160;</p>
<p style="position:absolute;top:293px;left:114px;white-space:nowrap" class="ft7118">≥50%&#160;improvement&#160;</p>
<p style="position:absolute;top:299px;left:458px;white-space:nowrap" class="ft712">6 (7.8%)&#160;</p>
<p style="position:absolute;top:299px;left:646px;white-space:nowrap" class="ft712">274 (91.0%)&#160;</p>
<p style="position:absolute;top:318px;left:114px;white-space:nowrap" class="ft712">PGA&#160;of&#160;cleared&#160;(0)&#160;or&#160;minimal&#160;(1)&#160;</p>
<p style="position:absolute;top:318px;left:458px;white-space:nowrap" class="ft712">3 (3.9%)&#160;</p>
<p style="position:absolute;top:318px;left:639px;white-space:nowrap" class="ft712">242 (82.9%)&#160;ab&#160;</p>
<p style="position:absolute;top:337px;left:114px;white-space:nowrap" class="ft7111">PGA&#160;of&#160;cleared (0),&#160;minimal&#160;(1), or&#160;<br/>mild (2)&#160;</p>
<p style="position:absolute;top:337px;left:450px;white-space:nowrap" class="ft712">14 (18.2%)&#160;</p>
<p style="position:absolute;top:337px;left:639px;white-space:nowrap" class="ft712">275 (94.2%)&#160;ab&#160;</p>
<p style="position:absolute;top:375px;left:114px;white-space:nowrap" class="ft711"><b>Week&#160;24&#160;</b></p>
<p style="position:absolute;top:375px;left:487px;white-space:nowrap" class="ft711"><b>&#160;</b></p>
<p style="position:absolute;top:375px;left:687px;white-space:nowrap" class="ft711"><b>&#160;</b></p>
<p style="position:absolute;top:394px;left:114px;white-space:nowrap" class="ft712">N&#160;</p>
<p style="position:absolute;top:394px;left:479px;white-space:nowrap" class="ft712">77&#160;</p>
<p style="position:absolute;top:394px;left:674px;white-space:nowrap" class="ft712">276&#160;</p>
<p style="position:absolute;top:407px;left:114px;white-space:nowrap" class="ft7118">≥90%&#160;improvement&#160;</p>
<p style="position:absolute;top:413px;left:458px;white-space:nowrap" class="ft712">1 (1.3%)&#160;</p>
<p style="position:absolute;top:413px;left:642px;white-space:nowrap" class="ft712">161 (58.3%)&#160;a&#160;</p>
<p style="position:absolute;top:426px;left:114px;white-space:nowrap" class="ft7118">≥75%&#160;improvement&#160;&#160;</p>
<p style="position:absolute;top:432px;left:458px;white-space:nowrap" class="ft712">3 (3.9%)&#160;</p>
<p style="position:absolute;top:432px;left:642px;white-space:nowrap" class="ft712">227 (82.2%)&#160;a&#160;</p>
<p style="position:absolute;top:445px;left:114px;white-space:nowrap" class="ft7118">≥50%&#160;improvement&#160;</p>
<p style="position:absolute;top:451px;left:458px;white-space:nowrap" class="ft712">5 (6.5%)&#160;</p>
<p style="position:absolute;top:451px;left:646px;white-space:nowrap" class="ft712">248 (89.9%)&#160;</p>
<p style="position:absolute;top:470px;left:114px;white-space:nowrap" class="ft712">PGA&#160;of&#160;cleared&#160;(0)&#160;or&#160;minimal&#160;(1)&#160;</p>
<p style="position:absolute;top:470px;left:458px;white-space:nowrap" class="ft712">2 (2.6%)&#160;</p>
<p style="position:absolute;top:470px;left:642px;white-space:nowrap" class="ft712">203 (73.6%)&#160;a&#160;</p>
<p style="position:absolute;top:489px;left:114px;white-space:nowrap" class="ft7111">PGA&#160;of&#160;cleared (0),&#160;minimal&#160;(1), or&#160;<br/>mild (2)&#160;</p>
<p style="position:absolute;top:489px;left:450px;white-space:nowrap" class="ft712">15 (19.5%)&#160;</p>
<p style="position:absolute;top:489px;left:642px;white-space:nowrap" class="ft712">246 (89.1%)&#160;a&#160;</p>
<p style="position:absolute;top:527px;left:114px;white-space:nowrap" class="ft711"><b>Week&#160;50&#160;</b></p>
<p style="position:absolute;top:527px;left:487px;white-space:nowrap" class="ft711"><b>&#160;</b></p>
<p style="position:absolute;top:527px;left:687px;white-space:nowrap" class="ft711"><b>&#160;</b></p>
<p style="position:absolute;top:546px;left:114px;white-space:nowrap" class="ft712">N&#160;</p>
<p style="position:absolute;top:546px;left:479px;white-space:nowrap" class="ft712">68&#160;</p>
<p style="position:absolute;top:546px;left:674px;white-space:nowrap" class="ft712">281&#160;</p>
<p style="position:absolute;top:559px;left:114px;white-space:nowrap" class="ft7118">≥90%&#160;improvement&#160;</p>
<p style="position:absolute;top:565px;left:450px;white-space:nowrap" class="ft712">34 (50.0%)&#160;</p>
<p style="position:absolute;top:565px;left:646px;white-space:nowrap" class="ft712">127 (45.2%)&#160;</p>
<p style="position:absolute;top:578px;left:114px;white-space:nowrap" class="ft7118">≥75%&#160;improvement&#160;&#160;</p>
<p style="position:absolute;top:584px;left:450px;white-space:nowrap" class="ft712">52 (76.5%)&#160;</p>
<p style="position:absolute;top:584px;left:646px;white-space:nowrap" class="ft712">170 (60.5%)&#160;</p>
<p style="position:absolute;top:597px;left:114px;white-space:nowrap" class="ft7118">≥50%&#160;improvement&#160;</p>
<p style="position:absolute;top:603px;left:450px;white-space:nowrap" class="ft712">61 (89.7%)&#160;</p>
<p style="position:absolute;top:603px;left:646px;white-space:nowrap" class="ft712">193 (68.7%)&#160;</p>
<p style="position:absolute;top:622px;left:114px;white-space:nowrap" class="ft712">PGA&#160;of&#160;cleared&#160;(0)&#160;or&#160;minimal&#160;(1)&#160;</p>
<p style="position:absolute;top:622px;left:450px;white-space:nowrap" class="ft712">46 (67.6%)&#160;</p>
<p style="position:absolute;top:622px;left:646px;white-space:nowrap" class="ft712">149 (53.0%)&#160;</p>
<p style="position:absolute;top:641px;left:114px;white-space:nowrap" class="ft7110">PGA&#160;of&#160;cleared (0),&#160;minimal&#160;(1), or&#160;<br/>mild (2)&#160;</p>
<p style="position:absolute;top:641px;left:450px;white-space:nowrap" class="ft712">59 (86.8%)&#160;</p>
<p style="position:absolute;top:641px;left:646px;white-space:nowrap" class="ft712">189 (67.3%)&#160;</p>
<p style="position:absolute;top:679px;left:114px;white-space:nowrap" class="ft711"><b>All&#160;nails clearedc&#160;</b>&#160;</p>
<p style="position:absolute;top:679px;left:487px;white-space:nowrap" class="ft712">&#160;</p>
<p style="position:absolute;top:679px;left:687px;white-space:nowrap" class="ft712">&#160;</p>
<p style="position:absolute;top:698px;left:114px;white-space:nowrap" class="ft712">Week&#160;10&#160;</p>
<p style="position:absolute;top:698px;left:450px;white-space:nowrap" class="ft712">1/65(1.5%)&#160;</p>
<p style="position:absolute;top:698px;left:639px;white-space:nowrap" class="ft712">16/235 (6.8%)&#160;</p>
<p style="position:absolute;top:717px;left:114px;white-space:nowrap" class="ft712">Week&#160;24&#160;</p>
<p style="position:absolute;top:717px;left:448px;white-space:nowrap" class="ft712">3/65 (4.6%)&#160;</p>
<p style="position:absolute;top:717px;left:631px;white-space:nowrap" class="ft712">58/223 (26.0%)&#160;a&#160;</p>
<p style="position:absolute;top:736px;left:114px;white-space:nowrap" class="ft712">Week&#160;50&#160;</p>
<p style="position:absolute;top:736px;left:440px;white-space:nowrap" class="ft712">27/64 (42.2%)&#160;</p>
<p style="position:absolute;top:736px;left:635px;white-space:nowrap" class="ft712">92/226 (40.7%)&#160;</p>
<p style="position:absolute;top:755px;left:114px;white-space:nowrap" class="ft7110">a&#160;&#160;p &lt;0.001,&#160;for&#160;each infliximab treatment&#160;group vs.&#160;control.&#160;<br/>b&#160;&#160;n =&#160;292.&#160;<br/>c&#160;&#160;Analysis&#160;was&#160;based on&#160;subjects&#160;with nail&#160;psoriasis&#160;at&#160;baseline&#160;(81.8%&#160;of&#160;subjects).&#160;Mean&#160;baseline&#160;</p>
<p style="position:absolute;top:812px;left:136px;white-space:nowrap" class="ft712">NAPSI&#160;scores&#160;were&#160;4.6 and&#160;4.3 in&#160;infliximab&#160;and placebo group.&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft7110">&#160;<br/>Significant&#160;improvements&#160;from&#160;baseline&#160;were&#160;demonstrated in DLQI&#160;(p&lt;0.001)&#160;and the&#160;physical&#160;and&#160;<br/>mental&#160;component&#160;scores&#160;of&#160;the SF&#160;36&#160;(p&lt;0.001 for&#160;each component&#160;comparison).&#160;<br/>&#160;<br/>Paediatric&#160;population&#160;<br/>&#160;<br/>The&#160;European Medicines&#160;Agency has&#160;waived the&#160;obligation to submit&#160;the&#160;results&#160;of&#160;studies&#160;with&#160;the&#160;<br/>reference&#160;medicinal product containing&#160;infliximab&#160;&#160;in&#160;all&#160;subsets of&#160;the&#160;paediatric population&#160;in&#160;<br/>rheumatoid&#160;arthritis,&#160;juvenile&#160;idiopathic&#160;arthritis, psoriatic&#160;arthritis, ankylosing spondylitis,&#160;psoriasis&#160;and&#160;<br/>Crohn’s&#160;disease&#160;(see&#160;section 4.2 for&#160;information on paediatric&#160;use).&#160;<br/>&#160;<br/><b>5.2&#160;</b></p>
<p style="position:absolute;top:1040px;left:149px;white-space:nowrap" class="ft711"><b>Pharmacokinetic&#160;properties&#160;</b></p>
<p style="position:absolute;top:1059px;left:106px;white-space:nowrap" class="ft7110">&#160;<br/>Absorption&#160;and&#160;distribution&#160;&#160;<br/>&#160;<br/>Single&#160;subcutaneous&#160;injections&#160;of&#160;120, 180 and&#160;240&#160;mg of&#160;infliximab&#160;yielded&#160;approximately&#160;dose&#160;<br/>proportional&#160;increases&#160;in&#160;the&#160;maximum serum concentration&#160;(Cmax)&#160;and&#160;area&#160;under&#160;the&#160;concentration-</p>
</div>
<!-- Page 72 -->
<a name="72"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page72-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft720">72&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft7210">time curve (AUC).&#160;The&#160;apparent&#160;volume&#160;of&#160;distribution during&#160;the&#160;terminal&#160;phase&#160;(mean of&#160;7.3&#160;to 8.8&#160;<br/>litres)&#160;was not&#160;dependent&#160;on&#160;the&#160;administered&#160;dose.&#160;&#160;<br/>&#160;<br/>After&#160;single&#160;doses&#160;of&#160;120,&#160;180 and 240&#160;mg&#160;of&#160;subcutaneous&#160;infliximab administered&#160;to&#160;healthy&#160;<br/>subjects, the&#160;mean Cmax&#160;values&#160;were&#160;10.0, 15.1&#160;and 23.1&#160;µg/mL, respectively,&#160;and&#160;for&#160;all&#160;doses&#160;<br/>infliximab&#160;could&#160;be&#160;detected&#160;in&#160;the&#160;serum&#160;for&#160;at&#160;least&#160;12&#160;weeks thereafter.&#160;&#160;<br/>&#160;<br/>The&#160;bioavailability of&#160;subcutaneous&#160;infliximab,&#160;estimated&#160;in a&#160;population PK&#160;model, was&#160;62%&#160;(95%&#160;<br/>CI:&#160;60%&#160;-&#160;64%).&#160;&#160;<br/>&#160;<br/>After&#160;administration of&#160;infliximab 120&#160;mg&#160;subcutaneously every 2 weeks&#160;(from&#160;Week 6 after&#160;2&#160;doses&#160;<br/>of&#160;intravenous&#160;infliximab&#160;at&#160;Weeks 0&#160;and&#160;2)&#160;to&#160;patients&#160;with&#160;active&#160;rheumatoid&#160;arthritis&#160;who&#160;were&#160;<br/>concomitantly treated with&#160;MTX, the&#160;median (CV%)&#160;Ctrough&#160;level&#160;at&#160;Week&#160;22&#160;(steady&#160;state)&#160;was&#160;<br/>12.8&#160;µg/mL&#160;(80.1%).&#160;&#160;<br/>&#160;<br/>After&#160;administration of&#160;infliximab 120&#160;mg&#160;subcutaneously every 2 weeks&#160;(from&#160;Week 6 after&#160;2&#160;doses&#160;<br/>of&#160;intravenous&#160;infliximab&#160;at&#160;Weeks 0&#160;and&#160;2)&#160;to&#160;patients&#160;with&#160;active Crohn’s disease&#160;and&#160;active&#160;<br/>ulcerative&#160;colitis,&#160;the&#160;median&#160;(CV%)&#160;Ctrough&#160;level&#160;at&#160;Week&#160;22&#160;(steady&#160;state)&#160;was&#160;20.1&#160;µg/mL&#160;(48.9%).&#160;<br/>&#160;<br/>Based&#160;on&#160;PK&#160;results&#160;from clinical studies&#160;in&#160;patients&#160;with&#160;active&#160;rheumatoid&#160;arthritis,&#160;active&#160;Crohn’s&#160;<br/>disease&#160;and active&#160;ulcerative&#160;colitis&#160;and population PK&#160;modelling,&#160;Ctrough&#160;levels&#160;at&#160;steady&#160;state would&#160;<br/>be&#160;higher&#160;after&#160;administration of&#160;infliximab&#160;120&#160;mg subcutaneous&#160;formulation given every 2 weeks&#160;<br/>compared&#160;with&#160;infliximab&#160;5&#160;mg/kg&#160;intravenous&#160;formulation&#160;given&#160;every&#160;8&#160;weeks.&#160;<br/>&#160;<br/>For&#160;the&#160;dosing&#160;regimen with subcutaneous&#160;loading&#160;in&#160;patients&#160;with&#160;rheumatoid arthritis,&#160;the&#160;predicted&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft7211">median AUC&#160;value&#160;was&#160;17,400 μg·h/mL&#160;from&#160;Week 0&#160;to 6 which was&#160;approximately 1.8&#160;fold&#160;lower&#160;<br/>than the&#160;predicted median AUC&#160;value&#160;for&#160;the&#160;dosing&#160;regimen&#160;with infliximab&#160;intravenous&#160;loading&#160;<br/>doses (32,100&#160;</p>
<p style="position:absolute;top:595px;left:202px;white-space:nowrap" class="ft7218">μg·h/mL).&#160;Whereas,&#160;the&#160;predicted&#160;median&#160;AUC&#160;values&#160;from&#160;Week&#160;6 to 14&#160;were&#160;</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft7210">comparable&#160;between&#160;the&#160;two dosing regimens&#160;with&#160;subcutaneous&#160;loading&#160;and intravenous&#160;loading&#160;<br/>(19,600 and&#160;18,100&#160;</p>
<p style="position:absolute;top:633px;left:239px;white-space:nowrap" class="ft7218">μg·h/mL,&#160;respectively).&#160;&#160;</p>
<p style="position:absolute;top:658px;left:106px;white-space:nowrap" class="ft7213">&#160;<br/>Elimination&#160;<br/>&#160;<br/>The&#160;elimination pathways&#160;for&#160;infliximab have&#160;not&#160;been&#160;characterised. Unchanged&#160;infliximab was&#160;not&#160;<br/>detected in&#160;urine. No&#160;major&#160;age-&#160;or&#160;weight-related&#160;differences&#160;in&#160;clearance or&#160;volume of&#160;distribution&#160;<br/>were observed&#160;in&#160;rheumatoid&#160;arthritis patients.&#160;&#160;<br/>&#160;<br/>In&#160;studies&#160;in&#160;healthy&#160;subjects,&#160;the&#160;mean&#160;(±&#160;SD)&#160;apparent&#160;clearance of&#160;Remsima 120&#160;mg&#160;administered&#160;<br/>subcutaneously&#160;was&#160;19.3&#160;±&#160;6.9&#160;mL/hr.&#160;&#160;<br/>&#160;<br/>In&#160;the RA&#160;patients,&#160;the mean&#160;(±&#160;SD)&#160;apparent&#160;clearance of&#160;Remsima 120&#160;mg subcutaneous&#160;at&#160;steady&#160;<br/>state&#160;was&#160;18.8&#160;±&#160;8.3&#160;mL/hr.&#160;In&#160;the active Crohn’s disease and&#160;active ulcerative&#160;colitis&#160;patients,&#160;the&#160;<br/>mean&#160;(±&#160;SD)&#160;apparent&#160;clearance of&#160;Remsima&#160;120&#160;mg&#160;subcutaneous at&#160;steady&#160;state&#160;was&#160;16.1&#160;±&#160;<br/>6.9&#160;mL/hr.&#160;<br/>&#160;<br/>The&#160;mean&#160;terminal&#160;half-life&#160;ranged from&#160;11.3 days&#160;to&#160;13.7&#160;days&#160;for&#160;120, 180&#160;and&#160;240&#160;mg of&#160;<br/>subcutaneous&#160;infliximab administered&#160;to healthy subjects.&#160;&#160;<br/>&#160;<br/>Special&#160;populations&#160;<br/><i>&#160;<br/>Elderly&#160;<br/>&#160;<br/></i>The&#160;pharmacokinetics&#160;of&#160;infliximab&#160;injected&#160;via&#160;subcutaneous&#160;route&#160;in elderly&#160;patients&#160;has&#160;not&#160;been&#160;<br/>studied.&#160;&#160;<br/>&#160;<br/><i>Paediatric&#160;population&#160;<br/></i>&#160;</p>
</div>
<!-- Page 73 -->
<a name="73"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page73-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft730">73&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft7310">Subcutaneous administration&#160;of&#160;Remsima is not&#160;recommended&#160;for&#160;paediatric use and&#160;no&#160;data&#160;are&#160;<br/>available on&#160;the use of&#160;Remsima&#160;administered&#160;subcutaneously in&#160;the&#160;paediatric&#160;population.&#160;<br/>&#160;<br/><i>Hepatic&#160;and renal&#160;impairment&#160;<br/>&#160;<br/></i>Studies&#160;with&#160;infliximab&#160;have&#160;not&#160;been&#160;performed in&#160;patients&#160;with&#160;liver&#160;or&#160;renal&#160;disease.&#160;<br/>&#160;<br/><b>5.3&#160;</b></p>
<p style="position:absolute;top:222px;left:149px;white-space:nowrap" class="ft731"><b>Preclinical&#160;safety&#160;data</b>&#160;</p>
<p style="position:absolute;top:241px;left:106px;white-space:nowrap" class="ft732">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft7310">Infliximab does&#160;not&#160;cross&#160;react&#160;with TNFα&#160;from&#160;species other&#160;than&#160;human&#160;and&#160;chimpanzees.&#160;<br/>Therefore, conventional&#160;preclinical&#160;safety&#160;data&#160;with&#160;infliximab&#160;are&#160;limited. In a&#160;developmental&#160;toxicity&#160;<br/>study&#160;conducted in&#160;mice&#160;using an analogous&#160;antibody that&#160;selectively&#160;inhibits&#160;the&#160;functional&#160;activity of&#160;<br/>mo</p>
<p style="position:absolute;top:311px;left:128px;white-space:nowrap" class="ft7318">use&#160;TNFα, there&#160;was&#160;no&#160;indication&#160;of&#160;maternal&#160;toxicity,&#160;embryotoxicity&#160;or&#160;teratogenicity. In a&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft7311">fertility and general&#160;reproductive&#160;function study,&#160;the&#160;number&#160;of&#160;pregnant&#160;mice&#160;was&#160;reduced&#160;following&#160;<br/>administration of&#160;the&#160;same&#160;analogous&#160;antibody.&#160;It&#160;is&#160;not&#160;known whether&#160;this&#160;finding was&#160;due&#160;to&#160;effects&#160;<br/>on&#160;the&#160;males and/or&#160;the females.&#160;In&#160;a 6-month repeated dose&#160;toxicity&#160;study in mice,&#160;using&#160;the&#160;same&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft7310">analogous&#160;antibody against&#160;mouse&#160;TNFα, crystalline&#160;deposits&#160;were&#160;observed on the&#160;lens&#160;capsule&#160;of&#160;<br/>some&#160;of&#160;the&#160;treated&#160;male&#160;mice. No specific&#160;ophthalmologic&#160;examinations&#160;have&#160;been performed&#160;in&#160;<br/>patients to&#160;investigate the relevance&#160;of&#160;this finding&#160;for&#160;humans.&#160;<br/>&#160;<br/>Long-term&#160;studies&#160;have&#160;not&#160;been performed&#160;to evaluate&#160;the&#160;carcinogenic&#160;potential&#160;of&#160;infliximab.&#160;<br/>Studies&#160;in&#160;mice&#160;</p>
<p style="position:absolute;top:481px;left:212px;white-space:nowrap" class="ft7318">deficient&#160;in&#160;TNFα&#160;demonstrated no&#160;increase&#160;in tumours&#160;when challenged with known&#160;</p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft7310">tumour&#160;initiators&#160;and/or&#160;promoters.&#160;<br/>&#160;<br/>The subcutaneous administration&#160;of&#160;Remsima to&#160;New&#160;Zealand&#160;White rabbits&#160;was&#160;well&#160;tolerated&#160;at&#160;the&#160;<br/>actual&#160;concentration&#160;to be&#160;used in&#160;humans.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:620px;left:149px;white-space:nowrap" class="ft731"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:639px;left:106px;white-space:nowrap" class="ft7311">&#160;<br/><b>6.1&#160;</b></p>
<p style="position:absolute;top:658px;left:149px;white-space:nowrap" class="ft731"><b>List&#160;of&#160;excipients</b>&#160;</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft7310"><i>&#160;<br/></i>Acetic acid&#160;<br/>Sodium acetate&#160;trihydrate&#160;<br/>Sorbitol&#160;<br/>Polysorbate&#160;80&#160;<br/>Water&#160;for&#160;injections&#160;<br/>&#160;<br/><b>6.2&#160;</b></p>
<p style="position:absolute;top:810px;left:149px;white-space:nowrap" class="ft731"><b>Incompatibilities</b>&#160;</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft7310">&#160;<br/>In&#160;the&#160;absence&#160;of&#160;compatibility&#160;studies,&#160;this&#160;medicinal product must&#160;not&#160;be&#160;mixed&#160;with&#160;other&#160;medicinal&#160;<br/>products.&#160;&#160;<br/>&#160;<br/><b>6.3&#160;</b></p>
<p style="position:absolute;top:905px;left:149px;white-space:nowrap" class="ft731"><b>Shelf&#160;life</b>&#160;</p>
<p style="position:absolute;top:924px;left:106px;white-space:nowrap" class="ft7311">&#160;<br/>45&#160;months&#160;<br/>&#160;<br/><b>6.4&#160;</b></p>
<p style="position:absolute;top:981px;left:149px;white-space:nowrap" class="ft731"><b>Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:1000px;left:106px;white-space:nowrap" class="ft7310">&#160;<br/>Store&#160;in a&#160;refrigerator&#160;(2°C&#160;-&#160;8°C).&#160;&#160;<br/>&#160;<br/>Do not&#160;freeze. Keep&#160;the&#160;medicinal product in&#160;its&#160;outer&#160;carton&#160;in order&#160;to protect&#160;from&#160;light.&#160;&#160;<br/>&#160;<br/>The&#160;medicinal&#160;product&#160;may&#160;be&#160;stored&#160;at temperatures&#160;up&#160;to&#160;a&#160;maximum of&#160;25°C&#160;for&#160;a&#160;period of&#160;up to&#160;<br/>28&#160;days.&#160;The&#160;medicinal&#160;product&#160;must&#160;be&#160;discarded&#160;if&#160;not&#160;used within the&#160;28-day period.&#160;&#160;<br/>&#160;<br/><b>6.5&#160;</b></p>
<p style="position:absolute;top:1151px;left:149px;white-space:nowrap" class="ft731"><b>Nature&#160;and&#160;contents&#160;of&#160;container&#160;</b></p>
</div>
<!-- Page 74 -->
<a name="74"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page74-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft740">74&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft7411">&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled syringe&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in single-use pre-filled&#160;syringe&#160;(type&#160;I&#160;glass)&#160;with a&#160;plunger&#160;<br/>stopper&#160;(flurotec-coated&#160;elastomer)&#160;and&#160;needle with&#160;a&#160;rigid needle&#160;shield.&#160;<br/>&#160;<br/>Packs of:&#160;</p>
<p style="position:absolute;top:199px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;1 prefilled syringe&#160;(1 mL&#160;sterile&#160;solution)&#160;with&#160;2 alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:219px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;2 prefilled syringes&#160;(1&#160;mL&#160;sterile&#160;solution)&#160;with 2&#160;alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:239px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;4 prefilled syringes&#160;(1&#160;mL&#160;sterile&#160;solution)&#160;with&#160;4 alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:259px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;6 prefilled syringes&#160;(1&#160;mL&#160;sterile&#160;solution)&#160;with&#160;6&#160;alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft7410">&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled syringe&#160;with&#160;automatic&#160;needle&#160;guard&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in single-use pre-filled&#160;syringe&#160;with automatic&#160;needle&#160;guard.&#160;<br/>The&#160;syringe&#160;is&#160;made&#160;from&#160;type&#160;I&#160;glass&#160;with a&#160;plunger&#160;stopper&#160;(flurotec-coated&#160;elastomer)&#160;and&#160;needle&#160;<br/>with&#160;a&#160;rigid needle&#160;shield.&#160;<br/>&#160;<br/>Packs of:&#160;</p>
<p style="position:absolute;top:412px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;1 prefilled syringe&#160;with automatic&#160;needle&#160;guard (1&#160;mL&#160;sterile&#160;solution)&#160;with 2&#160;alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:432px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;2 prefilled syringes&#160;with&#160;automatic needle guard&#160;(1&#160;mL&#160;sterile solution)&#160;with&#160;2 alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:453px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;4&#160;prefilled&#160;syringes with&#160;automatic needle guard&#160;(1&#160;mL&#160;sterile solution)&#160;with&#160;4 alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:473px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;6&#160;prefilled&#160;syringes&#160;with&#160;automatic&#160;needle&#160;guard&#160;(1&#160;mL&#160;sterile&#160;solution)&#160;with&#160;6&#160;alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:497px;left:106px;white-space:nowrap" class="ft7410">&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled&#160;pen&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in single-use pre-filled pen.&#160;The&#160;syringe&#160;inside the pen&#160;is made&#160;<br/>from&#160;type&#160;1&#160;glass&#160;with&#160;a&#160;plunger&#160;stopper&#160;(flurotec-coated elastomer)&#160;and&#160;needle&#160;with&#160;a&#160;rigid needle&#160;<br/>shield.&#160;<br/>&#160;<br/>Packs of:&#160;</p>
<p style="position:absolute;top:626px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;1 prefilled pen&#160;(1&#160;mL&#160;sterile&#160;solution)&#160;with 2 alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:646px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;2&#160;prefilled&#160;pens (1&#160;mL&#160;sterile solution)&#160;with&#160;2 alcohol&#160;pads.&#160;</p>
<p style="position:absolute;top:666px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;4&#160;prefilled&#160;pens (1&#160;mL&#160;sterile solution)&#160;with&#160;4 alcohol&#160;pads.&#160;&#160;</p>
<p style="position:absolute;top:686px;left:138px;white-space:nowrap" class="ft748">•&#160;&#160;6&#160;prefilled&#160;pens (1&#160;mL&#160;sterile solution)&#160;with&#160;6&#160;alcohol&#160;pads.&#160;&#160;</p>
<p style="position:absolute;top:710px;left:106px;white-space:nowrap" class="ft7411">&#160;<br/>Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;<br/>&#160;<br/><b>6.6&#160;</b></p>
<p style="position:absolute;top:767px;left:149px;white-space:nowrap" class="ft741"><b>Special&#160;precautions&#160;for&#160;disposal&#160;and other&#160;handling</b>&#160;</p>
<p style="position:absolute;top:786px;left:106px;white-space:nowrap" class="ft7410">&#160;<br/>Remsima&#160;is&#160;a&#160;solution that&#160;is&#160;clear&#160;to opalescent,&#160;colourless&#160;to&#160;pale&#160;brown. Do not&#160;use&#160;if&#160;the&#160;solution is&#160;<br/>cloudy,&#160;discoloured&#160;or&#160;contains&#160;visible&#160;particulate&#160;matter.&#160;<br/>&#160;<br/>After&#160;use,&#160;place&#160;the&#160;pre-filled&#160;syringe/&#160;pre-filled&#160;syringe&#160;with&#160;automatic needle guard/&#160;pre-filled pen&#160;<br/>into&#160;a puncture&#160;resistant&#160;container&#160;and&#160;discard&#160;as&#160;required&#160;by&#160;local&#160;regulations.&#160;Do&#160;not&#160;recycle&#160;the&#160;<br/>injecting&#160;device.&#160;Always keep&#160;the medicinal&#160;product&#160;out&#160;of&#160;the&#160;sight&#160;and&#160;reach&#160;of&#160;children.&#160;<br/>&#160;<br/>Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with local&#160;<br/>requirements.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:1014px;left:149px;white-space:nowrap" class="ft741"><b>MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:1033px;left:106px;white-space:nowrap" class="ft7411">&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Hungary&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 75 -->
<a name="75"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page75-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft750">75&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft751"><b>8.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft751"><b>MARKETING&#160;AUTHORISATION NUMBER(S)&#160;&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft7510">&#160;<br/>EU/1/13/853/006&#160;<br/>EU/1/13/853/007&#160;<br/>EU/1/13/853/008&#160;<br/>EU/1/13/853/009&#160;<br/>EU/1/13/853/010&#160;<br/>EU/1/13/853/011&#160;<br/>EU/1/13/853/012&#160;<br/>EU/1/13/853/013&#160;<br/>EU/1/13/853/014&#160;<br/>EU/1/13/853/015&#160;<br/>EU/1/13/853/016&#160;<br/>EU/1/13/853/017&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:393px;left:149px;white-space:nowrap" class="ft751"><b>DATE&#160;OF&#160;FIRST&#160;AUTHORISATION/RENEWAL&#160;OF&#160;THE&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft7510"><i>&#160;<br/></i>Date&#160;of&#160;first authorisation:&#160;22&#160;November&#160;2019<i>&#160;<br/></i>&#160;<br/>&#160;<br/><b>10.&#160;</b></p>
<p style="position:absolute;top:487px;left:149px;white-space:nowrap" class="ft751"><b>DATE OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;</b></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft7511">&#160;<br/>Detailed&#160;information on&#160;this&#160;medicinal&#160;product&#160;is&#160;available&#160;on the&#160;website&#160;of&#160;the&#160;European Medicines&#160;<br/>Agency&#160;http://www.ema.europa.eu.&#160;<br/>&#160;</p>
<p style="position:absolute;top:563px;left:322px;white-space:nowrap" class="ft752">&#160;</p>
</div>
<!-- Page 76 -->
<a name="76"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page76-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft760">76&#160;</p>
<p style="position:absolute;top:89px;left:447px;white-space:nowrap" class="ft7611">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:518px;left:409px;white-space:nowrap" class="ft761"><b>ANNEX II&#160;</b></p>
<p style="position:absolute;top:537px;left:149px;white-space:nowrap" class="ft762">&#160;</p>
<p style="position:absolute;top:557px;left:181px;white-space:nowrap" class="ft761"><b>A.&#160;</b></p>
<p style="position:absolute;top:557px;left:234px;white-space:nowrap" class="ft766"><b>MANUFACTURER OF&#160;THE&#160;BIOLOGICAL&#160;ACTIVE&#160;<br/>SUBSTANCE&#160;AND MANUFACTURER RESPONSIBLE&#160;FOR&#160;<br/>BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:613px;left:181px;white-space:nowrap" class="ft766"><b>&#160;<br/>B.&#160;</b></p>
<p style="position:absolute;top:632px;left:234px;white-space:nowrap" class="ft765"><b>CONDITIONS&#160;OR RESTRICTIONS&#160;REGARDING&#160;SUPPLY&#160;<br/>AND USE&#160;</b></p>
<p style="position:absolute;top:670px;left:181px;white-space:nowrap" class="ft766"><b>&#160;<br/>C.&#160;</b></p>
<p style="position:absolute;top:689px;left:234px;white-space:nowrap" class="ft765"><b>OTHER CONDITIONS&#160;AND REQUIREMENTS&#160;OF&#160;THE&#160;<br/>MARKETING&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:727px;left:181px;white-space:nowrap" class="ft765"><b>&#160;<br/>D.&#160;</b></p>
<p style="position:absolute;top:746px;left:234px;white-space:nowrap" class="ft766"><b>CONDITIONS&#160;OR RESTRICTIONS&#160;WITH&#160;REGARD TO&#160;<br/>THE SAFE AND&#160;EFFECTIVE USE OF&#160;THE&#160;MEDICINAL&#160;<br/>PRODUCT&#160;</b></p>
<p style="position:absolute;top:804px;left:149px;white-space:nowrap" class="ft762">&#160;</p>
</div>
<!-- Page 77 -->
<a name="77"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page77-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft770">77&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft771"><b>A.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft775"><b>MANUFACTURER OF&#160;THE&#160;BIOLOGICAL&#160;ACTIVE&#160;SUBSTANCE&#160;AND&#160;<br/>MANUFACTURER&#160;RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:127px;left:106px;white-space:nowrap" class="ft7711">&#160;<br/>Name&#160;and&#160;address of&#160;the&#160;manufacturer&#160;of&#160;the&#160;biological&#160;active substance&#160;<br/>&#160;<br/>CELLTRION,&#160;Inc.&#160;<br/>23, Academy-ro,&#160;<br/>Yeonsu-gu, Incheon,&#160;22014&#160;<br/>Republic&#160;of&#160;Korea&#160;<br/>&#160;<br/>CELLTRION,&#160;Inc.&#160;(Plant&#160;II,&#160;CLT2)&#160;<br/>20, Academy-ro 51&#160;beon-gil,&#160;<br/>Yeonsu-gu, Incheon,&#160;22014&#160;<br/>Republic&#160;of&#160;Korea&#160;<br/>&#160;<br/>Lonza&#160;Biologics&#160;Tuas&#160;Pte&#160;Ltd&#160;&#160;<br/>35 Tuas&#160;South Avenue&#160;6,&#160;&#160;<br/>Singapore&#160;637377,&#160;Singapore&#160;<br/>&#160;<br/>Name and&#160;address of&#160;the&#160;manufacturer&#160;responsible&#160;for&#160;batch&#160;release&#160;<br/>&#160;<br/>Millmount Healthcare&#160;Ltd.&#160;<br/>Block 7&#160;<br/>City&#160;North&#160;Business Campus&#160;&#160;<br/>Stamullen, Co. Meath K32&#160;YD60&#160;<br/>Ireland&#160;<br/>&#160;<br/>Nuvisan&#160;GmbH&#160;<br/>Wegenerstraße 13,&#160;&#160;<br/>89231 Neu Ulm,&#160;&#160;<br/>Germany&#160;<br/>&#160;<br/>Nuvisan&#160;France SARL&#160;<br/>2400, Route&#160;des&#160;Colles,&#160;&#160;<br/>06410, Biot,&#160;&#160;<br/>France&#160;<br/>&#160;<br/>The printed&#160;package leaflet&#160;of&#160;the medicinal&#160;product&#160;must&#160;state&#160;the name and&#160;address of&#160;the&#160;<br/>manufacturer&#160;responsible&#160;for&#160;the&#160;release of&#160;the concerned&#160;batch.&#160;<br/>&#160;<br/>&#160;<br/><b>B.&#160;</b></p>
<p style="position:absolute;top:878px;left:149px;white-space:nowrap" class="ft771"><b>CONDITIONS&#160;OR RESTRICTIONS&#160;REGARDING&#160;SUPPLY AND USE&#160;</b></p>
<p style="position:absolute;top:897px;left:106px;white-space:nowrap" class="ft7711">&#160;<br/>Medicinal&#160;product&#160;subject&#160;to&#160;restricted&#160;medical&#160;prescription&#160;(see Annex&#160;I:&#160;Summary&#160;of&#160;Product&#160;<br/>Characteristics,&#160;section&#160;4.2).&#160;<br/>&#160;<br/>&#160;<br/><b>C.&#160;</b></p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft776"><b>OTHER CONDITIONS&#160;AND REQUIREMENTS&#160;OF&#160;THE&#160;MARKETING&#160;<br/>AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:1033px;left:106px;white-space:nowrap" class="ft772">&#160;</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft778">•&#160;</p>
<p style="position:absolute;top:1052px;left:149px;white-space:nowrap" class="ft771"><b>Periodic&#160;safety&#160;update&#160;reports&#160;(PSURs)&#160;&#160;</b></p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft7711">&#160;<br/>The&#160;requirements&#160;for&#160;submission&#160;of&#160;PSURs&#160;for&#160;this&#160;medicinal product are&#160;set out&#160;in&#160;the&#160;list of&#160;<br/>Union reference&#160;dates&#160;(EURD&#160;list)&#160;provided&#160;for&#160;under&#160;Article&#160;107c(7)&#160;of&#160;Directive&#160;2001/83/EC&#160;<br/>and&#160;any subsequent&#160;updates&#160;published on&#160;the&#160;European&#160;medicines&#160;web-portal.&#160;<br/>&#160;</p>
</div>
<!-- Page 78 -->
<a name="78"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page78-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft780">78&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft7811">&#160;<br/><b>D.&#160;</b></p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft786"><b>CONDITIONS&#160;OR RESTRICTIONS&#160;WITH&#160;REGARD TO&#160;THE&#160;SAFE&#160;AND&#160;<br/>EFFECTIVE&#160;USE&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft782">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft788">•&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft781"><b>Risk&#160;management&#160;plan&#160;(RMP)&#160;</b></p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft7811">&#160;<br/>The&#160;marketing authorisation holder&#160;(MAH)&#160;shall&#160;perform&#160;the required&#160;pharmacovigilance&#160;<br/>activities&#160;and interventions&#160;detailed in the&#160;agreed RMP&#160;presented in Module&#160;1.8.2&#160;of&#160;the&#160;<br/>marketing&#160;authorisation and any agreed subsequent&#160;updates&#160;of&#160;the&#160;RMP.&#160;<br/>&#160;<br/>An updated RMP&#160;should be&#160;submitted:&#160;</p>
<p style="position:absolute;top:298px;left:133px;white-space:nowrap" class="ft788">•&#160;&#160;At&#160;the request&#160;of&#160;the European&#160;Medicines Agency;&#160;&#160;</p>
<p style="position:absolute;top:319px;left:133px;white-space:nowrap" class="ft788">•&#160;&#160;Whenever&#160;the&#160;risk&#160;management&#160;system&#160;is&#160;modified,&#160;especially&#160;as the result&#160;of&#160;new&#160;information&#160;</p>
<p style="position:absolute;top:343px;left:149px;white-space:nowrap" class="ft7811">being&#160;received&#160;that&#160;may lead to a&#160;significant&#160;change&#160;to&#160;the&#160;benefit/risk profile&#160;or&#160;as&#160;the&#160;result&#160;of&#160;<br/>an&#160;important&#160;(pharmacovigilance&#160;or&#160;risk minimisation)&#160;milestone&#160;being reached.&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft782">&#160;</p>
<p style="position:absolute;top:395px;left:106px;white-space:nowrap" class="ft788">•&#160;</p>
<p style="position:absolute;top:401px;left:149px;white-space:nowrap" class="ft781"><b>Additional&#160;risk&#160;minimisation&#160;measures&#160;</b></p>
<p style="position:absolute;top:420px;left:106px;white-space:nowrap" class="ft7811">&#160;<br/>The educational&#160;programme consists of&#160;a patient&#160;reminder&#160;card&#160;to&#160;be held&#160;by&#160;the&#160;patient.&#160;The&#160;card&#160;is&#160;<br/>aimed at&#160;both serving&#160;as&#160;a&#160;reminder&#160;to&#160;record&#160;the&#160;dates&#160;and&#160;outcomes of&#160;specific tests and&#160;to&#160;facilitate&#160;<br/>the patient&#160;sharing&#160;of&#160;special&#160;information&#160;with&#160;healthcare professionals(s)&#160;(HCPs)&#160;treating&#160;the patient&#160;<br/>about&#160;on-going treatment&#160;with the&#160;product.&#160;<br/>&#160;<br/><b>The&#160;patient&#160;reminder&#160;card&#160;</b>shall&#160;contain the&#160;following&#160;key&#160;messages:&#160;<br/>&#160;</p>
<p style="position:absolute;top:568px;left:106px;white-space:nowrap" class="ft788">•&#160;</p>
<p style="position:absolute;top:573px;left:149px;white-space:nowrap" class="ft7810">A&#160;reminder&#160;to patients&#160;to&#160;show&#160;the&#160;patient&#160;reminder&#160;card to all&#160;treating&#160;HCPs, including&#160;in&#160;<br/>conditions&#160;of&#160;emergency, and a&#160;message&#160;for&#160;HCPs&#160;that&#160;the&#160;patient&#160;is&#160;using&#160;Remsima&#160;</p>
<p style="position:absolute;top:611px;left:106px;white-space:nowrap" class="ft7814">&#160;<br/>•&#160;</p>
<p style="position:absolute;top:631px;left:149px;white-space:nowrap" class="ft782">A&#160;statement&#160;that&#160;the&#160;brand&#160;name&#160;and batch number&#160;should be&#160;recorded&#160;</p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft782">&#160;</p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft788">•&#160;</p>
<p style="position:absolute;top:670px;left:149px;white-space:nowrap" class="ft782">Provision&#160;to record the&#160;type,&#160;date,&#160;and result&#160;of&#160;TB&#160;screenings&#160;</p>
<p style="position:absolute;top:689px;left:106px;white-space:nowrap" class="ft7814">&#160;<br/>•&#160;</p>
<p style="position:absolute;top:710px;left:149px;white-space:nowrap" class="ft7810">That treatment&#160;with&#160;Remsima&#160;may increase&#160;the&#160;risks&#160;of&#160;serious&#160;infections/sepsis, opportunistic&#160;<br/>infections, tuberculosis, hepatitis&#160;B&#160;reactivation,&#160;and&#160;BCG&#160;breakthrough in infants&#160;with&#160;<i>in&#160;utero</i>&#160;<br/>or&#160;breast-feeding&#160;exposure&#160;to&#160;infliximab,&#160;and&#160;when to seek attention&#160;from&#160;a&#160;HCP&#160;</p>
<p style="position:absolute;top:766px;left:107px;white-space:nowrap" class="ft7814">&#160;<br/>•&#160;</p>
<p style="position:absolute;top:787px;left:149px;white-space:nowrap" class="ft782">Contact&#160;details&#160;of&#160;the prescriber&#160;</p>
<p style="position:absolute;top:806px;left:107px;white-space:nowrap" class="ft785"><b>&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:825px;left:323px;white-space:nowrap" class="ft782">&#160;</p>
</div>
<!-- Page 79 -->
<a name="79"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page79-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft790">79&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft796">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/><b>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</b></p>
<p style="position:absolute;top:506px;left:406px;white-space:nowrap" class="ft791"><b>ANNEX III&#160;</b></p>
<p style="position:absolute;top:525px;left:447px;white-space:nowrap" class="ft791"><b>&#160;</b></p>
<p style="position:absolute;top:544px;left:294px;white-space:nowrap" class="ft791"><b>LABELLING&#160;AND&#160;PACKAGE LEAFLET&#160;</b></p>
<p style="position:absolute;top:564px;left:106px;white-space:nowrap" class="ft7911">&#160;<br/>&#160;</p>
<p style="position:absolute;top:583px;left:322px;white-space:nowrap" class="ft792">&#160;</p>
</div>
<!-- Page 80 -->
<a name="80"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page80-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft800">80&#160;</p>
<p style="position:absolute;top:89px;left:447px;white-space:nowrap" class="ft8010">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:506px;left:387px;white-space:nowrap" class="ft801"><b>A.&#160;LABELLING&#160;</b></p>
<p style="position:absolute;top:525px;left:106px;white-space:nowrap" class="ft802">&#160;</p>
<p style="position:absolute;top:525px;left:322px;white-space:nowrap" class="ft801"><b>&#160;</b></p>
</div>
<!-- Page 81 -->
<a name="81"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft8137{font-size:17px;line-height:21px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page81-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft810">81&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft8137"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;<br/></b>&#160;<br/><b>OUTER CARTON</b>&#160;<br/>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft811"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT</b>&#160;</p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft8137">&#160;<br/>Remsima&#160;100&#160;mg powder&#160;for&#160;concentrate&#160;for&#160;solution&#160;for&#160;infusion&#160;<br/>infliximab<i>&#160;<br/></i>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:309px;left:149px;white-space:nowrap" class="ft811"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft8137">&#160;<br/>One&#160;vial&#160;contains&#160;100&#160;mg of&#160;infliximab.&#160;&#160;<br/>After&#160;reconstitution&#160;one&#160;ml&#160;contains&#160;10&#160;mg&#160;of&#160;infliximab.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:428px;left:149px;white-space:nowrap" class="ft811"><b>LIST OF&#160;EXCIPIENTS</b>&#160;</p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft8137"><i>&#160;<br/></i>Excipients:&#160;sucrose, polysorbate&#160;80, sodium&#160;dihydrogen&#160;phosphate&#160;monohydrate,&#160;disodium&#160;phosphate&#160;<br/>dihydrate.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:546px;left:149px;white-space:nowrap" class="ft811"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS</b>&#160;</p>
<p style="position:absolute;top:567px;left:106px;white-space:nowrap" class="ft8137">&#160;<br/>Powder&#160;for&#160;concentrate&#160;for&#160;solution for&#160;infusion.&#160;&#160;<br/>&#160;<br/>1&#160;vial&#160;<br/>2&#160;vials&#160;<br/>3&#160;vials&#160;<br/>4&#160;vials&#160;<br/>5&#160;vials&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:762px;left:149px;white-space:nowrap" class="ft811"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION</b>&#160;</p>
<p style="position:absolute;top:783px;left:106px;white-space:nowrap" class="ft8137">&#160;<br/>Read&#160;the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>Intravenous&#160;use.&#160;<br/>&#160;<br/>Reconstitute&#160;and&#160;dilute&#160;before use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:937px;left:149px;white-space:nowrap" class="ft815"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;<br/>OF&#160;THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN</b>&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft8137">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:1056px;left:149px;white-space:nowrap" class="ft811"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY</b>&#160;</p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft8137">&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:1118px;left:149px;white-space:nowrap" class="ft811"><b>EXPIRY DATE</b>&#160;</p>
<p style="position:absolute;top:1139px;left:106px;white-space:nowrap" class="ft8110">&#160;<br/>EXP&#160;</p>
</div>
<!-- Page 82 -->
<a name="82"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page82-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft820">82&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft8237">EXP, if&#160;not&#160;refrigerated ___________________&#160;<br/>&#160;<br/>&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft821"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS</b>&#160;</p>
<p style="position:absolute;top:169px;left:106px;white-space:nowrap" class="ft8237"><i>&#160;<br/></i>Store&#160;in&#160;a&#160;refrigerator.&#160;<br/>Can be&#160;stored at&#160;room&#160;temperature&#160;(up&#160;to 25°C)&#160;for&#160;a&#160;single&#160;period up&#160;to 6&#160;months,&#160;but&#160;not&#160;exceeding&#160;<br/>the&#160;original&#160;expiry date.&#160;<br/>&#160;<br/>&#160;<br/><b>10.&#160;</b></p>
<p style="position:absolute;top:286px;left:149px;white-space:nowrap" class="ft825"><b>SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;<br/>OR WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:345px;left:106px;white-space:nowrap" class="ft8237">&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:385px;left:149px;white-space:nowrap" class="ft821"><b>NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:407px;left:106px;white-space:nowrap" class="ft8237">&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd&#160;Office&#160;Building&#160;B&#160;torony&#160;<br/>Hungary&#160;<br/><b>&#160;<br/></b>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:544px;left:149px;white-space:nowrap" class="ft821"><b>MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b>&#160;</p>
<p style="position:absolute;top:565px;left:106px;white-space:nowrap" class="ft8237">&#160;<br/>EU/1/13/853/001&#160;1 vial&#160;<br/>EU/1/13/853/002 2&#160;vials&#160;<br/>EU/1/13/853/003 3&#160;vials&#160;<br/>EU/1/13/853/004 4&#160;vials&#160;<br/>EU/1/13/853/005 5&#160;vials&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:722px;left:149px;white-space:nowrap" class="ft821"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:743px;left:106px;white-space:nowrap" class="ft8237">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:821px;left:149px;white-space:nowrap" class="ft821"><b>GENERAL&#160;CLASSIFICATION FOR SUPPLY</b>&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft8210">&#160;<br/>&#160;</p>
<p style="position:absolute;top:884px;left:106px;white-space:nowrap" class="ft821"><b>15.&#160;</b></p>
<p style="position:absolute;top:884px;left:149px;white-space:nowrap" class="ft821"><b>INSTRUCTIONS&#160;ON USE</b>&#160;</p>
<p style="position:absolute;top:905px;left:106px;white-space:nowrap" class="ft8237"><i>&#160;<br/></i>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:946px;left:149px;white-space:nowrap" class="ft821"><b>INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:967px;left:106px;white-space:nowrap" class="ft8237"><i>&#160;<br/></i>Remsima&#160;100&#160;mg&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:1045px;left:149px;white-space:nowrap" class="ft821"><b>UNIQUE&#160;INDENTIFIER&#160;–&#160;2D BARCODE&#160;</b></p>
<p style="position:absolute;top:1066px;left:106px;white-space:nowrap" class="ft8210"><i>&#160;<br/></i>2D&#160;barcode&#160;carrying the&#160;unique&#160;identifier&#160;included.&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:1124px;left:322px;white-space:nowrap" class="ft822">&#160;</p>
</div>
<!-- Page 83 -->
<a name="83"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page83-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft830">83&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft831"><b>18.&#160;</b></p>
<p style="position:absolute;top:91px;left:149px;white-space:nowrap" class="ft831"><b>UNIQUE&#160;INDENTIFIER&#160;–&#160;HUMAN READABLE&#160;DATA&#160;</b></p>
<p style="position:absolute;top:113px;left:106px;white-space:nowrap" class="ft8311"><i>&#160;<br/></i>PC&#160;<br/>SN&#160;<br/>NN&#160;<br/>&#160;</p>
<p style="position:absolute;top:188px;left:322px;white-space:nowrap" class="ft832">&#160;</p>
</div>
<!-- Page 84 -->
<a name="84"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft8438{font-size:17px;line-height:21px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page84-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft840">84&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft8437"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR ON SMALL&#160;IMMEDIATE&#160;PACKAGING&#160;UNITS&#160;<br/>&#160;<br/>VIAL LABEL&#160;&#160;<br/></b>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft841"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft8437">&#160;<br/>Remsima&#160;100&#160;mg powder&#160;for&#160;concentrate&#160;<br/>infliximab&#160;<br/>IV&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:328px;left:149px;white-space:nowrap" class="ft841"><b>METHOD OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft8437"><i>&#160;<br/></i>For&#160;intravenous&#160;use&#160;after&#160;reconstitution and dilution&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:427px;left:149px;white-space:nowrap" class="ft841"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:449px;left:106px;white-space:nowrap" class="ft8437">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:527px;left:149px;white-space:nowrap" class="ft841"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:548px;left:106px;white-space:nowrap" class="ft8437">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft841"><b>CONTENTS&#160;BY WEIGHT,&#160;BY VOLUME&#160;OR BY&#160;UNIT&#160;</b></p>
<p style="position:absolute;top:647px;left:106px;white-space:nowrap" class="ft8437">&#160;<br/>100&#160;mg&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:726px;left:149px;white-space:nowrap" class="ft841"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft842">&#160;</p>
<p style="position:absolute;top:747px;left:322px;white-space:nowrap" class="ft842">&#160;</p>
</div>
<!-- Page 85 -->
<a name="85"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page85-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft850">85&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft8537"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;<br/></b>&#160;<br/><b>OUTER CARTON FOR PRE-FILLED SYRINGE&#160;WITH&#160;AUTOMATIC NEEDLE&#160;GUARD</b>&#160;<br/>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft851"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT</b>&#160;</p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft8537">&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled syringe&#160;&#160;<br/>infliximab<b>&#160;<br/></b>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:309px;left:149px;white-space:nowrap" class="ft851"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft8537">&#160;<br/>Each&#160;1&#160;mL&#160;single dose&#160;pre-filled&#160;syringe&#160;contains&#160;120&#160;mg&#160;of&#160;infliximab.&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:408px;left:149px;white-space:nowrap" class="ft851"><b>LIST OF&#160;EXCIPIENTS</b>&#160;</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft8537">&#160;<br/>Excipients:&#160;acetic&#160;acid,&#160;sodium&#160;acetate&#160;trihydrate,&#160;sorbitol,&#160;polysorbate&#160;80, water&#160;for&#160;injections&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:508px;left:149px;white-space:nowrap" class="ft851"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS</b>&#160;</p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft8537">&#160;<br/>Solution for&#160;injection&#160;<br/>&#160;<br/>1 pre-filled syringe&#160;with 2 alcohol&#160;pads&#160;<br/>1 pre-filled&#160;syringe&#160;with needle&#160;guard with 2 alcohol&#160;pads&#160;<br/>2 pre-filled&#160;syringes&#160;with 2&#160;alcohol&#160;pads&#160;<br/>2 pre-filled&#160;syringes&#160;with needle&#160;guard with 2&#160;alcohol&#160;pads&#160;<br/>4 pre-filled&#160;syringes&#160;with 4&#160;alcohol&#160;pads&#160;<br/>4 pre-filled&#160;syringes&#160;with needle&#160;guard&#160;with&#160;4 alcohol&#160;pads&#160;<br/>6&#160;pre-filled syringes&#160;with&#160;6&#160;alcohol&#160;pads&#160;<br/>6&#160;pre-filled&#160;syringes&#160;with needle&#160;guard&#160;with&#160;6&#160;alcohol&#160;pads&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:778px;left:149px;white-space:nowrap" class="ft851"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION</b>&#160;</p>
<p style="position:absolute;top:799px;left:106px;white-space:nowrap" class="ft8537">&#160;<br/>Subcutaneous&#160;use&#160;&#160;<br/>&#160;<br/>Read&#160;the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:915px;left:149px;white-space:nowrap" class="ft855"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;<br/>OF&#160;THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN</b>&#160;</p>
<p style="position:absolute;top:955px;left:106px;white-space:nowrap" class="ft8537">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:1034px;left:149px;white-space:nowrap" class="ft851"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY</b>&#160;</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft8537">&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:1095px;left:149px;white-space:nowrap" class="ft851"><b>EXPIRY DATE</b>&#160;</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft8511">&#160;<br/>EXP&#160;<br/>&#160;</p>
</div>
<!-- Page 86 -->
<a name="86"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page86-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft860">86&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft8637">&#160;<br/><b>9.&#160;</b></p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft861"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS</b>&#160;</p>
<p style="position:absolute;top:131px;left:106px;white-space:nowrap" class="ft8637">&#160;<br/>Store&#160;in&#160;a&#160;refrigerator.&#160;Do not&#160;freeze.&#160;Keep&#160;the&#160;pre-filled&#160;syringe&#160;in&#160;its&#160;package&#160;in&#160;order&#160;to protect&#160;from&#160;<br/>light.&#160;<br/>&#160;<br/>&#160;<br/><b>10.&#160;</b></p>
<p style="position:absolute;top:229px;left:149px;white-space:nowrap" class="ft865"><b>SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED MEDICINAL&#160;PRODUCTS&#160;<br/>OR WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:288px;left:106px;white-space:nowrap" class="ft8637">&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:328px;left:149px;white-space:nowrap" class="ft861"><b>NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft8637">&#160;<br/>CELLTRION&#160;Healthcare Hungary&#160;Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Hungary&#160;<br/>&#160;<br/>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:484px;left:149px;white-space:nowrap" class="ft861"><b>MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b>&#160;</p>
<p style="position:absolute;top:505px;left:106px;white-space:nowrap" class="ft8637">&#160;<br/>EU/1/13/853/006&#160;1 pre-filled&#160;syringe&#160;<br/>EU/1/13/853/009&#160;1 pre-filled syringe&#160;with&#160;automatic needle&#160;guard&#160;<br/>EU/1/13/853/007&#160;2 pre-filled syringes&#160;<br/>EU/1/13/853/010&#160;2&#160;pre-filled syringes&#160;with&#160;automatic&#160;needle&#160;guard&#160;<br/>EU/1/13/853/008&#160;4 pre-filled syringes&#160;<br/>EU/1/13/853/011&#160;4&#160;pre-filled syringes&#160;with&#160;automatic&#160;needle&#160;guard&#160;<br/>EU/1/13/853/015&#160;6&#160;pre-filled syringes&#160;<br/>EU/1/13/853/016&#160;6&#160;pre-filled syringes&#160;with automatic&#160;needle&#160;guard&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:717px;left:149px;white-space:nowrap" class="ft861"><b>BATCH&#160;NUMBER</b>&#160;</p>
<p style="position:absolute;top:738px;left:106px;white-space:nowrap" class="ft8637"><i>&#160;<br/></i>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:816px;left:149px;white-space:nowrap" class="ft861"><b>GENERAL&#160;CLASSIFICATION FOR SUPPLY</b>&#160;</p>
<p style="position:absolute;top:837px;left:106px;white-space:nowrap" class="ft8613"><i>&#160;<br/></i>&#160;</p>
<p style="position:absolute;top:879px;left:106px;white-space:nowrap" class="ft861"><b>15.&#160;</b></p>
<p style="position:absolute;top:879px;left:149px;white-space:nowrap" class="ft861"><b>INSTRUCTIONS&#160;ON USE</b>&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft8637">&#160;<br/>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:940px;left:149px;white-space:nowrap" class="ft861"><b>INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:961px;left:106px;white-space:nowrap" class="ft8637">&#160;<br/>Remsima&#160;120 mg&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:1040px;left:149px;white-space:nowrap" class="ft861"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE&#160;</b></p>
<p style="position:absolute;top:1061px;left:106px;white-space:nowrap" class="ft8610">&#160;<br/>2D&#160;barcode&#160;carrying the&#160;unique&#160;identifier&#160;included.&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 87 -->
<a name="87"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page87-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft870">87&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft871"><b>18.&#160;</b></p>
<p style="position:absolute;top:91px;left:149px;white-space:nowrap" class="ft871"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA&#160;</b></p>
<p style="position:absolute;top:113px;left:106px;white-space:nowrap" class="ft8711">&#160;<br/>PC&#160;<br/>SN&#160;&#160;<br/>NN&#160;</p>
<p style="position:absolute;top:171px;left:346px;white-space:nowrap" class="ft871"><b>&#160;</b></p>
</div>
<!-- Page 88 -->
<a name="88"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page88-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft880">88&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft8837"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR ON SMALL&#160;IMMEDIATE&#160;PACKAGING&#160;UNITS&#160;<br/>&#160;<br/>LABEL FOR&#160;PRE-FILLED SYRINGE&#160;WITH&#160;AUTOMATIC NEEDLE&#160;GUARD&#160;<br/></b>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft881"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft8837">&#160;<br/>Remsima&#160;120&#160;mg&#160;injection&#160;<br/>infliximab&#160;<br/>SC&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:328px;left:149px;white-space:nowrap" class="ft881"><b>METHOD OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft8837">&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:390px;left:149px;white-space:nowrap" class="ft881"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft8837">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:489px;left:149px;white-space:nowrap" class="ft881"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:510px;left:106px;white-space:nowrap" class="ft8837">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft881"><b>CONTENTS&#160;BY WEIGHT,&#160;BY VOLUME&#160;OR BY&#160;UNIT&#160;</b></p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft8837">&#160;<br/>120&#160;mg&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:688px;left:149px;white-space:nowrap" class="ft881"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft8811">&#160;<br/>&#160;</p>
</div>
<!-- Page 89 -->
<a name="89"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page89-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft890">89&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft8937"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;<br/></b>&#160;<br/><b>OUTER CARTON FOR PRE-FILLED&#160;PEN</b>&#160;<br/>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft891"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT</b>&#160;</p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft8937">&#160;<br/>Remsima&#160;120&#160;mg&#160;solution for&#160;injection&#160;in pre-filled&#160;pen&#160;<br/>infliximab<b>&#160;<br/></b>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:309px;left:149px;white-space:nowrap" class="ft891"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft8937">&#160;<br/>Each&#160;1&#160;mL&#160;single&#160;dose&#160;pre-filled&#160;pen contains&#160;120 mg of&#160;infliximab.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:408px;left:149px;white-space:nowrap" class="ft891"><b>LIST OF&#160;EXCIPIENTS</b>&#160;</p>
<p style="position:absolute;top:430px;left:106px;white-space:nowrap" class="ft8937">&#160;<br/>Excipients:&#160;acetic&#160;acid,&#160;sodium&#160;acetate&#160;trihydrate,&#160;sorbitol,&#160;polysorbate&#160;80, water&#160;for&#160;injections&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:508px;left:149px;white-space:nowrap" class="ft891"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS</b>&#160;</p>
<p style="position:absolute;top:529px;left:106px;white-space:nowrap" class="ft8937">&#160;<br/>Solution for&#160;injection&#160;<br/>&#160;<br/>1 pre-filled&#160;pen&#160;with 2&#160;alcohol&#160;pads&#160;<br/>2 pre-filled&#160;pens&#160;with&#160;2 alcohol&#160;pads&#160;<br/>4 pre-filled&#160;pens&#160;with&#160;4 alcohol&#160;pads&#160;<br/>6&#160;pre-filled&#160;pens&#160;with&#160;6&#160;alcohol&#160;pads&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:702px;left:149px;white-space:nowrap" class="ft891"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION</b>&#160;</p>
<p style="position:absolute;top:723px;left:106px;white-space:nowrap" class="ft8937">&#160;<br/>Subcutaneous&#160;use&#160;&#160;<br/>&#160;<br/>Read&#160;the package leaflet&#160;before&#160;use.&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:839px;left:149px;white-space:nowrap" class="ft895"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;<br/>OF&#160;THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN</b>&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft8937">&#160;<br/>Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;<br/>&#160;<br/>&#160;<br/><b>7.&#160;</b></p>
<p style="position:absolute;top:958px;left:149px;white-space:nowrap" class="ft891"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY</b>&#160;</p>
<p style="position:absolute;top:979px;left:106px;white-space:nowrap" class="ft8937">&#160;<br/>&#160;<br/><b>8.&#160;</b></p>
<p style="position:absolute;top:1019px;left:149px;white-space:nowrap" class="ft891"><b>EXPIRY DATE</b>&#160;</p>
<p style="position:absolute;top:1040px;left:106px;white-space:nowrap" class="ft8910">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 90 -->
<a name="90"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page90-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft900">90&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft901"><b>9.&#160;</b></p>
<p style="position:absolute;top:91px;left:149px;white-space:nowrap" class="ft901"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS</b>&#160;</p>
<p style="position:absolute;top:113px;left:106px;white-space:nowrap" class="ft9037">&#160;<br/>Store&#160;in&#160;a&#160;refrigerator.&#160;Do not&#160;freeze. Keep the&#160;pre-filled&#160;pen&#160;in its&#160;package&#160;in&#160;order&#160;to protect from&#160;<br/>light.&#160;<br/>&#160;<br/>&#160;<br/><b>10.&#160;</b></p>
<p style="position:absolute;top:210px;left:149px;white-space:nowrap" class="ft905"><b>SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED MEDICINAL&#160;PRODUCTS&#160;<br/>OR WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;<br/>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:269px;left:106px;white-space:nowrap" class="ft9037">&#160;<br/>&#160;<br/><b>11.&#160;</b></p>
<p style="position:absolute;top:309px;left:149px;white-space:nowrap" class="ft901"><b>NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft9037">&#160;<br/>CELLTRION&#160;Healthcare Hungary&#160;Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Hungary&#160;<br/>&#160;<br/>&#160;<br/><b>12.&#160;</b></p>
<p style="position:absolute;top:465px;left:149px;white-space:nowrap" class="ft901"><b>MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b>&#160;</p>
<p style="position:absolute;top:487px;left:106px;white-space:nowrap" class="ft9037">&#160;<br/>EU/1/13/853/012&#160;1 pre-filled&#160;pen&#160;<br/>EU/1/13/853/013&#160;2 pre-filled pens&#160;<br/>EU/1/13/853/014&#160;4 pre-filled pens&#160;<br/>EU/1/13/853/017&#160;6&#160;pre-filled pens&#160;<br/>&#160;<br/>&#160;<br/><b>13.&#160;</b></p>
<p style="position:absolute;top:622px;left:149px;white-space:nowrap" class="ft901"><b>BATCH&#160;NUMBER</b>&#160;</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft9037"><i>&#160;<br/></i>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>14.&#160;</b></p>
<p style="position:absolute;top:721px;left:149px;white-space:nowrap" class="ft901"><b>GENERAL&#160;CLASSIFICATION FOR SUPPLY</b>&#160;</p>
<p style="position:absolute;top:742px;left:106px;white-space:nowrap" class="ft9013"><i>&#160;<br/></i>&#160;</p>
<p style="position:absolute;top:784px;left:106px;white-space:nowrap" class="ft901"><b>15.&#160;</b></p>
<p style="position:absolute;top:784px;left:149px;white-space:nowrap" class="ft901"><b>INSTRUCTIONS&#160;ON USE</b>&#160;</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft9037">&#160;<br/>&#160;<br/><b>16.&#160;</b></p>
<p style="position:absolute;top:845px;left:149px;white-space:nowrap" class="ft901"><b>INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:867px;left:106px;white-space:nowrap" class="ft9037">&#160;<br/>Remsima&#160;120&#160;mg&#160;<br/>&#160;<br/>&#160;<br/><b>17.&#160;</b></p>
<p style="position:absolute;top:945px;left:149px;white-space:nowrap" class="ft901"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE&#160;</b></p>
<p style="position:absolute;top:966px;left:106px;white-space:nowrap" class="ft9037">&#160;<br/>2D&#160;barcode&#160;carrying the&#160;unique&#160;identifier&#160;included.&#160;<br/>&#160;<br/>&#160;<br/><b>18.&#160;</b></p>
<p style="position:absolute;top:1044px;left:149px;white-space:nowrap" class="ft901"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA&#160;</b></p>
<p style="position:absolute;top:1065px;left:106px;white-space:nowrap" class="ft9011">&#160;<br/>PC&#160;<br/>SN&#160;&#160;<br/>NN&#160;&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:1162px;left:322px;white-space:nowrap" class="ft901"><b>&#160;</b></p>
</div>
<!-- Page 91 -->
<a name="91"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page91-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft910">91&#160;</p>
<p style="position:absolute;top:91px;left:106px;white-space:nowrap" class="ft9137"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR ON&#160;SMALL&#160;IMMEDIATE&#160;PACKAGING&#160;UNITS&#160;<br/>&#160;<br/>LABEL FOR&#160;PRE-FILLED&#160;PEN&#160;&#160;<br/></b>&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:191px;left:149px;white-space:nowrap" class="ft911"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:212px;left:106px;white-space:nowrap" class="ft9137">&#160;<br/>Remsima&#160;120&#160;mg&#160;injection&#160;<br/>infliximab&#160;<br/>Subcutaneous&#160;use&#160;<br/>&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:328px;left:149px;white-space:nowrap" class="ft911"><b>METHOD OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft9137">&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:390px;left:149px;white-space:nowrap" class="ft911"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:411px;left:106px;white-space:nowrap" class="ft9137">&#160;<br/>EXP&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:489px;left:149px;white-space:nowrap" class="ft911"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:510px;left:106px;white-space:nowrap" class="ft9137">&#160;<br/>Lot&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:588px;left:149px;white-space:nowrap" class="ft911"><b>CONTENTS&#160;BY WEIGHT,&#160;BY VOLUME&#160;OR BY&#160;UNIT&#160;</b></p>
<p style="position:absolute;top:609px;left:106px;white-space:nowrap" class="ft9137">&#160;<br/>120 mg&#160;<br/>&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:688px;left:149px;white-space:nowrap" class="ft911"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft9111">&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:728px;left:322px;white-space:nowrap" class="ft911"><b>&#160;</b></p>
</div>
<!-- Page 92 -->
<a name="92"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft9239{font-size:24px;font-family:TimesNewRomanPS;color:#000000;}
	.ft9240{font-size:21px;font-family:TimesNewRomanPS;color:#000000;}
	.ft9241{font-size:21px;line-height:22px;font-family:TimesNewRomanPS;color:#000000;}
	.ft9242{font-size:17px;line-height:15px;font-family:TimesNewRomanPS;color:#000000;}
	.ft9243{font-size:17px;line-height:16px;font-family:TimesNewRomanPS;color:#000000;}
	.ft9244{font-size:21px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page92-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft920">92&#160;</p>
<p style="position:absolute;top:92px;left:229px;white-space:nowrap" class="ft9239"><b>Remsima&#160;</b></p>
<p style="position:absolute;top:117px;left:242px;white-space:nowrap" class="ft922">Infliximab&#160;</p>
<p style="position:absolute;top:136px;left:277px;white-space:nowrap" class="ft922">&#160;</p>
<p style="position:absolute;top:157px;left:156px;white-space:nowrap" class="ft9239"><b>Patient&#160;Reminder&#160;Card&#160;</b></p>
<p style="position:absolute;top:183px;left:115px;white-space:nowrap" class="ft9210">&#160;<br/>Show&#160;this&#160;card&#160;to any doctor&#160;involved in your&#160;<br/>treatment.&#160;</p>
<p style="position:absolute;top:240px;left:277px;white-space:nowrap" class="ft921"><b>&#160;</b></p>
<p style="position:absolute;top:259px;left:115px;white-space:nowrap" class="ft9210">This&#160;Patient&#160;Reminder&#160;Card contains&#160;important&#160;<br/>safety information that&#160;you need to&#160;be&#160;aware&#160;of&#160;<br/>before&#160;and during&#160;treatment&#160;with Remsima.&#160;<br/>&#160;<br/>Name patient:&#160;<br/>Name doctor:&#160;<br/>Telephone&#160;number&#160;doctor:&#160;<br/>&#160;<br/>When&#160;starting&#160;a&#160;new&#160;card,&#160;please&#160;keep&#160;this&#160;card&#160;<br/>as&#160;a reference for&#160;4&#160;months after&#160;your&#160;last&#160;dose&#160;<br/>of&#160;Remsima.&#160;<br/>&#160;<br/>&#160;<br/>Please read&#160;the Remsima&#160;‘Package Leaflet’&#160;<br/>carefully&#160;before&#160;you&#160;start&#160;using&#160;this medicine.&#160;<br/>&#160;<br/>Date&#160;of&#160;Remsima&#160;therapy&#160;initiation:&#160;<br/>&#160;<br/>&#160;<br/>Current&#160;administrations:&#160;<br/>&#160;<br/>&#160;<br/>It&#160;is&#160;important&#160;that&#160;you and&#160;your&#160;doctor&#160;record&#160;<br/>the&#160;brand&#160;name&#160;and batch number&#160;of&#160;your&#160;<br/>medicine.&#160;<br/>&#160;<br/>Brand&#160;name:&#160;<br/>Batch&#160;number:&#160;<br/>&#160;<br/>Ask your&#160;doctor&#160;to&#160;record&#160;the&#160;type&#160;and&#160;date&#160;of&#160;<br/>last&#160;screening(s)&#160;for&#160;tuberculosis&#160;(TB)&#160;below:&#160;<br/>Test:&#160;&#160;&#160;</p>
<p style="position:absolute;top:847px;left:274px;white-space:nowrap" class="ft922">Test:&#160;</p>
<p style="position:absolute;top:866px;left:115px;white-space:nowrap" class="ft922">Date:&#160;&#160;&#160;</p>
<p style="position:absolute;top:866px;left:274px;white-space:nowrap" class="ft922">Date:&#160;</p>
<p style="position:absolute;top:885px;left:115px;white-space:nowrap" class="ft922">Result:&#160;&#160;</p>
<p style="position:absolute;top:885px;left:274px;white-space:nowrap" class="ft922">Result:&#160;</p>
<p style="position:absolute;top:904px;left:115px;white-space:nowrap" class="ft9211">&#160;<br/>Please make sure&#160;you&#160;also&#160;have&#160;a list&#160;of&#160;all&#160;other&#160;<br/>medicines&#160;that&#160;you are&#160;using with&#160;you at&#160;any&#160;<br/>visit&#160;to&#160;a&#160;healthcare&#160;professional.&#160;<br/>&#160;<br/>List of&#160;allergies:&#160;<br/>&#160;<br/>List of&#160;other&#160;medicines:&#160;<br/>&#160;</p>
<p style="position:absolute;top:91px;left:455px;white-space:nowrap" class="ft9242"><b>Infections&#160;<br/>&#160;<br/>Before&#160;treatment with&#160;Remsima&#160;<br/></b>•&#160;</p>
<p style="position:absolute;top:153px;left:498px;white-space:nowrap" class="ft9210">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;have&#160;an&#160;infection&#160;<br/>even&#160;if&#160;it is&#160;a&#160;very&#160;minor&#160;one.&#160;</p>
<p style="position:absolute;top:187px;left:455px;white-space:nowrap" class="ft928">•&#160;</p>
<p style="position:absolute;top:192px;left:498px;white-space:nowrap" class="ft9210">It&#160;is&#160;very&#160;important&#160;that&#160;you tell&#160;your&#160;<br/>doctor&#160;if&#160;you&#160;have&#160;ever&#160;had&#160;tuberculosis&#160;<br/>(TB), or&#160;if&#160;you have&#160;been&#160;in close&#160;contact&#160;<br/>with someone&#160;who&#160;has&#160;had&#160;TB. Your&#160;<br/>doctor&#160;will&#160;test you&#160;to&#160;see&#160;if&#160;you have&#160;TB.&#160;<br/>Ask&#160;your&#160;doctor&#160;to record the&#160;type&#160;and&#160;<br/>date&#160;of&#160;your&#160;last&#160;screening(s)&#160;for&#160;TB&#160;on&#160;<br/>the&#160;card.&#160;</p>
<p style="position:absolute;top:340px;left:455px;white-space:nowrap" class="ft928">•&#160;</p>
<p style="position:absolute;top:345px;left:498px;white-space:nowrap" class="ft9210">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;have&#160;hepatitis&#160;B&#160;or&#160;<br/>if&#160;you know&#160;or&#160;suspect&#160;you&#160;are&#160;a&#160;carrier&#160;of&#160;<br/>the&#160;hepatitis&#160;B&#160;virus.&#160;</p>
<p style="position:absolute;top:402px;left:455px;white-space:nowrap" class="ft926"><b>&#160;<br/>During&#160;treatment&#160;with&#160;Remsima&#160;</b></p>
<p style="position:absolute;top:436px;left:455px;white-space:nowrap" class="ft928">•&#160;</p>
<p style="position:absolute;top:441px;left:492px;white-space:nowrap" class="ft9210">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;have&#160;<br/>signs&#160;of&#160;an infection. Signs&#160;include&#160;a&#160;fever,&#160;<br/>feeling&#160;tired, (persistent)&#160;cough, shortness&#160;<br/>of&#160;breath, weight&#160;loss, night&#160;sweats,&#160;<br/>diarrhoea, wounds, dental&#160;problems,&#160;<br/>burning&#160;when urinating&#160;or&#160;‘flu-like’&#160;signs.&#160;</p>
<p style="position:absolute;top:555px;left:455px;white-space:nowrap" class="ft9214"><b>&#160;<br/>Pregnancy,&#160;Breast-feeding&#160;and&#160;<br/>Vaccinations&#160;<br/></b>&#160;<br/>•&#160;&#160;In&#160;case you&#160;have received&#160;Remsima while&#160;</p>
<p style="position:absolute;top:653px;left:482px;white-space:nowrap" class="ft9210">you were&#160;pregnant&#160;or&#160;if&#160;you&#160;are breast-<br/>feeding, it&#160;is&#160;important&#160;that&#160;you&#160;inform&#160;your&#160;<br/>baby’s&#160;doctor&#160;about&#160;it&#160;before&#160;your&#160;baby&#160;<br/>receives&#160;any&#160;vaccine. Your&#160;baby should&#160;not&#160;<br/>receive&#160;a ‘live vaccine’,&#160;such&#160;as BCG&#160;(used&#160;<br/>to prevent&#160;tuberculosis)&#160;within&#160;12&#160;months&#160;<br/>after&#160;birth&#160;or&#160;while&#160;you are&#160;breast-feeding,&#160;<br/>unless&#160;your&#160;baby’s&#160;doctor&#160;recommends&#160;<br/>otherwise.&#160;</p>
<p style="position:absolute;top:823px;left:455px;white-space:nowrap" class="ft9211">&#160;<br/>Keep this&#160;card with you&#160;for&#160;4 months&#160;after&#160;your&#160;<br/>last&#160;dose&#160;of&#160;Remsima,&#160;or&#160;in&#160;case of&#160;pregnancy,&#160;<br/>for&#160;12&#160;months&#160;after&#160;the&#160;birth of&#160;your&#160;baby. Side&#160;<br/>effects&#160;may&#160;occur&#160;a long&#160;time after&#160;your&#160;last&#160;<br/>dose.&#160;</p>
<p style="position:absolute;top:1078px;left:447px;white-space:nowrap" class="ft9211">&#160;<br/>&#160;</p>
<p style="position:absolute;top:1117px;left:106px;white-space:nowrap" class="ft922">&#160;</p>
<p style="position:absolute;top:1117px;left:322px;white-space:nowrap" class="ft922">&#160;</p>
</div>
<!-- Page 93 -->
<a name="93"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page93-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft930">93&#160;</p>
<p style="position:absolute;top:89px;left:447px;white-space:nowrap" class="ft9311">&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:518px;left:355px;white-space:nowrap" class="ft931"><b>B.&#160;PACKAGE LEAFLET&#160;</b></p>
</div>
<!-- Page 94 -->
<a name="94"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft9445{font-size:14px;font-family:Verdana;color:#000000;}
-->
</style>
<div id="page94-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft940">94&#160;</p>
<p style="position:absolute;top:89px;left:303px;white-space:nowrap" class="ft941"><b>Package&#160;leaflet:&#160;Information&#160;for&#160;the user&#160;</b></p>
<p style="position:absolute;top:103px;left:447px;white-space:nowrap" class="ft9445"><b>&#160;</b></p>
<p style="position:absolute;top:124px;left:216px;white-space:nowrap" class="ft941"><b>Remsima 100&#160;mg&#160;powder&#160;for&#160;concentrate for solution&#160;for&#160;infusion&#160;</b></p>
<p style="position:absolute;top:143px;left:412px;white-space:nowrap" class="ft942">infliximab&#160;</p>
<p style="position:absolute;top:162px;left:447px;white-space:nowrap" class="ft9410">&#160;<br/>&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft945"><b>Read&#160;all&#160;of&#160;this&#160;leaflet&#160;carefully before&#160;you&#160;start&#160;using this&#160;medicine&#160;because it&#160;contains&#160;<br/>important information&#160;for&#160;you.&#160;</b></p>
<p style="position:absolute;top:234px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:240px;left:149px;white-space:nowrap" class="ft942">Keep&#160;this leaflet.&#160;You&#160;may&#160;need&#160;to&#160;read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:259px;left:149px;white-space:nowrap" class="ft9411">Your&#160;doctor&#160;will&#160;also&#160;give&#160;you a&#160;patient&#160;reminder&#160;card,&#160;which contains&#160;important&#160;safety&#160;<br/>information you need to be&#160;aware&#160;of&#160;before&#160;and during&#160;your&#160;treatment&#160;with Remsima.&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:299px;left:149px;white-space:nowrap" class="ft9410">When&#160;starting&#160;a new&#160;card,&#160;keep&#160;this card&#160;as a&#160;reference for&#160;4&#160;months&#160;after&#160;your&#160;last&#160;dose of&#160;<br/>Remsima.&#160;</p>
<p style="position:absolute;top:332px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:337px;left:149px;white-space:nowrap" class="ft942">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor.&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:357px;left:149px;white-space:nowrap" class="ft9411">This&#160;medicine&#160;has&#160;been prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them,&#160;<br/>even if&#160;their&#160;signs of&#160;illness&#160;are the same&#160;as&#160;yours.&#160;</p>
<p style="position:absolute;top:391px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:396px;left:149px;white-space:nowrap" class="ft9411">If&#160;you get&#160;any&#160;side&#160;effects,&#160;talk&#160;to your&#160;doctor. This&#160;includes&#160;any possible&#160;side&#160;effects&#160;not&#160;listed&#160;<br/>in&#160;this&#160;leaflet.&#160;See section&#160;4.&#160;</p>
<p style="position:absolute;top:435px;left:106px;white-space:nowrap" class="ft9411"><b>&#160;<br/>What&#160;is&#160;in&#160;this&#160;leaflet&#160;<br/></b>&#160;<br/>1.&#160;</p>
<p style="position:absolute;top:493px;left:149px;white-space:nowrap" class="ft942">What&#160;Remsima is and&#160;what&#160;it&#160;is&#160;used&#160;for&#160;</p>
<p style="position:absolute;top:513px;left:106px;white-space:nowrap" class="ft942">2.&#160;</p>
<p style="position:absolute;top:513px;left:149px;white-space:nowrap" class="ft942">What&#160;you need&#160;to know&#160;before&#160;you&#160;use Remsima&#160;</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft942">3.&#160;</p>
<p style="position:absolute;top:532px;left:149px;white-space:nowrap" class="ft942">How&#160;Remsima&#160;will be&#160;given&#160;</p>
<p style="position:absolute;top:552px;left:106px;white-space:nowrap" class="ft942">4.&#160;</p>
<p style="position:absolute;top:552px;left:149px;white-space:nowrap" class="ft942">Possible side&#160;effects&#160;</p>
<p style="position:absolute;top:571px;left:106px;white-space:nowrap" class="ft942">5.&#160;</p>
<p style="position:absolute;top:571px;left:149px;white-space:nowrap" class="ft942">How&#160;to&#160;store Remsima&#160;</p>
<p style="position:absolute;top:591px;left:106px;white-space:nowrap" class="ft942">6.&#160;</p>
<p style="position:absolute;top:591px;left:149px;white-space:nowrap" class="ft942">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft945"><b>&#160;<br/>&#160;<br/>1.&#160;</b></p>
<p style="position:absolute;top:649px;left:149px;white-space:nowrap" class="ft941"><b>What Remsima&#160;is&#160;and&#160;what it is&#160;used&#160;for&#160;</b></p>
<p style="position:absolute;top:668px;left:106px;white-space:nowrap" class="ft9411">&#160;<br/>Remsima&#160;contains the active&#160;substance infliximab.&#160;Infliximab is&#160;a&#160;monoclonal&#160;antibody&#160;-&#160;a&#160;type&#160;of&#160;<br/>protein&#160;that&#160;attaches&#160;to a&#160;specific&#160;target&#160;in the&#160;body&#160;called&#160;TNF&#160;(tumour&#160;necrosis&#160;factor)&#160;alpha.&#160;<br/>&#160;<br/>Remsima&#160;belongs&#160;to&#160;a&#160;group of&#160;medicines&#160;called ‘TNF&#160;blockers’. It&#160;is&#160;used&#160;in adults&#160;for&#160;the&#160;following&#160;<br/>inflammatory&#160;diseases:&#160;</p>
<p style="position:absolute;top:780px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:785px;left:149px;white-space:nowrap" class="ft942">Rheumatoid&#160;arthritis&#160;</p>
<p style="position:absolute;top:800px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:805px;left:149px;white-space:nowrap" class="ft942">Psoriatic&#160;arthritis&#160;</p>
<p style="position:absolute;top:819px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:824px;left:149px;white-space:nowrap" class="ft942">Ankylosing&#160;spondylitis&#160;(Bechterew’s&#160;disease)&#160;</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:844px;left:149px;white-space:nowrap" class="ft942">Psoriasis.&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft9411">&#160;<br/>Remsima is also&#160;used&#160;in&#160;adults and&#160;children&#160;6&#160;years of&#160;age or&#160;older&#160;for:&#160;</p>
<p style="position:absolute;top:897px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:902px;left:149px;white-space:nowrap" class="ft942">Crohn’s&#160;disease&#160;</p>
<p style="position:absolute;top:917px;left:106px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:922px;left:149px;white-space:nowrap" class="ft942">Ulcerative colitis.&#160;</p>
<p style="position:absolute;top:941px;left:107px;white-space:nowrap" class="ft9411">&#160;<br/>Remsima works&#160;by&#160;selectively&#160;attaching&#160;to&#160;TNF&#160;alpha&#160;and&#160;blocking its&#160;action.&#160;TNF alpha&#160;is&#160;involved&#160;<br/>in inflammatory processes&#160;of&#160;the&#160;body&#160;so&#160;blocking&#160;it&#160;can reduce&#160;the&#160;inflammation&#160;in your&#160;body.&#160;<br/>&#160;<br/><b>Rheumatoid arthritis&#160;<br/></b>Rheumatoid arthritis&#160;is&#160;an&#160;inflammatory disease&#160;of&#160;the&#160;joints<i>.&#160;</i>If&#160;you have&#160;active&#160;rheumatoid arthritis&#160;<br/>you will&#160;first&#160;be&#160;given&#160;other&#160;medicines.&#160;If&#160;these medicines&#160;do not&#160;work&#160;well&#160;enough, you will&#160;be&#160;given&#160;<br/>Remsima which&#160;you&#160;will&#160;take with&#160;another&#160;medicine called&#160;methotrexate&#160;to:&#160;</p>
<p style="position:absolute;top:1092px;left:107px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:1097px;left:149px;white-space:nowrap" class="ft942">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:1111px;left:107px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:1117px;left:149px;white-space:nowrap" class="ft942">slow&#160;down the&#160;damage&#160;in&#160;your&#160;joints,&#160;</p>
<p style="position:absolute;top:1131px;left:107px;white-space:nowrap" class="ft948">•&#160;</p>
<p style="position:absolute;top:1136px;left:149px;white-space:nowrap" class="ft942">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:1156px;left:107px;white-space:nowrap" class="ft941"><b>&#160;</b></p>
</div>
<!-- Page 95 -->
<a name="95"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page95-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft950">95&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft9511"><b>Psoriatic arthritis&#160;<br/></b>Psoriatic arthritis is&#160;an&#160;inflammatory&#160;disease of&#160;the joints,&#160;usually&#160;accompanied&#160;by&#160;psoriasis.&#160;If&#160;you&#160;<br/>have active psoriatic arthritis you&#160;will&#160;first&#160;be given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines&#160;do not&#160;work&#160;<br/>well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:167px;left:149px;white-space:nowrap" class="ft952">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:187px;left:149px;white-space:nowrap" class="ft952">slow&#160;down the&#160;damage&#160;in&#160;your&#160;joints,&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft952">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft9511"><b>&#160;<br/>Ankylosing&#160;spondylitis (Bechterew’s disease)&#160;<br/></b>Ankylosing&#160;spondylitis&#160;is&#160;an inflammatory&#160;disease&#160;of&#160;the&#160;spine. If&#160;you have&#160;ankylosing&#160;spondylitis&#160;<br/>you&#160;will&#160;first&#160;be given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines&#160;do not&#160;work well&#160;enough, you will&#160;be&#160;given&#160;<br/>Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:323px;left:149px;white-space:nowrap" class="ft952">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:338px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:343px;left:149px;white-space:nowrap" class="ft952">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft9511"><b>&#160;<br/>Psoriasis&#160;<br/></b>Psoriasis&#160;is an&#160;inflammatory&#160;disease of&#160;the&#160;skin.&#160;If&#160;you&#160;have&#160;moderate&#160;to severe&#160;plaque&#160;psoriasis, you&#160;<br/>will&#160;first&#160;be&#160;given&#160;other&#160;medicines&#160;or&#160;treatments, such&#160;as&#160;phototherapy.&#160;If&#160;these&#160;medicines&#160;or&#160;<br/>treatments&#160;do not&#160;work well&#160;enough, you will&#160;be&#160;given&#160;Remsima&#160;to reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;<br/>your&#160;disease.&#160;<br/><b>&#160;<br/>Ulcerative colitis&#160;<br/></b>Ulcerative colitis is an&#160;inflammatory&#160;disease of&#160;the&#160;bowel.&#160;If&#160;you&#160;have ulcerative colitis&#160;you&#160;will&#160;first&#160;<br/>be given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines&#160;do not&#160;work well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to&#160;<br/>treat&#160;your&#160;disease.&#160;<br/><b>&#160;<br/>Crohn’s&#160;disease&#160;<br/></b>Crohn’s disease&#160;is an&#160;inflammatory&#160;disease&#160;of&#160;the bowel.&#160;If&#160;you&#160;have Crohn’s disease you&#160;will&#160;first&#160;be&#160;<br/>given other&#160;medicines.&#160;If&#160;these medicines&#160;do&#160;not&#160;work well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:650px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:655px;left:149px;white-space:nowrap" class="ft952">treat&#160;active Crohn’s disease,&#160;</p>
<p style="position:absolute;top:669px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:674px;left:149px;white-space:nowrap" class="ft9511">reduce&#160;the&#160;number&#160;of&#160;abnormal&#160;openings&#160;(fistulae)&#160;between your&#160;bowel&#160;and&#160;your&#160;skin&#160;that&#160;have&#160;<br/>not&#160;been controlled&#160;by other&#160;medicines&#160;or&#160;surgery.&#160;</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft955"><b>&#160;<br/>&#160;<br/>2.&#160;</b></p>
<p style="position:absolute;top:753px;left:149px;white-space:nowrap" class="ft951"><b>What&#160;you&#160;need&#160;to know&#160;before&#160;you&#160;use&#160;Remsima&#160;</b></p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft955"><b>&#160;<br/>You&#160;must&#160;not&#160;be&#160;given&#160;Remsima&#160;if&#160;</b></p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:811px;left:149px;white-space:nowrap" class="ft9511">you are&#160;allergic&#160;to infliximab or&#160;any of&#160;the&#160;other&#160;ingredients&#160;of&#160;this&#160;medicine&#160;(listed&#160;in&#160;<br/>section&#160;6),&#160;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:850px;left:149px;white-space:nowrap" class="ft952">you&#160;are&#160;allergic&#160;to&#160;proteins&#160;that&#160;come&#160;from mice,&#160;</p>
<p style="position:absolute;top:864px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:870px;left:149px;white-space:nowrap" class="ft9511">you have&#160;tuberculosis&#160;(TB)&#160;or&#160;another&#160;serious&#160;infection&#160;such as&#160;pneumonia&#160;or&#160;sepsis&#160;(serious&#160;<br/>bacterial&#160;infection of&#160;the&#160;blood),&#160;</p>
<p style="position:absolute;top:903px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:908px;left:149px;white-space:nowrap" class="ft952">you have&#160;heart&#160;failure&#160;that&#160;is moderate&#160;or&#160;severe.&#160;</p>
<p style="position:absolute;top:928px;left:106px;white-space:nowrap" class="ft9511">&#160;<br/>Do not&#160;use&#160;Remsima&#160;if&#160;any&#160;of&#160;the&#160;above&#160;applies&#160;to you. If&#160;you are&#160;not&#160;sure,&#160;talk to&#160;your&#160;doctor&#160;before&#160;<br/>you are&#160;given Remsima.&#160;<br/><b>&#160;<br/>Warnings and&#160;precautions&#160;&#160;<br/></b>Talk&#160;to your&#160;doctor&#160;before&#160;or&#160;during&#160;treatment&#160;with&#160;Remsima&#160;if&#160;you&#160;have:&#160;<br/>&#160;<br/>Had treatment&#160;with&#160;any&#160;medicine&#160;containing&#160;infliximab before&#160;<br/>&#160;</p>
<p style="position:absolute;top:1098px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:1103px;left:149px;white-space:nowrap" class="ft9510">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;have&#160;had treatment&#160;with medicines&#160;containing infliximab in&#160;the&#160;past&#160;and&#160;<br/>are now&#160;starting&#160;Remsima&#160;treatment&#160;again.&#160;</p>
<p style="position:absolute;top:1137px;left:106px;white-space:nowrap" class="ft958">•&#160;</p>
<p style="position:absolute;top:1142px;left:149px;white-space:nowrap" class="ft9510">If&#160;you have&#160;had&#160;a&#160;break&#160;in&#160;your&#160;treatment with&#160;infliximab&#160;of&#160;more&#160;than&#160;16&#160;weeks,&#160;there&#160;is&#160;a&#160;<br/>higher&#160;risk&#160;for&#160;allergic&#160;reactions&#160;when you&#160;start&#160;the&#160;treatment&#160;again.&#160;</p>
</div>
<!-- Page 96 -->
<a name="96"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page96-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft960">96&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft9614">&#160;<br/>Infections&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft9610">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are given&#160;Remsima&#160;if&#160;you&#160;have&#160;an infection even if&#160;it&#160;is&#160;a&#160;very&#160;<br/>minor&#160;one.&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:187px;left:149px;white-space:nowrap" class="ft9611">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are given&#160;Remsima&#160;if&#160;you have&#160;ever&#160;lived&#160;in or&#160;travelled to&#160;an area&#160;<br/>where&#160;infections called&#160;histoplasmosis,&#160;coccidioidomycosis,&#160;or&#160;blastomycosis are&#160;common.&#160;<br/>These&#160;infections are caused&#160;by&#160;specific&#160;types of&#160;fungi&#160;that&#160;can&#160;affect&#160;the&#160;lungs&#160;or&#160;other&#160;parts&#160;of&#160;<br/>your&#160;body.&#160;</p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:264px;left:149px;white-space:nowrap" class="ft9610">You may&#160;get&#160;infections&#160;more&#160;easily when you&#160;are&#160;being treated with Remsima. If&#160;you are&#160;<br/>65&#160;years of&#160;age or&#160;older,&#160;you&#160;have&#160;a greater&#160;risk.&#160;</p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft9610">These&#160;infections&#160;may&#160;be&#160;serious&#160;and include&#160;tuberculosis, infections&#160;caused&#160;by&#160;viruses, fungi,&#160;<br/>bacteria or&#160;other&#160;organisms&#160;in&#160;the environment&#160;and&#160;sepsis that&#160;may&#160;be&#160;life-threatening.&#160;</p>
<p style="position:absolute;top:341px;left:106px;white-space:nowrap" class="ft9611">Tell&#160;your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;signs&#160;of&#160;infection during treatment&#160;with Remsima. Signs&#160;<br/>include&#160;fever,&#160;cough, flu-like&#160;signs,&#160;feeling unwell,&#160;red or&#160;hot&#160;skin, wounds&#160;or&#160;dental&#160;problems. Your&#160;<br/>doctor&#160;may recommend temporarily&#160;stopping&#160;Remsima.&#160;</p>
<p style="position:absolute;top:398px;left:128px;white-space:nowrap" class="ft962">&#160;</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft9610">Tuberculosis&#160;(TB)&#160;<br/>&#160;</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:457px;left:149px;white-space:nowrap" class="ft9610">It&#160;is&#160;very&#160;important&#160;that&#160;you tell&#160;your&#160;doctor&#160;if&#160;you have&#160;ever&#160;had TB&#160;or&#160;if&#160;you have&#160;been in&#160;<br/>close&#160;contact&#160;with&#160;someone&#160;who has&#160;had or&#160;has TB.&#160;</p>
<p style="position:absolute;top:490px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:496px;left:149px;white-space:nowrap" class="ft9610">Your&#160;doctor&#160;will&#160;test&#160;you&#160;to&#160;see&#160;if&#160;you have&#160;TB. Cases&#160;of&#160;TB&#160;have&#160;been reported&#160;in patients&#160;<br/>treated&#160;with&#160;infliximab,&#160;even in patients&#160;who have&#160;already been treated with&#160;medicines&#160;for&#160;TB.&#160;<br/>Your&#160;doctor&#160;will&#160;record&#160;these&#160;tests&#160;on your&#160;patient&#160;reminder&#160;card.&#160;</p>
<p style="position:absolute;top:549px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:554px;left:149px;white-space:nowrap" class="ft9610">If&#160;your&#160;doctor&#160;feels&#160;that&#160;you are&#160;at&#160;risk for&#160;TB, you may be&#160;treated&#160;with medicines&#160;for&#160;TB&#160;before&#160;<br/>you are&#160;given Remsima.&#160;</p>
<p style="position:absolute;top:592px;left:106px;white-space:nowrap" class="ft9610">Tell&#160;your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;signs&#160;of&#160;TB&#160;during&#160;treatment&#160;with Remsima. Signs&#160;include&#160;<br/>persistent&#160;cough, weight&#160;loss,&#160;feeling&#160;tired,&#160;fever,&#160;night&#160;sweats.&#160;</p>
<p style="position:absolute;top:630px;left:128px;white-space:nowrap" class="ft962">&#160;</p>
<p style="position:absolute;top:649px;left:106px;white-space:nowrap" class="ft9611">Hepatitis B&#160;virus&#160;<br/>&#160;</p>
<p style="position:absolute;top:683px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:688px;left:149px;white-space:nowrap" class="ft9610">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are given&#160;Remsima&#160;if&#160;you&#160;are a&#160;carrier&#160;of&#160;hepatitis&#160;B&#160;or&#160;have ever&#160;<br/>had it.&#160;</p>
<p style="position:absolute;top:722px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:727px;left:149px;white-space:nowrap" class="ft962">Tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you might&#160;be&#160;at&#160;risk&#160;of&#160;contracting&#160;hepatitis&#160;B.&#160;</p>
<p style="position:absolute;top:742px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:748px;left:149px;white-space:nowrap" class="ft962">Your&#160;doctor&#160;should&#160;test&#160;you for&#160;hepatitis&#160;B&#160;virus.&#160;</p>
<p style="position:absolute;top:762px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:768px;left:149px;white-space:nowrap" class="ft9610">Treatment&#160;with&#160;TNF&#160;blockers&#160;such&#160;as Remsima may&#160;result&#160;in&#160;reactivation&#160;of&#160;hepatitis&#160;B&#160;virus&#160;in&#160;<br/>patients&#160;who carry this&#160;virus, which&#160;can&#160;be&#160;life-threatening&#160;in&#160;some cases.&#160;</p>
<p style="position:absolute;top:802px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:807px;left:149px;white-space:nowrap" class="ft9610">If&#160;you experience&#160;reactivation of&#160;hepatitis&#160;B, your&#160;doctor&#160;may need&#160;to stop your&#160;treatment&#160;and&#160;<br/>may&#160;give&#160;you&#160;medicines&#160;such&#160;as&#160;effective antiviral&#160;therapy&#160;with&#160;supportive treatment.&#160;</p>
<p style="position:absolute;top:845px;left:106px;white-space:nowrap" class="ft9611">&#160;<br/>Heart&#160;problems&#160;<br/>&#160;</p>
<p style="position:absolute;top:898px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:903px;left:149px;white-space:nowrap" class="ft962">Tell&#160;your&#160;doctor&#160;if&#160;you have&#160;any heart&#160;problems, such&#160;as&#160;mild heart&#160;failure.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:924px;left:149px;white-space:nowrap" class="ft962">Your&#160;doctor&#160;will&#160;want&#160;to closely&#160;monitor&#160;your&#160;heart.&#160;</p>
<p style="position:absolute;top:942px;left:106px;white-space:nowrap" class="ft9611">Tell&#160;your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;new&#160;or&#160;worsening signs&#160;of&#160;heart&#160;failure&#160;during&#160;treatment&#160;with&#160;<br/>Remsima. Signs&#160;include&#160;shortness&#160;of&#160;breath or&#160;swelling of&#160;your&#160;feet.&#160;<br/>&#160;<br/>Cancer&#160;and lymphoma&#160;<br/>&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:1039px;left:149px;white-space:nowrap" class="ft9610">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are given&#160;Remsima&#160;if&#160;you&#160;have&#160;or&#160;have&#160;ever&#160;had lymphoma&#160;(a&#160;type&#160;<br/>of&#160;blood cancer)&#160;or&#160;any other&#160;cancer.&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:1078px;left:149px;white-space:nowrap" class="ft9610">Patients&#160;with severe&#160;rheumatoid arthritis, who have&#160;had the&#160;disease&#160;for&#160;a&#160;long&#160;time, may be&#160;at&#160;<br/>higher&#160;risk&#160;of&#160;developing lymphoma.&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft968">•&#160;</p>
<p style="position:absolute;top:1117px;left:149px;white-space:nowrap" class="ft9610">Children&#160;and&#160;adults&#160;taking&#160;Remsima may&#160;have an&#160;increased&#160;risk&#160;of&#160;developing&#160;lymphoma or&#160;<br/>another&#160;cancer.&#160;</p>
</div>
<!-- Page 97 -->
<a name="97"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page97-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft970">97&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:90px;left:149px;white-space:nowrap" class="ft9711">Some patients who&#160;have&#160;received&#160;TNF-blockers, including&#160;infliximab have&#160;developed a&#160;rare&#160;<br/>type of&#160;cancer&#160;called&#160;hepatosplenic&#160;T-cell&#160;lymphoma. Of&#160;these patients,&#160;most&#160;were&#160;teenage&#160;boys&#160;<br/>or&#160;young men&#160;and&#160;most&#160;had&#160;either&#160;Crohn’s disease&#160;or&#160;ulcerative&#160;colitis.&#160;This type of&#160;cancer&#160;has&#160;<br/>usually&#160;resulted&#160;in&#160;death.&#160;Almost&#160;all&#160;patients&#160;had&#160;also&#160;received&#160;medicines&#160;containing&#160;<br/>azathioprine&#160;or&#160;mercaptopurine&#160;in&#160;addition&#160;to&#160;TNF-blockers.&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:186px;left:149px;white-space:nowrap" class="ft9710">Some patients&#160;treated&#160;with&#160;infliximab&#160;have developed&#160;certain&#160;kinds of&#160;skin&#160;cancer.&#160;If&#160;there&#160;are&#160;<br/>any changes&#160;in&#160;your&#160;skin or&#160;growths&#160;on&#160;the&#160;skin&#160;during&#160;or&#160;after&#160;therapy,&#160;tell&#160;your&#160;doctor.&#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:226px;left:149px;white-space:nowrap" class="ft9710">Some&#160;women being&#160;treated for&#160;rheumatoid&#160;arthritis&#160;with infliximab&#160;have&#160;developed cervical&#160;<br/>cancer. For&#160;women&#160;taking&#160;Remsima&#160;including those&#160;over&#160;60&#160;years&#160;of&#160;age, your&#160;doctor&#160;may&#160;<br/>recommend&#160;regular&#160;screening&#160;for&#160;cervical&#160;cancer.&#160;</p>
<p style="position:absolute;top:283px;left:128px;white-space:nowrap" class="ft972">&#160;</p>
<p style="position:absolute;top:302px;left:106px;white-space:nowrap" class="ft9710">Lung disease&#160;or&#160;heavy smoking&#160;<br/>&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft9710">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;a&#160;lung&#160;disease&#160;called&#160;chronic&#160;<br/>obstructive&#160;pulmonary&#160;disease (COPD)&#160;or&#160;if&#160;you&#160;are a&#160;heavy&#160;smoker.&#160;</p>
<p style="position:absolute;top:375px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:380px;left:149px;white-space:nowrap" class="ft9710">Patients&#160;with COPD&#160;and patients&#160;who are&#160;heavy smokers&#160;may have&#160;a&#160;higher&#160;risk of&#160;developing&#160;<br/>cancer&#160;with&#160;Remsima treatment.&#160;</p>
<p style="position:absolute;top:418px;left:128px;white-space:nowrap" class="ft972">&#160;</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft9710">Nervous&#160;system&#160;disease&#160;<br/>&#160;</p>
<p style="position:absolute;top:471px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:477px;left:149px;white-space:nowrap" class="ft9711">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are given&#160;Remsima&#160;if&#160;you&#160;have or&#160;have ever&#160;had&#160;a problem&#160;that&#160;<br/>affects your&#160;nervous system.&#160;This includes&#160;multiple sclerosis,&#160;Guillain-Barré&#160;syndrome, if&#160;you&#160;<br/>have&#160;fits&#160;or&#160;have&#160;been diagnosed with&#160;‘optic&#160;neuritis’.&#160;</p>
<p style="position:absolute;top:534px;left:106px;white-space:nowrap" class="ft9710">Tell your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;symptoms&#160;of&#160;a&#160;nerve&#160;disease&#160;during&#160;treatment&#160;with Remsima.&#160;<br/>Signs&#160;include&#160;changes&#160;in your&#160;vision, weakness&#160;in&#160;your&#160;arms&#160;or&#160;legs, numbness&#160;or&#160;tingling in any&#160;part&#160;<br/>of&#160;your&#160;body.&#160;</p>
<p style="position:absolute;top:591px;left:128px;white-space:nowrap" class="ft972">&#160;</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft9714">Abnormal&#160;skin&#160;openings&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:649px;left:149px;white-space:nowrap" class="ft9710">Tell&#160;your&#160;doctor&#160;if&#160;you have&#160;any abnormal&#160;skin openings&#160;(fistulae)&#160;before&#160;you&#160;are&#160;given&#160;<br/>Remsima.&#160;</p>
<p style="position:absolute;top:687px;left:128px;white-space:nowrap" class="ft972">&#160;</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft9711">Vaccinations&#160;<br/>&#160;</p>
<p style="position:absolute;top:740px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:746px;left:149px;white-space:nowrap" class="ft972">Talk&#160;to your&#160;doctor&#160;if&#160;you&#160;recently&#160;have&#160;had or&#160;are&#160;due&#160;to have&#160;a&#160;vaccine.&#160;</p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft9710">You should&#160;receive&#160;recommended&#160;vaccinations before starting&#160;Remsima&#160;treatment.&#160;You may&#160;<br/>receive some&#160;vaccines&#160;during treatment&#160;with Remsima&#160;but&#160;you should not&#160;receive&#160;live&#160;vaccines&#160;<br/>(vaccines&#160;that&#160;contain a&#160;living but&#160;weakened infectious&#160;agent)&#160;while&#160;using&#160;Remsima&#160;because&#160;<br/>they&#160;may&#160;cause infections.&#160;</p>
<p style="position:absolute;top:838px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:843px;left:149px;white-space:nowrap" class="ft9711">If&#160;you received Remsima&#160;while&#160;you were&#160;pregnant, your&#160;baby may&#160;also&#160;be&#160;at&#160;higher&#160;risk&#160;for&#160;<br/>getting an infection&#160;as a&#160;result&#160;of&#160;receiving&#160;a&#160;live vaccine&#160;during&#160;the&#160;first&#160;year&#160;of&#160;life.&#160;It is&#160;<br/>important&#160;that&#160;you tell&#160;your&#160;baby's&#160;doctors&#160;and other&#160;health care&#160;professionals&#160;about&#160;your&#160;<br/>Remsima&#160;use&#160;so&#160;they&#160;can&#160;decide&#160;when your&#160;baby should receive&#160;any vaccine,&#160;including&#160;live&#160;<br/>vaccines&#160;such&#160;as&#160;the&#160;BCG&#160;vaccine&#160;(used&#160;to prevent&#160;tuberculosis).&#160;&#160;</p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:939px;left:149px;white-space:nowrap" class="ft9710">If&#160;you&#160;are breast-feeding,&#160;it&#160;is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;<br/>professionals&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;your&#160;baby is&#160;given any&#160;vaccine.&#160;For&#160;more&#160;<br/>information see&#160;section&#160;on Pregnancy&#160;and&#160;breast-feeding.&#160;</p>
<p style="position:absolute;top:996px;left:128px;white-space:nowrap" class="ft972">&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft9714">Therapeutic infectious&#160;agents&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:1055px;left:149px;white-space:nowrap" class="ft9710">Talk&#160;to&#160;your&#160;doctor&#160;if&#160;you&#160;have recently&#160;received&#160;or&#160;are&#160;scheduled&#160;to&#160;receive treatment&#160;with&#160;a&#160;<br/>therapeutic infectious&#160;agent&#160;(such&#160;as BCG&#160;instillation&#160;used&#160;for&#160;the&#160;treatment&#160;of&#160;cancer).&#160;</p>
<p style="position:absolute;top:1093px;left:128px;white-space:nowrap" class="ft972">&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft9710">Operations&#160;or&#160;dental&#160;procedures&#160;<br/>&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft978">•&#160;</p>
<p style="position:absolute;top:1151px;left:149px;white-space:nowrap" class="ft972">Tell&#160;your&#160;doctor&#160;if&#160;you are&#160;going&#160;to have&#160;any operations&#160;or&#160;dental&#160;procedures.&#160;</p>
</div>
<!-- Page 98 -->
<a name="98"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page98-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft980">98&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:90px;left:149px;white-space:nowrap" class="ft9810">Tell&#160;your&#160;surgeon&#160;or&#160;dentist&#160;that&#160;you&#160;are&#160;having&#160;treatment&#160;with Remsima&#160;by&#160;showing them&#160;your&#160;<br/>patient&#160;reminder&#160;card.&#160;</p>
<p style="position:absolute;top:129px;left:106px;white-space:nowrap" class="ft9814">&#160;<br/>Liver&#160;problems&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:188px;left:149px;white-space:nowrap" class="ft982">Some&#160;patients receiving&#160;infliximab&#160;have&#160;developed&#160;serious liver&#160;problems.&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:208px;left:149px;white-space:nowrap" class="ft9810">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;symptoms&#160;of&#160;liver&#160;problems&#160;during treatment&#160;with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;yellowing of&#160;the&#160;skin and eyes, dark-brown&#160;coloured urine, pain or&#160;<br/>swelling&#160;in&#160;the&#160;upper&#160;right side&#160;of&#160;the&#160;stomach&#160;area,&#160;joint&#160;pain,&#160;skin&#160;rashes,&#160;or&#160;fever.&#160;</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft9814">&#160;<br/>Low&#160;blood counts&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:325px;left:149px;white-space:nowrap" class="ft9810">In some&#160;patients&#160;receiving&#160;infliximab, the&#160;body&#160;may not&#160;make&#160;enough&#160;of&#160;the&#160;blood&#160;cells&#160;that&#160;<br/>help fight&#160;infections&#160;or&#160;help&#160;stop bleeding.&#160;</p>
<p style="position:absolute;top:358px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:364px;left:149px;white-space:nowrap" class="ft9810">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;symptoms&#160;of&#160;low&#160;blood counts&#160;during&#160;treatment&#160;with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;persistent&#160;fever, bleeding&#160;or&#160;bruising&#160;more&#160;easily,&#160;small&#160;red or&#160;purple&#160;<br/>spots&#160;caused by bleeding under&#160;the&#160;skin, or&#160;looking pale.&#160;</p>
<p style="position:absolute;top:420px;left:106px;white-space:nowrap" class="ft9814">&#160;<br/>Immune&#160;system&#160;disorder&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:480px;left:149px;white-space:nowrap" class="ft9810">Some patients&#160;receiving&#160;infliximab&#160;have developed&#160;symptoms&#160;of&#160;an&#160;immune system&#160;disorder&#160;<br/>called&#160;lupus.&#160;</p>
<p style="position:absolute;top:514px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:519px;left:149px;white-space:nowrap" class="ft9810">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you develop symptoms&#160;of&#160;lupus&#160;during treatment&#160;with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;joint&#160;pain or&#160;a&#160;rash&#160;on cheeks&#160;or&#160;arms that&#160;is sensitive&#160;to&#160;the sun.&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft9811">&#160;<br/><b>Children and adolescents&#160;<br/></b>The&#160;information above&#160;also&#160;applies&#160;to&#160;children and adolescents. In addition:&#160;<br/>&#160;</p>
<p style="position:absolute;top:630px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:635px;left:149px;white-space:nowrap" class="ft9810">Some children&#160;and&#160;teenage patients&#160;who&#160;have received&#160;TNF-blockers&#160;such as&#160;infliximab have&#160;<br/>developed&#160;cancers, including unusual&#160;types, which sometimes&#160;resulted in&#160;death.&#160;</p>
<p style="position:absolute;top:669px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:674px;left:149px;white-space:nowrap" class="ft982">More&#160;children&#160;taking&#160;infliximab developed infections&#160;as&#160;compared&#160;to adults.&#160;</p>
<p style="position:absolute;top:689px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:694px;left:149px;white-space:nowrap" class="ft9810">Children&#160;should&#160;receive recommended&#160;vaccinations&#160;before starting&#160;Remsima treatment.&#160;<br/>Children&#160;may&#160;receive&#160;some&#160;vaccines&#160;during&#160;treatment&#160;with&#160;Remsima&#160;but should&#160;not receive&#160;live&#160;<br/>vaccines&#160;while&#160;using Remsima.&#160;</p>
<p style="position:absolute;top:751px;left:128px;white-space:nowrap" class="ft982">&#160;</p>
<p style="position:absolute;top:771px;left:106px;white-space:nowrap" class="ft9811">Remsima&#160;should&#160;only&#160;be&#160;used in&#160;children&#160;if&#160;they&#160;are&#160;being treated for&#160;Crohn’s&#160;disease&#160;or&#160;ulcerative&#160;<br/>colitis.&#160;These&#160;children&#160;must&#160;be 6&#160;years&#160;of&#160;age&#160;or&#160;older.&#160;<br/>&#160;<br/>If&#160;you are&#160;not&#160;sure&#160;if&#160;any of&#160;the&#160;above&#160;applies&#160;to&#160;you,&#160;talk&#160;to your&#160;doctor&#160;before&#160;you are&#160;given&#160;<br/>Remsima.&#160;<br/><b>&#160;<br/>Other&#160;medicines and&#160;Remsima&#160;<br/></b>Patients&#160;who&#160;have inflammatory&#160;diseases already&#160;take medicines to&#160;treat&#160;their&#160;problem.&#160;These&#160;<br/>medicines&#160;may&#160;cause side&#160;effects. Your&#160;doctor&#160;will&#160;advise&#160;you what&#160;other&#160;medicines&#160;you&#160;must&#160;keep&#160;<br/>using while&#160;you&#160;are&#160;having&#160;Remsima.&#160;<br/>&#160;<br/>Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;using,&#160;have&#160;recently used or&#160;might&#160;use&#160;any&#160;other&#160;medicines,&#160;including any&#160;<br/>other&#160;medicines&#160;to&#160;treat&#160;Crohn’s&#160;disease,&#160;ulcerative&#160;colitis,&#160;rheumatoid&#160;arthritis,&#160;ankylosing&#160;<br/>spondylitis,&#160;psoriatic&#160;arthritis&#160;or&#160;psoriasis&#160;or&#160;medicines&#160;obtained without&#160;a&#160;prescription,&#160;such as&#160;<br/>vitamins and&#160;herbal&#160;medicines.&#160;<br/>&#160;<br/>In particular, tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;using any of&#160;the&#160;following&#160;medicines:&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:1102px;left:149px;white-space:nowrap" class="ft982">Medicines&#160;that&#160;affect&#160;your&#160;immune system.&#160;</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:1121px;left:149px;white-space:nowrap" class="ft982">Kineret&#160;(which contains&#160;anakinra). Remsima&#160;and Kineret&#160;should not&#160;be&#160;used&#160;together.&#160;</p>
<p style="position:absolute;top:1135px;left:106px;white-space:nowrap" class="ft988">•&#160;</p>
<p style="position:absolute;top:1141px;left:149px;white-space:nowrap" class="ft982">Orencia (which&#160;contains abatacept).&#160;Remsima and&#160;Orencia&#160;should&#160;not&#160;be&#160;used&#160;together.&#160;</p>
<p style="position:absolute;top:1160px;left:106px;white-space:nowrap" class="ft982">&#160;</p>
</div>
<!-- Page 99 -->
<a name="99"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page99-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:436px;white-space:nowrap" class="ft990">99&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft995">While using&#160;Remsima&#160;you&#160;should not&#160;receive&#160;live&#160;vaccines. If&#160;you were&#160;using Remsima&#160;during&#160;<br/>pregnancy&#160;or&#160;if&#160;you are&#160;receiving&#160;Remsima&#160;while breast-feeding, tell&#160;your&#160;baby’s&#160;doctor&#160;and other&#160;<br/>health care&#160;professionals&#160;caring&#160;for&#160;your&#160;baby&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;the&#160;baby receives&#160;any&#160;<br/>vaccines.&#160;<br/>&#160;<br/>If&#160;you are&#160;not&#160;sure&#160;if&#160;any of&#160;the&#160;above&#160;applies&#160;to&#160;you,&#160;talk&#160;to your&#160;doctor&#160;or&#160;pharmacist&#160;before&#160;using&#160;<br/>Remsima.&#160;<br/><b>&#160;<br/>Pregnancy,&#160;breast-feeding&#160;and&#160;fertility&#160;</b></p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft9911">If&#160;you are&#160;pregnant&#160;or&#160;breast-feeding, think&#160;you may&#160;be&#160;pregnant&#160;or&#160;are&#160;planning to&#160;have&#160;a&#160;baby,&#160;<br/>ask&#160;your&#160;doctor&#160;for&#160;advice&#160;before&#160;taking this&#160;medicine.&#160;Remsima&#160;should only be&#160;used during&#160;<br/>pregnancy&#160;or&#160;while&#160;breast-feeding&#160;if&#160;your&#160;doctor&#160;feels&#160;it&#160;is&#160;necessary&#160;for&#160;you.&#160;</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:323px;left:149px;white-space:nowrap" class="ft9911">You&#160;should&#160;avoid getting pregnant&#160;when you&#160;are&#160;being&#160;treated with Remsima&#160;and&#160;for&#160;6&#160;months&#160;<br/>after&#160;you stop being&#160;treated&#160;with&#160;it.&#160;Discuss the&#160;use&#160;of&#160;contraception during this&#160;time&#160;with your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:382px;left:149px;white-space:nowrap" class="ft9911">If&#160;you received Remsima&#160;during&#160;your&#160;pregnancy, your&#160;baby&#160;may have&#160;a&#160;higher&#160;risk for&#160;getting&#160;<br/>an infection.&#160;</p>
<p style="position:absolute;top:416px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:421px;left:149px;white-space:nowrap" class="ft9911">It&#160;is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;professionals&#160;about&#160;your&#160;<br/>Remsima use before&#160;your&#160;baby&#160;is&#160;given&#160;any vaccine. If&#160;you received Remsima&#160;while&#160;pregnant,&#160;<br/>giving&#160;BCG&#160;vaccine&#160;(used&#160;to prevent&#160;tuberculosis)&#160;to your&#160;baby within&#160;12&#160;months&#160;after&#160;birth&#160;<br/>may&#160;result&#160;in&#160;infection with&#160;serious&#160;complications,&#160;including death. Live&#160;vaccines&#160;such as&#160;the&#160;<br/>the&#160;BCG&#160;vaccine&#160;should&#160;not&#160;be&#160;given&#160;to&#160;your&#160;baby within&#160;12&#160;months&#160;after&#160;birth, unless&#160;your&#160;<br/>baby’s&#160;doctor&#160;recommends&#160;otherwise.&#160;For&#160;more&#160;information see&#160;section on vaccination.&#160;</p>
<p style="position:absolute;top:533px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:539px;left:149px;white-space:nowrap" class="ft9910">If&#160;you are&#160;breast-feeding, it&#160;is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;<br/>professionals&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;your&#160;baby is&#160;given&#160;any vaccine.&#160;Live vaccines&#160;<br/>should not&#160;be&#160;given&#160;to your&#160;baby while&#160;you are&#160;breast-feeding unless&#160;your&#160;baby’s&#160;doctor&#160;<br/>recommends otherwise.&#160;</p>
<p style="position:absolute;top:610px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:615px;left:149px;white-space:nowrap" class="ft9911">Severely&#160;decreased numbers&#160;of&#160;white&#160;blood cells&#160;have&#160;been&#160;reported in&#160;infants&#160;born to women&#160;<br/>treated&#160;with&#160;infliximab during pregnancy. If&#160;your&#160;baby&#160;has&#160;continual&#160;fevers&#160;or&#160;infections,&#160;<br/>contact&#160;your&#160;baby’s&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft995"><b>&#160;<br/>Driving and&#160;using&#160;machines&#160;<br/></b>Remsima&#160;is&#160;not&#160;likely&#160;to affect&#160;your&#160;ability&#160;to drive&#160;or&#160;use&#160;tools&#160;or&#160;machines. If&#160;you feel&#160;tired,&#160;dizzy,&#160;<br/>or&#160;unwell&#160;after&#160;having Remsima, do&#160;not&#160;drive&#160;or&#160;use&#160;any tools&#160;or&#160;machines.&#160;<br/><b>&#160;<br/>Remsima contains&#160;sodium&#160;<br/></b>This&#160;medicine&#160;contains less&#160;than&#160;1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;dose, i.e. essentially&#160;‘sodium-free’.&#160;<br/>However,&#160;before Remsima&#160;is&#160;given&#160;to you, it&#160;is&#160;mixed&#160;with a&#160;solution&#160;that&#160;contains&#160;sodium. Talk to&#160;<br/>your&#160;doctor&#160;if&#160;you&#160;are&#160;on a&#160;low&#160;salt&#160;diet.&#160;<br/><b>&#160;<br/>&#160;<br/>3.&#160;</b></p>
<p style="position:absolute;top:886px;left:149px;white-space:nowrap" class="ft991"><b>How&#160;to&#160;use&#160;Remsima&#160;</b></p>
<p style="position:absolute;top:906px;left:106px;white-space:nowrap" class="ft995"><b>&#160;<br/>Rheumatoid arthritis&#160;<br/></b>The usual&#160;dose&#160;is 3&#160;mg&#160;for&#160;every&#160;kg of&#160;body weight.&#160;<br/>&#160;<br/><b>Psoriatic&#160;arthritis, ankylosing spondylitis&#160;(Bechterew’s disease),&#160;psoriasis,&#160;ulcerative&#160;colitis and&#160;<br/>Crohn's disease&#160;<br/></b>The usual&#160;dose&#160;is 5&#160;mg&#160;for&#160;every&#160;kg of&#160;body weight.&#160;<br/><b>&#160;<br/>How&#160;Remsima&#160;is given&#160;</b></p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:1082px;left:149px;white-space:nowrap" class="ft992">Remsima&#160;will&#160;be&#160;given&#160;to you by your&#160;doctor&#160;or&#160;nurse.&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:1101px;left:149px;white-space:nowrap" class="ft992">Your&#160;doctor&#160;or&#160;nurse&#160;will&#160;prepare the&#160;medicine&#160;for&#160;infusion.&#160;</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft998">•&#160;</p>
<p style="position:absolute;top:1120px;left:149px;white-space:nowrap" class="ft9911">The&#160;medicine&#160;will be&#160;given&#160;as&#160;an&#160;infusion (drip)&#160;(over&#160;2&#160;hours)&#160;into&#160;one&#160;of&#160;your&#160;veins,&#160;usually in&#160;<br/>your&#160;arm. After&#160;the&#160;third&#160;treatment, your&#160;doctor&#160;may decide&#160;to give&#160;your&#160;dose&#160;of&#160;Remsima over&#160;<br/>1&#160;hour.&#160;</p>
</div>
<!-- Page 100 -->
<a name="100"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page100-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1000">100&#160;</p>
<p style="position:absolute;top:84px;left:106px;white-space:nowrap" class="ft1008">•&#160;</p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft1002">You will&#160;be&#160;monitored while&#160;you are&#160;given&#160;Remsima&#160;and also for&#160;1&#160;to 2&#160;hours&#160;afterwards.<b>&#160;</b></p>
<p style="position:absolute;top:109px;left:106px;white-space:nowrap" class="ft10042"><b>&#160;<br/>How&#160;much&#160;Remsima&#160;is given&#160;<br/></b>•&#160;</p>
<p style="position:absolute;top:149px;left:149px;white-space:nowrap" class="ft10010">The&#160;doctor&#160;will&#160;decide&#160;your&#160;dose&#160;and&#160;how&#160;often you will&#160;be&#160;given Remsima.&#160;This&#160;will&#160;depend&#160;<br/>on&#160;your&#160;disease,&#160;weight&#160;and&#160;how&#160;well&#160;you&#160;respond to&#160;Remsima.&#160;</p>
<p style="position:absolute;top:183px;left:106px;white-space:nowrap" class="ft1008">•&#160;</p>
<p style="position:absolute;top:188px;left:149px;white-space:nowrap" class="ft1002">The&#160;table&#160;below&#160;shows&#160;how&#160;often you will&#160;usually have&#160;this&#160;medicine&#160;after&#160;your&#160;first&#160;dose.&#160;</p>
<p style="position:absolute;top:207px;left:106px;white-space:nowrap" class="ft1002">&#160;</p>
<p style="position:absolute;top:227px;left:158px;white-space:nowrap" class="ft1002">2nd&#160;dose&#160;</p>
<p style="position:absolute;top:227px;left:419px;white-space:nowrap" class="ft1002">2&#160;weeks after&#160;your&#160;1st&#160;dose&#160;</p>
<p style="position:absolute;top:248px;left:158px;white-space:nowrap" class="ft1002">3rd&#160;dose&#160;</p>
<p style="position:absolute;top:248px;left:419px;white-space:nowrap" class="ft1002">6&#160;weeks after&#160;your&#160;1st&#160;dose&#160;</p>
<p style="position:absolute;top:268px;left:158px;white-space:nowrap" class="ft1002">Further&#160;doses&#160;</p>
<p style="position:absolute;top:268px;left:419px;white-space:nowrap" class="ft1002">Every 6&#160;to 8&#160;weeks&#160;depending on your&#160;disease&#160;&#160;</p>
<p style="position:absolute;top:288px;left:106px;white-space:nowrap" class="ft1005"><b>&#160;<br/>Use in&#160;children&#160;and&#160;adolescents&#160;<br/></b>In&#160;children (6&#160;years of&#160;age&#160;or&#160;older)&#160;treated&#160;for&#160;Crohn’s disease or&#160;ulcerative&#160;colitis,&#160;the&#160;recommended&#160;<br/>dose&#160;is&#160;the same as&#160;for&#160;adults.&#160;<br/><b>&#160;<br/>If&#160;you&#160;are given&#160;too&#160;much&#160;Remsima&#160;<br/></b>As&#160;this&#160;medicine&#160;is&#160;being given by your&#160;doctor&#160;or&#160;nurse, it&#160;is&#160;unlikely that&#160;you will&#160;be&#160;given too&#160;much.&#160;<br/>There&#160;are&#160;no known&#160;side&#160;effects&#160;of&#160;having&#160;too&#160;much of&#160;Remsima.&#160;<br/><b>&#160;<br/>If&#160;you&#160;forget&#160;or miss your&#160;Remsima&#160;infusion&#160;<br/></b>If&#160;you forget&#160;or&#160;miss&#160;an appointment&#160;to receive&#160;Remsima,&#160;make another&#160;appointment&#160;as soon&#160;as&#160;<br/>possible.&#160;<br/>&#160;<br/>If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor.&#160;<br/><b>&#160;<br/>&#160;<br/>4.&#160;</b></p>
<p style="position:absolute;top:600px;left:149px;white-space:nowrap" class="ft1001"><b>Possible side&#160;effects&#160;</b></p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft1005">&#160;<br/>Like&#160;all&#160;medicines,&#160;this&#160;medicine&#160;can cause&#160;side&#160;effects, although not&#160;everybody gets&#160;them.&#160;Most&#160;side&#160;<br/>effects&#160;are mild&#160;to&#160;moderate.&#160;However&#160;some&#160;patients may&#160;experience serious&#160;side&#160;effects and&#160;may&#160;<br/>require&#160;treatment.&#160;Side effects&#160;may&#160;also&#160;occur&#160;after&#160;your&#160;treatment&#160;with&#160;Remsima&#160;has stopped.&#160;<br/><b>&#160;<br/>Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;notice&#160;any of&#160;the&#160;following:&#160;</b></p>
<p style="position:absolute;top:731px;left:106px;white-space:nowrap" class="ft1008">•&#160;</p>
<p style="position:absolute;top:737px;left:149px;white-space:nowrap" class="ft10011"><b>Signs of&#160;an&#160;allergic reaction&#160;</b>such&#160;as&#160;swelling&#160;of&#160;your&#160;face, lips,&#160;mouth or&#160;throat&#160;which&#160;may&#160;<br/>cause&#160;difficulty in swallowing&#160;or&#160;breathing,&#160;skin rash, hives, swelling of&#160;the&#160;hands, feet&#160;or&#160;<br/>ankles.&#160;Some of&#160;these reactions&#160;may&#160;be serious&#160;or&#160;life-threatening.&#160;An allergic&#160;reaction could&#160;<br/>happen within 2&#160;hours&#160;of&#160;your&#160;injection or&#160;later.&#160;More&#160;signs&#160;of&#160;allergic&#160;side effects&#160;that&#160;may&#160;<br/>happen&#160;up to&#160;12&#160;days&#160;after&#160;your&#160;injection&#160;include&#160;pain&#160;in the&#160;muscles, fever,&#160;joint&#160;or&#160;jaw&#160;pain,&#160;<br/>sore&#160;throat&#160;or&#160;headache.&#160;</p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft1008">•&#160;</p>
<p style="position:absolute;top:854px;left:149px;white-space:nowrap" class="ft10011"><b>Signs&#160;of&#160;a&#160;heart&#160;problem&#160;</b>such&#160;as&#160;chest&#160;discomfort&#160;or&#160;pain,&#160;arm&#160;pain,&#160;stomach pain,&#160;shortness&#160;<br/>of&#160;breath,&#160;anxiety, lightheadedness,&#160;dizziness, fainting,&#160;sweating, nausea&#160;(feeling&#160;sick),&#160;<br/>vomiting,&#160;fluttering or&#160;pounding&#160;in your&#160;chest, a&#160;fast&#160;or&#160;a&#160;slow&#160;heartbeat, and&#160;swelling of&#160;your&#160;<br/>feet.&#160;</p>
<p style="position:absolute;top:926px;left:106px;white-space:nowrap" class="ft1008">•&#160;</p>
<p style="position:absolute;top:932px;left:149px;white-space:nowrap" class="ft10011"><b>Signs&#160;of&#160;infection (including&#160;TB)&#160;</b>such&#160;as&#160;fever,&#160;feeling&#160;tired,&#160;cough&#160;which may&#160;be&#160;persistent,&#160;<br/>shortness&#160;of&#160;breath, flu-like&#160;symptoms, weight&#160;loss,&#160;night&#160;sweats, diarrhoea, wounds,&#160;collection&#160;<br/>of&#160;pus&#160;in&#160;the&#160;gut&#160;or&#160;around&#160;the&#160;anus&#160;(abscess),&#160;dental&#160;problems&#160;or&#160;burning&#160;sensation&#160;when&#160;<br/>urinating.&#160;</p>
<p style="position:absolute;top:1004px;left:106px;white-space:nowrap" class="ft1008">•&#160;</p>
<p style="position:absolute;top:1010px;left:149px;white-space:nowrap" class="ft10011"><b>Possible signs&#160;of&#160;cancer&#160;</b>including&#160;but not&#160;limited&#160;to&#160;swelling of&#160;lymph nodes, weight&#160;loss,&#160;<br/>fever, unusual&#160;skin nodules, changes&#160;in moles&#160;or&#160;skin colouring,&#160;or&#160;unusual&#160;vaginal&#160;bleeding.&#160;</p>
<p style="position:absolute;top:1043px;left:106px;white-space:nowrap" class="ft1008">•&#160;</p>
<p style="position:absolute;top:1049px;left:149px;white-space:nowrap" class="ft1001"><b>Signs&#160;of&#160;a&#160;lung&#160;problem&#160;</b>such as&#160;coughing,&#160;breathing&#160;difficulties&#160;or&#160;tightness&#160;in&#160;the&#160;chest.&#160;</p>
<p style="position:absolute;top:1064px;left:106px;white-space:nowrap" class="ft1008">•&#160;</p>
<p style="position:absolute;top:1069px;left:149px;white-space:nowrap" class="ft10010"><b>Signs&#160;of&#160;a&#160;nervous&#160;system&#160;problem&#160;(including&#160;eye&#160;problems)&#160;</b>such&#160;as&#160;signs of&#160;a&#160;stroke&#160;<br/>(sudden numbness&#160;or&#160;weakness&#160;of&#160;your&#160;face,&#160;arm&#160;or&#160;leg, especially on one&#160;side&#160;of&#160;your&#160;body;&#160;<br/>sudden&#160;confusion,&#160;trouble&#160;speaking or&#160;understanding;&#160;trouble&#160;seeing in&#160;one&#160;or&#160;both eyes,&#160;trouble&#160;<br/>walking, dizziness,&#160;loss&#160;of&#160;balance or&#160;coordination&#160;or&#160;a severe&#160;headache),&#160;fits,&#160;</p>
</div>
<!-- Page 101 -->
<a name="101"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10146{font-size:18px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page101-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1010">101&#160;</p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft10111">tingling/numbness&#160;in&#160;any part&#160;of&#160;your&#160;body,&#160;or&#160;weakness in&#160;arms&#160;or&#160;legs,&#160;changes&#160;in&#160;eyesight&#160;<br/>such as&#160;double&#160;vision or&#160;other&#160;eye&#160;problems.<b>&#160;</b>&#160;</p>
<p style="position:absolute;top:122px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:127px;left:149px;white-space:nowrap" class="ft10111"><b>Signs&#160;of&#160;a&#160;liver&#160;problem&#160;</b>(including hepatitis&#160;B&#160;infection when you&#160;have&#160;had hepatitis&#160;B&#160;in&#160;the&#160;<br/>past)&#160;such as&#160;yellowing of&#160;the&#160;skin or&#160;eyes, dark-brown&#160;coloured urine,&#160;pain&#160;or&#160;swelling&#160;in&#160;the&#160;<br/>upper&#160;right&#160;side&#160;of&#160;the&#160;stomach&#160;area,&#160;joint&#160;pain, skin rashes, or&#160;fever.&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:186px;left:149px;white-space:nowrap" class="ft10111"><b>Signs&#160;of&#160;an&#160;immune&#160;system&#160;disorder called&#160;lupus&#160;</b>such as&#160;joint&#160;pain or&#160;a&#160;rash on cheeks&#160;or&#160;<br/>arms&#160;that&#160;is sensitive&#160;to&#160;the&#160;sun&#160;(lupus)&#160;or&#160;cough, shortness&#160;of&#160;breath,&#160;fever&#160;or&#160;skin&#160;rash&#160;<br/>(sarcoidosis).&#160;</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft10111"><b>Signs&#160;of&#160;low&#160;blood&#160;counts&#160;</b>such&#160;as&#160;persistent&#160;fever, bleeding or&#160;bruising&#160;more easily,&#160;small red&#160;<br/>or&#160;purple&#160;spots&#160;caused by bleeding under&#160;the&#160;skin,&#160;or&#160;looking pale.&#160;</p>
<p style="position:absolute;top:278px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:283px;left:149px;white-space:nowrap" class="ft10111"><b>Signs of&#160;serious skin&#160;problems</b>&#160;such&#160;as reddish-target-like spots or&#160;circular&#160;patches often&#160;with&#160;<br/>central&#160;blisters&#160;on&#160;the&#160;trunk, large&#160;areas&#160;of&#160;peeling and&#160;shedding&#160;(exfoliating)&#160;skin,&#160;ulcers&#160;of&#160;<br/>mouth, throat, nose, genitals&#160;and eyes&#160;or&#160;small&#160;pus-filled bumps&#160;that&#160;can spread&#160;over&#160;the&#160;body.&#160;<br/>These&#160;skin&#160;reactions can&#160;be&#160;accompanied&#160;by&#160;fever.&#160;</p>
<p style="position:absolute;top:361px;left:106px;white-space:nowrap" class="ft1015">&#160;<br/>Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;notice&#160;any&#160;of&#160;the&#160;above.&#160;<br/><b>&#160;<br/></b>The&#160;following&#160;side&#160;effects&#160;have been&#160;observed&#160;with&#160;Remsima:&#160;<br/><b>&#160;<br/>Very common:&#160;</b>may affect&#160;more&#160;than&#160;1 in&#160;10 people</p>
<p style="position:absolute;top:458px;left:454px;white-space:nowrap" class="ft10146"><b>&#160;</b></p>
<p style="position:absolute;top:472px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:478px;left:149px;white-space:nowrap" class="ft1012">Stomach pain, feeling sick&#160;</p>
<p style="position:absolute;top:492px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:497px;left:149px;white-space:nowrap" class="ft1012">Viral&#160;infections&#160;such&#160;as herpes or&#160;flu&#160;</p>
<p style="position:absolute;top:511px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:517px;left:149px;white-space:nowrap" class="ft1012">Upper&#160;respiratory&#160;infections such&#160;as sinusitis&#160;</p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:536px;left:149px;white-space:nowrap" class="ft1012">Headache&#160;</p>
<p style="position:absolute;top:551px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:556px;left:149px;white-space:nowrap" class="ft1012">Side&#160;effect&#160;due&#160;to an infusion&#160;</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:575px;left:149px;white-space:nowrap" class="ft1012">Pain.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1015"><b>&#160;<br/>Common:&#160;</b>may&#160;affect&#160;up&#160;to&#160;1 in 10&#160;people<b>&#160;</b></p>
<p style="position:absolute;top:628px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:634px;left:149px;white-space:nowrap" class="ft1012">Changes&#160;in how&#160;your&#160;liver&#160;works,&#160;increase&#160;in liver&#160;enzymes&#160;(shown in&#160;blood tests)&#160;</p>
<p style="position:absolute;top:648px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:653px;left:149px;white-space:nowrap" class="ft1012">Lung or&#160;chest&#160;infections&#160;such as&#160;bronchitis&#160;or&#160;pneumonia&#160;</p>
<p style="position:absolute;top:668px;left:106px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:673px;left:149px;white-space:nowrap" class="ft1012">Difficult&#160;or&#160;painful&#160;breathing,&#160;chest pain&#160;</p>
<p style="position:absolute;top:687px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:692px;left:149px;white-space:nowrap" class="ft1012">Bleeding in&#160;the&#160;stomach&#160;or&#160;intestines, diarrhoea, indigestion, heartburn, constipation&#160;</p>
<p style="position:absolute;top:706px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:712px;left:149px;white-space:nowrap" class="ft1012">Nettle-type&#160;rash&#160;(hives), itchy rash or&#160;dry&#160;skin&#160;</p>
<p style="position:absolute;top:726px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:731px;left:149px;white-space:nowrap" class="ft1012">Balance problems or&#160;feeling&#160;dizzy&#160;</p>
<p style="position:absolute;top:746px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:751px;left:149px;white-space:nowrap" class="ft1012">Fever,&#160;increased&#160;sweating&#160;</p>
<p style="position:absolute;top:765px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:770px;left:149px;white-space:nowrap" class="ft1012">Circulation problems&#160;such&#160;as&#160;low&#160;or&#160;high blood&#160;pressure&#160;</p>
<p style="position:absolute;top:785px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:790px;left:149px;white-space:nowrap" class="ft1012">Bruising, hot&#160;flush&#160;or&#160;nosebleed, warm, red skin&#160;(flushing)&#160;</p>
<p style="position:absolute;top:804px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:809px;left:149px;white-space:nowrap" class="ft1012">Feeling&#160;tired&#160;or&#160;weak&#160;</p>
<p style="position:absolute;top:823px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:829px;left:149px;white-space:nowrap" class="ft1012">Bacterial&#160;infections such&#160;as&#160;blood&#160;poisoning,&#160;abscess or&#160;infection&#160;of&#160;the skin&#160;(cellulitis)&#160;</p>
<p style="position:absolute;top:844px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:849px;left:149px;white-space:nowrap" class="ft1012">Infection of&#160;the&#160;skin due&#160;to&#160;a&#160;fungus&#160;</p>
<p style="position:absolute;top:863px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:869px;left:149px;white-space:nowrap" class="ft1012">Blood problems&#160;such as&#160;anaemia&#160;or&#160;low&#160;white&#160;blood&#160;cell&#160;count&#160;</p>
<p style="position:absolute;top:883px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:888px;left:149px;white-space:nowrap" class="ft1012">Swollen&#160;lymph nodes&#160;</p>
<p style="position:absolute;top:902px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:907px;left:149px;white-space:nowrap" class="ft1012">Depression,&#160;problems sleeping&#160;</p>
<p style="position:absolute;top:922px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:927px;left:149px;white-space:nowrap" class="ft1012">Eye&#160;problems,&#160;including red&#160;eyes&#160;and infections&#160;</p>
<p style="position:absolute;top:941px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:947px;left:149px;white-space:nowrap" class="ft1012">Fast&#160;heart&#160;beat&#160;(tachycardia)&#160;or&#160;palpitations&#160;</p>
<p style="position:absolute;top:961px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:966px;left:149px;white-space:nowrap" class="ft1012">Pain&#160;in&#160;the&#160;joints,&#160;muscles or&#160;back&#160;</p>
<p style="position:absolute;top:980px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:986px;left:149px;white-space:nowrap" class="ft1012">Urinary&#160;tract infection&#160;</p>
<p style="position:absolute;top:1000px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:1005px;left:149px;white-space:nowrap" class="ft1012">Psoriasis,&#160;skin&#160;problems&#160;such&#160;as&#160;eczema and&#160;hair&#160;loss&#160;</p>
<p style="position:absolute;top:1019px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:1024px;left:149px;white-space:nowrap" class="ft1012">Reactions&#160;at&#160;the&#160;injection site&#160;such as&#160;pain, swelling,&#160;redness&#160;or&#160;itching&#160;</p>
<p style="position:absolute;top:1039px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:1044px;left:149px;white-space:nowrap" class="ft1012">Chills,&#160;a&#160;build-up of&#160;fluid&#160;under&#160;the&#160;skin&#160;causing swelling&#160;</p>
<p style="position:absolute;top:1058px;left:107px;white-space:nowrap" class="ft1018">•&#160;</p>
<p style="position:absolute;top:1064px;left:149px;white-space:nowrap" class="ft1012">Feeling numb&#160;or&#160;having a&#160;tingling feeling.&#160;</p>
<p style="position:absolute;top:1083px;left:107px;white-space:nowrap" class="ft1011"><b>&#160;</b></p>
</div>
<!-- Page 102 -->
<a name="102"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page102-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1020">102&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1021"><b>Uncommon:&#160;</b>may&#160;affect&#160;up&#160;to 1&#160;in 100&#160;people<b>&#160;</b></p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft1022">Shortage&#160;of&#160;blood&#160;supply,&#160;swelling&#160;of&#160;a vein&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft1022">Collection of&#160;blood outside&#160;the&#160;blood&#160;vessels&#160;(haematoma)&#160;or&#160;bruising&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft10211">Skin problems&#160;such as&#160;blistering, warts,&#160;abnormal&#160;skin&#160;colouration&#160;or&#160;pigmentation, or&#160;swollen&#160;<br/>lips, or&#160;thickening&#160;of&#160;the&#160;skin, or&#160;red, scaly,&#160;and&#160;flaky skin&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:187px;left:149px;white-space:nowrap" class="ft10211">Severe allergic&#160;reactions&#160;(e.g. anaphylaxis), an immune&#160;system&#160;disorder&#160;called&#160;lupus, allergic&#160;<br/>reactions&#160;to foreign proteins&#160;</p>
<p style="position:absolute;top:221px;left:106px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:226px;left:149px;white-space:nowrap" class="ft1022">Wounds&#160;taking longer&#160;to&#160;heal&#160;</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:245px;left:149px;white-space:nowrap" class="ft1022">Swelling of&#160;the&#160;liver&#160;(hepatitis)&#160;or&#160;gall&#160;bladder,&#160;liver&#160;damage&#160;</p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft1022">Feeling forgetful,&#160;irritable,&#160;confused,&#160;nervous&#160;</p>
<p style="position:absolute;top:279px;left:106px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:284px;left:149px;white-space:nowrap" class="ft1022">Eye&#160;problems&#160;including blurred&#160;or&#160;reduced vision, puffy eyes&#160;or&#160;sties&#160;</p>
<p style="position:absolute;top:299px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:304px;left:149px;white-space:nowrap" class="ft1022">New&#160;or&#160;worsening heart&#160;failure, slow&#160;heart&#160;rate&#160;</p>
<p style="position:absolute;top:318px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:323px;left:149px;white-space:nowrap" class="ft1022">Fainting&#160;</p>
<p style="position:absolute;top:338px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:343px;left:149px;white-space:nowrap" class="ft1022">Convulsions, nerve&#160;problems&#160;</p>
<p style="position:absolute;top:357px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:362px;left:149px;white-space:nowrap" class="ft1022">A&#160;hole&#160;in the&#160;bowel&#160;or&#160;blockage&#160;of&#160;the&#160;intestine,&#160;stomach pain or&#160;cramps&#160;</p>
<p style="position:absolute;top:377px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:382px;left:149px;white-space:nowrap" class="ft1022">Swelling of&#160;your&#160;pancreas&#160;(pancreatitis)&#160;</p>
<p style="position:absolute;top:396px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:401px;left:149px;white-space:nowrap" class="ft1022">Fungal&#160;infections such&#160;as yeast&#160;infection,&#160;or&#160;fungal&#160;infection of&#160;the&#160;nails&#160;</p>
<p style="position:absolute;top:416px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:421px;left:149px;white-space:nowrap" class="ft1022">Lung problems&#160;(such as&#160;oedema)&#160;</p>
<p style="position:absolute;top:435px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:440px;left:149px;white-space:nowrap" class="ft1022">Fluid around the&#160;lungs&#160;(pleural&#160;effusion)&#160;</p>
<p style="position:absolute;top:455px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:460px;left:149px;white-space:nowrap" class="ft1022">Narrowed&#160;airway&#160;in&#160;the&#160;lungs, causing difficulty breathing&#160;</p>
<p style="position:absolute;top:474px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:479px;left:149px;white-space:nowrap" class="ft1022">Inflamed lining of&#160;the&#160;lung,&#160;causing sharp chest&#160;pains&#160;that&#160;feel&#160;worse&#160;with breathing (pleurisy)&#160;</p>
<p style="position:absolute;top:494px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:499px;left:149px;white-space:nowrap" class="ft1022">Tuberculosis&#160;</p>
<p style="position:absolute;top:513px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:518px;left:149px;white-space:nowrap" class="ft1022">Kidney infections&#160;</p>
<p style="position:absolute;top:533px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:538px;left:149px;white-space:nowrap" class="ft1022">Low&#160;platelet&#160;count, too many white&#160;blood cells&#160;</p>
<p style="position:absolute;top:552px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:557px;left:149px;white-space:nowrap" class="ft1022">Infections&#160;of&#160;the&#160;vagina&#160;</p>
<p style="position:absolute;top:573px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:578px;left:149px;white-space:nowrap" class="ft1022">Blood test&#160;result&#160;showing&#160;‘antibodies’&#160;against&#160;your&#160;own body.&#160;</p>
<p style="position:absolute;top:593px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:598px;left:149px;white-space:nowrap" class="ft1022">Changes&#160;in&#160;cholesterol&#160;and fat&#160;levels&#160;in the&#160;blood.&#160;</p>
<p style="position:absolute;top:617px;left:107px;white-space:nowrap" class="ft1025"><b>&#160;<br/>Rare:&#160;</b>may&#160;affect&#160;up&#160;to 1&#160;in&#160;1,000 people&#160;</p>
<p style="position:absolute;top:650px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:656px;left:149px;white-space:nowrap" class="ft1022">A&#160;type&#160;of&#160;blood cancer&#160;(lymphoma)&#160;</p>
<p style="position:absolute;top:670px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:675px;left:149px;white-space:nowrap" class="ft10211">Your&#160;blood not&#160;supplying&#160;enough oxygen&#160;to your&#160;body, circulation problems&#160;such&#160;as&#160;narrowing&#160;<br/>of&#160;a&#160;blood&#160;vessel&#160;</p>
<p style="position:absolute;top:709px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:714px;left:149px;white-space:nowrap" class="ft1022">Inflammation of&#160;the&#160;lining&#160;of&#160;the&#160;brain&#160;(meningitis)&#160;</p>
<p style="position:absolute;top:728px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:734px;left:149px;white-space:nowrap" class="ft1022">Infections&#160;due&#160;to&#160;a weakened&#160;immune system&#160;</p>
<p style="position:absolute;top:748px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:753px;left:149px;white-space:nowrap" class="ft1022">Hepatitis B&#160;infection&#160;when&#160;you&#160;have had&#160;hepatitis B&#160;in&#160;the past&#160;</p>
<p style="position:absolute;top:768px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:774px;left:149px;white-space:nowrap" class="ft1022">Inflamed liver&#160;caused&#160;by a&#160;problem&#160;with&#160;the&#160;immune&#160;system&#160;(autoimmune&#160;hepatitis)&#160;&#160;</p>
<p style="position:absolute;top:789px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:794px;left:149px;white-space:nowrap" class="ft1022">Liver&#160;problem&#160;that&#160;causes&#160;yellowing of&#160;the&#160;skin&#160;or&#160;eyes (jaundice)&#160;</p>
<p style="position:absolute;top:808px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:813px;left:149px;white-space:nowrap" class="ft1022">Abnormal&#160;tissue&#160;swelling or&#160;growth&#160;</p>
<p style="position:absolute;top:827px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:833px;left:149px;white-space:nowrap" class="ft10211">Severe allergic reaction&#160;that&#160;may&#160;cause&#160;loss of&#160;consciousness and&#160;could&#160;be&#160;life-threatening&#160;<br/>(anaphylactic shock)&#160;</p>
<p style="position:absolute;top:866px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:872px;left:149px;white-space:nowrap" class="ft1022">Swelling&#160;of&#160;small blood&#160;vessels&#160;(vasculitis)&#160;</p>
<p style="position:absolute;top:886px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:891px;left:149px;white-space:nowrap" class="ft1022">Immune&#160;disorders&#160;that&#160;could affect&#160;the&#160;lungs,&#160;skin and&#160;lymph nodes&#160;(such&#160;as&#160;sarcoidosis)&#160;</p>
<p style="position:absolute;top:905px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:911px;left:149px;white-space:nowrap" class="ft1022">Collections&#160;of&#160;immune&#160;cells&#160;resulting from&#160;an&#160;inflammatory response&#160;(granulomatous&#160;lesions)&#160;</p>
<p style="position:absolute;top:925px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:930px;left:149px;white-space:nowrap" class="ft1022">Lack&#160;of&#160;interest or&#160;emotion&#160;</p>
<p style="position:absolute;top:944px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:950px;left:149px;white-space:nowrap" class="ft10211">Serious skin&#160;problems&#160;such&#160;as toxic&#160;epidermal&#160;necrolysis,&#160;Stevens-Johnson syndrome&#160;and acute&#160;<br/>generalised&#160;exanthematous&#160;pustulosis&#160;</p>
<p style="position:absolute;top:983px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:989px;left:149px;white-space:nowrap" class="ft10211">Other&#160;skin&#160;problems&#160;such&#160;as&#160;erythema&#160;multiforme,&#160;blisters&#160;and&#160;peeling skin, or&#160;boils&#160;<br/>(furunculosis)&#160;</p>
<p style="position:absolute;top:1022px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:1028px;left:149px;white-space:nowrap" class="ft10211">Serious nervous system&#160;disorders such&#160;as transverse&#160;myelitis,&#160;multiple sclerosis-like disease,&#160;<br/>optic&#160;neuritis&#160;and&#160;Guillain-Barré&#160;syndrome&#160;</p>
<p style="position:absolute;top:1061px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:1067px;left:149px;white-space:nowrap" class="ft1022">Inflammation&#160;in the&#160;eye&#160;that&#160;may cause&#160;changes&#160;in the&#160;vision,&#160;including blindness&#160;</p>
<p style="position:absolute;top:1081px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:1086px;left:149px;white-space:nowrap" class="ft1022">Fluid in the&#160;lining&#160;of&#160;the&#160;heart&#160;(pericardial&#160;effusion)&#160;</p>
<p style="position:absolute;top:1100px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:1106px;left:149px;white-space:nowrap" class="ft1022">Serious&#160;lung&#160;problems&#160;(such&#160;as&#160;interstitial&#160;lung disease)&#160;</p>
<p style="position:absolute;top:1120px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:1125px;left:149px;white-space:nowrap" class="ft1022">Melanoma&#160;(a type of&#160;skin&#160;cancer)&#160;</p>
<p style="position:absolute;top:1139px;left:107px;white-space:nowrap" class="ft1028">•&#160;</p>
<p style="position:absolute;top:1145px;left:149px;white-space:nowrap" class="ft1022">Cervical&#160;cancer&#160;</p>
</div>
<!-- Page 103 -->
<a name="103"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page103-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1030">103&#160;</p>
<p style="position:absolute;top:84px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft1032">Low&#160;blood&#160;counts,&#160;including a&#160;severely decreased number&#160;of&#160;white&#160;blood&#160;cells&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft1032">Small&#160;red or&#160;purple&#160;spots&#160;caused&#160;by bleeding under&#160;the&#160;skin&#160;</p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:130px;left:149px;white-space:nowrap" class="ft10310">Abnormal&#160;values&#160;of&#160;a&#160;blood&#160;protein&#160;called ‘complement&#160;factor’&#160;which&#160;is&#160;part&#160;of&#160;the&#160;immune&#160;<br/>system&#160;</p>
<p style="position:absolute;top:164px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:169px;left:149px;white-space:nowrap" class="ft10311">Lichenoid&#160;reactions&#160;(itchy reddish-purple&#160;skin&#160;rash and/or&#160;threadlike&#160;white-grey lines&#160;on&#160;<br/>mucous&#160;membranes).&#160;&#160;<br/>&#160;</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft1031"><b>Not&#160;known:&#160;</b>frequency&#160;cannot&#160;be estimated&#160;from&#160;the available&#160;data<b>&#160;</b></p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:246px;left:149px;white-space:nowrap" class="ft1032">Cancer&#160;in&#160;children and adults&#160;</p>
<p style="position:absolute;top:260px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft10311">A&#160;rare&#160;blood cancer&#160;affecting mostly&#160;teenage boys or&#160;young&#160;men&#160;(hepatosplenic T-cell&#160;<br/>lymphoma)&#160;</p>
<p style="position:absolute;top:299px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:304px;left:149px;white-space:nowrap" class="ft1032">Liver&#160;failure&#160;</p>
<p style="position:absolute;top:318px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:324px;left:149px;white-space:nowrap" class="ft1032">Merkel&#160;cell&#160;carcinoma (a type&#160;of&#160;skin&#160;cancer)&#160;</p>
<p style="position:absolute;top:338px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:343px;left:149px;white-space:nowrap" class="ft10311">Kaposi’s&#160;sarcoma, a&#160;rare&#160;cancer&#160;related&#160;to infection with human herpes&#160;virus&#160;8. Kaposi’s&#160;<br/>sarcoma&#160;most&#160;commonly&#160;appears&#160;as&#160;purple&#160;lesions&#160;on the&#160;skin.&#160;</p>
<p style="position:absolute;top:377px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:382px;left:149px;white-space:nowrap" class="ft10311">Worsening of&#160;a&#160;condition called dermatomyositis&#160;(seen as&#160;a&#160;skin rash accompanying&#160;muscle&#160;<br/>weakness)&#160;</p>
<p style="position:absolute;top:417px;left:107px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:422px;left:149px;white-space:nowrap" class="ft1032">Heart&#160;attack&#160;</p>
<p style="position:absolute;top:437px;left:107px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:442px;left:149px;white-space:nowrap" class="ft1032">Stroke&#160;</p>
<p style="position:absolute;top:456px;left:107px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:462px;left:149px;white-space:nowrap" class="ft1032">Temporary loss&#160;of&#160;sight&#160;during or&#160;within&#160;2 hours&#160;of&#160;infusion&#160;</p>
<p style="position:absolute;top:476px;left:107px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft1032">Infection due&#160;to&#160;a&#160;live vaccine because&#160;of&#160;a&#160;weakened immune&#160;system.&#160;&#160;</p>
<p style="position:absolute;top:501px;left:107px;white-space:nowrap" class="ft10311">&#160;<br/><b>Additional&#160;side&#160;effects&#160;in children&#160;and adolescents&#160;<br/></b>Children&#160;who took&#160;infliximab&#160;for&#160;Crohn’s&#160;disease showed&#160;some differences in&#160;side effects&#160;compared&#160;<br/>with adults&#160;who&#160;took&#160;infliximab&#160;for&#160;Crohn's disease.&#160;The side effects that&#160;happened&#160;more in&#160;children&#160;<br/>were:&#160;low&#160;red blood&#160;cells&#160;(anaemia), blood&#160;in stool, low&#160;overall&#160;levels&#160;of&#160;white&#160;blood&#160;cells&#160;<br/>(leukopenia), redness&#160;or&#160;blushing&#160;(flushing), viral&#160;infections, low&#160;levels of&#160;white&#160;blood&#160;cells&#160;that&#160;fight&#160;<br/>infection&#160;(neutropenia), bone&#160;fracture, bacterial&#160;infection and allergic&#160;reactions&#160;of&#160;the&#160;breathing&#160;tract.&#160;<br/>&#160;<br/><b>Reporting&#160;of&#160;side effects&#160;<br/></b>If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor, pharmacist&#160;or&#160;nurse.&#160;This&#160;includes&#160;any possible&#160;side&#160;<br/>effects not&#160;listed&#160;in&#160;this leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side effects directly&#160;via&#160;the&#160;national&#160;reporting&#160;<br/>system&#160;listed&#160;in&#160;Appendix V.&#160;By reporting side&#160;effects&#160;you can&#160;help provide&#160;more&#160;information&#160;on the&#160;<br/>safety&#160;of&#160;this&#160;medicine.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:788px;left:149px;white-space:nowrap" class="ft1031"><b>How&#160;to&#160;store Remsima&#160;</b></p>
<p style="position:absolute;top:808px;left:106px;white-space:nowrap" class="ft10311">&#160;<br/>Remsima&#160;will&#160;generally&#160;be&#160;stored by&#160;the&#160;health professionals. The&#160;storage&#160;details&#160;should you need&#160;<br/>them&#160;are&#160;as&#160;follows:&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:866px;left:149px;white-space:nowrap" class="ft1032">Keep&#160;this&#160;medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:886px;left:149px;white-space:nowrap" class="ft10311">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date&#160;which is&#160;stated on the&#160;label&#160;and&#160;the&#160;carton after&#160;<br/>“EXP”. The&#160;expiry date&#160;refers&#160;to the&#160;last&#160;day&#160;of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:925px;left:149px;white-space:nowrap" class="ft1032">Store&#160;in&#160;a&#160;refrigerator (2°C&#160;–&#160;8°C).&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:944px;left:149px;white-space:nowrap" class="ft10311">This&#160;medicine&#160;can also&#160;be&#160;stored in&#160;the&#160;original&#160;carton&#160;outside&#160;of&#160;refrigerated&#160;storage&#160;up to a&#160;<br/>maximum&#160;of&#160;25°C&#160;for&#160;a&#160;single&#160;period of&#160;up&#160;to six&#160;months, but&#160;not&#160;beyond the&#160;original&#160;expiry&#160;<br/>date. In&#160;this&#160;situation, do not&#160;return to&#160;refrigerated&#160;storage&#160;again.&#160;Write&#160;the&#160;new&#160;expiry&#160;date&#160;on&#160;<br/>the&#160;carton&#160;including day/month/year. Discard this&#160;medicine&#160;if&#160;not&#160;used by&#160;the&#160;new&#160;expiry date&#160;<br/>or&#160;the&#160;expiry date&#160;printed&#160;on the&#160;carton, whichever&#160;is&#160;earlier.&#160;</p>
<p style="position:absolute;top:1037px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:1042px;left:149px;white-space:nowrap" class="ft10311">It&#160;is recommended&#160;that&#160;when&#160;Remsima&#160;is prepared&#160;for&#160;infusion,&#160;it&#160;is used&#160;as soon&#160;as possible&#160;<br/>(within 3&#160;hours). However,&#160;if&#160;the&#160;solution is&#160;prepared&#160;in germ-free&#160;conditions, it&#160;can&#160;be&#160;stored in&#160;<br/>a&#160;refrigerator at&#160;2°C&#160;–&#160;8°C&#160;up to&#160;60&#160;days&#160;and&#160;for&#160;an additional&#160;24&#160;hours&#160;at&#160;25&#160;°C&#160;after&#160;removal&#160;<br/>from&#160;the&#160;refrigerator.&#160;</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft1038">•&#160;</p>
<p style="position:absolute;top:1120px;left:149px;white-space:nowrap" class="ft1032">Do&#160;not&#160;use&#160;this&#160;medicine&#160;if&#160;it is&#160;discoloured&#160;or&#160;if&#160;there are&#160;particles&#160;present.&#160;</p>
<p style="position:absolute;top:1139px;left:106px;white-space:nowrap" class="ft1035"><b>&#160;<br/>&#160;</b></p>
</div>
<!-- Page 104 -->
<a name="104"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10447{font-size:17px;font-family:QJUVDH+TimesNewRomanPS;color:#000000;}
	.ft10448{font-size:17px;line-height:25px;font-family:TimesNewRomanPS;color:#000000;}
	.ft10449{font-size:15px;line-height:19px;font-family:TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page104-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1040">104&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1041"><b>6.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft1041"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:109px;left:106px;white-space:nowrap" class="ft1045"><b>&#160;<br/>What&#160;Remsima&#160;contains&#160;</b></p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft1048">•&#160;</p>
<p style="position:absolute;top:148px;left:149px;white-space:nowrap" class="ft10411">The active&#160;substance&#160;is&#160;infliximab.&#160;Each&#160;vial&#160;contains 100&#160;mg of&#160;infliximab.&#160;After&#160;preparation&#160;<br/>each&#160;mL&#160;contains&#160;10&#160;mg&#160;of&#160;infliximab.&#160;</p>
<p style="position:absolute;top:182px;left:106px;white-space:nowrap" class="ft1048">•&#160;</p>
<p style="position:absolute;top:187px;left:149px;white-space:nowrap" class="ft10411">The other&#160;ingredients are&#160;sucrose,&#160;polysorbate 80,&#160;sodium&#160;dihydrogen&#160;phosphate&#160;monohydrate&#160;<br/>and&#160;disodium&#160;phosphate&#160;dihydrate.&#160;</p>
<p style="position:absolute;top:226px;left:106px;white-space:nowrap" class="ft10411"><b>&#160;<br/>What&#160;Remsima&#160;looks&#160;like&#160;and contents&#160;of&#160;the&#160;pack&#160;<br/></b>Remsima is supplied&#160;as a glass vial&#160;containing&#160;a powder&#160;for&#160;concentrate&#160;for&#160;solution&#160;for&#160;infusion.&#160;The&#160;<br/>powder&#160;is&#160;white.&#160;<br/>&#160;<br/>Remsima&#160;is&#160;produced in&#160;packs&#160;of&#160;1, 2, 3,&#160;4 or&#160;5&#160;vials.&#160;Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;<br/><b>&#160;<br/>Marketing&#160;Authorisation Holder&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Hungary&#160;<br/><b>&#160;<br/>Manufacturer&#160;<br/></b>Millmount Healthcare&#160;Ltd.&#160;<br/>Block 7&#160;<br/>City&#160;North&#160;Business Campus&#160;&#160;<br/>Stamullen, Co. Meath K32&#160;YD60&#160;<br/>Ireland&#160;<br/>&#160;<br/>Nuvisan&#160;GmbH&#160;<br/>Wegenerstraße 13,&#160;&#160;<br/>89231 Neu Ulm,&#160;&#160;<br/>Germany&#160;<br/>&#160;<br/>Nuvisan&#160;France SARL&#160;<br/>2400, Route&#160;des&#160;Colles,&#160;&#160;<br/>06410, Biot,&#160;&#160;<br/>France&#160;<br/><b>&#160;<br/></b>For&#160;any&#160;information&#160;about&#160;this&#160;medicine,&#160;please&#160;contact&#160;the local&#160;representative of&#160;the&#160;Marketing&#160;<br/>Authorisation Holder:&#160;<br/>&#160;</p>
<p style="position:absolute;top:858px;left:114px;white-space:nowrap" class="ft10410"><b>België/Belgique/Belgien</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Belgium BVBA&#160;<br/>Tél/Tel:&#160;+&#160;32 1528&#160;7418&#160;</p>
<p style="position:absolute;top:899px;left:114px;white-space:nowrap" class="ft1042">&#160;</p>
<p style="position:absolute;top:858px;left:463px;white-space:nowrap" class="ft10410"><b>Lietuva</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Hungary Kft.&#160;<br/>Tel: +&#160;36 1&#160;231 0493&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:947px;left:114px;white-space:nowrap" class="ft10448"><b>България&#160;<br/></b>Celltrion&#160;Healthcare&#160;Hungary Kft.&#160;</p>
<p style="position:absolute;top:985px;left:114px;white-space:nowrap" class="ft10419">Teл.:&#160;+&#160;36 1 231 0493&#160;<br/>&#160;</p>
<p style="position:absolute;top:953px;left:463px;white-space:nowrap" class="ft10410"><b>Luxembourg/Luxemburg</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Belgium BVBA&#160;<br/>Tél/Tel:&#160;+&#160;32 1528&#160;7418&#160;</p>
<p style="position:absolute;top:994px;left:463px;white-space:nowrap" class="ft1042">&#160;</p>
<p style="position:absolute;top:1022px;left:114px;white-space:nowrap" class="ft10411"><b>Česká&#160;republika</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Hungary Kft.&#160;<br/>Tel: +&#160;36 1&#160;231 0493&#160;</p>
<p style="position:absolute;top:1070px;left:114px;white-space:nowrap" class="ft1042">&#160;</p>
<p style="position:absolute;top:1029px;left:463px;white-space:nowrap" class="ft10449"><b>Magyarország&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>Tel:&#160;+36&#160;1 231&#160;0493&#160;</p>
<p style="position:absolute;top:1131px;left:114px;white-space:nowrap" class="ft10410"><b>Danmark</b>&#160;<br/>Orion&#160;Pharma&#160;A/S&#160;</p>
<p style="position:absolute;top:1131px;left:463px;white-space:nowrap" class="ft1046"><b>Malta&#160;<br/></b>Mint Health&#160;Ltd.&#160;</p>
</div>
<!-- Page 105 -->
<a name="105"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10550{font-size:17px;font-family:TimesNewRomanPS;color:#000000;}
	.ft10551{font-size:17px;line-height:18px;font-family:TimesNewRomanPS;color:#000000;}
	.ft10552{font-size:17px;line-height:24px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page105-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1050">105&#160;</p>
<p style="position:absolute;top:89px;left:114px;white-space:nowrap" class="ft1052">Tlf:&#160;+&#160;45&#160;86&#160;14&#160;00&#160;00&#160;</p>
<p style="position:absolute;top:89px;left:463px;white-space:nowrap" class="ft10510">Tel:&#160;+&#160;356&#160;2093 9800&#160;<br/>info@mint.com.mt&#160;<br/>&#160;</p>
<p style="position:absolute;top:146px;left:114px;white-space:nowrap" class="ft10510"><b>Deutschland</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>Tel:&#160;+36&#160;1&#160;231 0493&#160;<br/>&#160;</p>
<p style="position:absolute;top:146px;left:463px;white-space:nowrap" class="ft10510"><b>Nederland</b>&#160;<br/>Celltrion&#160;Healthcare Netherlands&#160;B.V.&#160;<br/>Tel:&#160;+31 20&#160;888 7300&#160;<br/>&#160;</p>
<p style="position:absolute;top:222px;left:114px;white-space:nowrap" class="ft10510"><b>Eesti&#160;<br/></b>Orion&#160;Pharma Eesti&#160;OÜ&#160;<br/>Tel:&#160;+&#160;372&#160;6 644 550&#160;&#160;</p>
<p style="position:absolute;top:222px;left:463px;white-space:nowrap" class="ft10511"><b>Norge</b>&#160;<br/>Orion&#160;Pharma&#160;AS&#160;<br/>Tlf: +&#160;47&#160;40 00 42 10&#160;<br/>&#160;</p>
<p style="position:absolute;top:292px;left:114px;white-space:nowrap" class="ft10547"><b>Ελλάδα</b>&#160;</p>
<p style="position:absolute;top:311px;left:114px;white-space:nowrap" class="ft10518">ΒΙΑΝΕΞ&#160;Α.Ε.&#160;&#160;</p>
<p style="position:absolute;top:330px;left:114px;white-space:nowrap" class="ft10518">Τηλ:&#160;+30 210&#160;8009111&#160;–&#160;120&#160;</p>
<p style="position:absolute;top:298px;left:463px;white-space:nowrap" class="ft10510"><b>Österreich</b>&#160;<br/>Astro-Pharma&#160;GmbH&#160;<br/>Tel.:&#160;+43 1&#160;97 99 860&#160;<br/>office@astropharma.at&#160;</p>
<p style="position:absolute;top:374px;left:114px;white-space:nowrap" class="ft10511"><b>&#160;<br/>España&#160;<br/></b>Kern Pharma, S.L.&#160;<br/>Tel:&#160;+&#160;34 93 700 25 25&#160;</p>
<p style="position:absolute;top:374px;left:463px;white-space:nowrap" class="ft10511"><b>&#160;<br/>Polska<i>&#160;<br/></i></b>CELLTRION&#160;Healthcare Hungary&#160;Kft.&#160;<br/>Tel.: +&#160;36 1&#160;231 0493&#160;<br/>&#160;<br/>&#160;</p>
<p style="position:absolute;top:487px;left:114px;white-space:nowrap" class="ft10511"><b>France&#160;<br/></b>Celltrion&#160;Healthcare&#160;France&#160;SAS&#160;<br/>Tel:&#160;+33&#160;(0)1&#160;71 25 27 00<b>&#160;</b></p>
<p style="position:absolute;top:487px;left:463px;white-space:nowrap" class="ft10511"><b>Portugal</b>&#160;<br/>PharmaKERN&#160;Portugal&#160;–&#160;Produtos&#160;Farmacêuticos,&#160;<br/>Sociedade Unipessoal,&#160;Lda.&#160;&#160;<br/>Tel:&#160;+&#160;351&#160;214 200&#160;290&#160;&#160;<br/>&#160;</p>
<p style="position:absolute;top:582px;left:114px;white-space:nowrap" class="ft10510"><b>Hrvatska</b>&#160;<br/>OKTAL&#160;PHARMA d.o.o.&#160;&#160;<br/>Tel:&#160;+&#160;385 1&#160;6595 777&#160;<br/>oktal-pharma@oktal-pharma.hr&#160;<br/><b>&#160;<br/>Ireland</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Ireland&#160;Limited&#160;<br/>Tel:&#160;+353 1&#160;223 4026&#160;</p>
<p style="position:absolute;top:582px;left:463px;white-space:nowrap" class="ft10511"><b>România&#160;<br/></b>Celltrion&#160;Healthcare&#160;Hungary Kft.&#160;<br/>Tel: +&#160;36 1&#160;231 0493&#160;<br/>&#160;&#160;<br/><b>&#160;<br/>Slovenija</b>&#160;<br/>OPH&#160;Oktal&#160;Pharma&#160;d.o.o.&#160;<br/>Tel:&#160;+&#160;386&#160;1 519 29 22&#160;<br/>info@oktal-pharma.si&#160;<br/>&#160;</p>
<p style="position:absolute;top:772px;left:114px;white-space:nowrap" class="ft10510"><b>Ísland&#160;<br/></b>Vistor&#160;hf.&#160;<br/>Sími:&#160;+354 535 7000&#160;</p>
<p style="position:absolute;top:772px;left:463px;white-space:nowrap" class="ft10511"><b>Slovenská&#160;republika&#160;<br/></b>Celltrion&#160;Healthcare&#160;Hungary Kft.&#160;<br/>Tel: +&#160;36&#160;1 231&#160;0493&#160;<br/>&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:867px;left:114px;white-space:nowrap" class="ft10510"><b>Italia</b>&#160;<br/>Celltrion&#160;Healthcare Italy&#160;S.r.l.&#160;<br/>Via&#160;Luigi&#160;Galvani, 24&#160;-&#160;20124 Milano (MI)&#160;<br/>Tel: +39&#160;0247 927040&#160;</p>
<p style="position:absolute;top:928px;left:114px;white-space:nowrap" class="ft1052">&#160;</p>
<p style="position:absolute;top:867px;left:463px;white-space:nowrap" class="ft10510"><b>Suomi/Finland</b>&#160;<br/>Orion Pharma&#160;<br/>Puh/Tel:&#160;+&#160;358 10 4261&#160;&#160;<br/>&#160;</p>
<p style="position:absolute;top:937px;left:114px;white-space:nowrap" class="ft10552"><b>Κύπρος&#160;<br/></b>C.A. Papaellinas&#160;Ltd&#160;</p>
<p style="position:absolute;top:975px;left:114px;white-space:nowrap" class="ft10519">Τηλ:&#160;+&#160;357 22741741&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:943px;left:463px;white-space:nowrap" class="ft10511"><b>Sverige&#160;<br/></b>Orion&#160;Pharma&#160;AB&#160;<br/>Tel:&#160;+&#160;46 8&#160;623&#160;64 40<b>&#160;</b></p>
<p style="position:absolute;top:1019px;left:114px;white-space:nowrap" class="ft10510"><b>Latvija&#160;<br/></b>Celltrion&#160;Healthcare&#160;Hungary Kft.&#160;<br/>Tel: +&#160;36 1&#160;231 0493&#160;</p>
<p style="position:absolute;top:1060px;left:114px;white-space:nowrap" class="ft1052">&#160;</p>
<p style="position:absolute;top:1019px;left:463px;white-space:nowrap" class="ft10510"><b>United Kingdom&#160;(Norther&#160;Ireland)&#160;<br/></b>Celltrion&#160;Healthcare&#160;Ireland&#160;Limited&#160;<br/>Tel: +353 1&#160;223 4026&#160;</p>
<p style="position:absolute;top:1060px;left:463px;white-space:nowrap" class="ft1052">&#160;</p>
<p style="position:absolute;top:1076px;left:106px;white-space:nowrap" class="ft1055"><b>&#160;<br/>&#160;</b></p>
</div>
<!-- Page 106 -->
<a name="106"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page106-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1060">106&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft10611"><b>This leaflet&#160;was&#160;last&#160;revised&#160;in&#160;{MM/YYYY}.&#160;<br/>&#160;<br/>Other&#160;sources&#160;of&#160;information&#160;<br/>&#160;<br/></b>Detailed&#160;information on&#160;this&#160;medicine&#160;is&#160;available&#160;on&#160;the&#160;European&#160;Medicines&#160;Agency web&#160;site:&#160;<br/>http://www.ema.europa.eu.&#160;&#160;</p>
</div>
<!-- Page 107 -->
<a name="107"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10753{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page107-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1070">107&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft10711">---------------------------------------------------------------------------------------------------------------------------&#160;<br/>&#160;<br/>The&#160;following&#160;information&#160;is&#160;intended&#160;for&#160;healthcare&#160;professionals&#160;only:&#160;<br/><i><b>&#160;<br/></b></i>Patients treated&#160;with&#160;Remsima should&#160;be given&#160;the patient&#160;reminder&#160;card.&#160;<br/><i><b>&#160;<br/></b></i><b>Instructions&#160;for use and&#160;handling&#160;–&#160;storage&#160;conditions&#160;<br/><i>&#160;<br/></i></b>Store&#160;at&#160;2°C&#160;–&#160;8°C.&#160;<br/>&#160;<br/>Remsima may&#160;be stored&#160;at&#160;temperatures&#160;up&#160;to&#160;a&#160;maximum&#160;of&#160;25°C&#160;for&#160;a&#160;single&#160;period of&#160;up&#160;to 6&#160;<br/>months, but&#160;not&#160;exceeding the&#160;original&#160;expiry&#160;date. The&#160;new&#160;expiry date&#160;must&#160;be&#160;written on&#160;the&#160;carton.&#160;<br/>Upon removal&#160;from&#160;refrigerated storage, Remsima&#160;must&#160;not&#160;be&#160;returned&#160;to refrigerated&#160;storage.&#160;<br/><i><b>&#160;<br/></b></i><b>Instructions&#160;for use and&#160;handling&#160;–&#160;reconstitution,&#160;dilution and&#160;administration&#160;<br/>&#160;<br/></b>In order&#160;to&#160;improve&#160;the&#160;traceability of&#160;biological&#160;medicinal&#160;products,&#160;the&#160;tradename&#160;and batch number&#160;<br/>of&#160;the&#160;administered&#160;medicinal&#160;product&#160;should be&#160;clearly recorded.&#160;<br/>&#160;<br/>1.&#160;</p>
<p style="position:absolute;top:460px;left:149px;white-space:nowrap" class="ft10711">The dose and&#160;the&#160;number&#160;of&#160;Remsima&#160;vials have&#160;to&#160;be&#160;calculated.&#160;Each&#160;Remsima&#160;vial&#160;contains&#160;<br/>100&#160;mg&#160;infliximab.&#160;The&#160;required&#160;total volume&#160;of&#160;reconstituted&#160;Remsima&#160;solution&#160;has&#160;to&#160;be&#160;<br/>calculated.&#160;</p>
<p style="position:absolute;top:516px;left:106px;white-space:nowrap" class="ft10710">&#160;<br/>2.&#160;</p>
<p style="position:absolute;top:535px;left:149px;white-space:nowrap" class="ft10711">Under&#160;aseptic&#160;conditions, each Remsima&#160;vial&#160;should be&#160;reconstituted with 10&#160;mL&#160;of&#160;water for&#160;<br/>injections, using a&#160;syringe&#160;equipped with a&#160;21-gauge&#160;(0.8&#160;mm)&#160;or&#160;smaller&#160;needle.&#160;The&#160;flip-top&#160;<br/>from&#160;the&#160;vial&#160;has&#160;to be&#160;removed and the&#160;top has&#160;to be&#160;wiped with a&#160;70%&#160;alcohol&#160;swab. The&#160;<br/>syringe&#160;needle&#160;should be&#160;inserted&#160;into the&#160;vial&#160;through&#160;the&#160;centre&#160;of&#160;the&#160;rubber&#160;stopper&#160;and the&#160;<br/>stream of&#160;water&#160;for&#160;injections&#160;directed&#160;to&#160;the&#160;glass&#160;wall&#160;of&#160;the&#160;vial.&#160;The&#160;solution&#160;has&#160;to&#160;be&#160;gently&#160;<br/>swirled by rotating&#160;the&#160;vial&#160;to dissolve&#160;the&#160;powder. Prolonged&#160;or&#160;vigorous&#160;agitation must&#160;be&#160;<br/>avoided. THE&#160;VIAL&#160;MUST&#160;NOT&#160;BE&#160;SHAKEN. Foaming of&#160;the&#160;solution on&#160;reconstitution&#160;may&#160;<br/>occur. The&#160;reconstituted solution should&#160;stand for&#160;5&#160;minutes. The&#160;solution should&#160;be&#160;colourless&#160;<br/>to light&#160;yellow&#160;and opalescent. The&#160;solution&#160;may develop a&#160;few&#160;fine&#160;translucent&#160;particles,&#160;as&#160;<br/>infliximab is&#160;a&#160;protein.&#160;The&#160;solution&#160;must&#160;not&#160;be&#160;used if&#160;opaque&#160;particles,&#160;discolouration,&#160;or&#160;<br/>other&#160;foreign&#160;particles are present.&#160;</p>
<p style="position:absolute;top:744px;left:106px;white-space:nowrap" class="ft10711">&#160;<br/>3.&#160;</p>
<p style="position:absolute;top:764px;left:149px;white-space:nowrap" class="ft10711">The&#160;required volume&#160;of&#160;the&#160;reconstituted Remsima&#160;solution should be&#160;diluted&#160;to 250&#160;mL&#160;with&#160;<br/>sodium&#160;chloride&#160;9&#160;mg/mL&#160;(0.9%)&#160;solution for&#160;infusion.&#160;Do&#160;not&#160;dilute&#160;the&#160;reconstituted&#160;Remsima&#160;<br/>solution with any&#160;other&#160;diluent. The&#160;dilution&#160;can&#160;be&#160;accomplished by&#160;withdrawing&#160;a&#160;volume&#160;of&#160;<br/>the&#160;sodium&#160;chloride&#160;9&#160;mg/mL&#160;(0.9%)&#160;solution&#160;for&#160;infusion&#160;from&#160;the&#160;250-mL&#160;glass&#160;bottle&#160;or&#160;<br/>infusion bag&#160;equal&#160;to the&#160;volume&#160;of&#160;reconstituted Remsima. The&#160;required volume&#160;of&#160;<br/>reconstituted Remsima&#160;solution&#160;should slowly be&#160;added to&#160;the&#160;250-mL&#160;infusion&#160;bottle&#160;or&#160;bag&#160;<br/>and gently be&#160;mixed.&#160;For&#160;volumes&#160;greater&#160;than&#160;250&#160;ml,&#160;either&#160;use&#160;a larger&#160;infusion&#160;bag (e.g.&#160;<br/>500&#160;ml, 1000&#160;ml)&#160;or&#160;use&#160;multiple&#160;250&#160;ml&#160;infusion&#160;bags&#160;to&#160;ensure&#160;that&#160;the&#160;concentration of&#160;the&#160;<br/>infusion solution does&#160;not&#160;exceed&#160;4&#160;mg/ml.&#160;If&#160;stored refrigerated after&#160;reconstitution&#160;and&#160;<br/>dilution, the&#160;infusion solution must&#160;be&#160;allowed to&#160;equilibrate&#160;at&#160;room&#160;temperature&#160;to 25 °C&#160;for&#160;3&#160;<br/>hours&#160;prior&#160;to Step 4&#160;(infusion). Storage&#160;beyond 24 hours&#160;at&#160;2 °C&#160;-&#160;8 °C&#160;applies&#160;to&#160;preparation of&#160;<br/>Remsima&#160;in&#160;the&#160;infusion bag only.&#160;</p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft10711">&#160;<br/>4.&#160;</p>
<p style="position:absolute;top:1010px;left:149px;white-space:nowrap" class="ft10711">The&#160;infusion solution has&#160;to be&#160;administered&#160;over&#160;a&#160;period&#160;of&#160;not&#160;less&#160;than the&#160;infusion&#160;time&#160;<br/>recommended&#160;(see section&#160;3). Only&#160;an&#160;infusion set&#160;with an in-line, sterile, non-pyrogenic, low&#160;<br/>protein-binding filter&#160;(pore&#160;size&#160;1.2&#160;micrometre&#160;or&#160;less)&#160;should be&#160;used. Since&#160;no preservative&#160;is&#160;<br/>present,&#160;it&#160;is&#160;recommended&#160;that&#160;the&#160;administration of&#160;the&#160;solution&#160;for&#160;infusion is&#160;to&#160;be&#160;started&#160;as&#160;<br/>soon as&#160;possible&#160;and within&#160;3&#160;hours&#160;of&#160;reconstitution and&#160;dilution.&#160;If&#160;not&#160;used&#160;immediately, in&#160;<br/>use&#160;storage&#160;times&#160;and&#160;conditions&#160;prior&#160;to&#160;use&#160;are&#160;the&#160;responsibility of&#160;the&#160;user&#160;and&#160;would&#160;<br/>normally not&#160;be&#160;longer&#160;than&#160;24&#160;hours&#160;at&#160;2°C&#160;–&#160;8°C, unless&#160;reconstitution/dilution&#160;has been&#160;taken&#160;<br/>place&#160;in&#160;controlled and validated&#160;aseptic&#160;conditions. Any unused portion of&#160;the&#160;infusion&#160;solution&#160;<br/>should not&#160;be&#160;stored&#160;for&#160;reuse.&#160;</p>
</div>
<!-- Page 108 -->
<a name="108"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page108-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1080">108&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft10811">&#160;<br/>5.&#160;</p>
<p style="position:absolute;top:109px;left:149px;white-space:nowrap" class="ft10811">Remsima&#160;should&#160;be&#160;visually inspected&#160;for&#160;particulate&#160;matter&#160;or&#160;discolouration prior&#160;to&#160;<br/>administration.&#160;If&#160;visibly opaque&#160;particles, discolouration or&#160;foreign particles&#160;are&#160;observed&#160;it&#160;<br/>should not&#160;be&#160;used.&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft10810">&#160;<br/>6.&#160;</p>
<p style="position:absolute;top:184px;left:149px;white-space:nowrap" class="ft10811">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with&#160;<br/>local requirements.<b>&#160;</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1081"><b>&#160;</b></p>
<p style="position:absolute;top:222px;left:322px;white-space:nowrap" class="ft1081"><b>&#160;</b></p>
</div>
<!-- Page 109 -->
<a name="109"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page109-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1090">109&#160;</p>
<p style="position:absolute;top:89px;left:303px;white-space:nowrap" class="ft1091"><b>Package&#160;leaflet:&#160;Information&#160;for&#160;the user&#160;</b></p>
<p style="position:absolute;top:108px;left:447px;white-space:nowrap" class="ft1092">&#160;</p>
<p style="position:absolute;top:127px;left:239px;white-space:nowrap" class="ft1091"><b>Remsima 120&#160;mg&#160;solution&#160;for&#160;injection&#160;in pre-filled&#160;syringe&#160;</b></p>
<p style="position:absolute;top:146px;left:412px;white-space:nowrap" class="ft1092">infliximab&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft10914">&#160;<br/>&#160;<br/><b>Read&#160;all&#160;of&#160;this leaflet&#160;carefully&#160;before you&#160;start&#160;using&#160;this medicine because it&#160;contains&#160;<br/>important information&#160;for&#160;you.</b>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:242px;left:149px;white-space:nowrap" class="ft1092">Keep&#160;this leaflet.&#160;You&#160;may&#160;need&#160;to&#160;read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:262px;left:149px;white-space:nowrap" class="ft10910">Your&#160;doctor&#160;will&#160;also&#160;give&#160;you a&#160;patient&#160;reminder&#160;card,&#160;which contains&#160;important&#160;safety&#160;<br/>information you need to be&#160;aware&#160;of&#160;before&#160;and during&#160;your&#160;treatment&#160;with Remsima.&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:301px;left:149px;white-space:nowrap" class="ft10910">When&#160;starting&#160;a new&#160;card,&#160;keep&#160;this card&#160;as a&#160;reference for&#160;4&#160;months&#160;after&#160;your&#160;last&#160;dose&#160;of&#160;<br/>Remsima.&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft1092">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor, pharmacist&#160;or&#160;nurse.&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:361px;left:149px;white-space:nowrap" class="ft10910">This&#160;medicine&#160;has&#160;been prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them,&#160;<br/>even if&#160;their&#160;signs of&#160;illness&#160;are the same&#160;as&#160;yours.&#160;</p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:400px;left:149px;white-space:nowrap" class="ft10910">If&#160;you get&#160;any&#160;side&#160;effects,&#160;talk&#160;to your&#160;doctor, pharmacist&#160;or&#160;nurse. This&#160;includes&#160;any possible&#160;<br/>side&#160;effects&#160;not listed&#160;in&#160;this&#160;leaflet.&#160;See section&#160;4.&#160;</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft10911">&#160;<br/><b>What&#160;is&#160;in&#160;this&#160;leaflet&#160;<br/></b>&#160;<br/>1.&#160;</p>
<p style="position:absolute;top:495px;left:139px;white-space:nowrap" class="ft1092">What&#160;Remsima&#160;is&#160;and&#160;what&#160;it&#160;is&#160;used for&#160;&#160;</p>
<p style="position:absolute;top:513px;left:106px;white-space:nowrap" class="ft1092">2.&#160;</p>
<p style="position:absolute;top:513px;left:139px;white-space:nowrap" class="ft1092">What&#160;you need&#160;to know&#160;before&#160;you use&#160;Remsima&#160;&#160;</p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft1092">3.&#160;</p>
<p style="position:absolute;top:532px;left:139px;white-space:nowrap" class="ft1092">How&#160;to use&#160;Remsima&#160;&#160;</p>
<p style="position:absolute;top:551px;left:106px;white-space:nowrap" class="ft1092">4.&#160;</p>
<p style="position:absolute;top:551px;left:139px;white-space:nowrap" class="ft1092">Possible side&#160;effects&#160;&#160;</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft1092">5.&#160;</p>
<p style="position:absolute;top:570px;left:139px;white-space:nowrap" class="ft1092">How&#160;to store&#160;Remsima&#160;</p>
<p style="position:absolute;top:589px;left:106px;white-space:nowrap" class="ft1092">6.&#160;</p>
<p style="position:absolute;top:589px;left:139px;white-space:nowrap" class="ft1092">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:608px;left:106px;white-space:nowrap" class="ft1092">7.&#160;</p>
<p style="position:absolute;top:608px;left:139px;white-space:nowrap" class="ft1092">Instructions&#160;for&#160;use&#160;</p>
<p style="position:absolute;top:627px;left:107px;white-space:nowrap" class="ft10910">&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:665px;left:149px;white-space:nowrap" class="ft1091"><b>What Remsima&#160;is&#160;and&#160;what it is&#160;used&#160;for&#160;</b></p>
<p style="position:absolute;top:684px;left:106px;white-space:nowrap" class="ft10911">&#160;<br/>Remsima&#160;contains the active&#160;substance infliximab.&#160;Infliximab is&#160;a&#160;monoclonal&#160;antibody&#160;-&#160;a&#160;type&#160;of&#160;<br/>protein&#160;that&#160;attaches to&#160;a specific&#160;target&#160;in&#160;the body&#160;called&#160;TNF&#160;(tumour&#160;necrosis&#160;factor)&#160;alpha.&#160;<br/>&#160;<br/>Remsima&#160;belongs&#160;to&#160;a&#160;group of&#160;medicines&#160;called ‘TNF&#160;blockers’. It&#160;is&#160;used&#160;in adults&#160;for&#160;the&#160;following&#160;<br/>inflammatory&#160;diseases:&#160;</p>
<p style="position:absolute;top:794px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:799px;left:149px;white-space:nowrap" class="ft1092">Rheumatoid&#160;arthritis&#160;</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:819px;left:149px;white-space:nowrap" class="ft1092">Psoriatic&#160;arthritis&#160;</p>
<p style="position:absolute;top:834px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:840px;left:149px;white-space:nowrap" class="ft1092">Ankylosing&#160;spondylitis&#160;(Bechterew’s&#160;disease)&#160;</p>
<p style="position:absolute;top:854px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:860px;left:149px;white-space:nowrap" class="ft1092">Psoriasis&#160;</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft1092">Crohn’s&#160;disease&#160;</p>
<p style="position:absolute;top:895px;left:107px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:900px;left:149px;white-space:nowrap" class="ft1092">Ulcerative colitis.&#160;</p>
<p style="position:absolute;top:919px;left:107px;white-space:nowrap" class="ft10911">&#160;<br/>Remsima&#160;works&#160;by&#160;selectively&#160;attaching&#160;to&#160;TNF&#160;alpha&#160;and&#160;blocking its&#160;action.&#160;TNF&#160;alpha&#160;is&#160;involved&#160;<br/>in inflammatory processes&#160;of&#160;the&#160;body&#160;so blocking&#160;it&#160;can reduce&#160;the&#160;inflammation&#160;in your&#160;body.&#160;<br/>&#160;<br/><b>Rheumatoid arthritis&#160;<br/></b>Rheumatoid&#160;arthritis&#160;is&#160;an&#160;inflammatory&#160;disease&#160;of&#160;the&#160;joints<i>.&#160;</i>If&#160;you have&#160;active&#160;rheumatoid arthritis&#160;<br/>you&#160;will&#160;first&#160;be&#160;given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines&#160;do not&#160;work well&#160;enough, you will&#160;be&#160;given&#160;<br/>Remsima&#160;which you will&#160;take&#160;with another&#160;medicine&#160;called&#160;methotrexate&#160;to:&#160;</p>
<p style="position:absolute;top:1067px;left:107px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:1072px;left:149px;white-space:nowrap" class="ft1092">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:1087px;left:107px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:1092px;left:149px;white-space:nowrap" class="ft1092">slow&#160;down the&#160;damage&#160;in&#160;your&#160;joints,&#160;</p>
<p style="position:absolute;top:1107px;left:107px;white-space:nowrap" class="ft1098">•&#160;</p>
<p style="position:absolute;top:1112px;left:149px;white-space:nowrap" class="ft1092">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:1131px;left:107px;white-space:nowrap" class="ft1092">&#160;</p>
</div>
<!-- Page 110 -->
<a name="110"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page110-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1100">110&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft11011"><b>Psoriatic arthritis&#160;<br/></b>Psoriatic arthritis is&#160;an&#160;inflammatory&#160;disease of&#160;the joints,&#160;usually&#160;accompanied&#160;by&#160;psoriasis.&#160;If&#160;you&#160;<br/>have active psoriatic arthritis you&#160;will&#160;first&#160;be given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines do&#160;not&#160;work&#160;<br/>well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft1102">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:186px;left:149px;white-space:nowrap" class="ft1102">slow&#160;down the&#160;damage&#160;in&#160;your&#160;joints,&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft1102">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft11011"><b>&#160;<br/>Ankylosing&#160;spondylitis (Bechterew’s disease)&#160;<br/></b>Ankylosing&#160;spondylitis&#160;is&#160;an inflammatory&#160;disease&#160;of&#160;the&#160;spine. If&#160;you have&#160;ankylosing&#160;spondylitis&#160;<br/>you will&#160;first&#160;be&#160;given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines&#160;do not&#160;work well&#160;enough, you will&#160;be&#160;given&#160;<br/>Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:321px;left:149px;white-space:nowrap" class="ft1102">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:342px;left:149px;white-space:nowrap" class="ft1102">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:361px;left:106px;white-space:nowrap" class="ft11011"><b>&#160;<br/>Psoriasis&#160;<br/></b>Psoriasis is&#160;an&#160;inflammatory disease&#160;of&#160;the&#160;skin. If&#160;you&#160;have&#160;moderate&#160;to severe&#160;plaque&#160;psoriasis, you&#160;<br/>will&#160;first&#160;be&#160;given&#160;other&#160;medicines&#160;or&#160;treatments, such&#160;as&#160;phototherapy.&#160;If&#160;these&#160;medicines&#160;or&#160;<br/>treatments&#160;do not&#160;work well&#160;enough, you will&#160;be&#160;given&#160;Remsima&#160;to reduce&#160;the&#160;signs&#160;and symptoms&#160;of&#160;<br/>your&#160;disease.&#160;<br/>&#160;<br/><b>Ulcerative colitis&#160;<br/></b>Ulcerative colitis is an&#160;inflammatory&#160;disease of&#160;the&#160;bowel.&#160;If&#160;you&#160;have ulcerative colitis&#160;you&#160;will first&#160;<br/>be&#160;given other&#160;medicines. If&#160;these&#160;medicines&#160;do not&#160;work well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to&#160;<br/>treat&#160;your&#160;disease.&#160;<br/><b>&#160;<br/>Crohn’s disease&#160;<br/></b>Crohn’s disease&#160;is an&#160;inflammatory&#160;disease&#160;of&#160;the bowel.&#160;If&#160;you&#160;have Crohn’s disease you&#160;will&#160;first&#160;be&#160;<br/>given other&#160;medicines.&#160;If&#160;these medicines&#160;do not&#160;work&#160;well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:646px;left:149px;white-space:nowrap" class="ft1102">treat&#160;active Crohn’s disease,&#160;</p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:666px;left:149px;white-space:nowrap" class="ft11010">reduce&#160;the&#160;number&#160;of&#160;abnormal&#160;openings&#160;(fistulae)&#160;between your&#160;bowel&#160;and&#160;your&#160;skin&#160;that&#160;have&#160;<br/>not&#160;been controlled&#160;by other&#160;medicines&#160;or surgery.&#160;</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft11010">&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:742px;left:149px;white-space:nowrap" class="ft1101"><b>What&#160;you&#160;need&#160;to know&#160;before&#160;you&#160;use&#160;Remsima</b>&#160;<b>&#160;</b></p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft11042">&#160;<br/><b>You must&#160;not&#160;use&#160;Remsima&#160;if&#160;<br/></b>•&#160;</p>
<p style="position:absolute;top:800px;left:149px;white-space:nowrap" class="ft11010">you&#160;are&#160;allergic&#160;to&#160;infliximab&#160;or&#160;any&#160;of&#160;the&#160;other&#160;ingredients&#160;of&#160;this&#160;medicine&#160;(listed&#160;in&#160;<br/>section&#160;6),&#160;</p>
<p style="position:absolute;top:834px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:840px;left:149px;white-space:nowrap" class="ft1102">you&#160;are&#160;allergic&#160;to&#160;proteins&#160;that&#160;come&#160;from mice,&#160;</p>
<p style="position:absolute;top:854px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:860px;left:149px;white-space:nowrap" class="ft11010">you&#160;have&#160;tuberculosis&#160;(TB)&#160;or&#160;another&#160;serious&#160;infection&#160;such as&#160;pneumonia&#160;or&#160;sepsis&#160;(serious&#160;<br/>bacterial&#160;infection of&#160;the&#160;blood),&#160;</p>
<p style="position:absolute;top:893px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft1102">you&#160;have heart&#160;failure&#160;that&#160;is moderate&#160;or&#160;severe.&#160;</p>
<p style="position:absolute;top:918px;left:107px;white-space:nowrap" class="ft11011">&#160;<br/>Do not&#160;use&#160;Remsima&#160;if&#160;any&#160;of&#160;the&#160;above&#160;applies&#160;to you. If&#160;you are&#160;not&#160;sure,&#160;talk&#160;to&#160;your&#160;doctor&#160;before&#160;<br/>you are&#160;given&#160;Remsima.&#160;<br/>&#160;<br/><b>Warnings&#160;and&#160;precautions&#160;<br/></b>Talk&#160;to your&#160;doctor&#160;before&#160;or&#160;during&#160;treatment&#160;with&#160;Remsima&#160;if&#160;you have:&#160;<br/>&#160;<br/>Had treatment&#160;with&#160;any&#160;medicine&#160;containing&#160;infliximab before&#160;<br/>&#160;</p>
<p style="position:absolute;top:1085px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:1090px;left:149px;white-space:nowrap" class="ft11010">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;have&#160;had&#160;treatment with&#160;medicines&#160;containing&#160;infliximab&#160;in&#160;the&#160;past and&#160;<br/>are now&#160;starting&#160;Remsima&#160;treatment&#160;again.&#160;</p>
<p style="position:absolute;top:1124px;left:106px;white-space:nowrap" class="ft1108">•&#160;</p>
<p style="position:absolute;top:1129px;left:149px;white-space:nowrap" class="ft11010">If&#160;you have&#160;had&#160;a&#160;break&#160;in&#160;your&#160;treatment&#160;with&#160;infliximab of&#160;more&#160;than 16 weeks, there&#160;is&#160;a&#160;<br/>higher&#160;risk&#160;for&#160;allergic&#160;reactions&#160;when you&#160;start&#160;the&#160;treatment&#160;again.&#160;</p>
</div>
<!-- Page 111 -->
<a name="111"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page111-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1110">111&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft11114">&#160;<br/>Local&#160;injection&#160;site&#160;reactions&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft11111">Some&#160;patients&#160;receiving&#160;infliximab&#160;via&#160;injection under&#160;the&#160;skin&#160;have&#160;experienced&#160;local injection&#160;<br/>site&#160;reactions. Signs&#160;of&#160;a&#160;local injection&#160;site&#160;reaction can&#160;include&#160;redness, pain,&#160;itching, swelling,&#160;<br/>hardness,&#160;bruising, bleeding, cold&#160;sensation,&#160;tingling&#160;sensation, irritation,&#160;rash,&#160;ulcer, hives,&#160;<br/>blisters and&#160;scab&#160;on the&#160;skin of&#160;the&#160;injection&#160;site.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft1112">Most&#160;of&#160;these&#160;reactions are mild&#160;to&#160;moderate&#160;and&#160;mostly&#160;resolve&#160;on their&#160;own within a&#160;day.&#160;</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft11111">&#160;<br/>Infections&#160;<br/>&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:301px;left:149px;white-space:nowrap" class="ft11110">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;an infection even if&#160;it&#160;is&#160;a&#160;very&#160;<br/>minor&#160;one.&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft11110">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given&#160;Remsima&#160;if&#160;you have&#160;ever&#160;lived in&#160;or&#160;travelled&#160;to an&#160;area&#160;<br/>where&#160;infections called&#160;histoplasmosis,&#160;coccidioidomycosis,&#160;or&#160;blastomycosis are&#160;common.&#160;<br/>These&#160;infections are caused&#160;by&#160;specific&#160;types of&#160;fungi&#160;that&#160;can&#160;affect&#160;the&#160;lungs or&#160;other&#160;parts&#160;of&#160;<br/>your&#160;body.&#160;</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:418px;left:149px;white-space:nowrap" class="ft11110">You may&#160;get&#160;infections&#160;more&#160;easily when you&#160;are&#160;being treated with Remsima. If&#160;you are&#160;65&#160;<br/>years&#160;of&#160;age&#160;or&#160;older, you have&#160;a&#160;greater&#160;risk.&#160;</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:457px;left:149px;white-space:nowrap" class="ft11110">These&#160;infections&#160;may&#160;be&#160;serious&#160;and include&#160;tuberculosis, infections&#160;caused&#160;by&#160;viruses, fungi,&#160;<br/>bacteria or&#160;other&#160;organisms&#160;in&#160;the environment&#160;and&#160;sepsis&#160;that&#160;may&#160;be life-threatening.&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft11111">Tell&#160;your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;signs&#160;of&#160;infection during treatment&#160;with Remsima. Signs&#160;<br/>include&#160;fever,&#160;cough, flu-like&#160;signs,&#160;feeling unwell,&#160;red or&#160;hot&#160;skin, wounds&#160;or&#160;dental&#160;problems. Your&#160;<br/>doctor&#160;may recommend temporarily&#160;stopping&#160;Remsima.&#160;<br/>&#160;<br/>Tuberculosis&#160;(TB)&#160;<br/>&#160;</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:610px;left:149px;white-space:nowrap" class="ft11110">It&#160;is&#160;very&#160;important&#160;that&#160;you tell&#160;your&#160;doctor&#160;if&#160;you have&#160;ever&#160;had TB&#160;or&#160;if&#160;you have&#160;been in&#160;<br/>close&#160;contact&#160;with&#160;someone&#160;who has&#160;had or&#160;has&#160;TB.&#160;</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:649px;left:149px;white-space:nowrap" class="ft11111">Your&#160;doctor&#160;will&#160;test&#160;you&#160;to&#160;see&#160;if&#160;you have&#160;TB. Cases&#160;of&#160;TB&#160;have&#160;been reported&#160;in&#160;patients&#160;<br/>treated&#160;with&#160;infliximab,&#160;even in patients&#160;who have&#160;already been treated with&#160;medicines&#160;for&#160;TB.&#160;<br/>Your&#160;doctor&#160;will&#160;record&#160;these&#160;tests&#160;on your&#160;patient&#160;reminder&#160;card.&#160;</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:707px;left:149px;white-space:nowrap" class="ft11110">If&#160;your&#160;doctor&#160;feels&#160;that&#160;you are&#160;at&#160;risk for&#160;TB, you may be&#160;treated&#160;with&#160;medicines&#160;for&#160;TB&#160;before&#160;<br/>you are&#160;given Remsima.&#160;</p>
<p style="position:absolute;top:745px;left:106px;white-space:nowrap" class="ft11114">Tell&#160;your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;signs&#160;of&#160;TB&#160;during&#160;treatment&#160;with Remsima. Signs&#160;include&#160;<br/>persistent&#160;cough, weight&#160;loss, feeling&#160;tired,&#160;fever,&#160;night&#160;sweats.&#160;<br/>&#160;<br/>Hepatitis B&#160;virus&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:841px;left:149px;white-space:nowrap" class="ft11110">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are using&#160;Remsima&#160;if&#160;you&#160;are a&#160;carrier&#160;of&#160;hepatitis B&#160;or&#160;have ever&#160;<br/>had it.&#160;</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft1112">Tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you might&#160;be&#160;at&#160;risk&#160;of&#160;contracting&#160;hepatitis&#160;B.&#160;</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:900px;left:149px;white-space:nowrap" class="ft1112">Your&#160;doctor&#160;should&#160;test&#160;you for&#160;hepatitis&#160;B&#160;virus.&#160;</p>
<p style="position:absolute;top:915px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:920px;left:149px;white-space:nowrap" class="ft11110">Treatment&#160;with&#160;TNF&#160;blockers&#160;such&#160;as Remsima may result&#160;in reactivation of&#160;hepatitis&#160;B&#160;virus&#160;in&#160;<br/>patients&#160;who carry this&#160;virus, which&#160;can&#160;be&#160;life-threatening&#160;in&#160;some cases.&#160;</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:959px;left:149px;white-space:nowrap" class="ft11110">If&#160;you experience&#160;reactivation of&#160;hepatitis&#160;B, your&#160;doctor&#160;may need&#160;to stop your&#160;treatment&#160;and&#160;<br/>may&#160;give you&#160;medicines such&#160;as effective&#160;antiviral&#160;therapy&#160;with&#160;supportive&#160;treatment.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft11111">&#160;<br/>Heart&#160;problems&#160;<br/>&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:1056px;left:149px;white-space:nowrap" class="ft1112">Tell&#160;your&#160;doctor&#160;if&#160;you have&#160;any heart&#160;problems, such&#160;as&#160;mild heart&#160;failure.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1118">•&#160;</p>
<p style="position:absolute;top:1076px;left:149px;white-space:nowrap" class="ft1112">Your&#160;doctor&#160;will&#160;want&#160;to closely&#160;monitor&#160;your&#160;heart.&#160;</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft11111">Tell&#160;your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;new&#160;or&#160;worsening signs&#160;of&#160;heart&#160;failure&#160;during&#160;treatment&#160;with&#160;<br/>Remsima. Signs&#160;include&#160;shortness&#160;of&#160;breath or&#160;swelling of&#160;your&#160;feet.&#160;<br/>&#160;</p>
</div>
<!-- Page 112 -->
<a name="112"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page112-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1120">112&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft11211">Cancer&#160;and lymphoma&#160;<br/>&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft11210">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;or&#160;have&#160;ever&#160;had lymphoma&#160;(a&#160;type&#160;<br/>of&#160;blood cancer)&#160;or&#160;any&#160;other&#160;cancer.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:167px;left:149px;white-space:nowrap" class="ft11210">Patients&#160;with severe&#160;rheumatoid arthritis, who have&#160;had the&#160;disease&#160;for&#160;a&#160;long&#160;time, may be&#160;at&#160;<br/>higher&#160;risk&#160;of&#160;developing lymphoma.&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft11210">Patients&#160;taking Remsima&#160;may have&#160;an&#160;increased&#160;risk of&#160;developing lymphoma&#160;or&#160;another&#160;<br/>cancer.&#160;</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:246px;left:149px;white-space:nowrap" class="ft11211">Some patients&#160;who&#160;have received&#160;TNF-blockers, including&#160;infliximab have&#160;developed a&#160;rare&#160;<br/>type&#160;of&#160;cancer&#160;called hepatosplenic&#160;T-cell&#160;lymphoma.&#160;Of&#160;these patients,&#160;most&#160;were teenage&#160;boys&#160;<br/>or&#160;young men and&#160;most&#160;had&#160;either&#160;Crohn’s&#160;disease&#160;or&#160;ulcerative&#160;colitis. This&#160;type&#160;of&#160;cancer&#160;has&#160;<br/>usually&#160;resulted&#160;in death.&#160;Almost&#160;all&#160;patients&#160;had&#160;also received&#160;medicines&#160;containing&#160;<br/>azathioprine&#160;or&#160;mercaptopurine&#160;in&#160;addition to TNF-blockers.&#160;&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:342px;left:149px;white-space:nowrap" class="ft11210">Some patients&#160;treated&#160;with&#160;infliximab&#160;have developed&#160;certain&#160;kinds of&#160;skin&#160;cancer.&#160;If&#160;there are&#160;<br/>any changes&#160;in your&#160;skin or&#160;growths&#160;on&#160;the&#160;skin&#160;during&#160;or&#160;after&#160;therapy,&#160;tell&#160;your&#160;doctor.&#160;</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:381px;left:149px;white-space:nowrap" class="ft11210">Some&#160;women&#160;being treated&#160;for&#160;rheumatoid arthritis&#160;with infliximab&#160;have&#160;developed cervical&#160;<br/>cancer. For&#160;women&#160;taking&#160;Remsima&#160;including those&#160;over&#160;60&#160;years&#160;of&#160;age, your&#160;doctor&#160;may&#160;<br/>recommend&#160;regular&#160;screening&#160;for&#160;cervical&#160;cancer.&#160;</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft11214">&#160;<br/>Lung disease&#160;or&#160;heavy smoking&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:496px;left:149px;white-space:nowrap" class="ft11210">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;a&#160;lung&#160;disease&#160;called chronic&#160;<br/>obstructive&#160;pulmonary disease&#160;(COPD)&#160;or&#160;if&#160;you are&#160;a&#160;heavy&#160;smoker.&#160;</p>
<p style="position:absolute;top:530px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:535px;left:149px;white-space:nowrap" class="ft11210">Patients&#160;with COPD&#160;and patients&#160;who are&#160;heavy smokers&#160;may have&#160;a&#160;higher&#160;risk of&#160;developing&#160;<br/>cancer&#160;with&#160;Remsima treatment.&#160;</p>
<p style="position:absolute;top:573px;left:106px;white-space:nowrap" class="ft11214">&#160;<br/>Nervous system&#160;disease&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:631px;left:149px;white-space:nowrap" class="ft11210">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;or&#160;have&#160;ever&#160;had a&#160;problem&#160;that&#160;<br/>affects&#160;your&#160;nervous&#160;system.&#160;This&#160;includes&#160;multiple&#160;sclerosis,&#160;Guillain-Barré&#160;syndrome, if&#160;you&#160;<br/>have&#160;fits&#160;or&#160;have&#160;been diagnosed with&#160;‘optic&#160;neuritis’.&#160;</p>
<p style="position:absolute;top:688px;left:106px;white-space:nowrap" class="ft11214">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;symptoms&#160;of&#160;a&#160;nerve&#160;disease&#160;during treatment&#160;with&#160;Remsima.&#160;<br/>Signs&#160;include&#160;changes&#160;in your&#160;vision, weakness&#160;in&#160;your&#160;arms&#160;or&#160;legs, numbness&#160;or&#160;tingling in any&#160;part&#160;<br/>of&#160;your&#160;body.&#160;<br/>&#160;<br/>Abnormal&#160;skin&#160;openings&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:803px;left:149px;white-space:nowrap" class="ft11210">Tell&#160;your&#160;doctor&#160;if&#160;you have&#160;any abnormal&#160;skin openings&#160;(fistulae)&#160;before&#160;you&#160;are&#160;given&#160;<br/>Remsima.&#160;</p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft11210">&#160;<br/>Vaccinations&#160;<br/>&#160;</p>
<p style="position:absolute;top:894px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft1122">Talk&#160;to your&#160;doctor&#160;if&#160;you&#160;recently&#160;have&#160;had&#160;or&#160;are due&#160;to&#160;have a vaccine.&#160;</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:919px;left:149px;white-space:nowrap" class="ft11210">You should receive&#160;recommended vaccinations&#160;before&#160;starting Remsima&#160;treatment. You&#160;may&#160;<br/>receive&#160;some vaccines&#160;during&#160;treatment&#160;with&#160;Remsima&#160;but&#160;you&#160;should&#160;not&#160;receive&#160;live vaccines&#160;<br/>(vaccines that&#160;contain&#160;a living but&#160;weakened infectious&#160;agent)&#160;while&#160;using Remsima&#160;because&#160;<br/>they&#160;may&#160;cause infections.&#160;</p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:996px;left:149px;white-space:nowrap" class="ft11211">If&#160;you received Remsima&#160;while&#160;you were&#160;pregnant, your&#160;baby may also be&#160;at&#160;higher&#160;risk&#160;for&#160;<br/>getting an infection&#160;as a&#160;result&#160;of&#160;receiving&#160;a&#160;live vaccine&#160;during&#160;the&#160;first&#160;year&#160;of&#160;life.&#160;It is&#160;<br/>important&#160;that&#160;you tell&#160;your&#160;baby's&#160;doctors&#160;and other&#160;health care&#160;professionals&#160;about&#160;your&#160;<br/>Remsima&#160;use&#160;so&#160;they&#160;can&#160;decide&#160;when your&#160;baby should receive&#160;any vaccine,&#160;including&#160;live&#160;<br/>vaccines&#160;such&#160;as&#160;the&#160;BCG&#160;vaccine&#160;(used&#160;to&#160;prevent&#160;tuberculosis).&#160;&#160;</p>
<p style="position:absolute;top:1087px;left:106px;white-space:nowrap" class="ft1128">•&#160;</p>
<p style="position:absolute;top:1092px;left:149px;white-space:nowrap" class="ft11211">If&#160;you are&#160;breast-feeding,&#160;it&#160;is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;<br/>professionals&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;your&#160;baby is&#160;given any&#160;vaccine.&#160;For&#160;more&#160;<br/>information see&#160;section&#160;on Pregnancy&#160;and&#160;breast-feeding.&#160;</p>
<p style="position:absolute;top:1149px;left:106px;white-space:nowrap" class="ft1122">&#160;</p>
</div>
<!-- Page 113 -->
<a name="113"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page113-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1130">113&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft11311">Therapeutic infectious&#160;agents&#160;<br/>&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft11310">Talk to&#160;your&#160;doctor&#160;if&#160;you&#160;have recently&#160;received&#160;or&#160;are&#160;scheduled&#160;to&#160;receive treatment&#160;with&#160;a&#160;<br/>therapeutic infectious&#160;agent&#160;(such&#160;as BCG&#160;instillation&#160;used&#160;for&#160;the&#160;treatment&#160;of&#160;cancer).&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft11311">&#160;<br/>Operations&#160;or&#160;dental&#160;procedures&#160;<br/>&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft1132">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;going to&#160;have&#160;any&#160;operations or&#160;dental&#160;procedures.&#160;</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft11310">Tell&#160;your&#160;surgeon&#160;or&#160;dentist&#160;that&#160;you&#160;are&#160;having&#160;treatment&#160;with Remsima&#160;by&#160;showing them&#160;your&#160;<br/>patient&#160;reminder&#160;card.&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft11314">&#160;<br/>Liver&#160;problems&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft1132">Some&#160;patients&#160;receiving infliximab&#160;have&#160;developed serious&#160;liver&#160;problems.&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:361px;left:149px;white-space:nowrap" class="ft11310">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;symptoms&#160;of&#160;liver&#160;problems&#160;during treatment&#160;with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;yellowing of&#160;the&#160;skin and eyes, dark-brown&#160;coloured urine, pain or&#160;<br/>swelling in the&#160;upper&#160;right&#160;side&#160;of&#160;the&#160;stomach&#160;area, joint&#160;pain,&#160;skin&#160;rashes,&#160;or fever.&#160;</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft11314">&#160;<br/>Low blood&#160;counts&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:476px;left:149px;white-space:nowrap" class="ft11310">In some&#160;patients&#160;receiving&#160;infliximab, the&#160;body&#160;may not&#160;make&#160;enough&#160;of&#160;the&#160;blood&#160;cells&#160;that&#160;<br/>help fight&#160;infections&#160;or&#160;help&#160;stop bleeding.&#160;&#160;</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:515px;left:149px;white-space:nowrap" class="ft11310">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;symptoms&#160;of&#160;low&#160;blood counts&#160;during&#160;treatment with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;persistent&#160;fever,&#160;bleeding&#160;or&#160;bruising&#160;more&#160;easily,&#160;small&#160;red or&#160;purple&#160;<br/>spots&#160;caused by bleeding under&#160;the&#160;skin, or&#160;looking pale.&#160;</p>
<p style="position:absolute;top:572px;left:106px;white-space:nowrap" class="ft11311">&#160;<br/>Immune&#160;system disorder&#160;<br/>&#160;</p>
<p style="position:absolute;top:625px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:630px;left:149px;white-space:nowrap" class="ft11310">Some patients&#160;receiving&#160;infliximab&#160;have&#160;developed symptoms&#160;of&#160;an&#160;immune system&#160;disorder&#160;<br/>called&#160;lupus.&#160;&#160;</p>
<p style="position:absolute;top:664px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:669px;left:149px;white-space:nowrap" class="ft11310">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you develop symptoms&#160;of&#160;lupus&#160;during&#160;treatment with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;joint pain&#160;or&#160;a&#160;rash&#160;on&#160;cheeks&#160;or&#160;arms that&#160;is&#160;sensitive&#160;to&#160;the&#160;sun.&#160;</p>
<p style="position:absolute;top:707px;left:106px;white-space:nowrap" class="ft11311">&#160;<br/><b>Children and adolescents&#160;<br/></b>Do&#160;not&#160;give&#160;this&#160;medicine to&#160;children&#160;and&#160;adolescents&#160;under&#160;18&#160;years&#160;of&#160;age because there are no&#160;data&#160;<br/>that&#160;show&#160;that&#160;this&#160;medicine&#160;is&#160;safe&#160;and&#160;works&#160;in&#160;this&#160;age&#160;group.&#160;&#160;<br/><b>&#160;<br/>Other medicines&#160;and&#160;Remsima</b>&#160;<br/>Patients who&#160;have&#160;inflammatory&#160;diseases&#160;already&#160;take&#160;medicines&#160;to&#160;treat their&#160;problem.&#160;These&#160;<br/>medicines&#160;may cause&#160;side&#160;effects. Your&#160;doctor&#160;will&#160;advise&#160;you what&#160;other&#160;medicines&#160;you&#160;must&#160;keep&#160;<br/>using while&#160;you&#160;are&#160;having&#160;Remsima.&#160;<br/>&#160;<br/>Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;using,&#160;have&#160;recently&#160;used&#160;or&#160;might&#160;use&#160;any other&#160;medicines, including any&#160;<br/>other&#160;medicines&#160;to&#160;treat&#160;Crohn’s disease,&#160;ulcerative&#160;colitis,&#160;rheumatoid arthritis,&#160;ankylosing&#160;<br/>spondylitis,&#160;psoriatic arthritis or&#160;psoriasis&#160;or&#160;medicines&#160;obtained without&#160;a&#160;prescription,&#160;such as&#160;<br/>vitamins&#160;and&#160;herbal&#160;medicines.&#160;&#160;<br/>&#160;<br/>In&#160;particular, tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;using any of&#160;the&#160;following&#160;medicines:&#160;</p>
<p style="position:absolute;top:1006px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:1012px;left:149px;white-space:nowrap" class="ft1132">Medicines&#160;that&#160;affect&#160;your&#160;immune system.&#160;</p>
<p style="position:absolute;top:1026px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:1032px;left:149px;white-space:nowrap" class="ft1132">Kineret&#160;(which contains&#160;anakinra). Remsima&#160;and Kineret&#160;should not&#160;be&#160;used&#160;together.&#160;</p>
<p style="position:absolute;top:1047px;left:106px;white-space:nowrap" class="ft1138">•&#160;</p>
<p style="position:absolute;top:1052px;left:149px;white-space:nowrap" class="ft1132">Orencia (which&#160;contains abatacept).&#160;Remsima and&#160;Orencia&#160;should not&#160;be&#160;used&#160;together.&#160;</p>
<p style="position:absolute;top:1071px;left:107px;white-space:nowrap" class="ft11311">While using&#160;Remsima&#160;you&#160;should not&#160;receive&#160;live&#160;vaccines. If&#160;you were&#160;using&#160;Remsima&#160;during&#160;<br/>pregnancy&#160;or&#160;if&#160;you are&#160;receiving&#160;Remsima&#160;while breast-feeding, tell&#160;your&#160;baby’s&#160;doctor&#160;and other&#160;<br/>health&#160;care professionals&#160;caring&#160;for&#160;your&#160;baby&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;the&#160;baby&#160;receives&#160;any&#160;<br/>vaccines.&#160;<br/>&#160;</p>
</div>
<!-- Page 114 -->
<a name="114"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page114-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1140">114&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft11411">If&#160;you are&#160;not&#160;sure&#160;if&#160;any of&#160;the&#160;above&#160;applies&#160;to&#160;you,&#160;talk&#160;to your&#160;doctor, pharmacist&#160;or&#160;nurse&#160;before&#160;<br/>using&#160;Remsima.&#160;<br/>&#160;<br/><b>Pregnancy,&#160;breast-feeding&#160;and&#160;fertility&#160;</b></p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft1148">•&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft11411">If&#160;you are&#160;pregnant&#160;or&#160;breast-feeding,&#160;think you&#160;may be&#160;pregnant&#160;or&#160;are&#160;planning to&#160;have&#160;a&#160;baby,&#160;<br/>ask your&#160;doctor&#160;for&#160;advice&#160;before&#160;taking this&#160;medicine.&#160;Remsima&#160;should&#160;only&#160;be&#160;used during&#160;<br/>pregnancy&#160;or&#160;while&#160;breast-feeding&#160;if&#160;your&#160;doctor&#160;feels&#160;it&#160;is&#160;necessary&#160;for&#160;you.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1148">•&#160;</p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft11410">You should avoid getting pregnant&#160;when you&#160;are&#160;being&#160;treated with Remsima&#160;and&#160;for&#160;6&#160;months&#160;<br/>after&#160;you stop being&#160;treated&#160;with&#160;it. Discuss&#160;the&#160;use&#160;of&#160;contraception during this&#160;time&#160;with your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft1148">•&#160;</p>
<p style="position:absolute;top:282px;left:149px;white-space:nowrap" class="ft11410">If&#160;you received Remsima&#160;during&#160;your&#160;pregnancy, your&#160;baby&#160;may have&#160;a&#160;higher&#160;risk for&#160;getting&#160;<br/>an infection.&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1148">•&#160;</p>
<p style="position:absolute;top:321px;left:149px;white-space:nowrap" class="ft11411">It&#160;is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;professionals&#160;about&#160;your&#160;<br/>Remsima&#160;use&#160;before&#160;your&#160;baby is&#160;given any vaccine. If&#160;you received&#160;Remsima while pregnant,&#160;<br/>giving BCG&#160;vaccine&#160;(used&#160;to prevent&#160;tuberculosis)&#160;to your&#160;baby within&#160;12&#160;months&#160;after&#160;birth&#160;<br/>may&#160;result&#160;in&#160;infection with&#160;serious&#160;complications,&#160;including death. Live&#160;vaccines&#160;such as&#160;the&#160;<br/>BCG&#160;vaccine&#160;should&#160;not&#160;be&#160;given&#160;to your&#160;baby&#160;within&#160;12&#160;months&#160;after&#160;birth, unless&#160;your&#160;baby’s&#160;<br/>doctor&#160;recommends&#160;otherwise.&#160;For&#160;more&#160;information see&#160;section on&#160;vaccination.&#160;</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1148">•&#160;</p>
<p style="position:absolute;top:436px;left:149px;white-space:nowrap" class="ft11410">If&#160;you are&#160;breast-feeding, it&#160;is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;<br/>professionals&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;your&#160;baby is&#160;given any&#160;vaccine.&#160;Live vaccines&#160;<br/>should not&#160;be&#160;given&#160;to your&#160;baby while&#160;you are&#160;breast-feeding unless&#160;your&#160;baby’s&#160;doctor&#160;<br/>recommends otherwise.&#160;</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft1148">•&#160;</p>
<p style="position:absolute;top:513px;left:149px;white-space:nowrap" class="ft11411">Severely&#160;decreased numbers&#160;of&#160;white&#160;blood cells&#160;have&#160;been&#160;reported in&#160;infants&#160;born to&#160;women&#160;<br/>treated with infliximab during pregnancy. If&#160;your&#160;baby&#160;has&#160;continual&#160;fevers&#160;or&#160;infections,&#160;<br/>contact&#160;your&#160;baby’s&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft11410">&#160;<br/><b>Driving and&#160;using&#160;machines&#160;<br/></b>Remsima&#160;is&#160;not&#160;likely&#160;to affect&#160;your&#160;ability&#160;to drive&#160;or&#160;use&#160;tools&#160;or&#160;machines. If&#160;you feel&#160;tired, dizzy, or&#160;<br/>unwell&#160;after&#160;having&#160;Remsima, do&#160;not&#160;drive&#160;or&#160;use&#160;any&#160;tools&#160;or&#160;machines.&#160;<br/>&#160;<br/><b>Remsima contains&#160;sodium&#160;and&#160;sorbitol&#160;<br/></b>This medicine contains&#160;less&#160;than&#160;1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;dose, i.e. essentially&#160;‘sodium-free’&#160;and&#160;<br/>45 mg&#160;sorbitol&#160;in each 120&#160;mg dose.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:760px;left:149px;white-space:nowrap" class="ft1141"><b>How&#160;to&#160;use&#160;Remsima&#160;</b></p>
<p style="position:absolute;top:779px;left:106px;white-space:nowrap" class="ft11411">&#160;<br/>Always use&#160;this&#160;medicine&#160;exactly as&#160;your&#160;doctor&#160;has&#160;told you. Check with&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;not&#160;<br/>sure.&#160;&#160;<br/>&#160;<br/><b>Rheumatoid arthritis&#160;<br/></b>Your&#160;doctor&#160;will start your&#160;treatment with&#160;or&#160;without&#160;two&#160;Remsima&#160;intravenous&#160;infusion&#160;doses&#160;of&#160;3&#160;mg&#160;<br/>for&#160;every kg of&#160;body&#160;weight&#160;(given&#160;to you into&#160;a&#160;vein,&#160;usually&#160;in your&#160;arm, over&#160;a&#160;period of&#160;2 hours).&#160;If&#160;<br/>Remsima&#160;intravenous infusion&#160;doses are given&#160;to&#160;start&#160;the treatment,&#160;they&#160;are&#160;administered&#160;2&#160;weeks&#160;<br/>apart&#160;via&#160;intravenous&#160;infusion.&#160;After&#160;4 weeks&#160;from&#160;the&#160;last&#160;intravenous&#160;infusion, you will&#160;be&#160;given&#160;<br/>Remsima&#160;via&#160;injection under&#160;the&#160;skin&#160;(subcutaneous&#160;injection).&#160;&#160;<br/>The usual&#160;recommended&#160;dose&#160;of&#160;Remsima&#160;subcutaneous injection&#160;is&#160;120&#160;mg&#160;once&#160;every&#160;2&#160;weeks&#160;<br/>regardless&#160;of&#160;weight.&#160;<br/><b>&#160;<br/>Psoriatic arthritis,&#160;ankylosing&#160;spondylitis&#160;(Bechterew’s disease)&#160;and&#160;psoriasis&#160;&#160;<br/></b>Your&#160;doctor&#160;will&#160;start&#160;your&#160;treatment&#160;with&#160;two Remsima&#160;intravenous&#160;infusion&#160;doses&#160;of&#160;5&#160;mg for&#160;every&#160;<br/>kg of&#160;body weight&#160;(given&#160;to&#160;you into a&#160;vein, usually&#160;in&#160;your&#160;arm, over&#160;a&#160;period of&#160;2 hours). They are&#160;<br/>administered&#160;2&#160;weeks&#160;apart&#160;via&#160;intravenous&#160;infusion.&#160;After&#160;4 weeks&#160;from&#160;the&#160;last&#160;intravenous&#160;infusion,&#160;<br/>you will&#160;be&#160;given Remsima&#160;via&#160;injection&#160;under&#160;the&#160;skin&#160;(subcutaneous&#160;injection).&#160;&#160;<br/>The usual&#160;recommended&#160;dose of&#160;Remsima&#160;subcutaneous injection&#160;is 120&#160;mg&#160;once&#160;every&#160;2&#160;weeks&#160;<br/>regardless&#160;of&#160;weight.&#160;&#160;<br/><b>&#160;</b></p>
</div>
<!-- Page 115 -->
<a name="115"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft11554{font-size:17px;font-family:HTETHZ+Calibri;color:#000000;}
	.ft11555{font-size:14px;font-family:Verdana;color:#000000;}
-->
</style>
<div id="page115-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1150">115&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1155"><b>Crohn’s disease and&#160;ulcerative colitis&#160;<br/></b>Your&#160;doctor&#160;will&#160;start&#160;your&#160;treatment&#160;with&#160;two Remsima&#160;intravenous&#160;infusion&#160;doses&#160;of&#160;5&#160;mg for&#160;every&#160;<br/>kg of&#160;body weight&#160;(given&#160;to&#160;you into a&#160;vein, usually&#160;in&#160;your&#160;arm, over&#160;a&#160;period of&#160;2 hours). They are&#160;<br/>administered 2&#160;weeks&#160;apart&#160;via&#160;intravenous&#160;infusion.&#160;After&#160;4&#160;weeks&#160;from&#160;the&#160;last&#160;intravenous&#160;infusion,&#160;<br/>you will&#160;be&#160;given Remsima&#160;via&#160;injection&#160;under&#160;the&#160;skin&#160;(subcutaneous&#160;injection).&#160;&#160;<br/>The usual&#160;recommended&#160;dose of&#160;Remsima&#160;subcutaneous injection&#160;is 120&#160;mg once&#160;every 2 weeks&#160;<br/>regardless&#160;of&#160;weight.&#160;<br/><b>&#160;<br/>How&#160;Remsima&#160;is given&#160;</b></p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft1158">•&#160;</p>
<p style="position:absolute;top:261px;left:149px;white-space:nowrap" class="ft11511">Remsima&#160;120 mg&#160;solution for&#160;injection&#160;is&#160;administered&#160;by injection under&#160;the&#160;skin&#160;<br/>(subcutaneous&#160;use)&#160;only.&#160;It&#160;is important&#160;to&#160;check&#160;the product&#160;labels to&#160;ensure&#160;that&#160;the correct&#160;<br/>formulation is&#160;being&#160;given as&#160;prescribed.&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1158">•&#160;</p>
<p style="position:absolute;top:319px;left:149px;white-space:nowrap" class="ft11511">For&#160;patients&#160;with rheumatoid arthritis, your&#160;doctor&#160;may&#160;start&#160;your&#160;Remsima&#160;treatment&#160;with or&#160;<br/>without&#160;two&#160;Remsima&#160;intravenous&#160;infusion doses.&#160;For&#160;patients&#160;with&#160;Crohn’s&#160;disease, ulcerative&#160;<br/>colitis, ankylosing spondylitis,&#160;psoriatic&#160;arthritis&#160;or&#160;psoriasis, two Remsima&#160;infusion doses&#160;will&#160;<br/>be&#160;given to&#160;start your&#160;Remsima&#160;treatment.&#160;</p>
<p style="position:absolute;top:391px;left:106px;white-space:nowrap" class="ft1158">•&#160;</p>
<p style="position:absolute;top:396px;left:149px;white-space:nowrap" class="ft11510">If&#160;Remsima&#160;treatment is&#160;initiated&#160;without&#160;two&#160;Remsima&#160;intravenous&#160;infusion&#160;doses,&#160;the table&#160;<br/>below&#160;shows&#160;how&#160;often&#160;you will&#160;usually have&#160;this&#160;medicine&#160;after&#160;your&#160;first&#160;dose.&#160;</p>
<p style="position:absolute;top:434px;left:160px;white-space:nowrap" class="ft1152">&#160;</p>
<p style="position:absolute;top:455px;left:158px;white-space:nowrap" class="ft1152">2nd&#160;dose&#160;</p>
<p style="position:absolute;top:455px;left:419px;white-space:nowrap" class="ft1152">1&#160;week&#160;after your 1st&#160;dose&#160;</p>
<p style="position:absolute;top:475px;left:158px;white-space:nowrap" class="ft1152">3rd&#160;dose&#160;</p>
<p style="position:absolute;top:475px;left:419px;white-space:nowrap" class="ft1152">2&#160;weeks after&#160;your&#160;1st&#160;dose&#160;</p>
<p style="position:absolute;top:495px;left:158px;white-space:nowrap" class="ft1152">4th&#160;dose&#160;</p>
<p style="position:absolute;top:495px;left:419px;white-space:nowrap" class="ft1152">3&#160;weeks&#160;after&#160;your&#160;1st&#160;dose&#160;</p>
<p style="position:absolute;top:516px;left:158px;white-space:nowrap" class="ft1152">5th&#160;dose&#160;</p>
<p style="position:absolute;top:516px;left:419px;white-space:nowrap" class="ft1152">4&#160;weeks&#160;after&#160;your&#160;1st&#160;dose&#160;</p>
<p style="position:absolute;top:536px;left:158px;white-space:nowrap" class="ft1152">Further&#160;doses&#160;</p>
<p style="position:absolute;top:536px;left:419px;white-space:nowrap" class="ft11511">6&#160;weeks&#160;after&#160;your&#160;1st&#160;dose&#160;and&#160;every&#160;2&#160;weeks&#160;<br/>thereafter&#160;</p>
<p style="position:absolute;top:575px;left:106px;white-space:nowrap" class="ft1152">&#160;</p>
<p style="position:absolute;top:590px;left:106px;white-space:nowrap" class="ft1158">•&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft11510">If&#160;two Remsima&#160;intravenous&#160;infusion doses&#160;are&#160;given&#160;by your&#160;doctor&#160;or&#160;nurse&#160;to&#160;start&#160;the&#160;<br/>treatment,&#160;they will&#160;be&#160;given 2 weeks&#160;apart&#160;and&#160;the&#160;first Remsima&#160;subcutaneous&#160;injection&#160;will&#160;<br/>be&#160;given&#160;4&#160;weeks after&#160;the last&#160;intravenous&#160;infusion&#160;followed by&#160;Remsima&#160;subcutaneous&#160;<br/>injections&#160;given every&#160;2 weeks.&#160;&#160;</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft1158">•&#160;</p>
<p style="position:absolute;top:672px;left:149px;white-space:nowrap" class="ft11510">The&#160;first&#160;subcutaneous&#160;injection&#160;of&#160;Remsima&#160;will&#160;be&#160;administered under&#160;the&#160;supervision of&#160;your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft1158">•&#160;</p>
<p style="position:absolute;top:712px;left:149px;white-space:nowrap" class="ft11510">After proper&#160;training,&#160;if&#160;you feel&#160;you&#160;are&#160;well-trained&#160;and confident&#160;to&#160;inject&#160;Remsima&#160;yourself,&#160;<br/>your&#160;doctor&#160;may&#160;allow&#160;you&#160;to&#160;inject&#160;subsequent&#160;doses&#160;of&#160;Remsima&#160;yourself&#160;at home.&#160;</p>
<p style="position:absolute;top:745px;left:106px;white-space:nowrap" class="ft1158">•&#160;</p>
<p style="position:absolute;top:751px;left:149px;white-space:nowrap" class="ft11510">Talk&#160;to your&#160;doctor&#160;if&#160;you&#160;have&#160;any questions&#160;about&#160;giving yourself&#160;an&#160;injection.&#160;You will&#160;find&#160;<br/>detailed&#160;<b>“Instructions for Use”</b>&#160;at&#160;the end&#160;of&#160;this leaflet.&#160;&#160;</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft1155">&#160;<br/><b>If&#160;you&#160;use&#160;more&#160;Remsima&#160;than&#160;you&#160;should&#160;<br/></b>If&#160;you have&#160;used more&#160;Remsima&#160;than you should&#160;(either&#160;by injecting&#160;too&#160;much on&#160;a&#160;single&#160;occasion or&#160;<br/>by&#160;using it&#160;too frequently),&#160;talk to&#160;a&#160;doctor,&#160;pharmacist&#160;or&#160;nurse&#160;immediately.&#160;Always&#160;have&#160;the&#160;outer&#160;<br/>carton of&#160;the&#160;medicine&#160;with&#160;you,&#160;even&#160;if&#160;it&#160;is&#160;empty.&#160;&#160;<br/>&#160;<br/><b>If&#160;you&#160;forget&#160;to&#160;use&#160;Remsima&#160;<br/>&#160;<br/></b>Missed dose&#160;for&#160;up to 7 days</p>
<p style="position:absolute;top:935px;left:296px;white-space:nowrap" class="ft11554">&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft11537">If&#160;you miss&#160;a&#160;dose&#160;of&#160;Remsima&#160;for&#160;up&#160;to 7 days, after&#160;the&#160;original&#160;scheduled dose,&#160;you should&#160;take&#160;the&#160;<br/>missed&#160;dose&#160;immediately.&#160;Take&#160;your&#160;next&#160;dose&#160;on&#160;the&#160;next&#160;originally&#160;planned&#160;date&#160;and&#160;then follow&#160;the&#160;<br/>original dosing&#160;schedule.</p>
<p style="position:absolute;top:1003px;left:272px;white-space:nowrap" class="ft11555">&#160;</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft11510">&#160;<br/>Missed&#160;dose for&#160;8&#160;days&#160;or&#160;more&#160;&#160;<br/>If&#160;you miss&#160;a&#160;dose&#160;of&#160;Remsima&#160;for&#160;8&#160;days&#160;or&#160;more, after&#160;the&#160;original&#160;scheduled&#160;dose, you should not&#160;take&#160;<br/>the&#160;missed&#160;dose.&#160;Take&#160;your&#160;next&#160;dose&#160;on&#160;the&#160;next&#160;originally&#160;planned&#160;date&#160;and&#160;then&#160;follow&#160;the&#160;original&#160;<br/>dosing&#160;schedule.&#160;&#160;<br/>&#160;<br/>If&#160;you&#160;are not&#160;sure when&#160;to&#160;inject&#160;Remsima,&#160;call&#160;your&#160;doctor.&#160;&#160;</p>
</div>
<!-- Page 116 -->
<a name="116"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page116-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1160">116&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft11610">&#160;<br/>If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor, pharmacist&#160;or&#160;nurse.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:165px;left:149px;white-space:nowrap" class="ft1161"><b>Possible side&#160;effects</b>&#160;</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft11611">&#160;<br/>Like all&#160;medicines,&#160;this medicine can&#160;cause&#160;side&#160;effects, although not&#160;everybody gets&#160;them.&#160;Most&#160;side&#160;<br/>effects&#160;are mild&#160;to&#160;moderate.&#160;However&#160;some&#160;patients may&#160;experience serious&#160;side&#160;effects and&#160;may&#160;<br/>require&#160;treatment.&#160;Side effects&#160;may&#160;also&#160;occur&#160;after&#160;your&#160;treatment&#160;with&#160;Remsima&#160;has&#160;stopped.&#160;&#160;<br/>&#160;<br/><b>Tell your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;notice&#160;any of&#160;the&#160;following:&#160;</b></p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:299px;left:149px;white-space:nowrap" class="ft11611"><b>Signs of&#160;an&#160;allergic reaction&#160;</b>such&#160;as&#160;swelling&#160;of&#160;your&#160;face, lips,&#160;mouth or&#160;throat&#160;which&#160;may&#160;<br/>cause&#160;difficulty&#160;in&#160;swallowing or&#160;breathing, skin&#160;rash,&#160;hives, swelling of&#160;the&#160;hands, feet&#160;or&#160;<br/>ankles.&#160;Some of&#160;these reactions&#160;may&#160;be serious&#160;or&#160;life-threatening.&#160;An allergic&#160;reaction could&#160;<br/>happen within 2&#160;hours&#160;of&#160;your&#160;injection or&#160;later.&#160;More signs&#160;of&#160;allergic&#160;side effects&#160;that&#160;may&#160;<br/>happen&#160;up to&#160;12&#160;days&#160;after&#160;your&#160;injection include&#160;pain in&#160;the&#160;muscles,&#160;fever,&#160;joint&#160;or&#160;jaw&#160;pain,&#160;<br/>sore&#160;throat&#160;or&#160;headache.&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:414px;left:149px;white-space:nowrap" class="ft11610"><b>Signs&#160;of&#160;a&#160;local&#160;injection&#160;site reaction&#160;</b>such&#160;as&#160;redness, pain, itching,&#160;swelling, hardness,&#160;<br/>bruising, bleeding, cold&#160;sensation,&#160;tingling sensation,&#160;irritation,&#160;rash, ulcer, hives,&#160;blisters&#160;and&#160;<br/>scab.&#160;<b>&#160;</b></p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:472px;left:149px;white-space:nowrap" class="ft11611"><b>Signs&#160;of&#160;a&#160;heart&#160;problem</b>&#160;such as&#160;chest&#160;discomfort&#160;or&#160;pain,&#160;arm&#160;pain,&#160;stomach pain, shortness&#160;<br/>of&#160;breath,&#160;anxiety, lightheadedness,&#160;dizziness, fainting,&#160;sweating, nausea&#160;(feeling sick),&#160;<br/>vomiting,&#160;fluttering or&#160;pounding&#160;in your&#160;chest, a&#160;fast&#160;or&#160;a&#160;slow&#160;heartbeat, and swelling&#160;of&#160;your&#160;<br/>feet.&#160;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:549px;left:149px;white-space:nowrap" class="ft11611"><b>Signs&#160;of&#160;infection (including&#160;TB)&#160;</b>such&#160;as&#160;fever,&#160;feeling&#160;tired,&#160;cough&#160;which may&#160;be&#160;persistent,&#160;<br/>shortness&#160;of&#160;breath, flu-like&#160;symptoms, weight&#160;loss,&#160;night&#160;sweats, diarrhoea, wounds,&#160;collection&#160;<br/>of&#160;pus&#160;in&#160;the&#160;gut&#160;or&#160;around&#160;the&#160;anus&#160;(abscess),&#160;dental&#160;problems&#160;or&#160;burning&#160;sensation&#160;when&#160;<br/>urinating.&#160;</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:625px;left:149px;white-space:nowrap" class="ft11611"><b>Possible signs&#160;of&#160;cancer&#160;</b>including but&#160;not&#160;limited&#160;to swelling of&#160;lymph nodes, weight&#160;loss,&#160;<br/>fever, unusual&#160;skin nodules, changes&#160;in moles&#160;or&#160;skin colouring,&#160;or&#160;unusual&#160;vaginal&#160;bleeding.&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:665px;left:149px;white-space:nowrap" class="ft1161"><b>Signs&#160;of&#160;a&#160;lung&#160;problem&#160;</b>such as&#160;coughing,&#160;breathing&#160;difficulties&#160;or&#160;tightness&#160;in&#160;the&#160;chest.&#160;</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:685px;left:149px;white-space:nowrap" class="ft11611"><b>Signs&#160;of&#160;a&#160;nervous&#160;system&#160;problem&#160;(including&#160;eye&#160;problems)&#160;</b>such&#160;as&#160;signs of&#160;a&#160;stroke&#160;<br/>(sudden numbness&#160;or&#160;weakness&#160;of&#160;your&#160;face,&#160;arm&#160;or&#160;leg, especially on one&#160;side&#160;of&#160;your&#160;body;&#160;<br/>sudden&#160;confusion,&#160;trouble&#160;speaking or&#160;understanding;&#160;trouble&#160;seeing in&#160;one&#160;or&#160;both eyes,&#160;trouble&#160;<br/>walking,&#160;dizziness,&#160;loss&#160;of&#160;balance or&#160;coordination&#160;or&#160;a&#160;severe headache),&#160;fits,&#160;<br/>tingling/numbness&#160;in&#160;any part&#160;of&#160;your&#160;body,&#160;or&#160;weakness in&#160;arms&#160;or&#160;legs,&#160;changes&#160;in&#160;eyesight&#160;<br/>such as&#160;double&#160;vision or&#160;other&#160;eye&#160;problems.&#160;</p>
<p style="position:absolute;top:795px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:800px;left:149px;white-space:nowrap" class="ft11610"><b>Signs&#160;of&#160;a&#160;liver&#160;problem&#160;</b>(including hepatitis&#160;B&#160;infection when you&#160;have&#160;had hepatitis&#160;B&#160;in the&#160;<br/>past)&#160;such as&#160;yellowing of&#160;the&#160;skin or&#160;eyes, dark-brown&#160;coloured urine,&#160;pain&#160;or&#160;swelling&#160;in&#160;the&#160;<br/>upper&#160;right&#160;side&#160;of&#160;the&#160;stomach&#160;area,&#160;joint&#160;pain, skin rashes, or&#160;fever.&#160;</p>
<p style="position:absolute;top:853px;left:106px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:858px;left:149px;white-space:nowrap" class="ft11610"><b>Signs&#160;of&#160;an&#160;immune&#160;system&#160;disorder&#160;called lupus&#160;</b>such as&#160;joint&#160;pain or&#160;a&#160;rash on cheeks&#160;or&#160;<br/>arms&#160;that&#160;is sensitive&#160;to&#160;the&#160;sun&#160;(lupus)&#160;or&#160;cough, shortness&#160;of&#160;breath,&#160;fever&#160;or&#160;skin&#160;rash&#160;<br/>(sarcoidosis).&#160;</p>
<p style="position:absolute;top:911px;left:107px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:917px;left:149px;white-space:nowrap" class="ft11610"><b>Signs&#160;of&#160;low&#160;blood&#160;counts&#160;</b>such&#160;as&#160;persistent&#160;fever, bleeding or&#160;bruising&#160;more&#160;easily,&#160;small red&#160;<br/>or&#160;purple&#160;spots&#160;caused by bleeding under&#160;the&#160;skin,&#160;or&#160;looking pale.&#160;</p>
<p style="position:absolute;top:949px;left:107px;white-space:nowrap" class="ft1168">•&#160;</p>
<p style="position:absolute;top:955px;left:149px;white-space:nowrap" class="ft11611"><b>Signs of&#160;serious skin&#160;problems</b>&#160;such&#160;as reddish-target-like spots or&#160;circular&#160;patches often&#160;with&#160;<br/>central&#160;blisters&#160;on&#160;the&#160;trunk, large&#160;areas&#160;of&#160;peeling and&#160;shedding&#160;(exfoliating)&#160;skin,&#160;ulcers&#160;of&#160;<br/>mouth, throat, nose, genitals&#160;and eyes&#160;or&#160;small&#160;pus-filled bumps&#160;that&#160;can spread&#160;over&#160;the&#160;body.&#160;<br/>These&#160;skin&#160;reactions can&#160;be&#160;accompanied&#160;by&#160;fever.&#160;</p>
<p style="position:absolute;top:1032px;left:107px;white-space:nowrap" class="ft11614">&#160;<br/>Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;notice&#160;any&#160;of&#160;the&#160;above.&#160;<br/>&#160;<br/>The following&#160;side&#160;effects&#160;have been&#160;observed&#160;with&#160;Remsima:&#160;<br/>&#160;<br/><b>Very common:&#160;</b>may&#160;affect&#160;more&#160;than&#160;1 in&#160;10 people&#160;<br/>•&#160;</p>
<p style="position:absolute;top:1147px;left:149px;white-space:nowrap" class="ft1162">Stomach pain, feeling sick&#160;</p>
</div>
<!-- Page 117 -->
<a name="117"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page117-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1170">117&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:90px;left:149px;white-space:nowrap" class="ft1172">Viral&#160;infections&#160;such&#160;as herpes or&#160;flu&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft1172">Upper&#160;respiratory&#160;infections such&#160;as sinusitis&#160;</p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:131px;left:149px;white-space:nowrap" class="ft1172">Headache&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:151px;left:149px;white-space:nowrap" class="ft1172">Side&#160;effect&#160;due&#160;to an injection&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:171px;left:149px;white-space:nowrap" class="ft1172">Pain.&#160;</p>
<p style="position:absolute;top:190px;left:106px;white-space:nowrap" class="ft11711">&#160;<br/><b>Common:&#160;</b>may&#160;affect&#160;up&#160;to&#160;1 in 10&#160;people&#160;</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:229px;left:149px;white-space:nowrap" class="ft1172">Changes&#160;in&#160;how&#160;your&#160;liver&#160;works,&#160;increase&#160;in liver&#160;enzymes&#160;(shown in&#160;blood tests)&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:249px;left:149px;white-space:nowrap" class="ft1172">Lung or&#160;chest&#160;infections&#160;such as&#160;bronchitis&#160;or&#160;pneumonia&#160;</p>
<p style="position:absolute;top:264px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:269px;left:149px;white-space:nowrap" class="ft1172">Difficult&#160;or&#160;painful&#160;breathing,&#160;chest pain&#160;</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:289px;left:149px;white-space:nowrap" class="ft1172">Bleeding&#160;in the&#160;stomach&#160;or&#160;intestines, diarrhoea, indigestion, heartburn, constipation&#160;</p>
<p style="position:absolute;top:304px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:310px;left:149px;white-space:nowrap" class="ft1172">Nettle-type&#160;rash&#160;(hives), itchy rash or&#160;dry&#160;skin&#160;</p>
<p style="position:absolute;top:324px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:330px;left:149px;white-space:nowrap" class="ft1172">Balance problems or&#160;feeling&#160;dizzy&#160;</p>
<p style="position:absolute;top:345px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:350px;left:149px;white-space:nowrap" class="ft1172">Fever,&#160;increased&#160;sweating&#160;</p>
<p style="position:absolute;top:365px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:370px;left:149px;white-space:nowrap" class="ft1172">Circulation problems&#160;such&#160;as&#160;low&#160;or&#160;high blood&#160;pressure&#160;</p>
<p style="position:absolute;top:385px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:390px;left:149px;white-space:nowrap" class="ft1172">Bruising,&#160;hot&#160;flush or&#160;nosebleed, warm, red skin&#160;(flushing)&#160;</p>
<p style="position:absolute;top:405px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:410px;left:149px;white-space:nowrap" class="ft1172">Feeling&#160;tired&#160;or&#160;weak&#160;</p>
<p style="position:absolute;top:425px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:430px;left:149px;white-space:nowrap" class="ft1172">Bacterial&#160;infections&#160;such as&#160;blood&#160;poisoning, abscess&#160;or&#160;infection of&#160;the&#160;skin (cellulitis)&#160;</p>
<p style="position:absolute;top:445px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:451px;left:149px;white-space:nowrap" class="ft1172">Infection of&#160;the&#160;skin due&#160;to&#160;a&#160;fungus&#160;</p>
<p style="position:absolute;top:465px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:471px;left:149px;white-space:nowrap" class="ft1172">Blood problems&#160;such as&#160;anaemia&#160;or&#160;low&#160;white&#160;blood&#160;cell&#160;count&#160;</p>
<p style="position:absolute;top:486px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:491px;left:149px;white-space:nowrap" class="ft1172">Swollen&#160;lymph nodes&#160;</p>
<p style="position:absolute;top:506px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:511px;left:149px;white-space:nowrap" class="ft1172">Depression,&#160;problems sleeping&#160;</p>
<p style="position:absolute;top:526px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft1172">Eye&#160;problems,&#160;including&#160;red eyes&#160;and infections&#160;</p>
<p style="position:absolute;top:546px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:551px;left:149px;white-space:nowrap" class="ft1172">Fast&#160;heart&#160;beat&#160;(tachycardia)&#160;or&#160;palpitations&#160;</p>
<p style="position:absolute;top:566px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:572px;left:149px;white-space:nowrap" class="ft1172">Pain&#160;in&#160;the&#160;joints,&#160;muscles or&#160;back&#160;</p>
<p style="position:absolute;top:586px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:592px;left:149px;white-space:nowrap" class="ft1172">Urinary&#160;tract infection&#160;</p>
<p style="position:absolute;top:607px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:612px;left:149px;white-space:nowrap" class="ft1172">Psoriasis,&#160;skin&#160;problems&#160;such&#160;as&#160;eczema and&#160;hair&#160;loss&#160;</p>
<p style="position:absolute;top:627px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:632px;left:149px;white-space:nowrap" class="ft1172">Reactions&#160;at&#160;the injection&#160;site such&#160;as pain,&#160;swelling,&#160;redness&#160;or&#160;itching&#160;</p>
<p style="position:absolute;top:647px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:652px;left:149px;white-space:nowrap" class="ft1172">Chills,&#160;a&#160;build-up of&#160;fluid&#160;under&#160;the&#160;skin&#160;causing swelling&#160;</p>
<p style="position:absolute;top:667px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:672px;left:149px;white-space:nowrap" class="ft1172">Feeling numb&#160;or&#160;having a&#160;tingling feeling.&#160;</p>
<p style="position:absolute;top:691px;left:107px;white-space:nowrap" class="ft11714">&#160;<br/><b>Uncommon:&#160;</b>may&#160;affect&#160;up&#160;to 1&#160;in 100&#160;people&#160;<br/>•&#160;</p>
<p style="position:absolute;top:730px;left:149px;white-space:nowrap" class="ft1172">Shortage&#160;of&#160;blood&#160;supply, swelling of&#160;a&#160;vein&#160;</p>
<p style="position:absolute;top:745px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:751px;left:149px;white-space:nowrap" class="ft1172">Collection of&#160;blood outside&#160;the&#160;blood&#160;vessels&#160;(haematoma)&#160;or&#160;bruising&#160;</p>
<p style="position:absolute;top:765px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:770px;left:149px;white-space:nowrap" class="ft11711">Skin problems&#160;such as&#160;blistering, warts,&#160;abnormal&#160;skin&#160;colouration&#160;or&#160;pigmentation, or&#160;swollen&#160;<br/>lips, or&#160;thickening&#160;of&#160;the&#160;skin, or&#160;red, scaly,&#160;and&#160;flaky skin&#160;</p>
<p style="position:absolute;top:804px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:810px;left:149px;white-space:nowrap" class="ft11710">Severe&#160;allergic&#160;reactions&#160;(e.g. anaphylaxis), an immune&#160;system&#160;disorder&#160;called lupus,&#160;allergic&#160;<br/>reactions&#160;to foreign proteins&#160;</p>
<p style="position:absolute;top:844px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:849px;left:149px;white-space:nowrap" class="ft1172">Wounds&#160;taking longer&#160;to&#160;heal&#160;</p>
<p style="position:absolute;top:864px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:869px;left:149px;white-space:nowrap" class="ft1172">Swelling of&#160;the&#160;liver&#160;(hepatitis)&#160;or&#160;gall&#160;bladder,&#160;liver&#160;damage&#160;</p>
<p style="position:absolute;top:884px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:889px;left:149px;white-space:nowrap" class="ft1172">Feeling forgetful,&#160;irritable,&#160;confused,&#160;nervous&#160;</p>
<p style="position:absolute;top:904px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:909px;left:149px;white-space:nowrap" class="ft1172">Eye&#160;problems&#160;including blurred&#160;or&#160;reduced vision, puffy eyes&#160;or&#160;sties&#160;</p>
<p style="position:absolute;top:924px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:929px;left:149px;white-space:nowrap" class="ft1172">New&#160;or&#160;worsening heart&#160;failure, slow&#160;heart&#160;rate&#160;</p>
<p style="position:absolute;top:944px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:950px;left:149px;white-space:nowrap" class="ft1172">Fainting&#160;</p>
<p style="position:absolute;top:964px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:970px;left:149px;white-space:nowrap" class="ft1172">Convulsions, nerve&#160;problems&#160;</p>
<p style="position:absolute;top:985px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:990px;left:149px;white-space:nowrap" class="ft1172">A&#160;hole&#160;in the&#160;bowel&#160;or&#160;blockage&#160;of&#160;the&#160;intestine,&#160;stomach pain or&#160;cramps&#160;</p>
<p style="position:absolute;top:1005px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:1010px;left:149px;white-space:nowrap" class="ft1172">Swelling of&#160;your&#160;pancreas&#160;(pancreatitis)&#160;</p>
<p style="position:absolute;top:1025px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:1030px;left:149px;white-space:nowrap" class="ft1172">Fungal&#160;infections such&#160;as yeast&#160;infection, or&#160;fungal&#160;infection&#160;of&#160;the&#160;nails&#160;</p>
<p style="position:absolute;top:1045px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:1050px;left:150px;white-space:nowrap" class="ft1172">Lung problems&#160;(such as&#160;oedema)&#160;</p>
<p style="position:absolute;top:1065px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:1071px;left:150px;white-space:nowrap" class="ft1172">Fluid around the&#160;lungs&#160;(pleural&#160;effusion)&#160;</p>
<p style="position:absolute;top:1085px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:1091px;left:150px;white-space:nowrap" class="ft1172">Narrowed&#160;airway&#160;in&#160;the&#160;lungs, causing difficulty breathing&#160;</p>
<p style="position:absolute;top:1106px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:1111px;left:150px;white-space:nowrap" class="ft1172">Inflamed&#160;lining&#160;of&#160;the&#160;lung,&#160;causing sharp chest&#160;pains&#160;that&#160;feel&#160;worse&#160;with breathing&#160;(pleurisy)&#160;</p>
<p style="position:absolute;top:1126px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:1131px;left:150px;white-space:nowrap" class="ft1172">Tuberculosis&#160;</p>
<p style="position:absolute;top:1146px;left:107px;white-space:nowrap" class="ft1178">•&#160;</p>
<p style="position:absolute;top:1151px;left:150px;white-space:nowrap" class="ft1172">Kidney infections&#160;</p>
</div>
<!-- Page 118 -->
<a name="118"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page118-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1180">118&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:90px;left:149px;white-space:nowrap" class="ft1182">Low&#160;platelet&#160;count, too many white&#160;blood cells&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft1182">Infections&#160;of&#160;the&#160;vagina&#160;</p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:131px;left:149px;white-space:nowrap" class="ft1182">Blood test&#160;result&#160;showing&#160;‘antibodies’&#160;against&#160;your&#160;own body&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:151px;left:149px;white-space:nowrap" class="ft1182">Changes&#160;in&#160;cholesterol&#160;and fat&#160;levels&#160;in the&#160;blood.&#160;</p>
<p style="position:absolute;top:170px;left:106px;white-space:nowrap" class="ft11811">&#160;<br/><b>Rare:&#160;</b>may affect&#160;up to&#160;1 in&#160;1,000 people&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:209px;left:149px;white-space:nowrap" class="ft1182">A&#160;type&#160;of&#160;blood cancer&#160;(lymphoma)&#160;</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:229px;left:149px;white-space:nowrap" class="ft11810">Your&#160;blood not&#160;supplying&#160;enough oxygen&#160;to your&#160;body, circulation problems&#160;such&#160;as&#160;narrowing&#160;<br/>of&#160;a&#160;blood&#160;vessel&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:268px;left:149px;white-space:nowrap" class="ft1182">Inflammation&#160;of&#160;the&#160;lining&#160;of&#160;the&#160;brain&#160;(meningitis)&#160;</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:288px;left:149px;white-space:nowrap" class="ft1182">Infections&#160;due&#160;to&#160;a weakened&#160;immune system&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:308px;left:149px;white-space:nowrap" class="ft1182">Hepatitis&#160;B&#160;infection when&#160;you have&#160;had hepatitis&#160;B&#160;in&#160;the&#160;past&#160;</p>
<p style="position:absolute;top:323px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:329px;left:149px;white-space:nowrap" class="ft1182">Inflamed liver&#160;caused&#160;by a&#160;problem&#160;with&#160;the&#160;immune&#160;system&#160;(autoimmune&#160;hepatitis)&#160;&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft1182">Liver&#160;problem&#160;that&#160;causes&#160;yellowing of&#160;the&#160;skin or&#160;eyes&#160;(jaundice)&#160;</p>
<p style="position:absolute;top:363px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1182">Abnormal&#160;tissue&#160;swelling or&#160;growth&#160;</p>
<p style="position:absolute;top:382px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft11811">Severe allergic reaction&#160;that&#160;may&#160;cause&#160;loss of&#160;consciousness and&#160;could&#160;be&#160;life-threatening&#160;<br/>(anaphylactic shock)&#160;</p>
<p style="position:absolute;top:421px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:427px;left:149px;white-space:nowrap" class="ft1182">Swelling&#160;of&#160;small blood&#160;vessels&#160;(vasculitis)&#160;</p>
<p style="position:absolute;top:441px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:446px;left:149px;white-space:nowrap" class="ft1182">Immune&#160;disorders&#160;that&#160;could affect&#160;the&#160;lungs,&#160;skin and&#160;lymph nodes&#160;(such&#160;as&#160;sarcoidosis)&#160;</p>
<p style="position:absolute;top:460px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:465px;left:149px;white-space:nowrap" class="ft1182">Collections&#160;of&#160;immune&#160;cells&#160;resulting from&#160;an&#160;inflammatory response&#160;(granulomatous&#160;lesions)&#160;</p>
<p style="position:absolute;top:480px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:485px;left:149px;white-space:nowrap" class="ft1182">Lack&#160;of&#160;interest or&#160;emotion&#160;</p>
<p style="position:absolute;top:499px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:505px;left:149px;white-space:nowrap" class="ft11811">Serious skin&#160;problems&#160;such&#160;as toxic&#160;epidermal&#160;necrolysis,&#160;Stevens-Johnson syndrome&#160;and&#160;acute&#160;<br/>generalised&#160;exanthematous&#160;pustulosis&#160;</p>
<p style="position:absolute;top:538px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:544px;left:149px;white-space:nowrap" class="ft11811">Other&#160;skin&#160;problems&#160;such&#160;as&#160;erythema&#160;multiforme,&#160;blisters&#160;and&#160;peeling skin, or&#160;boils&#160;<br/>(furunculosis)&#160;</p>
<p style="position:absolute;top:577px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:582px;left:149px;white-space:nowrap" class="ft11811">Serious nervous system&#160;disorders such&#160;as transverse&#160;myelitis,&#160;multiple sclerosis-like disease,&#160;<br/>optic&#160;neuritis&#160;and Guillain-Barré&#160;syndrome&#160;</p>
<p style="position:absolute;top:616px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:622px;left:149px;white-space:nowrap" class="ft1182">Inflammation&#160;in the&#160;eye&#160;that&#160;may&#160;cause&#160;changes&#160;in&#160;the&#160;vision, including&#160;blindness&#160;</p>
<p style="position:absolute;top:637px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:642px;left:149px;white-space:nowrap" class="ft1182">Fluid in the&#160;lining&#160;of&#160;the&#160;heart&#160;(pericardial&#160;effusion)&#160;</p>
<p style="position:absolute;top:657px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:662px;left:149px;white-space:nowrap" class="ft1182">Serious&#160;lung&#160;problems&#160;(such&#160;as&#160;interstitial&#160;lung disease)&#160;</p>
<p style="position:absolute;top:677px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:682px;left:149px;white-space:nowrap" class="ft1182">Melanoma&#160;(a type of&#160;skin&#160;cancer)&#160;</p>
<p style="position:absolute;top:697px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:702px;left:149px;white-space:nowrap" class="ft1182">Cervical&#160;cancer&#160;</p>
<p style="position:absolute;top:717px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:722px;left:149px;white-space:nowrap" class="ft1182">Low&#160;blood&#160;counts,&#160;including a&#160;severely decreased number&#160;of&#160;white&#160;blood&#160;cells&#160;</p>
<p style="position:absolute;top:737px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:743px;left:149px;white-space:nowrap" class="ft1182">Small&#160;red or&#160;purple&#160;spots&#160;caused&#160;by bleeding under&#160;the&#160;skin&#160;</p>
<p style="position:absolute;top:757px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:763px;left:149px;white-space:nowrap" class="ft11810">Abnormal&#160;values&#160;of&#160;a&#160;blood&#160;protein&#160;called ‘complement&#160;factor’&#160;which&#160;is&#160;part&#160;of&#160;the&#160;immune&#160;<br/>system&#160;</p>
<p style="position:absolute;top:797px;left:107px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:802px;left:149px;white-space:nowrap" class="ft11810">Lichenoid&#160;reactions&#160;(itchy reddish-purple&#160;skin rash&#160;and/or&#160;threadlike&#160;white-grey lines&#160;on&#160;<br/>mucous&#160;membranes).&#160;&#160;</p>
<p style="position:absolute;top:840px;left:107px;white-space:nowrap" class="ft11814">&#160;<br/><b>Not&#160;known:&#160;</b>frequency&#160;cannot&#160;be estimated&#160;from&#160;the available&#160;data&#160;<br/>•&#160;</p>
<p style="position:absolute;top:879px;left:149px;white-space:nowrap" class="ft1182">Cancer&#160;</p>
<p style="position:absolute;top:893px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:898px;left:149px;white-space:nowrap" class="ft1182">A&#160;rare&#160;blood cancer&#160;affecting mostly young&#160;men&#160;(hepatosplenic T-cell lymphoma)&#160;</p>
<p style="position:absolute;top:913px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:919px;left:149px;white-space:nowrap" class="ft1182">Liver&#160;failure&#160;</p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:939px;left:149px;white-space:nowrap" class="ft1182">Merkel&#160;cell&#160;carcinoma (a&#160;type of&#160;skin&#160;cancer)&#160;</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:959px;left:149px;white-space:nowrap" class="ft11810">Kaposi’s&#160;sarcoma, a&#160;rare&#160;cancer&#160;related&#160;to infection with human herpes&#160;virus&#160;8. Kaposi’s&#160;<br/>sarcoma&#160;most&#160;commonly&#160;appears&#160;as&#160;purple&#160;lesions&#160;on&#160;the&#160;skin.&#160;</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:998px;left:149px;white-space:nowrap" class="ft11810">Worsening of&#160;a&#160;condition called dermatomyositis&#160;(seen as&#160;a&#160;skin rash accompanying&#160;muscle&#160;<br/>weakness)&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:1037px;left:149px;white-space:nowrap" class="ft1182">Heart&#160;attack&#160;</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:1057px;left:149px;white-space:nowrap" class="ft1182">Stroke&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:1078px;left:149px;white-space:nowrap" class="ft1182">Temporary loss&#160;of&#160;sight&#160;during or&#160;within&#160;2 hours&#160;of&#160;infusion&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft1188">•&#160;</p>
<p style="position:absolute;top:1097px;left:149px;white-space:nowrap" class="ft1182">Infection due&#160;to&#160;a&#160;live vaccine because&#160;of&#160;a&#160;weakened&#160;immune&#160;system.&#160;&#160;</p>
<p style="position:absolute;top:1116px;left:106px;white-space:nowrap" class="ft1185"><b>&#160;<br/>Reporting&#160;of&#160;side effects&#160;</b></p>
</div>
<!-- Page 119 -->
<a name="119"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft11956{font-size:17px;font-family:TimesNewRomanPSMT;color:#ff0000;}
-->
</style>
<div id="page119-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1190">119&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft11910">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor,&#160;pharmacist,&#160;or&#160;nurse.&#160;This&#160;includes&#160;any&#160;possible side&#160;<br/>effects not&#160;listed&#160;in&#160;this leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side effects directly&#160;via&#160;the&#160;national&#160;reporting&#160;<br/>system&#160;listed&#160;in&#160;Appendix V. By reporting side&#160;effects&#160;you can&#160;help provide&#160;more&#160;information&#160;on the&#160;<br/>safety&#160;of&#160;this&#160;medicine.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft1191"><b>How&#160;to&#160;store&#160;Remsima&#160;</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft11942"><b>&#160;<br/></b>•&#160;</p>
<p style="position:absolute;top:242px;left:149px;white-space:nowrap" class="ft1192">Keep&#160;this&#160;medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1198">•&#160;</p>
<p style="position:absolute;top:262px;left:149px;white-space:nowrap" class="ft11910">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date which&#160;is&#160;stated&#160;on&#160;the label&#160;and&#160;the&#160;carton&#160;after&#160;<br/>“EXP”. The&#160;expiry date&#160;refers&#160;to the&#160;last&#160;day&#160;of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft1198">•&#160;</p>
<p style="position:absolute;top:301px;left:149px;white-space:nowrap" class="ft11910">Store&#160;in a&#160;refrigerator&#160;(2°C&#160;-&#160;8°C). Do not&#160;freeze. Keep&#160;the&#160;medicinal&#160;product&#160;in its&#160;outer&#160;carton&#160;<br/>to&#160;protect from light.&#160;&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1198">•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft11911">This&#160;medicine&#160;can also&#160;be&#160;stored in&#160;the&#160;original&#160;carton&#160;outside&#160;of&#160;refrigerated&#160;storage&#160;up to a&#160;<br/>maximum&#160;of&#160;25°C&#160;for&#160;a&#160;single&#160;period of&#160;up&#160;to&#160;28&#160;days,&#160;but&#160;not&#160;beyond&#160;the&#160;original&#160;expiry date.&#160;<br/>In&#160;this&#160;situation,&#160;do&#160;not&#160;return&#160;to refrigerated&#160;storage&#160;again. Write&#160;the new&#160;expiry&#160;date on&#160;the&#160;<br/>carton&#160;including day/month/year. Discard this&#160;medicine&#160;if&#160;not&#160;used&#160;by the&#160;new&#160;expiry&#160;date&#160;or&#160;<br/>the&#160;expiry date&#160;printed on&#160;the&#160;carton, whichever&#160;is&#160;earlier.&#160;</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1198">•&#160;</p>
<p style="position:absolute;top:436px;left:149px;white-space:nowrap" class="ft11911">Do&#160;not&#160;throw&#160;away&#160;any&#160;medicines&#160;via wastewater&#160;or&#160;household&#160;waste.&#160;Ask&#160;your&#160;pharmacist&#160;<br/>how&#160;to&#160;throw&#160;away&#160;medicines&#160;you no longer&#160;use.&#160;These&#160;measures&#160;will&#160;help protect&#160;the&#160;<br/>environment.&#160;</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft11911">&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft1191"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft11911">&#160;<br/><b>What&#160;Remsima&#160;contains&#160;&#160;</b></p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft1198">•&#160;</p>
<p style="position:absolute;top:589px;left:149px;white-space:nowrap" class="ft11910">The active substance&#160;is&#160;infliximab.&#160;Each&#160;1&#160;ml single&#160;dose&#160;pre-filled syringe&#160;contains&#160;120&#160;mg&#160;of&#160;<br/>infliximab.&#160;&#160;</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft1198">•&#160;</p>
<p style="position:absolute;top:628px;left:149px;white-space:nowrap" class="ft11910">The&#160;other&#160;ingredients&#160;are&#160;acetic&#160;acid, sodium&#160;acetate&#160;trihydrate, sorbitol,&#160;polysorbate&#160;80 and&#160;<br/>water&#160;for&#160;injections.&#160;&#160;</p>
<p style="position:absolute;top:666px;left:107px;white-space:nowrap" class="ft11910">&#160;<br/><b>What&#160;Remsima&#160;looks&#160;like&#160;and contents&#160;of&#160;the&#160;pack&#160;<br/></b>Remsima&#160;is a clear&#160;to&#160;opalescent,&#160;colourless&#160;to&#160;pale&#160;brown&#160;solution&#160;which&#160;is supplied&#160;as&#160;a single use&#160;<br/>pre-filled syringe.&#160;&#160;<br/>&#160;<br/>Each pack contains&#160;1&#160;pre-filled&#160;syringe&#160;with&#160;2&#160;alcohol&#160;pads,&#160;2 pre-filled syringes&#160;with&#160;2 alcohol&#160;pads,&#160;<br/>4 pre-filled syringes&#160;with 4&#160;alcohol&#160;pads&#160;or&#160;6&#160;pre-filled&#160;syringes&#160;with 6 alcohol&#160;pads.&#160;&#160;<br/>&#160;<br/>Each pack contains&#160;1&#160;pre-filled syringe&#160;with automatic&#160;needle&#160;guard with 2&#160;alcohol&#160;pads, 2&#160;pre-filled&#160;<br/>syringes&#160;with automatic&#160;needle&#160;guard with 2&#160;alcohol&#160;pads,&#160;4&#160;pre-filled&#160;syringes&#160;with&#160;automatic needle&#160;<br/>guard with&#160;4 alcohol&#160;pads&#160;or&#160;6&#160;pre-filled&#160;syringes with&#160;automatic&#160;needle&#160;guard with 6&#160;alcohol&#160;pads.&#160;&#160;<br/>&#160;<br/>Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;<br/>&#160;<br/><b>Marketing&#160;Authorisation&#160;Holder&#160;&#160;&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Hungary&#160;<br/>&#160;<br/><b>Manufacturer</b>&#160;<br/>Millmount Healthcare&#160;Ltd.&#160;<br/>Block 7&#160;<br/>City&#160;North&#160;Business Campus&#160;<br/>Stamullen, Co. Meath K32&#160;YD60&#160;<br/>Ireland&#160;<br/>&#160;</p>
</div>
<!-- Page 120 -->
<a name="120"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page120-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1200">120&#160;</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft12010">Nuvisan&#160;GmbH&#160;<br/>Wegenerstraße 13,&#160;&#160;<br/>89231 Neu Ulm,&#160;&#160;<br/>Germany&#160;<br/>&#160;<br/>Nuvisan&#160;France SARL&#160;<br/>2400, Route&#160;des&#160;Colles,&#160;&#160;<br/>06410, Biot,&#160;&#160;<br/>France&#160;<br/>&#160;<br/>For&#160;any&#160;information&#160;about&#160;this&#160;medicine,&#160;please&#160;contact&#160;the local&#160;representative of&#160;the&#160;Marketing&#160;<br/>Authorisation Holder:&#160;<br/>&#160;</p>
<p style="position:absolute;top:333px;left:114px;white-space:nowrap" class="ft12011"><b>België/Belgique/Belgien</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Belgium&#160;BVBA&#160;&#160;<br/>Tél/Tel:&#160;+&#160;32&#160;1528 7418&#160;<br/>BEinfo@celltrionhc.com&#160;</p>
<p style="position:absolute;top:333px;left:455px;white-space:nowrap" class="ft12011"><b>Lietuva</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Vengrija&#160;<br/>&#160;</p>
<p style="position:absolute;top:441px;left:114px;white-space:nowrap" class="ft12010"><b>България&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062&#160;Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd&#160;Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:517px;left:114px;white-space:nowrap" class="ft12019">Унгария&#160;<br/>&#160;</p>
<p style="position:absolute;top:447px;left:455px;white-space:nowrap" class="ft12010"><b>Luxembourg/Luxemburg</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Belgium&#160;BVBA&#160;<br/>Tél/Tel:&#160;+&#160;32 1528&#160;7418&#160;<br/>BEinfo@celltrionhc.com&#160;</p>
<p style="position:absolute;top:554px;left:114px;white-space:nowrap" class="ft12011"><b>Česká&#160;republika</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:631px;left:114px;white-space:nowrap" class="ft12018">Maďarsko&#160;</p>
<p style="position:absolute;top:640px;left:114px;white-space:nowrap" class="ft1202">&#160;</p>
<p style="position:absolute;top:561px;left:455px;white-space:nowrap" class="ft12010"><b>Magyarország&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Magyarország&#160;</p>
<p style="position:absolute;top:640px;left:455px;white-space:nowrap" class="ft1202">&#160;</p>
<p style="position:absolute;top:655px;left:114px;white-space:nowrap" class="ft12010"><b>Danmark</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungarn&#160;</p>
<p style="position:absolute;top:735px;left:114px;white-space:nowrap" class="ft1202">&#160;</p>
<p style="position:absolute;top:655px;left:455px;white-space:nowrap" class="ft12010"><b>Malta&#160;<br/></b>Mint Health&#160;Ltd.&#160;<br/>Tel:&#160;+356&#160;2093 9800&#160;<br/>info@mint.com.mt&#160;<br/>&#160;</p>
<p style="position:absolute;top:750px;left:114px;white-space:nowrap" class="ft12010"><b>Deutschland</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungarn&#160;<br/>&#160;</p>
<p style="position:absolute;top:750px;left:455px;white-space:nowrap" class="ft12011"><b>Nederland</b>&#160;<br/>Celltrion Healthcare&#160;Netherlands&#160;B.V.&#160;<br/>Tel:&#160;+&#160;31 20 888 7300&#160;<br/>NLinfo@celltrionhc.com&#160;</p>
<p style="position:absolute;top:864px;left:114px;white-space:nowrap" class="ft12011"><b>Eesti&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungari&#160;</p>
<p style="position:absolute;top:944px;left:114px;white-space:nowrap" class="ft1202">&#160;</p>
<p style="position:absolute;top:864px;left:455px;white-space:nowrap" class="ft12010"><b>Norge</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungarn&#160;<br/>&#160;</p>
<p style="position:absolute;top:972px;left:114px;white-space:nowrap" class="ft12047"><b>Ελλάδα</b>&#160;</p>
<p style="position:absolute;top:991px;left:114px;white-space:nowrap" class="ft12018">ΒΙΑΝΕΞ&#160;Α.Ε.&#160;</p>
<p style="position:absolute;top:1010px;left:114px;white-space:nowrap" class="ft12018">Τηλ:&#160;+30 210&#160;8009111&#160;–&#160;120&#160;</p>
<p style="position:absolute;top:1020px;left:114px;white-space:nowrap" class="ft1202">&#160;</p>
<p style="position:absolute;top:978px;left:455px;white-space:nowrap" class="ft12010"><b>Österreich</b>&#160;<br/>Astro-Pharma&#160;GmbH&#160;<br/>Tel:&#160;+43 1&#160;97 99 860&#160;<br/>office@astropharma.at&#160;<br/>&#160;</p>
<p style="position:absolute;top:1073px;left:114px;white-space:nowrap" class="ft12010"><b>España&#160;<br/></b>Kern Pharma, S.L.&#160;<br/>Tel:&#160;+34 93&#160;700 25&#160;25&#160;</p>
<p style="position:absolute;top:1115px;left:114px;white-space:nowrap" class="ft1202">&#160;</p>
<p style="position:absolute;top:1073px;left:455px;white-space:nowrap" class="ft12011"><b>Polska<i>&#160;<br/></i></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3.&#160;WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:1143px;left:455px;white-space:nowrap" class="ft12018">Węgry&#160;</p>
</div>
<!-- Page 121 -->
<a name="121"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page121-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1210">121&#160;</p>
<p style="position:absolute;top:89px;left:455px;white-space:nowrap" class="ft1212">&#160;</p>
<p style="position:absolute;top:108px;left:114px;white-space:nowrap" class="ft12111"><b>France&#160;<br/></b>Celltrion&#160;Healthcare&#160;France&#160;SAS&#160;<br/>Tél: +&#160;33&#160;(0)1 71 25&#160;27 00<b>&#160;</b></p>
<p style="position:absolute;top:108px;left:455px;white-space:nowrap" class="ft12110"><b>Portugal</b>&#160;<br/>PharmaKERN&#160;Portugal&#160;–&#160;Produtos&#160;<br/>Farmacêuticos,&#160;<br/>Sociedade Unipessoal,&#160;Lda.&#160;<br/>Tel:&#160;+351 214 200&#160;290&#160;<br/>&#160;</p>
<p style="position:absolute;top:222px;left:114px;white-space:nowrap" class="ft12110"><b>Hrvatska</b>&#160;<br/>OKTAL&#160;PHARMA d.o.o.&#160;<br/>Tel:&#160;+385 1&#160;6595 777&#160;<br/>oktal-pharma@oktal-pharma.hr&#160;<br/>&#160;</p>
<p style="position:absolute;top:222px;left:455px;white-space:nowrap" class="ft1216"><b>România&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungaria<b>&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:336px;left:114px;white-space:nowrap" class="ft12111"><b>Ireland</b>&#160;<br/>Celltrion&#160;Healthcare Ireland&#160;Limited&#160;<br/>Tel:&#160;+353 1&#160;223 4026&#160;</p>
<p style="position:absolute;top:336px;left:455px;white-space:nowrap" class="ft12110"><b>Slovenija</b>&#160;<br/>OKTAL&#160;PHARMA d.o.o.&#160;<br/>Tel:&#160;+386 1&#160;519 29&#160;22&#160;<br/>info@oktal-pharma.si&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:431px;left:114px;white-space:nowrap" class="ft12110"><b>Ísland&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungverjaland&#160;</p>
<p style="position:absolute;top:510px;left:114px;white-space:nowrap" class="ft1212">&#160;</p>
<p style="position:absolute;top:431px;left:455px;white-space:nowrap" class="ft12110"><b>Slovenská&#160;republika&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:500px;left:455px;white-space:nowrap" class="ft12136">Maďarsko&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:544px;left:114px;white-space:nowrap" class="ft12111"><b>Italia</b>&#160;<br/>Celltrion&#160;Healthcare Italy&#160;S.r.l.&#160;<br/>Via&#160;Luigi&#160;Galvani, 24&#160;-&#160;20124 Milano (MI)&#160;<br/>Tel: +39&#160;0247 927040&#160;</p>
<p style="position:absolute;top:544px;left:455px;white-space:nowrap" class="ft12110"><b>Suomi/Finland</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Unkari&#160;<br/>&#160;</p>
<p style="position:absolute;top:652px;left:114px;white-space:nowrap" class="ft12152"><b>Κύπρος&#160;<br/></b>C.A. Papaellinas&#160;Ltd&#160;</p>
<p style="position:absolute;top:690px;left:114px;white-space:nowrap" class="ft12118">Τηλ:&#160;+&#160;357 22741741<b>&#160;</b></p>
<p style="position:absolute;top:658px;left:455px;white-space:nowrap" class="ft12110"><b>Sverige&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungern&#160;</p>
<p style="position:absolute;top:738px;left:455px;white-space:nowrap" class="ft1211"><b>&#160;</b></p>
<p style="position:absolute;top:753px;left:114px;white-space:nowrap" class="ft12110"><b>Latvija&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:823px;left:114px;white-space:nowrap" class="ft12118">Ungārija&#160;</p>
<p style="position:absolute;top:753px;left:455px;white-space:nowrap" class="ft12111"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;<br/></b>Celltrion&#160;Healthcare&#160;Ireland&#160;Limited&#160;&#160;<br/>Tel: +353 1&#160;223 4026&#160;</p>
<p style="position:absolute;top:848px;left:106px;white-space:nowrap" class="ft12110"><b>&#160;<br/>&#160;<br/>This&#160;leaflet&#160;was&#160;last&#160;revised&#160;in&#160;{MM/YYYY}.&#160;<br/></b>&#160;<br/><b>Other&#160;sources&#160;of&#160;information&#160;<br/></b>&#160;<br/>Detailed&#160;information on&#160;this&#160;medicine&#160;is&#160;available&#160;on&#160;the&#160;European&#160;Medicines&#160;Agency web&#160;site:&#160;<br/>http://www.ema.europa.eu.&#160;&#160;<br/>&#160;<br/>This&#160;leaflet is&#160;available&#160;in&#160;all&#160;EU/EEA&#160;languages on&#160;the European&#160;Medicines Agency&#160;website.&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 122 -->
<a name="122"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page122-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1220">122&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1221"><b>7.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft1221"><b>Instructions for&#160;use&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft12211"><b>&#160;<br/></b>Read carefully&#160;these&#160;instructions&#160;before&#160;using&#160;the&#160;Remsima&#160;syringe.&#160;Consult&#160;your&#160;healthcare&#160;provider&#160;<br/>if&#160;you have&#160;questions&#160;about&#160;using&#160;the&#160;Remsima&#160;syringe.&#160;<br/>&#160;<br/><b>Important&#160;information&#160;</b></p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft1228">•&#160;&#160;Use the&#160;syringe&#160;<b>ONLY if&#160;</b>your&#160;healthcare&#160;provider&#160;has&#160;trained&#160;you on&#160;the&#160;right&#160;way to prepare&#160;for&#160;</p>
<p style="position:absolute;top:223px;left:137px;white-space:nowrap" class="ft1222">and&#160;to give&#160;an injection.&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1228">•&#160;&#160;Ask your&#160;healthcare&#160;provider&#160;how&#160;often you will&#160;need&#160;to give&#160;an&#160;injection.&#160;</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft1228">•&#160;&#160;Rotate&#160;the&#160;injection&#160;site&#160;each time&#160;you give&#160;an injection. Each new&#160;injection site&#160;should be&#160;at&#160;least&#160;</p>
<p style="position:absolute;top:282px;left:137px;white-space:nowrap" class="ft1222">3&#160;cm&#160;away&#160;from&#160;the previous injection&#160;site.&#160;</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1228">•&#160;&#160;<b>Do not&#160;</b>use&#160;the&#160;syringe&#160;if&#160;it&#160;has&#160;been dropped or&#160;is&#160;visibly damaged. A&#160;damaged&#160;syringe&#160;may not&#160;</p>
<p style="position:absolute;top:321px;left:137px;white-space:nowrap" class="ft1222">function&#160;properly.<b>&#160;</b></p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1228">•&#160;&#160;<b>Do not</b>&#160;reuse the&#160;syringe.&#160;</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft1226">•&#160;&#160;<b>Do not</b>&#160;shake the&#160;syringe&#160;at&#160;any time.&#160;&#160;&#160;<br/><b>&#160;<br/>About the&#160;Remsima&#160;syringe&#160;<br/>&#160;<br/>Parts of&#160;the&#160;syringe (see&#160;<i>Figure A</i></b><b>):&#160;</b></p>
<p style="position:absolute;top:788px;left:372px;white-space:nowrap" class="ft1222">&#160;</p>
<p style="position:absolute;top:788px;left:404px;white-space:nowrap" class="ft1222">&#160;</p>
<p style="position:absolute;top:788px;left:447px;white-space:nowrap" class="ft1222">&#160;</p>
<p style="position:absolute;top:788px;left:489px;white-space:nowrap" class="ft1222">&#160;</p>
<p style="position:absolute;top:788px;left:532px;white-space:nowrap" class="ft1222">&#160;</p>
<p style="position:absolute;top:788px;left:574px;white-space:nowrap" class="ft1222">&#160;</p>
<p style="position:absolute;top:803px;left:313px;white-space:nowrap" class="ft1223"><i>Figure&#160;A<b>&#160;</b></i></p>
<p style="position:absolute;top:822px;left:106px;white-space:nowrap" class="ft12214">&#160;<br/>•&#160;&#160;<b>Do not</b>&#160;remove the&#160;cap until&#160;you are&#160;ready to inject. Once&#160;you&#160;remove&#160;the&#160;cap,&#160;<b>do&#160;not</b>&#160;recap&#160;the&#160;</p>
<p style="position:absolute;top:861px;left:137px;white-space:nowrap" class="ft1222">syringe.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1226">&#160;<br/><b>Prepare&#160;for&#160;the&#160;injection&#160;<br/>&#160;<br/>1.&#160;Gather the supplies for the&#160;injection.&#160;</b></p>
<p style="position:absolute;top:956px;left:123px;white-space:nowrap" class="ft12210">a.&#160;&#160;Prepare a&#160;clean,&#160;flat&#160;surface,&#160;such&#160;as a&#160;table&#160;or&#160;countertop, in&#160;a&#160;well-lit&#160;area.&#160;<br/>b.&#160;&#160;Remove&#160;the&#160;syringe&#160;from&#160;the&#160;carton&#160;stored&#160;in your&#160;refrigerator&#160;by holding the&#160;middle&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:994px;left:166px;white-space:nowrap" class="ft1222">syringe&#160;body.&#160;</p>
<p style="position:absolute;top:1013px;left:123px;white-space:nowrap" class="ft1222">c.&#160;&#160;Ensure&#160;you have&#160;the&#160;following supplies:&#160;</p>
<p style="position:absolute;top:1028px;left:149px;white-space:nowrap" class="ft1228">•&#160;&#160;Syringe&#160;</p>
<p style="position:absolute;top:1048px;left:149px;white-space:nowrap" class="ft1228">•&#160;&#160;Alcohol&#160;swab&#160;</p>
<p style="position:absolute;top:1068px;left:149px;white-space:nowrap" class="ft1228">•&#160;&#160;Cotton&#160;ball&#160;or&#160;gauze*&#160;</p>
<p style="position:absolute;top:1088px;left:149px;white-space:nowrap" class="ft1228">•&#160;&#160;Adhesive&#160;bandage*&#160;</p>
<p style="position:absolute;top:1108px;left:149px;white-space:nowrap" class="ft12219">•&#160;&#160;Sharps&#160;disposal&#160;container*&#160;<br/><i>*Items&#160;not&#160;included&#160;in the&#160;carton.&#160;</i></p>
<p style="position:absolute;top:1152px;left:107px;white-space:nowrap" class="ft1221"><b>&#160;</b></p>
</div>
<!-- Page 123 -->
<a name="123"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page123-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1230">123&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1231"><b>2. Inspect&#160;the&#160;syringe.&#160;</b></p>
<p style="position:absolute;top:108px;left:107px;white-space:nowrap" class="ft1231"><b>Do not&#160;</b>use the&#160;syringe&#160;if:&#160;</p>
<p style="position:absolute;top:123px;left:149px;white-space:nowrap" class="ft1238">•&#160;&#160;It&#160;is cracked&#160;or&#160;damaged.&#160;</p>
<p style="position:absolute;top:143px;left:149px;white-space:nowrap" class="ft1238">•&#160;&#160;The expiration&#160;date&#160;has passed.&#160;</p>
<p style="position:absolute;top:167px;left:106px;white-space:nowrap" class="ft1235"><b>&#160;<br/>3.&#160;Inspect&#160;the medicine&#160;(see&#160;<i>Figure B</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft1232">The&#160;liquid should be&#160;clear&#160;and colourless&#160;to&#160;pale&#160;brown.&#160;</p>
<p style="position:absolute;top:224px;left:107px;white-space:nowrap" class="ft12313"><b>Do not&#160;</b>use the&#160;syringe&#160;if&#160;the&#160;liquid&#160;is&#160;cloudy,&#160;<br/>discoloured&#160;or&#160;contains&#160;particles&#160;in it.&#160;<i>&#160;<br/>Note:&#160;You&#160;may&#160;see&#160;air&#160;bubbles&#160;in the&#160;liquid.&#160;This&#160;is&#160;</i></p>
<p style="position:absolute;top:281px;left:106px;white-space:nowrap" class="ft1233"><i>normal.&#160;</i></p>
<p style="position:absolute;top:491px;left:769px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:507px;left:544px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:507px;left:586px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:507px;left:629px;white-space:nowrap" class="ft1233"><i>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;&#160; &#160;&#160;Figure&#160;B&#160;</i></p>
<p style="position:absolute;top:526px;left:106px;white-space:nowrap" class="ft1236"><b>&#160;<br/>4. Wait&#160;30&#160;minutes.&#160;</b></p>
<p style="position:absolute;top:564px;left:131px;white-space:nowrap" class="ft1232">a.&#160;&#160;Leave the&#160;syringe&#160;at&#160;room&#160;temperature&#160;for&#160;30&#160;minutes&#160;to allow&#160;it&#160;to&#160;naturally warm&#160;up.&#160;&#160;</p>
<p style="position:absolute;top:583px;left:107px;white-space:nowrap" class="ft1231"><b>Do not&#160;</b>warm&#160;the&#160;syringe&#160;using&#160;heat&#160;sources such&#160;as&#160;hot&#160;water&#160;or&#160;a&#160;microwave.&#160;</p>
<p style="position:absolute;top:602px;left:609px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:602px;left:651px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:602px;left:694px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:602px;left:736px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:602px;left:779px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:621px;left:106px;white-space:nowrap" class="ft12313"><i>&#160;<br/></i><b>5. Choose&#160;an&#160;injection&#160;site&#160;(see&#160;<i>Figure&#160;C</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:658px;left:131px;white-space:nowrap" class="ft1232">a.&#160;&#160;Select an&#160;injection&#160;site.&#160;You&#160;may&#160;inject into:&#160;</p>
<p style="position:absolute;top:673px;left:157px;white-space:nowrap" class="ft1238">•&#160;&#160;The&#160;front&#160;of&#160;the&#160;thighs.&#160;</p>
<p style="position:absolute;top:694px;left:157px;white-space:nowrap" class="ft1238">•&#160;&#160;The&#160;abdomen except&#160;for&#160;the&#160;5 cm&#160;around&#160;the&#160;</p>
<p style="position:absolute;top:718px;left:189px;white-space:nowrap" class="ft1232">belly button&#160;(navel).&#160;</p>
<p style="position:absolute;top:733px;left:157px;white-space:nowrap" class="ft1238">•&#160;&#160;The&#160;outer&#160;area&#160;of&#160;the&#160;upper&#160;arms&#160;(caregiver&#160;</p>
<p style="position:absolute;top:757px;left:189px;white-space:nowrap" class="ft1232">ONLY).&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft12313"><b>Do not</b>&#160;inject into&#160;skin&#160;that&#160;is&#160;within 5 cm&#160;of&#160;your&#160;belly&#160;<br/>button&#160;(navel), or&#160;is&#160;tender, damaged,&#160;bruised,&#160;or&#160;scarred.&#160;<br/><i>Note:&#160;Rotate&#160;the&#160;injection&#160;site&#160;each&#160;time&#160;you&#160;give&#160;an&#160;<br/>injection. Each new&#160;injection site&#160;should be&#160;at&#160;least&#160;3 cm&#160;<br/>away&#160;from&#160;the&#160;previous&#160;injection site.&#160;</i></p>
<p style="position:absolute;top:871px;left:114px;white-space:nowrap" class="ft1232">&#160;</p>
<p style="position:absolute;top:945px;left:779px;white-space:nowrap" class="ft1233"><i>&#160;</i></p>
<p style="position:absolute;top:960px;left:719px;white-space:nowrap" class="ft1233"><i>Figure&#160;C&#160;</i></p>
<p style="position:absolute;top:979px;left:106px;white-space:nowrap" class="ft1236"><b>&#160;<br/>6. Wash&#160;your&#160;hands.&#160;</b></p>
<p style="position:absolute;top:1017px;left:123px;white-space:nowrap" class="ft1232">a.&#160;&#160;Wash&#160;your&#160;hands&#160;with soap&#160;and water&#160;and dry them&#160;thoroughly.&#160;</p>
<p style="position:absolute;top:1036px;left:106px;white-space:nowrap" class="ft12310">&#160;<br/><b>7.&#160;Clean the&#160;injection&#160;site.&#160;</b></p>
<p style="position:absolute;top:1074px;left:123px;white-space:nowrap" class="ft12310">a.&#160;&#160;Clean&#160;the&#160;injection&#160;site&#160;with&#160;an&#160;alcohol swab.&#160;<br/>b.&#160;&#160;Let&#160;the&#160;skin dry before&#160;injecting.&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft12310"><b>Do not</b>&#160;blow&#160;on or&#160;touch&#160;the&#160;injection site&#160;again before&#160;giving the&#160;injection.&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:1131px;left:322px;white-space:nowrap" class="ft1231"><b>&#160;</b></p>
</div>
<!-- Page 124 -->
<a name="124"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page124-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1240">124&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1246"><b>Give&#160;the&#160;injection&#160;<br/>&#160;<br/>8. Remove&#160;the&#160;cap&#160;(see&#160;<i>Figure D</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:146px;left:131px;white-space:nowrap" class="ft1242">a.&#160;&#160;Pull the&#160;cap&#160;straight&#160;off&#160;and&#160;set&#160;it&#160;aside.&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft12410"><b>Do not&#160;</b>touch the&#160;needle.&#160;Doing so may result&#160;in a&#160;needle&#160;<br/>stick injury.&#160;<br/>Note:&#160;It is&#160;normal&#160;to see&#160;a&#160;drop of&#160;liquid at&#160;the&#160;end&#160;of&#160;the&#160;<br/>needle.&#160;</p>
<p style="position:absolute;top:241px;left:114px;white-space:nowrap" class="ft1242">&#160;</p>
<p style="position:absolute;top:432px;left:779px;white-space:nowrap" class="ft1243"><i>&#160;</i></p>
<p style="position:absolute;top:448px;left:717px;white-space:nowrap" class="ft1243"><i>Figure&#160;D</i>&#160;</p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft1245"><b>&#160;<br/>9.&#160;Insert&#160;the&#160;syringe&#160;into&#160;the&#160;injection&#160;site&#160;(see<i>&#160;Figure E</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:504px;left:129px;white-space:nowrap" class="ft1242">a.&#160;&#160;Hold the&#160;syringe&#160;by&#160;its&#160;body in one&#160;hand&#160;</p>
<p style="position:absolute;top:523px;left:159px;white-space:nowrap" class="ft1242">between your&#160;thumb&#160;and&#160;index finger.&#160;</p>
<p style="position:absolute;top:542px;left:129px;white-space:nowrap" class="ft1242">b.&#160;&#160;Using your&#160;other&#160;hand, gently pinch a&#160;fold&#160;of&#160;</p>
<p style="position:absolute;top:561px;left:159px;white-space:nowrap" class="ft1242">skin&#160;you&#160;cleaned.&#160;</p>
<p style="position:absolute;top:580px;left:129px;white-space:nowrap" class="ft1242">c.&#160;&#160;With a&#160;quick and&#160;“dart-like”&#160;motion,&#160;insert&#160;the&#160;</p>
<p style="position:absolute;top:599px;left:159px;white-space:nowrap" class="ft12410">needle&#160;completely&#160;into&#160;the&#160;fold&#160;of&#160;the&#160;skin&#160;at a&#160;<br/>45-degree angle.&#160;</p>
<p style="position:absolute;top:637px;left:114px;white-space:nowrap" class="ft1242">&#160;</p>
<p style="position:absolute;top:791px;left:779px;white-space:nowrap" class="ft1243"><i>&#160;</i></p>
<p style="position:absolute;top:806px;left:720px;white-space:nowrap" class="ft1243"><i>Figure&#160;E</i>&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1245"><b>&#160;<br/>10.&#160;Give&#160;the&#160;injection&#160;(see&#160;<i>Figure F</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:863px;left:127px;white-space:nowrap" class="ft1242">a.&#160;</p>
<p style="position:absolute;top:863px;left:159px;white-space:nowrap" class="ft12411">After the&#160;needle is&#160;inserted,&#160;let&#160;go of&#160;the&#160;pinched&#160;<br/>skin.&#160;</p>
<p style="position:absolute;top:901px;left:127px;white-space:nowrap" class="ft1242">b.&#160;&#160;Push the&#160;plunger&#160;down slowly&#160;and as&#160;far&#160;as&#160;it&#160;</p>
<p style="position:absolute;top:920px;left:159px;white-space:nowrap" class="ft1242">will go&#160;until&#160;the&#160;syringe&#160;is&#160;empty.&#160;</p>
<p style="position:absolute;top:939px;left:114px;white-space:nowrap" class="ft1242">&#160;</p>
<p style="position:absolute;top:1142px;left:779px;white-space:nowrap" class="ft1243"><i>&#160;</i></p>
<p style="position:absolute;top:1158px;left:543px;white-space:nowrap" class="ft1243"><i>&#160;</i></p>
<p style="position:absolute;top:1158px;left:585px;white-space:nowrap" class="ft1243"><i>&#160;</i></p>
<p style="position:absolute;top:1158px;left:628px;white-space:nowrap" class="ft1243"><i>&#160;</i></p>
<p style="position:absolute;top:1158px;left:670px;white-space:nowrap" class="ft1243"><i>&#160; &#160;&#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160; &#160;&#160;Figure&#160;F</i>&#160;</p>
</div>
<!-- Page 125 -->
<a name="125"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft12557{font-size:17px;font-family:TimesNewRomanPS;color:#221e1f;}
-->
</style>
<div id="page125-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1250">125&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1255"><b>&#160;<br/>11. Remove&#160;the&#160;needle from&#160;the&#160;injection&#160;site&#160;(see&#160;<i>Figure G</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:127px;left:131px;white-space:nowrap" class="ft1252">a.&#160;&#160;Remove&#160;the&#160;needle from&#160;the&#160;skin&#160;at&#160;the same&#160;</p>
<p style="position:absolute;top:146px;left:161px;white-space:nowrap" class="ft1252">angle it&#160;was inserted.&#160;</p>
<p style="position:absolute;top:165px;left:131px;white-space:nowrap" class="ft1252">b.&#160;&#160;Gently&#160;press a cotton&#160;ball&#160;or&#160;gauze over&#160;the&#160;</p>
<p style="position:absolute;top:184px;left:161px;white-space:nowrap" class="ft1252">injection site&#160;and hold for&#160;10 seconds.&#160;</p>
<p style="position:absolute;top:203px;left:131px;white-space:nowrap" class="ft1252">c.&#160;&#160;Apply an adhesive&#160;bandage,&#160;if&#160;necessary.&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1251"><b>Do not&#160;</b>rub&#160;the&#160;injection&#160;site.&#160;</p>
<p style="position:absolute;top:413px;left:776px;white-space:nowrap" class="ft1253"><i>&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;&#160;&#160;</i></p>
<p style="position:absolute;top:428px;left:719px;white-space:nowrap" class="ft1253"><i>&#160;Figure&#160;G</i>&#160;</p>
<p style="position:absolute;top:448px;left:106px;white-space:nowrap" class="ft1256"><b>&#160;<br/>After the injection&#160;<br/>&#160;<br/>12.&#160;Dispose of&#160;the&#160;syringe&#160;(see&#160;<i>Figure&#160;H</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:523px;left:131px;white-space:nowrap" class="ft1252">a.&#160;&#160;Put&#160;the&#160;used&#160;syringe&#160;in an approved sharps&#160;</p>
<p style="position:absolute;top:542px;left:161px;white-space:nowrap" class="ft1252">disposal&#160;container&#160;immediately&#160;after&#160;use.&#160;</p>
<p style="position:absolute;top:561px;left:131px;white-space:nowrap" class="ft1252">b.&#160;&#160;If&#160;you&#160;do&#160;not&#160;have&#160;an&#160;approved sharps&#160;disposal&#160;</p>
<p style="position:absolute;top:580px;left:161px;white-space:nowrap" class="ft12510">container, you may use&#160;a&#160;household container&#160;<br/>that is:&#160;</p>
<p style="position:absolute;top:614px;left:157px;white-space:nowrap" class="ft1258">•&#160;&#160;made&#160;of&#160;a&#160;heavy-duty plastic;&#160;</p>
<p style="position:absolute;top:634px;left:157px;white-space:nowrap" class="ft1258">•&#160;&#160;able&#160;to close&#160;with a&#160;tight-fitting,&#160;</p>
<p style="position:absolute;top:658px;left:189px;white-space:nowrap" class="ft12511">puncture-resistant&#160;lid, without&#160;sharps&#160;being&#160;<br/>able&#160;to come&#160;out;&#160;</p>
<p style="position:absolute;top:692px;left:157px;white-space:nowrap" class="ft1258">•&#160;&#160;upright&#160;and stable&#160;during use;&#160;</p>
<p style="position:absolute;top:712px;left:157px;white-space:nowrap" class="ft1258">•&#160;&#160;leak-resistant;&#160;and&#160;</p>
<p style="position:absolute;top:733px;left:157px;white-space:nowrap" class="ft1258">•&#160;&#160;properly&#160;labelled&#160;to warn of&#160;hazardous&#160;</p>
<p style="position:absolute;top:757px;left:189px;white-space:nowrap" class="ft1252">waste inside the&#160;container.&#160;</p>
<p style="position:absolute;top:776px;left:131px;white-space:nowrap" class="ft1252">c.&#160;&#160;When&#160;your&#160;sharps&#160;disposal&#160;container&#160;is&#160;almost&#160;</p>
<p style="position:absolute;top:795px;left:161px;white-space:nowrap" class="ft12510">full,&#160;it&#160;should&#160;be&#160;disposed&#160;of&#160;in&#160;accordance&#160;with&#160;<br/>local&#160;requirements.<b>&#160;</b></p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft1257"><b>Do not&#160;</b>recap&#160;the&#160;syringe.&#160;<br/><i>Note:&#160;Keep&#160;the&#160;syringe&#160;and&#160;sharps&#160;disposal&#160;container&#160;<br/>out of the&#160;sight and&#160;reach&#160;of children.</i>&#160;</p>
<p style="position:absolute;top:809px;left:779px;white-space:nowrap" class="ft1253"><i>&#160;</i></p>
<p style="position:absolute;top:825px;left:718px;white-space:nowrap" class="ft1253"><i>Figure&#160;H&#160;</i></p>
<p style="position:absolute;top:890px;left:106px;white-space:nowrap" class="ft12510">&#160;<br/>&#160;</p>
<p style="position:absolute;top:909px;left:322px;white-space:nowrap" class="ft1252">&#160;</p>
</div>
<!-- Page 126 -->
<a name="126"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft12658{font-size:17px;line-height:15px;font-family:TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page126-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1260">126&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1265">Read carefully&#160;these&#160;instructions&#160;before&#160;using&#160;the&#160;Remsima&#160;syringe. Consult&#160;your&#160;healthcare&#160;provider&#160;<br/>if&#160;you have&#160;questions&#160;about&#160;using&#160;the&#160;Remsima&#160;syringe.&#160;<br/><b>&#160;<br/>Important&#160;information&#160;</b></p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft1268">•&#160;&#160;Use the syringe&#160;<b>ONLY if</b>&#160;your&#160;healthcare&#160;provider&#160;has&#160;trained&#160;you on&#160;the&#160;right&#160;way to prepare&#160;for&#160;</p>
<p style="position:absolute;top:185px;left:137px;white-space:nowrap" class="ft1262">and&#160;to give&#160;an injection.&#160;</p>
<p style="position:absolute;top:200px;left:106px;white-space:nowrap" class="ft1268">•&#160;&#160;Ask your&#160;healthcare&#160;provider&#160;how&#160;often you will&#160;need&#160;to give&#160;an&#160;injection.&#160;</p>
<p style="position:absolute;top:220px;left:106px;white-space:nowrap" class="ft1268">•&#160;&#160;Rotate the injection&#160;site each&#160;time&#160;you give&#160;an injection. Each new&#160;injection site&#160;should be&#160;at&#160;least&#160;</p>
<p style="position:absolute;top:244px;left:137px;white-space:nowrap" class="ft1262">3&#160;cm&#160;away&#160;from&#160;the previous injection&#160;site.&#160;</p>
<p style="position:absolute;top:259px;left:106px;white-space:nowrap" class="ft1268">•&#160;&#160;<b>Do not&#160;</b>use&#160;the&#160;syringe&#160;if&#160;it&#160;has&#160;been dropped or&#160;is&#160;visibly damaged. A&#160;damaged&#160;syringe&#160;may not&#160;</p>
<p style="position:absolute;top:284px;left:137px;white-space:nowrap" class="ft1262">function&#160;properly.<b>&#160;</b></p>
<p style="position:absolute;top:298px;left:106px;white-space:nowrap" class="ft1268">•&#160;&#160;<b>Do not</b>&#160;reuse the&#160;syringe.&#160;</p>
<p style="position:absolute;top:319px;left:106px;white-space:nowrap" class="ft12611">•&#160;&#160;<b>Do not</b>&#160;shake the syringe at&#160;any&#160;time.&#160;<br/>&#160;<br/><b>About&#160;the Remsima&#160;syringe&#160;<br/></b>&#160;<br/><b>Parts of&#160;the&#160;syringe&#160;(see&#160;<i>Figure A</i></b><b>):&#160;</b></p>
<p style="position:absolute;top:705px;left:397px;white-space:nowrap" class="ft1261"><b>&#160;</b></p>
<p style="position:absolute;top:720px;left:330px;white-space:nowrap" class="ft1263"><i>Figure&#160;A&#160;</i></p>
<p style="position:absolute;top:739px;left:106px;white-space:nowrap" class="ft12658"><i>&#160;<br/></i>•&#160;&#160;<b>Do not&#160;</b>remove&#160;the&#160;cap until&#160;you are&#160;ready to inject. Once&#160;you&#160;remove&#160;the&#160;cap,&#160;<b>do&#160;not</b>&#160;recap&#160;the&#160;</p>
<p style="position:absolute;top:778px;left:137px;white-space:nowrap" class="ft1262">syringe.<b>&#160;</b></p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft1266">&#160;<br/><b>Prepare&#160;for&#160;the&#160;injection&#160;<br/>&#160;<br/>1.&#160;Gather the supplies for the&#160;injection.&#160;</b></p>
<p style="position:absolute;top:874px;left:123px;white-space:nowrap" class="ft12610">a.&#160;&#160;Prepare a&#160;clean,&#160;flat&#160;surface,&#160;such&#160;as a&#160;table or&#160;countertop,&#160;in&#160;a well-lit&#160;area.&#160;<br/>b.&#160;&#160;Remove&#160;the&#160;syringe&#160;from&#160;the&#160;carton stored in&#160;your&#160;refrigerator&#160;by holding the&#160;middle&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:912px;left:153px;white-space:nowrap" class="ft1262">syringe&#160;body.&#160;&#160;</p>
<p style="position:absolute;top:931px;left:123px;white-space:nowrap" class="ft1262">c.&#160;&#160;Ensure&#160;you have&#160;the&#160;following supplies:&#160;</p>
<p style="position:absolute;top:946px;left:149px;white-space:nowrap" class="ft1268">•&#160;&#160;Syringe&#160;</p>
<p style="position:absolute;top:966px;left:149px;white-space:nowrap" class="ft1268">•&#160;&#160;Alcohol&#160;swab&#160;</p>
<p style="position:absolute;top:986px;left:149px;white-space:nowrap" class="ft1268">•&#160;&#160;Cotton&#160;ball&#160;or&#160;gauze*&#160;</p>
<p style="position:absolute;top:1006px;left:149px;white-space:nowrap" class="ft1268">•&#160;&#160;Adhesive&#160;bandage*&#160;</p>
<p style="position:absolute;top:1027px;left:149px;white-space:nowrap" class="ft12619">•&#160;&#160;Sharps&#160;disposal&#160;container*&#160;<br/><i>*Items&#160;not&#160;included&#160;in the&#160;carton.&#160;</i></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1261"><b>&#160;</b></p>
</div>
<!-- Page 127 -->
<a name="127"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft12759{font-size:17px;font-family:TimesNewRomanPSMT;color:#231f20;}
	.ft12760{font-size:17px;font-family:TimesNewRomanPS;color:#231f20;}
	.ft12761{font-size:17px;line-height:19px;font-family:TimesNewRomanPSMT;color:#231f20;}
	.ft12762{font-size:17px;line-height:19px;font-family:TimesNewRomanPS;color:#231f20;}
-->
</style>
<div id="page127-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1270">127&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1275"><b>2.&#160;Inspect&#160;the syringe.&#160;<br/>Do not</b>&#160;use the syringe if:&#160;</p>
<p style="position:absolute;top:123px;left:151px;white-space:nowrap" class="ft1278">•&#160;&#160;It&#160;is cracked&#160;or&#160;damaged.&#160;</p>
<p style="position:absolute;top:143px;left:151px;white-space:nowrap" class="ft1278">•&#160;&#160;The expiration&#160;date&#160;has passed.<i>&#160;</i></p>
<p style="position:absolute;top:167px;left:106px;white-space:nowrap" class="ft1277"><b>&#160;<br/>3.&#160;Inspect&#160;the medicine&#160;(see&#160;<i>Figure B</i></b><b>).&#160;<br/></b>The&#160;liquid should be&#160;clear&#160;and colourless&#160;to&#160;pale&#160;brown.&#160;<br/><b>Do not&#160;</b>use the syringe if&#160;the liquid&#160;is&#160;cloudy,&#160;<br/>discoloured&#160;or&#160;contains&#160;particles&#160;in it.<b>&#160;<br/></b><i>Note:&#160;You&#160;may&#160;see&#160;air&#160;bubbles&#160;in the&#160;liquid.&#160;This&#160;is&#160;<br/>normal.</i>&#160;</p>
<p style="position:absolute;top:446px;left:779px;white-space:nowrap" class="ft1273"><i>&#160;</i></p>
<p style="position:absolute;top:462px;left:719px;white-space:nowrap" class="ft1273"><i>Figure&#160;B&#160;</i></p>
<p style="position:absolute;top:506px;left:106px;white-space:nowrap" class="ft1276"><b>&#160;<br/>4. Wait&#160;30&#160;minutes.&#160;</b></p>
<p style="position:absolute;top:544px;left:131px;white-space:nowrap" class="ft1272">a.&#160;&#160;Leave&#160;the&#160;syringe&#160;at&#160;room&#160;temperature&#160;for&#160;30&#160;minutes&#160;to allow&#160;it&#160;to&#160;naturally warm&#160;up.&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft1271"><b>Do not&#160;</b>warm&#160;the&#160;syringe&#160;using&#160;heat&#160;sources such&#160;as&#160;hot&#160;water&#160;or&#160;a&#160;microwave.&#160;</p>
<p style="position:absolute;top:582px;left:775px;white-space:nowrap" class="ft1272">&#160;</p>
<p style="position:absolute;top:601px;left:106px;white-space:nowrap" class="ft1276"><b>&#160;<br/>5. Choose&#160;an&#160;injection&#160;site&#160;(see&#160;<i>Figure&#160;C</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:639px;left:131px;white-space:nowrap" class="ft1272">a.&#160;&#160;Select an&#160;injection&#160;site.&#160;You&#160;may&#160;inject into:&#160;</p>
<p style="position:absolute;top:654px;left:157px;white-space:nowrap" class="ft1278">•&#160;&#160;The&#160;front&#160;of&#160;the&#160;thighs.&#160;</p>
<p style="position:absolute;top:674px;left:157px;white-space:nowrap" class="ft1278">•&#160;&#160;The&#160;abdomen except&#160;for&#160;the&#160;5 cm&#160;around&#160;the&#160;</p>
<p style="position:absolute;top:698px;left:189px;white-space:nowrap" class="ft1272">belly button&#160;(navel).&#160;</p>
<p style="position:absolute;top:713px;left:157px;white-space:nowrap" class="ft1278">•&#160;&#160;The&#160;outer&#160;area&#160;of&#160;the&#160;upper&#160;arms&#160;(caregiver&#160;</p>
<p style="position:absolute;top:737px;left:189px;white-space:nowrap" class="ft1272">ONLY).&#160;</p>
<p style="position:absolute;top:756px;left:106px;white-space:nowrap" class="ft1277"><b>Do not&#160;</b>inject&#160;into skin that&#160;is&#160;within 5 cm&#160;of&#160;your&#160;belly&#160;<br/>button&#160;(navel), or&#160;is&#160;tender,&#160;damaged, bruised,&#160;or&#160;scarred.<b>&#160;<br/></b><i>Note:&#160;Rotate&#160;the&#160;injection&#160;site&#160;each&#160;time&#160;you&#160;give&#160;an&#160;<br/>injection. Each new&#160;injection site&#160;should be&#160;at&#160;least&#160;3 cm&#160;<br/>away&#160;from&#160;the&#160;previous&#160;injection site.</i>&#160;</p>
<p style="position:absolute;top:925px;left:779px;white-space:nowrap" class="ft1273"><i>&#160;</i></p>
<p style="position:absolute;top:940px;left:718px;white-space:nowrap" class="ft1273"><i>Figure&#160;C&#160;</i></p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft1276"><b>&#160;<br/>6. Wash&#160;your&#160;hands.&#160;</b></p>
<p style="position:absolute;top:997px;left:131px;white-space:nowrap" class="ft1272">a.&#160;&#160;Wash&#160;your&#160;hands with&#160;soap&#160;and&#160;water&#160;and dry them&#160;thoroughly.<i>&#160;</i></p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft1276"><b>&#160;<br/>7.&#160;Clean the&#160;injection&#160;site.&#160;</b></p>
<p style="position:absolute;top:1054px;left:131px;white-space:nowrap" class="ft12710">a.&#160;&#160;Clean&#160;the&#160;injection&#160;site&#160;with&#160;an&#160;alcohol swab.&#160;&#160;<br/>b.&#160;&#160;Let&#160;the&#160;skin dry before&#160;injecting.&#160;</p>
<p style="position:absolute;top:1092px;left:107px;white-space:nowrap" class="ft12713"><b>Do not</b>&#160;blow&#160;on or&#160;touch&#160;the&#160;injection site&#160;again before&#160;giving the&#160;injection.<i>&#160;<br/></i><b>&#160;</b></p>
</div>
<!-- Page 128 -->
<a name="128"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page128-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1197px;left:433px;white-space:nowrap" class="ft1280">128&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1286"><b>Give&#160;the&#160;injection&#160;<br/>&#160;<br/>8.&#160;Remove the cap&#160;(see&#160;<i>Figure D</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:146px;left:131px;white-space:nowrap" class="ft1282">a.&#160;&#160;Pull&#160;the cap&#160;straight&#160;off&#160;and&#160;set&#160;it&#160;aside.&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft12810"><b>Do not&#160;</b>touch&#160;the&#160;needle.&#160;Doing so may result&#160;in a&#160;needle&#160;<br/>stick injury.&#160;<br/>Note:&#160;It is&#160;normal&#160;to see&#160;a&#160;drop of&#160;liquid at&#160;the&#160;end&#160;of&#160;the&#160;<br/>needle.&#160;</p>
<p style="position:absolute;top:432px;left:779px;white-space:nowrap" class="ft1283"><i>&#160;</i></p>
<p style="position:absolute;top:448px;left:717px;white-space:nowrap" class="ft1283"><i>Figure&#160;D&#160;</i></p>
<p style="position:absolute;top:466px;left:106px;white-space:nowrap" class="ft1285"><b>&#160;<br/>9.&#160;Insert&#160;the syringe into&#160;the injection&#160;site (see<i>&#160;Figure E</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:504px;left:127px;white-space:nowrap" class="ft1282">a.&#160;</p>
<p style="position:absolute;top:504px;left:159px;white-space:nowrap" class="ft12810">Hold the&#160;syringe&#160;by&#160;its&#160;body in one&#160;hand between&#160;<br/>your&#160;thumb and&#160;index finger.&#160;</p>
<p style="position:absolute;top:542px;left:127px;white-space:nowrap" class="ft1282">b.&#160;</p>
<p style="position:absolute;top:542px;left:159px;white-space:nowrap" class="ft12810">Using your&#160;other&#160;hand, gently pinch a&#160;fold&#160;of&#160;skin&#160;<br/>you cleaned.&#160;</p>
<p style="position:absolute;top:580px;left:127px;white-space:nowrap" class="ft1282">c.&#160;</p>
<p style="position:absolute;top:580px;left:159px;white-space:nowrap" class="ft12810">With a&#160;quick and&#160;“dart-like”&#160;motion,&#160;insert&#160;the&#160;<br/>needle&#160;completely&#160;into&#160;the&#160;fold&#160;of&#160;the&#160;skin&#160;at a&#160;<br/>45-degree angle.&#160;</p>
<p style="position:absolute;top:791px;left:779px;white-space:nowrap" class="ft1283"><i>&#160;</i></p>
<p style="position:absolute;top:806px;left:719px;white-space:nowrap" class="ft1283"><i>Figure&#160;E&#160;</i></p>
</div>
<!-- Page 129 -->
<a name="129"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page129-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1290">129&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1292">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1291"><b>10.&#160;Give&#160;the&#160;injection&#160;(see&#160;<i>Figure F</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft1292">a.&#160;&#160;After&#160;the&#160;needle&#160;is&#160;inserted,&#160;let&#160;go of&#160;the&#160;pinched&#160;</p>
<p style="position:absolute;top:127px;left:159px;white-space:nowrap" class="ft1292">skin.&#160;</p>
<p style="position:absolute;top:146px;left:129px;white-space:nowrap" class="ft1292">b.&#160;&#160;Push the&#160;plunger&#160;down&#160;slowly and&#160;as&#160;far&#160;as&#160;it&#160;will&#160;</p>
<p style="position:absolute;top:165px;left:159px;white-space:nowrap" class="ft1292">go until&#160;the&#160;syringe&#160;is&#160;empty.&#160;</p>
<p style="position:absolute;top:394px;left:782px;white-space:nowrap" class="ft1293"><i>&#160;</i></p>
<p style="position:absolute;top:410px;left:723px;white-space:nowrap" class="ft1293"><i>Figure&#160;F&#160;</i></p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft12911">&#160;<br/><b>11.&#160;Remove the syringe from&#160;the injection&#160;site&#160;(see&#160;<i>Figure G</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:466px;left:131px;white-space:nowrap" class="ft1292">a.&#160;&#160;After&#160;the&#160;syringe&#160;is&#160;empty,&#160;slowly&#160;lift your&#160;thumb&#160;</p>
<p style="position:absolute;top:485px;left:161px;white-space:nowrap" class="ft12910">from the&#160;plunger&#160;until needle&#160;is&#160;completely&#160;<br/>covered by&#160;the&#160;automatic&#160;needle&#160;guard.&#160;</p>
<p style="position:absolute;top:523px;left:131px;white-space:nowrap" class="ft1292">b.&#160;&#160;Gently&#160;press&#160;a cotton&#160;ball&#160;or&#160;gauze over&#160;the&#160;</p>
<p style="position:absolute;top:542px;left:161px;white-space:nowrap" class="ft1292">injection&#160;site&#160;and hold for&#160;10 seconds.&#160;</p>
<p style="position:absolute;top:561px;left:131px;white-space:nowrap" class="ft1292">c.&#160;&#160;Apply an&#160;adhesive&#160;bandage, if&#160;necessary.&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft1291"><b>Do not&#160;</b>rub&#160;the&#160;injection&#160;site.&#160;</p>
<p style="position:absolute;top:753px;left:779px;white-space:nowrap" class="ft1293"><i>&#160;&#160;</i></p>
<p style="position:absolute;top:768px;left:718px;white-space:nowrap" class="ft1293"><i>Figure&#160;G&#160;</i></p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft12910">&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:806px;left:322px;white-space:nowrap" class="ft1291"><b>&#160;</b></p>
</div>
<!-- Page 130 -->
<a name="130"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page130-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1300">130&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1302">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1306"><b>After the injection&#160;<br/>&#160;<br/>12.&#160;Dispose of&#160;the syringe&#160;(see&#160;<i>Figure&#160;H</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:146px;left:131px;white-space:nowrap" class="ft1302">a.&#160;&#160;Put&#160;the&#160;used syringe&#160;in an&#160;approved sharps&#160;</p>
<p style="position:absolute;top:165px;left:161px;white-space:nowrap" class="ft1302">disposal&#160;container&#160;immediately&#160;after&#160;use.&#160;</p>
<p style="position:absolute;top:184px;left:131px;white-space:nowrap" class="ft1302">b.&#160;&#160;If&#160;you do not&#160;have&#160;an&#160;approved sharps&#160;disposal&#160;</p>
<p style="position:absolute;top:203px;left:161px;white-space:nowrap" class="ft13010">container, you may use&#160;a&#160;household container&#160;<br/>that is:&#160;</p>
<p style="position:absolute;top:237px;left:157px;white-space:nowrap" class="ft1308">•&#160;&#160;made&#160;of&#160;a&#160;heavy-duty plastic;&#160;</p>
<p style="position:absolute;top:257px;left:157px;white-space:nowrap" class="ft1308">•&#160;&#160;able&#160;to close&#160;with a&#160;tight-fitting,&#160;</p>
<p style="position:absolute;top:281px;left:189px;white-space:nowrap" class="ft13010">puncture-resistant&#160;lid, without&#160;sharps&#160;being&#160;<br/>able&#160;to come&#160;out;&#160;</p>
<p style="position:absolute;top:315px;left:157px;white-space:nowrap" class="ft1308">•&#160;&#160;upright&#160;and stable&#160;during use;&#160;</p>
<p style="position:absolute;top:335px;left:157px;white-space:nowrap" class="ft1308">•&#160;&#160;leak-resistant;&#160;and&#160;</p>
<p style="position:absolute;top:355px;left:157px;white-space:nowrap" class="ft1308">•&#160;&#160;properly&#160;labelled&#160;to warn of&#160;hazardous&#160;</p>
<p style="position:absolute;top:380px;left:189px;white-space:nowrap" class="ft1302">waste inside the&#160;container.&#160;</p>
<p style="position:absolute;top:399px;left:131px;white-space:nowrap" class="ft1302">c.&#160;&#160;When&#160;your&#160;sharps&#160;disposal&#160;container&#160;is&#160;almost&#160;</p>
<p style="position:absolute;top:417px;left:161px;white-space:nowrap" class="ft13011">full, it&#160;should be&#160;disposed&#160;of&#160;in&#160;accordance&#160;with&#160;<br/>local requirements.&#160;</p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft13010"><b>Do not&#160;</b>recap the&#160;syringe.&#160;<br/><i>Note:&#160;Keep the&#160;syringe&#160;and&#160;sharps&#160;disposal&#160;container&#160;<br/>out of the&#160;sight and&#160;reach&#160;of children.</i>&#160;<br/>&#160;</p>
<p style="position:absolute;top:432px;left:784px;white-space:nowrap" class="ft1303"><i>&#160;</i></p>
<p style="position:absolute;top:448px;left:723px;white-space:nowrap" class="ft1303"><i>Figure&#160;H&#160;</i></p>
<p style="position:absolute;top:531px;left:106px;white-space:nowrap" class="ft13010">&#160;<br/>&#160;</p>
<p style="position:absolute;top:550px;left:322px;white-space:nowrap" class="ft1302">&#160;</p>
</div>
<!-- Page 131 -->
<a name="131"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page131-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1310">131&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1312">&#160;</p>
<p style="position:absolute;top:89px;left:303px;white-space:nowrap" class="ft1311"><b>Package&#160;leaflet:&#160;Information&#160;for&#160;the user</b>&#160;</p>
<p style="position:absolute;top:108px;left:447px;white-space:nowrap" class="ft1312">&#160;</p>
<p style="position:absolute;top:127px;left:252px;white-space:nowrap" class="ft1311"><b>Remsima 120&#160;mg&#160;solution&#160;for&#160;injection&#160;in pre-filled&#160;pen&#160;</b></p>
<p style="position:absolute;top:146px;left:412px;white-space:nowrap" class="ft1312">infliximab&#160;</p>
<p style="position:absolute;top:165px;left:447px;white-space:nowrap" class="ft1312">&#160;</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft13114">&#160;<br/><b>Read&#160;all&#160;of&#160;this leaflet&#160;carefully&#160;before you&#160;start&#160;using&#160;this medicine because it&#160;contains&#160;<br/>important information&#160;for&#160;you.</b>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:242px;left:149px;white-space:nowrap" class="ft1312">Keep&#160;this leaflet.&#160;You&#160;may&#160;need&#160;to&#160;read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:262px;left:149px;white-space:nowrap" class="ft13110">Your&#160;doctor&#160;will&#160;also&#160;give&#160;you a&#160;patient&#160;reminder&#160;card,&#160;which contains&#160;important&#160;safety&#160;<br/>information you need to be&#160;aware&#160;of&#160;before&#160;and during&#160;your&#160;treatment&#160;with Remsima.&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:301px;left:149px;white-space:nowrap" class="ft13110">When&#160;starting&#160;a new&#160;card,&#160;keep&#160;this card&#160;as a&#160;reference for&#160;4&#160;months&#160;after&#160;your&#160;last&#160;dose&#160;of&#160;<br/>Remsima.&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft1312">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor, pharmacist&#160;or&#160;nurse.&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:361px;left:149px;white-space:nowrap" class="ft13110">This&#160;medicine&#160;has&#160;been prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them,&#160;<br/>even if&#160;their&#160;signs of&#160;illness&#160;are the same&#160;as&#160;yours.&#160;</p>
<p style="position:absolute;top:394px;left:106px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:400px;left:149px;white-space:nowrap" class="ft13110">If&#160;you get&#160;any&#160;side&#160;effects,&#160;talk&#160;to your&#160;doctor, pharmacist&#160;or&#160;nurse. This&#160;includes&#160;any possible&#160;<br/>side effects&#160;not listed&#160;in&#160;this&#160;leaflet.&#160;See section&#160;4.&#160;</p>
<p style="position:absolute;top:438px;left:107px;white-space:nowrap" class="ft13111">&#160;<br/><b>What&#160;is&#160;in&#160;this&#160;leaflet&#160;<br/></b>&#160;<br/>1.&#160;</p>
<p style="position:absolute;top:495px;left:139px;white-space:nowrap" class="ft1312">What&#160;Remsima&#160;is&#160;and&#160;what&#160;it&#160;is&#160;used for&#160;&#160;</p>
<p style="position:absolute;top:513px;left:107px;white-space:nowrap" class="ft1312">2.&#160;</p>
<p style="position:absolute;top:513px;left:139px;white-space:nowrap" class="ft1312">What&#160;you need&#160;to know&#160;before&#160;you use&#160;Remsima&#160;&#160;</p>
<p style="position:absolute;top:532px;left:107px;white-space:nowrap" class="ft1312">3.&#160;</p>
<p style="position:absolute;top:532px;left:139px;white-space:nowrap" class="ft1312">How&#160;to use&#160;Remsima&#160;&#160;</p>
<p style="position:absolute;top:551px;left:107px;white-space:nowrap" class="ft1312">4.&#160;</p>
<p style="position:absolute;top:551px;left:139px;white-space:nowrap" class="ft1312">Possible side&#160;effects&#160;&#160;</p>
<p style="position:absolute;top:570px;left:107px;white-space:nowrap" class="ft1312">5.&#160;</p>
<p style="position:absolute;top:570px;left:139px;white-space:nowrap" class="ft1312">How&#160;to store&#160;Remsima&#160;</p>
<p style="position:absolute;top:589px;left:107px;white-space:nowrap" class="ft1312">6.&#160;</p>
<p style="position:absolute;top:589px;left:139px;white-space:nowrap" class="ft1312">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:608px;left:107px;white-space:nowrap" class="ft1312">7.&#160;</p>
<p style="position:absolute;top:608px;left:139px;white-space:nowrap" class="ft1312">Instructions&#160;for&#160;use&#160;</p>
<p style="position:absolute;top:627px;left:107px;white-space:nowrap" class="ft13110">&#160;<br/>&#160;<br/><b>1.&#160;</b></p>
<p style="position:absolute;top:665px;left:149px;white-space:nowrap" class="ft1311"><b>What Remsima&#160;is&#160;and&#160;what it is&#160;used&#160;for&#160;</b></p>
<p style="position:absolute;top:684px;left:107px;white-space:nowrap" class="ft13111">&#160;<br/>Remsima&#160;contains the active&#160;substance infliximab.&#160;Infliximab is&#160;a&#160;monoclonal&#160;antibody&#160;-&#160;a&#160;type&#160;of&#160;<br/>protein&#160;that&#160;attaches to&#160;a specific&#160;target&#160;in&#160;the body&#160;called&#160;TNF&#160;(tumour&#160;necrosis&#160;factor)&#160;alpha.&#160;<br/>&#160;<br/>Remsima&#160;belongs&#160;to&#160;a&#160;group of&#160;medicines&#160;called ‘TNF&#160;blockers’. It&#160;is&#160;used&#160;in adults&#160;for&#160;the&#160;following&#160;<br/>inflammatory&#160;diseases:&#160;</p>
<p style="position:absolute;top:794px;left:106px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:799px;left:149px;white-space:nowrap" class="ft1312">Rheumatoid&#160;arthritis&#160;</p>
<p style="position:absolute;top:814px;left:106px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:819px;left:149px;white-space:nowrap" class="ft1312">Psoriatic&#160;arthritis&#160;</p>
<p style="position:absolute;top:834px;left:106px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:840px;left:149px;white-space:nowrap" class="ft1312">Ankylosing&#160;spondylitis&#160;(Bechterew’s&#160;disease)&#160;</p>
<p style="position:absolute;top:854px;left:107px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:860px;left:149px;white-space:nowrap" class="ft1312">Psoriasis&#160;</p>
<p style="position:absolute;top:875px;left:107px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft1312">Crohn’s&#160;disease&#160;</p>
<p style="position:absolute;top:895px;left:107px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:900px;left:149px;white-space:nowrap" class="ft1312">Ulcerative colitis.&#160;</p>
<p style="position:absolute;top:919px;left:107px;white-space:nowrap" class="ft13111">&#160;<br/>Remsima&#160;works&#160;by&#160;selectively&#160;attaching&#160;to&#160;TNF&#160;alpha&#160;and&#160;blocking its&#160;action.&#160;TNF&#160;alpha&#160;is&#160;involved&#160;<br/>in&#160;inflammatory processes&#160;of&#160;the&#160;body&#160;so blocking&#160;it&#160;can reduce&#160;the&#160;inflammation&#160;in your&#160;body.&#160;<br/>&#160;<br/><b>Rheumatoid arthritis&#160;<br/></b>Rheumatoid&#160;arthritis&#160;is&#160;an&#160;inflammatory&#160;disease&#160;of&#160;the&#160;joints<i>.&#160;</i>If&#160;you have&#160;active&#160;rheumatoid arthritis&#160;<br/>you will&#160;first&#160;be&#160;given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines&#160;do not&#160;work well&#160;enough, you will&#160;be&#160;given&#160;<br/>Remsima&#160;which you will&#160;take&#160;with another&#160;medicine&#160;called&#160;methotrexate&#160;to:&#160;</p>
<p style="position:absolute;top:1067px;left:107px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:1072px;left:149px;white-space:nowrap" class="ft1312">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:1087px;left:107px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:1092px;left:149px;white-space:nowrap" class="ft1312">slow&#160;down the&#160;damage&#160;in&#160;your&#160;joints,&#160;</p>
<p style="position:absolute;top:1107px;left:107px;white-space:nowrap" class="ft1318">•&#160;</p>
<p style="position:absolute;top:1112px;left:149px;white-space:nowrap" class="ft1312">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:1131px;left:107px;white-space:nowrap" class="ft1312">&#160;</p>
</div>
<!-- Page 132 -->
<a name="132"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page132-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1320">132&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1322">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft13211"><b>Psoriatic arthritis&#160;<br/></b>Psoriatic arthritis is&#160;an&#160;inflammatory&#160;disease of&#160;the joints,&#160;usually&#160;accompanied&#160;by&#160;psoriasis.&#160;If&#160;you&#160;<br/>have active psoriatic arthritis you&#160;will&#160;first&#160;be given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines&#160;do not&#160;work&#160;<br/>well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft1322">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:181px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:186px;left:149px;white-space:nowrap" class="ft1322">slow&#160;down the&#160;damage&#160;in&#160;your&#160;joints,&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft1322">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft13211"><b>&#160;<br/>Ankylosing&#160;spondylitis (Bechterew’s disease)&#160;<br/></b>Ankylosing&#160;spondylitis&#160;is&#160;an inflammatory&#160;disease&#160;of&#160;the&#160;spine. If&#160;you have&#160;ankylosing&#160;spondylitis&#160;<br/>you will&#160;first&#160;be&#160;given&#160;other&#160;medicines.&#160;If&#160;these&#160;medicines&#160;do not&#160;work well&#160;enough, you will&#160;be&#160;given&#160;<br/>Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:321px;left:149px;white-space:nowrap" class="ft1322">reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;your&#160;disease,&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:342px;left:149px;white-space:nowrap" class="ft1322">improve&#160;your&#160;physical&#160;function.&#160;</p>
<p style="position:absolute;top:361px;left:106px;white-space:nowrap" class="ft13211"><b>&#160;<br/>Psoriasis&#160;<br/></b>Psoriasis&#160;is&#160;an&#160;inflammatory disease&#160;of&#160;the&#160;skin. If&#160;you&#160;have&#160;moderate&#160;to severe&#160;plaque&#160;psoriasis, you&#160;<br/>will&#160;first&#160;be&#160;given&#160;other&#160;medicines&#160;or&#160;treatments, such&#160;as&#160;phototherapy.&#160;If&#160;these&#160;medicines&#160;or&#160;<br/>treatments&#160;do not&#160;work well&#160;enough, you will&#160;be&#160;given&#160;Remsima&#160;to reduce&#160;the&#160;signs&#160;and&#160;symptoms&#160;of&#160;<br/>your&#160;disease.&#160;<br/>&#160;<br/><b>Ulcerative colitis&#160;<br/></b>Ulcerative colitis is an&#160;inflammatory&#160;disease of&#160;the&#160;bowel.&#160;If&#160;you&#160;have ulcerative colitis&#160;you&#160;will first&#160;<br/>be&#160;given other&#160;medicines. If&#160;these&#160;medicines&#160;do not&#160;work well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to&#160;<br/>treat&#160;your&#160;disease.&#160;<br/><b>&#160;<br/>Crohn’s disease&#160;<br/></b>Crohn’s disease&#160;is an&#160;inflammatory&#160;disease&#160;of&#160;the bowel.&#160;If&#160;you&#160;have Crohn’s disease you&#160;will&#160;first&#160;be&#160;<br/>given other&#160;medicines.&#160;If&#160;these medicines&#160;do not&#160;work&#160;well&#160;enough,&#160;you will&#160;be&#160;given Remsima&#160;to:&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:646px;left:149px;white-space:nowrap" class="ft1322">treat&#160;active Crohn’s disease,&#160;</p>
<p style="position:absolute;top:661px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:666px;left:149px;white-space:nowrap" class="ft13210">reduce&#160;the&#160;number&#160;of&#160;abnormal&#160;openings&#160;(fistulae)&#160;between your&#160;bowel&#160;and&#160;your&#160;skin&#160;that&#160;have&#160;<br/>not&#160;been controlled&#160;by other&#160;medicines&#160;or surgery.&#160;</p>
<p style="position:absolute;top:704px;left:106px;white-space:nowrap" class="ft13210">&#160;<br/>&#160;<br/><b>2.&#160;</b></p>
<p style="position:absolute;top:742px;left:149px;white-space:nowrap" class="ft1321"><b>What&#160;you&#160;need&#160;to know&#160;before&#160;you&#160;use&#160;Remsima</b>&#160;<b>&#160;</b></p>
<p style="position:absolute;top:761px;left:106px;white-space:nowrap" class="ft13242"><b>&#160;<br/>You must&#160;not&#160;use&#160;Remsima&#160;if&#160;<br/></b>•&#160;</p>
<p style="position:absolute;top:801px;left:149px;white-space:nowrap" class="ft13210">you&#160;are&#160;allergic&#160;to&#160;infliximab&#160;or&#160;any&#160;of&#160;the&#160;other&#160;ingredients&#160;of&#160;this&#160;medicine&#160;(listed&#160;in&#160;<br/>section&#160;6),&#160;</p>
<p style="position:absolute;top:834px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:840px;left:149px;white-space:nowrap" class="ft1322">you&#160;are&#160;allergic&#160;to&#160;proteins&#160;that&#160;come&#160;from mice,&#160;</p>
<p style="position:absolute;top:854px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:860px;left:149px;white-space:nowrap" class="ft13210">you&#160;have&#160;tuberculosis&#160;(TB)&#160;or&#160;another&#160;serious&#160;infection&#160;such as&#160;pneumonia&#160;or&#160;sepsis&#160;(serious&#160;<br/>bacterial&#160;infection of&#160;the&#160;blood),&#160;</p>
<p style="position:absolute;top:893px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft1322">you&#160;have heart&#160;failure&#160;that&#160;is moderate&#160;or&#160;severe.&#160;</p>
<p style="position:absolute;top:918px;left:107px;white-space:nowrap" class="ft13211">&#160;<br/>Do not&#160;use&#160;Remsima&#160;if&#160;any&#160;of&#160;the&#160;above&#160;applies&#160;to you. If&#160;you are&#160;not&#160;sure,&#160;talk&#160;to&#160;your&#160;doctor&#160;before&#160;<br/>you are&#160;given&#160;Remsima.&#160;<br/>&#160;<br/><b>Warnings and&#160;precautions&#160;&#160;<br/></b>Talk&#160;to your&#160;doctor&#160;before&#160;or&#160;during&#160;treatment&#160;with&#160;Remsima&#160;if&#160;you have:&#160;<br/>&#160;<br/>Had treatment&#160;with&#160;any&#160;medicine&#160;containing&#160;infliximab before&#160;<br/>&#160;</p>
<p style="position:absolute;top:1085px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:1090px;left:149px;white-space:nowrap" class="ft13210">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;have&#160;had&#160;treatment with&#160;medicines&#160;containing&#160;infliximab&#160;in&#160;the&#160;past and&#160;<br/>are now&#160;starting&#160;Remsima&#160;treatment&#160;again.&#160;</p>
<p style="position:absolute;top:1124px;left:106px;white-space:nowrap" class="ft1328">•&#160;</p>
<p style="position:absolute;top:1129px;left:149px;white-space:nowrap" class="ft13210">If&#160;you have&#160;had&#160;a&#160;break&#160;in&#160;your&#160;treatment&#160;with&#160;infliximab of&#160;more&#160;than 16 weeks, there&#160;is&#160;a&#160;<br/>higher&#160;risk&#160;for&#160;allergic&#160;reactions&#160;when you&#160;start&#160;the&#160;treatment&#160;again.&#160;</p>
</div>
<!-- Page 133 -->
<a name="133"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page133-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1330">133&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1332">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft13314">&#160;<br/>Local&#160;injection&#160;site&#160;reactions&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft13311">Some&#160;patients&#160;receiving&#160;infliximab&#160;via&#160;injection under&#160;the&#160;skin&#160;have&#160;experienced&#160;local injection&#160;<br/>site&#160;reactions. Signs&#160;of&#160;a&#160;local injection&#160;site&#160;reaction can&#160;include&#160;redness, pain,&#160;itching, swelling,&#160;<br/>hardness,&#160;bruising, bleeding, cold&#160;sensation,&#160;tingling&#160;sensation, irritation,&#160;rash,&#160;ulcer, hives,&#160;<br/>blisters and&#160;scab&#160;on the&#160;skin of&#160;the&#160;injection&#160;site.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft1332">Most&#160;of&#160;these&#160;reactions are mild&#160;to&#160;moderate&#160;and&#160;mostly&#160;resolve&#160;on&#160;their&#160;own within a&#160;day.&#160;</p>
<p style="position:absolute;top:243px;left:106px;white-space:nowrap" class="ft13311">&#160;<br/>Infections&#160;<br/>&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:301px;left:149px;white-space:nowrap" class="ft13310">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;an infection even if&#160;it&#160;is&#160;a&#160;very&#160;<br/>minor&#160;one.&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft13310">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given&#160;Remsima&#160;if&#160;you have&#160;ever&#160;lived in&#160;or&#160;travelled&#160;to an&#160;area&#160;<br/>where&#160;infections called&#160;histoplasmosis,&#160;coccidioidomycosis,&#160;or&#160;blastomycosis&#160;are&#160;common.&#160;<br/>These&#160;infections are caused&#160;by&#160;specific&#160;types of&#160;fungi&#160;that&#160;can&#160;affect&#160;the&#160;lungs or&#160;other&#160;parts&#160;of&#160;<br/>your&#160;body.&#160;</p>
<p style="position:absolute;top:412px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:418px;left:149px;white-space:nowrap" class="ft13310">You may&#160;get&#160;infections&#160;more&#160;easily when you&#160;are&#160;being treated with Remsima. If&#160;you are&#160;65&#160;<br/>years&#160;of&#160;age&#160;or&#160;older, you&#160;have a greater&#160;risk.&#160;</p>
<p style="position:absolute;top:451px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:457px;left:149px;white-space:nowrap" class="ft13310">These&#160;infections&#160;may&#160;be&#160;serious&#160;and include&#160;tuberculosis, infections&#160;caused&#160;by&#160;viruses, fungi,&#160;<br/>bacteria or&#160;other&#160;organisms&#160;in&#160;the environment&#160;and&#160;sepsis&#160;that&#160;may&#160;be life-threatening.&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft13311">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;signs&#160;of&#160;infection during treatment&#160;with Remsima. Signs&#160;<br/>include&#160;fever,&#160;cough, flu-like&#160;signs,&#160;feeling unwell,&#160;red or&#160;hot&#160;skin, wounds&#160;or&#160;dental&#160;problems. Your&#160;<br/>doctor&#160;may recommend temporarily&#160;stopping&#160;Remsima.&#160;<br/>&#160;<br/>Tuberculosis&#160;(TB)&#160;<br/>&#160;</p>
<p style="position:absolute;top:604px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:610px;left:149px;white-space:nowrap" class="ft13310">It is&#160;very&#160;important that&#160;you&#160;tell your&#160;doctor&#160;if&#160;you have&#160;ever&#160;had TB&#160;or&#160;if&#160;you have&#160;been in&#160;<br/>close&#160;contact&#160;with&#160;someone&#160;who has&#160;had or&#160;has&#160;TB.&#160;</p>
<p style="position:absolute;top:643px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:649px;left:149px;white-space:nowrap" class="ft13311">Your&#160;doctor&#160;will&#160;test&#160;you&#160;to&#160;see&#160;if&#160;you have&#160;TB. Cases&#160;of&#160;TB&#160;have&#160;been reported&#160;in patients&#160;<br/>treated&#160;with&#160;infliximab,&#160;even in patients&#160;who have&#160;already been treated with&#160;medicines&#160;for&#160;TB.&#160;<br/>Your&#160;doctor&#160;will&#160;record&#160;these&#160;tests&#160;on your&#160;patient&#160;reminder&#160;card.&#160;</p>
<p style="position:absolute;top:702px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:707px;left:149px;white-space:nowrap" class="ft13310">If&#160;your&#160;doctor&#160;feels&#160;that&#160;you are&#160;at&#160;risk for&#160;TB, you may be&#160;treated&#160;with medicines&#160;for&#160;TB&#160;before&#160;<br/>you are&#160;given Remsima.&#160;</p>
<p style="position:absolute;top:745px;left:106px;white-space:nowrap" class="ft13314">Tell&#160;your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;signs&#160;of&#160;TB&#160;during&#160;treatment&#160;with Remsima. Signs&#160;include&#160;<br/>persistent&#160;cough, weight&#160;loss, feeling&#160;tired,&#160;fever,&#160;night&#160;sweats.&#160;<br/>&#160;<br/>Hepatitis B&#160;virus&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:841px;left:149px;white-space:nowrap" class="ft13310">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;using Remsima&#160;if&#160;you&#160;are&#160;a&#160;carrier&#160;of&#160;hepatitis&#160;B&#160;or&#160;have&#160;ever&#160;<br/>had&#160;it.&#160;</p>
<p style="position:absolute;top:875px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft1332">Tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you might&#160;be&#160;at&#160;risk&#160;of&#160;contracting&#160;hepatitis&#160;B.&#160;</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:900px;left:149px;white-space:nowrap" class="ft1332">Your&#160;doctor&#160;should&#160;test&#160;you for&#160;hepatitis&#160;B&#160;virus.&#160;</p>
<p style="position:absolute;top:915px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:920px;left:149px;white-space:nowrap" class="ft13310">Treatment&#160;with&#160;TNF&#160;blockers&#160;such&#160;as Remsima may&#160;result&#160;in&#160;reactivation&#160;of&#160;hepatitis&#160;B&#160;virus&#160;in&#160;<br/>patients&#160;who carry this&#160;virus,&#160;which&#160;can&#160;be life-threatening&#160;in&#160;some cases.&#160;</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:959px;left:149px;white-space:nowrap" class="ft13310">If&#160;you experience&#160;reactivation of&#160;hepatitis&#160;B, your&#160;doctor&#160;may need&#160;to stop your&#160;treatment&#160;and&#160;<br/>may&#160;give&#160;you&#160;medicines&#160;such&#160;as&#160;effective antiviral&#160;therapy&#160;with&#160;supportive treatment.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft13311">&#160;<br/>Heart&#160;problems&#160;<br/>&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:1056px;left:149px;white-space:nowrap" class="ft1332">Tell&#160;your&#160;doctor&#160;if&#160;you have&#160;any heart&#160;problems, such&#160;as&#160;mild heart&#160;failure.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1338">•&#160;</p>
<p style="position:absolute;top:1076px;left:149px;white-space:nowrap" class="ft1332">Your&#160;doctor&#160;will&#160;want&#160;to closely&#160;monitor&#160;your&#160;heart.&#160;</p>
<p style="position:absolute;top:1095px;left:106px;white-space:nowrap" class="ft13311">Tell&#160;your&#160;doctor&#160;straight&#160;away if&#160;you get&#160;new&#160;or&#160;worsening signs&#160;of&#160;heart&#160;failure&#160;during&#160;treatment&#160;with&#160;<br/>Remsima. Signs&#160;include&#160;shortness&#160;of&#160;breath or&#160;swelling of&#160;your&#160;feet.&#160;<br/>&#160;</p>
</div>
<!-- Page 134 -->
<a name="134"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page134-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1340">134&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1342">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft13411">Cancer&#160;and lymphoma&#160;<br/>&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft13410">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;or&#160;have&#160;ever&#160;had lymphoma&#160;(a&#160;type&#160;<br/>of&#160;blood cancer)&#160;or&#160;any other&#160;cancer.&#160;</p>
<p style="position:absolute;top:162px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:167px;left:149px;white-space:nowrap" class="ft13410">Patients&#160;with severe&#160;rheumatoid arthritis, who have had&#160;the disease for&#160;a&#160;long&#160;time,&#160;may&#160;be&#160;at&#160;<br/>higher&#160;risk&#160;of&#160;developing lymphoma.&#160;</p>
<p style="position:absolute;top:201px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:206px;left:149px;white-space:nowrap" class="ft13410">Patients&#160;taking Remsima&#160;may have&#160;an&#160;increased&#160;risk of&#160;developing lymphoma&#160;or&#160;another&#160;<br/>cancer.&#160;</p>
<p style="position:absolute;top:240px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:246px;left:149px;white-space:nowrap" class="ft13411">Some patients who&#160;have&#160;received&#160;TNF-blockers, including&#160;infliximab have&#160;developed&#160;a rare&#160;<br/>type&#160;of&#160;cancer&#160;called hepatosplenic&#160;T-cell&#160;lymphoma.&#160;Of&#160;these patients,&#160;most&#160;were teenage&#160;boys&#160;<br/>or&#160;young&#160;men&#160;and&#160;most&#160;had&#160;either&#160;Crohn’s disease&#160;or&#160;ulcerative&#160;colitis.&#160;This type of&#160;cancer&#160;has&#160;<br/>usually&#160;resulted&#160;in death.&#160;Almost&#160;all&#160;patients&#160;had&#160;also received medicines&#160;containing&#160;<br/>azathioprine&#160;or&#160;mercaptopurine&#160;in&#160;addition to TNF-blockers.&#160;&#160;</p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:342px;left:149px;white-space:nowrap" class="ft13410">Some patients&#160;treated&#160;with&#160;infliximab&#160;have developed&#160;certain&#160;kinds of&#160;skin&#160;cancer.&#160;If&#160;there are&#160;<br/>any changes&#160;in your&#160;skin or&#160;growths&#160;on&#160;the&#160;skin&#160;during&#160;or&#160;after&#160;therapy,&#160;tell&#160;your&#160;doctor.&#160;</p>
<p style="position:absolute;top:376px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:381px;left:149px;white-space:nowrap" class="ft13410">Some&#160;women&#160;being treated&#160;for&#160;rheumatoid arthritis&#160;with infliximab&#160;have&#160;developed cervical&#160;<br/>cancer. For&#160;women&#160;taking&#160;Remsima&#160;including those&#160;over&#160;60&#160;years&#160;of&#160;age, your&#160;doctor&#160;may&#160;<br/>recommend&#160;regular&#160;screening&#160;for&#160;cervical&#160;cancer.&#160;</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft13414">&#160;<br/>Lung disease&#160;or&#160;heavy smoking&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:496px;left:149px;white-space:nowrap" class="ft13410">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;a&#160;lung&#160;disease&#160;called chronic&#160;<br/>obstructive&#160;pulmonary disease&#160;(COPD)&#160;or&#160;if&#160;you are&#160;a&#160;heavy&#160;smoker.&#160;</p>
<p style="position:absolute;top:530px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:535px;left:149px;white-space:nowrap" class="ft13410">Patients&#160;with COPD&#160;and patients&#160;who are&#160;heavy smokers&#160;may have&#160;a&#160;higher&#160;risk of&#160;developing&#160;<br/>cancer&#160;with&#160;Remsima treatment.&#160;</p>
<p style="position:absolute;top:573px;left:106px;white-space:nowrap" class="ft13414">&#160;<br/>Nervous system&#160;disease&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:631px;left:149px;white-space:nowrap" class="ft13410">Tell&#160;your&#160;doctor&#160;before&#160;you&#160;are&#160;given Remsima&#160;if&#160;you&#160;have&#160;or&#160;have&#160;ever&#160;had a&#160;problem&#160;that&#160;<br/>affects your&#160;nervous system.&#160;This includes&#160;multiple sclerosis,&#160;Guillain-Barré&#160;syndrome, if&#160;you&#160;<br/>have&#160;fits&#160;or&#160;have&#160;been diagnosed with&#160;‘optic&#160;neuritis’.&#160;</p>
<p style="position:absolute;top:688px;left:106px;white-space:nowrap" class="ft13414">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;symptoms&#160;of&#160;a&#160;nerve&#160;disease&#160;during treatment&#160;with&#160;Remsima.&#160;<br/>Signs&#160;include&#160;changes&#160;in your&#160;vision, weakness&#160;in&#160;your&#160;arms&#160;or&#160;legs, numbness&#160;or&#160;tingling in any part&#160;<br/>of&#160;your&#160;body.&#160;<br/>&#160;<br/>Abnormal&#160;skin&#160;openings&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:803px;left:149px;white-space:nowrap" class="ft13410">Tell&#160;your&#160;doctor&#160;if&#160;you have&#160;any abnormal&#160;skin openings&#160;(fistulae)&#160;before&#160;you&#160;are&#160;given&#160;<br/>Remsima.&#160;</p>
<p style="position:absolute;top:841px;left:106px;white-space:nowrap" class="ft13410">&#160;<br/>Vaccinations&#160;<br/>&#160;</p>
<p style="position:absolute;top:894px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft1342">Talk&#160;to your&#160;doctor&#160;if&#160;you&#160;recently&#160;have&#160;had or&#160;are&#160;due&#160;to have&#160;a&#160;vaccine.&#160;</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:919px;left:149px;white-space:nowrap" class="ft13410">You should receive&#160;recommended vaccinations&#160;before&#160;starting Remsima&#160;treatment. You&#160;may&#160;<br/>receive&#160;some vaccines&#160;during&#160;treatment&#160;with&#160;Remsima&#160;but&#160;you&#160;should&#160;not&#160;receive&#160;live vaccines&#160;<br/>(vaccines&#160;that&#160;contain a&#160;living but&#160;weakened infectious&#160;agent)&#160;while&#160;using Remsima because&#160;<br/>they&#160;may&#160;cause infections.&#160;</p>
<p style="position:absolute;top:991px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:996px;left:149px;white-space:nowrap" class="ft13411">If&#160;you received&#160;Remsima&#160;while&#160;you were&#160;pregnant, your&#160;baby may also be&#160;at&#160;higher&#160;risk&#160;for&#160;<br/>getting an infection&#160;as a&#160;result&#160;of&#160;receiving&#160;a&#160;live vaccine during&#160;the&#160;first&#160;year&#160;of&#160;life.&#160;It is&#160;<br/>important that you&#160;tell your&#160;baby's&#160;doctors&#160;and other&#160;health care&#160;professionals&#160;about&#160;your&#160;<br/>Remsima&#160;use&#160;so&#160;they&#160;can&#160;decide&#160;when your&#160;baby should receive&#160;any vaccine,&#160;including&#160;live&#160;<br/>vaccines&#160;such&#160;as&#160;the&#160;BCG&#160;vaccine&#160;(used&#160;to&#160;prevent&#160;tuberculosis).&#160;&#160;</p>
<p style="position:absolute;top:1087px;left:106px;white-space:nowrap" class="ft1348">•&#160;</p>
<p style="position:absolute;top:1092px;left:149px;white-space:nowrap" class="ft13411">If&#160;you are&#160;breast-feeding,&#160;it is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;<br/>professionals&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;your&#160;baby is&#160;given any&#160;vaccine.&#160;For&#160;more&#160;<br/>information see&#160;section&#160;on Pregnancy&#160;and&#160;breast-feeding.&#160;</p>
<p style="position:absolute;top:1149px;left:106px;white-space:nowrap" class="ft1342">&#160;</p>
</div>
<!-- Page 135 -->
<a name="135"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page135-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1350">135&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1352">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft13511">Therapeutic infectious&#160;agents&#160;<br/>&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:128px;left:149px;white-space:nowrap" class="ft13510">Talk to&#160;your&#160;doctor&#160;if&#160;you&#160;have recently&#160;received&#160;or&#160;are&#160;scheduled&#160;to&#160;receive treatment&#160;with&#160;a&#160;<br/>therapeutic infectious&#160;agent&#160;(such&#160;as BCG&#160;instillation&#160;used&#160;for&#160;the&#160;treatment&#160;of&#160;cancer).&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft13511">&#160;<br/>Operations&#160;or&#160;dental&#160;procedures&#160;<br/>&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft1352">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;going to&#160;have&#160;any&#160;operations or&#160;dental&#160;procedures.&#160;</p>
<p style="position:absolute;top:239px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:244px;left:149px;white-space:nowrap" class="ft13510">Tell&#160;your&#160;surgeon&#160;or&#160;dentist&#160;that&#160;you&#160;are&#160;having&#160;treatment&#160;with Remsima&#160;by&#160;showing them&#160;your&#160;<br/>patient&#160;reminder&#160;card.&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft13514">&#160;<br/>Liver&#160;problems&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft1352">Some&#160;patients&#160;receiving infliximab&#160;have&#160;developed serious&#160;liver&#160;problems.&#160;</p>
<p style="position:absolute;top:355px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:361px;left:149px;white-space:nowrap" class="ft13510">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;symptoms&#160;of&#160;liver&#160;problems&#160;during treatment&#160;with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;yellowing of&#160;the&#160;skin and eyes, dark-brown&#160;coloured urine, pain or&#160;<br/>swelling&#160;in&#160;the&#160;upper&#160;right&#160;side&#160;of&#160;the&#160;stomach area,&#160;joint&#160;pain, skin rashes, or&#160;fever.&#160;</p>
<p style="position:absolute;top:417px;left:106px;white-space:nowrap" class="ft13514">&#160;<br/>Low blood&#160;counts&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:476px;left:149px;white-space:nowrap" class="ft13510">In some&#160;patients&#160;receiving&#160;infliximab, the&#160;body&#160;may not&#160;make&#160;enough&#160;of&#160;the&#160;blood&#160;cells&#160;that&#160;<br/>help fight&#160;infections&#160;or&#160;help&#160;stop bleeding.&#160;&#160;</p>
<p style="position:absolute;top:509px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:515px;left:149px;white-space:nowrap" class="ft13510">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;get&#160;symptoms&#160;of&#160;low&#160;blood counts&#160;during&#160;treatment&#160;with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;persistent&#160;fever,&#160;bleeding&#160;or&#160;bruising&#160;more&#160;easily,&#160;small&#160;red or&#160;purple&#160;<br/>spots&#160;caused by bleeding under&#160;the&#160;skin, or&#160;looking pale.&#160;</p>
<p style="position:absolute;top:572px;left:106px;white-space:nowrap" class="ft13514">&#160;<br/>Immune&#160;system disorder&#160;<br/>&#160;<br/>•&#160;</p>
<p style="position:absolute;top:631px;left:149px;white-space:nowrap" class="ft13510">Some patients&#160;receiving&#160;infliximab&#160;have developed&#160;symptoms&#160;of&#160;an&#160;immune&#160;system&#160;disorder&#160;<br/>called&#160;lupus.&#160;</p>
<p style="position:absolute;top:665px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:670px;left:149px;white-space:nowrap" class="ft13510">Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you develop symptoms&#160;of&#160;lupus&#160;during treatment&#160;with&#160;<br/>Remsima.&#160;Signs&#160;include&#160;joint&#160;pain&#160;or&#160;a&#160;rash&#160;on&#160;cheeks&#160;or&#160;arms that&#160;is sensitive&#160;to&#160;the sun.&#160;</p>
<p style="position:absolute;top:708px;left:106px;white-space:nowrap" class="ft13511">&#160;<br/><b>Children and adolescents&#160;<br/></b>Do&#160;not&#160;give&#160;this&#160;medicine to&#160;children&#160;and&#160;adolescents&#160;under&#160;18&#160;years&#160;of&#160;age because there are no&#160;data&#160;<br/>that show&#160;that this&#160;medicine&#160;is&#160;safe&#160;and&#160;works&#160;in&#160;this&#160;age&#160;group.&#160;<br/><b>&#160;<br/>Other medicines&#160;and&#160;Remsima</b>&#160;<br/>Patients&#160;who&#160;have inflammatory&#160;diseases already&#160;take medicines to&#160;treat&#160;their&#160;problem.&#160;These&#160;<br/>medicines&#160;may cause&#160;side&#160;effects. Your&#160;doctor&#160;will&#160;advise&#160;you what&#160;other&#160;medicines&#160;you&#160;must&#160;keep&#160;<br/>using while&#160;you&#160;are&#160;having Remsima.&#160;<br/>&#160;<br/>Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;using,&#160;have&#160;recently&#160;used&#160;or&#160;might&#160;use&#160;any&#160;other&#160;medicines, including any&#160;<br/>other&#160;medicines&#160;to&#160;treat&#160;Crohn’s disease,&#160;ulcerative&#160;colitis,&#160;rheumatoid arthritis,&#160;ankylosing&#160;<br/>spondylitis, psoriatic&#160;arthritis&#160;or&#160;psoriasis&#160;or&#160;medicines&#160;obtained without&#160;a&#160;prescription,&#160;such as&#160;<br/>vitamins&#160;and&#160;herbal&#160;medicines.&#160;&#160;<br/>&#160;<br/>In particular, tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;using any of&#160;the&#160;following&#160;medicines:&#160;</p>
<p style="position:absolute;top:1007px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1352">Medicines&#160;that&#160;affect&#160;your&#160;immune system.&#160;</p>
<p style="position:absolute;top:1027px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:1033px;left:149px;white-space:nowrap" class="ft1352">Kineret&#160;(which&#160;contains&#160;anakinra).&#160;Remsima&#160;and Kineret&#160;should not&#160;be&#160;used&#160;together.&#160;</p>
<p style="position:absolute;top:1048px;left:106px;white-space:nowrap" class="ft1358">•&#160;</p>
<p style="position:absolute;top:1053px;left:149px;white-space:nowrap" class="ft1352">Orencia (which&#160;contains abatacept).&#160;Remsima and&#160;Orencia&#160;should&#160;not&#160;be&#160;used&#160;together.&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft13511">While using&#160;Remsima&#160;you&#160;should not&#160;receive&#160;live&#160;vaccines. If&#160;you were&#160;using&#160;Remsima&#160;during&#160;<br/>pregnancy&#160;or&#160;if&#160;you&#160;are receiving&#160;Remsima&#160;while breast-feeding, tell&#160;your&#160;baby’s&#160;doctor&#160;and other&#160;<br/>health care&#160;professionals&#160;caring&#160;for&#160;your&#160;baby&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;the&#160;baby&#160;receives&#160;any&#160;<br/>vaccines.&#160;<br/>&#160;</p>
</div>
<!-- Page 136 -->
<a name="136"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page136-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1360">136&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1362">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft13611">If&#160;you are&#160;not&#160;sure&#160;if&#160;any of&#160;the&#160;above&#160;applies&#160;to&#160;you,&#160;talk&#160;to your&#160;doctor, pharmacist&#160;or&#160;nurse&#160;before&#160;<br/>using&#160;Remsima.&#160;<br/>&#160;<br/><b>Pregnancy,&#160;breast-feeding&#160;and&#160;fertility&#160;</b></p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft1368">•&#160;</p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft13611">If&#160;you are&#160;pregnant&#160;or&#160;breast-feeding,&#160;think you&#160;may be&#160;pregnant&#160;or&#160;are&#160;planning to&#160;have&#160;a&#160;baby,&#160;<br/>ask your&#160;doctor&#160;for&#160;advice&#160;before&#160;taking this&#160;medicine.&#160;Remsima&#160;should&#160;only&#160;be&#160;used during&#160;<br/>pregnancy&#160;or&#160;while&#160;breast-feeding&#160;if&#160;your&#160;doctor&#160;feels&#160;it&#160;is&#160;necessary&#160;for&#160;you.&#160;</p>
<p style="position:absolute;top:219px;left:106px;white-space:nowrap" class="ft1368">•&#160;</p>
<p style="position:absolute;top:224px;left:149px;white-space:nowrap" class="ft13610">You should avoid getting pregnant&#160;when you&#160;are&#160;being&#160;treated with Remsima&#160;and&#160;for&#160;6&#160;months&#160;<br/>after&#160;you stop being&#160;treated&#160;with&#160;it. Discuss&#160;the&#160;use&#160;of&#160;contraception&#160;during this&#160;time&#160;with your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:277px;left:106px;white-space:nowrap" class="ft1368">•&#160;</p>
<p style="position:absolute;top:282px;left:149px;white-space:nowrap" class="ft13610">If&#160;you received Remsima&#160;during&#160;your&#160;pregnancy, your&#160;baby&#160;may have&#160;a&#160;higher&#160;risk for&#160;getting&#160;<br/>an infection.&#160;</p>
<p style="position:absolute;top:316px;left:106px;white-space:nowrap" class="ft1368">•&#160;</p>
<p style="position:absolute;top:321px;left:149px;white-space:nowrap" class="ft13611">It&#160;is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;professionals&#160;about&#160;your&#160;<br/>Remsima&#160;use&#160;before&#160;your&#160;baby is&#160;given any vaccine. If&#160;you received Remsima&#160;while&#160;pregnant,&#160;<br/>giving BCG&#160;vaccine&#160;(used&#160;to prevent&#160;tuberculosis)&#160;to your&#160;baby within&#160;12&#160;months&#160;after&#160;birth&#160;<br/>may&#160;result&#160;in&#160;infection with&#160;serious&#160;complications,&#160;including death. Live&#160;vaccines&#160;such as&#160;the&#160;<br/>BCG&#160;vaccine&#160;should&#160;not&#160;be&#160;given&#160;to your&#160;baby within&#160;12&#160;months&#160;after&#160;birth, unless&#160;your&#160;baby’s&#160;<br/>doctor&#160;recommends&#160;otherwise.&#160;For more&#160;information&#160;LOsee section&#160;on&#160;vaccination.&#160;</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1368">•&#160;</p>
<p style="position:absolute;top:436px;left:149px;white-space:nowrap" class="ft13610">If&#160;you are&#160;breast-feeding, it&#160;is&#160;important&#160;that&#160;you tell&#160;your&#160;baby’s&#160;doctors&#160;and other&#160;healthcare&#160;<br/>professionals&#160;about&#160;your&#160;Remsima&#160;use&#160;before&#160;your&#160;baby is&#160;given any&#160;vaccine.&#160;Live vaccines&#160;<br/>should not&#160;be&#160;given&#160;to your&#160;baby&#160;while&#160;you are&#160;breast-feeding unless&#160;your&#160;baby’s&#160;doctor&#160;<br/>recommends otherwise.&#160;</p>
<p style="position:absolute;top:508px;left:106px;white-space:nowrap" class="ft1368">•&#160;</p>
<p style="position:absolute;top:513px;left:149px;white-space:nowrap" class="ft13611">Severely&#160;decreased numbers&#160;of&#160;white&#160;blood cells&#160;have&#160;been&#160;reported in&#160;infants&#160;born to women&#160;<br/>treated with infliximab during pregnancy. If&#160;your&#160;baby&#160;has&#160;continual&#160;fevers&#160;or&#160;infections,&#160;<br/>contact&#160;your&#160;baby’s&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:570px;left:106px;white-space:nowrap" class="ft13610">&#160;<br/><b>Driving and&#160;using&#160;machines&#160;<br/></b>Remsima&#160;is&#160;not&#160;likely&#160;to affect&#160;your&#160;ability&#160;to drive&#160;or&#160;use&#160;tools&#160;or&#160;machines. If&#160;you feel&#160;tired, dizzy, or&#160;<br/>unwell&#160;after&#160;having&#160;Remsima, do&#160;not&#160;drive&#160;or&#160;use&#160;any&#160;tools&#160;or&#160;machines.&#160;<br/>&#160;<br/><b>Remsima contains&#160;sodium&#160;and&#160;sorbitol&#160;<br/></b>This medicine contains&#160;less&#160;than 1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;dose, i.e. essentially&#160;‘sodium-free’&#160;and&#160;<br/>45 mg&#160;sorbitol&#160;in each 120&#160;mg dose.&#160;&#160;<br/>&#160;<br/>&#160;<br/><b>3.&#160;</b></p>
<p style="position:absolute;top:760px;left:149px;white-space:nowrap" class="ft1361"><b>How&#160;to&#160;use&#160;Remsima&#160;</b></p>
<p style="position:absolute;top:779px;left:106px;white-space:nowrap" class="ft13611">&#160;<br/>Always use&#160;this&#160;medicine&#160;exactly as&#160;your&#160;doctor&#160;has&#160;told you. Check with&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;not&#160;<br/>sure.&#160;&#160;<br/>&#160;<br/><b>Rheumatoid arthritis&#160;<br/></b>Your&#160;doctor&#160;will start your&#160;treatment with&#160;or&#160;without&#160;two&#160;Remsima&#160;intravenous&#160;infusion&#160;doses&#160;of&#160;3&#160;mg&#160;<br/>for&#160;every kg of&#160;body&#160;weight&#160;(given to&#160;you&#160;into a&#160;vein,&#160;usually&#160;in your&#160;arm, over&#160;a&#160;period of&#160;2 hours).&#160;If&#160;<br/>Remsima&#160;intravenous infusion&#160;doses are given&#160;to&#160;start&#160;the treatment,&#160;they&#160;are&#160;administered&#160;2&#160;weeks&#160;<br/>apart&#160;via&#160;intravenous&#160;infusion.&#160;After&#160;4 weeks&#160;from&#160;the&#160;last&#160;intravenous&#160;infusion, you will&#160;be&#160;given&#160;<br/>Remsima&#160;via&#160;injection under&#160;the&#160;skin&#160;(subcutaneous&#160;injection).&#160;&#160;<br/>The usual&#160;recommended&#160;dose&#160;of&#160;Remsima&#160;subcutaneous injection&#160;is&#160;120&#160;mg&#160;once&#160;every&#160;2&#160;weeks&#160;<br/>regardless&#160;of&#160;weight.&#160;<br/><b>&#160;<br/>Psoriatic arthritis,&#160;ankylosing&#160;spondylitis&#160;(Bechterew’s disease)&#160;and&#160;psoriasis&#160;&#160;<br/></b>Your&#160;doctor&#160;will&#160;start&#160;your&#160;treatment&#160;with&#160;two Remsima&#160;intravenous&#160;infusion&#160;doses&#160;of&#160;5&#160;mg for&#160;every&#160;<br/>kg of&#160;body weight&#160;(given&#160;to&#160;you into a&#160;vein, usually&#160;in&#160;your&#160;arm, over&#160;a&#160;period of&#160;2 hours). They are&#160;<br/>administered&#160;2&#160;weeks&#160;apart&#160;via&#160;intravenous&#160;infusion.&#160;After&#160;4 weeks&#160;from&#160;the&#160;last&#160;intravenous&#160;infusion,&#160;<br/>you will&#160;be&#160;given Remsima&#160;via&#160;injection&#160;under&#160;the&#160;skin&#160;(subcutaneous&#160;injection).&#160;&#160;<br/>The usual&#160;recommended&#160;dose of&#160;Remsima&#160;subcutaneous injection&#160;is 120&#160;mg&#160;once&#160;every&#160;2&#160;weeks&#160;<br/>regardless&#160;of&#160;weight.&#160;&#160;<br/><b>&#160;</b></p>
</div>
<!-- Page 137 -->
<a name="137"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page137-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1370">137&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1372">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1375"><b>Crohn’s&#160;disease and&#160;ulcerative colitis&#160;<br/></b>Your&#160;doctor&#160;will&#160;start&#160;your&#160;treatment&#160;with&#160;two Remsima&#160;intravenous&#160;infusion&#160;doses&#160;of&#160;5&#160;mg for&#160;every&#160;<br/>kg of&#160;body weight&#160;(given&#160;to&#160;you into a&#160;vein, usually&#160;in&#160;your&#160;arm, over&#160;a&#160;period of&#160;2 hours). They are&#160;<br/>administered&#160;2&#160;weeks apart&#160;via&#160;intravenous&#160;infusion.&#160;After&#160;4&#160;weeks&#160;from&#160;the&#160;last&#160;intravenous&#160;infusion,&#160;<br/>you will&#160;be&#160;given Remsima&#160;via&#160;injection&#160;under&#160;the&#160;skin&#160;(subcutaneous&#160;injection).&#160;&#160;<br/>The usual&#160;recommended&#160;dose of&#160;Remsima&#160;subcutaneous injection&#160;is 120&#160;mg&#160;once&#160;every&#160;2&#160;weeks&#160;<br/>regardless&#160;of&#160;weight.&#160;<br/><b>&#160;<br/>How&#160;Remsima&#160;is given&#160;</b></p>
<p style="position:absolute;top:256px;left:106px;white-space:nowrap" class="ft1378">•&#160;</p>
<p style="position:absolute;top:261px;left:149px;white-space:nowrap" class="ft13711">Remsima&#160;120 mg&#160;solution for&#160;injection&#160;is&#160;administered&#160;by injection under&#160;the&#160;skin&#160;<br/>(subcutaneous&#160;use)&#160;only.&#160;It&#160;is important&#160;to&#160;check&#160;the product&#160;labels to&#160;ensure&#160;that&#160;the correct&#160;<br/>formulation is&#160;being&#160;given as&#160;prescribed.&#160;</p>
<p style="position:absolute;top:314px;left:106px;white-space:nowrap" class="ft1378">•&#160;</p>
<p style="position:absolute;top:319px;left:149px;white-space:nowrap" class="ft13711">For&#160;patients&#160;with rheumatoid arthritis, your&#160;doctor&#160;may&#160;start&#160;your&#160;Remsima&#160;treatment&#160;with or&#160;<br/>without&#160;two&#160;Remsima&#160;intravenous&#160;infusion doses.&#160;For&#160;patients&#160;with&#160;Crohn’s&#160;disease, ulcerative&#160;<br/>colitis, ankylosing spondylitis,&#160;psoriatic&#160;arthritis&#160;or&#160;psoriasis, two Remsima&#160;infusion doses&#160;will&#160;<br/>be&#160;given to start&#160;your&#160;Remsima&#160;treatment.&#160;&#160;&#160;</p>
<p style="position:absolute;top:391px;left:106px;white-space:nowrap" class="ft1378">•&#160;</p>
<p style="position:absolute;top:396px;left:149px;white-space:nowrap" class="ft13710">If&#160;Remsima&#160;treatment is&#160;initiated&#160;without&#160;two&#160;Remsima&#160;intravenous&#160;infusion&#160;doses,&#160;the table&#160;<br/>below&#160;shows&#160;how&#160;often you will&#160;usually have&#160;this&#160;medicine&#160;after&#160;your&#160;first&#160;dose.&#160;</p>
<p style="position:absolute;top:434px;left:160px;white-space:nowrap" class="ft1372">&#160;</p>
<p style="position:absolute;top:455px;left:158px;white-space:nowrap" class="ft1372">2nd&#160;dose&#160;</p>
<p style="position:absolute;top:455px;left:419px;white-space:nowrap" class="ft1372">1&#160;week&#160;after your 1st&#160;dose&#160;</p>
<p style="position:absolute;top:475px;left:158px;white-space:nowrap" class="ft1372">3rd&#160;dose&#160;</p>
<p style="position:absolute;top:475px;left:419px;white-space:nowrap" class="ft1372">2&#160;weeks after&#160;your&#160;1st&#160;dose&#160;</p>
<p style="position:absolute;top:495px;left:158px;white-space:nowrap" class="ft1372">4th&#160;dose&#160;</p>
<p style="position:absolute;top:495px;left:419px;white-space:nowrap" class="ft1372">3&#160;weeks&#160;after&#160;your&#160;1st&#160;dose&#160;</p>
<p style="position:absolute;top:516px;left:158px;white-space:nowrap" class="ft1372">5th&#160;dose&#160;</p>
<p style="position:absolute;top:516px;left:419px;white-space:nowrap" class="ft1372">4&#160;weeks&#160;after&#160;your&#160;1st&#160;dose&#160;</p>
<p style="position:absolute;top:536px;left:158px;white-space:nowrap" class="ft1372">Further&#160;doses&#160;</p>
<p style="position:absolute;top:536px;left:419px;white-space:nowrap" class="ft13711">6&#160;weeks&#160;after&#160;your&#160;1st&#160;dose&#160;and&#160;every&#160;2&#160;weeks&#160;<br/>thereafter&#160;</p>
<p style="position:absolute;top:575px;left:106px;white-space:nowrap" class="ft1372">&#160;</p>
<p style="position:absolute;top:590px;left:106px;white-space:nowrap" class="ft1378">•&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft13710">If&#160;two Remsima&#160;intravenous&#160;infusion doses&#160;are&#160;given&#160;by your&#160;doctor&#160;or&#160;nurse&#160;to&#160;start&#160;the&#160;<br/>treatment,&#160;they will&#160;be&#160;given 2 weeks&#160;apart&#160;and&#160;the&#160;first Remsima&#160;subcutaneous&#160;injection&#160;will&#160;<br/>be&#160;given&#160;4&#160;weeks after&#160;the last&#160;intravenous&#160;infusion&#160;followed by&#160;Remsima&#160;subcutaneous&#160;<br/>injections&#160;given every&#160;2 weeks.&#160;&#160;</p>
<p style="position:absolute;top:667px;left:106px;white-space:nowrap" class="ft1378">•&#160;</p>
<p style="position:absolute;top:672px;left:149px;white-space:nowrap" class="ft13710">The&#160;first&#160;subcutaneous&#160;injection&#160;of&#160;Remsima&#160;will&#160;be&#160;administered under&#160;the&#160;supervision of&#160;your&#160;<br/>doctor.&#160;</p>
<p style="position:absolute;top:706px;left:106px;white-space:nowrap" class="ft1378">•&#160;</p>
<p style="position:absolute;top:712px;left:149px;white-space:nowrap" class="ft13710">After proper&#160;training,&#160;if&#160;you feel&#160;you&#160;are&#160;well-trained&#160;and confident&#160;to&#160;inject&#160;Remsima&#160;yourself,&#160;<br/>your&#160;doctor&#160;may&#160;allow&#160;you&#160;to&#160;inject&#160;subsequent&#160;doses&#160;of&#160;Remsima&#160;yourself&#160;at home.&#160;</p>
<p style="position:absolute;top:745px;left:106px;white-space:nowrap" class="ft1378">•&#160;</p>
<p style="position:absolute;top:751px;left:149px;white-space:nowrap" class="ft13710">Talk&#160;to your&#160;doctor&#160;if&#160;you&#160;have&#160;any questions&#160;about&#160;giving yourself&#160;an&#160;injection.&#160;You will&#160;find&#160;<br/>detailed&#160;<b>“Instructions for Use”</b>&#160;at&#160;the end&#160;of&#160;this leaflet.&#160;&#160;</p>
<p style="position:absolute;top:789px;left:106px;white-space:nowrap" class="ft13711">&#160;<br/><b>If&#160;you&#160;use&#160;more&#160;Remsima&#160;than&#160;you&#160;should&#160;<br/></b>If&#160;you have&#160;used more&#160;Remsima&#160;than you should&#160;(either&#160;by injecting&#160;too&#160;much on&#160;a&#160;single&#160;occasion or&#160;<br/>by&#160;using it&#160;too frequently),&#160;talk to&#160;a&#160;doctor,&#160;pharmacist&#160;or&#160;nurse&#160;immediately.&#160;Always&#160;have&#160;the&#160;outer&#160;<br/>carton of&#160;the&#160;medicine&#160;with&#160;you,&#160;even&#160;if&#160;it&#160;is&#160;empty.&#160;&#160;<br/>&#160;<br/><b>If&#160;you&#160;forget&#160;to&#160;use Remsima&#160;<br/></b>&#160;<br/>Missed dose&#160;for&#160;up to 7 days</p>
<p style="position:absolute;top:935px;left:296px;white-space:nowrap" class="ft13754">&#160;</p>
<p style="position:absolute;top:962px;left:106px;white-space:nowrap" class="ft13737">If&#160;you miss&#160;a&#160;dose&#160;of&#160;Remsima&#160;for&#160;up&#160;to 7 days, after&#160;the&#160;original&#160;scheduled dose,&#160;you should&#160;take&#160;the&#160;<br/>missed&#160;dose&#160;immediately.&#160;Take&#160;your&#160;next&#160;dose&#160;on&#160;the&#160;next&#160;originally&#160;planned&#160;date&#160;and&#160;then follow&#160;the&#160;<br/>original&#160;dosing schedule.</p>
<p style="position:absolute;top:1003px;left:272px;white-space:nowrap" class="ft13755">&#160;</p>
<p style="position:absolute;top:1028px;left:106px;white-space:nowrap" class="ft13710">&#160;<br/>Missed&#160;dose for&#160;8&#160;days&#160;or&#160;more&#160;&#160;<br/>If&#160;you miss&#160;a&#160;dose&#160;of&#160;Remsima&#160;for&#160;8&#160;days&#160;or&#160;more, after&#160;the&#160;original&#160;scheduled&#160;dose, you should not&#160;take&#160;<br/>the&#160;missed&#160;dose.&#160;Take&#160;your&#160;next&#160;dose&#160;on&#160;the&#160;next&#160;originally&#160;planned&#160;date&#160;and&#160;then&#160;follow&#160;the&#160;original&#160;<br/>dosing schedule.&#160;&#160;<br/>&#160;<br/>If&#160;you are&#160;not&#160;sure&#160;when&#160;to&#160;inject&#160;Remsima,&#160;call&#160;your&#160;doctor.&#160;&#160;</p>
</div>
<!-- Page 138 -->
<a name="138"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page138-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1380">138&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1382">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft13810">&#160;<br/>If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor, pharmacist&#160;or&#160;nurse.&#160;<br/>&#160;<br/>&#160;<br/><b>4.&#160;</b></p>
<p style="position:absolute;top:165px;left:149px;white-space:nowrap" class="ft1381"><b>Possible side&#160;effects</b>&#160;</p>
<p style="position:absolute;top:184px;left:106px;white-space:nowrap" class="ft13811">&#160;<br/>Like&#160;all&#160;medicines,&#160;this&#160;medicine&#160;can cause&#160;side&#160;effects, although not&#160;everybody gets&#160;them.&#160;Most&#160;side&#160;<br/>effects&#160;are mild&#160;to&#160;moderate.&#160;However&#160;some&#160;patients may&#160;experience serious&#160;side&#160;effects and&#160;may&#160;<br/>require&#160;treatment.&#160;Side effects&#160;may&#160;also&#160;occur&#160;after&#160;your&#160;treatment&#160;with&#160;Remsima&#160;has&#160;stopped.&#160;&#160;<br/>&#160;<br/><b>Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;notice&#160;any&#160;of&#160;the&#160;following:&#160;</b></p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:299px;left:149px;white-space:nowrap" class="ft13811"><b>Signs of&#160;an&#160;allergic reaction&#160;</b>such&#160;as&#160;swelling&#160;of&#160;your&#160;face, lips,&#160;mouth or&#160;throat&#160;which&#160;may&#160;<br/>cause&#160;difficulty&#160;in&#160;swallowing or&#160;breathing, skin&#160;rash,&#160;hives, swelling of&#160;the&#160;hands, feet&#160;or&#160;<br/>ankles.&#160;Some of&#160;these reactions&#160;may&#160;be serious&#160;or&#160;life-threatening.&#160;An allergic&#160;reaction could&#160;<br/>happen within 2&#160;hours&#160;of&#160;your&#160;injection or&#160;later.&#160;More signs&#160;of&#160;allergic&#160;side effects&#160;that&#160;may&#160;<br/>happen&#160;up to&#160;12&#160;days&#160;after&#160;your&#160;injection&#160;include&#160;pain&#160;in the&#160;muscles, fever,&#160;joint&#160;or&#160;jaw&#160;pain,&#160;<br/>sore&#160;throat&#160;or&#160;headache.&#160;</p>
<p style="position:absolute;top:409px;left:106px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:414px;left:149px;white-space:nowrap" class="ft13810"><b>Signs&#160;of&#160;a&#160;local&#160;injection&#160;site reaction&#160;</b>such&#160;as&#160;redness, pain, itching,&#160;swelling, hardness,&#160;<br/>bruising,&#160;bleeding,&#160;cold sensation, tingling&#160;sensation, irritation,&#160;rash, ulcer, hives,&#160;blisters&#160;and&#160;<br/>scab.&#160;<b>&#160;</b></p>
<p style="position:absolute;top:467px;left:106px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:472px;left:149px;white-space:nowrap" class="ft13811"><b>Signs&#160;of&#160;a&#160;heart&#160;problem</b>&#160;such as&#160;chest&#160;discomfort&#160;or&#160;pain,&#160;arm&#160;pain,&#160;stomach pain, shortness&#160;<br/>of&#160;breath,&#160;anxiety, lightheadedness,&#160;dizziness, fainting,&#160;sweating, nausea&#160;(feeling sick),&#160;<br/>vomiting, fluttering&#160;or&#160;pounding&#160;in your&#160;chest, a&#160;fast&#160;or&#160;a&#160;slow&#160;heartbeat, and swelling&#160;of&#160;your&#160;<br/>feet.&#160;</p>
<p style="position:absolute;top:544px;left:106px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:549px;left:149px;white-space:nowrap" class="ft13811"><b>Signs&#160;of&#160;infection (including&#160;TB)&#160;</b>such&#160;as&#160;fever,&#160;feeling&#160;tired,&#160;cough&#160;which may&#160;be&#160;persistent,&#160;<br/>shortness&#160;of&#160;breath, flu-like&#160;symptoms, weight&#160;loss,&#160;night&#160;sweats, diarrhoea, wounds,&#160;collection&#160;<br/>of&#160;pus&#160;in&#160;the&#160;gut&#160;or&#160;around&#160;the&#160;anus&#160;(abscess),&#160;dental&#160;problems&#160;or&#160;burning&#160;sensation&#160;when&#160;<br/>urinating.&#160;</p>
<p style="position:absolute;top:620px;left:106px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:625px;left:149px;white-space:nowrap" class="ft13811"><b>Possible signs&#160;of&#160;cancer&#160;</b>including but&#160;not&#160;limited&#160;to swelling of&#160;lymph nodes, weight&#160;loss,&#160;<br/>fever, unusual&#160;skin nodules, changes&#160;in&#160;moles&#160;or&#160;skin colouring,&#160;or&#160;unusual&#160;vaginal&#160;bleeding.&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:665px;left:149px;white-space:nowrap" class="ft1381"><b>Signs&#160;of&#160;a&#160;lung&#160;problem&#160;</b>such as&#160;coughing,&#160;breathing&#160;difficulties&#160;or&#160;tightness&#160;in&#160;the&#160;chest.&#160;</p>
<p style="position:absolute;top:680px;left:106px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:685px;left:149px;white-space:nowrap" class="ft13811"><b>Signs&#160;of&#160;a&#160;nervous&#160;system&#160;problem&#160;(including&#160;eye&#160;problems)&#160;</b>such&#160;as&#160;signs of&#160;a&#160;stroke&#160;<br/>(sudden numbness&#160;or&#160;weakness&#160;of&#160;your&#160;face,&#160;arm&#160;or&#160;leg, especially on one&#160;side&#160;of&#160;your&#160;body;&#160;<br/>sudden&#160;confusion,&#160;trouble&#160;speaking or&#160;understanding;&#160;trouble&#160;seeing in&#160;one&#160;or&#160;both eyes,&#160;trouble&#160;<br/>walking,&#160;dizziness,&#160;loss&#160;of&#160;balance or&#160;coordination&#160;or&#160;a severe&#160;headache),&#160;fits,&#160;<br/>tingling/numbness&#160;in&#160;any part&#160;of&#160;your&#160;body,&#160;or&#160;weakness in&#160;arms&#160;or&#160;legs,&#160;changes&#160;in&#160;eyesight&#160;<br/>such as&#160;double&#160;vision or&#160;other&#160;eye&#160;problems.&#160;</p>
<p style="position:absolute;top:795px;left:107px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:800px;left:149px;white-space:nowrap" class="ft13810"><b>Signs&#160;of&#160;a&#160;liver&#160;problem&#160;</b>(including hepatitis&#160;B&#160;infection when you&#160;have&#160;had hepatitis&#160;B&#160;in&#160;the&#160;<br/>past)&#160;such as&#160;yellowing of&#160;the&#160;skin or&#160;eyes, dark-brown&#160;coloured urine,&#160;pain&#160;or&#160;swelling&#160;in&#160;the&#160;<br/>upper&#160;right&#160;side&#160;of&#160;the&#160;stomach&#160;area,&#160;joint&#160;pain, skin rashes, or&#160;fever.&#160;</p>
<p style="position:absolute;top:853px;left:107px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:858px;left:149px;white-space:nowrap" class="ft13810"><b>Signs&#160;of&#160;an&#160;immune&#160;system&#160;disorder&#160;called lupus&#160;</b>such as&#160;joint&#160;pain or&#160;a&#160;rash on cheeks&#160;or&#160;<br/>arms&#160;that&#160;is sensitive&#160;to&#160;the&#160;sun&#160;(lupus)&#160;or&#160;cough, shortness&#160;of&#160;breath,&#160;fever&#160;or&#160;skin&#160;rash&#160;<br/>(sarcoidosis).&#160;</p>
<p style="position:absolute;top:911px;left:107px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:917px;left:149px;white-space:nowrap" class="ft13810"><b>Signs&#160;of&#160;low&#160;blood&#160;counts&#160;</b>such&#160;as&#160;persistent&#160;fever, bleeding or&#160;bruising&#160;more&#160;easily,&#160;small red&#160;<br/>or&#160;purple&#160;spots&#160;caused by bleeding under&#160;the&#160;skin,&#160;or&#160;looking pale.&#160;</p>
<p style="position:absolute;top:949px;left:107px;white-space:nowrap" class="ft1388">•&#160;</p>
<p style="position:absolute;top:955px;left:149px;white-space:nowrap" class="ft13811"><b>Signs of&#160;serious skin&#160;problems</b>&#160;such&#160;as reddish-target-like spots or&#160;circular&#160;patches often&#160;with&#160;<br/>central&#160;blisters&#160;on&#160;the&#160;trunk, large&#160;areas&#160;of&#160;peeling and&#160;shedding&#160;(exfoliating)&#160;skin, ulcers&#160;of&#160;<br/>mouth, throat, nose, genitals&#160;and eyes&#160;or&#160;small&#160;pus-filled bumps&#160;that&#160;can spread&#160;over&#160;the&#160;body.&#160;<br/>These&#160;skin&#160;reactions can&#160;be&#160;accompanied&#160;by&#160;fever.&#160;</p>
<p style="position:absolute;top:1032px;left:107px;white-space:nowrap" class="ft13814">&#160;<br/>Tell&#160;your&#160;doctor&#160;straight&#160;away&#160;if&#160;you&#160;notice&#160;any&#160;of&#160;the&#160;above.&#160;<br/>&#160;<br/>The&#160;following side&#160;effects&#160;have been&#160;observed&#160;with&#160;Remsima:&#160;<br/>&#160;<br/><b>Very common:&#160;</b>may affect&#160;more&#160;than&#160;1 in&#160;10 people&#160;<br/>•&#160;</p>
<p style="position:absolute;top:1148px;left:149px;white-space:nowrap" class="ft1382">Stomach pain, feeling sick&#160;</p>
</div>
<!-- Page 139 -->
<a name="139"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page139-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1390">139&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1392">&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:90px;left:149px;white-space:nowrap" class="ft1392">Viral&#160;infections&#160;such&#160;as herpes or&#160;flu&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft1392">Upper&#160;respiratory&#160;infections such&#160;as sinusitis&#160;</p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:131px;left:149px;white-space:nowrap" class="ft1392">Headache&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:151px;left:149px;white-space:nowrap" class="ft1392">Side&#160;effect&#160;due&#160;to an injection&#160;</p>
<p style="position:absolute;top:165px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:171px;left:149px;white-space:nowrap" class="ft1392">Pain.&#160;</p>
<p style="position:absolute;top:190px;left:106px;white-space:nowrap" class="ft13911">&#160;<br/><b>Common:&#160;</b>may&#160;affect&#160;up&#160;to&#160;1 in 10&#160;people&#160;</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:229px;left:149px;white-space:nowrap" class="ft1392">Changes&#160;in how&#160;your&#160;liver&#160;works,&#160;increase&#160;in liver&#160;enzymes&#160;(shown in&#160;blood tests)&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:249px;left:149px;white-space:nowrap" class="ft1392">Lung or&#160;chest&#160;infections&#160;such as&#160;bronchitis&#160;or&#160;pneumonia&#160;</p>
<p style="position:absolute;top:264px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:269px;left:149px;white-space:nowrap" class="ft1392">Difficult&#160;or&#160;painful&#160;breathing,&#160;chest pain&#160;</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:289px;left:149px;white-space:nowrap" class="ft1392">Bleeding&#160;in the&#160;stomach&#160;or&#160;intestines, diarrhoea, indigestion, heartburn, constipation&#160;</p>
<p style="position:absolute;top:304px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:310px;left:149px;white-space:nowrap" class="ft1392">Nettle-type&#160;rash&#160;(hives), itchy rash or&#160;dry&#160;skin&#160;</p>
<p style="position:absolute;top:324px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:330px;left:149px;white-space:nowrap" class="ft1392">Balance problems or&#160;feeling&#160;dizzy&#160;</p>
<p style="position:absolute;top:345px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:350px;left:149px;white-space:nowrap" class="ft1392">Fever,&#160;increased&#160;sweating&#160;</p>
<p style="position:absolute;top:365px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:370px;left:149px;white-space:nowrap" class="ft1392">Circulation problems&#160;such&#160;as&#160;low&#160;or&#160;high blood&#160;pressure&#160;</p>
<p style="position:absolute;top:385px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:390px;left:149px;white-space:nowrap" class="ft1392">Bruising,&#160;hot&#160;flush or&#160;nosebleed, warm, red&#160;skin (flushing)&#160;</p>
<p style="position:absolute;top:405px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:410px;left:149px;white-space:nowrap" class="ft1392">Feeling&#160;tired&#160;or&#160;weak&#160;</p>
<p style="position:absolute;top:425px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:430px;left:149px;white-space:nowrap" class="ft1392">Bacterial&#160;infections such&#160;as&#160;blood&#160;poisoning,&#160;abscess or&#160;infection&#160;of&#160;the skin&#160;(cellulitis)&#160;</p>
<p style="position:absolute;top:445px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:451px;left:149px;white-space:nowrap" class="ft1392">Infection of&#160;the&#160;skin due&#160;to&#160;a&#160;fungus&#160;</p>
<p style="position:absolute;top:465px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:471px;left:149px;white-space:nowrap" class="ft1392">Blood problems&#160;such as&#160;anaemia&#160;or&#160;low&#160;white&#160;blood&#160;cell&#160;count&#160;</p>
<p style="position:absolute;top:486px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:491px;left:149px;white-space:nowrap" class="ft1392">Swollen&#160;lymph nodes&#160;</p>
<p style="position:absolute;top:506px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:511px;left:149px;white-space:nowrap" class="ft1392">Depression, problems&#160;sleeping&#160;</p>
<p style="position:absolute;top:526px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft1392">Eye&#160;problems,&#160;including red&#160;eyes&#160;and infections&#160;</p>
<p style="position:absolute;top:546px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:551px;left:149px;white-space:nowrap" class="ft1392">Fast&#160;heart&#160;beat&#160;(tachycardia)&#160;or&#160;palpitations&#160;</p>
<p style="position:absolute;top:566px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:572px;left:149px;white-space:nowrap" class="ft1392">Pain&#160;in&#160;the&#160;joints,&#160;muscles or&#160;back&#160;</p>
<p style="position:absolute;top:586px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:592px;left:149px;white-space:nowrap" class="ft1392">Urinary&#160;tract infection&#160;</p>
<p style="position:absolute;top:607px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:612px;left:149px;white-space:nowrap" class="ft1392">Psoriasis,&#160;skin&#160;problems&#160;such&#160;as&#160;eczema and&#160;hair&#160;loss&#160;</p>
<p style="position:absolute;top:627px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:632px;left:149px;white-space:nowrap" class="ft1392">Reactions&#160;at&#160;the&#160;injection site&#160;such as&#160;pain, swelling,&#160;redness&#160;or&#160;itching&#160;</p>
<p style="position:absolute;top:647px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:652px;left:149px;white-space:nowrap" class="ft1392">Chills,&#160;a&#160;build-up of&#160;fluid&#160;under&#160;the&#160;skin&#160;causing swelling&#160;</p>
<p style="position:absolute;top:667px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:672px;left:149px;white-space:nowrap" class="ft1392">Feeling numb&#160;or&#160;having a&#160;tingling feeling.&#160;</p>
<p style="position:absolute;top:691px;left:107px;white-space:nowrap" class="ft13914">&#160;<br/><b>Uncommon:&#160;</b>may&#160;affect&#160;up&#160;to 1&#160;in 100&#160;people&#160;<br/>•&#160;</p>
<p style="position:absolute;top:730px;left:149px;white-space:nowrap" class="ft1392">Shortage&#160;of&#160;blood&#160;supply, swelling of&#160;a&#160;vein&#160;</p>
<p style="position:absolute;top:745px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:751px;left:149px;white-space:nowrap" class="ft1392">Collection of&#160;blood outside&#160;the&#160;blood&#160;vessels&#160;(haematoma)&#160;or&#160;bruising&#160;</p>
<p style="position:absolute;top:765px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:770px;left:149px;white-space:nowrap" class="ft13911">Skin problems&#160;such as&#160;blistering, warts,&#160;abnormal&#160;skin&#160;colouration&#160;or&#160;pigmentation, or&#160;swollen&#160;<br/>lips, or&#160;thickening&#160;of&#160;the&#160;skin, or&#160;red, scaly,&#160;and&#160;flaky skin&#160;</p>
<p style="position:absolute;top:804px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:810px;left:149px;white-space:nowrap" class="ft13910">Severe allergic reactions&#160;(e.g. anaphylaxis), an immune&#160;system&#160;disorder&#160;called&#160;lupus, allergic&#160;<br/>reactions&#160;to foreign proteins&#160;</p>
<p style="position:absolute;top:844px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:849px;left:149px;white-space:nowrap" class="ft1392">Wounds&#160;taking longer&#160;to&#160;heal&#160;</p>
<p style="position:absolute;top:864px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:869px;left:149px;white-space:nowrap" class="ft1392">Swelling of&#160;the&#160;liver&#160;(hepatitis)&#160;or&#160;gall&#160;bladder,&#160;liver&#160;damage&#160;</p>
<p style="position:absolute;top:884px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:889px;left:149px;white-space:nowrap" class="ft1392">Feeling forgetful,&#160;irritable,&#160;confused,&#160;nervous&#160;</p>
<p style="position:absolute;top:904px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:909px;left:149px;white-space:nowrap" class="ft1392">Eye&#160;problems&#160;including blurred&#160;or&#160;reduced vision, puffy eyes&#160;or&#160;sties&#160;</p>
<p style="position:absolute;top:924px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:929px;left:149px;white-space:nowrap" class="ft1392">New&#160;or&#160;worsening heart&#160;failure, slow&#160;heart&#160;rate&#160;</p>
<p style="position:absolute;top:944px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:950px;left:149px;white-space:nowrap" class="ft1392">Fainting&#160;</p>
<p style="position:absolute;top:964px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:970px;left:149px;white-space:nowrap" class="ft1392">Convulsions, nerve&#160;problems&#160;</p>
<p style="position:absolute;top:985px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:990px;left:149px;white-space:nowrap" class="ft1392">A&#160;hole&#160;in the&#160;bowel&#160;or&#160;blockage&#160;of&#160;the&#160;intestine,&#160;stomach pain or&#160;cramps&#160;</p>
<p style="position:absolute;top:1005px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:1010px;left:149px;white-space:nowrap" class="ft1392">Swelling of&#160;your&#160;pancreas&#160;(pancreatitis)&#160;</p>
<p style="position:absolute;top:1025px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:1030px;left:149px;white-space:nowrap" class="ft1392">Fungal&#160;infections such&#160;as yeast&#160;infection, or&#160;fungal&#160;infection of&#160;the&#160;nails&#160;</p>
<p style="position:absolute;top:1045px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:1050px;left:149px;white-space:nowrap" class="ft1392">Lung problems&#160;(such as&#160;oedema)&#160;</p>
<p style="position:absolute;top:1065px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:1071px;left:150px;white-space:nowrap" class="ft1392">Fluid around the&#160;lungs&#160;(pleural&#160;effusion)&#160;</p>
<p style="position:absolute;top:1085px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:1091px;left:150px;white-space:nowrap" class="ft1392">Narrowed&#160;airway&#160;in&#160;the&#160;lungs, causing difficulty breathing&#160;</p>
<p style="position:absolute;top:1106px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:1111px;left:150px;white-space:nowrap" class="ft1392">Inflamed lining of&#160;the&#160;lung,&#160;causing sharp chest&#160;pains&#160;that&#160;feel&#160;worse&#160;with breathing&#160;(pleurisy)&#160;</p>
<p style="position:absolute;top:1126px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:1131px;left:150px;white-space:nowrap" class="ft1392">Tuberculosis&#160;</p>
<p style="position:absolute;top:1146px;left:107px;white-space:nowrap" class="ft1398">•&#160;</p>
<p style="position:absolute;top:1151px;left:150px;white-space:nowrap" class="ft1392">Kidney infections&#160;</p>
</div>
<!-- Page 140 -->
<a name="140"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page140-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1400">140&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1402">&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:90px;left:149px;white-space:nowrap" class="ft1402">Low&#160;platelet&#160;count, too many white&#160;blood cells&#160;</p>
<p style="position:absolute;top:105px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft1402">Infections&#160;of&#160;the&#160;vagina&#160;</p>
<p style="position:absolute;top:125px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:131px;left:149px;white-space:nowrap" class="ft1402">Blood test&#160;result&#160;showing&#160;‘antibodies’&#160;against&#160;your&#160;own body&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:151px;left:149px;white-space:nowrap" class="ft1402">Changes&#160;in&#160;cholesterol&#160;and fat levels&#160;in&#160;the&#160;blood.&#160;</p>
<p style="position:absolute;top:170px;left:106px;white-space:nowrap" class="ft14011">&#160;<br/><b>Rare:&#160;</b>may&#160;affect&#160;up&#160;to 1&#160;in&#160;1,000 people&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:209px;left:149px;white-space:nowrap" class="ft1402">A&#160;type&#160;of&#160;blood cancer&#160;(lymphoma)&#160;</p>
<p style="position:absolute;top:224px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:229px;left:149px;white-space:nowrap" class="ft14010">Your&#160;blood not&#160;supplying&#160;enough oxygen&#160;to your&#160;body, circulation problems&#160;such&#160;as&#160;narrowing&#160;<br/>of&#160;a&#160;blood&#160;vessel&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:268px;left:149px;white-space:nowrap" class="ft1402">Inflammation of&#160;the&#160;lining&#160;of&#160;the&#160;brain&#160;(meningitis)&#160;</p>
<p style="position:absolute;top:283px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:288px;left:149px;white-space:nowrap" class="ft1402">Infections&#160;due&#160;to&#160;a weakened&#160;immune system&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:308px;left:149px;white-space:nowrap" class="ft1402">Hepatitis B&#160;infection&#160;when&#160;you&#160;have had&#160;hepatitis B&#160;in&#160;the past&#160;</p>
<p style="position:absolute;top:323px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:329px;left:149px;white-space:nowrap" class="ft1402">Inflamed liver&#160;caused&#160;by a&#160;problem&#160;with&#160;the&#160;immune&#160;system&#160;(autoimmune&#160;hepatitis)&#160;&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft1402">Liver&#160;problem&#160;that&#160;causes&#160;yellowing of&#160;the&#160;skin or&#160;eyes&#160;(jaundice)&#160;</p>
<p style="position:absolute;top:363px;left:106px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1402">Abnormal&#160;tissue&#160;swelling or&#160;growth&#160;</p>
<p style="position:absolute;top:382px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft14011">Severe allergic reaction&#160;that&#160;may&#160;cause&#160;loss of&#160;consciousness and&#160;could&#160;be&#160;life-threatening&#160;<br/>(anaphylactic shock)&#160;</p>
<p style="position:absolute;top:421px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:427px;left:149px;white-space:nowrap" class="ft1402">Swelling&#160;of&#160;small blood&#160;vessels&#160;(vasculitis)&#160;</p>
<p style="position:absolute;top:441px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:446px;left:149px;white-space:nowrap" class="ft1402">Immune&#160;disorders&#160;that&#160;could affect&#160;the&#160;lungs,&#160;skin and&#160;lymph nodes&#160;(such&#160;as&#160;sarcoidosis)&#160;</p>
<p style="position:absolute;top:460px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:465px;left:149px;white-space:nowrap" class="ft1402">Collections&#160;of&#160;immune&#160;cells&#160;resulting from&#160;an&#160;inflammatory response&#160;(granulomatous lesions)&#160;</p>
<p style="position:absolute;top:480px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:485px;left:149px;white-space:nowrap" class="ft1402">Lack&#160;of&#160;interest or&#160;emotion&#160;</p>
<p style="position:absolute;top:499px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:505px;left:149px;white-space:nowrap" class="ft14011">Serious skin&#160;problems&#160;such&#160;as toxic&#160;epidermal&#160;necrolysis,&#160;Stevens-Johnson syndrome&#160;and&#160;acute&#160;<br/>generalised&#160;exanthematous&#160;pustulosis&#160;</p>
<p style="position:absolute;top:538px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:544px;left:149px;white-space:nowrap" class="ft14011">Other&#160;skin&#160;problems&#160;such&#160;as&#160;erythema&#160;multiforme,&#160;blisters&#160;and&#160;peeling skin, or&#160;boils&#160;<br/>(furunculosis)&#160;</p>
<p style="position:absolute;top:577px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:582px;left:149px;white-space:nowrap" class="ft14011">Serious nervous system&#160;disorders such&#160;as transverse&#160;myelitis,&#160;multiple sclerosis-like disease,&#160;<br/>optic&#160;neuritis&#160;and Guillain-Barré&#160;syndrome&#160;</p>
<p style="position:absolute;top:616px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:622px;left:149px;white-space:nowrap" class="ft1402">Inflammation&#160;in the&#160;eye&#160;that&#160;may cause&#160;changes&#160;in the&#160;vision,&#160;including blindness&#160;</p>
<p style="position:absolute;top:637px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:642px;left:149px;white-space:nowrap" class="ft1402">Fluid in the&#160;lining&#160;of&#160;the&#160;heart&#160;(pericardial&#160;effusion)&#160;</p>
<p style="position:absolute;top:657px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:662px;left:149px;white-space:nowrap" class="ft1402">Serious&#160;lung&#160;problems&#160;(such&#160;as&#160;interstitial&#160;lung disease)&#160;</p>
<p style="position:absolute;top:677px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:682px;left:149px;white-space:nowrap" class="ft1402">Melanoma&#160;(a type of&#160;skin&#160;cancer)&#160;</p>
<p style="position:absolute;top:697px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:702px;left:149px;white-space:nowrap" class="ft1402">Cervical&#160;cancer&#160;</p>
<p style="position:absolute;top:717px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:722px;left:149px;white-space:nowrap" class="ft1402">Low&#160;blood&#160;counts,&#160;including a&#160;severely decreased number&#160;of&#160;white&#160;blood&#160;cells&#160;</p>
<p style="position:absolute;top:737px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:743px;left:149px;white-space:nowrap" class="ft1402">Small&#160;red or&#160;purple&#160;spots&#160;caused&#160;by bleeding under&#160;the&#160;skin&#160;</p>
<p style="position:absolute;top:757px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:763px;left:149px;white-space:nowrap" class="ft14010">Abnormal&#160;values&#160;of&#160;a&#160;blood&#160;protein&#160;called ‘complement&#160;factor’&#160;which&#160;is&#160;part&#160;of&#160;the&#160;immune&#160;<br/>system&#160;</p>
<p style="position:absolute;top:797px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:802px;left:149px;white-space:nowrap" class="ft14010">Lichenoid&#160;reactions&#160;(itchy reddish-purple&#160;skin&#160;rash and/or&#160;threadlike&#160;white-grey lines&#160;on&#160;<br/>mucous&#160;membranes).&#160;&#160;</p>
<p style="position:absolute;top:840px;left:107px;white-space:nowrap" class="ft14014">&#160;<br/><b>Not&#160;known:&#160;</b>frequency&#160;cannot&#160;be estimated&#160;from&#160;the available&#160;data&#160;<br/>•&#160;</p>
<p style="position:absolute;top:879px;left:149px;white-space:nowrap" class="ft1402">Cancer&#160;</p>
<p style="position:absolute;top:893px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:898px;left:149px;white-space:nowrap" class="ft1402">A&#160;rare&#160;blood cancer&#160;affecting mostly young&#160;men&#160;(hepatosplenic T-cell lymphoma)&#160;</p>
<p style="position:absolute;top:913px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:919px;left:149px;white-space:nowrap" class="ft1402">Liver&#160;failure&#160;</p>
<p style="position:absolute;top:933px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:939px;left:149px;white-space:nowrap" class="ft1402">Merkel&#160;cell&#160;carcinoma (a type&#160;of&#160;skin&#160;cancer)&#160;</p>
<p style="position:absolute;top:954px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:959px;left:149px;white-space:nowrap" class="ft14010">Kaposi’s&#160;sarcoma, a&#160;rare&#160;cancer&#160;related&#160;to infection with human herpes&#160;virus&#160;8. Kaposi’s&#160;<br/>sarcoma&#160;most&#160;commonly&#160;appears&#160;as&#160;purple&#160;lesions&#160;on&#160;the&#160;skin.&#160;</p>
<p style="position:absolute;top:993px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:998px;left:149px;white-space:nowrap" class="ft14010">Worsening of&#160;a&#160;condition called dermatomyositis&#160;(seen as&#160;a&#160;skin rash accompanying&#160;muscle&#160;<br/>weakness)&#160;</p>
<p style="position:absolute;top:1032px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:1037px;left:149px;white-space:nowrap" class="ft1402">Heart&#160;attack&#160;</p>
<p style="position:absolute;top:1052px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:1057px;left:149px;white-space:nowrap" class="ft1402">Stroke&#160;</p>
<p style="position:absolute;top:1072px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:1078px;left:149px;white-space:nowrap" class="ft1402">Temporary loss&#160;of&#160;sight&#160;during or&#160;within&#160;2 hours&#160;of&#160;infusion&#160;</p>
<p style="position:absolute;top:1091px;left:107px;white-space:nowrap" class="ft1408">•&#160;</p>
<p style="position:absolute;top:1097px;left:149px;white-space:nowrap" class="ft1402">Infection due&#160;to&#160;a&#160;live vaccine because&#160;of&#160;a&#160;weakened&#160;immune&#160;system.&#160;&#160;</p>
<p style="position:absolute;top:1116px;left:107px;white-space:nowrap" class="ft1405"><b>&#160;<br/>Reporting&#160;of&#160;side effects&#160;</b></p>
</div>
<!-- Page 141 -->
<a name="141"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page141-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1410">141&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1412">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft14110">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor, pharmacist,&#160;or&#160;nurse.&#160;This&#160;includes&#160;any&#160;possible side&#160;<br/>effects not&#160;listed&#160;in&#160;this leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side effects directly&#160;via&#160;the&#160;national&#160;reporting&#160;<br/>system&#160;listed&#160;in&#160;Appendix V. By reporting side&#160;effects&#160;you can&#160;help provide&#160;more&#160;information&#160;on the&#160;<br/>safety&#160;of&#160;this&#160;medicine.&#160;<br/>&#160;<br/>&#160;<br/><b>5.&#160;</b></p>
<p style="position:absolute;top:203px;left:149px;white-space:nowrap" class="ft1411"><b>How&#160;to&#160;store&#160;Remsima&#160;</b></p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft14114">&#160;<br/>•&#160;</p>
<p style="position:absolute;top:242px;left:149px;white-space:nowrap" class="ft1412">Keep&#160;this&#160;medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:257px;left:106px;white-space:nowrap" class="ft1418">•&#160;</p>
<p style="position:absolute;top:262px;left:149px;white-space:nowrap" class="ft14110">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date&#160;which is&#160;stated&#160;on&#160;the label&#160;and&#160;the&#160;carton&#160;after&#160;<br/>“EXP”. The&#160;expiry date&#160;refers&#160;to the&#160;last&#160;day&#160;of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:296px;left:106px;white-space:nowrap" class="ft1418">•&#160;</p>
<p style="position:absolute;top:301px;left:149px;white-space:nowrap" class="ft14110">Store&#160;in a&#160;refrigerator&#160;(2°C&#160;-&#160;8°C). Do not&#160;freeze. Keep&#160;the&#160;medicinal&#160;product&#160;in its&#160;outer&#160;carton&#160;<br/>to&#160;protect from light.&#160;&#160;</p>
<p style="position:absolute;top:335px;left:106px;white-space:nowrap" class="ft1418">•&#160;</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft14111">This medicine can&#160;also&#160;be&#160;stored in&#160;the&#160;original&#160;carton&#160;outside&#160;of&#160;refrigerated&#160;storage&#160;up to a&#160;<br/>maximum&#160;of&#160;25°C&#160;for&#160;a&#160;single&#160;period of&#160;up&#160;to&#160;28&#160;days,&#160;but&#160;not&#160;beyond&#160;the&#160;original&#160;expiry date.&#160;<br/>In this&#160;situation, do not&#160;return to&#160;refrigerated storage&#160;again.&#160;Write&#160;the&#160;new&#160;expiry date&#160;on the&#160;<br/>carton&#160;including day/month/year. Discard this&#160;medicine&#160;if&#160;not&#160;used&#160;by the&#160;new&#160;expiry&#160;date&#160;or&#160;<br/>the&#160;expiry date&#160;printed on&#160;the&#160;carton, whichever&#160;is&#160;earlier.&#160;</p>
<p style="position:absolute;top:431px;left:106px;white-space:nowrap" class="ft1418">•&#160;</p>
<p style="position:absolute;top:436px;left:149px;white-space:nowrap" class="ft14111">Do not&#160;throw&#160;away any&#160;medicines&#160;via&#160;wastewater&#160;or&#160;household&#160;waste.&#160;Ask&#160;your&#160;pharmacist&#160;<br/>how&#160;to throw&#160;away&#160;medicines you&#160;no&#160;longer&#160;use.&#160;These&#160;measures will&#160;help&#160;protect&#160;the&#160;<br/>environment.&#160;</p>
<p style="position:absolute;top:493px;left:106px;white-space:nowrap" class="ft14111">&#160;<br/>&#160;<br/><b>6.&#160;</b></p>
<p style="position:absolute;top:531px;left:149px;white-space:nowrap" class="ft1411"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:550px;left:106px;white-space:nowrap" class="ft14111">&#160;<br/><b>What&#160;Remsima&#160;contains&#160;&#160;</b></p>
<p style="position:absolute;top:584px;left:106px;white-space:nowrap" class="ft1418">•&#160;</p>
<p style="position:absolute;top:589px;left:149px;white-space:nowrap" class="ft14110">The active substance&#160;is&#160;infliximab.&#160;Each&#160;1&#160;ml single&#160;dose&#160;pre-filled&#160;pen&#160;contains&#160;120&#160;mg of&#160;<br/>infliximab.&#160;&#160;</p>
<p style="position:absolute;top:623px;left:106px;white-space:nowrap" class="ft1418">•&#160;</p>
<p style="position:absolute;top:628px;left:149px;white-space:nowrap" class="ft14110">The&#160;other&#160;ingredients&#160;are&#160;acetic&#160;acid, sodium&#160;acetate&#160;trihydrate, sorbitol,&#160;polysorbate&#160;80 and&#160;<br/>water&#160;for&#160;injections.&#160;&#160;</p>
<p style="position:absolute;top:666px;left:106px;white-space:nowrap" class="ft14110">&#160;<br/><b>What&#160;Remsima&#160;looks&#160;like&#160;and contents&#160;of&#160;the&#160;pack&#160;<br/></b>Remsima&#160;is a clear&#160;to&#160;opalescent,&#160;colourless&#160;to&#160;pale&#160;brown solution which is&#160;supplied as&#160;a&#160;single&#160;use&#160;<br/>pre-filled&#160;pen.&#160;&#160;<br/>&#160;<br/>Each pack contains&#160;1 pre-filled pen with&#160;2 alcohol&#160;pads, 2 pre-filled pens&#160;with 2 alcohol&#160;pads,&#160;4&#160;<br/>pre-filled pens&#160;with 4&#160;alcohol&#160;pads&#160;or&#160;6 pre-filled pens&#160;with 6&#160;alcohol&#160;pads.&#160;<br/>&#160;<br/>Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;&#160;<br/>&#160;<br/><b>Marketing&#160;Authorisation&#160;Holder&#160;&#160;&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Hungary&#160;<br/>&#160;<br/><b>Manufacturer</b>&#160;<br/>Millmount Healthcare&#160;Ltd.&#160;<br/>Block 7&#160;<br/>City&#160;North&#160;Business Campus&#160;<br/>Stamullen, Co. Meath K32&#160;YD60&#160;<br/>Ireland&#160;<br/>&#160;<br/>Nuvisan&#160;GmbH&#160;<br/>Wegenerstraße 13,&#160;&#160;<br/>89231 Neu Ulm,&#160;&#160;<br/>Germany&#160;</p>
</div>
<!-- Page 142 -->
<a name="142"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page142-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1420">142&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1422">&#160;</p>
<p style="position:absolute;top:88px;left:106px;white-space:nowrap" class="ft14210">&#160;<br/>Nuvisan&#160;France SARL&#160;<br/>2400, Route&#160;des&#160;Colles,&#160;&#160;<br/>06410, Biot,&#160;&#160;<br/>France&#160;<br/>&#160;<br/>For&#160;any&#160;information&#160;about&#160;this&#160;medicine,&#160;please&#160;contact the&#160;local&#160;representative&#160;of&#160;the Marketing&#160;<br/>Authorisation Holder:&#160;<br/>&#160;</p>
<p style="position:absolute;top:258px;left:114px;white-space:nowrap" class="ft14210"><b>België/Belgique/Belgien</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Belgium&#160;BVBA&#160;&#160;<br/>Tél/Tel:&#160;+&#160;32&#160;1528 7418&#160;<br/>BEinfo@celltrionhc.com&#160;</p>
<p style="position:absolute;top:258px;left:455px;white-space:nowrap" class="ft14211"><b>Lietuva</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Vengrija&#160;<br/>&#160;</p>
<p style="position:absolute;top:366px;left:114px;white-space:nowrap" class="ft14210"><b>България&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062&#160;Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:442px;left:114px;white-space:nowrap" class="ft14219">Унгария&#160;<br/>&#160;</p>
<p style="position:absolute;top:372px;left:455px;white-space:nowrap" class="ft14210"><b>Luxembourg/Luxemburg</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Belgium&#160;BVBA&#160;<br/>Tél/Tel:&#160;+&#160;32 1528&#160;7418&#160;<br/>BEinfo@celltrionhc.com&#160;</p>
<p style="position:absolute;top:480px;left:114px;white-space:nowrap" class="ft14210"><b>Česká&#160;republika</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:556px;left:114px;white-space:nowrap" class="ft14218">Maďarsko&#160;</p>
<p style="position:absolute;top:565px;left:114px;white-space:nowrap" class="ft1422">&#160;</p>
<p style="position:absolute;top:486px;left:455px;white-space:nowrap" class="ft14210"><b>Magyarország&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd&#160;Office&#160;Building&#160;B&#160;torony&#160;<br/>Magyarország&#160;</p>
<p style="position:absolute;top:565px;left:455px;white-space:nowrap" class="ft1422">&#160;</p>
<p style="position:absolute;top:581px;left:114px;white-space:nowrap" class="ft14210"><b>Danmark</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungarn&#160;</p>
<p style="position:absolute;top:660px;left:114px;white-space:nowrap" class="ft1422">&#160;</p>
<p style="position:absolute;top:581px;left:455px;white-space:nowrap" class="ft14210"><b>Malta&#160;<br/></b>Mint Health&#160;Ltd.&#160;<br/>Tel:&#160;+356&#160;2093 9800&#160;<br/>info@mint.com.mt&#160;<br/>&#160;</p>
<p style="position:absolute;top:675px;left:114px;white-space:nowrap" class="ft14211"><b>Deutschland</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungarn&#160;<br/>&#160;</p>
<p style="position:absolute;top:675px;left:455px;white-space:nowrap" class="ft14210"><b>Nederland</b>&#160;<br/>Celltrion Healthcare&#160;Netherlands&#160;B.V.&#160;<br/>Tel:&#160;+&#160;31 20 888 7300&#160;<br/>NLinfo@celltrionhc.com&#160;</p>
<p style="position:absolute;top:789px;left:114px;white-space:nowrap" class="ft14211"><b>Eesti&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3.&#160;WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungari&#160;</p>
<p style="position:absolute;top:869px;left:114px;white-space:nowrap" class="ft1422">&#160;</p>
<p style="position:absolute;top:789px;left:455px;white-space:nowrap" class="ft14210"><b>Norge</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungarn&#160;<br/>&#160;</p>
<p style="position:absolute;top:897px;left:114px;white-space:nowrap" class="ft14247"><b>Ελλάδα</b>&#160;</p>
<p style="position:absolute;top:916px;left:114px;white-space:nowrap" class="ft14218">ΒΙΑΝΕΞ&#160;Α.Ε.&#160;</p>
<p style="position:absolute;top:935px;left:114px;white-space:nowrap" class="ft14218">Τηλ:&#160;+30 210&#160;8009111&#160;–&#160;120&#160;</p>
<p style="position:absolute;top:945px;left:114px;white-space:nowrap" class="ft1422">&#160;</p>
<p style="position:absolute;top:903px;left:455px;white-space:nowrap" class="ft14210"><b>Österreich</b>&#160;<br/>Astro-Pharma&#160;GmbH&#160;<br/>Tel:&#160;+43 1&#160;97 99 860&#160;<br/>office@astropharma.at&#160;<br/>&#160;</p>
<p style="position:absolute;top:998px;left:114px;white-space:nowrap" class="ft14211"><b>España&#160;<br/></b>Kern Pharma, S.L.&#160;<br/>Tel:&#160;+34 93&#160;700 25&#160;25&#160;</p>
<p style="position:absolute;top:1040px;left:114px;white-space:nowrap" class="ft1422">&#160;</p>
<p style="position:absolute;top:998px;left:455px;white-space:nowrap" class="ft14210"><b>Polska<i>&#160;<br/></i></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:1068px;left:455px;white-space:nowrap" class="ft14236">Węgry&#160;<br/>&#160;</p>
</div>
<!-- Page 143 -->
<a name="143"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page143-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1430">143&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1432">&#160;</p>
<p style="position:absolute;top:89px;left:114px;white-space:nowrap" class="ft14310"><b>France&#160;<br/></b>Celltrion&#160;Healthcare&#160;France&#160;SAS&#160;<br/>Tél: +&#160;33&#160;(0)1 71 25&#160;27 00<b>&#160;</b></p>
<p style="position:absolute;top:89px;left:455px;white-space:nowrap" class="ft14311"><b>Portugal</b>&#160;<br/>PharmaKERN&#160;Portugal&#160;–&#160;Produtos&#160;<br/>Farmacêuticos,&#160;<br/>Sociedade Unipessoal,&#160;Lda.&#160;<br/>Tel:&#160;+351 214 200&#160;290&#160;<br/>&#160;</p>
<p style="position:absolute;top:203px;left:114px;white-space:nowrap" class="ft14311"><b>Hrvatska</b>&#160;<br/>OKTAL&#160;PHARMA d.o.o.&#160;<br/>Tel:&#160;+385 1&#160;6595 777&#160;<br/>oktal-pharma@oktal-pharma.hr&#160;<br/>&#160;</p>
<p style="position:absolute;top:203px;left:455px;white-space:nowrap" class="ft1436"><b>România&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungaria<b>&#160;<br/></b>&#160;</p>
<p style="position:absolute;top:317px;left:114px;white-space:nowrap" class="ft14310"><b>Ireland</b>&#160;<br/>Celltrion&#160;Healthcare&#160;Ireland&#160;Limited&#160;<br/>Tel:&#160;+353 1&#160;223 4026&#160;</p>
<p style="position:absolute;top:317px;left:455px;white-space:nowrap" class="ft14310"><b>Slovenija</b>&#160;<br/>OKTAL&#160;PHARMA d.o.o.&#160;<br/>Tel:&#160;+386 1&#160;519&#160;29&#160;22&#160;<br/>info@oktal-pharma.si&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:412px;left:114px;white-space:nowrap" class="ft14310"><b>Ísland&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungverjaland&#160;</p>
<p style="position:absolute;top:491px;left:114px;white-space:nowrap" class="ft1432">&#160;</p>
<p style="position:absolute;top:412px;left:455px;white-space:nowrap" class="ft14311"><b>Slovenská&#160;republika&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:482px;left:455px;white-space:nowrap" class="ft14319">Maďarsko&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:525px;left:114px;white-space:nowrap" class="ft14310"><b>Italia</b>&#160;<br/>Celltrion&#160;Healthcare Italy&#160;S.r.l.&#160;<br/>Via&#160;Luigi&#160;Galvani, 24&#160;-&#160;20124 Milano (MI)&#160;<br/>Tel: +39&#160;0247 927040&#160;</p>
<p style="position:absolute;top:525px;left:455px;white-space:nowrap" class="ft14310"><b>Suomi/Finland</b>&#160;<br/>Celltrion Healthcare&#160;Hungary Kft.&#160;&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Unkari&#160;<br/>&#160;</p>
<p style="position:absolute;top:633px;left:114px;white-space:nowrap" class="ft14348"><b>Κύπρος&#160;<br/></b>C.A.&#160;Papaellinas Ltd&#160;</p>
<p style="position:absolute;top:671px;left:114px;white-space:nowrap" class="ft14318">Τηλ:&#160;+&#160;357 22741741<b>&#160;</b></p>
<p style="position:absolute;top:639px;left:455px;white-space:nowrap" class="ft14310"><b>Sverige&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;<br/>Ungern&#160;</p>
<p style="position:absolute;top:719px;left:455px;white-space:nowrap" class="ft1431"><b>&#160;</b></p>
<p style="position:absolute;top:734px;left:114px;white-space:nowrap" class="ft14311"><b>Latvija&#160;<br/></b>Celltrion Healthcare&#160;Hungary Kft.&#160;<br/>1062 Budapest&#160;<br/>Váci&#160;út&#160;1-3. WestEnd Office&#160;Building&#160;B&#160;torony&#160;</p>
<p style="position:absolute;top:804px;left:114px;white-space:nowrap" class="ft14318">Ungārija&#160;</p>
<p style="position:absolute;top:734px;left:455px;white-space:nowrap" class="ft14310"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;<br/></b>Celltrion&#160;Healthcare&#160;Ireland&#160;Limited&#160;&#160;<br/>Tel: +353 1&#160;223 4026&#160;</p>
<p style="position:absolute;top:829px;left:106px;white-space:nowrap" class="ft14311"><b>&#160;<br/>&#160;<br/>This leaflet&#160;was&#160;last&#160;revised&#160;in&#160;{MM/YYYY}.&#160;<br/></b>&#160;<br/><b>Other&#160;sources&#160;of&#160;information&#160;<br/></b>&#160;<br/>Detailed&#160;information on&#160;this&#160;medicine&#160;is&#160;available&#160;on&#160;the&#160;European&#160;Medicines&#160;Agency web&#160;site:&#160;<br/>http://www.ema.europa.eu.&#160;<br/>&#160;<br/>This&#160;leaflet&#160;is available&#160;in&#160;all&#160;EU/EEA&#160;languages on&#160;the European&#160;Medicines Agency&#160;website.&#160;<br/>&#160;<br/>&#160;</p>
</div>
<!-- Page 144 -->
<a name="144"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page144-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1440">144&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1442">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1441"><b>7.&#160;</b></p>
<p style="position:absolute;top:89px;left:149px;white-space:nowrap" class="ft1441"><b>Instructions for&#160;use&#160;</b></p>
<p style="position:absolute;top:108px;left:106px;white-space:nowrap" class="ft14411">&#160;<br/>Read carefully&#160;these&#160;instructions&#160;before&#160;using&#160;the&#160;Remsima&#160;pen. Consult&#160;your&#160;healthcare&#160;provider&#160;if&#160;<br/>you have&#160;questions&#160;about&#160;using&#160;the&#160;Remsima&#160;pen.&#160;<br/>&#160;<br/><b>Important&#160;information&#160;</b></p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft1448">•&#160;&#160;Use the&#160;pen&#160;<b>ONLY</b>&#160;<b>if&#160;</b>your&#160;healthcare&#160;provider&#160;has&#160;trained you on the&#160;right&#160;way&#160;to&#160;prepare&#160;for&#160;and&#160;</p>
<p style="position:absolute;top:223px;left:137px;white-space:nowrap" class="ft1442">to give&#160;an&#160;injection.&#160;</p>
<p style="position:absolute;top:238px;left:106px;white-space:nowrap" class="ft1448">•&#160;&#160;Ask your&#160;healthcare&#160;provider&#160;how&#160;often you will&#160;need&#160;to give&#160;an&#160;injection.&#160;</p>
<p style="position:absolute;top:258px;left:106px;white-space:nowrap" class="ft1448">•&#160;&#160;Rotate&#160;the&#160;injection&#160;site&#160;each time&#160;you give&#160;an injection. Each new&#160;injection site&#160;should be&#160;at&#160;least&#160;</p>
<p style="position:absolute;top:282px;left:137px;white-space:nowrap" class="ft1442">3&#160;cm&#160;away&#160;from&#160;the&#160;previous&#160;injection&#160;site.&#160;</p>
<p style="position:absolute;top:297px;left:106px;white-space:nowrap" class="ft1448">•&#160;&#160;<b>Do not&#160;</b>use&#160;the&#160;pen&#160;if&#160;it&#160;has&#160;been dropped or&#160;is&#160;visibly damaged. A&#160;damaged pen&#160;may not&#160;function&#160;</p>
<p style="position:absolute;top:321px;left:137px;white-space:nowrap" class="ft1442">properly.<b>&#160;</b></p>
<p style="position:absolute;top:336px;left:106px;white-space:nowrap" class="ft1448">•&#160;&#160;<b>Do not</b>&#160;reuse the&#160;pen.&#160;</p>
<p style="position:absolute;top:356px;left:106px;white-space:nowrap" class="ft1446">•&#160;&#160;<b>Do not</b>&#160;shake the&#160;pen at&#160;any time.&#160;&#160;<br/>&#160;<br/><b>About the&#160;Remsima&#160;pen&#160;<br/>&#160;<br/>Parts of&#160;the&#160;pen&#160;(see&#160;<i>Figure A</i></b><b>):&#160;</b></p>
<p style="position:absolute;top:756px;left:385px;white-space:nowrap" class="ft1442">&#160;</p>
<p style="position:absolute;top:772px;left:321px;white-space:nowrap" class="ft1443"><i>Figure&#160;A&#160;</i></p>
<p style="position:absolute;top:791px;left:106px;white-space:nowrap" class="ft14414">&#160;<br/>•&#160;&#160;<b>Do not&#160;</b>remove&#160;the&#160;cap until&#160;you are&#160;ready to inject. Once&#160;you&#160;remove&#160;the&#160;cap,&#160;<b>do&#160;not</b>&#160;recap&#160;the&#160;</p>
<p style="position:absolute;top:830px;left:137px;white-space:nowrap" class="ft1442">pen.<b>&#160;</b></p>
<p style="position:absolute;top:849px;left:106px;white-space:nowrap" class="ft1446">&#160;<br/><b>Prepare&#160;for&#160;the&#160;injection&#160;<br/>&#160;<br/>1.&#160;Gather the supplies for the&#160;injection.&#160;</b></p>
<p style="position:absolute;top:925px;left:123px;white-space:nowrap" class="ft14410">a.&#160;&#160;Prepare a&#160;clean,&#160;flat&#160;surface,&#160;such&#160;as a&#160;table or&#160;countertop,&#160;in&#160;a&#160;well-lit&#160;area.&#160;<br/>b.&#160;&#160;Remove&#160;the&#160;pen&#160;from&#160;the&#160;carton stored in&#160;your&#160;refrigerator.&#160;<br/>c.&#160;&#160;Ensure&#160;you have&#160;the&#160;following supplies:&#160;</p>
<p style="position:absolute;top:977px;left:149px;white-space:nowrap" class="ft1448">•&#160;&#160;Pen&#160;</p>
<p style="position:absolute;top:998px;left:149px;white-space:nowrap" class="ft1448">•&#160;&#160;Alcohol&#160;swab&#160;</p>
<p style="position:absolute;top:1018px;left:149px;white-space:nowrap" class="ft1448">•&#160;&#160;Cotton&#160;ball&#160;or&#160;gauze*&#160;</p>
<p style="position:absolute;top:1038px;left:149px;white-space:nowrap" class="ft1448">•&#160;&#160;Adhesive&#160;bandage*&#160;</p>
<p style="position:absolute;top:1058px;left:149px;white-space:nowrap" class="ft14419">•&#160;&#160;Sharps&#160;disposal&#160;container*&#160;&#160;<br/><i>*Items&#160;not&#160;included in the&#160;carton.</i>&#160;</p>
<p style="position:absolute;top:1101px;left:107px;white-space:nowrap" class="ft1442">&#160;</p>
</div>
<!-- Page 145 -->
<a name="145"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page145-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1450">145&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1452">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1455"><b>2.&#160;Inspect&#160;the&#160;pen.&#160;<br/>Do not&#160;</b>use the&#160;pen&#160;if:<b>&#160;</b></p>
<p style="position:absolute;top:123px;left:151px;white-space:nowrap" class="ft1458">•&#160;&#160;It&#160;is cracked&#160;or&#160;damaged.&#160;</p>
<p style="position:absolute;top:143px;left:151px;white-space:nowrap" class="ft1458">•&#160;&#160;The expiration&#160;date&#160;has passed.&#160;</p>
<p style="position:absolute;top:167px;left:793px;white-space:nowrap" class="ft1452">&#160;</p>
<p style="position:absolute;top:186px;left:106px;white-space:nowrap" class="ft14513">&#160;<br/><b>3.&#160;Inspect&#160;the&#160;medicine&#160;(see&#160;<i>Figure B</i></b><b>).&#160;<br/></b>The&#160;liquid should be&#160;clear&#160;and colourless&#160;to&#160;pale&#160;brown.&#160;<br/><b>Do not&#160;</b>use the&#160;pen if&#160;the&#160;liquid is&#160;cloudy,&#160;discoloured&#160;or&#160;<br/>contains&#160;particles&#160;in it.<b>&#160;<br/></b><i>Note:&#160;You&#160;may&#160;see&#160;air&#160;bubbles&#160;in the&#160;liquid.&#160;This&#160;is&#160;<br/>normal.</i>&#160;</p>
<p style="position:absolute;top:508px;left:779px;white-space:nowrap" class="ft1453"><i>&#160;</i></p>
<p style="position:absolute;top:523px;left:720px;white-space:nowrap" class="ft1453"><i>Figure&#160;B</i>&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft14511">&#160;<br/><b>4.&#160;Wait&#160;30 minutes.&#160;</b></p>
<p style="position:absolute;top:580px;left:131px;white-space:nowrap" class="ft1452">a.&#160;&#160;Leave the&#160;pen at&#160;room&#160;temperature&#160;for&#160;30&#160;minutes&#160;to allow&#160;it&#160;to naturally warm&#160;up.&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft1451"><b>Do not&#160;</b>warm&#160;the&#160;pen using&#160;heat&#160;sources such&#160;as&#160;hot&#160;water&#160;or&#160;a&#160;microwave.<b>&#160;</b></p>
<p style="position:absolute;top:618px;left:779px;white-space:nowrap" class="ft1452">&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft14511">&#160;<br/><b>5.&#160;Choose&#160;an&#160;injection&#160;site&#160;(see&#160;<i>Figure&#160;C</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:675px;left:131px;white-space:nowrap" class="ft1452">a.&#160;&#160;Select an&#160;injection&#160;site.&#160;You&#160;may&#160;inject into:&#160;</p>
<p style="position:absolute;top:690px;left:157px;white-space:nowrap" class="ft1458">•&#160;&#160;The&#160;front&#160;of&#160;the&#160;thighs.&#160;</p>
<p style="position:absolute;top:710px;left:157px;white-space:nowrap" class="ft1458">•&#160;&#160;The&#160;abdomen except&#160;for&#160;the&#160;5 cm&#160;around&#160;</p>
<p style="position:absolute;top:735px;left:189px;white-space:nowrap" class="ft1452">the&#160;belly button (navel).&#160;</p>
<p style="position:absolute;top:749px;left:157px;white-space:nowrap" class="ft1458">•&#160;&#160;The&#160;outer&#160;area&#160;of&#160;the&#160;upper&#160;arms&#160;(caregiver&#160;</p>
<p style="position:absolute;top:774px;left:189px;white-space:nowrap" class="ft1452">ONLY).&#160;</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft14513"><b>Do not</b>&#160;inject&#160;into skin that&#160;is&#160;within 5 cm&#160;of&#160;your&#160;belly&#160;<br/>button&#160;(navel), or&#160;is&#160;tender, damaged,&#160;bruised,&#160;or&#160;<br/>scarred.&#160;<br/><i>Note:&#160;Rotate&#160;the&#160;injection&#160;site&#160;each&#160;time&#160;you&#160;give&#160;an&#160;<br/>injection. Each new&#160;injection site&#160;should be&#160;at&#160;least&#160;3&#160;<br/>cm&#160;away from&#160;the previous&#160;injection&#160;site.</i><b>&#160;</b></p>
<p style="position:absolute;top:961px;left:779px;white-space:nowrap" class="ft1453"><i>&#160;</i></p>
<p style="position:absolute;top:977px;left:718px;white-space:nowrap" class="ft1453"><i>Figure&#160;C&#160;</i></p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft14510">&#160;<br/><b>6.&#160;Wash your&#160;hands.&#160;</b></p>
<p style="position:absolute;top:1034px;left:128px;white-space:nowrap" class="ft1452">a.&#160;</p>
<p style="position:absolute;top:1034px;left:159px;white-space:nowrap" class="ft1452">Wash&#160;your&#160;hands&#160;with soap&#160;and water&#160;and dry them&#160;thoroughly.<b>&#160;</b></p>
<p style="position:absolute;top:1053px;left:779px;white-space:nowrap" class="ft1452">&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft14511">&#160;<br/><b>7.&#160;Clean the&#160;injection&#160;site.&#160;</b></p>
<p style="position:absolute;top:1110px;left:128px;white-space:nowrap" class="ft1452">a.&#160;</p>
<p style="position:absolute;top:1110px;left:159px;white-space:nowrap" class="ft1452">Clean&#160;the&#160;injection&#160;site&#160;with&#160;an&#160;alcohol swab.&#160;</p>
<p style="position:absolute;top:1129px;left:128px;white-space:nowrap" class="ft1452">b.&#160;&#160;Let&#160;the skin&#160;dry&#160;before&#160;injecting.&#160;</p>
<p style="position:absolute;top:1148px;left:106px;white-space:nowrap" class="ft1451"><b>Do not&#160;</b>blow&#160;on or&#160;touch&#160;the&#160;injection site&#160;again before&#160;giving the&#160;injection.&#160;</p>
</div>
<!-- Page 146 -->
<a name="146"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page146-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1460">146&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1462">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft14611">&#160;<br/><b>Give&#160;the&#160;injection&#160;<br/></b>&#160;<br/><b>8.&#160;Remove the&#160;cap&#160;(see&#160;<i>Figure D</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:165px;left:131px;white-space:nowrap" class="ft1462">a.&#160;&#160;Pull&#160;the&#160;olive&#160;green&#160;cap&#160;straight&#160;off&#160;and&#160;set&#160;it&#160;</p>
<p style="position:absolute;top:184px;left:158px;white-space:nowrap" class="ft1462">aside.&#160;</p>
<p style="position:absolute;top:203px;left:106px;white-space:nowrap" class="ft14611"><b>Do not</b>&#160;touch the&#160;needle&#160;cover. Doing so&#160;may result&#160;in&#160;a&#160;<br/>needle&#160;stick injury.&#160;&#160;<br/>Note:&#160;It&#160;is&#160;normal&#160;to see&#160;a&#160;drop of&#160;liquid at&#160;the&#160;end&#160;of&#160;<br/>the needle.&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:449px;left:779px;white-space:nowrap" class="ft1463"><i>&#160;</i></p>
<p style="position:absolute;top:464px;left:717px;white-space:nowrap" class="ft1463"><i>Figure&#160;D&#160;</i></p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft14610">&#160;<br/><b>9.&#160;Place the&#160;pen&#160;on the&#160;injection&#160;site&#160;(see&#160;<i>Figure E</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:521px;left:131px;white-space:nowrap" class="ft14610">a.&#160;&#160;Hold the&#160;pen&#160;so&#160;that&#160;you&#160;can see&#160;the&#160;window.&#160;<br/>b.&#160;&#160;Without&#160;pinching or&#160;stretching the&#160;skin,&#160;place&#160;the&#160;</p>
<p style="position:absolute;top:559px;left:158px;white-space:nowrap" class="ft1462">pen over&#160;the&#160;injection&#160;site&#160;at&#160;a&#160;90-degree angle.<b>&#160;</b></p>
<p style="position:absolute;top:807px;left:779px;white-space:nowrap" class="ft1463"><i>&#160;</i></p>
<p style="position:absolute;top:823px;left:720px;white-space:nowrap" class="ft1463"><i>Figure&#160;E&#160;</i></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1462">&#160;</p>
</div>
<!-- Page 147 -->
<a name="147"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page147-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1470">147&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1472">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1471"><b>10.&#160;Start the&#160;injection&#160;(see&#160;<i>Figure F</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:108px;left:131px;white-space:nowrap" class="ft1472">a.&#160;&#160;Press&#160;the&#160;pen&#160;<b>firmly</b>&#160;against&#160;the skin.&#160;</p>
<p style="position:absolute;top:127px;left:114px;white-space:nowrap" class="ft14713"><i>Note:&#160;When&#160;the injection&#160;starts&#160;you&#160;will&#160;hear the 1</i>st&#160;<i>loud&#160;<br/>“click”&#160;and&#160;the olive green&#160;plunger&#160;rod&#160;will begin&#160;to&#160;fill&#160;<br/>the&#160;window.&#160;</i></p>
<p style="position:absolute;top:184px;left:131px;white-space:nowrap" class="ft1472">b.&#160;&#160;Keep holding the&#160;pen&#160;<b>firmly</b>&#160;against&#160;the&#160;skin and&#160;</p>
<p style="position:absolute;top:203px;left:158px;white-space:nowrap" class="ft1472">listen&#160;for&#160;the&#160;2nd&#160;loud “click.”<b>&#160;</b></p>
<p style="position:absolute;top:394px;left:779px;white-space:nowrap" class="ft1473"><i>&#160;</i></p>
<p style="position:absolute;top:410px;left:720px;white-space:nowrap" class="ft1473"><i>Figure&#160;F&#160;</i></p>
<p style="position:absolute;top:428px;left:106px;white-space:nowrap" class="ft14711">&#160;<br/><b>11.&#160;Finish&#160;the&#160;injection&#160;(see<i>&#160;Figure&#160;G</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:466px;left:131px;white-space:nowrap" class="ft1472">a.&#160;&#160;After&#160;you hear&#160;the&#160;2nd&#160;loud&#160;“click,”&#160;<b>continue&#160;to&#160;</b></p>
<p style="position:absolute;top:485px;left:158px;white-space:nowrap" class="ft14710"><b>hold the&#160;pen&#160;firmly&#160;against&#160;the&#160;skin&#160;and&#160;count&#160;<br/>slowly to at&#160;least&#160;five</b>&#160;to&#160;ensure&#160;you&#160;inject&#160;the&#160;full&#160;<br/>dose.&#160;</p>
<p style="position:absolute;top:753px;left:779px;white-space:nowrap" class="ft1473"><i>&#160;</i></p>
<p style="position:absolute;top:768px;left:718px;white-space:nowrap" class="ft1473"><i>Figure&#160;G&#160;</i></p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft1472">&#160;</p>
</div>
<!-- Page 148 -->
<a name="148"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page148-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1480">148&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1482">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft1481"><b>12.&#160;Remove the&#160;pen&#160;from&#160;the&#160;injection&#160;site.&#160;</b></p>
<p style="position:absolute;top:108px;left:131px;white-space:nowrap" class="ft1482">a.&#160;&#160;Look&#160;at&#160;the&#160;pen and&#160;confirm&#160;that&#160;the&#160;olive&#160;green&#160;</p>
<p style="position:absolute;top:127px;left:158px;white-space:nowrap" class="ft1482">plunger&#160;rod is&#160;filling the&#160;window&#160;completely.&#160;</p>
<p style="position:absolute;top:146px;left:131px;white-space:nowrap" class="ft14810">b.&#160;&#160;Lift the&#160;pen&#160;from&#160;the injection&#160;site (see&#160;<i>Figure&#160;H</i>).&#160;<br/>c.&#160;&#160;Gently&#160;press a cotton&#160;ball&#160;or&#160;gauze over&#160;the&#160;</p>
<p style="position:absolute;top:184px;left:158px;white-space:nowrap" class="ft14810">injection site&#160;and apply an adhesive&#160;bandage, if&#160;<br/>necessary.&#160;</p>
<p style="position:absolute;top:222px;left:106px;white-space:nowrap" class="ft1487"><b>Do not&#160;</b>rub&#160;the&#160;injection&#160;site.&#160;<br/><i>Note:&#160;After you&#160;remove the&#160;pen from&#160;the&#160;injection site,&#160;the&#160;<br/>needle will&#160;be automatically covered&#160;(see Figure&#160;I).</i>&#160;<br/><i>Note:&#160;If&#160;the&#160;olive&#160;green plunger&#160;rod does&#160;not&#160;fill&#160;the&#160;<br/>window&#160;completely, you did&#160;not&#160;receive&#160;your&#160;full&#160;dose.&#160;<br/>Do not&#160;reuse&#160;the&#160;pen&#160;in&#160;this&#160;case. Call&#160;your&#160;healthcare&#160;<br/>provider immediately.</i>&#160;</p>
<p style="position:absolute;top:410px;left:718px;white-space:nowrap" class="ft1483"><i>Figure&#160;H&#160;</i></p>
<p style="position:absolute;top:428px;left:779px;white-space:nowrap" class="ft1483"><i>&#160;</i></p>
<p style="position:absolute;top:448px;left:114px;white-space:nowrap" class="ft1482">&#160;</p>
<p style="position:absolute;top:749px;left:724px;white-space:nowrap" class="ft1483"><i>Figure&#160;I&#160;</i></p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft14811">&#160;<br/><b>&#160;</b></p>
<p style="position:absolute;top:787px;left:322px;white-space:nowrap" class="ft1481"><b>&#160;</b></p>
</div>
<!-- Page 149 -->
<a name="149"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page149-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1177px;left:433px;white-space:nowrap" class="ft1490">149&#160;</p>
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1492">&#160;</p>
<p style="position:absolute;top:89px;left:106px;white-space:nowrap" class="ft14910"><b>After the injection&#160;<br/></b>&#160;<br/><b>13.&#160;Dispose of&#160;the&#160;pen&#160;(see&#160;<i>Figure J</i></b><b>).&#160;</b></p>
<p style="position:absolute;top:146px;left:131px;white-space:nowrap" class="ft1492">a.&#160;&#160;Put&#160;the&#160;used&#160;pen in&#160;an approved sharps&#160;disposal&#160;</p>
<p style="position:absolute;top:165px;left:158px;white-space:nowrap" class="ft1492">container&#160;immediately&#160;after&#160;use.&#160;</p>
<p style="position:absolute;top:184px;left:131px;white-space:nowrap" class="ft1492">b.&#160;&#160;If&#160;you do not&#160;have&#160;an&#160;approved sharps&#160;disposal&#160;</p>
<p style="position:absolute;top:203px;left:158px;white-space:nowrap" class="ft14910">container, you may&#160;use&#160;a&#160;household container&#160;that&#160;<br/>is:&#160;</p>
<p style="position:absolute;top:237px;left:157px;white-space:nowrap" class="ft1498">•&#160;&#160;made&#160;of&#160;a&#160;heavy-duty plastic;&#160;</p>
<p style="position:absolute;top:257px;left:157px;white-space:nowrap" class="ft1498">•&#160;&#160;able&#160;to close&#160;with a&#160;tight-fitting,&#160;</p>
<p style="position:absolute;top:281px;left:189px;white-space:nowrap" class="ft14910">puncture-resistant&#160;lid, without&#160;sharps&#160;being&#160;<br/>able&#160;to come&#160;out;&#160;</p>
<p style="position:absolute;top:315px;left:157px;white-space:nowrap" class="ft1498">•&#160;&#160;upright&#160;and stable&#160;during use;&#160;</p>
<p style="position:absolute;top:335px;left:157px;white-space:nowrap" class="ft1498">•&#160;&#160;leak-resistant;&#160;and&#160;</p>
<p style="position:absolute;top:355px;left:157px;white-space:nowrap" class="ft1498">•&#160;&#160;properly&#160;labelled&#160;to warn of&#160;hazardous&#160;waste&#160;</p>
<p style="position:absolute;top:380px;left:189px;white-space:nowrap" class="ft1492">inside&#160;the&#160;container.&#160;</p>
<p style="position:absolute;top:398px;left:131px;white-space:nowrap" class="ft1492">c.&#160;&#160;When&#160;your&#160;sharps&#160;disposal&#160;container&#160;is&#160;almost&#160;</p>
<p style="position:absolute;top:417px;left:158px;white-space:nowrap" class="ft14911">full, it&#160;should be&#160;disposed&#160;of&#160;in&#160;accordance&#160;with&#160;<br/>local requirements.&#160;</p>
<p style="position:absolute;top:455px;left:106px;white-space:nowrap" class="ft14910"><b>Do not&#160;</b>recap&#160;the&#160;pen.&#160;<br/><i>Note:&#160;Keep&#160;the&#160;pen and&#160;sharps&#160;disposal&#160;container&#160;out&#160;of&#160;<br/>the&#160;sight&#160;and&#160;reach of&#160;children.</i>&#160;<br/>&#160;</p>
<p style="position:absolute;top:448px;left:714px;white-space:nowrap" class="ft1493"><i>Figure&#160;J&#160;</i></p>
<p style="position:absolute;top:532px;left:106px;white-space:nowrap" class="ft1492">&#160;</p>
</div>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="remsima-epar-product-information_en.html#1">SUMMARY OF PRODUCT CHARACTERISTICS</a></li>
<li><a href="remsima-epar-product-information_en.html#77">A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</a></li>
<li><a href="remsima-epar-product-information_en.html#77">B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</a></li>
<li><a href="remsima-epar-product-information_en.html#77">C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</a></li>
<li><a href="remsima-epar-product-information_en.html#78">D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</a></li>
<li><a href="remsima-epar-product-information_en.html#80">A. LABELLING</a></li>
<li><a href="remsima-epar-product-information_en.html#93">B. PACKAGE LEAFLET</a></li>
</ul>
<hr/>
</body>
</html>
